data_1dd2_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1dd2 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 . . . . . 0 C--O 1.231 0.122 0 CA-C-O 121.145 0.498 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 51.8 mt -81.7 111.45 26.12 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.242 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.45 136.98 29.76 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.047 1.832 . . . . 0.0 112.305 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -72.18 147.17 90.48 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.516 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.89 -25.89 16.15 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.252 1.968 . . . . 0.0 112.464 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 pp -165.98 179.32 5.89 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.451 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.34 102.69 9.72 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.437 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -127.87 171.1 19.22 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.0 m -105.37 135.25 47.09 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.136 0.494 . . . . 0.0 110.416 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 26.0 t -69.93 122.14 20.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.129 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -101.03 -54.42 2.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.576 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.3 ttpm? -151.66 145.85 25.37 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.487 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 3.4 mp -105.36 133.7 48.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.115 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.8 mp -98.15 -44.83 6.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.648 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.4 ' CG1' ' CG1' ' A' ' 76' ' ' VAL . 35.9 m -88.67 150.49 3.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.743 -179.708 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 3.5 ptpt -136.08 161.37 35.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.181 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -61.22 98.6 0.08 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.526 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -29.98 2.38 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.49 148.04 26.74 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.125 0.488 . . . . 0.0 110.578 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 24.5 m -95.2 142.17 27.95 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.192 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.4 ' CG1' ' CG1' ' A' ' 70' ' ' VAL . 23.8 m -120.19 163.73 17.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.638 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.1 mttp -123.04 147.47 46.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.153 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.11 92.9 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.693 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.2 -35.37 2.03 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -63.36 143.51 57.74 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.135 0.493 . . . . 0.0 110.614 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.7 m -66.87 137.2 56.4 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.219 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 30.7 m -115.17 -30.24 2.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.206 -179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 9.0 tt -163.27 150.14 12.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.127 0.489 . . . . 0.0 110.855 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 t -102.13 130.59 51.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.998 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.6 mt -119.1 132.23 55.98 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.664 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.054 179.547 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 . . . . . 0 N--CA 1.462 0.137 0 CA-C-O 121.14 0.495 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.9 m -118.45 127.67 53.87 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.32 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -84.07 130.85 34.85 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.643 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.3 mm -104.94 116.22 48.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.124 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 82.5 m-20 -103.03 143.71 32.22 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.426 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.6 143.3 96.47 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.358 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -73.15 -37.65 3.28 Favored 'Trans proline' 0 CA--C 1.527 0.17 0 C-N-CA 122.072 1.848 . . . . 0.0 112.24 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 15.6 p -145.78 162.2 38.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.387 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -67.76 142.3 56.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.456 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.57 -157.25 27.52 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.1 ttmt -133.91 147.25 51.09 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.142 0.496 . . . . 0.0 110.544 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.2 t -75.32 107.26 5.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.301 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -93.39 -28.04 16.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.65 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -158.56 130.93 6.9 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.077 0.465 . . . . 0.0 110.396 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.4 t -97.96 109.39 23.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.31 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.2 mt -90.29 30.37 1.13 Allowed 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.641 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 25.6 m -155.47 137.47 6.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 121.073 0.463 . . . . 0.0 110.252 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 24.9 mmtt -128.9 167.01 18.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.385 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -62.27 147.61 47.53 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.426 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 11.0 mmp_? 60.69 32.32 20.26 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.598 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -122.74 136.43 54.87 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.354 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.28 136.68 32.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.487 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.5 m -119.18 150.73 21.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.394 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -98.15 149.28 22.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.449 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.92 117.3 11.16 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 105.84 -28.12 15.18 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 -59.57 138.33 57.74 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 121.041 0.448 . . . . 0.0 110.586 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.68 121.43 26.58 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 24.5 mt -88.92 -51.81 5.43 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.073 0.463 . . . . 0.0 110.404 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 48.4 mt -142.82 144.78 23.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.407 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -96.51 125.29 40.89 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.238 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.6 mm -106.06 143.87 16.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.536 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.772 0 CA-C-O 117.989 -1.45 . . . . 0.0 110.716 179.956 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 121.078 0.466 . . . . 0.0 110.481 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 28.5 mt -79.01 115.01 49.21 Favored Pre-proline 0 CA--C 1.535 0.386 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.006 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.84 140.04 37.76 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 121.963 1.775 . . . . 0.0 112.329 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -75.25 146.53 81.74 Favored Pre-proline 0 CA--C 1.531 0.219 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.454 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.71 -24.34 18.42 Favored 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 122.232 1.954 . . . . 0.0 112.47 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -161.08 175.23 12.65 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.457 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -87.83 110.26 20.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.402 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -138.09 177.85 19.69 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 18.9 m -104.75 136.58 43.99 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.142 0.496 . . . . 0.0 110.481 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 32.0 t -70.28 117.83 13.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.25 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.8 p -99.61 -51.86 3.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.525 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.3 ptpt -151.73 145.28 24.9 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.528 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.7 mt -100.77 141.23 17.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.009 179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -101.6 -30.44 11.37 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.109 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.4 ' CG1' ' CG1' ' A' ' 76' ' ' VAL . 34.5 m -124.91 133.65 68.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.244 0.545 . . . . 0.0 110.854 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.75 149.3 37.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.853 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.8 121.06 5.96 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.387 0.613 . . . . 0.0 111.108 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.17 -28.83 4.48 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.51 158.82 15.37 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-O 121.054 0.454 . . . . 0.0 110.425 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -97.91 141.22 31.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.428 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.4 ' CG1' ' CG1' ' A' ' 70' ' ' VAL . 29.2 m -123.83 158.31 29.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.485 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 32.3 mttm -117.68 157.83 25.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.35 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.42 106.84 0.82 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.515 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.3 -31.47 4.66 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 -62.77 140.62 58.76 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.125 0.488 . . . . 0.0 110.532 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 7.5 m -67.54 139.38 56.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.305 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.4 m -114.43 -31.54 2.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.053 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 8.5 tt -166.41 146.9 6.19 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.103 0.478 . . . . 0.0 110.841 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.1 t -103.08 135.88 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.131 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 51.9 mt -118.32 166.27 12.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.706 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.336 179.911 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 21.5 mt-10 . . . . . 0 C--O 1.23 0.071 0 CA-C-O 121.056 0.455 . . . . 0.0 110.433 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.0 m -117.45 109.04 16.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.276 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -77.97 140.64 39.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.604 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 37.2 mm -103.68 140.67 21.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.057 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 38.3 m-20 -128.76 143.48 50.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.665 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.25 138.62 96.18 Favored Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.259 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.99 -31.86 11.87 Favored 'Trans proline' 0 N--CA 1.472 0.209 0 C-N-CA 122.09 1.86 . . . . 0.0 112.416 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 40.9 p -147.17 164.95 31.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.483 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -66.42 143.61 57.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.399 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.48 -160.43 27.98 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -135.02 136.87 42.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.139 0.495 . . . . 0.0 110.431 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 4.2 t -73.16 107.26 3.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.86 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -87.68 -29.39 21.17 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.001 -179.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 13.7 tttt -163.95 138.13 5.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.407 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.6 t -107.92 110.49 32.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.416 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.8 mt -79.24 -31.59 43.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.394 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.3 m -82.56 142.84 13.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.501 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 54.2 mttt -136.47 163.11 31.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.246 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -60.79 147.29 43.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.519 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 5.5 tpt180 61.13 35.45 18.58 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.479 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -127.98 140.32 52.05 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.388 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.51 136.24 33.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.517 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.0 m -120.24 152.06 23.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.341 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -97.36 140.19 32.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.501 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.7 87.92 0.04 OUTLIER Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 137.54 -28.08 2.79 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -61.59 146.93 47.3 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.157 0.503 . . . . 0.0 110.515 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.56 118.87 16.16 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 71.8 mt -87.14 -53.15 5.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.082 0.468 . . . . 0.0 110.485 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.436 HD12 HG22 ' A' ' 120' ' ' ILE . 55.5 mt -140.9 151.59 20.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.477 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -97.22 133.99 41.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.209 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 35.9 mm -114.25 145.18 20.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.438 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.781 0 CA-C-O 118.011 -1.438 . . . . 0.0 110.774 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.998 0.428 . . . . 0.0 110.499 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.1 mm -80.22 120.6 80.07 Favored Pre-proline 0 CA--C 1.536 0.431 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.923 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -72.05 128.0 13.47 Favored 'Trans proline' 0 N--CA 1.472 0.222 0 C-N-CA 121.892 1.728 . . . . 0.0 112.1 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.05 142.12 93.22 Favored Pre-proline 0 CA--C 1.532 0.28 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.471 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -73.62 -27.54 12.73 Favored 'Trans proline' 0 CA--C 1.528 0.188 0 C-N-CA 122.181 1.921 . . . . 0.0 112.374 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -161.33 159.92 29.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.472 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.59 125.39 30.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.402 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -159.06 -140.22 2.86 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 14.8 m -136.56 139.13 41.96 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.082 0.468 . . . . 0.0 110.406 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 27.9 t -70.71 124.61 27.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.208 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.0 t -98.42 -54.23 3.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.675 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -153.67 145.02 23.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.529 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 35.7 mt -99.65 135.16 36.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.118 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.3 mt -98.48 -44.13 6.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.617 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 34.6 m -98.83 144.69 11.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.502 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 46.1 pttt -137.3 164.28 28.94 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.206 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -57.05 102.29 0.08 Allowed 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.692 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.13 -31.97 2.22 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -90.15 152.94 20.88 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.062 0.458 . . . . 0.0 110.387 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -98.84 146.79 25.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.474 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.4 m -121.47 162.44 20.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.344 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -127.29 156.85 41.27 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.488 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.34 90.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.55 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.65 -30.36 3.0 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 16.3 tt0 -61.88 143.32 56.56 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.077 0.465 . . . . 0.0 110.672 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.9 m -68.9 138.97 55.1 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.148 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 28.4 m -117.63 -33.86 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.35 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.6 tt -161.52 153.15 19.02 Favored 'General case' 0 C--N 1.332 -0.175 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.167 -179.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.4 t -107.55 138.4 33.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.923 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -120.26 168.53 11.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.191 0.52 . . . . 0.0 110.457 -179.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.357 179.961 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 121.063 0.459 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.2 m -114.4 122.34 46.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.232 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -82.52 130.22 35.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.62 -179.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 25.7 mm -103.19 147.45 9.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.011 179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -139.27 142.38 37.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.152 0.501 . . . . 0.0 110.779 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.65 109.76 2.72 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.291 179.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -64.93 -13.77 41.46 Favored 'Trans proline' 0 N--CA 1.476 0.46 0 C-N-CA 122.148 1.899 . . . . 0.0 112.885 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -135.94 135.96 40.04 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.097 0.475 . . . . 0.0 110.359 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -63.36 151.29 41.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.422 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 159.36 -154.66 25.73 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.0 ttmt -135.69 148.03 48.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.141 0.496 . . . . 0.0 110.448 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.9 t -75.69 111.26 11.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.208 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -95.21 -30.07 14.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.784 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.7 ttpt -162.01 130.17 4.13 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.569 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.0 t -103.57 113.89 41.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.295 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.0 mt -81.59 -37.17 28.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.374 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 32.9 m -77.44 147.45 7.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.574 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -133.49 163.68 28.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.075 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -62.71 138.55 58.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.394 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER 67.2 37.16 3.76 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.564 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.41 151.07 40.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.278 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -95.61 133.46 39.63 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.513 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.4 m -120.8 179.8 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.356 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 81.7 mm-40 -136.05 147.67 48.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.425 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.32 113.07 5.31 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 111.18 -30.78 7.69 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -60.18 140.33 57.02 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.138 0.494 . . . . 0.0 110.675 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.49 120.49 22.72 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 91.6 mt -87.06 -53.59 4.79 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.103 0.478 . . . . 0.0 110.423 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.452 HG23 HD11 ' A' ' 120' ' ' ILE . 52.3 mt -141.32 151.82 19.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.326 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 39.1 mttt -93.76 128.19 39.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.382 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.431 HG23 HD12 ' A' ' 122' ' ' ILE . 37.1 mm -109.87 145.76 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.37 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.748 0 CA-C-O 117.991 -1.449 . . . . 0.0 110.728 179.925 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 . . . . . 0 N--CA 1.46 0.074 0 CA-C-O 121.067 0.46 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 45.7 mt -78.9 111.45 19.86 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.127 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -70.38 142.42 45.17 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.099 1.866 . . . . 0.0 112.465 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -77.67 148.53 76.51 Favored Pre-proline 0 CA--C 1.531 0.24 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.521 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -73.11 -26.66 14.71 Favored 'Trans proline' 0 CA--C 1.528 0.212 0 C-N-CA 122.206 1.937 . . . . 0.0 112.461 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -164.63 156.98 16.37 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.472 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.0 121.92 19.07 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.423 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -150.96 -145.17 4.07 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.7 m -136.97 139.02 41.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.138 0.494 . . . . 0.0 110.413 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 25.2 t -71.98 126.23 32.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.181 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 32.7 t -96.03 -53.41 3.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.655 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.32 150.55 31.62 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.178 0.513 . . . . 0.0 110.74 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 32.8 mt -105.87 116.48 49.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.051 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 64.2 mt -98.75 13.78 31.05 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.622 -179.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 28.4 m -148.22 133.56 11.0 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 CA-C-O 121.122 0.486 . . . . 0.0 110.691 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -116.86 161.2 19.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.195 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.21 95.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.621 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.22 -35.79 1.86 Allowed Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.52 146.77 47.59 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.093 0.473 . . . . 0.0 110.481 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -96.67 137.51 35.63 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.578 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 18.8 m -126.91 166.76 22.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.395 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -130.3 157.23 43.11 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.309 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.39 88.62 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.401 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.15 -33.51 2.08 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -63.15 145.66 55.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.145 0.498 . . . . 0.0 110.451 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.1 m -67.33 139.57 57.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.425 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 28.1 m -120.14 -35.49 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.17 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.6 tt -162.05 152.71 17.45 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.261 0.553 . . . . 0.0 111.032 -179.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.9 t -103.54 145.1 13.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.794 179.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 11.1 mt -126.67 160.3 31.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.52 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.423 179.907 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 . . . . . 0 C--O 1.231 0.09 0 CA-C-O 121.016 0.436 . . . . 0.0 110.196 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.3 m -118.75 117.58 29.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.393 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -83.04 133.82 35.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.457 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 33.7 mm -103.71 152.78 6.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.172 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 47.6 m-80 -139.88 148.08 41.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.495 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.89 139.18 95.66 Favored Pre-proline 0 CA--C 1.533 0.316 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.399 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -76.02 -28.65 7.38 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.128 1.886 . . . . 0.0 112.387 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 3.7 p -145.63 168.27 21.06 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.535 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -69.57 141.71 53.73 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.514 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 159.78 -168.16 35.48 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -129.13 168.4 16.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.229 0.538 . . . . 0.0 110.637 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.4 t -82.4 111.56 18.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.439 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -92.95 -30.13 15.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.42 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 4.9 tmtt? -159.05 128.77 5.62 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.275 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.7 t -101.3 105.73 18.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.117 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.0 mt -85.84 9.45 16.66 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.863 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 28.4 m -129.33 146.0 34.89 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-O 121.192 0.52 . . . . 0.0 110.629 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 20.5 mtpt -128.39 166.5 18.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.263 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -63.49 140.89 58.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.323 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 17.7 mmt85 65.83 36.71 5.96 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.67 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -121.89 137.44 54.78 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.272 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.2 134.21 34.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.521 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.2 m -120.72 156.96 23.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.367 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -97.51 144.12 27.53 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.393 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.3 108.05 1.62 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.96 -27.06 9.41 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.05 -0.82 . . . . 0.0 111.05 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 24.1 tt0 -59.83 143.52 50.96 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-O 121.126 0.489 . . . . 0.0 110.631 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.63 119.84 19.93 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 70.6 mt -89.67 -52.82 4.81 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.136 0.493 . . . . 0.0 110.172 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 46.3 mt -145.21 144.14 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.16 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 9.3 tttt -94.99 135.48 36.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.143 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 40.8 mm -109.2 142.69 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.412 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.815 0 CA-C-O 118.061 -1.41 . . . . 0.0 110.833 -179.919 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 . . . . . 0 C--O 1.232 0.162 0 CA-C-O 121.09 0.471 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.5 mt -78.29 118.79 74.39 Favored Pre-proline 0 CA--C 1.535 0.39 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.185 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -71.53 135.33 26.14 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 121.98 1.787 . . . . 0.0 112.331 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.52 148.4 98.1 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.456 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.79 -34.73 6.48 Favored 'Trans proline' 0 N--CA 1.472 0.224 0 C-N-CA 122.276 1.984 . . . . 0.0 112.236 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -162.67 159.06 23.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.411 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.77 81.91 0.19 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.288 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -115.01 -172.79 17.5 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.9 m -109.89 136.7 48.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.061 0.458 . . . . 0.0 110.388 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.3 t -71.73 117.02 14.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.094 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.8 t -92.93 -49.99 5.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.679 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -155.37 148.35 24.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.246 0.546 . . . . 0.0 110.608 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 48.5 mt -103.37 130.15 54.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.95 179.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.7 mp -94.29 -30.72 14.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.854 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 31.0 m -114.72 145.77 20.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.112 0.482 . . . . 0.0 110.728 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -138.88 166.87 23.32 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.331 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -56.96 104.95 0.18 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.839 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 132.1 -31.02 3.1 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -87.35 144.49 26.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.108 0.48 . . . . 0.0 110.57 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.2 m -93.51 150.45 20.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.293 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.9 m -125.14 166.9 20.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.568 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -129.48 147.51 51.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.204 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.52 92.02 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.629 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.17 -30.55 2.62 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.6 tt0 -69.25 143.04 54.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.107 0.479 . . . . 0.0 110.618 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 27.1 m -65.02 138.21 58.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.206 179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.6 m -115.7 -26.38 2.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.449 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 9.1 tt -165.26 150.02 9.0 Favored 'General case' 0 C--N 1.332 -0.166 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.966 -179.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.0 t -106.74 137.91 35.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.017 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 11.8 mt -115.66 164.75 13.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.184 0.516 . . . . 0.0 110.595 -179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.363 179.959 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 . . . . . 0 N--CA 1.461 0.108 0 CA-C-O 121.128 0.49 . . . . 0.0 110.55 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.7 m -122.02 112.61 18.48 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.233 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -87.4 143.0 27.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.487 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 4.8 mp -116.52 126.24 73.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.123 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -101.07 153.95 19.13 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.261 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.06 141.37 95.77 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.325 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.26 -32.72 7.98 Favored 'Trans proline' 0 N--CA 1.472 0.208 0 C-N-CA 122.133 1.889 . . . . 0.0 112.212 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 73.1 p -148.16 155.92 41.97 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.348 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -63.73 142.85 58.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.393 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 169.34 -156.38 27.43 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -134.35 150.97 50.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.092 0.472 . . . . 0.0 110.372 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.9 t -78.3 111.03 14.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.276 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -93.55 -30.94 14.74 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.646 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.61 151.74 27.88 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.221 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.9 t -131.95 113.26 21.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.304 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.1 mt -84.63 -33.07 23.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.348 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 32.7 m -80.46 144.24 11.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.585 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -133.36 164.19 27.67 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.247 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 -61.28 144.35 54.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.458 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 2.5 ttt-85 61.48 35.02 17.78 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.44 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 17.2 t0 -124.62 148.04 48.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.428 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.3 141.33 28.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.469 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.8 m -122.41 156.18 27.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.379 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -100.58 140.18 35.21 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.346 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.51 98.97 0.16 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.3 -27.55 6.32 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.7 tt0 -59.56 142.63 52.28 Favored 'General case' 0 N--CA 1.462 0.127 0 CA-C-O 121.062 0.458 . . . . 0.0 110.656 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.26 121.64 26.03 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.761 -0.935 . . . . 0.0 110.761 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 79.6 mt -87.78 -54.46 4.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.075 0.464 . . . . 0.0 110.394 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 52.9 mt -141.24 149.39 20.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.312 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 14.8 tttp -98.14 126.75 43.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.343 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 36.7 mm -102.62 145.68 11.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.331 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.689 0 CA-C-O 117.988 -1.451 . . . . 0.0 110.784 179.967 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 121.132 0.492 . . . . 0.0 110.3 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 54.5 mt -78.04 113.67 35.27 Favored Pre-proline 0 CA--C 1.535 0.395 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.068 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.08 132.71 23.37 Favored 'Trans proline' 0 N--CA 1.472 0.249 0 C-N-CA 122.08 1.853 . . . . 0.0 112.297 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.94 147.97 98.54 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.584 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.33 -29.01 11.77 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.256 1.971 . . . . 0.0 112.314 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -163.81 -179.85 6.61 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.528 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.19 98.45 9.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.42 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.76 -177.55 14.99 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.3 m -113.63 141.27 47.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.132 0.492 . . . . 0.0 110.418 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.89 126.02 30.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.293 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.1 t -100.65 -52.28 3.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.58 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 7.2 ttmm -150.52 148.56 28.85 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.654 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 44.8 mt -102.66 131.71 50.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.019 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.9 mt -99.79 -36.37 9.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.786 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.4 ' CG1' ' CG1' ' A' ' 76' ' ' VAL . 33.6 m -110.47 146.92 15.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 121.172 0.511 . . . . 0.0 110.835 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.3 pttt -137.3 165.6 25.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.182 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -58.42 101.74 0.09 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.606 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.07 -32.6 2.17 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -88.54 146.28 25.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.129 0.49 . . . . 0.0 110.392 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -96.28 148.33 22.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.32 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.4 ' CG1' ' CG1' ' A' ' 70' ' ' VAL . 30.9 m -125.77 169.79 16.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.52 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 43.6 tttt -132.37 153.97 50.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.31 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.94 97.97 0.07 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.595 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.27 -36.75 2.19 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 14.9 tt0 -62.49 139.08 58.59 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.056 0.455 . . . . 0.0 110.67 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.6 m -65.86 137.11 56.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.206 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 24.3 m -115.67 -31.39 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.229 -179.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.5 tt -161.35 153.0 19.18 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.177 0.513 . . . . 0.0 110.86 -179.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -101.35 140.55 19.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.038 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 12.5 mt -122.78 139.24 54.21 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.161 0.505 . . . . 0.0 110.643 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.373 179.931 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.461 0.097 0 CA-C-O 121.117 0.484 . . . . 0.0 110.507 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.6 m -113.5 123.36 49.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.312 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -84.64 130.65 34.69 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.523 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 35.6 mm -106.23 114.9 46.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.184 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -102.11 146.91 27.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.289 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.09 141.53 95.79 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.322 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.62 -34.78 6.77 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.077 1.852 . . . . 0.0 112.211 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 17.4 p -147.85 162.57 38.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.271 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -68.19 141.18 56.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.328 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.47 -158.34 29.4 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 5.6 ttpm? -132.95 149.7 52.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.976 0.417 . . . . 0.0 110.336 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.9 t -75.99 110.16 10.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.21 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -92.77 -29.97 15.74 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.582 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 27.6 tttm -159.2 129.65 5.85 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.157 0.503 . . . . 0.0 110.486 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 33.2 t -100.19 102.84 13.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.168 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.2 mt -85.24 6.38 26.29 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.64 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.7 m -120.89 136.23 58.54 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.109 0 CA-C-O 121.181 0.515 . . . . 0.0 110.312 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 83.3 mttt -126.23 164.41 21.04 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.313 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -62.1 145.33 53.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.38 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 36.6 mtt180 60.13 35.6 21.18 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.588 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -114.64 141.68 47.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.373 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.61 129.27 38.59 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.572 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.5 m -119.09 179.7 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.259 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 64.3 mt-30 -140.68 152.45 45.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.512 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.82 105.09 0.83 Allowed Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.9 -31.39 4.97 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -60.05 135.32 57.68 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.131 0.491 . . . . 0.0 110.541 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.81 121.07 25.4 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 62.3 mt -87.36 -56.51 3.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.012 0.434 . . . . 0.0 110.296 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 49.1 mt -143.15 150.89 17.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.126 179.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -96.2 125.7 40.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.265 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.8 mm -106.46 143.36 17.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.516 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.697 0 CA-C-O 117.951 -1.471 . . . . 0.0 110.767 179.977 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 . . . . . 0 N--CA 1.461 0.101 0 CA-C-O 121.026 0.441 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.424 HG22 HD11 ' A' ' 57' ' ' ILE . 54.3 mt -82.11 111.06 24.26 Favored Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.282 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -71.57 142.67 40.71 Favored 'Trans proline' 0 N--CA 1.472 0.263 0 C-N-CA 122.0 1.8 . . . . 0.0 112.295 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -74.7 147.14 84.15 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.397 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -72.49 -26.51 16.77 Favored 'Trans proline' 0 N--CA 1.471 0.199 0 C-N-CA 122.182 1.921 . . . . 0.0 112.366 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -164.55 157.57 17.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.362 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -73.52 97.15 2.53 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.43 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.86 -144.55 6.22 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 3.9 m -136.54 132.18 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.095 0.474 . . . . 0.0 110.358 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.8 t -67.71 130.5 33.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.254 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 4.8 p -101.6 -53.98 2.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.542 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 23.8 ttpt -152.82 147.26 25.82 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.588 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 47.3 mt -100.23 133.48 43.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.116 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 25.7 mt -98.64 -31.3 12.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.638 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.0 m -104.51 149.95 7.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.701 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 67.7 mttt -137.19 163.43 30.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.206 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -62.36 97.0 0.08 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.258 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.19 -29.19 2.43 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -85.43 147.82 26.3 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.082 0.467 . . . . 0.0 110.442 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.88 150.21 20.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.147 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 31.6 m -128.54 170.02 18.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.653 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.5 mmtt -131.38 146.26 52.2 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.22 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -58.84 96.51 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.717 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.16 -34.5 2.3 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 23.6 tt0 -67.84 144.46 55.3 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.14 0.495 . . . . 0.0 110.515 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.5 m -65.13 136.73 57.05 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.315 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.3 m -112.73 -33.09 2.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.921 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.5 tt -160.4 150.75 18.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.686 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.2 t -102.55 136.64 33.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.184 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -117.16 164.1 15.28 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.519 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.28 179.985 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 121.068 0.461 . . . . 0.0 110.459 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 24.1 m -116.47 124.64 50.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.388 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -85.01 134.14 34.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.486 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.468 HD12 HG22 ' A' ' 94' ' ' ILE . 38.3 mm -102.66 126.1 56.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.242 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 13.7 p30 -110.25 140.06 44.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.314 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.11 139.24 96.03 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.311 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.81 -31.04 8.75 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.166 1.911 . . . . 0.0 112.227 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 78.2 p -147.01 151.31 36.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.344 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -66.78 142.67 57.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.352 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.62 -147.93 8.76 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -140.88 145.47 36.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.076 0.465 . . . . 0.0 110.316 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 24.7 t -77.8 107.45 9.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.327 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -91.92 -28.42 17.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.729 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 17.8 ttpt -160.75 130.89 5.14 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.099 0.476 . . . . 0.0 110.544 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.49 109.52 28.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.347 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.6 mt -78.92 -31.8 45.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.476 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 31.5 m -80.18 152.84 4.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.593 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -135.79 155.11 50.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.268 179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -59.01 141.99 52.44 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.632 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER 60.75 36.39 19.34 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.499 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -119.45 151.11 39.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.286 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -93.64 133.4 37.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.491 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.7 m -120.39 152.01 23.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.453 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -100.17 144.93 28.62 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.354 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.62 105.63 0.96 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 117.91 -28.04 7.19 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 37.3 tt0 -59.85 139.96 56.96 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 121.127 0.489 . . . . 0.0 110.597 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.36 126.58 40.3 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 41.5 mt -89.43 -58.94 2.35 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.153 0.501 . . . . 0.0 110.567 -179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 58.4 mt -140.95 145.57 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.164 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -93.41 123.76 36.94 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.536 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.1 mm -101.23 145.07 12.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.274 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.678 0 CA-C-O 117.947 -1.474 . . . . 0.0 110.875 -179.996 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 . . . . . 0 C--O 1.232 0.145 0 CA-C-O 121.072 0.463 . . . . 0.0 110.453 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 43.4 mt -79.27 120.22 79.77 Favored Pre-proline 0 CA--C 1.534 0.335 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.157 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.22 138.72 31.01 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 121.998 1.799 . . . . 0.0 112.375 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -75.2 147.92 83.44 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.42 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -72.27 -28.53 15.21 Favored 'Trans proline' 0 CA--C 1.527 0.156 0 C-N-CA 122.324 2.016 . . . . 0.0 112.409 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.6 pp -163.25 163.2 25.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.436 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.16 98.17 5.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.437 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -123.65 -148.04 7.43 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.742 -0.943 . . . . 0.0 110.742 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.1 m -136.4 140.21 43.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.064 0.459 . . . . 0.0 110.439 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t -72.28 120.12 20.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.16 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -96.82 -51.28 4.33 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.693 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -152.97 144.08 23.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.64 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 33.3 mt -97.45 131.46 44.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.0 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.3 mp -100.11 -29.44 12.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.884 -179.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 28.3 m -118.71 145.76 24.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-O 121.255 0.55 . . . . 0.0 110.685 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.3 pttm -136.52 167.04 22.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.175 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 9.1 mp0 -60.51 105.27 0.42 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.49 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -31.55 2.26 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 50.4 m-20 -93.82 149.49 21.19 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.064 0.459 . . . . 0.0 110.497 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -102.18 143.44 31.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.286 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 22.9 m -122.03 162.1 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.551 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -122.98 158.07 31.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.265 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.47 101.83 0.2 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.518 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.29 -36.09 2.31 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -65.45 137.97 57.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.054 0.454 . . . . 0.0 110.563 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 11.1 m -64.13 139.38 58.76 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.172 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 33.1 m -113.96 -30.53 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.19 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 8.9 tt -164.66 151.64 11.17 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.088 0.47 . . . . 0.0 110.782 -179.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 t -104.21 136.84 35.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.077 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 16.0 mt -118.07 159.79 22.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.651 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 . . . . . 0 C--N 1.33 -0.242 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.376 179.897 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 . . . . . 0 C--O 1.232 0.164 0 CA-C-O 121.028 0.442 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 24.7 m -116.08 124.41 50.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.341 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -82.17 132.26 35.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.479 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.458 HD13 HG21 ' A' ' 94' ' ' ILE . 36.2 mm -102.15 121.49 53.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.248 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -109.73 143.65 39.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.352 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.57 143.5 93.49 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.407 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -72.67 -35.54 5.85 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.118 1.879 . . . . 0.0 112.223 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 19.6 p -148.7 166.1 29.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.365 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -66.65 141.59 57.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.471 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.04 -162.35 32.91 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 6.8 ttpm? -133.07 147.53 52.18 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.034 0.445 . . . . 0.0 110.465 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.8 t -77.75 111.08 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.166 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -94.86 -30.07 14.38 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.638 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.7 tttp -159.02 131.01 6.54 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.345 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.3 t -96.66 110.68 25.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.312 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 29.8 mt -90.27 30.24 1.14 Allowed 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.633 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 23.2 m -155.59 139.24 8.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-O 121.02 0.438 . . . . 0.0 110.259 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.67 165.13 18.45 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.134 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -60.91 147.19 43.96 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.555 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 60.99 35.76 18.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.505 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.9 t0 -121.36 137.72 54.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.412 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -89.24 134.75 33.91 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.432 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.0 m -122.39 155.91 27.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.417 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -100.23 145.88 27.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.453 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.17 112.36 4.65 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 109.85 -27.8 11.51 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -57.45 145.33 33.36 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 121.07 0.462 . . . . 0.0 110.779 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.01 122.02 28.37 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 97.8 mt -90.42 -56.77 3.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.114 0.483 . . . . 0.0 110.523 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.5 mt -140.94 145.74 24.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.301 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 7.2 ttmt -92.46 124.44 36.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.365 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.6 mm -103.46 145.1 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.448 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.218 -0.848 0 CA-C-O 118.076 -1.402 . . . . 0.0 110.701 179.952 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.23 0.073 0 CA-C-O 121.02 0.438 . . . . 0.0 110.382 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 55.3 mt -80.25 111.22 20.53 Favored Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.053 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -70.68 141.86 42.51 Favored 'Trans proline' 0 N--CA 1.472 0.262 0 C-N-CA 122.032 1.821 . . . . 0.0 112.292 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -75.85 144.89 77.06 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.475 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -73.71 -24.74 15.43 Favored 'Trans proline' 0 N--CA 1.472 0.217 0 C-N-CA 122.188 1.925 . . . . 0.0 112.59 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -161.55 167.54 25.2 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.454 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -91.7 95.49 9.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.369 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -122.83 -139.67 5.56 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.9 m -136.12 134.61 38.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.083 0.468 . . . . 0.0 110.406 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 26.4 t -71.34 125.61 30.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.279 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.9 t -95.7 -54.79 3.23 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.578 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -152.43 149.52 28.67 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.523 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 48.9 mt -102.27 133.39 46.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.221 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.9 mp -98.82 -31.5 11.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.618 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 33.2 m -114.79 144.91 21.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.681 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.85 165.54 25.39 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.26 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -59.33 101.52 0.1 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.598 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.09 -31.81 2.24 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -90.11 150.03 22.23 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.089 0.471 . . . . 0.0 110.486 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -96.23 149.43 21.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.332 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 30.3 m -122.73 168.33 15.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.464 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 21.4 ttpt -128.34 148.49 50.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.346 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.05 100.83 0.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.612 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.11 -31.31 4.75 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.1 tt0 -64.08 143.73 57.65 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.057 0.456 . . . . 0.0 110.67 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 21.4 m -65.44 138.84 58.38 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.219 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 28.4 m -118.49 -32.2 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.384 -179.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.5 tt -161.04 152.28 18.91 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.311 0.577 . . . . 0.0 111.296 -179.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 19.7 t -103.45 147.32 9.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.557 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 7.4 mt -127.48 170.44 12.57 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.156 0.503 . . . . 0.0 110.785 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 . . . . . 0 C--N 1.33 -0.244 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.478 -179.832 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.173 0.511 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -112.13 176.19 5.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.656 179.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -146.02 134.87 22.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.28 0.562 . . . . 0.0 110.648 -179.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 37.3 mm -102.57 153.7 5.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.146 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -136.91 141.45 42.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.353 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.93 135.52 94.65 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.309 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -73.85 -31.64 8.09 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.073 1.849 . . . . 0.0 112.268 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 25.1 p -146.13 157.57 43.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.411 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -65.86 141.81 58.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.279 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.66 -158.52 26.69 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 26.5 ttpt -133.74 148.54 51.42 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.144 0.497 . . . . 0.0 110.413 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 23.7 t -75.47 105.83 4.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.27 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -92.49 -26.67 17.85 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.859 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 27.9 ttmt -158.93 129.08 5.81 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.098 0.475 . . . . 0.0 110.635 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 24.9 t -102.29 106.13 19.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.194 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 18.1 mt -89.5 13.33 14.11 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.632 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 30.7 m -130.12 143.77 40.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 CA-C-O 121.079 0.466 . . . . 0.0 110.312 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 13.6 mtmm -126.08 168.01 14.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.387 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -72.29 143.25 48.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.338 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 16.3 mtm180 61.42 38.5 15.98 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.514 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -126.45 148.04 49.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.336 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.83 140.0 30.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.56 -179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.9 m -122.8 156.02 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.274 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 39.0 mm-40 -101.94 142.39 33.31 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.337 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.38 111.38 3.38 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 108.72 -25.02 20.52 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -59.9 140.97 56.3 Favored 'General case' 0 N--CA 1.462 0.15 0 CA-C-O 121.017 0.437 . . . . 0.0 110.791 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.48 118.37 14.6 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 33.2 mt -88.58 -54.02 4.37 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.124 0.487 . . . . 0.0 110.497 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.4 HG22 HD13 ' A' ' 120' ' ' ILE . 52.2 mt -142.4 142.74 26.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.325 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.0 122.49 38.88 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.097 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.0 mm -100.66 142.46 15.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.479 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.667 0 CA-C-O 117.972 -1.46 . . . . 0.0 110.758 179.931 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 121.079 0.466 . . . . 0.0 110.542 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.5 mt -79.49 120.28 79.79 Favored Pre-proline 0 CA--C 1.534 0.348 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.081 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -72.19 146.06 45.27 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 121.996 1.797 . . . . 0.0 112.352 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -74.55 148.47 85.58 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.41 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.85 -28.5 13.43 Favored 'Trans proline' 0 N--CA 1.472 0.207 0 C-N-CA 122.207 1.938 . . . . 0.0 112.345 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.7 pp -166.27 165.3 17.49 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.494 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.69 84.21 3.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.396 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -120.92 -166.57 13.06 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.8 m -112.28 135.78 52.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.132 0.492 . . . . 0.0 110.357 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 25.1 t -70.79 126.11 30.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.247 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 4.5 p -97.82 -61.63 1.36 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.604 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 9.1 mmmt -141.47 150.23 41.97 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.607 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 33.6 mt -110.22 120.55 61.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.842 179.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.4 mt -96.82 27.66 3.85 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.344 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 31.5 m -155.5 151.18 10.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 121.195 0.521 . . . . 0.0 110.483 179.642 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.9 pttt -141.6 160.33 40.39 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.054 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -60.34 95.05 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.431 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.18 -26.63 2.57 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -80.64 149.05 29.98 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.161 0.505 . . . . 0.0 110.457 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.6 m -97.32 137.71 35.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.228 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 34.6 m -119.78 145.03 26.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.556 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 mtmt -108.74 147.53 31.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.235 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -58.5 102.04 0.1 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.812 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.01 -32.72 3.38 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 12.7 tt0 -65.15 143.9 57.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.055 0.455 . . . . 0.0 110.501 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.9 m -66.95 138.45 57.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.221 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 32.3 m -119.37 -31.29 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.531 -179.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 9.9 tt -162.37 146.23 11.85 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.129 0.49 . . . . 0.0 111.032 -179.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.0 t -108.81 143.08 19.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.89 179.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -124.38 163.59 21.42 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.186 0.517 . . . . 0.0 110.798 -179.6 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.2 mt-10 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.371 179.906 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 121.14 0.495 . . . . 0.0 110.52 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.9 m -113.15 116.55 30.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.22 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -91.78 125.91 36.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.526 -179.751 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 5.3 mp -108.72 148.46 12.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.954 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -135.89 156.12 49.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.165 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.56 135.58 95.61 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.337 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.37 -32.47 8.05 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.044 1.829 . . . . 0.0 112.224 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.1 p -145.61 159.33 43.3 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.315 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -63.64 140.03 58.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.339 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.17 -161.69 32.78 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.3 ttmp? -135.62 146.75 48.22 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.062 0.458 . . . . 0.0 110.444 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 30.3 t -75.99 114.07 15.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.147 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -94.94 -30.02 14.36 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.778 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 77.6 tttt -159.98 128.91 5.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.546 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.1 t -107.62 108.71 25.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.271 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 mt -79.21 -31.62 43.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.447 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.6 m -80.77 145.27 9.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.567 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -130.36 157.67 41.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.21 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 66.5 mt-10 -59.27 143.21 49.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.668 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 24.4 ttt180 61.76 32.84 18.15 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.305 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -116.24 151.06 36.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.427 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.83 135.51 34.06 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.442 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.8 m -120.53 179.67 2.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.43 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -135.42 145.29 47.11 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.366 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.45 109.43 2.48 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.0 -29.32 8.13 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.3 tt0 -60.11 140.82 56.65 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 121.146 0.498 . . . . 0.0 110.609 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.38 122.04 28.06 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 87.7 mt -89.22 -61.63 1.66 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.132 0.491 . . . . 0.0 110.503 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.433 HD13 HG22 ' A' ' 120' ' ' ILE . 55.4 mt -140.96 151.83 20.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.362 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 33.0 tttm -98.63 134.63 41.3 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.386 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 35.4 mm -108.06 146.87 13.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.424 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.779 0 CA-C-O 118.049 -1.417 . . . . 0.0 110.786 179.958 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 . . . . . 0 C--O 1.231 0.081 0 CA-C-O 121.015 0.435 . . . . 0.0 110.272 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.4 HD11 HG23 ' A' ' 57' ' ' ILE . 54.8 mt -80.1 111.41 21.8 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.17 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -71.1 153.41 62.68 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.011 1.807 . . . . 0.0 112.218 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.97 143.05 60.92 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.468 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -74.13 -27.91 11.33 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.121 1.881 . . . . 0.0 112.309 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -163.9 162.91 23.75 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.364 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.56 92.07 5.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.39 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -126.16 -141.85 5.59 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 19.8 m -138.04 138.3 38.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.003 0.43 . . . . 0.0 110.459 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.66 125.31 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.208 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.1 t -98.24 -46.42 5.83 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.564 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 36.0 mtmt -149.16 169.84 19.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.606 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 51.7 mt -129.8 125.81 61.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.946 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 20.4 mt -97.24 -28.11 14.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.12 -179.383 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 32.9 m -101.47 156.77 4.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.346 0.593 . . . . 0.0 111.218 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 22.5 mttp -135.96 151.9 50.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.843 179.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -60.78 90.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.52 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.09 -25.86 2.63 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 63.8 m-20 -78.72 148.66 32.96 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.143 0.497 . . . . 0.0 110.5 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 5.3 m -97.02 140.04 32.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.184 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 30.0 m -121.91 171.26 10.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.66 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -127.42 138.66 53.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.191 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -56.11 100.25 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.029 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.86 -38.84 1.63 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 45.3 tt0 -69.35 144.82 53.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.065 0.459 . . . . 0.0 110.599 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 17.6 m -65.02 139.11 58.71 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.317 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 35.1 m -115.05 -25.88 3.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.397 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.7 tt -166.58 146.52 5.86 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 121.052 0.453 . . . . 0.0 110.702 -179.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -105.1 141.26 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.133 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 12.1 mt -120.11 158.28 27.22 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.553 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 . . . . . 0 C--N 1.33 -0.251 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.397 179.94 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 . . . . . 0 N--CA 1.461 0.122 0 CA-C-O 121.171 0.51 . . . . 0.0 110.41 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.8 m -129.0 113.0 14.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.131 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -87.22 142.98 27.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.717 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 4.6 mp -115.21 127.08 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.907 179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 42.4 m-20 -102.5 153.31 20.19 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.207 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.85 136.22 94.84 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.345 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -72.62 -35.25 6.23 Favored 'Trans proline' 0 N--CA 1.471 0.2 0 C-N-CA 122.09 1.86 . . . . 0.0 112.172 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.5 p -147.36 155.32 41.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.296 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -64.49 140.43 58.87 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.384 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.21 -157.94 26.14 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 15.7 ttmm -132.31 143.7 50.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.065 0.459 . . . . 0.0 110.468 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 36.0 t -78.78 110.08 14.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.171 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.09 -29.65 16.43 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.84 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 8.0 ttpt -157.86 131.03 7.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.448 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.8 t -101.06 115.46 42.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.243 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 19.9 mt -89.95 28.52 1.36 Allowed 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.698 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 19.2 m -155.69 142.5 11.3 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 121.038 0.447 . . . . 0.0 110.378 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.5 tttt -125.89 165.03 19.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.188 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -59.61 143.05 51.51 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.615 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 30.2 mtm180 60.14 34.01 21.15 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.558 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -114.21 149.16 36.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.338 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.92 134.98 34.29 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.526 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.6 m -122.38 149.91 25.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.331 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 55.9 mt-30 -99.68 144.1 29.15 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.416 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.42 110.07 2.71 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.739 -0.945 . . . . 0.0 110.739 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 110.24 -27.29 11.85 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -59.64 139.77 56.94 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.056 0.455 . . . . 0.0 110.668 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.12 123.08 31.53 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 65.8 mt -87.57 -54.01 4.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.032 0.444 . . . . 0.0 110.405 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 50.2 mt -141.5 149.64 20.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.426 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.0 tttm -99.25 130.51 45.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.299 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.446 HG22 HD12 ' A' ' 122' ' ' ILE . 37.2 mm -107.63 144.71 15.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.506 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.797 0 CA-C-O 117.964 -1.464 . . . . 0.0 110.806 179.969 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.1 0.476 . . . . 0.0 110.477 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 45.0 mt -78.82 111.76 22.04 Favored Pre-proline 0 CA--C 1.534 0.363 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.212 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.94 137.82 32.82 Favored 'Trans proline' 0 N--CA 1.473 0.267 0 C-N-CA 122.084 1.856 . . . . 0.0 112.374 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.72 149.13 98.02 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.465 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.52 -27.55 15.53 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.253 1.969 . . . . 0.0 112.414 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 pp -164.79 165.22 20.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.443 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.34 96.49 5.32 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.363 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -128.4 -141.11 5.14 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.776 -0.929 . . . . 0.0 110.776 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.1 m -136.71 141.51 43.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.002 0.43 . . . . 0.0 110.46 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 23.1 t -71.21 128.64 34.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.218 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 t -98.67 -62.0 1.3 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.518 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 9.8 mtpt -150.16 144.81 25.92 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.457 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 42.2 mt -99.24 128.85 50.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.039 179.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.9 mp -97.67 -36.03 10.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.829 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 33.7 m -115.17 139.26 42.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.263 0.554 . . . . 0.0 110.78 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 20.9 pttt -135.91 162.75 31.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.793 179.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -54.61 108.64 0.41 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.279 0.561 . . . . 0.0 110.783 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.42 -29.98 2.35 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -102.53 155.12 18.49 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.974 0.416 . . . . 0.0 110.396 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.4 m -96.91 150.43 20.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.43 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 30.3 m -123.97 168.28 16.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.498 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 28.4 mmtm -129.69 155.28 46.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.448 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.2 105.76 0.64 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.453 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.25 -29.37 7.07 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -61.32 142.7 56.7 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.104 0.478 . . . . 0.0 110.564 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.9 m -67.1 138.14 56.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.271 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.4 m -118.17 -34.26 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.208 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 6.5 tt -162.11 152.02 16.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.134 0.492 . . . . 0.0 111.078 -179.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.8 t -102.89 143.15 15.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.654 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -119.49 167.69 11.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.229 0.538 . . . . 0.0 110.782 -179.559 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.365 179.897 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 . . . . . 0 N--CA 1.461 0.109 0 CA-C-O 121.14 0.495 . . . . 0.0 110.403 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 14.0 m -118.47 123.09 44.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.33 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -84.51 132.26 34.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.59 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 30.8 mm -105.45 148.72 9.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.049 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -139.29 150.83 45.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.612 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.63 143.73 96.35 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.399 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -72.62 -34.42 7.21 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.186 1.924 . . . . 0.0 112.26 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 14.3 p -146.95 168.45 21.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.312 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -68.82 142.26 54.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.463 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.1 -161.25 32.27 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.2 ttpt -133.62 138.91 46.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.062 0.458 . . . . 0.0 110.464 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 22.3 t -74.22 123.73 30.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.238 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -99.03 -33.17 10.92 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.588 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -160.88 147.82 15.29 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.412 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 11.9 t -101.29 119.0 48.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.008 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mt -89.53 21.56 3.36 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.919 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 30.6 m -154.56 156.3 5.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-O 121.093 0.473 . . . . 0.0 110.673 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.5 mtmp? -130.85 159.03 38.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.25 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 64.4 mt-10 -60.51 151.26 28.99 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.513 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? 60.99 32.33 19.92 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.521 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -122.91 150.9 42.31 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.452 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.01 137.56 32.27 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.348 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.5 m -121.12 148.71 24.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.432 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -98.1 140.66 32.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.259 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.54 96.28 0.09 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 127.51 -27.87 4.61 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -59.31 142.71 51.39 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.086 0.47 . . . . 0.0 110.704 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.22 120.93 24.71 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 14.1 mt -89.78 -50.2 6.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.079 0.466 . . . . 0.0 110.418 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 45.9 mt -145.27 147.82 18.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.297 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.5 mttp -95.43 130.34 42.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.158 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.5 mm -110.39 144.67 18.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.357 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.711 0 CA-C-O 117.974 -1.459 . . . . 0.0 110.76 -179.997 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 . . . . . 0 C--O 1.231 0.083 0 CA-C-O 121.107 0.48 . . . . 0.0 110.459 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 35.5 mt -81.81 112.22 32.93 Favored Pre-proline 0 CA--C 1.535 0.366 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.167 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -70.73 128.56 15.3 Favored 'Trans proline' 0 N--CA 1.472 0.233 0 C-N-CA 122.017 1.811 . . . . 0.0 112.363 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.95 148.64 87.75 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.49 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.99 -26.82 18.08 Favored 'Trans proline' 0 N--CA 1.471 0.15 0 C-N-CA 122.283 1.989 . . . . 0.0 112.509 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -163.75 168.54 19.58 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.423 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.75 102.83 13.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.499 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -133.98 -140.73 4.37 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 16.0 m -137.15 142.1 42.23 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.104 0.478 . . . . 0.0 110.369 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 23.1 t -71.96 131.99 33.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.122 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -101.37 -54.17 2.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.502 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 33.5 tttt -155.74 147.0 22.59 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.594 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 8.8 mt -100.43 130.78 49.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.972 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.1 mt -101.56 -41.88 6.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.691 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 29.5 m -93.54 149.88 4.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.761 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -135.11 162.22 33.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.255 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -60.94 96.6 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.543 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.0 -31.22 2.3 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -79.78 147.07 31.99 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.127 0.489 . . . . 0.0 110.449 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 6.7 m -95.9 141.12 29.7 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.382 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.9 m -120.06 160.93 20.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.555 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 tttt -120.08 146.97 45.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.311 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.84 93.46 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.69 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.42 -32.43 2.55 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -67.84 141.12 56.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.976 0.417 . . . . 0.0 110.52 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.0 m -63.34 137.22 58.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.189 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.6 m -114.01 -35.1 2.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.781 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.0 tt -159.18 151.49 21.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.449 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.2 t -102.9 143.44 15.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.042 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -124.06 164.75 18.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.582 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.338 179.989 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 . . . . . 0 N--CA 1.461 0.102 0 CA-C-O 121.167 0.508 . . . . 0.0 110.43 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.5 m -119.41 120.42 36.8 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.425 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -85.09 129.98 34.7 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.514 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.415 HD12 HG23 ' A' ' 94' ' ' ILE . 33.6 mm -103.13 124.55 57.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.327 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -110.29 147.76 33.23 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.376 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.78 138.42 96.96 Favored Pre-proline 0 CA--C 1.532 0.282 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.346 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.65 -32.87 7.18 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.087 1.858 . . . . 0.0 112.162 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 5.7 p -149.63 155.03 39.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.345 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -61.85 141.96 57.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.443 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 170.07 -157.37 28.75 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.1 ttmp? -134.82 148.07 50.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.129 0.49 . . . . 0.0 110.523 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 26.2 t -77.06 113.54 16.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.326 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -93.26 -30.83 14.97 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.699 -179.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 13.1 ttpt -159.45 133.57 7.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.569 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.92 108.11 23.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.144 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mt -89.58 13.13 14.77 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.578 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.3 m -130.72 136.59 57.92 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-O 121.123 0.487 . . . . 0.0 110.186 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -125.49 172.16 9.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.226 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -72.05 150.63 43.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.311 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 37.3 mtt-85 61.45 30.89 19.07 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.664 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -125.88 139.33 53.56 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.285 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.17 141.57 28.44 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.449 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.2 m -121.09 156.95 24.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.391 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -99.22 144.6 28.15 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.373 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.12 106.08 1.03 Allowed Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 117.56 -28.51 7.08 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.0 tt0 -59.21 137.7 57.87 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.126 0.489 . . . . 0.0 110.713 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.15 123.25 31.96 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 17.1 mt -86.5 -55.85 3.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.191 0.52 . . . . 0.0 110.534 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.8 mt -140.88 152.31 20.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.336 -179.779 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -96.92 132.52 42.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.476 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 36.9 mm -109.52 145.18 16.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.303 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.791 0 CA-C-O 118.095 -1.392 . . . . 0.0 110.757 -179.953 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 121.066 0.46 . . . . 0.0 110.354 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 45.4 mt -79.74 111.63 22.9 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.263 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -72.48 129.8 15.25 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 121.982 1.788 . . . . 0.0 112.217 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.09 139.43 96.0 Favored Pre-proline 0 CA--C 1.532 0.274 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.274 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -75.43 -12.0 20.7 Favored 'Trans proline' 0 CA--C 1.533 0.445 0 C-N-CA 122.091 1.861 . . . . 0.0 113.038 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -160.73 179.55 8.44 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-O 121.099 0.476 . . . . 0.0 110.48 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -109.76 113.34 26.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.401 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -149.5 -138.87 3.0 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 12.3 m -135.82 139.36 43.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.103 0.478 . . . . 0.0 110.411 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 28.1 t -70.48 126.5 30.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.18 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t -97.04 -55.06 2.98 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.574 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 ttpt -153.08 149.09 27.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.521 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 41.7 mt -103.01 135.66 39.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.059 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 9.7 mp -99.72 -45.08 5.88 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.818 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 34.8 m -97.2 148.16 5.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.218 0.532 . . . . 0.0 110.876 -179.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 pttt -137.24 163.66 30.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.195 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -59.64 102.59 0.15 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.584 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.51 2.26 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -91.91 151.45 20.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.119 0.485 . . . . 0.0 110.492 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.58 153.67 17.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.312 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 30.9 m -126.14 167.67 20.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.562 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 mttm -129.05 148.05 50.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.37 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.16 93.14 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.715 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.88 -34.8 2.17 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -64.0 143.95 57.46 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.086 0.469 . . . . 0.0 110.582 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 9.0 m -66.92 139.58 57.72 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.336 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 35.6 m -114.11 -32.68 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.939 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.9 tt -161.49 148.38 14.52 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.106 0.479 . . . . 0.0 110.797 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -103.4 140.37 21.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.113 179.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 2.1 mt -119.83 172.09 7.95 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.56 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.444 179.995 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 121.06 0.457 . . . . 0.0 110.569 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.5 m -112.41 117.54 32.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.283 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -84.99 135.52 33.99 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.56 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 41.1 mm -106.7 122.33 60.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.255 179.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -104.95 142.81 34.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.362 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.13 144.11 91.53 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -72.57 -38.95 2.94 Favored 'Trans proline' 0 CA--C 1.528 0.216 0 C-N-CA 122.175 1.917 . . . . 0.0 112.168 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.8 p -148.39 165.14 31.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.309 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -66.6 141.43 57.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.393 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 172.82 -157.37 26.58 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 17.7 ttmt -136.11 146.69 47.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.104 0.478 . . . . 0.0 110.488 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 23.0 t -74.7 108.72 6.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.186 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -91.52 -29.12 17.15 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.809 -179.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.4 ttmm -159.33 130.27 6.0 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.095 0.474 . . . . 0.0 110.53 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 32.3 t -102.19 105.72 18.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.184 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.4 mt -88.0 10.21 19.74 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.67 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 23.7 m -125.59 136.13 61.81 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.062 0 CA-C-O 121.11 0.481 . . . . 0.0 110.258 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.8 ttpm? -122.56 169.36 11.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.391 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 -66.65 142.5 57.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.356 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER 63.17 38.14 10.82 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.66 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -117.8 142.36 47.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.319 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.91 131.61 36.43 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.427 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.8 m -119.59 179.82 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.452 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -141.46 149.35 40.84 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.427 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.55 104.4 0.7 Allowed Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.64 -31.49 4.57 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -61.64 135.9 57.81 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.091 0.472 . . . . 0.0 110.445 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -63.01 118.89 15.27 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 69.3 mt -88.38 -56.21 3.41 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.074 0.464 . . . . 0.0 110.392 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 50.9 mt -142.26 144.94 24.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.323 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.7 tttt -96.55 132.76 41.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.333 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 39.2 mm -107.25 144.88 15.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.416 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.738 0 CA-C-O 117.958 -1.468 . . . . 0.0 110.813 -179.992 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 121.104 0.478 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.6 mt -77.84 111.67 19.51 Favored Pre-proline 0 CA--C 1.534 0.364 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.175 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -70.83 145.02 49.89 Favored 'Trans proline' 0 N--CA 1.472 0.248 0 C-N-CA 122.035 1.823 . . . . 0.0 112.394 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -82.11 147.52 57.73 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.468 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -71.82 -23.26 22.59 Favored 'Trans proline' 0 N--CA 1.472 0.251 0 C-N-CA 122.278 1.986 . . . . 0.0 112.658 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -161.68 173.38 14.77 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.089 0.471 . . . . 0.0 110.486 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.55 91.81 5.23 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.411 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -103.42 175.15 23.44 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.4 m -105.81 7.17 32.23 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.639 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t 63.15 117.75 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 CA-C-O 121.075 0.464 . . . . 0.0 110.322 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.5 t -95.89 -57.37 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.577 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 34.4 tttm -155.11 146.38 22.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.59 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 23.7 mt -105.09 120.82 56.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.867 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 16.8 mt -98.39 25.49 6.26 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.303 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 30.6 m -153.16 147.73 14.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.133 0.492 . . . . 0.0 110.644 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.3 pttt -135.05 161.3 35.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.151 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 51.5 mt-10 -60.07 99.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.519 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -30.45 2.35 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -77.36 151.89 34.68 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.11 0.481 . . . . 0.0 110.412 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 5.1 m -100.77 132.52 46.12 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.488 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.3 m -115.68 150.56 17.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.409 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -111.62 153.62 26.07 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.383 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.85 100.62 0.11 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.603 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.89 -31.45 4.11 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 5.6 tt0 -63.66 143.81 57.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.117 0.484 . . . . 0.0 110.524 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.2 m -66.27 136.34 55.7 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.334 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.6 m -119.1 -35.38 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.213 -179.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.1 tt -159.64 149.74 18.74 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.838 -179.315 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 t -107.94 154.99 8.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.898 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.5 mp -123.78 173.12 8.36 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.196 0.522 . . . . 0.0 110.636 -179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 . . . . . 0 C--N 1.33 -0.261 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.308 179.953 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 . . . . . 0 C--O 1.23 0.064 0 CA-C-O 121.134 0.492 . . . . 0.0 110.413 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.21 103.44 9.84 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.291 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -79.85 143.44 34.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.646 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 40.7 mm -105.93 156.31 6.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.052 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 22.3 m-80 -134.24 143.07 47.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.47 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.11 142.0 98.17 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.318 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.5 -36.02 4.28 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.12 1.88 . . . . 0.0 112.288 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.7 p -145.76 161.47 39.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.433 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -65.27 142.51 58.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.322 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.8 -158.4 25.32 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.5 ttmt -135.5 145.88 47.55 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.05 0.453 . . . . 0.0 110.549 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 26.2 t -74.33 110.25 8.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.245 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -95.24 -29.54 14.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.723 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -160.51 135.39 7.67 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.517 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.1 t -101.37 109.27 25.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.21 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 29.4 mt -90.08 29.66 1.19 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.639 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 29.6 m -155.2 145.17 13.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 121.055 0.455 . . . . 0.0 110.361 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.4 mmtm -127.25 160.85 30.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.259 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -60.02 142.99 52.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.524 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 3.1 ttm180 61.35 34.35 18.45 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.492 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -114.18 140.15 48.77 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.388 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -88.63 126.11 35.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.531 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.7 m -122.11 157.79 26.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.395 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -96.57 143.69 27.33 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.414 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.32 92.64 0.07 OUTLIER Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.6 -27.81 2.92 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -60.94 141.35 57.33 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-O 121.031 0.444 . . . . 0.0 110.54 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.08 123.81 33.6 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 92.3 mt -86.61 -51.83 5.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.055 0.455 . . . . 0.0 110.539 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.5 mt -140.88 150.23 20.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.395 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -97.78 128.4 44.4 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.309 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.6 mm -107.17 143.61 17.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.478 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.749 0 CA-C-O 117.982 -1.455 . . . . 0.0 110.781 179.975 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 121.08 0.467 . . . . 0.0 110.571 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 38.5 mt -80.72 111.2 21.21 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.131 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -70.61 135.64 28.89 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 122.085 1.857 . . . . 0.0 112.387 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -73.02 153.39 90.85 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.398 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.62 -27.9 14.8 Favored 'Trans proline' 0 CA--C 1.528 0.2 0 C-N-CA 122.211 1.941 . . . . 0.0 112.404 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.9 pp -165.95 165.71 17.9 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.418 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.76 104.73 10.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.286 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.22 -142.43 4.91 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.9 m -135.78 134.22 38.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.068 0.461 . . . . 0.0 110.468 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.9 t -72.14 127.94 34.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.126 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.31 -53.54 3.32 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.68 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 16.8 tttp -152.03 147.19 26.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.598 -179.749 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 47.9 mt -100.82 133.14 44.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.992 179.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.3 mp -99.6 -29.85 12.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.929 -179.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 34.9 m -110.7 148.66 13.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 121.241 0.543 . . . . 0.0 110.878 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.8 ptpp? -135.13 163.96 28.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.14 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -61.87 99.08 0.11 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.502 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.62 -30.9 2.36 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -84.73 147.53 26.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.14 0.495 . . . . 0.0 110.455 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.5 m -96.38 145.95 25.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.294 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 26.8 m -120.88 170.42 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.655 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 35.5 mttt -130.19 147.11 51.88 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.199 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.7 95.89 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.74 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.05 -34.21 2.48 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 11.0 tt0 -66.46 139.25 57.96 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.082 0.467 . . . . 0.0 110.527 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 19.4 m -62.76 137.68 58.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.313 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.83 -32.27 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.952 -179.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.1 tt -162.74 150.21 13.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.159 0.504 . . . . 0.0 110.624 -179.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.1 t -103.49 143.57 15.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.119 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.5 tp -124.66 165.81 17.25 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.631 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.321 -179.978 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 . . . . . 0 C--O 1.231 0.095 0 CA-C-O 121.046 0.45 . . . . 0.0 110.423 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.9 m -119.19 115.65 24.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.383 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -83.7 129.93 34.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.489 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 37.3 mm -104.14 122.51 57.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.306 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -109.84 144.01 38.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.253 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.51 141.88 94.4 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.42 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.39 -37.9 3.97 Favored 'Trans proline' 0 N--CA 1.471 0.178 0 C-N-CA 122.125 1.883 . . . . 0.0 112.302 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 3.0 p -147.19 159.93 43.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.403 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -62.7 141.36 58.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.351 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.3 -157.0 25.47 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -137.95 147.03 43.91 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.081 0.467 . . . . 0.0 110.416 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 25.0 t -76.88 112.61 14.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.191 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -95.31 -30.07 14.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.741 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.2 tttm -159.75 127.43 4.74 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.604 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 24.1 t -104.16 114.85 44.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.255 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mt -82.31 -39.06 23.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.405 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 33.2 m -74.64 150.27 7.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.545 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 43.4 mttt -133.6 161.13 35.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.316 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -61.56 139.98 58.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.458 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.44 37.52 16.62 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.354 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -123.92 146.98 48.08 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.386 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.18 138.14 31.78 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.519 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.2 m -122.33 162.39 22.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.336 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 13.6 mt-30 -103.12 141.06 36.49 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.293 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.38 105.95 0.92 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.03 -26.97 9.99 Favored Glycine 0 CA--C 1.527 0.831 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 -58.15 148.89 25.3 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-O 121.109 0.48 . . . . 0.0 110.773 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.16 122.85 30.81 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 92.3 mt -89.61 -60.86 1.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.086 0.469 . . . . 0.0 110.423 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.432 HD11 HG22 ' A' ' 120' ' ' ILE . 54.4 mt -140.95 152.52 20.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.243 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 55.3 mttt -95.86 127.38 41.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.415 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.1 mm -107.15 145.16 14.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.396 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.027 -1.429 . . . . 0.0 110.798 -179.998 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 121.119 0.485 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.4 mt -78.22 111.66 20.16 Favored Pre-proline 0 CA--C 1.535 0.372 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.237 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -71.32 138.39 32.88 Favored 'Trans proline' 0 N--CA 1.472 0.221 0 C-N-CA 121.997 1.798 . . . . 0.0 112.348 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.66 146.66 99.09 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.404 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.81 -27.73 14.4 Favored 'Trans proline' 0 CA--C 1.528 0.196 0 C-N-CA 122.254 1.97 . . . . 0.0 112.291 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -164.64 171.02 14.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.46 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.71 93.53 6.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.447 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.95 -148.76 7.41 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.1 m -136.46 138.0 41.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.071 0.462 . . . . 0.0 110.551 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 19.5 t -71.05 116.72 13.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.2 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 t -98.61 -48.65 4.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.622 -179.804 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -150.4 144.67 25.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.622 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 21.8 mt -105.35 135.12 44.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.905 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.6 mp -97.14 -30.62 12.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.846 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.3 m -119.47 145.7 25.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.187 0.518 . . . . 0.0 110.742 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.9 pttm -133.6 164.21 27.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.252 179.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -60.54 103.82 0.28 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.452 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.04 -29.68 2.41 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -94.94 153.15 17.8 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.098 0.475 . . . . 0.0 110.475 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.4 m -96.69 153.08 18.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.311 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 30.4 m -128.61 168.64 21.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.73 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.4 mtpp -129.96 151.69 50.24 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.19 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.57 102.16 0.17 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.71 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.85 -37.74 2.05 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 32.3 tt0 -62.55 140.57 58.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.12 0.486 . . . . 0.0 110.692 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 9.2 m -67.34 141.07 57.26 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.227 179.791 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 34.9 m -115.61 -24.25 3.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.592 -179.405 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 8.3 tt -166.26 152.94 9.29 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.211 0.529 . . . . 0.0 110.885 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.9 134.7 57.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.042 179.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 55.8 mt -115.47 161.59 18.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.611 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.132 179.889 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 121.112 0.482 . . . . 0.0 110.569 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.9 m -115.07 123.6 49.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.224 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 14.8 mt-10 -94.07 129.91 40.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.788 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.402 ' CD1' ' N ' ' A' ' 94' ' ' ILE . 4.4 mp -115.5 112.37 39.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.633 179.489 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -99.48 153.97 18.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.419 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.98 142.54 95.19 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.293 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.33 -36.22 5.67 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.175 1.917 . . . . 0.0 112.196 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -146.12 168.83 20.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.299 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -68.55 141.9 55.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.334 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.24 -161.16 31.12 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 74.9 tttt -134.51 148.12 50.47 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.096 0.474 . . . . 0.0 110.429 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.6 t -74.75 103.7 2.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.202 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -90.39 -29.29 18.11 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.774 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.5 tttt -158.32 123.53 4.37 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.139 0.495 . . . . 0.0 110.518 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 24.5 t -100.37 106.79 19.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.332 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.4 mt -90.48 33.76 0.9 Allowed 'General case' 0 CA--C 1.533 0.326 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.421 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 19.2 m -156.4 137.26 4.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 121.031 0.443 . . . . 0.0 110.101 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.4 mptp? -125.85 175.82 7.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.272 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -72.2 147.63 46.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.401 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 63.16 34.51 13.51 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.537 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -121.87 145.0 48.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.26 179.754 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.24 136.99 32.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.629 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 20.7 m -120.23 179.73 2.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.383 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -133.05 141.97 48.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.367 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.8 102.36 0.33 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.849 -0.901 . . . . 0.0 110.849 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.33 -31.32 4.7 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -60.24 142.5 54.44 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.093 0.473 . . . . 0.0 110.583 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -65.45 126.64 30.77 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 92.6 mt -89.98 -55.49 3.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.993 0.425 . . . . 0.0 110.271 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 45.6 mt -143.51 149.25 18.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.333 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.2 ttmt -96.44 130.84 43.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.276 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.452 HG22 HD12 ' A' ' 122' ' ' ILE . 37.6 mm -107.22 144.17 16.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.49 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.758 0 CA-C-O 117.998 -1.446 . . . . 0.0 110.737 179.991 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 121.116 0.484 . . . . 0.0 110.341 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 47.4 mt -82.5 114.85 54.6 Favored Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.24 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.38 148.98 55.9 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.054 1.836 . . . . 0.0 112.278 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -81.13 145.26 56.04 Favored Pre-proline 0 CA--C 1.532 0.25 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.431 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -73.44 -27.34 13.29 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.238 1.958 . . . . 0.0 112.399 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.7 pp -162.57 158.26 23.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.472 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -75.19 91.28 2.61 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.337 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -121.03 -170.24 13.99 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 18.9 m -106.93 134.98 49.28 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.057 0.456 . . . . 0.0 110.408 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 32.6 t -69.59 121.49 19.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.15 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t -95.66 -60.14 1.72 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.398 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -150.32 146.52 26.8 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.465 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 32.8 mt -102.46 124.05 56.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.922 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 8.4 mp -97.61 27.88 4.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.991 -179.561 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 26.3 m -153.9 154.85 6.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 121.178 0.514 . . . . 0.0 110.486 179.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -141.6 158.2 44.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.122 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -60.52 92.5 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.45 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.19 -27.06 2.55 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -78.42 144.62 35.7 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.077 0.465 . . . . 0.0 110.489 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -95.54 135.45 37.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.355 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 26.6 m -115.4 160.28 14.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.573 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 23.8 mttm -118.52 142.91 47.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.286 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -57.76 95.7 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.761 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.19 -31.88 2.64 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.8 tt0 -68.01 151.17 47.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.137 0.494 . . . . 0.0 110.399 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.5 m -69.76 136.65 51.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.401 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.1 m -113.6 -32.11 2.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.901 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 8.3 tt -160.75 146.76 14.9 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.111 0.482 . . . . 0.0 110.705 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -101.85 137.1 30.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.094 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 12.8 mt -120.4 165.73 14.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.496 -179.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.3 mt-10 . . . . . 0 C--N 1.331 -0.212 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.327 179.955 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.061 0.458 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.8 m -113.07 120.21 40.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.333 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 -84.65 135.84 34.0 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.492 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.468 HD12 HG21 ' A' ' 94' ' ' ILE . 37.8 mm -104.85 126.85 59.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.296 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -108.73 141.23 41.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.427 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.32 143.17 95.79 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.324 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -73.08 -37.99 3.11 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.121 1.88 . . . . 0.0 112.273 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.2 p -145.01 155.71 43.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.302 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -65.64 141.45 58.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.375 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 178.15 -155.31 16.68 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -134.83 143.44 47.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.023 0.44 . . . . 0.0 110.38 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 26.0 t -79.04 114.13 19.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.139 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -95.44 -30.37 13.92 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.606 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.3 ttpt -158.0 131.89 7.94 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.464 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 26.8 t -108.72 102.22 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.267 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.1 mt -74.32 -33.61 63.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.446 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 29.9 m -73.52 150.68 7.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.346 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -140.88 157.29 45.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.473 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 61.7 mt-10 -61.17 145.62 50.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.51 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.14 37.54 17.55 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.33 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -127.28 145.0 50.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.454 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.9 137.46 32.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.493 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.1 m -121.32 156.12 25.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.376 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 13.6 mt-30 -101.6 144.57 30.17 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.376 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.31 107.18 1.36 Allowed Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.84 -27.64 8.17 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -59.75 141.72 54.67 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.054 0.454 . . . . 0.0 110.645 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.35 127.11 41.55 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 91.7 mt -91.17 -56.29 3.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.086 0.469 . . . . 0.0 110.459 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 53.5 mt -141.12 151.28 19.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.342 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.0 tttt -97.36 126.63 42.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.42 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.5 mm -105.24 145.64 13.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.397 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.82 0 CA-C-O 118.002 -1.443 . . . . 0.0 110.813 179.968 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 . . . . . 0 C--O 1.232 0.169 0 CA-C-O 121.096 0.474 . . . . 0.0 110.506 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.6 mt -79.01 116.69 61.95 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.159 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -71.6 137.62 30.62 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 121.991 1.794 . . . . 0.0 112.279 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -71.0 148.17 94.3 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.404 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -72.58 -28.75 13.96 Favored 'Trans proline' 0 CA--C 1.528 0.194 0 C-N-CA 122.238 1.959 . . . . 0.0 112.216 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.5 pp -162.34 173.51 14.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.511 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -86.67 95.8 9.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.384 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.22 -145.39 6.52 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 13.8 m -136.33 139.72 42.79 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.128 0.49 . . . . 0.0 110.512 -179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.66 121.96 19.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.097 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 92.7 p -99.45 -53.15 3.29 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.627 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.3 tptt -152.33 144.77 24.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.558 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 21.8 mt -103.14 133.19 47.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.989 179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.3 mt -99.77 -29.57 12.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.952 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 32.6 m -110.98 147.87 14.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.249 0.547 . . . . 0.0 110.765 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.8 pttt -136.18 166.01 24.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.244 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 14.8 mt-10 -61.79 100.03 0.14 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.495 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.06 -31.98 2.23 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -85.42 147.15 26.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.068 0.461 . . . . 0.0 110.461 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.1 m -98.29 146.8 25.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.348 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 24.9 m -126.75 165.52 25.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.614 -179.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 22.2 pttt -127.2 150.51 49.49 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.285 179.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -58.62 98.23 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.748 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.31 -37.91 1.83 Allowed Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 21.1 tt0 -65.18 143.82 57.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.072 0.463 . . . . 0.0 110.639 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.1 m -67.37 138.93 57.11 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.204 179.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 34.8 m -113.75 -34.38 2.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.84 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.9 tt -160.45 147.34 15.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.788 -179.415 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -104.97 139.43 25.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.001 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 2.4 mt -120.02 165.36 14.8 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.19 0.519 . . . . 0.0 110.691 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 . . . . . 0 C--N 1.331 -0.22 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.532 -179.833 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 121.14 0.495 . . . . 0.0 110.412 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.2 m -119.85 114.52 22.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.437 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -82.4 143.5 31.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.579 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.479 HG21 HD12 ' A' ' 94' ' ' ILE . 39.7 mm -105.14 127.62 59.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.162 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -105.42 142.16 35.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.341 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.86 132.2 91.76 Favored Pre-proline 0 CA--C 1.534 0.33 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.371 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -72.79 -32.19 9.5 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 121.99 1.793 . . . . 0.0 112.243 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 4.6 p -146.68 156.91 43.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.419 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -68.32 142.73 55.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.44 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 172.19 -156.77 26.1 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -135.43 146.46 48.26 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.057 0.456 . . . . 0.0 110.415 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 23.0 t -74.86 107.75 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.271 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -90.59 -30.98 16.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.563 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.5 tptm -156.11 130.57 8.87 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.586 -179.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 25.4 t -98.92 106.1 18.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.347 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.2 mt -89.59 12.06 17.82 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.511 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 28.3 m -127.33 136.16 61.38 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.095 0 CA-C-O 121.121 0.486 . . . . 0.0 110.122 179.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 40.1 tttt -128.5 156.21 43.62 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.373 -179.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -60.7 150.22 32.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.487 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 61.45 31.79 19.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.443 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -124.36 142.78 51.01 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.264 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.5 136.84 32.83 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.609 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.69 157.16 23.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.306 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 -100.14 142.19 31.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.504 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.07 107.64 1.41 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.61 -28.32 8.65 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.4 tt0 -57.62 147.14 28.19 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.087 0.47 . . . . 0.0 110.76 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -63.33 121.85 25.38 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.941 -0.863 . . . . 0.0 110.941 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 56.5 mt -87.25 -52.56 5.33 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.056 0.455 . . . . 0.0 110.501 179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 48.9 mt -142.31 148.3 20.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.35 179.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -95.75 128.04 42.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.345 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.4 mm -107.68 145.34 15.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.484 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.798 0 CA-C-O 117.984 -1.454 . . . . 0.0 110.824 179.999 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 . . . . . 0 C--O 1.23 0.071 0 CA-C-O 121.066 0.46 . . . . 0.0 110.357 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.0 mt -79.39 111.45 20.8 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.144 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.33 141.98 40.18 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.016 1.811 . . . . 0.0 112.288 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -76.75 144.49 73.15 Favored Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.275 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.73 -22.35 20.6 Favored 'Trans proline' 0 CA--C 1.529 0.241 0 C-N-CA 122.181 1.921 . . . . 0.0 112.702 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.5 pp -161.7 167.38 25.19 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.128 0.489 . . . . 0.0 110.457 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -86.37 119.67 26.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.455 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -152.04 -141.4 3.31 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 6.6 m -137.56 143.42 41.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.139 0.495 . . . . 0.0 110.439 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 37.3 t -68.17 128.63 31.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.172 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.6 m -98.18 -59.75 1.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.683 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 12.6 mtpt -149.49 147.18 27.9 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.541 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . 0.413 HD13 HG22 ' A' ' 68' ' ' ILE . 51.8 mt -102.87 123.25 56.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.075 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.6 mp -94.09 -46.04 7.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.657 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 33.4 m -95.23 143.9 10.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.694 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 3.5 pttt -133.36 165.33 25.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.182 179.76 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -59.31 102.03 0.12 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.666 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 137.91 -31.89 2.42 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -84.9 149.99 25.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.09 0.471 . . . . 0.0 110.501 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 9.3 m -96.64 142.98 28.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.352 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 31.5 m -120.7 154.22 24.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.548 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 13.0 tptt -116.57 151.22 36.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.192 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.08 96.69 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.647 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.62 -30.81 3.35 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -64.79 139.52 58.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.082 0.468 . . . . 0.0 110.602 -179.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.0 m -65.57 136.16 56.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.187 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.0 m -115.09 -29.57 2.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.294 -179.533 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tt -165.29 152.22 10.47 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.133 0.492 . . . . 0.0 110.778 -179.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -107.66 139.81 28.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.153 179.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.8 mt -120.58 160.78 22.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.497 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.232 179.916 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 . . . . . 0 C--O 1.232 0.148 0 CA-C-O 121.053 0.454 . . . . 0.0 110.372 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.1 m -119.76 126.18 50.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.367 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -82.7 129.9 35.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.361 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 23.6 mm -106.39 118.2 53.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.188 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 22.9 p30 -110.65 152.18 26.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.333 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.23 142.19 95.91 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.359 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -73.54 -32.97 7.26 Favored 'Trans proline' 0 N--CA 1.471 0.173 0 C-N-CA 122.171 1.914 . . . . 0.0 112.232 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -148.64 161.08 42.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.385 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -64.24 142.79 58.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.407 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.21 -153.02 19.63 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 26.3 ttmt -139.84 147.07 40.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.103 0.478 . . . . 0.0 110.428 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.9 t -74.74 107.91 5.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.315 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -91.85 -27.74 17.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.865 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -161.4 136.1 7.24 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.07 0.462 . . . . 0.0 110.481 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.8 t -103.05 108.61 24.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.269 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.6 mt -90.5 31.1 1.06 Allowed 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.605 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 25.8 m -155.54 144.54 12.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 121.032 0.444 . . . . 0.0 110.342 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.4 mptt -130.52 165.85 21.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.277 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -60.99 145.41 50.74 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.472 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 14.2 mmt85 60.64 37.12 19.43 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.507 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -117.93 144.7 45.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.351 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.01 129.24 38.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.457 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.8 m -122.09 150.38 25.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.475 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 -99.44 148.4 24.26 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.432 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -63.59 103.26 0.65 Allowed Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.48 -28.66 5.69 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -59.51 137.89 57.87 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.109 0.481 . . . . 0.0 110.665 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.23 119.73 19.8 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 44.8 mt -87.2 -54.74 4.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.133 0.492 . . . . 0.0 110.484 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.1 mt -140.99 143.76 27.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.226 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 7.2 tttt -95.16 129.99 42.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.517 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.443 HD12 HG21 ' A' ' 122' ' ' ILE . 37.2 mm -104.62 145.57 13.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.32 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.731 0 CA-C-O 118.011 -1.438 . . . . 0.0 110.768 179.97 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 66.2 mt-10 . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.915 0.388 . . . . 0.0 110.146 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.401 ' CD1' ' HD2' ' A' ' 97' ' ' PRO . 41.5 mm -83.16 110.49 24.02 Favored Pre-proline 0 CA--C 1.534 0.338 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.068 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -71.57 131.02 18.0 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 121.972 1.782 . . . . 0.0 112.101 -179.741 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.61 145.9 81.75 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.64 -179.867 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -75.62 -29.75 6.98 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.292 1.995 . . . . 0.0 112.5 -179.86 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.4 pp -157.5 164.43 37.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.552 -179.681 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.9 108.02 13.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.437 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -134.65 -146.63 5.43 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.8 m -136.33 138.18 41.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.095 0.474 . . . . 0.0 110.401 -179.991 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 29.2 t -70.42 118.57 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.039 179.867 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.7 p -96.25 -53.67 3.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.845 -179.749 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 37.9 mttt -148.64 145.28 27.68 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 121.108 0.48 . . . . 0.0 110.703 -179.607 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 38.9 mt -101.78 128.81 53.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.986 179.507 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 15.4 mt -97.64 -49.04 5.0 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.819 -179.592 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.6 m -93.73 146.04 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.217 0.532 . . . . 0.0 110.797 -179.831 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.8 pttp -135.31 162.72 31.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.034 179.789 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -59.26 103.19 0.16 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.54 -179.971 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.4 2.27 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.881 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -89.79 149.61 22.63 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.135 0.493 . . . . 0.0 110.445 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.4 m -97.22 141.51 30.25 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.444 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 27.1 m -117.43 156.33 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.464 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -117.53 157.03 27.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.438 179.864 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.81 96.48 0.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.557 -179.888 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.52 -28.24 4.52 Favored Glycine 0 CA--C 1.527 0.829 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.806 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -63.3 142.91 58.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.113 0.482 . . . . 0.0 110.684 -179.746 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.9 m -67.65 139.48 56.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.227 179.747 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 30.8 m -119.37 -32.62 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.399 -179.415 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.1 tt -163.09 152.09 14.71 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.228 0.537 . . . . 0.0 111.049 -179.297 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -106.1 139.81 26.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.857 179.574 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 12.5 mt -122.09 168.01 12.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.153 0.502 . . . . 0.0 110.759 -179.719 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 72.2 mt-10 . . . . . 0 C--N 1.331 -0.23 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.364 179.974 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 . . . . . 0 N--CA 1.461 0.103 0 CA-C-O 121.105 0.478 . . . . 0.0 110.501 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 7.0 m -113.53 115.21 27.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.241 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -80.98 128.66 33.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.525 -179.793 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.408 HD13 HG23 ' A' ' 94' ' ' ILE . 35.4 mm -101.54 144.08 13.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.06 179.707 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -138.14 134.82 35.06 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.731 -179.686 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.89 109.6 2.41 Favored Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.225 179.641 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.401 ' HD2' ' CD1' ' A' ' 57' ' ' ILE . 41.8 Cg_endo -65.0 -12.49 34.86 Favored 'Trans proline' 0 N--CA 1.475 0.425 0 C-N-CA 122.275 1.983 . . . . 0.0 113.147 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.91 134.83 39.12 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 121.014 0.435 . . . . 0.0 110.54 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -62.57 159.15 16.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.459 -179.911 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 154.29 -156.2 26.69 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.962 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 16.9 ttpt -133.02 146.78 52.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.125 0.488 . . . . 0.0 110.334 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.4 t -78.53 109.23 12.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.25 -179.966 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -94.64 -30.53 14.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.59 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -157.1 130.92 8.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.449 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.2 t -97.92 112.64 30.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.259 -179.974 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.6 mt -90.12 28.48 1.4 Allowed 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.737 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 23.2 m -155.39 137.33 6.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.118 0.485 . . . . 0.0 110.336 -179.944 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 13.8 pttm -127.5 167.01 16.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.346 179.954 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -60.09 145.76 45.49 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.77 179.993 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.05 37.41 17.94 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.354 179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -123.36 138.62 54.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.442 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.34 131.35 36.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.493 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.0 m -120.95 154.55 24.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.419 179.97 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 19.9 mp0 -96.65 141.93 29.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.325 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.77 90.38 0.06 OUTLIER Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.848 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.3 -30.35 2.81 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -58.63 154.58 14.11 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.115 0.483 . . . . 0.0 110.681 -179.997 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.64 125.76 37.79 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 -179.681 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 58.4 mt -94.77 -59.41 1.93 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.151 0.5 . . . . 0.0 110.225 179.744 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.9 mt -141.33 141.95 29.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.181 179.884 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.3 tttt -88.5 127.06 35.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.433 179.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.441 HG21 HD11 ' A' ' 122' ' ' ILE . 37.5 mm -106.82 141.27 22.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.364 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.03 -1.428 . . . . 0.0 110.796 179.959 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.161 0.505 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.417 HG23 HD12 ' A' ' 57' ' ' ILE . 53.8 mt -79.01 111.71 22.05 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.154 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -71.09 149.09 57.85 Favored 'Trans proline' 0 N--CA 1.472 0.247 0 C-N-CA 122.074 1.849 . . . . 0.0 112.299 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -84.24 150.76 58.48 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.447 -179.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -72.83 -28.5 13.46 Favored 'Trans proline' 0 CA--C 1.527 0.164 0 C-N-CA 122.251 1.968 . . . . 0.0 112.311 179.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.8 pp -164.84 161.99 20.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.43 179.968 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.67 104.72 2.06 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.386 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.87 178.56 18.05 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.972 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.7 m -104.07 134.86 46.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.084 0.469 . . . . 0.0 110.368 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.2 t -72.04 118.66 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.102 179.878 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -100.02 -50.19 4.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.629 -179.72 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.95 140.53 21.61 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.769 -179.653 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 36.1 mt -105.41 126.15 60.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.836 179.579 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.34 28.65 3.99 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.978 -179.564 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 13.6 m -151.07 153.18 10.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.338 0.59 . . . . 0.0 110.897 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -137.26 154.82 50.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.918 179.502 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -58.18 91.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.165 0.507 . . . . 0.0 110.681 -179.881 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.88 -29.1 2.47 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -179.919 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -65.06 148.27 51.96 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.055 0.455 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.2 m -97.67 132.28 43.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.237 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.1 m -121.54 163.77 19.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.633 -179.821 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -129.63 154.18 47.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.593 -0.731 . . . . 0.0 110.184 179.74 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.01 91.21 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.482 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.07 -34.98 1.95 Allowed Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -62.56 140.03 58.63 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.028 0.442 . . . . 0.0 110.45 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.9 m -66.92 136.84 55.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.124 179.815 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.8 m -116.97 -29.76 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.493 -179.382 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 10.2 tt -161.04 159.13 28.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.303 0.573 . . . . 0.0 111.016 -179.439 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -125.7 131.69 71.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.809 179.513 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 19.8 mt -116.09 168.95 9.64 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.202 0.525 . . . . 0.0 110.747 -179.554 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.156 179.687 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 121.111 0.482 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 8.7 m -114.46 116.96 29.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.202 179.906 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -84.38 131.7 34.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.438 -179.951 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 37.7 mm -106.4 155.95 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.293 179.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 10.6 m120 -142.28 145.42 34.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.455 -179.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.64 142.38 94.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.418 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -74.59 -36.24 3.05 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.157 1.905 . . . . 0.0 112.375 -179.929 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -146.55 170.45 16.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.413 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -69.31 142.2 54.11 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.6 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 160.29 -166.7 35.34 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 -179.989 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 13.9 ptpt -129.17 168.8 15.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.355 0.598 . . . . 0.0 110.657 179.798 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.6 t -82.48 113.89 22.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.547 -179.72 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -94.61 -33.08 13.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.455 179.894 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.1 ttpp -160.63 123.75 3.37 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.606 179.871 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 23.1 t -102.1 109.99 27.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.325 179.799 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.4 mt -82.21 -30.43 30.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.452 179.763 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.6 m -82.04 143.25 12.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.796 -179.824 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 20.2 mmtt -131.32 158.79 39.72 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.107 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -61.99 147.33 47.41 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.496 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 8.1 mmm180 64.16 34.43 11.03 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.759 179.85 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -131.98 140.81 49.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.413 179.676 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.8 140.75 29.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.554 -179.904 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.0 m -121.69 163.52 19.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.374 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 12.4 mm100 -98.35 142.63 29.75 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.299 179.966 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.96 106.28 1.06 Allowed Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.749 -0.941 . . . . 0.0 110.749 -179.972 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.63 -25.57 10.19 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -179.833 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 -59.73 143.05 51.9 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 121.102 0.477 . . . . 0.0 110.651 -179.822 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.34 124.84 36.03 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 179.954 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 49.2 mt -89.76 -54.9 3.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.092 0.472 . . . . 0.0 110.452 -179.979 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.464 HG21 HD12 ' A' ' 120' ' ' ILE . 47.3 mt -145.86 147.8 18.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.121 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 14.7 ttmt -95.89 136.44 36.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.153 179.774 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.8 mm -110.0 143.16 20.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.433 -179.899 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.745 0 CA-C-O 117.987 -1.452 . . . . 0.0 110.766 -179.997 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 17.0 mt-10 . . . . . 0 N--CA 1.461 0.099 0 CA-C-O 121.11 0.481 . . . . 0.0 110.465 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.418 HD11 HG23 ' A' ' 57' ' ' ILE . 55.8 mt -79.98 111.61 23.19 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.309 -179.997 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.81 131.67 18.79 Favored 'Trans proline' 0 N--CA 1.472 0.217 0 C-N-CA 122.035 1.823 . . . . 0.0 112.287 179.931 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.46 147.57 98.78 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.396 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -72.29 -27.9 15.86 Favored 'Trans proline' 0 CA--C 1.528 0.205 0 C-N-CA 122.188 1.926 . . . . 0.0 112.325 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -163.92 159.65 21.14 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.464 179.983 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.72 101.57 4.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.373 -179.995 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.11 -141.26 5.07 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.94 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.0 m -137.81 135.86 36.66 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.169 0.509 . . . . 0.0 110.45 -179.859 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.7 t -69.64 120.06 16.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.225 179.956 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 79.2 p -97.02 -53.45 3.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.749 -179.829 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 45.6 tttt -152.06 148.37 27.6 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.603 -179.813 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 48.9 mt -104.15 134.39 45.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.061 179.756 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.3 mt -99.22 -31.46 11.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.758 -179.694 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 34.5 m -113.18 145.07 19.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.229 0.538 . . . . 0.0 110.589 -179.871 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.78 163.89 30.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.211 179.771 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -58.36 102.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.582 -179.864 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.25 -28.29 2.48 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.824 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -95.69 151.81 19.02 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.1 0.476 . . . . 0.0 110.421 -179.97 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -98.46 147.58 24.59 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.392 179.894 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 24.9 m -121.83 169.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.498 -179.94 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.2 mmtp -130.23 155.25 46.59 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.36 -179.969 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.74 103.51 0.35 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.474 -179.979 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.4 -30.79 5.66 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 179.94 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.8 tt0 -61.29 143.2 56.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.621 -179.853 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.5 m -67.76 138.51 56.26 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.266 179.831 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 28.1 m -118.68 -33.6 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.265 -179.443 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.4 tt -161.05 152.87 19.61 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.21 0.529 . . . . 0.0 111.017 -179.303 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.2 t -106.45 143.34 17.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.999 179.665 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 14.9 mt -120.55 163.16 18.4 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.51 -179.904 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 . . . . . 0 C--O 1.233 0.197 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.458 -179.944 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 . . . . . 0 C--O 1.23 0.068 0 CA-C-O 121.175 0.512 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 4.1 m -115.87 119.5 36.18 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.277 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 26.3 mt-10 -82.39 131.09 35.23 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.628 -179.82 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 26.9 mm -105.58 148.54 9.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.093 179.815 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -137.23 151.06 48.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.565 -179.911 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.68 144.88 98.83 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.279 179.976 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -73.94 -34.63 5.01 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.153 1.902 . . . . 0.0 112.252 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 32.9 p -145.65 167.46 23.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.37 179.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -68.77 142.97 54.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.396 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 170.15 -160.15 32.92 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -133.23 149.24 52.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.145 0.497 . . . . 0.0 110.409 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 22.0 t -75.1 106.86 5.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.316 179.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -92.95 -29.98 15.6 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.725 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.9 tttt -158.02 127.93 6.04 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.466 179.998 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.4 t -100.52 110.8 28.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.322 179.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.5 mt -90.09 29.38 1.23 Allowed 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.676 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 24.4 m -155.44 142.12 11.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.062 0.458 . . . . 0.0 110.353 179.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 16.8 mmtt -125.86 175.37 7.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.392 179.979 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -73.06 148.34 44.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.395 179.937 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.4 34.2 18.39 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.584 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -123.09 149.91 43.86 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.329 179.838 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.17 135.22 33.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.541 -179.952 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.7 m -121.17 151.64 24.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.279 179.919 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -98.56 140.46 32.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.328 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.19 108.45 1.63 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 109.53 -26.55 14.31 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -179.782 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -57.63 145.24 34.69 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 121.134 0.492 . . . . 0.0 110.862 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.18 118.21 13.79 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.848 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 94.5 mt -88.33 -54.75 4.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.169 0.509 . . . . 0.0 110.177 179.799 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 44.8 mt -143.18 149.19 18.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.145 179.819 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 42.7 tttt -97.34 130.01 44.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.319 179.885 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.9 mm -107.71 144.44 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.425 -179.843 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.764 0 CA-C-O 118.025 -1.431 . . . . 0.0 110.747 179.955 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.957 0.408 . . . . 0.0 110.421 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.446 HG22 HD12 ' A' ' 57' ' ' ILE . 54.3 mt -80.42 111.1 19.81 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.167 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -72.31 135.08 23.98 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.024 1.816 . . . . 0.0 112.351 -179.893 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -70.27 148.89 95.88 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.427 179.977 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -72.31 -28.44 15.19 Favored 'Trans proline' 0 N--CA 1.472 0.207 0 C-N-CA 122.228 1.952 . . . . 0.0 112.303 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.2 pp -164.26 162.71 22.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.389 179.952 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.29 117.84 16.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.443 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -145.83 -146.87 4.49 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 25.9 m -137.18 132.6 34.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.172 0.51 . . . . 0.0 110.376 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.4 t -70.23 132.31 33.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.301 179.907 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.0 t -101.52 -57.61 2.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.586 -179.958 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 32.2 ttpt -150.2 146.58 26.93 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.492 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 21.6 mt -98.92 133.95 39.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.149 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.6 mp -98.23 -31.57 12.01 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.617 -179.828 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 34.0 m -113.72 145.92 18.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.207 0.527 . . . . 0.0 110.761 -179.841 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.4 ptpp? -133.67 167.13 21.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.042 179.605 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -57.58 113.14 1.67 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.623 -179.972 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.39 21.06 5.29 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.588 -179.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -135.01 141.1 46.12 Favored 'General case' 0 C--O 1.231 0.081 0 CA-C-O 121.094 0.474 . . . . 0.0 110.138 179.601 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -95.29 132.02 40.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.611 -179.711 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 19.9 m -114.5 168.08 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.312 179.922 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 7.8 mmmt -121.65 139.91 52.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.258 179.829 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -56.27 97.95 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.972 -179.81 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.96 -37.39 1.9 Allowed Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.9 tt0 -66.07 149.12 50.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.033 0.444 . . . . 0.0 110.526 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -67.13 136.51 55.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.295 179.971 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 25.6 m -114.77 -31.5 2.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.124 -179.739 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.7 tt -160.67 151.83 19.01 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -179.674 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.0 t -102.87 128.26 55.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.055 179.871 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -111.76 159.41 18.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.643 -179.771 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.301 179.867 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 . . . . . 0 C--O 1.231 0.081 0 CA-C-O 121.064 0.459 . . . . 0.0 110.474 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 20.2 m -120.29 139.55 52.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.343 179.894 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -85.92 135.09 33.81 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.481 -179.862 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.1 mm -107.82 119.24 57.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.237 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 14.0 p-10 -104.2 142.36 34.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.457 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.82 141.62 92.79 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.492 -179.963 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -73.55 -36.45 3.86 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.198 1.932 . . . . 0.0 112.172 179.932 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 69.4 p -147.24 153.92 40.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.345 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -65.38 141.89 58.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.415 179.863 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.67 -155.34 19.6 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.967 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.7 ttpt -133.48 143.81 49.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.174 0.511 . . . . 0.0 110.593 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 22.0 t -75.97 111.23 12.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.079 179.828 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -95.69 -32.49 12.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.82 -179.662 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -161.03 129.84 4.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.117 0.484 . . . . 0.0 110.285 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.8 t -103.85 112.64 38.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.263 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.3 mt -79.81 -31.62 40.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.562 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.0 m -83.76 146.92 6.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.615 -179.801 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 18.9 mttm -129.36 172.15 11.79 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.252 179.943 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.41 139.27 54.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.247 -179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 60.78 40.85 15.54 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.57 179.965 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -121.94 145.83 47.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.404 179.846 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.86 131.12 37.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.381 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.3 m -120.3 153.26 23.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.37 179.924 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -98.86 145.84 26.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.36 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.9 110.24 2.91 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.998 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.55 -28.73 8.36 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.906 -0.877 . . . . 0.0 110.906 -179.83 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -58.02 141.01 51.19 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 121.128 0.49 . . . . 0.0 110.815 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.3 125.85 36.77 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.87 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 89.9 mt -88.96 -57.23 2.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.009 0.433 . . . . 0.0 110.4 -179.994 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 53.2 mt -141.29 151.3 19.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.431 179.926 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.7 mttt -94.02 121.68 35.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.132 179.813 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.3 mm -104.01 142.55 17.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.486 -179.845 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.771 0 CA-C-O 117.97 -1.461 . . . . 0.0 110.777 -179.981 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 . . . . . 0 N--CA 1.461 0.096 0 CA-C-O 121.088 0.47 . . . . 0.0 110.473 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.3 mt -79.15 118.5 72.84 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.213 -179.942 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -71.81 138.03 30.83 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 122.057 1.838 . . . . 0.0 112.343 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -71.66 147.76 92.28 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.405 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.29 -26.47 17.48 Favored 'Trans proline' 0 CA--C 1.528 0.207 0 C-N-CA 122.232 1.954 . . . . 0.0 112.451 179.913 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.9 pp -163.07 175.27 11.25 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.485 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -89.79 93.01 9.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.428 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.66 -145.41 6.61 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.5 m -137.03 140.71 42.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.122 0.487 . . . . 0.0 110.415 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.8 t -70.79 127.98 33.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.156 179.949 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 7.9 p -99.55 -54.5 2.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.623 -179.84 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.6 tttt -151.05 147.98 27.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.564 -179.804 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 38.1 mt -102.4 133.15 46.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.151 179.792 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.402 ' CD1' ' CG2' ' A' ' 81' ' ' THR . 50.3 mt -99.16 -47.73 5.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.686 -179.809 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.3 m -99.98 146.91 8.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.552 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -137.15 164.21 29.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.119 179.749 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -58.5 106.01 0.35 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.61 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.99 2.22 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -96.63 151.08 19.95 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.129 0.49 . . . . 0.0 110.361 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.1 m -96.44 151.65 19.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.46 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 26.7 m -125.75 168.22 18.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.49 -179.951 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.1 ttpt -129.57 153.84 47.66 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.322 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.76 100.8 0.16 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.503 -179.917 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.19 -32.89 3.47 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.87 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.4 tt0 -63.99 143.12 58.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.038 0.447 . . . . 0.0 110.513 -179.84 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.402 ' CG2' ' CD1' ' A' ' 69' ' ' LEU . 2.2 m -67.51 137.57 55.88 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.196 179.838 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.0 m -117.13 -34.02 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.124 -179.497 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.6 tt -161.72 153.62 19.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.227 0.537 . . . . 0.0 110.952 -179.453 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -108.55 143.09 19.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.932 179.52 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.4 tp -122.49 170.63 9.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.675 -179.693 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.466 179.997 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 . . . . . 0 N--CA 1.46 0.061 0 CA-C-O 121.115 0.483 . . . . 0.0 110.539 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -114.72 111.25 20.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.201 179.956 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -81.72 127.94 33.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.586 -179.829 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 34.4 mm -103.97 144.63 13.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.128 179.689 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -135.29 148.87 49.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.426 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.79 138.39 97.37 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.273 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -74.38 -31.2 7.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.052 1.835 . . . . 0.0 112.258 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 15.9 p -145.74 163.9 33.5 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.435 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -68.11 142.7 55.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.363 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.76 -161.41 33.54 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.7 ttpt -132.27 147.25 52.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.412 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.7 t -75.2 106.68 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.198 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -92.12 -29.13 16.68 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.776 -179.846 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 5.6 tttt -160.07 131.02 5.72 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.112 0.482 . . . . 0.0 110.508 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.3 t -100.8 109.01 24.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.198 179.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 23.5 mt -90.13 31.02 1.02 Allowed 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.65 -179.99 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 24.6 m -155.58 137.11 5.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-O 121.061 0.458 . . . . 0.0 110.174 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 34.1 mtmt -123.63 177.56 5.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.379 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -68.93 144.64 54.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.491 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 34.1 mtt180 60.12 33.25 21.17 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.619 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -111.49 142.86 43.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.36 -179.978 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.75 134.28 34.54 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.5 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.3 m -120.77 -179.92 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.398 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -140.84 147.94 39.77 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.397 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.02 106.43 1.11 Allowed Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 179.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 119.82 -31.79 5.22 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 -179.938 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -60.61 134.49 57.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.064 0.459 . . . . 0.0 110.571 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.14 123.06 31.47 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.781 -0.927 . . . . 0.0 110.781 179.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 62.7 mt -88.67 -54.88 3.95 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.068 0.461 . . . . 0.0 110.467 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 52.9 mt -140.93 148.91 21.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.368 179.992 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.8 mttt -95.35 127.15 41.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.335 179.885 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.3 mm -108.02 143.52 18.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.359 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.698 0 CA-C-O 117.982 -1.454 . . . . 0.0 110.761 -179.984 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 . . . . . 0 N--CA 1.461 0.105 0 CA-C-O 121.085 0.469 . . . . 0.0 110.427 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 42.7 mt -80.8 111.13 20.71 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.284 179.885 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -71.02 137.27 31.46 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.079 1.852 . . . . 0.0 112.33 -179.854 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.32 151.01 97.57 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.458 179.994 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -72.7 -27.5 15.0 Favored 'Trans proline' 0 CA--C 1.529 0.23 0 C-N-CA 122.212 1.941 . . . . 0.0 112.35 -179.974 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -164.23 172.47 13.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.368 179.97 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.8 92.3 7.22 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.31 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -123.81 -146.16 6.94 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.931 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.3 m -135.79 137.57 41.73 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.102 0.477 . . . . 0.0 110.362 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.1 t -68.22 128.27 31.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.319 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -97.72 -61.55 1.37 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.428 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -149.71 145.87 26.92 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.403 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 49.5 mt -97.76 129.42 47.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.079 179.789 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 22.3 mt -97.41 -43.54 7.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.818 -179.703 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.405 ' CG1' ' CG1' ' A' ' 76' ' ' VAL . 31.4 m -104.2 145.83 12.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.216 0.531 . . . . 0.0 110.781 -179.691 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.1 pttt -137.24 161.93 34.89 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.945 179.718 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -57.16 107.88 0.47 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.766 -179.926 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -31.02 2.31 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -179.686 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -98.83 152.71 19.43 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.972 0.415 . . . . 0.0 110.36 179.86 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.61 151.07 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.45 179.995 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.405 ' CG1' ' CG1' ' A' ' 70' ' ' VAL . 23.5 m -127.81 169.97 18.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.41 -179.929 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 17.4 mmmt -132.49 153.75 50.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.409 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.79 104.47 0.36 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.577 -179.845 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 126.35 -34.69 3.14 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.857 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 -64.43 140.43 58.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.116 0.484 . . . . 0.0 110.513 -179.908 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 11.1 m -67.42 136.55 54.88 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.333 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 30.0 m -112.82 -29.23 2.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.042 -179.737 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.7 tt -163.99 147.53 9.8 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 121.12 0.486 . . . . 0.0 110.86 -179.516 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -98.86 134.15 38.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.961 179.593 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -116.04 167.71 10.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.542 -179.729 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 . . . . . 0 C--N 1.331 -0.239 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.493 179.962 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 121.136 0.493 . . . . 0.0 110.314 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 11.8 m -116.04 128.14 55.47 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.493 -179.931 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -85.51 133.31 34.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.445 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.2 mm -102.38 118.3 49.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.223 179.869 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -104.24 143.93 32.29 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.315 -179.887 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.21 140.31 91.23 Favored Pre-proline 0 CA--C 1.533 0.32 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.556 -179.983 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -73.25 -33.33 7.33 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.186 1.924 . . . . 0.0 112.338 -179.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 81.1 p -147.84 163.44 36.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.354 179.976 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -67.98 142.91 55.82 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.531 179.92 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.51 -159.97 31.8 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.995 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 13.3 ttmt -136.55 141.61 43.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.105 0.479 . . . . 0.0 110.517 -179.911 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 22.0 t -72.03 125.9 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.262 179.856 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -102.63 -31.23 10.48 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.783 -179.915 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 2.2 ttmt -164.4 139.08 5.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.674 -179.772 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.0 t -106.67 109.01 26.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.128 179.807 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.4 mt -80.01 -31.81 39.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.302 179.898 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 29.0 m -79.85 147.7 6.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.49 -179.965 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 24.3 mttp -127.83 164.1 22.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.149 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -65.95 142.38 57.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.397 179.997 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 63.54 37.77 10.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.619 179.885 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -121.64 152.16 39.63 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.389 179.681 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.97 134.52 34.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.476 -179.909 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.7 m -120.42 150.24 23.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.456 179.943 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 21.8 mt-30 -101.17 139.44 36.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.336 179.919 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.38 92.11 0.05 OUTLIER Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 132.81 -28.47 3.37 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.867 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -60.0 144.9 48.13 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 121.108 0.48 . . . . 0.0 110.645 -179.95 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.87 122.88 28.97 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.885 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 88.6 mt -88.18 -59.44 2.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.061 0.458 . . . . 0.0 110.385 179.853 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 49.7 mt -141.77 149.21 20.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.358 179.803 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -94.04 131.41 39.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.332 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 35.7 mm -107.7 146.02 14.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.397 -179.9 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.718 0 CA-C-O 118.002 -1.443 . . . . 0.0 110.746 179.903 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 . . . . . 0 N--CA 1.462 0.159 0 CA-C-O 121.215 0.531 . . . . 0.0 110.677 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.9 mt -80.45 125.92 79.85 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.341 -179.835 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -74.85 156.65 43.65 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 121.885 1.723 . . . . 0.0 112.247 179.737 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -84.89 143.36 40.15 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.305 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -73.89 -27.93 11.79 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.225 1.95 . . . . 0.0 112.484 -179.97 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -163.65 172.49 14.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.51 -179.908 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.3 98.64 11.7 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.506 179.925 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.68 -144.31 5.62 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 8.9 m -137.71 135.9 36.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.149 0.499 . . . . 0.0 110.458 179.926 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.9 t -71.1 125.89 30.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.24 179.86 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.5 p -98.99 -57.54 2.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.74 -179.707 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 5.6 ptpt -149.52 146.37 27.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.679 -179.728 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 30.8 mt -101.62 136.83 31.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.16 179.74 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 46.3 mt -100.0 -40.21 7.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.576 -179.847 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.0 m -100.73 138.15 25.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.148 0.499 . . . . 0.0 110.581 -179.873 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 10.2 pttp -122.7 163.26 20.45 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.044 179.825 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -60.47 104.02 0.3 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.569 -179.895 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 137.56 -31.82 2.46 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -83.17 154.99 23.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.052 0.453 . . . . 0.0 110.557 179.969 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.5 m -98.47 144.78 27.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.322 179.952 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 31.1 m -120.78 158.12 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.511 -179.914 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 41.6 mttt -122.7 151.12 41.87 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.261 179.832 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.29 90.99 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.694 -179.919 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.53 -30.36 3.01 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.921 -0.871 . . . . 0.0 110.921 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -61.85 142.8 57.14 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.158 0.504 . . . . 0.0 110.571 -179.855 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.1 m -67.22 140.53 57.42 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.123 179.779 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 32.4 m -121.76 -32.49 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.631 -179.459 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 8.0 tt -161.23 152.84 19.21 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 120.169 -0.612 . . . . 0.0 111.557 -179.244 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.6 t -103.96 137.64 31.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.638 179.405 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.1 tp -121.0 165.7 14.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.176 0.512 . . . . 0.0 110.656 -179.776 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.463 -179.949 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 121.082 0.468 . . . . 0.0 110.288 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.2 m -121.71 129.54 52.8 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.368 -179.987 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -84.29 138.04 33.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.564 -179.902 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.442 HG21 HD11 ' A' ' 94' ' ' ILE . 38.2 mm -103.21 150.48 6.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.077 179.853 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -138.05 142.15 40.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.507 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.11 139.79 96.02 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.293 -179.98 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.1 -30.35 10.8 Favored 'Trans proline' 0 N--CA 1.472 0.223 0 C-N-CA 122.061 1.841 . . . . 0.0 112.081 179.894 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.0 p -147.01 162.79 38.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.198 179.879 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 11.6 p30 -67.54 147.71 52.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.204 0.526 . . . . 0.0 110.315 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 169.92 -160.04 32.87 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -179.832 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -135.58 142.89 45.38 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.068 0.461 . . . . 0.0 110.455 -179.915 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 23.6 t -75.59 111.48 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.905 179.699 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -97.36 -31.21 12.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.833 -179.488 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -161.77 132.01 4.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.148 0.499 . . . . 0.0 110.786 -179.878 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.0 t -102.71 123.78 56.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.923 179.685 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 35.3 mt -82.77 -29.92 29.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.98 -179.587 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 35.3 m -95.97 158.82 3.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 121.213 0.53 . . . . 0.0 110.936 -179.677 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 37.2 mttt -132.08 163.53 28.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.167 179.65 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -60.72 141.42 56.89 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.544 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? 61.43 39.11 15.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.393 179.988 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -123.88 151.38 43.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.327 179.852 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.63 144.21 25.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.473 -179.912 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.75 179.53 3.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.37 179.801 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -130.04 140.88 50.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.323 179.937 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -58.78 105.93 0.77 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.837 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.99 -31.05 6.24 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.995 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.1 tt0 -58.4 140.61 53.43 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 121.141 0.496 . . . . 0.0 110.763 -179.909 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.71 124.01 34.43 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 179.934 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 90.1 mt -90.38 -49.31 6.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.036 0.446 . . . . 0.0 110.844 -179.585 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.41 HD11 HG21 ' A' ' 120' ' ' ILE . 50.7 mt -142.33 153.61 18.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.576 -179.852 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.4 tttt -98.19 125.21 43.14 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.354 179.835 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 39.4 mm -108.37 140.4 27.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.397 -179.93 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.701 0 CA-C-O 117.979 -1.456 . . . . 0.0 110.943 179.93 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 . . . . . 0 N--CA 1.462 0.129 0 CA-C-O 121.106 0.479 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.4 ' CD1' ' HD2' ' A' ' 97' ' ' PRO . 42.9 mm -79.09 124.48 84.6 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.051 179.879 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.9 132.77 17.42 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 121.924 1.749 . . . . 0.0 112.223 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.34 146.16 98.98 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.427 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -72.9 -29.95 11.7 Favored 'Trans proline' 0 N--CA 1.471 0.2 0 C-N-CA 122.191 1.927 . . . . 0.0 112.295 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.2 pp -163.67 166.38 22.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.393 179.996 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.1 101.82 6.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.339 179.929 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.63 -149.91 6.33 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.989 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.8 m -136.21 140.6 43.65 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.149 0.5 . . . . 0.0 110.437 179.933 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 23.2 t -73.24 121.69 24.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.252 179.918 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -99.49 -49.69 4.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.555 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 17.2 ttpt -152.56 146.51 25.28 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.535 -179.735 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 2.9 mp -105.59 135.82 42.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.09 179.7 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 7.1 mp -100.03 -36.34 9.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.653 -179.783 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.0 m -101.16 143.2 14.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.72 -179.819 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.4 pttp -133.47 162.67 31.23 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.063 179.81 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -59.16 101.12 0.09 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.534 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.22 -29.6 2.4 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.836 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -90.7 148.03 22.87 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.093 0.473 . . . . 0.0 110.43 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.6 m -95.72 144.72 25.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.396 179.972 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.4 m -119.78 160.68 19.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.505 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 88.2 mttt -125.06 154.32 41.52 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.327 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.36 97.61 0.05 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.732 -179.802 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.83 -30.66 3.69 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 28.2 tt0 -63.94 141.24 58.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.101 0.477 . . . . 0.0 110.735 -179.816 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.2 m -65.45 138.6 58.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.235 179.744 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 31.4 m -117.91 -32.95 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.247 -179.373 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.8 tt -161.47 153.51 19.61 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.284 0.564 . . . . 0.0 111.111 -179.268 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -107.01 137.3 38.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.911 179.504 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 15.3 mt -115.36 162.61 16.88 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.28 0.562 . . . . 0.0 110.782 -179.657 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.274 179.804 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 121.108 0.48 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 11.1 m -112.09 119.58 38.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.318 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -82.1 129.11 34.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.852 -179.587 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 39.0 mm -101.35 149.45 6.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.997 179.569 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 67.9 m-20 -139.2 134.34 32.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.161 0.505 . . . . 0.0 110.863 -179.665 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.13 110.46 3.56 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.946 179.363 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.4 ' HD2' ' CD1' ' A' ' 57' ' ' ILE . 40.6 Cg_endo -64.27 -15.13 47.85 Favored 'Trans proline' 0 N--CA 1.476 0.484 0 C-N-CA 122.182 1.921 . . . . 0.0 113.105 179.834 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 61.1 p -135.9 136.66 40.68 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-O 121.145 0.498 . . . . 0.0 110.425 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -64.02 163.31 12.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.468 -179.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 149.03 -155.93 26.58 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.5 ttmt -134.55 147.89 50.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.084 0.469 . . . . 0.0 110.506 -179.833 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 22.1 t -77.44 111.81 14.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.165 179.802 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -95.94 -27.59 15.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.987 -179.774 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -162.69 127.38 3.14 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.064 0.459 . . . . 0.0 110.453 -179.864 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.62 112.5 36.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.307 179.954 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.5 mt -80.05 -31.44 39.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.503 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 33.6 m -87.08 141.56 14.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.71 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -128.39 171.54 11.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.438 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -63.29 137.74 58.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.414 179.995 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.76 38.88 6.57 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.618 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -118.79 144.82 46.06 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.224 179.635 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.98 134.99 34.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.485 -179.955 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.7 m -122.32 179.9 2.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.319 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -137.19 147.81 46.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.416 179.891 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.74 114.31 6.45 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.88 -30.37 9.14 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.928 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.4 tt0 -60.9 137.06 58.24 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.034 0.445 . . . . 0.0 110.567 -179.967 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.86 119.19 17.15 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 41.3 mt -88.92 -51.04 5.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.109 0.48 . . . . 0.0 110.378 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.465 HG21 HD11 ' A' ' 120' ' ' ILE . 53.5 mt -140.91 144.91 26.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 8.1 tttt -93.94 129.75 40.29 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.357 179.947 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . 0.424 HG21 HD11 ' A' ' 122' ' ' ILE . 36.6 mm -106.44 148.82 10.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.426 -179.776 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.739 0 CA-C-O 118.015 -1.436 . . . . 0.0 110.85 -179.991 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 121.187 0.517 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 32.7 mt -80.11 119.93 78.09 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.138 179.756 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -72.19 139.47 32.44 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 122.0 1.8 . . . . 0.0 112.277 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -71.8 146.77 91.12 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.373 179.948 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -72.85 -27.14 14.91 Favored 'Trans proline' 0 N--CA 1.471 0.184 0 C-N-CA 122.227 1.951 . . . . 0.0 112.393 179.972 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.2 pp -162.18 174.58 12.71 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.394 -179.941 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -90.24 82.21 6.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.306 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -109.26 -144.47 10.63 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.7 m -136.99 138.8 40.92 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.062 0.458 . . . . 0.0 110.525 -179.943 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 25.7 t -70.95 124.18 26.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.077 179.897 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.3 t -101.9 -59.12 1.75 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.787 -179.7 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 tptt -149.81 138.79 21.08 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.738 -179.583 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 38.9 mt -95.92 135.52 29.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.965 179.532 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 11.5 mt -100.91 -30.82 11.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.93 -179.556 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.3 m -108.49 149.81 11.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.144 0.497 . . . . 0.0 110.733 -179.854 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 12.6 ptpt -137.66 164.16 29.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.164 179.856 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -60.58 102.97 0.21 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.5 -179.985 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 138.55 -31.48 2.41 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 23.8 m-20 -88.18 147.6 24.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.108 0.48 . . . . 0.0 110.482 -179.946 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 19.6 m -95.52 142.93 27.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.303 179.914 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.4 m -119.42 156.63 21.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.53 -179.883 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.4 mptt -117.79 152.58 35.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.288 179.888 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.24 93.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.644 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.23 -31.49 2.78 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 17.7 tt0 -62.42 141.96 58.1 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.078 0.466 . . . . 0.0 110.562 -179.98 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.9 m -68.12 138.84 56.03 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.212 179.819 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.4 m -121.07 -32.42 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.657 -179.243 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.5 tm? -160.34 136.74 8.76 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.863 -179.11 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 20.1 t -102.3 136.35 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.459 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 88.4 mt -114.12 166.56 11.5 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.584 -179.874 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.316 179.899 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 . . . . . 0 C--O 1.232 0.137 0 CA-C-O 121.152 0.501 . . . . 0.0 110.526 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 23.9 m -117.44 112.64 20.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.353 179.983 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -80.64 132.97 35.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.765 -179.724 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 35.7 mm -101.88 155.91 4.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.066 179.648 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -136.84 149.34 47.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.568 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.71 139.8 97.06 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.242 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.65 -30.99 11.25 Favored 'Trans proline' 0 N--CA 1.472 0.226 0 C-N-CA 122.087 1.858 . . . . 0.0 112.197 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.07 163.61 35.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.313 179.943 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -68.17 141.94 55.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.352 179.969 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.48 -159.48 27.43 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 10.1 ttpt -133.36 143.71 49.14 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.045 0.45 . . . . 0.0 110.338 -179.849 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.9 t -75.72 111.71 12.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.224 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -92.75 -29.72 15.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.69 -179.85 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.5 ttpt -158.79 134.03 8.48 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.127 0.489 . . . . 0.0 110.575 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 26.9 t -101.19 107.91 22.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.346 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.7 mt -80.07 -32.2 39.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.222 179.697 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 31.4 m -77.3 143.63 12.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.416 179.917 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 10.6 mmmt -135.05 151.86 51.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.156 179.81 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 16.4 mp0 -58.41 137.74 57.07 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.781 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 8.2 ttp-105 63.41 39.08 9.55 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.344 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -125.09 144.63 50.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.289 179.815 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.79 140.13 30.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.558 -179.99 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.9 m -121.14 179.93 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.371 179.978 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 9.3 mt-30 -141.06 146.86 37.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.412 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.23 103.4 0.53 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.03 -29.78 5.45 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 -179.889 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -61.61 138.51 58.3 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-O 121.066 0.46 . . . . 0.0 110.402 -179.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.62 118.46 14.81 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.919 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 64.5 mt -89.02 -54.73 3.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.017 0.436 . . . . 0.0 110.334 179.81 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 46.6 mt -142.79 147.02 21.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.321 179.796 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.2 mtpt -96.22 127.21 42.02 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.339 179.963 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 36.1 mm -109.17 145.03 16.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.552 -179.883 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 117.976 -1.458 . . . . 0.0 110.777 179.971 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 . . . . . 0 C--O 1.23 0.07 0 CA-C-O 121.08 0.467 . . . . 0.0 110.359 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.2 mt -79.64 111.36 20.54 Favored Pre-proline 0 CA--C 1.535 0.383 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.258 179.993 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -71.22 131.31 18.97 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 121.962 1.775 . . . . 0.0 112.302 -179.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.19 145.17 97.41 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.352 179.976 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.34 -28.03 12.78 Favored 'Trans proline' 0 CA--C 1.528 0.222 0 C-N-CA 122.22 1.946 . . . . 0.0 112.276 -179.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -159.59 162.87 35.39 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.357 179.971 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.35 113.81 21.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.332 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -137.75 -140.7 4.08 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -179.92 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 19.7 m -136.46 139.71 42.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.067 0.46 . . . . 0.0 110.435 179.988 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.3 t -71.09 126.59 31.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.999 179.982 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 8.2 t -101.24 -54.47 2.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.665 -179.828 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.2 tptm -157.2 140.27 15.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.602 -179.819 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 31.3 mt -94.38 140.26 16.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.995 179.719 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 22.6 mt -104.84 -37.89 6.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.631 -179.793 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.404 ' CG1' ' CG1' ' A' ' 76' ' ' VAL . 33.1 m -110.88 148.12 14.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.801 -179.927 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -139.62 166.77 23.7 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.213 179.897 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -58.1 108.91 0.66 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.702 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.04 -31.4 2.81 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -93.19 151.38 19.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.061 0.458 . . . . 0.0 110.481 179.975 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -100.68 148.65 24.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.238 179.879 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.404 ' CG1' ' CG1' ' A' ' 70' ' ' VAL . 31.6 m -124.99 165.96 21.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.58 -179.824 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.8 tppt? -124.78 153.91 41.74 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.251 179.894 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.43 97.97 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.541 -179.87 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.16 -36.64 2.11 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.904 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -62.88 139.46 58.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.496 . . . . 0.0 110.563 -179.959 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.9 m -67.07 141.87 57.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.282 -179.997 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 31.5 m -113.58 -27.04 2.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.225 -179.604 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.0 tt -168.4 150.99 5.3 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.177 0.513 . . . . 0.0 110.622 -179.619 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -102.83 135.98 37.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.955 179.622 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 17.8 mt -115.2 163.3 15.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.587 -179.681 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.267 179.972 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 121.14 0.495 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 19.6 m -121.01 125.91 48.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.418 -179.956 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -87.38 143.01 27.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.475 -179.96 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.447 HG21 HD12 ' A' ' 94' ' ' ILE . 38.7 mm -105.56 112.06 37.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.373 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -98.48 140.54 32.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.378 -179.945 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.41 142.38 96.27 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.341 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.24 -35.29 5.21 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.16 1.907 . . . . 0.0 112.357 179.95 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -146.8 162.34 38.79 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.337 -179.968 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -66.67 143.34 57.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.396 179.901 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.43 -160.86 31.45 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.972 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 28.6 tttp -130.23 147.23 51.93 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.032 0.444 . . . . 0.0 110.526 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.3 t -75.67 109.12 8.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.293 179.898 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -93.93 -29.91 15.03 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.76 -179.892 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 29.8 tttt -157.47 128.09 6.49 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.163 0.506 . . . . 0.0 110.642 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 29.0 t -102.59 102.45 13.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.224 179.824 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 12.5 mt -76.25 -32.22 58.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.213 179.716 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 34.8 m -77.86 142.01 14.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.632 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 12.7 mmmt -139.82 158.45 44.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.994 179.676 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -55.81 161.72 2.08 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.976 -179.794 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 37.18 41.24 0.21 Allowed 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.486 -179.737 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -128.99 142.16 51.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.265 179.882 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -93.51 136.99 33.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.623 -179.781 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.1 m -118.8 161.29 17.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.312 179.781 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 -102.06 143.21 32.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.438 -179.998 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.2 108.66 2.02 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.962 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.14 -26.28 10.59 Favored Glycine 0 CA--C 1.528 0.859 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 -179.798 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -58.44 144.73 41.12 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-O 121.134 0.492 . . . . 0.0 110.787 -179.966 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.96 120.74 24.1 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.962 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 89.3 mt -88.01 -59.61 2.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.105 0.478 . . . . 0.0 110.453 -179.96 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 55.0 mt -140.85 145.2 25.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.377 -179.988 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -91.4 121.56 33.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.167 179.797 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.2 mm -104.29 141.44 19.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.455 -179.957 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.75 0 CA-C-O 117.953 -1.471 . . . . 0.0 110.765 179.988 . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 . . . . . 0 N--CA 1.462 0.127 0 CA-C-O 121.212 0.53 . . . . 0.0 110.75 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.432 HG21 HD11 ' A' ' 57' ' ' ILE . 51.3 mt -81.03 117.1 66.63 Favored Pre-proline 0 CA--C 1.533 0.31 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.14 179.86 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -71.92 137.23 29.04 Favored 'Trans proline' 0 N--CA 1.472 0.228 0 C-N-CA 121.932 1.755 . . . . 0.0 112.315 -179.984 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.44 146.69 89.06 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.389 -179.879 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -72.13 -28.69 15.45 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.2 1.934 . . . . 0.0 112.263 179.928 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -165.32 166.9 18.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.41 -179.965 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.43 85.1 6.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.449 179.949 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.35 -160.94 10.86 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -179.93 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.3 m -114.41 140.62 48.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.122 0.487 . . . . 0.0 110.56 -179.969 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 29.6 t -64.94 127.67 26.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.194 179.908 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.3 -61.27 1.42 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.703 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.6 mttt -149.97 145.68 26.59 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.11 0.481 . . . . 0.0 110.654 -179.812 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.5 mt -101.04 125.24 55.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.721 179.443 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 19.8 mt -96.31 -31.21 13.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.979 -179.429 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.6 m -111.62 147.18 15.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.201 0.524 . . . . 0.0 110.732 -179.719 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.5 163.96 29.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.154 179.795 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -59.34 102.45 0.14 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.699 -179.919 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.03 -30.31 2.37 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.974 -0.851 . . . . 0.0 110.974 179.969 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.84 150.91 20.3 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.175 0.512 . . . . 0.0 110.586 -179.866 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.5 m -96.02 148.14 22.97 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.297 179.931 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.8 m -119.13 166.3 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.513 -179.97 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 32.1 mmtm -128.88 147.84 50.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.24 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.81 90.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.779 -179.877 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.53 -31.34 2.6 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.827 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -64.1 141.15 58.87 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.171 0.51 . . . . 0.0 110.668 -179.769 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.4 m -65.97 137.01 56.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.082 179.788 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 31.1 m -121.68 -32.19 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.66 -179.318 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 16.3 tp -158.97 151.8 22.02 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.083 0.468 . . . . 0.0 110.816 -179.124 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.2 t -113.9 144.08 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.769 179.323 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 16.6 mt -120.62 158.81 26.58 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.168 0.509 . . . . 0.0 110.789 -179.64 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 . . . . . 0 C--N 1.331 -0.219 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.385 -179.916 . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 121.088 0.47 . . . . 0.0 110.363 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -123.33 113.24 18.58 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.406 179.968 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -79.5 139.31 37.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.601 -179.889 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 5.1 mp -110.27 155.88 11.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.729 179.902 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 11.3 m-80 -139.5 152.57 47.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.543 -179.918 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.16 139.75 96.1 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.305 180.0 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -73.77 -35.47 4.46 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.114 1.876 . . . . 0.0 112.153 179.977 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 24.0 p -144.96 163.17 34.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.343 179.944 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -65.28 140.87 58.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.337 179.859 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.34 -159.6 29.74 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.919 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 22.8 ttmt -135.21 148.76 49.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.078 0.466 . . . . 0.0 110.421 -179.901 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 22.4 t -78.16 110.4 13.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.197 179.929 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -92.97 -27.54 16.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.884 -179.931 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -157.35 130.82 7.92 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.093 0.473 . . . . 0.0 110.653 -179.773 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.7 t -101.32 102.98 14.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.132 179.806 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 14.0 mt -88.31 10.38 19.96 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.531 179.862 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 31.3 m -123.76 135.42 63.49 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.074 0 CA-C-O 121.177 0.513 . . . . 0.0 110.212 179.705 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 9.7 tttp -123.5 152.9 41.26 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.277 -179.943 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -59.98 146.29 43.07 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.598 -179.967 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 20.8 mtm180 61.02 34.19 19.39 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.505 -179.943 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -120.14 149.74 41.74 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.346 179.819 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.11 135.9 33.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.566 -179.981 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.4 m -121.71 -179.99 2.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.273 179.906 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -138.55 144.7 40.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.423 -179.994 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.51 111.14 3.43 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.962 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 111.86 -28.77 9.06 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.88 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.0 tt0 -59.49 135.89 57.81 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.075 0.464 . . . . 0.0 110.573 -179.899 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.25 116.1 8.85 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.946 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 71.8 mt -88.77 -54.58 4.08 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.017 0.436 . . . . 0.0 110.472 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 49.5 mt -142.7 145.0 23.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.391 -179.975 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 25.1 tttt -98.06 129.0 44.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.453 179.869 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.1 mm -103.54 145.54 12.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.475 -179.782 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.75 0 CA-C-O 118.016 -1.436 . . . . 0.0 110.753 179.891 . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 121.122 0.487 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.5 mt -78.89 112.45 27.45 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.156 179.937 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.09 141.62 40.27 Favored 'Trans proline' 0 N--CA 1.472 0.262 0 C-N-CA 122.115 1.877 . . . . 0.0 112.395 -179.932 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.2 148.59 71.38 Favored Pre-proline 0 CA--C 1.531 0.235 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.423 179.911 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -72.2 -27.45 16.67 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.31 2.007 . . . . 0.0 112.365 -179.949 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -158.61 171.08 20.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.321 179.968 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -91.07 83.43 5.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.415 179.998 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -109.7 -136.16 7.4 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.946 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.0 m -139.08 138.55 37.2 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.173 0.511 . . . . 0.0 110.488 179.933 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.9 t -66.82 124.0 21.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.284 179.991 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.2 t -98.58 -60.31 1.57 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.478 -179.957 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.8 mttt -148.69 147.3 28.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.461 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 24.0 mt -106.04 118.02 52.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.923 179.899 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.5 mt -95.12 21.79 7.41 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.385 -179.525 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 25.2 m -150.0 148.29 15.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 121.239 0.543 . . . . 0.0 110.524 179.812 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 12.0 mtpp -132.17 157.36 44.48 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.185 179.874 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 27.0 mt-10 -59.11 95.33 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.516 179.989 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.15 -30.41 2.35 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.777 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 59.8 m-20 -73.13 146.39 45.72 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.062 0.458 . . . . 0.0 110.319 179.963 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.4 m -98.45 127.68 44.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.423 179.928 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 22.7 m -112.56 151.79 14.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.409 179.971 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.5 mttp -112.99 149.05 33.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.324 179.908 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -57.98 95.56 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.803 -179.854 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.39 -33.92 2.24 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.4 tt0 -69.34 140.17 54.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.083 0.468 . . . . 0.0 110.481 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.6 m -60.43 137.82 58.09 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.488 179.905 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 34.6 m -113.95 -33.65 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.947 -179.609 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.9 tt -161.17 149.61 15.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.583 -179.558 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -104.46 140.69 21.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.183 179.836 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.6 mt -117.75 171.41 8.06 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.44 -179.848 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.422 179.994 . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 . . . . . 0 C--O 1.231 0.084 0 CA-C-O 121.094 0.473 . . . . 0.0 110.541 . . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.6 m -120.76 121.06 37.4 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.212 179.961 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -84.8 131.98 34.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.57 -179.894 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.8 mm -102.25 124.87 56.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.167 179.767 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -103.64 140.94 36.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.345 -179.934 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.29 142.31 93.66 Favored Pre-proline 0 CA--C 1.532 0.26 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.403 -179.872 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.77 -36.8 4.36 Favored 'Trans proline' 0 N--CA 1.471 0.194 0 C-N-CA 122.109 1.873 . . . . 0.0 112.352 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 23.0 p -149.48 157.48 43.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.321 -179.989 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -63.53 140.85 58.91 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.358 179.91 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.81 -155.99 19.64 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.983 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 5.8 ttmt -136.93 142.23 42.68 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.143 0.497 . . . . 0.0 110.631 -179.931 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 31.3 t -74.12 112.17 10.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.246 179.9 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -96.11 -30.41 13.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.584 179.972 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 29.5 ttmt -158.97 133.77 8.14 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.468 179.954 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.1 t -99.93 109.2 24.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.237 -179.977 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.7 mt -90.12 30.34 1.11 Allowed 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.688 179.971 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.7 m -155.46 138.34 7.15 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-O 120.987 0.423 . . . . 0.0 110.261 -179.999 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 21.2 mttt -124.55 162.48 23.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.364 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 53.3 mt-10 -61.22 149.96 36.04 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.445 179.911 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 61.18 32.56 19.5 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.255 -179.803 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -120.18 148.42 43.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.378 179.9 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.47 140.58 29.61 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.472 -179.995 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.8 m -120.35 -179.99 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.5 -179.986 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.5 144.68 42.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.432 179.897 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.76 107.95 1.64 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.969 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.12 -27.96 9.7 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -60.64 137.14 58.21 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 121.199 0.523 . . . . 0.0 110.562 -179.85 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.96 119.19 17.73 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.968 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 59.5 mt -89.96 -49.75 6.42 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.091 0.472 . . . . 0.0 110.573 -179.873 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 47.8 mt -141.1 138.4 33.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.343 -179.918 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -91.13 130.22 37.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.394 179.887 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.4 mm -108.51 140.75 25.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.408 -179.996 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.834 0 CA-C-O 117.967 -1.463 . . . . 0.0 110.788 179.966 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 143.31 100.07 0.33 Allowed Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -117.61 156.28 28.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.107 0.48 . . . . 0.0 110.372 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 110.01 51.69 0.63 Allowed Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -171.05 151.66 3.31 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.073 0.463 . . . . 0.0 110.415 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -88.77 169.74 11.37 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.345 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 154.19 -32.97 0.72 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -90.32 52.27 2.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.308 0.575 . . . . 0.0 110.578 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 94.64 -22.47 37.42 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 120.899 -0.667 . . . . 0.0 111.551 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -76.54 139.09 40.59 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-O 121.145 0.498 . . . . 0.0 110.851 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 51.8 mt -81.7 111.45 26.12 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.242 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.45 136.98 29.76 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.047 1.832 . . . . 0.0 112.305 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -72.18 147.17 90.48 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.516 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.89 -25.89 16.15 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.252 1.968 . . . . 0.0 112.464 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 pp -165.98 179.32 5.89 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.451 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.34 102.69 9.72 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.437 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -127.87 171.1 19.22 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.0 m -105.37 135.25 47.09 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.136 0.494 . . . . 0.0 110.416 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 26.0 t -69.93 122.14 20.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.129 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -101.03 -54.42 2.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.576 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.3 ttpm? -151.66 145.85 25.37 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.487 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 3.4 mp -105.36 133.7 48.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.115 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.8 mp -98.15 -44.83 6.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.648 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.4 ' CG1' ' CG1' ' A' ' 76' ' ' VAL . 35.9 m -88.67 150.49 3.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.743 -179.708 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 3.5 ptpt -136.08 161.37 35.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.181 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -61.22 98.6 0.08 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.526 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -29.98 2.38 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.49 148.04 26.74 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.125 0.488 . . . . 0.0 110.578 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 24.5 m -95.2 142.17 27.95 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.192 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.4 ' CG1' ' CG1' ' A' ' 70' ' ' VAL . 23.8 m -120.19 163.73 17.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.638 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.1 mttp -123.04 147.47 46.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.153 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.11 92.9 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.693 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.2 -35.37 2.03 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -63.36 143.51 57.74 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.135 0.493 . . . . 0.0 110.614 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.7 m -66.87 137.2 56.4 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.219 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 30.7 m -115.17 -30.24 2.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.206 -179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 9.0 tt -163.27 150.14 12.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.127 0.489 . . . . 0.0 110.855 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 t -102.13 130.59 51.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.998 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.6 mt -119.1 132.23 55.98 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.664 -179.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -100.4 86.94 3.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.054 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -96.95 117.81 31.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.081 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 41.0 mtm 61.5 56.08 2.65 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.438 0.637 . . . . 0.0 109.487 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 17.5 pttp 43.79 40.17 2.96 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 115.033 -0.985 . . . . 0.0 111.449 -179.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.0 ttp -136.23 125.93 25.5 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.358 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -70.79 119.24 14.65 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.411 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.9 m -118.45 127.67 53.87 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.32 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -84.07 130.85 34.85 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.643 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.3 mm -104.94 116.22 48.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.124 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 82.5 m-20 -103.03 143.71 32.22 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.426 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.6 143.3 96.47 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.358 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -73.15 -37.65 3.28 Favored 'Trans proline' 0 CA--C 1.527 0.17 0 C-N-CA 122.072 1.848 . . . . 0.0 112.24 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 15.6 p -145.78 162.2 38.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.387 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -67.76 142.3 56.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.456 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.57 -157.25 27.52 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.1 ttmt -133.91 147.25 51.09 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.142 0.496 . . . . 0.0 110.544 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.2 t -75.32 107.26 5.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.301 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -93.39 -28.04 16.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.65 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -158.56 130.93 6.9 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.077 0.465 . . . . 0.0 110.396 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.4 t -97.96 109.39 23.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.31 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.2 mt -90.29 30.37 1.13 Allowed 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.641 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 25.6 m -155.47 137.47 6.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 121.073 0.463 . . . . 0.0 110.252 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 24.9 mmtt -128.9 167.01 18.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.385 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -62.27 147.61 47.53 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.426 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 11.0 mmp_? 60.69 32.32 20.26 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.598 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -122.74 136.43 54.87 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.354 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.28 136.68 32.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.487 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.5 m -119.18 150.73 21.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.394 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -98.15 149.28 22.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.449 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.92 117.3 11.16 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 105.84 -28.12 15.18 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 -59.57 138.33 57.74 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 121.041 0.448 . . . . 0.0 110.586 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.68 121.43 26.58 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 24.5 mt -88.92 -51.81 5.43 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.073 0.463 . . . . 0.0 110.404 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 48.4 mt -142.82 144.78 23.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.407 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -96.51 125.29 40.89 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.238 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.6 mm -106.06 143.87 16.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.536 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.772 0 CA-C-O 117.989 -1.45 . . . . 0.0 110.716 179.956 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 124.86 94.58 1.03 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -63.93 -37.13 86.29 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.05 0.452 . . . . 0.0 110.412 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.97 140.14 0.02 OUTLIER Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -99.24 40.73 1.19 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.256 0.55 . . . . 0.0 110.373 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -143.84 111.34 5.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.394 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -168.63 48.1 0.22 Allowed Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.3 tt0 -165.53 33.39 0.06 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.154 0.502 . . . . 0.0 110.397 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 122.83 -32.15 4.52 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -78.29 134.55 37.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.078 0.466 . . . . 0.0 110.481 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 28.5 mt -79.01 115.01 49.21 Favored Pre-proline 0 CA--C 1.535 0.386 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.006 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.84 140.04 37.76 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 121.963 1.775 . . . . 0.0 112.329 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -75.25 146.53 81.74 Favored Pre-proline 0 CA--C 1.531 0.219 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.454 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.71 -24.34 18.42 Favored 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 122.232 1.954 . . . . 0.0 112.47 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -161.08 175.23 12.65 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.457 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -87.83 110.26 20.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.402 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -138.09 177.85 19.69 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 18.9 m -104.75 136.58 43.99 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.142 0.496 . . . . 0.0 110.481 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 32.0 t -70.28 117.83 13.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.25 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.8 p -99.61 -51.86 3.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.525 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.3 ptpt -151.73 145.28 24.9 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.528 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.7 mt -100.77 141.23 17.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.009 179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -101.6 -30.44 11.37 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.109 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.4 ' CG1' ' CG1' ' A' ' 76' ' ' VAL . 34.5 m -124.91 133.65 68.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.244 0.545 . . . . 0.0 110.854 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.75 149.3 37.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.853 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.8 121.06 5.96 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.387 0.613 . . . . 0.0 111.108 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.17 -28.83 4.48 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.51 158.82 15.37 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-O 121.054 0.454 . . . . 0.0 110.425 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -97.91 141.22 31.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.428 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.4 ' CG1' ' CG1' ' A' ' 70' ' ' VAL . 29.2 m -123.83 158.31 29.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.485 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 32.3 mttm -117.68 157.83 25.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.35 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.42 106.84 0.82 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.515 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.3 -31.47 4.66 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 -62.77 140.62 58.76 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.125 0.488 . . . . 0.0 110.532 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 7.5 m -67.54 139.38 56.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.305 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.4 m -114.43 -31.54 2.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.053 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 8.5 tt -166.41 146.9 6.19 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.103 0.478 . . . . 0.0 110.841 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.1 t -103.08 135.88 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.131 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 51.9 mt -118.32 166.27 12.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.706 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -141.38 82.63 1.83 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.336 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -97.11 120.52 37.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.457 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 22.4 mmt 62.35 43.11 8.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.413 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.5 mttp 59.81 38.52 21.39 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.628 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 82.8 mtp -131.71 110.54 10.96 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.459 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 21.5 mt-10 -66.08 109.14 2.47 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.433 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.0 m -117.45 109.04 16.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.276 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -77.97 140.64 39.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.604 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 37.2 mm -103.68 140.67 21.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.057 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 38.3 m-20 -128.76 143.48 50.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.665 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.25 138.62 96.18 Favored Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.259 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.99 -31.86 11.87 Favored 'Trans proline' 0 N--CA 1.472 0.209 0 C-N-CA 122.09 1.86 . . . . 0.0 112.416 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 40.9 p -147.17 164.95 31.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.483 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -66.42 143.61 57.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.399 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.48 -160.43 27.98 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -135.02 136.87 42.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.139 0.495 . . . . 0.0 110.431 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 4.2 t -73.16 107.26 3.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.86 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -87.68 -29.39 21.17 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.001 -179.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 13.7 tttt -163.95 138.13 5.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.407 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.6 t -107.92 110.49 32.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.416 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.8 mt -79.24 -31.59 43.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.394 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.3 m -82.56 142.84 13.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.501 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 54.2 mttt -136.47 163.11 31.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.246 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -60.79 147.29 43.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.519 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 5.5 tpt180 61.13 35.45 18.58 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.479 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -127.98 140.32 52.05 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.388 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.51 136.24 33.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.517 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.0 m -120.24 152.06 23.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.341 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -97.36 140.19 32.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.501 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.7 87.92 0.04 OUTLIER Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 137.54 -28.08 2.79 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -61.59 146.93 47.3 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.157 0.503 . . . . 0.0 110.515 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.56 118.87 16.16 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 71.8 mt -87.14 -53.15 5.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.082 0.468 . . . . 0.0 110.485 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.436 HD12 HG22 ' A' ' 120' ' ' ILE . 55.5 mt -140.9 151.59 20.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.477 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -97.22 133.99 41.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.209 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 35.9 mm -114.25 145.18 20.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.438 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.781 0 CA-C-O 118.011 -1.438 . . . . 0.0 110.774 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -159.28 110.78 0.46 Allowed Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -149.75 37.31 0.72 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.28 0.562 . . . . 0.0 110.379 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.85 148.38 45.57 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 39.8 tttm -130.18 159.43 36.85 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.146 0.498 . . . . 0.0 110.394 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -109.1 179.12 4.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.474 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 151.72 -46.09 0.6 Allowed Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -112.77 96.2 5.84 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.116 0.484 . . . . 0.0 110.513 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 93.79 -52.66 2.3 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -82.31 134.8 35.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.998 0.428 . . . . 0.0 110.499 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.1 mm -80.22 120.6 80.07 Favored Pre-proline 0 CA--C 1.536 0.431 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.923 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -72.05 128.0 13.47 Favored 'Trans proline' 0 N--CA 1.472 0.222 0 C-N-CA 121.892 1.728 . . . . 0.0 112.1 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.05 142.12 93.22 Favored Pre-proline 0 CA--C 1.532 0.28 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.471 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -73.62 -27.54 12.73 Favored 'Trans proline' 0 CA--C 1.528 0.188 0 C-N-CA 122.181 1.921 . . . . 0.0 112.374 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -161.33 159.92 29.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.472 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.59 125.39 30.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.402 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -159.06 -140.22 2.86 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 14.8 m -136.56 139.13 41.96 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.082 0.468 . . . . 0.0 110.406 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 27.9 t -70.71 124.61 27.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.208 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.0 t -98.42 -54.23 3.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.675 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -153.67 145.02 23.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.529 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 35.7 mt -99.65 135.16 36.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.118 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.3 mt -98.48 -44.13 6.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.617 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 34.6 m -98.83 144.69 11.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.502 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 46.1 pttt -137.3 164.28 28.94 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.206 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -57.05 102.29 0.08 Allowed 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.692 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.13 -31.97 2.22 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -90.15 152.94 20.88 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.062 0.458 . . . . 0.0 110.387 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -98.84 146.79 25.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.474 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.4 m -121.47 162.44 20.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.344 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -127.29 156.85 41.27 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.488 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.34 90.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.55 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.65 -30.36 3.0 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 16.3 tt0 -61.88 143.32 56.56 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.077 0.465 . . . . 0.0 110.672 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.9 m -68.9 138.97 55.1 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.148 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 28.4 m -117.63 -33.86 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.35 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.6 tt -161.52 153.15 19.02 Favored 'General case' 0 C--N 1.332 -0.175 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.167 -179.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.4 t -107.55 138.4 33.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.923 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -120.26 168.53 11.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.191 0.52 . . . . 0.0 110.457 -179.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -133.6 115.38 14.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.357 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.52 142.82 25.17 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.509 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 56.8 mtp 60.36 32.71 20.74 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.6 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.4 33.04 20.76 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.55 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 14.8 ttm -146.69 120.51 9.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.441 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -66.0 128.1 34.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.613 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.2 m -114.4 122.34 46.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.232 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -82.52 130.22 35.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.62 -179.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 25.7 mm -103.19 147.45 9.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.011 179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -139.27 142.38 37.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.152 0.501 . . . . 0.0 110.779 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.65 109.76 2.72 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.291 179.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -64.93 -13.77 41.46 Favored 'Trans proline' 0 N--CA 1.476 0.46 0 C-N-CA 122.148 1.899 . . . . 0.0 112.885 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -135.94 135.96 40.04 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.097 0.475 . . . . 0.0 110.359 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -63.36 151.29 41.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.422 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 159.36 -154.66 25.73 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.0 ttmt -135.69 148.03 48.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.141 0.496 . . . . 0.0 110.448 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.9 t -75.69 111.26 11.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.208 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -95.21 -30.07 14.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.784 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.7 ttpt -162.01 130.17 4.13 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.569 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.0 t -103.57 113.89 41.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.295 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.0 mt -81.59 -37.17 28.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.374 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 32.9 m -77.44 147.45 7.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.574 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -133.49 163.68 28.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.075 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -62.71 138.55 58.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.394 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER 67.2 37.16 3.76 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.564 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.41 151.07 40.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.278 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -95.61 133.46 39.63 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.513 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.4 m -120.8 179.8 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.356 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 81.7 mm-40 -136.05 147.67 48.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.425 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.32 113.07 5.31 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 111.18 -30.78 7.69 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -60.18 140.33 57.02 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.138 0.494 . . . . 0.0 110.675 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.49 120.49 22.72 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 91.6 mt -87.06 -53.59 4.79 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.103 0.478 . . . . 0.0 110.423 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.452 HG23 HD11 ' A' ' 120' ' ' ILE . 52.3 mt -141.32 151.82 19.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.326 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 39.1 mttt -93.76 128.19 39.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.382 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.431 HG23 HD12 ' A' ' 122' ' ' ILE . 37.1 mm -109.87 145.76 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.37 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.748 0 CA-C-O 117.991 -1.449 . . . . 0.0 110.728 179.925 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 144.79 -40.99 1.11 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -117.45 -70.1 0.81 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.033 0.444 . . . . 0.0 110.359 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -96.55 -160.22 32.1 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -163.71 40.37 0.09 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.266 0.555 . . . . 0.0 110.27 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -154.84 178.31 10.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.334 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 138.44 -45.84 1.02 Allowed Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -105.38 80.69 1.61 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.259 0.552 . . . . 0.0 110.495 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.99 -48.4 1.01 Allowed Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -83.69 128.94 34.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.067 0.46 . . . . 0.0 110.503 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 45.7 mt -78.9 111.45 19.86 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.127 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -70.38 142.42 45.17 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.099 1.866 . . . . 0.0 112.465 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -77.67 148.53 76.51 Favored Pre-proline 0 CA--C 1.531 0.24 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.521 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -73.11 -26.66 14.71 Favored 'Trans proline' 0 CA--C 1.528 0.212 0 C-N-CA 122.206 1.937 . . . . 0.0 112.461 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -164.63 156.98 16.37 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.472 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.0 121.92 19.07 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.423 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -150.96 -145.17 4.07 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.7 m -136.97 139.02 41.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.138 0.494 . . . . 0.0 110.413 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 25.2 t -71.98 126.23 32.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.181 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 32.7 t -96.03 -53.41 3.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.655 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.32 150.55 31.62 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.178 0.513 . . . . 0.0 110.74 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 32.8 mt -105.87 116.48 49.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.051 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 64.2 mt -98.75 13.78 31.05 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.622 -179.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 28.4 m -148.22 133.56 11.0 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 CA-C-O 121.122 0.486 . . . . 0.0 110.691 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -116.86 161.2 19.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.195 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.21 95.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.621 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.22 -35.79 1.86 Allowed Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.52 146.77 47.59 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.093 0.473 . . . . 0.0 110.481 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -96.67 137.51 35.63 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.578 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 18.8 m -126.91 166.76 22.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.395 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -130.3 157.23 43.11 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.309 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.39 88.62 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.401 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.15 -33.51 2.08 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -63.15 145.66 55.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.145 0.498 . . . . 0.0 110.451 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.1 m -67.33 139.57 57.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.425 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 28.1 m -120.14 -35.49 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.17 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.6 tt -162.05 152.71 17.45 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.261 0.553 . . . . 0.0 111.032 -179.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.9 t -103.54 145.1 13.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.794 179.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 11.1 mt -126.67 160.3 31.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.52 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -131.13 114.37 15.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.423 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.57 140.6 22.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.299 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 34.3 mtt 60.91 32.01 20.0 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.572 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 33.3 mtmt 59.61 31.99 21.27 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.702 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 6.9 mtt -139.82 121.1 14.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.509 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -64.01 127.66 32.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.196 179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.3 m -118.75 117.58 29.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.393 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -83.04 133.82 35.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.457 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 33.7 mm -103.71 152.78 6.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.172 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 47.6 m-80 -139.88 148.08 41.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.495 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.89 139.18 95.66 Favored Pre-proline 0 CA--C 1.533 0.316 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.399 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -76.02 -28.65 7.38 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.128 1.886 . . . . 0.0 112.387 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 3.7 p -145.63 168.27 21.06 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.535 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -69.57 141.71 53.73 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.514 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 159.78 -168.16 35.48 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -129.13 168.4 16.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.229 0.538 . . . . 0.0 110.637 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 27.4 t -82.4 111.56 18.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.439 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -92.95 -30.13 15.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.42 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 4.9 tmtt? -159.05 128.77 5.62 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.275 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.7 t -101.3 105.73 18.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.117 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.0 mt -85.84 9.45 16.66 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.863 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 28.4 m -129.33 146.0 34.89 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-O 121.192 0.52 . . . . 0.0 110.629 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 20.5 mtpt -128.39 166.5 18.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.263 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -63.49 140.89 58.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.323 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 17.7 mmt85 65.83 36.71 5.96 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.67 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -121.89 137.44 54.78 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.272 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.2 134.21 34.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.521 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.2 m -120.72 156.96 23.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.367 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -97.51 144.12 27.53 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.393 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.3 108.05 1.62 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.96 -27.06 9.41 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.05 -0.82 . . . . 0.0 111.05 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 24.1 tt0 -59.83 143.52 50.96 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-O 121.126 0.489 . . . . 0.0 110.631 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.63 119.84 19.93 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 70.6 mt -89.67 -52.82 4.81 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.136 0.493 . . . . 0.0 110.172 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 46.3 mt -145.21 144.14 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.16 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 9.3 tttt -94.99 135.48 36.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.143 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 40.8 mm -109.2 142.69 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.412 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.815 0 CA-C-O 118.061 -1.41 . . . . 0.0 110.833 -179.919 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.26 174.06 15.25 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.94 -36.67 19.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.17 0.51 . . . . 0.0 110.492 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 68.8 -134.56 27.82 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 63.8 mttt -132.21 40.88 3.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.325 0.584 . . . . 0.0 110.471 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -148.72 176.69 10.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.456 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.44 -35.8 2.96 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -92.23 52.01 1.88 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.409 0.624 . . . . 0.0 110.437 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 114.76 -40.02 2.6 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -85.35 136.56 33.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.09 0.471 . . . . 0.0 110.42 -179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.5 mt -78.29 118.79 74.39 Favored Pre-proline 0 CA--C 1.535 0.39 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.185 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -71.53 135.33 26.14 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 121.98 1.787 . . . . 0.0 112.331 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.52 148.4 98.1 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.456 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.79 -34.73 6.48 Favored 'Trans proline' 0 N--CA 1.472 0.224 0 C-N-CA 122.276 1.984 . . . . 0.0 112.236 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -162.67 159.06 23.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.411 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.77 81.91 0.19 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.288 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -115.01 -172.79 17.5 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.9 m -109.89 136.7 48.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.061 0.458 . . . . 0.0 110.388 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.3 t -71.73 117.02 14.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.094 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.8 t -92.93 -49.99 5.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.679 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -155.37 148.35 24.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.246 0.546 . . . . 0.0 110.608 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 48.5 mt -103.37 130.15 54.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.95 179.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.7 mp -94.29 -30.72 14.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.854 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 31.0 m -114.72 145.77 20.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.112 0.482 . . . . 0.0 110.728 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -138.88 166.87 23.32 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.331 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -56.96 104.95 0.18 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.839 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 132.1 -31.02 3.1 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -87.35 144.49 26.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.108 0.48 . . . . 0.0 110.57 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.2 m -93.51 150.45 20.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.293 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.9 m -125.14 166.9 20.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.568 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -129.48 147.51 51.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.204 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.52 92.02 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.629 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.17 -30.55 2.62 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.6 tt0 -69.25 143.04 54.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.107 0.479 . . . . 0.0 110.618 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 27.1 m -65.02 138.21 58.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.206 179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.6 m -115.7 -26.38 2.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.449 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 9.1 tt -165.26 150.02 9.0 Favored 'General case' 0 C--N 1.332 -0.166 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.966 -179.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.0 t -106.74 137.91 35.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.017 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 11.8 mt -115.66 164.75 13.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.184 0.516 . . . . 0.0 110.595 -179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -135.1 101.07 4.75 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.363 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -147.11 150.94 36.0 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.445 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 67.4 mtt 60.17 29.4 18.97 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.872 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 35.0 mtpt 59.46 31.76 21.26 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.886 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.1 ptp -146.16 139.49 25.96 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.461 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -76.91 125.98 30.21 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.55 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.7 m -122.02 112.61 18.48 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.233 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -87.4 143.0 27.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.487 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 4.8 mp -116.52 126.24 73.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.123 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -101.07 153.95 19.13 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.261 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.06 141.37 95.77 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.325 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.26 -32.72 7.98 Favored 'Trans proline' 0 N--CA 1.472 0.208 0 C-N-CA 122.133 1.889 . . . . 0.0 112.212 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 73.1 p -148.16 155.92 41.97 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.348 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -63.73 142.85 58.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.393 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 169.34 -156.38 27.43 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -134.35 150.97 50.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.092 0.472 . . . . 0.0 110.372 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.9 t -78.3 111.03 14.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.276 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -93.55 -30.94 14.74 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.646 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.61 151.74 27.88 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.221 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.9 t -131.95 113.26 21.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.304 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.1 mt -84.63 -33.07 23.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.348 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 32.7 m -80.46 144.24 11.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.585 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -133.36 164.19 27.67 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.247 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 -61.28 144.35 54.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.458 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 2.5 ttt-85 61.48 35.02 17.78 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.44 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 17.2 t0 -124.62 148.04 48.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.428 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.3 141.33 28.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.469 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.8 m -122.41 156.18 27.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.379 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -100.58 140.18 35.21 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.346 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.51 98.97 0.16 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.3 -27.55 6.32 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.7 tt0 -59.56 142.63 52.28 Favored 'General case' 0 N--CA 1.462 0.127 0 CA-C-O 121.062 0.458 . . . . 0.0 110.656 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.26 121.64 26.03 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.761 -0.935 . . . . 0.0 110.761 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 79.6 mt -87.78 -54.46 4.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.075 0.464 . . . . 0.0 110.394 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 52.9 mt -141.24 149.39 20.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.312 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 14.8 tttp -98.14 126.75 43.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.343 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 36.7 mm -102.62 145.68 11.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.331 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.689 0 CA-C-O 117.988 -1.451 . . . . 0.0 110.784 179.967 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -76.77 -91.19 0.25 Allowed Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -121.2 -59.03 1.75 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.164 0.506 . . . . 0.0 110.494 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 98.94 131.87 7.46 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.804 -0.919 . . . . 0.0 110.804 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 17.2 pttt -150.41 151.45 32.81 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.133 0.492 . . . . 0.0 110.474 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.63 173.09 1.04 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.284 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -178.89 -50.71 0.08 OUTLIER Glycine 0 CA--C 1.526 0.738 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.308 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -61.92 -82.37 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.027 0.441 . . . . 0.0 110.709 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -137.64 19.2 3.36 Favored Glycine 0 CA--C 1.528 0.862 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.586 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 -92.16 139.41 30.65 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 121.132 0.492 . . . . 0.0 110.3 179.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 54.5 mt -78.04 113.67 35.27 Favored Pre-proline 0 CA--C 1.535 0.395 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.068 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.08 132.71 23.37 Favored 'Trans proline' 0 N--CA 1.472 0.249 0 C-N-CA 122.08 1.853 . . . . 0.0 112.297 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.94 147.97 98.54 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.584 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.33 -29.01 11.77 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.256 1.971 . . . . 0.0 112.314 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -163.81 -179.85 6.61 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.528 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.19 98.45 9.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.42 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.76 -177.55 14.99 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.3 m -113.63 141.27 47.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.132 0.492 . . . . 0.0 110.418 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.89 126.02 30.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.293 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.1 t -100.65 -52.28 3.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.58 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 7.2 ttmm -150.52 148.56 28.85 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.654 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 44.8 mt -102.66 131.71 50.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.019 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.9 mt -99.79 -36.37 9.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.786 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.4 ' CG1' ' CG1' ' A' ' 76' ' ' VAL . 33.6 m -110.47 146.92 15.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 121.172 0.511 . . . . 0.0 110.835 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.3 pttt -137.3 165.6 25.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.182 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -58.42 101.74 0.09 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.606 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.07 -32.6 2.17 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -88.54 146.28 25.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.129 0.49 . . . . 0.0 110.392 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -96.28 148.33 22.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.32 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.4 ' CG1' ' CG1' ' A' ' 70' ' ' VAL . 30.9 m -125.77 169.79 16.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.52 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 43.6 tttt -132.37 153.97 50.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.31 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.94 97.97 0.07 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.595 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.27 -36.75 2.19 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 14.9 tt0 -62.49 139.08 58.59 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.056 0.455 . . . . 0.0 110.67 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.6 m -65.86 137.11 56.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.206 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 24.3 m -115.67 -31.39 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.229 -179.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.5 tt -161.35 153.0 19.18 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.177 0.513 . . . . 0.0 110.86 -179.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -101.35 140.55 19.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.038 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 12.5 mt -122.78 139.24 54.21 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.161 0.505 . . . . 0.0 110.643 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -102.69 107.74 18.74 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.373 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.1 149.47 31.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.476 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 24.4 mmm 60.38 31.07 20.28 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.686 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 38.6 mmtt 59.11 29.28 18.8 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.901 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 20.0 ptp -145.34 161.17 40.27 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.477 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -86.24 127.67 34.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.507 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.6 m -113.5 123.36 49.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.312 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -84.64 130.65 34.69 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.523 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 35.6 mm -106.23 114.9 46.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.184 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -102.11 146.91 27.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.289 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.09 141.53 95.79 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.322 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.62 -34.78 6.77 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.077 1.852 . . . . 0.0 112.211 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 17.4 p -147.85 162.57 38.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.271 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -68.19 141.18 56.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.328 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.47 -158.34 29.4 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 5.6 ttpm? -132.95 149.7 52.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.976 0.417 . . . . 0.0 110.336 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.9 t -75.99 110.16 10.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.21 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -92.77 -29.97 15.74 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.582 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 27.6 tttm -159.2 129.65 5.85 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.157 0.503 . . . . 0.0 110.486 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 33.2 t -100.19 102.84 13.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.168 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.2 mt -85.24 6.38 26.29 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.64 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.7 m -120.89 136.23 58.54 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.109 0 CA-C-O 121.181 0.515 . . . . 0.0 110.312 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 83.3 mttt -126.23 164.41 21.04 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.313 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -62.1 145.33 53.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.38 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 36.6 mtt180 60.13 35.6 21.18 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.588 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -114.64 141.68 47.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.373 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.61 129.27 38.59 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.572 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.5 m -119.09 179.7 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.259 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 64.3 mt-30 -140.68 152.45 45.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.512 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.82 105.09 0.83 Allowed Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.9 -31.39 4.97 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -60.05 135.32 57.68 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.131 0.491 . . . . 0.0 110.541 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.81 121.07 25.4 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 62.3 mt -87.36 -56.51 3.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.012 0.434 . . . . 0.0 110.296 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 49.1 mt -143.15 150.89 17.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.126 179.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -96.2 125.7 40.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.265 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.8 mm -106.46 143.36 17.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.516 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.697 0 CA-C-O 117.951 -1.471 . . . . 0.0 110.767 179.977 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -78.19 73.18 2.21 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -131.42 104.29 6.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.135 0.493 . . . . 0.0 110.41 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -179.59 -68.64 0.07 OUTLIER Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -147.35 132.15 17.99 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.07 0.462 . . . . 0.0 110.416 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.59 178.81 0.7 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.416 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -167.6 -69.62 0.03 OUTLIER Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -127.06 114.13 17.35 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.023 0.44 . . . . 0.0 110.378 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 106.69 -52.65 0.66 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -83.34 134.64 34.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.026 0.441 . . . . 0.0 110.38 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.424 HG22 HD11 ' A' ' 57' ' ' ILE . 54.3 mt -82.11 111.06 24.26 Favored Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.282 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -71.57 142.67 40.71 Favored 'Trans proline' 0 N--CA 1.472 0.263 0 C-N-CA 122.0 1.8 . . . . 0.0 112.295 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -74.7 147.14 84.15 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.397 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -72.49 -26.51 16.77 Favored 'Trans proline' 0 N--CA 1.471 0.199 0 C-N-CA 122.182 1.921 . . . . 0.0 112.366 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -164.55 157.57 17.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.362 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -73.52 97.15 2.53 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.43 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.86 -144.55 6.22 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 3.9 m -136.54 132.18 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.095 0.474 . . . . 0.0 110.358 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.8 t -67.71 130.5 33.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.254 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 4.8 p -101.6 -53.98 2.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.542 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 23.8 ttpt -152.82 147.26 25.82 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.588 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 47.3 mt -100.23 133.48 43.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.116 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 25.7 mt -98.64 -31.3 12.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.638 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.0 m -104.51 149.95 7.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.701 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 67.7 mttt -137.19 163.43 30.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.206 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -62.36 97.0 0.08 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.258 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.19 -29.19 2.43 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -85.43 147.82 26.3 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.082 0.467 . . . . 0.0 110.442 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.88 150.21 20.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.147 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 31.6 m -128.54 170.02 18.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.653 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.5 mmtt -131.38 146.26 52.2 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.22 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -58.84 96.51 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.717 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.16 -34.5 2.3 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 23.6 tt0 -67.84 144.46 55.3 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.14 0.495 . . . . 0.0 110.515 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.5 m -65.13 136.73 57.05 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.315 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.3 m -112.73 -33.09 2.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.921 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.5 tt -160.4 150.75 18.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.686 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.2 t -102.55 136.64 33.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.184 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -117.16 164.1 15.28 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.519 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -135.97 112.84 10.25 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.28 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -145.84 138.61 25.78 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.49 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 12.2 mmt 60.68 32.68 20.31 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.512 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 61.11 33.26 19.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.374 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 28.1 ttm -140.03 121.81 15.42 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.496 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -69.98 125.09 25.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.459 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 24.1 m -116.47 124.64 50.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.388 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -85.01 134.14 34.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.486 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.468 HD12 HG22 ' A' ' 94' ' ' ILE . 38.3 mm -102.66 126.1 56.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.242 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 13.7 p30 -110.25 140.06 44.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.314 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.11 139.24 96.03 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.311 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.81 -31.04 8.75 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.166 1.911 . . . . 0.0 112.227 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 78.2 p -147.01 151.31 36.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.344 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -66.78 142.67 57.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.352 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.62 -147.93 8.76 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -140.88 145.47 36.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.076 0.465 . . . . 0.0 110.316 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 24.7 t -77.8 107.45 9.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.327 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -91.92 -28.42 17.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.729 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 17.8 ttpt -160.75 130.89 5.14 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.099 0.476 . . . . 0.0 110.544 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.49 109.52 28.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.347 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.6 mt -78.92 -31.8 45.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.476 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 31.5 m -80.18 152.84 4.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.593 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -135.79 155.11 50.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.268 179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -59.01 141.99 52.44 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.632 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER 60.75 36.39 19.34 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.499 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -119.45 151.11 39.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.286 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -93.64 133.4 37.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.491 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.7 m -120.39 152.01 23.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.453 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -100.17 144.93 28.62 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.354 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.62 105.63 0.96 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 117.91 -28.04 7.19 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 37.3 tt0 -59.85 139.96 56.96 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 121.127 0.489 . . . . 0.0 110.597 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.36 126.58 40.3 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 41.5 mt -89.43 -58.94 2.35 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.153 0.501 . . . . 0.0 110.567 -179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 58.4 mt -140.95 145.57 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.164 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -93.41 123.76 36.94 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.536 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.1 mm -101.23 145.07 12.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.274 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.678 0 CA-C-O 117.947 -1.474 . . . . 0.0 110.875 -179.996 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.89 94.56 2.36 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.729 -0.948 . . . . 0.0 110.729 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.49 84.3 6.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.001 0.429 . . . . 0.0 110.457 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 159.83 -175.85 36.62 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 46.0 mttt -143.61 40.05 1.41 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.338 0.59 . . . . 0.0 110.322 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -145.66 135.22 23.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.426 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -141.18 -95.34 0.25 Allowed Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.846 -0.902 . . . . 0.0 110.846 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -92.86 114.24 26.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.158 0.504 . . . . 0.0 110.438 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.04 -60.36 0.34 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -83.89 128.35 34.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.072 0.463 . . . . 0.0 110.453 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 43.4 mt -79.27 120.22 79.77 Favored Pre-proline 0 CA--C 1.534 0.335 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.157 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.22 138.72 31.01 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 121.998 1.799 . . . . 0.0 112.375 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -75.2 147.92 83.44 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.42 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -72.27 -28.53 15.21 Favored 'Trans proline' 0 CA--C 1.527 0.156 0 C-N-CA 122.324 2.016 . . . . 0.0 112.409 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.6 pp -163.25 163.2 25.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.436 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.16 98.17 5.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.437 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -123.65 -148.04 7.43 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.742 -0.943 . . . . 0.0 110.742 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.1 m -136.4 140.21 43.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.064 0.459 . . . . 0.0 110.439 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t -72.28 120.12 20.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.16 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -96.82 -51.28 4.33 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.693 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -152.97 144.08 23.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.64 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 33.3 mt -97.45 131.46 44.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.0 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.3 mp -100.11 -29.44 12.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.884 -179.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 28.3 m -118.71 145.76 24.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-O 121.255 0.55 . . . . 0.0 110.685 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.3 pttm -136.52 167.04 22.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.175 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 9.1 mp0 -60.51 105.27 0.42 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.49 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -31.55 2.26 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 50.4 m-20 -93.82 149.49 21.19 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.064 0.459 . . . . 0.0 110.497 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -102.18 143.44 31.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.286 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 22.9 m -122.03 162.1 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.551 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -122.98 158.07 31.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.265 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.47 101.83 0.2 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.518 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.29 -36.09 2.31 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -65.45 137.97 57.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.054 0.454 . . . . 0.0 110.563 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 11.1 m -64.13 139.38 58.76 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.172 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 33.1 m -113.96 -30.53 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.19 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 8.9 tt -164.66 151.64 11.17 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.088 0.47 . . . . 0.0 110.782 -179.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 t -104.21 136.84 35.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.077 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 16.0 mt -118.07 159.79 22.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.651 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -132.87 111.11 10.8 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.376 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -145.56 143.95 30.22 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.465 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 42.7 mmm 60.5 33.17 20.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.473 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.85 33.8 19.86 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.511 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 2.7 ttt -143.96 136.19 26.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.444 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -82.16 126.17 31.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.517 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 24.7 m -116.08 124.41 50.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.341 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -82.17 132.26 35.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.479 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.458 HD13 HG21 ' A' ' 94' ' ' ILE . 36.2 mm -102.15 121.49 53.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.248 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -109.73 143.65 39.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.352 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.57 143.5 93.49 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.407 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -72.67 -35.54 5.85 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.118 1.879 . . . . 0.0 112.223 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 19.6 p -148.7 166.1 29.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.365 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -66.65 141.59 57.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.471 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.04 -162.35 32.91 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 6.8 ttpm? -133.07 147.53 52.18 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.034 0.445 . . . . 0.0 110.465 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.8 t -77.75 111.08 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.166 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -94.86 -30.07 14.38 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.638 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.7 tttp -159.02 131.01 6.54 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.345 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.3 t -96.66 110.68 25.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.312 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 29.8 mt -90.27 30.24 1.14 Allowed 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.633 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 23.2 m -155.59 139.24 8.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-O 121.02 0.438 . . . . 0.0 110.259 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.67 165.13 18.45 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.134 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -60.91 147.19 43.96 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.555 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 60.99 35.76 18.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.505 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.9 t0 -121.36 137.72 54.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.412 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -89.24 134.75 33.91 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.432 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.0 m -122.39 155.91 27.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.417 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -100.23 145.88 27.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.453 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.17 112.36 4.65 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 109.85 -27.8 11.51 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -57.45 145.33 33.36 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 121.07 0.462 . . . . 0.0 110.779 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.01 122.02 28.37 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 97.8 mt -90.42 -56.77 3.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.114 0.483 . . . . 0.0 110.523 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.5 mt -140.94 145.74 24.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.301 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 7.2 ttmt -92.46 124.44 36.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.365 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.6 mm -103.46 145.1 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.448 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.218 -0.848 0 CA-C-O 118.076 -1.402 . . . . 0.0 110.701 179.952 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 118.95 -43.87 1.51 Allowed Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.91 110.17 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.114 0.483 . . . . 0.0 110.553 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 178.61 -153.41 12.66 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 21.5 mmtt -135.24 39.57 2.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.258 0.552 . . . . 0.0 110.421 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -153.03 162.67 41.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.321 179.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 156.52 -55.74 0.39 Allowed Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.814 -0.915 . . . . 0.0 110.814 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -102.34 86.48 2.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.089 0.471 . . . . 0.0 110.492 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.04 -49.65 0.92 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -82.92 130.27 35.12 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.02 0.438 . . . . 0.0 110.382 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 55.3 mt -80.25 111.22 20.53 Favored Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.053 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -70.68 141.86 42.51 Favored 'Trans proline' 0 N--CA 1.472 0.262 0 C-N-CA 122.032 1.821 . . . . 0.0 112.292 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -75.85 144.89 77.06 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.475 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -73.71 -24.74 15.43 Favored 'Trans proline' 0 N--CA 1.472 0.217 0 C-N-CA 122.188 1.925 . . . . 0.0 112.59 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -161.55 167.54 25.2 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.454 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -91.7 95.49 9.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.369 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -122.83 -139.67 5.56 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.9 m -136.12 134.61 38.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.083 0.468 . . . . 0.0 110.406 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 26.4 t -71.34 125.61 30.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.279 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.9 t -95.7 -54.79 3.23 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.578 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -152.43 149.52 28.67 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.523 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 48.9 mt -102.27 133.39 46.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.221 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.9 mp -98.82 -31.5 11.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.618 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 33.2 m -114.79 144.91 21.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.681 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.85 165.54 25.39 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.26 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -59.33 101.52 0.1 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.598 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.09 -31.81 2.24 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -90.11 150.03 22.23 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.089 0.471 . . . . 0.0 110.486 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -96.23 149.43 21.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.332 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 30.3 m -122.73 168.33 15.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.464 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 21.4 ttpt -128.34 148.49 50.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.346 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.05 100.83 0.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.612 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.11 -31.31 4.75 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.1 tt0 -64.08 143.73 57.65 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.057 0.456 . . . . 0.0 110.67 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 21.4 m -65.44 138.84 58.38 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.219 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 28.4 m -118.49 -32.2 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.384 -179.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.5 tt -161.04 152.28 18.91 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.311 0.577 . . . . 0.0 111.296 -179.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 19.7 t -103.45 147.32 9.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.557 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 7.4 mt -127.48 170.44 12.57 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.156 0.503 . . . . 0.0 110.785 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -139.28 110.92 7.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.478 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -145.88 142.68 29.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.486 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 24.9 mmt 60.52 32.36 20.46 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.572 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 52.4 mttt 60.61 32.69 20.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.476 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -141.28 127.75 20.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.412 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -68.58 129.23 39.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.565 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -112.13 176.19 5.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.656 179.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -146.02 134.87 22.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.28 0.562 . . . . 0.0 110.648 -179.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 37.3 mm -102.57 153.7 5.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.146 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -136.91 141.45 42.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.353 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.93 135.52 94.65 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.309 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -73.85 -31.64 8.09 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.073 1.849 . . . . 0.0 112.268 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 25.1 p -146.13 157.57 43.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.411 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -65.86 141.81 58.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.279 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.66 -158.52 26.69 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 26.5 ttpt -133.74 148.54 51.42 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.144 0.497 . . . . 0.0 110.413 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 23.7 t -75.47 105.83 4.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.27 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -92.49 -26.67 17.85 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.859 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 27.9 ttmt -158.93 129.08 5.81 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.098 0.475 . . . . 0.0 110.635 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 24.9 t -102.29 106.13 19.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.194 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 18.1 mt -89.5 13.33 14.11 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.632 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 30.7 m -130.12 143.77 40.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 CA-C-O 121.079 0.466 . . . . 0.0 110.312 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 13.6 mtmm -126.08 168.01 14.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.387 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -72.29 143.25 48.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.338 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 16.3 mtm180 61.42 38.5 15.98 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.514 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -126.45 148.04 49.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.336 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.83 140.0 30.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.56 -179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.9 m -122.8 156.02 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.274 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 39.0 mm-40 -101.94 142.39 33.31 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.337 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.38 111.38 3.38 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 108.72 -25.02 20.52 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -59.9 140.97 56.3 Favored 'General case' 0 N--CA 1.462 0.15 0 CA-C-O 121.017 0.437 . . . . 0.0 110.791 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.48 118.37 14.6 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 33.2 mt -88.58 -54.02 4.37 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.124 0.487 . . . . 0.0 110.497 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.4 HG22 HD13 ' A' ' 120' ' ' ILE . 52.2 mt -142.4 142.74 26.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.325 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.0 122.49 38.88 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.097 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.0 mm -100.66 142.46 15.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.479 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.667 0 CA-C-O 117.972 -1.46 . . . . 0.0 110.758 179.931 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -144.79 170.46 26.32 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.801 -0.919 . . . . 0.0 110.801 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -133.65 113.15 12.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.1 0.476 . . . . 0.0 110.468 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 111.89 39.27 1.31 Allowed Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt -126.02 154.52 42.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.107 0.479 . . . . 0.0 110.464 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -84.54 169.89 13.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.417 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 141.01 47.25 0.05 OUTLIER Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -167.52 33.82 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.099 0.476 . . . . 0.0 110.391 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 117.11 -32.42 5.45 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -77.28 140.48 40.06 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.079 0.466 . . . . 0.0 110.542 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.5 mt -79.49 120.28 79.79 Favored Pre-proline 0 CA--C 1.534 0.348 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.081 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -72.19 146.06 45.27 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 121.996 1.797 . . . . 0.0 112.352 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -74.55 148.47 85.58 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.41 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.85 -28.5 13.43 Favored 'Trans proline' 0 N--CA 1.472 0.207 0 C-N-CA 122.207 1.938 . . . . 0.0 112.345 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.7 pp -166.27 165.3 17.49 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.494 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.69 84.21 3.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.396 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -120.92 -166.57 13.06 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.8 m -112.28 135.78 52.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.132 0.492 . . . . 0.0 110.357 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 25.1 t -70.79 126.11 30.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.247 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 4.5 p -97.82 -61.63 1.36 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.604 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 9.1 mmmt -141.47 150.23 41.97 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.607 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 33.6 mt -110.22 120.55 61.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.842 179.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.4 mt -96.82 27.66 3.85 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.344 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 31.5 m -155.5 151.18 10.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 121.195 0.521 . . . . 0.0 110.483 179.642 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.9 pttt -141.6 160.33 40.39 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.054 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -60.34 95.05 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.431 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.18 -26.63 2.57 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -80.64 149.05 29.98 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.161 0.505 . . . . 0.0 110.457 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.6 m -97.32 137.71 35.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.228 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 34.6 m -119.78 145.03 26.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.556 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 mtmt -108.74 147.53 31.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.235 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -58.5 102.04 0.1 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.812 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.01 -32.72 3.38 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 12.7 tt0 -65.15 143.9 57.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.055 0.455 . . . . 0.0 110.501 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.9 m -66.95 138.45 57.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.221 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 32.3 m -119.37 -31.29 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.531 -179.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 9.9 tt -162.37 146.23 11.85 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.129 0.49 . . . . 0.0 111.032 -179.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.0 t -108.81 143.08 19.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.89 179.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -124.38 163.59 21.42 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.186 0.517 . . . . 0.0 110.798 -179.6 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.2 mt-10 -137.22 111.39 8.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.371 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -147.38 146.87 29.78 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.5 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 7.8 mmt 60.34 34.04 20.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.584 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 27.1 mtpt 60.92 33.4 19.86 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.495 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 12.9 mtm -141.75 155.81 45.61 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.399 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -98.15 128.68 44.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.52 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.9 m -113.15 116.55 30.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.22 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -91.78 125.91 36.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.526 -179.751 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 5.3 mp -108.72 148.46 12.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.954 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -135.89 156.12 49.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.165 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.56 135.58 95.61 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.337 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.37 -32.47 8.05 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.044 1.829 . . . . 0.0 112.224 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.1 p -145.61 159.33 43.3 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.315 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -63.64 140.03 58.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.339 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.17 -161.69 32.78 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.3 ttmp? -135.62 146.75 48.22 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.062 0.458 . . . . 0.0 110.444 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 30.3 t -75.99 114.07 15.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.147 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -94.94 -30.02 14.36 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.778 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 77.6 tttt -159.98 128.91 5.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.546 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.1 t -107.62 108.71 25.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.271 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 mt -79.21 -31.62 43.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.447 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.6 m -80.77 145.27 9.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.567 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -130.36 157.67 41.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.21 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 66.5 mt-10 -59.27 143.21 49.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.668 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 24.4 ttt180 61.76 32.84 18.15 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.305 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -116.24 151.06 36.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.427 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.83 135.51 34.06 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.442 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.8 m -120.53 179.67 2.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.43 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -135.42 145.29 47.11 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.366 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.45 109.43 2.48 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.0 -29.32 8.13 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.3 tt0 -60.11 140.82 56.65 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 121.146 0.498 . . . . 0.0 110.609 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.38 122.04 28.06 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 87.7 mt -89.22 -61.63 1.66 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.132 0.491 . . . . 0.0 110.503 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.433 HD13 HG22 ' A' ' 120' ' ' ILE . 55.4 mt -140.96 151.83 20.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.362 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 33.0 tttm -98.63 134.63 41.3 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.386 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 35.4 mm -108.06 146.87 13.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.424 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.779 0 CA-C-O 118.049 -1.417 . . . . 0.0 110.786 179.958 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -149.21 -152.88 5.85 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.62 161.99 0.06 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.12 0.486 . . . . 0.0 110.518 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 88.4 -78.63 1.73 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 16.5 ttmt -142.22 142.26 32.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.108 0.48 . . . . 0.0 110.353 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.75 175.47 1.45 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.382 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -175.59 -43.9 0.06 OUTLIER Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -63.72 -149.85 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.472 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -87.98 18.12 42.07 Favored Glycine 0 CA--C 1.534 1.272 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.907 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -81.84 152.41 26.9 Favored 'General case' 0 C--O 1.231 0.081 0 CA-C-O 121.015 0.435 . . . . 0.0 110.272 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.4 HD11 HG23 ' A' ' 57' ' ' ILE . 54.8 mt -80.1 111.41 21.8 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.17 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -71.1 153.41 62.68 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.011 1.807 . . . . 0.0 112.218 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.97 143.05 60.92 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.468 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -74.13 -27.91 11.33 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.121 1.881 . . . . 0.0 112.309 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -163.9 162.91 23.75 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.364 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.56 92.07 5.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.39 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -126.16 -141.85 5.59 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 19.8 m -138.04 138.3 38.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.003 0.43 . . . . 0.0 110.459 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.9 t -70.66 125.31 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.208 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.1 t -98.24 -46.42 5.83 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.564 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 36.0 mtmt -149.16 169.84 19.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.606 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 51.7 mt -129.8 125.81 61.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.946 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 20.4 mt -97.24 -28.11 14.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.12 -179.383 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 32.9 m -101.47 156.77 4.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.346 0.593 . . . . 0.0 111.218 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 22.5 mttp -135.96 151.9 50.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.843 179.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -60.78 90.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.52 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.09 -25.86 2.63 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 63.8 m-20 -78.72 148.66 32.96 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.143 0.497 . . . . 0.0 110.5 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 5.3 m -97.02 140.04 32.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.184 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 30.0 m -121.91 171.26 10.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.66 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -127.42 138.66 53.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.191 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -56.11 100.25 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.029 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.86 -38.84 1.63 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 45.3 tt0 -69.35 144.82 53.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.065 0.459 . . . . 0.0 110.599 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 17.6 m -65.02 139.11 58.71 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.317 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 35.1 m -115.05 -25.88 3.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.397 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.7 tt -166.58 146.52 5.86 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 121.052 0.453 . . . . 0.0 110.702 -179.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -105.1 141.26 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.133 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 12.1 mt -120.11 158.28 27.22 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.553 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -137.53 114.89 11.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.397 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.76 136.76 19.58 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.418 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 69.0 mtp 60.68 32.22 20.26 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.537 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 11.5 mtmm 60.53 32.68 20.51 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.568 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.1 ttt -135.71 104.74 5.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.381 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -62.04 128.52 36.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.41 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.8 m -129.0 113.0 14.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.131 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -87.22 142.98 27.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.717 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 4.6 mp -115.21 127.08 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.907 179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 42.4 m-20 -102.5 153.31 20.19 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.207 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.85 136.22 94.84 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.345 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -72.62 -35.25 6.23 Favored 'Trans proline' 0 N--CA 1.471 0.2 0 C-N-CA 122.09 1.86 . . . . 0.0 112.172 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.5 p -147.36 155.32 41.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.296 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -64.49 140.43 58.87 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.384 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.21 -157.94 26.14 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 15.7 ttmm -132.31 143.7 50.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.065 0.459 . . . . 0.0 110.468 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 36.0 t -78.78 110.08 14.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.171 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.09 -29.65 16.43 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.84 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 8.0 ttpt -157.86 131.03 7.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.448 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.8 t -101.06 115.46 42.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.243 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 19.9 mt -89.95 28.52 1.36 Allowed 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.698 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 19.2 m -155.69 142.5 11.3 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 121.038 0.447 . . . . 0.0 110.378 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.5 tttt -125.89 165.03 19.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.188 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -59.61 143.05 51.51 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.615 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 30.2 mtm180 60.14 34.01 21.15 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.558 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -114.21 149.16 36.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.338 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.92 134.98 34.29 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.526 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.6 m -122.38 149.91 25.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.331 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 55.9 mt-30 -99.68 144.1 29.15 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.416 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.42 110.07 2.71 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.739 -0.945 . . . . 0.0 110.739 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 110.24 -27.29 11.85 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -59.64 139.77 56.94 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.056 0.455 . . . . 0.0 110.668 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.12 123.08 31.53 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 65.8 mt -87.57 -54.01 4.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.032 0.444 . . . . 0.0 110.405 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 50.2 mt -141.5 149.64 20.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.426 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.0 tttm -99.25 130.51 45.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.299 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.446 HG22 HD12 ' A' ' 122' ' ' ILE . 37.2 mm -107.63 144.71 15.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.506 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.797 0 CA-C-O 117.964 -1.464 . . . . 0.0 110.806 179.969 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -99.87 117.01 5.74 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -162.21 89.25 0.69 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.096 0.474 . . . . 0.0 110.41 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 134.98 139.06 4.0 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 46.6 mttp -120.43 40.73 3.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.326 0.584 . . . . 0.0 110.394 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -151.44 179.51 8.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.433 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.71 -49.03 0.93 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.716 -0.953 . . . . 0.0 110.716 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -92.46 75.55 5.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.273 0.559 . . . . 0.0 110.408 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 99.78 -41.51 2.17 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 -83.92 130.04 34.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.1 0.476 . . . . 0.0 110.477 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 45.0 mt -78.82 111.76 22.04 Favored Pre-proline 0 CA--C 1.534 0.363 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.212 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.94 137.82 32.82 Favored 'Trans proline' 0 N--CA 1.473 0.267 0 C-N-CA 122.084 1.856 . . . . 0.0 112.374 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.72 149.13 98.02 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.465 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.52 -27.55 15.53 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.253 1.969 . . . . 0.0 112.414 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 pp -164.79 165.22 20.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.443 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.34 96.49 5.32 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.363 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -128.4 -141.11 5.14 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.776 -0.929 . . . . 0.0 110.776 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.1 m -136.71 141.51 43.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.002 0.43 . . . . 0.0 110.46 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 23.1 t -71.21 128.64 34.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.218 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 t -98.67 -62.0 1.3 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.518 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 9.8 mtpt -150.16 144.81 25.92 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.457 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 42.2 mt -99.24 128.85 50.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.039 179.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.9 mp -97.67 -36.03 10.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.829 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 33.7 m -115.17 139.26 42.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.263 0.554 . . . . 0.0 110.78 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 20.9 pttt -135.91 162.75 31.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.793 179.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -54.61 108.64 0.41 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.279 0.561 . . . . 0.0 110.783 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.42 -29.98 2.35 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -102.53 155.12 18.49 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.974 0.416 . . . . 0.0 110.396 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.4 m -96.91 150.43 20.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.43 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 30.3 m -123.97 168.28 16.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.498 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 28.4 mmtm -129.69 155.28 46.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.448 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.2 105.76 0.64 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.453 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.25 -29.37 7.07 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -61.32 142.7 56.7 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.104 0.478 . . . . 0.0 110.564 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.9 m -67.1 138.14 56.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.271 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.4 m -118.17 -34.26 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.208 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 6.5 tt -162.11 152.02 16.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.134 0.492 . . . . 0.0 111.078 -179.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.8 t -102.89 143.15 15.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.654 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -119.49 167.69 11.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.229 0.538 . . . . 0.0 110.782 -179.559 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -138.33 109.21 6.7 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.365 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.57 133.72 17.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.333 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 66.9 mtm 61.06 50.71 4.84 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.26 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.2 ptpp? 41.41 32.22 0.21 Allowed 'General case' 0 N--CA 1.474 0.739 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.984 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 19.5 ttm -139.52 112.3 7.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.424 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -61.8 130.75 47.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.403 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 14.0 m -118.47 123.09 44.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.33 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -84.51 132.26 34.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.59 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 30.8 mm -105.45 148.72 9.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.049 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -139.29 150.83 45.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.612 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.63 143.73 96.35 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.399 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -72.62 -34.42 7.21 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.186 1.924 . . . . 0.0 112.26 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 14.3 p -146.95 168.45 21.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.312 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -68.82 142.26 54.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.463 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.1 -161.25 32.27 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.2 ttpt -133.62 138.91 46.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.062 0.458 . . . . 0.0 110.464 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 22.3 t -74.22 123.73 30.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.238 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -99.03 -33.17 10.92 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.588 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -160.88 147.82 15.29 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.412 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 11.9 t -101.29 119.0 48.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.008 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mt -89.53 21.56 3.36 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.919 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 30.6 m -154.56 156.3 5.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-O 121.093 0.473 . . . . 0.0 110.673 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.5 mtmp? -130.85 159.03 38.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.25 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 64.4 mt-10 -60.51 151.26 28.99 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.513 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? 60.99 32.33 19.92 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.521 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -122.91 150.9 42.31 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.452 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.01 137.56 32.27 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.348 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.5 m -121.12 148.71 24.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.432 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -98.1 140.66 32.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.259 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.54 96.28 0.09 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 127.51 -27.87 4.61 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -59.31 142.71 51.39 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.086 0.47 . . . . 0.0 110.704 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.22 120.93 24.71 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 14.1 mt -89.78 -50.2 6.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.079 0.466 . . . . 0.0 110.418 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 45.9 mt -145.27 147.82 18.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.297 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.5 mttp -95.43 130.34 42.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.158 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.5 mm -110.39 144.67 18.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.357 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.711 0 CA-C-O 117.974 -1.459 . . . . 0.0 110.76 -179.997 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 143.97 -33.04 1.76 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -176.75 116.86 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.047 0.451 . . . . 0.0 110.435 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 68.27 -163.11 48.91 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 2.4 mtpm? -160.88 40.74 0.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.301 0.572 . . . . 0.0 110.494 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -145.42 99.12 3.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.344 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -104.6 -75.19 1.01 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.836 -0.905 . . . . 0.0 110.836 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -123.82 100.46 6.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.101 0.477 . . . . 0.0 110.443 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 130.17 -57.93 0.71 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 -83.97 137.06 33.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.107 0.48 . . . . 0.0 110.459 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 35.5 mt -81.81 112.22 32.93 Favored Pre-proline 0 CA--C 1.535 0.366 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.167 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -70.73 128.56 15.3 Favored 'Trans proline' 0 N--CA 1.472 0.233 0 C-N-CA 122.017 1.811 . . . . 0.0 112.363 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.95 148.64 87.75 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.49 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.99 -26.82 18.08 Favored 'Trans proline' 0 N--CA 1.471 0.15 0 C-N-CA 122.283 1.989 . . . . 0.0 112.509 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -163.75 168.54 19.58 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.423 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.75 102.83 13.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.499 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -133.98 -140.73 4.37 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 16.0 m -137.15 142.1 42.23 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.104 0.478 . . . . 0.0 110.369 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 23.1 t -71.96 131.99 33.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.122 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -101.37 -54.17 2.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.502 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 33.5 tttt -155.74 147.0 22.59 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.594 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 8.8 mt -100.43 130.78 49.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.972 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.1 mt -101.56 -41.88 6.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.691 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 29.5 m -93.54 149.88 4.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.761 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -135.11 162.22 33.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.255 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -60.94 96.6 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.543 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.0 -31.22 2.3 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -79.78 147.07 31.99 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.127 0.489 . . . . 0.0 110.449 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 6.7 m -95.9 141.12 29.7 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.382 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.9 m -120.06 160.93 20.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.555 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 tttt -120.08 146.97 45.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.311 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.84 93.46 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.69 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.42 -32.43 2.55 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -67.84 141.12 56.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.976 0.417 . . . . 0.0 110.52 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.0 m -63.34 137.22 58.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.189 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.6 m -114.01 -35.1 2.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.781 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.0 tt -159.18 151.49 21.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.449 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.2 t -102.9 143.44 15.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.042 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -124.06 164.75 18.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.582 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -137.38 115.42 11.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.338 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.65 136.95 23.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.391 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 15.7 mtt 60.83 32.93 20.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.514 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.9 mptt 60.95 35.14 19.21 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.477 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.7 mtt -139.43 126.77 21.43 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.461 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -71.05 128.68 36.75 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.43 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.5 m -119.41 120.42 36.8 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.425 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -85.09 129.98 34.7 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.514 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.415 HD12 HG23 ' A' ' 94' ' ' ILE . 33.6 mm -103.13 124.55 57.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.327 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -110.29 147.76 33.23 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.376 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.78 138.42 96.96 Favored Pre-proline 0 CA--C 1.532 0.282 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.346 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.65 -32.87 7.18 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.087 1.858 . . . . 0.0 112.162 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 5.7 p -149.63 155.03 39.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.345 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -61.85 141.96 57.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.443 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 170.07 -157.37 28.75 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.1 ttmp? -134.82 148.07 50.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.129 0.49 . . . . 0.0 110.523 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 26.2 t -77.06 113.54 16.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.326 179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -93.26 -30.83 14.97 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.699 -179.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 13.1 ttpt -159.45 133.57 7.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.569 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.6 t -101.92 108.11 23.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.144 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mt -89.58 13.13 14.77 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.578 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.3 m -130.72 136.59 57.92 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-O 121.123 0.487 . . . . 0.0 110.186 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -125.49 172.16 9.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.226 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -72.05 150.63 43.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.311 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 37.3 mtt-85 61.45 30.89 19.07 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.664 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -125.88 139.33 53.56 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.285 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.17 141.57 28.44 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.449 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.2 m -121.09 156.95 24.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.391 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -99.22 144.6 28.15 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.373 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.12 106.08 1.03 Allowed Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 117.56 -28.51 7.08 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.0 tt0 -59.21 137.7 57.87 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.126 0.489 . . . . 0.0 110.713 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.15 123.25 31.96 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 17.1 mt -86.5 -55.85 3.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.191 0.52 . . . . 0.0 110.534 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.8 mt -140.88 152.31 20.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.336 -179.779 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -96.92 132.52 42.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.476 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 36.9 mm -109.52 145.18 16.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.303 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.791 0 CA-C-O 118.095 -1.392 . . . . 0.0 110.757 -179.953 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 176.54 90.79 0.08 OUTLIER Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -97.77 145.37 26.43 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.127 0.489 . . . . 0.0 110.433 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -95.18 -55.17 1.4 Allowed Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 11.3 ptmt -152.46 145.06 24.19 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.08 0.466 . . . . 0.0 110.424 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -70.74 178.18 3.2 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.483 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -179.05 95.89 0.1 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 59.2 101.6 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.132 0.491 . . . . 0.0 110.731 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 118.2 -61.17 0.46 Allowed Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 -83.51 136.76 34.16 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.066 0.46 . . . . 0.0 110.354 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 45.4 mt -79.74 111.63 22.9 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.263 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -72.48 129.8 15.25 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 121.982 1.788 . . . . 0.0 112.217 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -62.09 139.43 96.0 Favored Pre-proline 0 CA--C 1.532 0.274 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.274 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -75.43 -12.0 20.7 Favored 'Trans proline' 0 CA--C 1.533 0.445 0 C-N-CA 122.091 1.861 . . . . 0.0 113.038 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -160.73 179.55 8.44 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-O 121.099 0.476 . . . . 0.0 110.48 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -109.76 113.34 26.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.401 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -149.5 -138.87 3.0 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 12.3 m -135.82 139.36 43.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.103 0.478 . . . . 0.0 110.411 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 28.1 t -70.48 126.5 30.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.18 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t -97.04 -55.06 2.98 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.574 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 ttpt -153.08 149.09 27.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.521 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 41.7 mt -103.01 135.66 39.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.059 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 9.7 mp -99.72 -45.08 5.88 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.818 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 34.8 m -97.2 148.16 5.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.218 0.532 . . . . 0.0 110.876 -179.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 pttt -137.24 163.66 30.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.195 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -59.64 102.59 0.15 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.584 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.51 2.26 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -91.91 151.45 20.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.119 0.485 . . . . 0.0 110.492 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.58 153.67 17.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.312 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 30.9 m -126.14 167.67 20.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.562 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 mttm -129.05 148.05 50.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.37 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.16 93.14 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.715 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.88 -34.8 2.17 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -64.0 143.95 57.46 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.086 0.469 . . . . 0.0 110.582 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 9.0 m -66.92 139.58 57.72 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.336 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 35.6 m -114.11 -32.68 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.939 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.9 tt -161.49 148.38 14.52 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.106 0.479 . . . . 0.0 110.797 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -103.4 140.37 21.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.113 179.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 2.1 mt -119.83 172.09 7.95 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.56 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -135.09 106.71 6.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.444 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.92 152.26 34.72 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.465 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 16.4 mtt 60.02 30.5 19.98 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.648 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 52.5 mttt 59.81 31.54 20.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.684 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 14.8 ptp -148.72 153.41 38.17 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.352 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -80.79 128.24 33.43 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.569 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.5 m -112.41 117.54 32.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.283 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -84.99 135.52 33.99 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.56 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 41.1 mm -106.7 122.33 60.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.255 179.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -104.95 142.81 34.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.362 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.13 144.11 91.53 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -72.57 -38.95 2.94 Favored 'Trans proline' 0 CA--C 1.528 0.216 0 C-N-CA 122.175 1.917 . . . . 0.0 112.168 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.8 p -148.39 165.14 31.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.309 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -66.6 141.43 57.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.393 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 172.82 -157.37 26.58 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 17.7 ttmt -136.11 146.69 47.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.104 0.478 . . . . 0.0 110.488 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 23.0 t -74.7 108.72 6.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.186 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -91.52 -29.12 17.15 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.809 -179.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.4 ttmm -159.33 130.27 6.0 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.095 0.474 . . . . 0.0 110.53 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 32.3 t -102.19 105.72 18.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.184 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.4 mt -88.0 10.21 19.74 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.67 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 23.7 m -125.59 136.13 61.81 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.062 0 CA-C-O 121.11 0.481 . . . . 0.0 110.258 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.8 ttpm? -122.56 169.36 11.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.391 -179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 -66.65 142.5 57.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.356 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER 63.17 38.14 10.82 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.66 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -117.8 142.36 47.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.319 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.91 131.61 36.43 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.427 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.8 m -119.59 179.82 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.452 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -141.46 149.35 40.84 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.427 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.55 104.4 0.7 Allowed Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.64 -31.49 4.57 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -61.64 135.9 57.81 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.091 0.472 . . . . 0.0 110.445 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -63.01 118.89 15.27 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 69.3 mt -88.38 -56.21 3.41 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.074 0.464 . . . . 0.0 110.392 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 50.9 mt -142.26 144.94 24.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.323 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.7 tttt -96.55 132.76 41.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.333 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 39.2 mm -107.25 144.88 15.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.416 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.738 0 CA-C-O 117.958 -1.468 . . . . 0.0 110.813 -179.992 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 99.95 -98.97 1.98 Allowed Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.69 95.68 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.105 0.479 . . . . 0.0 110.501 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -101.55 143.32 16.03 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 14.5 pttm -162.67 142.48 9.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.085 0.469 . . . . 0.0 110.453 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.43 178.77 0.51 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.391 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.87 -88.72 0.07 OUTLIER Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.0 tm-20 -128.59 124.15 35.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.111 0.482 . . . . 0.0 110.458 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 107.93 -49.73 0.84 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -84.26 136.39 33.95 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.104 0.478 . . . . 0.0 110.438 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.6 mt -77.84 111.67 19.51 Favored Pre-proline 0 CA--C 1.534 0.364 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.175 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -70.83 145.02 49.89 Favored 'Trans proline' 0 N--CA 1.472 0.248 0 C-N-CA 122.035 1.823 . . . . 0.0 112.394 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -82.11 147.52 57.73 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.468 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -71.82 -23.26 22.59 Favored 'Trans proline' 0 N--CA 1.472 0.251 0 C-N-CA 122.278 1.986 . . . . 0.0 112.658 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -161.68 173.38 14.77 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.089 0.471 . . . . 0.0 110.486 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.55 91.81 5.23 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.411 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -103.42 175.15 23.44 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.4 m -105.81 7.17 32.23 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.639 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t 63.15 117.75 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 CA-C-O 121.075 0.464 . . . . 0.0 110.322 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.5 t -95.89 -57.37 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.577 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 34.4 tttm -155.11 146.38 22.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.59 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 23.7 mt -105.09 120.82 56.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.867 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 16.8 mt -98.39 25.49 6.26 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.303 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 30.6 m -153.16 147.73 14.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.133 0.492 . . . . 0.0 110.644 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.3 pttt -135.05 161.3 35.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.151 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 51.5 mt-10 -60.07 99.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.519 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -30.45 2.35 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -77.36 151.89 34.68 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.11 0.481 . . . . 0.0 110.412 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 5.1 m -100.77 132.52 46.12 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.488 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.3 m -115.68 150.56 17.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.409 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -111.62 153.62 26.07 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.383 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.85 100.62 0.11 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.603 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.89 -31.45 4.11 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 5.6 tt0 -63.66 143.81 57.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.117 0.484 . . . . 0.0 110.524 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.2 m -66.27 136.34 55.7 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.334 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.6 m -119.1 -35.38 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.213 -179.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.1 tt -159.64 149.74 18.74 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.838 -179.315 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 t -107.94 154.99 8.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.898 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.5 mp -123.78 173.12 8.36 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.196 0.522 . . . . 0.0 110.636 -179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -137.52 106.72 6.04 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.308 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.93 135.71 22.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.49 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 26.8 mtt 60.15 29.29 18.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.704 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt 59.42 35.46 22.98 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.712 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 10.7 mmm -133.61 130.81 38.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.546 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -70.9 117.49 12.48 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.413 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.21 103.44 9.84 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.291 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -79.85 143.44 34.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.646 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 40.7 mm -105.93 156.31 6.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.052 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 22.3 m-80 -134.24 143.07 47.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.47 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.11 142.0 98.17 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.318 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.5 -36.02 4.28 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.12 1.88 . . . . 0.0 112.288 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.7 p -145.76 161.47 39.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.433 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -65.27 142.51 58.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.322 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.8 -158.4 25.32 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.5 ttmt -135.5 145.88 47.55 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.05 0.453 . . . . 0.0 110.549 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 26.2 t -74.33 110.25 8.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.245 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -95.24 -29.54 14.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.723 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -160.51 135.39 7.67 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.517 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.1 t -101.37 109.27 25.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.21 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 29.4 mt -90.08 29.66 1.19 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.639 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 29.6 m -155.2 145.17 13.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 121.055 0.455 . . . . 0.0 110.361 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.4 mmtm -127.25 160.85 30.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.259 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -60.02 142.99 52.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.524 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 3.1 ttm180 61.35 34.35 18.45 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.492 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -114.18 140.15 48.77 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.388 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -88.63 126.11 35.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.531 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.7 m -122.11 157.79 26.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.395 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -96.57 143.69 27.33 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.414 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.32 92.64 0.07 OUTLIER Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.6 -27.81 2.92 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -60.94 141.35 57.33 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-O 121.031 0.444 . . . . 0.0 110.54 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.08 123.81 33.6 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 92.3 mt -86.61 -51.83 5.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.055 0.455 . . . . 0.0 110.539 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.5 mt -140.88 150.23 20.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.395 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -97.78 128.4 44.4 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.309 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.6 mm -107.17 143.61 17.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.478 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.749 0 CA-C-O 117.982 -1.455 . . . . 0.0 110.781 179.975 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -102.91 -138.48 9.98 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -98.31 114.33 26.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.101 0.477 . . . . 0.0 110.434 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 114.49 179.36 18.85 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.1 mtmt -141.93 41.96 1.68 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.338 0.59 . . . . 0.0 110.332 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -147.35 179.23 7.8 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.432 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 154.9 -85.59 0.14 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.791 -0.923 . . . . 0.0 110.791 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -83.79 96.19 8.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.035 0.445 . . . . 0.0 110.574 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.6 -54.92 0.65 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -82.28 124.85 30.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.08 0.467 . . . . 0.0 110.571 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 38.5 mt -80.72 111.2 21.21 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.131 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -70.61 135.64 28.89 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 122.085 1.857 . . . . 0.0 112.387 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -73.02 153.39 90.85 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.398 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.62 -27.9 14.8 Favored 'Trans proline' 0 CA--C 1.528 0.2 0 C-N-CA 122.211 1.941 . . . . 0.0 112.404 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.9 pp -165.95 165.71 17.9 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.418 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.76 104.73 10.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.286 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.22 -142.43 4.91 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.9 m -135.78 134.22 38.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.068 0.461 . . . . 0.0 110.468 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.9 t -72.14 127.94 34.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.126 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.31 -53.54 3.32 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.68 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 16.8 tttp -152.03 147.19 26.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.598 -179.749 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 47.9 mt -100.82 133.14 44.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.992 179.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.3 mp -99.6 -29.85 12.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.929 -179.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 34.9 m -110.7 148.66 13.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 121.241 0.543 . . . . 0.0 110.878 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.8 ptpp? -135.13 163.96 28.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.14 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -61.87 99.08 0.11 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.502 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.62 -30.9 2.36 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -84.73 147.53 26.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.14 0.495 . . . . 0.0 110.455 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.5 m -96.38 145.95 25.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.294 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 26.8 m -120.88 170.42 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.655 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 35.5 mttt -130.19 147.11 51.88 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.199 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.7 95.89 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.74 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.05 -34.21 2.48 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 11.0 tt0 -66.46 139.25 57.96 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.082 0.467 . . . . 0.0 110.527 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 19.4 m -62.76 137.68 58.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.313 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.83 -32.27 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.952 -179.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.1 tt -162.74 150.21 13.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.159 0.504 . . . . 0.0 110.624 -179.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.1 t -103.49 143.57 15.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.119 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.5 tp -124.66 165.81 17.25 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.631 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -132.54 118.75 19.64 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.321 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -148.0 151.74 36.28 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.545 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 2.5 ptt? 41.8 39.92 1.36 Allowed 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 115.598 -0.728 . . . . 0.0 112.069 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.6 mttt 59.79 39.41 20.75 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.608 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.4 ttt -148.7 140.17 23.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.436 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -78.65 133.1 37.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.423 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.9 m -119.19 115.65 24.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.383 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -83.7 129.93 34.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.489 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 37.3 mm -104.14 122.51 57.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.306 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -109.84 144.01 38.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.253 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.51 141.88 94.4 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.42 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.39 -37.9 3.97 Favored 'Trans proline' 0 N--CA 1.471 0.178 0 C-N-CA 122.125 1.883 . . . . 0.0 112.302 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 3.0 p -147.19 159.93 43.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.403 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -62.7 141.36 58.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.351 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.3 -157.0 25.47 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -137.95 147.03 43.91 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.081 0.467 . . . . 0.0 110.416 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 25.0 t -76.88 112.61 14.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.191 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -95.31 -30.07 14.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.741 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.2 tttm -159.75 127.43 4.74 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.604 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 24.1 t -104.16 114.85 44.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.255 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mt -82.31 -39.06 23.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.405 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 33.2 m -74.64 150.27 7.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.545 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 43.4 mttt -133.6 161.13 35.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.316 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -61.56 139.98 58.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.458 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.44 37.52 16.62 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.354 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -123.92 146.98 48.08 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.386 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.18 138.14 31.78 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.519 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.2 m -122.33 162.39 22.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.336 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 13.6 mt-30 -103.12 141.06 36.49 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.293 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.38 105.95 0.92 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.03 -26.97 9.99 Favored Glycine 0 CA--C 1.527 0.831 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 -58.15 148.89 25.3 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-O 121.109 0.48 . . . . 0.0 110.773 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.16 122.85 30.81 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 92.3 mt -89.61 -60.86 1.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.086 0.469 . . . . 0.0 110.423 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.432 HD11 HG22 ' A' ' 120' ' ' ILE . 54.4 mt -140.95 152.52 20.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.243 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 55.3 mttt -95.86 127.38 41.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.415 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.1 mm -107.15 145.16 14.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.396 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.027 -1.429 . . . . 0.0 110.798 -179.998 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -166.94 116.69 0.69 Allowed Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.809 -0.917 . . . . 0.0 110.809 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -145.05 32.69 1.11 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.057 0.456 . . . . 0.0 110.45 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.51 84.55 0.19 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 3.1 ttpt -174.81 128.85 0.31 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.071 0.462 . . . . 0.0 110.443 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.81 179.24 3.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.503 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.79 -103.87 0.4 Allowed Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.742 -0.943 . . . . 0.0 110.742 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 65.4 mt-10 -113.28 120.65 41.91 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.062 0.458 . . . . 0.0 110.398 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 110.62 -48.46 0.93 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -84.03 133.59 34.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.119 0.485 . . . . 0.0 110.405 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.4 mt -78.22 111.66 20.16 Favored Pre-proline 0 CA--C 1.535 0.372 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.237 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -71.32 138.39 32.88 Favored 'Trans proline' 0 N--CA 1.472 0.221 0 C-N-CA 121.997 1.798 . . . . 0.0 112.348 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.66 146.66 99.09 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.404 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.81 -27.73 14.4 Favored 'Trans proline' 0 CA--C 1.528 0.196 0 C-N-CA 122.254 1.97 . . . . 0.0 112.291 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -164.64 171.02 14.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.46 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.71 93.53 6.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.447 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.95 -148.76 7.41 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.1 m -136.46 138.0 41.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.071 0.462 . . . . 0.0 110.551 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 19.5 t -71.05 116.72 13.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.2 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 t -98.61 -48.65 4.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.622 -179.804 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -150.4 144.67 25.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.622 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 21.8 mt -105.35 135.12 44.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.905 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.6 mp -97.14 -30.62 12.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.846 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.3 m -119.47 145.7 25.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.187 0.518 . . . . 0.0 110.742 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.9 pttm -133.6 164.21 27.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.252 179.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -60.54 103.82 0.28 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.452 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.04 -29.68 2.41 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -94.94 153.15 17.8 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.098 0.475 . . . . 0.0 110.475 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.4 m -96.69 153.08 18.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.311 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 30.4 m -128.61 168.64 21.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.73 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.4 mtpp -129.96 151.69 50.24 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.19 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.57 102.16 0.17 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.71 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.85 -37.74 2.05 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 32.3 tt0 -62.55 140.57 58.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.12 0.486 . . . . 0.0 110.692 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 9.2 m -67.34 141.07 57.26 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.227 179.791 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 34.9 m -115.61 -24.25 3.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.592 -179.405 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 8.3 tt -166.26 152.94 9.29 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.211 0.529 . . . . 0.0 110.885 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.9 134.7 57.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.042 179.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 55.8 mt -115.47 161.59 18.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.611 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -139.11 82.33 1.89 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.132 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -92.66 104.75 17.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.245 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 55.1 mtp 64.95 48.24 2.38 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.339 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.4 mtpt 60.96 39.45 16.56 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.625 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 13.6 tpp -127.72 101.06 6.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.46 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.12 113.53 3.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.569 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.9 m -115.07 123.6 49.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.224 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 14.8 mt-10 -94.07 129.91 40.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.788 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.402 ' CD1' ' N ' ' A' ' 94' ' ' ILE . 4.4 mp -115.5 112.37 39.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.633 179.489 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -99.48 153.97 18.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.419 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.98 142.54 95.19 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.293 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.33 -36.22 5.67 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.175 1.917 . . . . 0.0 112.196 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -146.12 168.83 20.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.299 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -68.55 141.9 55.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.334 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.24 -161.16 31.12 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 74.9 tttt -134.51 148.12 50.47 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.096 0.474 . . . . 0.0 110.429 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.6 t -74.75 103.7 2.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.202 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -90.39 -29.29 18.11 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.774 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.5 tttt -158.32 123.53 4.37 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.139 0.495 . . . . 0.0 110.518 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 24.5 t -100.37 106.79 19.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.332 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.4 mt -90.48 33.76 0.9 Allowed 'General case' 0 CA--C 1.533 0.326 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.421 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 19.2 m -156.4 137.26 4.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 121.031 0.443 . . . . 0.0 110.101 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.4 mptp? -125.85 175.82 7.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.272 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -72.2 147.63 46.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.401 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 63.16 34.51 13.51 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.537 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -121.87 145.0 48.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.26 179.754 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.24 136.99 32.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.629 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 20.7 m -120.23 179.73 2.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.383 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -133.05 141.97 48.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.367 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.8 102.36 0.33 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.849 -0.901 . . . . 0.0 110.849 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.33 -31.32 4.7 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -60.24 142.5 54.44 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.093 0.473 . . . . 0.0 110.583 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -65.45 126.64 30.77 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 92.6 mt -89.98 -55.49 3.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.993 0.425 . . . . 0.0 110.271 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 45.6 mt -143.51 149.25 18.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.333 179.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.2 ttmt -96.44 130.84 43.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.276 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.452 HG22 HD12 ' A' ' 122' ' ' ILE . 37.6 mm -107.22 144.17 16.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.49 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.758 0 CA-C-O 117.998 -1.446 . . . . 0.0 110.737 179.991 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -91.98 -163.55 38.15 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -123.36 -69.64 0.81 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.141 0.496 . . . . 0.0 110.502 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 160.33 -43.2 0.43 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 26.8 pttt -175.03 130.6 0.3 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.067 0.46 . . . . 0.0 110.494 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.92 179.13 2.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.414 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 140.68 46.67 0.06 OUTLIER Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -172.51 36.22 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.122 0.487 . . . . 0.0 110.386 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 116.21 -31.81 5.87 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -78.29 142.54 37.71 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.116 0.484 . . . . 0.0 110.341 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 47.4 mt -82.5 114.85 54.6 Favored Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.24 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.38 148.98 55.9 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.054 1.836 . . . . 0.0 112.278 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -81.13 145.26 56.04 Favored Pre-proline 0 CA--C 1.532 0.25 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.431 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -73.44 -27.34 13.29 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.238 1.958 . . . . 0.0 112.399 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.7 pp -162.57 158.26 23.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.472 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -75.19 91.28 2.61 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.337 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -121.03 -170.24 13.99 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 18.9 m -106.93 134.98 49.28 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.057 0.456 . . . . 0.0 110.408 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 32.6 t -69.59 121.49 19.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.15 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t -95.66 -60.14 1.72 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.398 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -150.32 146.52 26.8 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.465 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 32.8 mt -102.46 124.05 56.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.922 179.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 8.4 mp -97.61 27.88 4.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.991 -179.561 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 26.3 m -153.9 154.85 6.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 121.178 0.514 . . . . 0.0 110.486 179.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -141.6 158.2 44.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.122 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -60.52 92.5 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.45 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.19 -27.06 2.55 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -78.42 144.62 35.7 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.077 0.465 . . . . 0.0 110.489 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -95.54 135.45 37.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.355 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 26.6 m -115.4 160.28 14.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.573 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 23.8 mttm -118.52 142.91 47.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.286 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -57.76 95.7 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.761 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.19 -31.88 2.64 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.8 tt0 -68.01 151.17 47.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.137 0.494 . . . . 0.0 110.399 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.5 m -69.76 136.65 51.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.401 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.1 m -113.6 -32.11 2.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.901 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 8.3 tt -160.75 146.76 14.9 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.111 0.482 . . . . 0.0 110.705 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -101.85 137.1 30.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.094 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 12.8 mt -120.4 165.73 14.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.496 -179.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.3 mt-10 -131.07 110.94 11.56 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.327 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.49 141.62 30.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.374 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 68.5 mtp 60.6 32.66 20.41 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.601 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.1 mmmt 60.87 33.1 20.05 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.557 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -142.0 142.89 32.96 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.403 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -81.1 122.78 27.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.394 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.8 m -113.07 120.21 40.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.333 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 -84.65 135.84 34.0 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.492 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.468 HD12 HG21 ' A' ' 94' ' ' ILE . 37.8 mm -104.85 126.85 59.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.296 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -108.73 141.23 41.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.427 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.32 143.17 95.79 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.324 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -73.08 -37.99 3.11 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.121 1.88 . . . . 0.0 112.273 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.2 p -145.01 155.71 43.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.302 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -65.64 141.45 58.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.375 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 178.15 -155.31 16.68 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -134.83 143.44 47.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.023 0.44 . . . . 0.0 110.38 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 26.0 t -79.04 114.13 19.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.139 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -95.44 -30.37 13.92 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.606 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.3 ttpt -158.0 131.89 7.94 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.464 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 26.8 t -108.72 102.22 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.267 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.1 mt -74.32 -33.61 63.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.446 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 29.9 m -73.52 150.68 7.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.346 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -140.88 157.29 45.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.473 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 61.7 mt-10 -61.17 145.62 50.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.51 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.14 37.54 17.55 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.33 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -127.28 145.0 50.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.454 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.9 137.46 32.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.493 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.1 m -121.32 156.12 25.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.376 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 13.6 mt-30 -101.6 144.57 30.17 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.376 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.31 107.18 1.36 Allowed Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.84 -27.64 8.17 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -59.75 141.72 54.67 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.054 0.454 . . . . 0.0 110.645 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.35 127.11 41.55 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 91.7 mt -91.17 -56.29 3.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.086 0.469 . . . . 0.0 110.459 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 53.5 mt -141.12 151.28 19.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.342 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.0 tttt -97.36 126.63 42.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.42 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.5 mm -105.24 145.64 13.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.397 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.82 0 CA-C-O 118.002 -1.443 . . . . 0.0 110.813 179.968 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -172.32 -76.37 0.05 OUTLIER Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.59 97.87 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.119 0.485 . . . . 0.0 110.528 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 173.99 76.86 0.05 OUTLIER Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 33.1 mttt -129.61 134.29 47.63 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.157 0.503 . . . . 0.0 110.374 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.42 176.62 0.6 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.445 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.79 46.54 0.07 OUTLIER Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -169.74 35.01 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.18 0.514 . . . . 0.0 110.369 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 116.4 -32.98 5.33 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -80.09 143.33 34.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.096 0.474 . . . . 0.0 110.506 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.6 mt -79.01 116.69 61.95 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.159 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -71.6 137.62 30.62 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 121.991 1.794 . . . . 0.0 112.279 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -71.0 148.17 94.3 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.404 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -72.58 -28.75 13.96 Favored 'Trans proline' 0 CA--C 1.528 0.194 0 C-N-CA 122.238 1.959 . . . . 0.0 112.216 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.5 pp -162.34 173.51 14.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.511 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -86.67 95.8 9.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.384 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.22 -145.39 6.52 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 13.8 m -136.33 139.72 42.79 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.128 0.49 . . . . 0.0 110.512 -179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.66 121.96 19.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.097 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 92.7 p -99.45 -53.15 3.29 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.627 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.3 tptt -152.33 144.77 24.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.558 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 21.8 mt -103.14 133.19 47.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.989 179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.3 mt -99.77 -29.57 12.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.952 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 32.6 m -110.98 147.87 14.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.249 0.547 . . . . 0.0 110.765 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.8 pttt -136.18 166.01 24.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.244 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 14.8 mt-10 -61.79 100.03 0.14 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.495 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.06 -31.98 2.23 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -85.42 147.15 26.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.068 0.461 . . . . 0.0 110.461 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.1 m -98.29 146.8 25.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.348 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 24.9 m -126.75 165.52 25.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.614 -179.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 22.2 pttt -127.2 150.51 49.49 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.285 179.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -58.62 98.23 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.748 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.31 -37.91 1.83 Allowed Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 21.1 tt0 -65.18 143.82 57.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.072 0.463 . . . . 0.0 110.639 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.1 m -67.37 138.93 57.11 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.204 179.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 34.8 m -113.75 -34.38 2.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.84 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.9 tt -160.45 147.34 15.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.788 -179.415 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -104.97 139.43 25.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.001 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 2.4 mt -120.02 165.36 14.8 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.19 0.519 . . . . 0.0 110.691 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -135.36 112.81 10.65 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.532 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.31 142.06 27.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.388 179.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 4.5 mtp 60.54 33.72 20.44 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.528 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.3 mttt 60.91 34.45 19.53 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.465 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.1 tpp -140.26 141.61 35.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.49 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -89.8 122.36 32.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.412 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.2 m -119.85 114.52 22.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.437 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -82.4 143.5 31.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.579 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.479 HG21 HD12 ' A' ' 94' ' ' ILE . 39.7 mm -105.14 127.62 59.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.162 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -105.42 142.16 35.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.341 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.86 132.2 91.76 Favored Pre-proline 0 CA--C 1.534 0.33 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.371 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -72.79 -32.19 9.5 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 121.99 1.793 . . . . 0.0 112.243 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 4.6 p -146.68 156.91 43.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.419 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -68.32 142.73 55.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.44 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 172.19 -156.77 26.1 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -135.43 146.46 48.26 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.057 0.456 . . . . 0.0 110.415 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 23.0 t -74.86 107.75 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.271 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -90.59 -30.98 16.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.563 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.5 tptm -156.11 130.57 8.87 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.586 -179.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 25.4 t -98.92 106.1 18.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.347 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.2 mt -89.59 12.06 17.82 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.511 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 28.3 m -127.33 136.16 61.38 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.095 0 CA-C-O 121.121 0.486 . . . . 0.0 110.122 179.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 40.1 tttt -128.5 156.21 43.62 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.373 -179.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -60.7 150.22 32.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.487 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 61.45 31.79 19.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.443 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -124.36 142.78 51.01 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.264 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.5 136.84 32.83 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.609 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.69 157.16 23.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.306 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 -100.14 142.19 31.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.504 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.07 107.64 1.41 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.61 -28.32 8.65 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.4 tt0 -57.62 147.14 28.19 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.087 0.47 . . . . 0.0 110.76 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -63.33 121.85 25.38 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.941 -0.863 . . . . 0.0 110.941 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 56.5 mt -87.25 -52.56 5.33 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.056 0.455 . . . . 0.0 110.501 179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 48.9 mt -142.31 148.3 20.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.35 179.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -95.75 128.04 42.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.345 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.4 mm -107.68 145.34 15.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.484 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.798 0 CA-C-O 117.984 -1.454 . . . . 0.0 110.824 179.999 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.72 79.13 1.24 Allowed Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -158.92 173.47 16.46 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.107 0.48 . . . . 0.0 110.444 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -171.13 158.96 30.71 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 19.1 mtpt 60.65 161.27 0.05 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.111 0.481 . . . . 0.0 110.503 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -115.31 178.05 4.44 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.422 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -158.69 -105.04 0.21 Allowed Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -108.17 120.89 43.63 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.08 0.467 . . . . 0.0 110.382 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 107.41 -48.5 0.94 Allowed Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -83.62 131.86 34.93 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.066 0.46 . . . . 0.0 110.357 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.0 mt -79.39 111.45 20.8 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.144 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.33 141.98 40.18 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.016 1.811 . . . . 0.0 112.288 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -76.75 144.49 73.15 Favored Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.275 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.73 -22.35 20.6 Favored 'Trans proline' 0 CA--C 1.529 0.241 0 C-N-CA 122.181 1.921 . . . . 0.0 112.702 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.5 pp -161.7 167.38 25.19 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.128 0.489 . . . . 0.0 110.457 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -86.37 119.67 26.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.455 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -152.04 -141.4 3.31 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 6.6 m -137.56 143.42 41.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.139 0.495 . . . . 0.0 110.439 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 37.3 t -68.17 128.63 31.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.172 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.6 m -98.18 -59.75 1.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.683 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 12.6 mtpt -149.49 147.18 27.9 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.541 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . 0.413 HD13 HG22 ' A' ' 68' ' ' ILE . 51.8 mt -102.87 123.25 56.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.075 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.6 mp -94.09 -46.04 7.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.657 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 33.4 m -95.23 143.9 10.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.694 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 3.5 pttt -133.36 165.33 25.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.182 179.76 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -59.31 102.03 0.12 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.666 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 137.91 -31.89 2.42 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -84.9 149.99 25.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.09 0.471 . . . . 0.0 110.501 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 9.3 m -96.64 142.98 28.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.352 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 31.5 m -120.7 154.22 24.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.548 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 13.0 tptt -116.57 151.22 36.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.192 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.08 96.69 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.647 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.62 -30.81 3.35 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -64.79 139.52 58.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.082 0.468 . . . . 0.0 110.602 -179.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.0 m -65.57 136.16 56.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.187 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.0 m -115.09 -29.57 2.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.294 -179.533 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tt -165.29 152.22 10.47 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.133 0.492 . . . . 0.0 110.778 -179.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -107.66 139.81 28.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.153 179.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.8 mt -120.58 160.78 22.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.497 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -133.16 120.53 21.32 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.232 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.08 146.33 30.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.287 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 6.8 ptm 41.77 40.6 1.53 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.968 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 19.5 mtpp 61.11 40.28 15.11 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.599 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 35.3 ttp -144.71 121.7 11.37 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.501 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -79.44 127.6 32.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.372 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.1 m -119.76 126.18 50.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.367 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -82.7 129.9 35.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.361 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 23.6 mm -106.39 118.2 53.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.188 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 22.9 p30 -110.65 152.18 26.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.333 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.23 142.19 95.91 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.359 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -73.54 -32.97 7.26 Favored 'Trans proline' 0 N--CA 1.471 0.173 0 C-N-CA 122.171 1.914 . . . . 0.0 112.232 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -148.64 161.08 42.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.385 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -64.24 142.79 58.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.407 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.21 -153.02 19.63 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 26.3 ttmt -139.84 147.07 40.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.103 0.478 . . . . 0.0 110.428 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.9 t -74.74 107.91 5.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.315 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -91.85 -27.74 17.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.865 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -161.4 136.1 7.24 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.07 0.462 . . . . 0.0 110.481 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.8 t -103.05 108.61 24.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.269 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.6 mt -90.5 31.1 1.06 Allowed 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.605 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 25.8 m -155.54 144.54 12.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 121.032 0.444 . . . . 0.0 110.342 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.4 mptt -130.52 165.85 21.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.277 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -60.99 145.41 50.74 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.472 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 14.2 mmt85 60.64 37.12 19.43 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.507 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -117.93 144.7 45.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.351 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.01 129.24 38.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.457 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.8 m -122.09 150.38 25.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.475 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 -99.44 148.4 24.26 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.432 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -63.59 103.26 0.65 Allowed Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.48 -28.66 5.69 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -59.51 137.89 57.87 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.109 0.481 . . . . 0.0 110.665 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.23 119.73 19.8 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 44.8 mt -87.2 -54.74 4.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.133 0.492 . . . . 0.0 110.484 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.1 mt -140.99 143.76 27.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.226 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 7.2 tttt -95.16 129.99 42.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.517 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.443 HD12 HG21 ' A' ' 122' ' ' ILE . 37.2 mm -104.62 145.57 13.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.32 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.731 0 CA-C-O 118.011 -1.438 . . . . 0.0 110.768 179.97 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -116.54 -75.43 0.57 Allowed Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.984 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -108.1 33.57 4.05 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.191 0.52 . . . . 0.0 110.446 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.85 162.67 12.99 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 2.9 ptpt -169.43 60.55 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.334 0.588 . . . . 0.0 110.801 179.883 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -132.19 147.24 52.41 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.44 179.692 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.39 -169.62 16.64 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.518 -1.033 . . . . 0.0 110.518 179.735 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 60.2 -145.71 0.49 Allowed 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -89.72 20.95 32.32 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.632 179.814 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 66.2 mt-10 -83.72 137.56 33.7 Favored 'General case' 0 C--O 1.23 0.076 0 CA-C-O 120.915 0.388 . . . . 0.0 110.146 179.725 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.401 ' CD1' ' HD2' ' A' ' 97' ' ' PRO . 41.5 mm -83.16 110.49 24.02 Favored Pre-proline 0 CA--C 1.534 0.338 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.068 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -71.57 131.02 18.0 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 121.972 1.782 . . . . 0.0 112.101 -179.741 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -59.61 145.9 81.75 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.64 -179.867 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -75.62 -29.75 6.98 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.292 1.995 . . . . 0.0 112.5 -179.86 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.4 pp -157.5 164.43 37.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.552 -179.681 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.9 108.02 13.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.437 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -134.65 -146.63 5.43 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.8 m -136.33 138.18 41.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.095 0.474 . . . . 0.0 110.401 -179.991 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 29.2 t -70.42 118.57 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.039 179.867 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.7 p -96.25 -53.67 3.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.845 -179.749 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 37.9 mttt -148.64 145.28 27.68 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 121.108 0.48 . . . . 0.0 110.703 -179.607 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 38.9 mt -101.78 128.81 53.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.986 179.507 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 15.4 mt -97.64 -49.04 5.0 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.819 -179.592 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.6 m -93.73 146.04 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.217 0.532 . . . . 0.0 110.797 -179.831 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.8 pttp -135.31 162.72 31.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.034 179.789 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -59.26 103.19 0.16 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.54 -179.971 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.4 2.27 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.881 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -89.79 149.61 22.63 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.135 0.493 . . . . 0.0 110.445 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.4 m -97.22 141.51 30.25 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.444 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 27.1 m -117.43 156.33 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.464 179.975 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -117.53 157.03 27.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.438 179.864 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.81 96.48 0.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.557 -179.888 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.52 -28.24 4.52 Favored Glycine 0 CA--C 1.527 0.829 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.806 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -63.3 142.91 58.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.113 0.482 . . . . 0.0 110.684 -179.746 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.9 m -67.65 139.48 56.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.227 179.747 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 30.8 m -119.37 -32.62 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.399 -179.415 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.1 tt -163.09 152.09 14.71 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.228 0.537 . . . . 0.0 111.049 -179.297 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -106.1 139.81 26.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.857 179.574 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 12.5 mt -122.09 168.01 12.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.153 0.502 . . . . 0.0 110.759 -179.719 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 72.2 mt-10 -131.5 113.19 13.38 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.364 179.974 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -144.37 138.68 27.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.533 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 4.1 mmt 60.13 32.47 20.95 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.628 179.913 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 19.3 mttt 60.69 32.9 20.32 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.417 -179.979 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -142.4 122.24 13.54 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.19 -179.961 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -62.01 126.13 26.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.501 -179.956 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 7.0 m -113.53 115.21 27.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.241 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -80.98 128.66 33.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.525 -179.793 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.408 HD13 HG23 ' A' ' 94' ' ' ILE . 35.4 mm -101.54 144.08 13.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.06 179.707 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -138.14 134.82 35.06 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.731 -179.686 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.89 109.6 2.41 Favored Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.225 179.641 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.401 ' HD2' ' CD1' ' A' ' 57' ' ' ILE . 41.8 Cg_endo -65.0 -12.49 34.86 Favored 'Trans proline' 0 N--CA 1.475 0.425 0 C-N-CA 122.275 1.983 . . . . 0.0 113.147 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.91 134.83 39.12 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 121.014 0.435 . . . . 0.0 110.54 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -62.57 159.15 16.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.459 -179.911 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 154.29 -156.2 26.69 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.962 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 16.9 ttpt -133.02 146.78 52.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.125 0.488 . . . . 0.0 110.334 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.4 t -78.53 109.23 12.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.25 -179.966 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -94.64 -30.53 14.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.59 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -157.1 130.92 8.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.449 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.2 t -97.92 112.64 30.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.259 -179.974 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.6 mt -90.12 28.48 1.4 Allowed 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.737 179.984 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 23.2 m -155.39 137.33 6.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.118 0.485 . . . . 0.0 110.336 -179.944 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 13.8 pttm -127.5 167.01 16.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.346 179.954 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -60.09 145.76 45.49 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.77 179.993 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.05 37.41 17.94 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.354 179.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -123.36 138.62 54.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.442 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.34 131.35 36.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.493 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.0 m -120.95 154.55 24.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.419 179.97 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 19.9 mp0 -96.65 141.93 29.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.325 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.77 90.38 0.06 OUTLIER Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.848 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.3 -30.35 2.81 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -58.63 154.58 14.11 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.115 0.483 . . . . 0.0 110.681 -179.997 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.64 125.76 37.79 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 -179.681 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 58.4 mt -94.77 -59.41 1.93 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.151 0.5 . . . . 0.0 110.225 179.744 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.9 mt -141.33 141.95 29.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.181 179.884 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.3 tttt -88.5 127.06 35.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.433 179.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.441 HG21 HD11 ' A' ' 122' ' ' ILE . 37.5 mm -106.82 141.27 22.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.364 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.03 -1.428 . . . . 0.0 110.796 179.959 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 169.5 175.73 38.87 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.957 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -87.19 -32.77 19.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.048 0.451 . . . . 0.0 110.417 179.992 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -68.23 143.24 40.74 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.918 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -137.99 41.58 2.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.356 0.598 . . . . 0.0 110.222 179.918 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -157.5 -179.46 8.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.49 -179.936 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 130.98 -49.07 0.94 Allowed Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.761 -0.935 . . . . 0.0 110.761 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -80.45 63.32 4.86 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.394 0.616 . . . . 0.0 110.425 -179.86 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.25 -37.86 3.51 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 179.778 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -82.96 129.25 35.01 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.161 0.505 . . . . 0.0 110.554 -179.823 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.417 HG23 HD12 ' A' ' 57' ' ' ILE . 53.8 mt -79.01 111.71 22.05 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.154 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -71.09 149.09 57.85 Favored 'Trans proline' 0 N--CA 1.472 0.247 0 C-N-CA 122.074 1.849 . . . . 0.0 112.299 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -84.24 150.76 58.48 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.447 -179.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -72.83 -28.5 13.46 Favored 'Trans proline' 0 CA--C 1.527 0.164 0 C-N-CA 122.251 1.968 . . . . 0.0 112.311 179.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.8 pp -164.84 161.99 20.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.43 179.968 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.67 104.72 2.06 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.386 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.87 178.56 18.05 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.972 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.7 m -104.07 134.86 46.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.084 0.469 . . . . 0.0 110.368 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.2 t -72.04 118.66 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.102 179.878 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -100.02 -50.19 4.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.629 -179.72 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.95 140.53 21.61 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.769 -179.653 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 36.1 mt -105.41 126.15 60.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.836 179.579 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.34 28.65 3.99 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.978 -179.564 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 13.6 m -151.07 153.18 10.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.338 0.59 . . . . 0.0 110.897 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -137.26 154.82 50.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.918 179.502 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -58.18 91.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.165 0.507 . . . . 0.0 110.681 -179.881 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.88 -29.1 2.47 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -179.919 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -65.06 148.27 51.96 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.055 0.455 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.2 m -97.67 132.28 43.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.237 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.1 m -121.54 163.77 19.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.633 -179.821 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -129.63 154.18 47.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.593 -0.731 . . . . 0.0 110.184 179.74 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.01 91.21 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.482 -179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.07 -34.98 1.95 Allowed Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -62.56 140.03 58.63 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.028 0.442 . . . . 0.0 110.45 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.9 m -66.92 136.84 55.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.124 179.815 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.8 m -116.97 -29.76 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.493 -179.382 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 10.2 tt -161.04 159.13 28.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.303 0.573 . . . . 0.0 111.016 -179.439 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -125.7 131.69 71.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.809 179.513 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 19.8 mt -116.09 168.95 9.64 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.202 0.525 . . . . 0.0 110.747 -179.554 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -139.9 80.71 1.78 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.156 179.687 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -92.37 124.89 36.76 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.609 -179.675 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 13.8 mmt 60.34 39.21 19.03 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.38 179.788 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 59.9 mttt 61.67 40.15 13.55 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.238 -179.908 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 11.4 tpp -135.13 114.21 12.15 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.591 -179.915 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -63.69 118.57 8.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.446 179.822 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 8.7 m -114.46 116.96 29.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.202 179.906 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -84.38 131.7 34.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.438 -179.951 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 37.7 mm -106.4 155.95 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.293 179.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 10.6 m120 -142.28 145.42 34.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.455 -179.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.64 142.38 94.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.418 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -74.59 -36.24 3.05 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.157 1.905 . . . . 0.0 112.375 -179.929 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -146.55 170.45 16.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.413 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -69.31 142.2 54.11 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.6 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 160.29 -166.7 35.34 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 -179.989 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 13.9 ptpt -129.17 168.8 15.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.355 0.598 . . . . 0.0 110.657 179.798 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.6 t -82.48 113.89 22.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.547 -179.72 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -94.61 -33.08 13.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.455 179.894 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.1 ttpp -160.63 123.75 3.37 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.606 179.871 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 23.1 t -102.1 109.99 27.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.325 179.799 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.4 mt -82.21 -30.43 30.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.452 179.763 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.6 m -82.04 143.25 12.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.796 -179.824 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 20.2 mmtt -131.32 158.79 39.72 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.107 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -61.99 147.33 47.41 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.496 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 8.1 mmm180 64.16 34.43 11.03 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.759 179.85 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 31.4 m-20 -131.98 140.81 49.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.413 179.676 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.8 140.75 29.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.554 -179.904 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.0 m -121.69 163.52 19.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.374 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 12.4 mm100 -98.35 142.63 29.75 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.299 179.966 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.96 106.28 1.06 Allowed Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.749 -0.941 . . . . 0.0 110.749 -179.972 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.63 -25.57 10.19 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -179.833 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 -59.73 143.05 51.9 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 121.102 0.477 . . . . 0.0 110.651 -179.822 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.34 124.84 36.03 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 179.954 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 49.2 mt -89.76 -54.9 3.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.092 0.472 . . . . 0.0 110.452 -179.979 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.464 HG21 HD12 ' A' ' 120' ' ' ILE . 47.3 mt -145.86 147.8 18.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.121 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 14.7 ttmt -95.89 136.44 36.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.153 179.774 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.8 mm -110.0 143.16 20.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.433 -179.899 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.745 0 CA-C-O 117.987 -1.452 . . . . 0.0 110.766 -179.997 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 118.35 -48.23 0.96 Allowed Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.967 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.48 160.97 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.134 0.492 . . . . 0.0 110.591 -179.997 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.4 136.22 0.21 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.971 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 35.3 mttp -142.18 41.29 1.64 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.261 0.553 . . . . 0.0 110.287 179.932 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -150.54 -179.56 7.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.528 179.985 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.61 -46.16 1.09 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -93.89 72.49 4.13 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.313 0.578 . . . . 0.0 110.367 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 102.23 -41.97 2.01 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 17.0 mt-10 -83.82 134.14 34.72 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.11 0.481 . . . . 0.0 110.465 -179.898 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.418 HD11 HG23 ' A' ' 57' ' ' ILE . 55.8 mt -79.98 111.61 23.19 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.309 -179.997 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.81 131.67 18.79 Favored 'Trans proline' 0 N--CA 1.472 0.217 0 C-N-CA 122.035 1.823 . . . . 0.0 112.287 179.931 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.46 147.57 98.78 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.396 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -72.29 -27.9 15.86 Favored 'Trans proline' 0 CA--C 1.528 0.205 0 C-N-CA 122.188 1.926 . . . . 0.0 112.325 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -163.92 159.65 21.14 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.464 179.983 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.72 101.57 4.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.373 -179.995 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.11 -141.26 5.07 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.94 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.0 m -137.81 135.86 36.66 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.169 0.509 . . . . 0.0 110.45 -179.859 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.7 t -69.64 120.06 16.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.225 179.956 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 79.2 p -97.02 -53.45 3.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.749 -179.829 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 45.6 tttt -152.06 148.37 27.6 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.603 -179.813 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 48.9 mt -104.15 134.39 45.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.061 179.756 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.3 mt -99.22 -31.46 11.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.758 -179.694 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 34.5 m -113.18 145.07 19.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.229 0.538 . . . . 0.0 110.589 -179.871 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.78 163.89 30.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.211 179.771 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -58.36 102.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.582 -179.864 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.25 -28.29 2.48 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.824 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -95.69 151.81 19.02 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.1 0.476 . . . . 0.0 110.421 -179.97 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -98.46 147.58 24.59 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.392 179.894 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 24.9 m -121.83 169.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.498 -179.94 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.2 mmtp -130.23 155.25 46.59 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.36 -179.969 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.74 103.51 0.35 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.474 -179.979 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.4 -30.79 5.66 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 179.94 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.8 tt0 -61.29 143.2 56.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.621 -179.853 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.5 m -67.76 138.51 56.26 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.266 179.831 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 28.1 m -118.68 -33.6 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.265 -179.443 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.4 tt -161.05 152.87 19.61 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.21 0.529 . . . . 0.0 111.017 -179.303 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.2 t -106.45 143.34 17.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.999 179.665 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 14.9 mt -120.55 163.16 18.4 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.51 -179.904 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -133.52 103.49 5.95 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.458 -179.944 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -148.52 153.15 38.03 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.247 179.908 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 32.1 mtp 60.54 31.06 20.18 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.699 -179.931 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.4 tttp 59.12 29.37 18.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.765 179.791 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 12.9 ptm -148.66 133.91 18.39 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.106 0.479 . . . . 0.0 110.464 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -70.51 130.61 42.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.592 -179.852 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 4.1 m -115.87 119.5 36.18 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.277 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 26.3 mt-10 -82.39 131.09 35.23 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.628 -179.82 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 26.9 mm -105.58 148.54 9.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.093 179.815 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -137.23 151.06 48.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.565 -179.911 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.68 144.88 98.83 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.279 179.976 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -73.94 -34.63 5.01 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.153 1.902 . . . . 0.0 112.252 -179.998 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 32.9 p -145.65 167.46 23.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.37 179.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -68.77 142.97 54.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.396 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 170.15 -160.15 32.92 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -133.23 149.24 52.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.145 0.497 . . . . 0.0 110.409 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 22.0 t -75.1 106.86 5.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.316 179.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -92.95 -29.98 15.6 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.725 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.9 tttt -158.02 127.93 6.04 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.466 179.998 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 20.4 t -100.52 110.8 28.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.322 179.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.5 mt -90.09 29.38 1.23 Allowed 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.676 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 24.4 m -155.44 142.12 11.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.062 0.458 . . . . 0.0 110.353 179.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 16.8 mmtt -125.86 175.37 7.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.392 179.979 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -73.06 148.34 44.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.395 179.937 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.4 34.2 18.39 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.584 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -123.09 149.91 43.86 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.329 179.838 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.17 135.22 33.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.541 -179.952 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.7 m -121.17 151.64 24.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.279 179.919 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -98.56 140.46 32.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.328 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.19 108.45 1.63 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.982 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 109.53 -26.55 14.31 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -179.782 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -57.63 145.24 34.69 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 121.134 0.492 . . . . 0.0 110.862 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.18 118.21 13.79 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.848 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 94.5 mt -88.33 -54.75 4.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.169 0.509 . . . . 0.0 110.177 179.799 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 44.8 mt -143.18 149.19 18.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.145 179.819 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 42.7 tttt -97.34 130.01 44.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.319 179.885 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.9 mm -107.71 144.44 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.425 -179.843 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.764 0 CA-C-O 118.025 -1.431 . . . . 0.0 110.747 179.955 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 174.87 -178.12 46.73 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -89.43 -70.85 0.63 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.108 0.48 . . . . 0.0 110.438 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -65.81 -176.66 6.6 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 179.999 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.5 mttt -156.93 40.07 0.32 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.235 0.541 . . . . 0.0 110.42 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -151.63 141.36 21.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.253 179.83 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -177.63 -39.56 0.06 OUTLIER Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.164 -0.774 . . . . 0.0 111.164 179.94 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -77.9 -79.98 0.11 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.086 0.469 . . . . 0.0 110.891 -179.669 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -117.64 -4.61 15.03 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.562 179.721 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -92.18 132.77 36.38 Favored 'General case' 0 C--O 1.23 0.049 0 O-C-N 122.494 -0.415 . . . . 0.0 110.421 -179.958 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.446 HG22 HD12 ' A' ' 57' ' ' ILE . 54.3 mt -80.42 111.1 19.81 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.167 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -72.31 135.08 23.98 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.024 1.816 . . . . 0.0 112.351 -179.893 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -70.27 148.89 95.88 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.427 179.977 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -72.31 -28.44 15.19 Favored 'Trans proline' 0 N--CA 1.472 0.207 0 C-N-CA 122.228 1.952 . . . . 0.0 112.303 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.2 pp -164.26 162.71 22.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.389 179.952 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.29 117.84 16.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.443 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -145.83 -146.87 4.49 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 25.9 m -137.18 132.6 34.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.172 0.51 . . . . 0.0 110.376 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.4 t -70.23 132.31 33.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.301 179.907 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.0 t -101.52 -57.61 2.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.586 -179.958 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 32.2 ttpt -150.2 146.58 26.93 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.492 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 21.6 mt -98.92 133.95 39.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.149 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.6 mp -98.23 -31.57 12.01 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.617 -179.828 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 34.0 m -113.72 145.92 18.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.207 0.527 . . . . 0.0 110.761 -179.841 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.4 ptpp? -133.67 167.13 21.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.042 179.605 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -57.58 113.14 1.67 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.623 -179.972 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.39 21.06 5.29 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.588 -179.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -135.01 141.1 46.12 Favored 'General case' 0 C--O 1.231 0.081 0 CA-C-O 121.094 0.474 . . . . 0.0 110.138 179.601 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -95.29 132.02 40.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.611 -179.711 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 19.9 m -114.5 168.08 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.312 179.922 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 7.8 mmmt -121.65 139.91 52.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.258 179.829 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -56.27 97.95 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.972 -179.81 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.96 -37.39 1.9 Allowed Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.9 tt0 -66.07 149.12 50.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.033 0.444 . . . . 0.0 110.526 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -67.13 136.51 55.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.295 179.971 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 25.6 m -114.77 -31.5 2.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.124 -179.739 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.7 tt -160.67 151.83 19.01 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -179.674 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.0 t -102.87 128.26 55.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.055 179.871 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -111.76 159.41 18.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.643 -179.771 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -139.84 84.3 1.97 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.301 179.867 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -91.17 112.63 24.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.368 -179.836 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 35.4 mtt 63.61 46.03 4.36 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.393 0.615 . . . . 0.0 110.265 179.829 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 18.4 mtmt 61.06 39.81 15.83 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.396 179.909 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 1.2 tpt -129.34 96.4 4.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.359 179.922 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -62.44 112.23 2.36 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.474 179.967 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 20.2 m -120.29 139.55 52.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.343 179.894 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -85.92 135.09 33.81 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.481 -179.862 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.1 mm -107.82 119.24 57.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.237 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 14.0 p-10 -104.2 142.36 34.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.457 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.82 141.62 92.79 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.492 -179.963 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -73.55 -36.45 3.86 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.198 1.932 . . . . 0.0 112.172 179.932 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 69.4 p -147.24 153.92 40.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.345 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -65.38 141.89 58.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.415 179.863 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.67 -155.34 19.6 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.967 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.7 ttpt -133.48 143.81 49.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.174 0.511 . . . . 0.0 110.593 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 22.0 t -75.97 111.23 12.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.079 179.828 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -95.69 -32.49 12.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.82 -179.662 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -161.03 129.84 4.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.117 0.484 . . . . 0.0 110.285 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.8 t -103.85 112.64 38.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.263 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.3 mt -79.81 -31.62 40.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.562 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 27.0 m -83.76 146.92 6.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.615 -179.801 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 18.9 mttm -129.36 172.15 11.79 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.252 179.943 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.41 139.27 54.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.247 -179.983 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 60.78 40.85 15.54 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.57 179.965 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -121.94 145.83 47.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.404 179.846 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.86 131.12 37.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.381 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.3 m -120.3 153.26 23.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.37 179.924 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -98.86 145.84 26.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.36 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.9 110.24 2.91 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.998 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.55 -28.73 8.36 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.906 -0.877 . . . . 0.0 110.906 -179.83 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -58.02 141.01 51.19 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 121.128 0.49 . . . . 0.0 110.815 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.3 125.85 36.77 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.87 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 89.9 mt -88.96 -57.23 2.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.009 0.433 . . . . 0.0 110.4 -179.994 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 53.2 mt -141.29 151.3 19.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.431 179.926 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.7 mttt -94.02 121.68 35.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.132 179.813 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.3 mm -104.01 142.55 17.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.486 -179.845 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.771 0 CA-C-O 117.97 -1.461 . . . . 0.0 110.777 -179.981 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.41 -59.21 0.11 Allowed Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -141.85 78.07 1.61 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.271 0.558 . . . . 0.0 110.318 179.924 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 168.58 43.28 0.03 OUTLIER Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.871 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.8 pttt -153.64 143.56 21.99 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.051 0.453 . . . . 0.0 110.404 179.964 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.04 173.74 1.03 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.492 -179.9 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -162.04 -66.92 0.02 OUTLIER Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 179.95 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -134.48 105.85 6.75 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.121 0.486 . . . . 0.0 110.451 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 116.14 -52.06 0.69 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 -83.84 132.99 34.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.088 0.47 . . . . 0.0 110.473 -179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.3 mt -79.15 118.5 72.84 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.213 -179.942 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -71.81 138.03 30.83 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 122.057 1.838 . . . . 0.0 112.343 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -71.66 147.76 92.28 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.405 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.29 -26.47 17.48 Favored 'Trans proline' 0 CA--C 1.528 0.207 0 C-N-CA 122.232 1.954 . . . . 0.0 112.451 179.913 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.9 pp -163.07 175.27 11.25 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.485 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -89.79 93.01 9.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.428 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.66 -145.41 6.61 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.5 m -137.03 140.71 42.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.122 0.487 . . . . 0.0 110.415 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.8 t -70.79 127.98 33.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.156 179.949 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 7.9 p -99.55 -54.5 2.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.623 -179.84 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.6 tttt -151.05 147.98 27.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.564 -179.804 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 38.1 mt -102.4 133.15 46.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.151 179.792 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.402 ' CD1' ' CG2' ' A' ' 81' ' ' THR . 50.3 mt -99.16 -47.73 5.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.686 -179.809 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.3 m -99.98 146.91 8.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.552 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -137.15 164.21 29.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.119 179.749 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -58.5 106.01 0.35 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.61 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.99 2.22 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -96.63 151.08 19.95 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.129 0.49 . . . . 0.0 110.361 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.1 m -96.44 151.65 19.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.46 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 26.7 m -125.75 168.22 18.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.49 -179.951 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.1 ttpt -129.57 153.84 47.66 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.322 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.76 100.8 0.16 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.503 -179.917 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.19 -32.89 3.47 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.87 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.4 tt0 -63.99 143.12 58.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.038 0.447 . . . . 0.0 110.513 -179.84 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.402 ' CG2' ' CD1' ' A' ' 69' ' ' LEU . 2.2 m -67.51 137.57 55.88 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.196 179.838 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.0 m -117.13 -34.02 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.124 -179.497 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.6 tt -161.72 153.62 19.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.227 0.537 . . . . 0.0 110.952 -179.453 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -108.55 143.09 19.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.932 179.52 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.4 tp -122.49 170.63 9.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.675 -179.693 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -137.83 117.6 13.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.466 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -148.96 133.7 17.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.399 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 12.5 mtt 60.66 33.2 20.33 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.468 -179.99 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 28.3 mmtt 60.23 33.96 20.99 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.609 -179.946 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 4.2 mmt -136.99 122.43 19.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.419 179.958 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -62.9 128.33 35.38 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.539 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -114.72 111.25 20.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.201 179.956 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -81.72 127.94 33.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.586 -179.829 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 34.4 mm -103.97 144.63 13.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.128 179.689 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -135.29 148.87 49.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.426 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.79 138.39 97.37 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.273 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -74.38 -31.2 7.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.052 1.835 . . . . 0.0 112.258 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 15.9 p -145.74 163.9 33.5 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.435 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -68.11 142.7 55.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.363 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.76 -161.41 33.54 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.7 ttpt -132.27 147.25 52.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.412 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.7 t -75.2 106.68 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.198 -179.986 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -92.12 -29.13 16.68 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.776 -179.846 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 5.6 tttt -160.07 131.02 5.72 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.112 0.482 . . . . 0.0 110.508 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.3 t -100.8 109.01 24.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.198 179.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 23.5 mt -90.13 31.02 1.02 Allowed 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.65 -179.99 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 24.6 m -155.58 137.11 5.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-O 121.061 0.458 . . . . 0.0 110.174 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 34.1 mtmt -123.63 177.56 5.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.379 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -68.93 144.64 54.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.491 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 34.1 mtt180 60.12 33.25 21.17 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.619 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -111.49 142.86 43.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.36 -179.978 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.75 134.28 34.54 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.5 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.3 m -120.77 -179.92 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.398 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -140.84 147.94 39.77 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.397 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.02 106.43 1.11 Allowed Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 179.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 119.82 -31.79 5.22 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 -179.938 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -60.61 134.49 57.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.064 0.459 . . . . 0.0 110.571 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.14 123.06 31.47 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.781 -0.927 . . . . 0.0 110.781 179.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 62.7 mt -88.67 -54.88 3.95 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.068 0.461 . . . . 0.0 110.467 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 52.9 mt -140.93 148.91 21.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.368 179.992 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.8 mttt -95.35 127.15 41.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.335 179.885 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.3 mm -108.02 143.52 18.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.359 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.698 0 CA-C-O 117.982 -1.454 . . . . 0.0 110.761 -179.984 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -178.57 68.74 0.08 OUTLIER Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.55 89.91 5.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.121 0.486 . . . . 0.0 110.394 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 138.76 -146.79 18.62 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 58.1 mttm -153.68 40.5 0.51 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.235 0.54 . . . . 0.0 110.418 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -148.47 132.98 17.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.353 179.837 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -141.86 -91.41 0.17 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 35.5 mt-10 -99.89 93.88 6.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.057 0.456 . . . . 0.0 110.529 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 128.88 -56.9 0.73 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.758 -0.937 . . . . 0.0 110.758 179.936 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -84.62 129.67 34.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.085 0.469 . . . . 0.0 110.427 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 42.7 mt -80.8 111.13 20.71 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.284 179.885 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -71.02 137.27 31.46 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.079 1.852 . . . . 0.0 112.33 -179.854 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.32 151.01 97.57 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.458 179.994 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -72.7 -27.5 15.0 Favored 'Trans proline' 0 CA--C 1.529 0.23 0 C-N-CA 122.212 1.941 . . . . 0.0 112.35 -179.974 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -164.23 172.47 13.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.368 179.97 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.8 92.3 7.22 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.31 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -123.81 -146.16 6.94 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.931 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.3 m -135.79 137.57 41.73 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.102 0.477 . . . . 0.0 110.362 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.1 t -68.22 128.27 31.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.319 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -97.72 -61.55 1.37 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.428 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -149.71 145.87 26.92 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.403 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 49.5 mt -97.76 129.42 47.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.079 179.789 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 22.3 mt -97.41 -43.54 7.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.818 -179.703 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.405 ' CG1' ' CG1' ' A' ' 76' ' ' VAL . 31.4 m -104.2 145.83 12.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.216 0.531 . . . . 0.0 110.781 -179.691 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.1 pttt -137.24 161.93 34.89 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.945 179.718 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -57.16 107.88 0.47 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.766 -179.926 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -31.02 2.31 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -179.686 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -98.83 152.71 19.43 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.972 0.415 . . . . 0.0 110.36 179.86 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -96.61 151.07 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.45 179.995 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.405 ' CG1' ' CG1' ' A' ' 70' ' ' VAL . 23.5 m -127.81 169.97 18.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.41 -179.929 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 17.4 mmmt -132.49 153.75 50.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.409 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.79 104.47 0.36 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.577 -179.845 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 126.35 -34.69 3.14 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.857 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 -64.43 140.43 58.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.116 0.484 . . . . 0.0 110.513 -179.908 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 11.1 m -67.42 136.55 54.88 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.333 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 30.0 m -112.82 -29.23 2.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.042 -179.737 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.7 tt -163.99 147.53 9.8 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 121.12 0.486 . . . . 0.0 110.86 -179.516 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -98.86 134.15 38.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.961 179.593 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -116.04 167.71 10.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.542 -179.729 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -136.33 110.93 8.61 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.493 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -147.27 143.35 28.05 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.49 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 9.5 mmt 60.43 31.72 20.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.682 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.7 mmtp 59.78 34.56 21.94 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.464 -179.944 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.2 mtt -147.28 118.08 7.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.482 -179.87 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -62.95 127.07 29.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.314 179.939 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 11.8 m -116.04 128.14 55.47 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.493 -179.931 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -85.51 133.31 34.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.445 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.2 mm -102.38 118.3 49.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.223 179.869 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -104.24 143.93 32.29 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.315 -179.887 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.21 140.31 91.23 Favored Pre-proline 0 CA--C 1.533 0.32 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.556 -179.983 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -73.25 -33.33 7.33 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.186 1.924 . . . . 0.0 112.338 -179.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 81.1 p -147.84 163.44 36.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.354 179.976 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -67.98 142.91 55.82 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.531 179.92 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.51 -159.97 31.8 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.995 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 13.3 ttmt -136.55 141.61 43.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.105 0.479 . . . . 0.0 110.517 -179.911 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 22.0 t -72.03 125.9 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.262 179.856 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -102.63 -31.23 10.48 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.783 -179.915 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 2.2 ttmt -164.4 139.08 5.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.674 -179.772 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.0 t -106.67 109.01 26.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.128 179.807 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.4 mt -80.01 -31.81 39.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.302 179.898 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 29.0 m -79.85 147.7 6.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.49 -179.965 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 24.3 mttp -127.83 164.1 22.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.149 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -65.95 142.38 57.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.397 179.997 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 63.54 37.77 10.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.619 179.885 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -121.64 152.16 39.63 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.389 179.681 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.97 134.52 34.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.476 -179.909 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.7 m -120.42 150.24 23.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.456 179.943 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 21.8 mt-30 -101.17 139.44 36.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.336 179.919 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.38 92.11 0.05 OUTLIER Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 132.81 -28.47 3.37 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.867 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -60.0 144.9 48.13 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 121.108 0.48 . . . . 0.0 110.645 -179.95 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.87 122.88 28.97 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.885 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 88.6 mt -88.18 -59.44 2.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.061 0.458 . . . . 0.0 110.385 179.853 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 49.7 mt -141.77 149.21 20.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.358 179.803 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -94.04 131.41 39.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.332 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 35.7 mm -107.7 146.02 14.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.397 -179.9 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.718 0 CA-C-O 118.002 -1.443 . . . . 0.0 110.746 179.903 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.54 58.56 0.39 Allowed Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.931 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -174.79 119.45 0.21 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.072 0.463 . . . . 0.0 110.349 179.966 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -153.35 165.1 31.25 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 179.952 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 12.5 pttm -140.96 149.23 41.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.136 0.493 . . . . 0.0 110.386 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -61.79 -179.96 0.23 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.487 -179.95 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 172.88 -45.06 0.17 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 -179.965 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -66.32 -148.86 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.525 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -70.91 -7.09 61.35 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.17 -179.83 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -76.61 143.18 40.38 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 121.215 0.531 . . . . 0.0 110.677 -179.621 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.9 mt -80.45 125.92 79.85 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.341 -179.835 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -74.85 156.65 43.65 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 121.885 1.723 . . . . 0.0 112.247 179.737 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -84.89 143.36 40.15 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.305 179.993 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -73.89 -27.93 11.79 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.225 1.95 . . . . 0.0 112.484 -179.97 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -163.65 172.49 14.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.51 -179.908 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.3 98.64 11.7 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.506 179.925 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.68 -144.31 5.62 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 8.9 m -137.71 135.9 36.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.149 0.499 . . . . 0.0 110.458 179.926 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.9 t -71.1 125.89 30.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.24 179.86 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.5 p -98.99 -57.54 2.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.74 -179.707 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 5.6 ptpt -149.52 146.37 27.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.679 -179.728 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 30.8 mt -101.62 136.83 31.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.16 179.74 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 46.3 mt -100.0 -40.21 7.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.576 -179.847 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.0 m -100.73 138.15 25.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.148 0.499 . . . . 0.0 110.581 -179.873 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 10.2 pttp -122.7 163.26 20.45 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.044 179.825 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -60.47 104.02 0.3 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.569 -179.895 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 137.56 -31.82 2.46 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -83.17 154.99 23.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.052 0.453 . . . . 0.0 110.557 179.969 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.5 m -98.47 144.78 27.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.322 179.952 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 31.1 m -120.78 158.12 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.511 -179.914 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 41.6 mttt -122.7 151.12 41.87 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.261 179.832 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.29 90.99 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.694 -179.919 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.53 -30.36 3.01 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.921 -0.871 . . . . 0.0 110.921 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -61.85 142.8 57.14 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.158 0.504 . . . . 0.0 110.571 -179.855 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.1 m -67.22 140.53 57.42 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.123 179.779 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 32.4 m -121.76 -32.49 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.631 -179.459 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 8.0 tt -161.23 152.84 19.21 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 120.169 -0.612 . . . . 0.0 111.557 -179.244 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.6 t -103.96 137.64 31.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.638 179.405 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.1 tp -121.0 165.7 14.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.176 0.512 . . . . 0.0 110.656 -179.776 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -138.24 120.11 15.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.463 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -150.63 138.61 20.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.397 179.983 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 44.8 mtp 60.73 36.12 19.46 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.598 -179.954 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 60.52 31.21 20.23 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.53 179.983 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 9.4 ttt -141.01 121.12 13.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.568 179.991 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -73.48 130.38 39.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.288 179.917 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.2 m -121.71 129.54 52.8 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.368 -179.987 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -84.29 138.04 33.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.564 -179.902 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.442 HG21 HD11 ' A' ' 94' ' ' ILE . 38.2 mm -103.21 150.48 6.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.077 179.853 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -138.05 142.15 40.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.507 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.11 139.79 96.02 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.293 -179.98 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.1 -30.35 10.8 Favored 'Trans proline' 0 N--CA 1.472 0.223 0 C-N-CA 122.061 1.841 . . . . 0.0 112.081 179.894 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.0 p -147.01 162.79 38.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.198 179.879 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 11.6 p30 -67.54 147.71 52.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.204 0.526 . . . . 0.0 110.315 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 169.92 -160.04 32.87 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -179.832 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -135.58 142.89 45.38 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.068 0.461 . . . . 0.0 110.455 -179.915 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 23.6 t -75.59 111.48 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.905 179.699 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -97.36 -31.21 12.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.833 -179.488 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -161.77 132.01 4.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.148 0.499 . . . . 0.0 110.786 -179.878 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.0 t -102.71 123.78 56.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.923 179.685 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 35.3 mt -82.77 -29.92 29.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.98 -179.587 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 35.3 m -95.97 158.82 3.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 121.213 0.53 . . . . 0.0 110.936 -179.677 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 37.2 mttt -132.08 163.53 28.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.167 179.65 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -60.72 141.42 56.89 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.544 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? 61.43 39.11 15.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.393 179.988 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -123.88 151.38 43.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.327 179.852 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.63 144.21 25.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.473 -179.912 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.75 179.53 3.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.37 179.801 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -130.04 140.88 50.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.323 179.937 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -58.78 105.93 0.77 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.837 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.99 -31.05 6.24 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.995 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.1 tt0 -58.4 140.61 53.43 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 121.141 0.496 . . . . 0.0 110.763 -179.909 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.71 124.01 34.43 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 179.934 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 90.1 mt -90.38 -49.31 6.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.036 0.446 . . . . 0.0 110.844 -179.585 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.41 HD11 HG21 ' A' ' 120' ' ' ILE . 50.7 mt -142.33 153.61 18.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.576 -179.852 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 23.4 tttt -98.19 125.21 43.14 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.354 179.835 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 39.4 mm -108.37 140.4 27.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.397 -179.93 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.701 0 CA-C-O 117.979 -1.456 . . . . 0.0 110.943 179.93 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -127.13 84.71 0.34 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.994 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.64 104.07 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.07 0.462 . . . . 0.0 110.567 -179.913 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -125.3 58.72 0.66 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 -179.927 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.3 mtmt -147.43 166.77 26.22 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.003 0.43 . . . . 0.0 110.439 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -118.07 128.64 54.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.399 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -176.53 42.89 0.11 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.706 -0.958 . . . . 0.0 110.706 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -164.02 32.2 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.106 0.479 . . . . 0.0 110.503 -179.966 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 122.53 -32.26 4.54 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.995 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -80.45 139.98 36.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.106 0.479 . . . . 0.0 110.509 -179.846 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.4 ' CD1' ' HD2' ' A' ' 97' ' ' PRO . 42.9 mm -79.09 124.48 84.6 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.051 179.879 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.9 132.77 17.42 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 121.924 1.749 . . . . 0.0 112.223 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -65.34 146.16 98.98 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.427 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -72.9 -29.95 11.7 Favored 'Trans proline' 0 N--CA 1.471 0.2 0 C-N-CA 122.191 1.927 . . . . 0.0 112.295 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.2 pp -163.67 166.38 22.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.393 179.996 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.1 101.82 6.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.339 179.929 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.63 -149.91 6.33 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.989 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.8 m -136.21 140.6 43.65 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.149 0.5 . . . . 0.0 110.437 179.933 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 23.2 t -73.24 121.69 24.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.252 179.918 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -99.49 -49.69 4.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.555 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 17.2 ttpt -152.56 146.51 25.28 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.535 -179.735 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 2.9 mp -105.59 135.82 42.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.09 179.7 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 7.1 mp -100.03 -36.34 9.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.653 -179.783 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.0 m -101.16 143.2 14.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.72 -179.819 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.4 pttp -133.47 162.67 31.23 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.063 179.81 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -59.16 101.12 0.09 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.534 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.22 -29.6 2.4 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.836 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -90.7 148.03 22.87 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.093 0.473 . . . . 0.0 110.43 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.6 m -95.72 144.72 25.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.396 179.972 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.4 m -119.78 160.68 19.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.505 -179.965 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 88.2 mttt -125.06 154.32 41.52 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.327 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.36 97.61 0.05 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.732 -179.802 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.83 -30.66 3.69 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 28.2 tt0 -63.94 141.24 58.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.101 0.477 . . . . 0.0 110.735 -179.816 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.2 m -65.45 138.6 58.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.235 179.744 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 31.4 m -117.91 -32.95 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.247 -179.373 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.8 tt -161.47 153.51 19.61 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.284 0.564 . . . . 0.0 111.111 -179.268 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -107.01 137.3 38.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.911 179.504 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 15.3 mt -115.36 162.61 16.88 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.28 0.562 . . . . 0.0 110.782 -179.657 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -140.14 79.68 1.72 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.274 179.804 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -94.8 119.83 34.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.436 -179.854 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 37.0 mtt 62.66 39.64 11.06 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.361 179.846 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.2 mtmt 62.06 40.03 12.49 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.588 179.742 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 6.5 mmt -131.96 113.17 13.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.246 179.654 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -65.71 109.96 2.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.721 -179.845 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 11.1 m -112.09 119.58 38.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.318 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -82.1 129.11 34.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.852 -179.587 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 39.0 mm -101.35 149.45 6.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.997 179.569 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 67.9 m-20 -139.2 134.34 32.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.161 0.505 . . . . 0.0 110.863 -179.665 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.13 110.46 3.56 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.946 179.363 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.4 ' HD2' ' CD1' ' A' ' 57' ' ' ILE . 40.6 Cg_endo -64.27 -15.13 47.85 Favored 'Trans proline' 0 N--CA 1.476 0.484 0 C-N-CA 122.182 1.921 . . . . 0.0 113.105 179.834 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 61.1 p -135.9 136.66 40.68 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-O 121.145 0.498 . . . . 0.0 110.425 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -64.02 163.31 12.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.468 -179.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 149.03 -155.93 26.58 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.5 ttmt -134.55 147.89 50.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.084 0.469 . . . . 0.0 110.506 -179.833 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 22.1 t -77.44 111.81 14.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.165 179.802 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -95.94 -27.59 15.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.987 -179.774 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -162.69 127.38 3.14 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.064 0.459 . . . . 0.0 110.453 -179.864 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.62 112.5 36.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.307 179.954 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.5 mt -80.05 -31.44 39.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.503 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 33.6 m -87.08 141.56 14.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.71 -179.918 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -128.39 171.54 11.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.438 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -63.29 137.74 58.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.414 179.995 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.76 38.88 6.57 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.618 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -118.79 144.82 46.06 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.224 179.635 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.98 134.99 34.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.485 -179.955 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.7 m -122.32 179.9 2.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.319 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -137.19 147.81 46.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.416 179.891 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.74 114.31 6.45 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.88 -30.37 9.14 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.928 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.4 tt0 -60.9 137.06 58.24 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.034 0.445 . . . . 0.0 110.567 -179.967 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.86 119.19 17.15 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 41.3 mt -88.92 -51.04 5.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.109 0.48 . . . . 0.0 110.378 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.465 HG21 HD11 ' A' ' 120' ' ' ILE . 53.5 mt -140.91 144.91 26.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 8.1 tttt -93.94 129.75 40.29 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.357 179.947 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . 0.424 HG21 HD11 ' A' ' 122' ' ' ILE . 36.6 mm -106.44 148.82 10.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.426 -179.776 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.739 0 CA-C-O 118.015 -1.436 . . . . 0.0 110.85 -179.991 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 63.79 -100.73 0.4 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -159.79 89.27 0.87 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.078 0.466 . . . . 0.0 110.41 179.956 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 165.67 -156.31 28.18 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? 60.63 177.44 0.1 Allowed 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.1 0.476 . . . . 0.0 110.538 -179.917 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -131.32 179.39 6.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.355 179.983 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 133.95 -33.24 2.56 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.992 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -91.12 51.91 2.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.265 0.555 . . . . 0.0 110.548 -179.836 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.44 -28.17 15.37 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 179.828 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -76.6 138.44 40.12 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.187 0.517 . . . . 0.0 110.698 -179.694 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 32.7 mt -80.11 119.93 78.09 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.138 179.756 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -72.19 139.47 32.44 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 122.0 1.8 . . . . 0.0 112.277 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -71.8 146.77 91.12 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.373 179.948 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -72.85 -27.14 14.91 Favored 'Trans proline' 0 N--CA 1.471 0.184 0 C-N-CA 122.227 1.951 . . . . 0.0 112.393 179.972 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.2 pp -162.18 174.58 12.71 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.394 -179.941 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -90.24 82.21 6.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.306 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -109.26 -144.47 10.63 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.7 m -136.99 138.8 40.92 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.062 0.458 . . . . 0.0 110.525 -179.943 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 25.7 t -70.95 124.18 26.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.077 179.897 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.3 t -101.9 -59.12 1.75 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.787 -179.7 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 tptt -149.81 138.79 21.08 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.738 -179.583 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 38.9 mt -95.92 135.52 29.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.965 179.532 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 11.5 mt -100.91 -30.82 11.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.93 -179.556 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.3 m -108.49 149.81 11.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.144 0.497 . . . . 0.0 110.733 -179.854 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 12.6 ptpt -137.66 164.16 29.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.164 179.856 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -60.58 102.97 0.21 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.5 -179.985 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 138.55 -31.48 2.41 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 23.8 m-20 -88.18 147.6 24.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.108 0.48 . . . . 0.0 110.482 -179.946 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 19.6 m -95.52 142.93 27.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.303 179.914 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.4 m -119.42 156.63 21.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.53 -179.883 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.4 mptt -117.79 152.58 35.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.288 179.888 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.24 93.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.644 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.23 -31.49 2.78 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 17.7 tt0 -62.42 141.96 58.1 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.078 0.466 . . . . 0.0 110.562 -179.98 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.9 m -68.12 138.84 56.03 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.212 179.819 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.4 m -121.07 -32.42 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.657 -179.243 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 1.5 tm? -160.34 136.74 8.76 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.863 -179.11 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 20.1 t -102.3 136.35 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.459 -179.977 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 88.4 mt -114.12 166.56 11.5 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.584 -179.874 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -142.19 80.81 1.72 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.316 179.899 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -92.24 115.04 27.74 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.349 -179.986 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 8.5 mtp 62.73 46.03 5.5 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.237 179.94 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 50.2 mttt 60.35 30.97 20.24 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.553 -179.823 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 9.0 tpt -118.44 95.93 5.08 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.41 -179.989 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -61.39 107.75 0.83 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.526 -179.898 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 23.9 m -117.44 112.64 20.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.353 179.983 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -80.64 132.97 35.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.765 -179.724 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 35.7 mm -101.88 155.91 4.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.066 179.648 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -136.84 149.34 47.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.568 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.71 139.8 97.06 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.242 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.65 -30.99 11.25 Favored 'Trans proline' 0 N--CA 1.472 0.226 0 C-N-CA 122.087 1.858 . . . . 0.0 112.197 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.07 163.61 35.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.313 179.943 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -68.17 141.94 55.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.352 179.969 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.48 -159.48 27.43 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 10.1 ttpt -133.36 143.71 49.14 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.045 0.45 . . . . 0.0 110.338 -179.849 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.9 t -75.72 111.71 12.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.224 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -92.75 -29.72 15.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.69 -179.85 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.5 ttpt -158.79 134.03 8.48 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.127 0.489 . . . . 0.0 110.575 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 26.9 t -101.19 107.91 22.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.346 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.7 mt -80.07 -32.2 39.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.222 179.697 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 31.4 m -77.3 143.63 12.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.416 179.917 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 10.6 mmmt -135.05 151.86 51.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.156 179.81 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 16.4 mp0 -58.41 137.74 57.07 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.781 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 8.2 ttp-105 63.41 39.08 9.55 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.344 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -125.09 144.63 50.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.289 179.815 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.79 140.13 30.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.558 -179.99 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.9 m -121.14 179.93 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.371 179.978 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 9.3 mt-30 -141.06 146.86 37.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.412 179.976 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.23 103.4 0.53 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.03 -29.78 5.45 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 -179.889 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -61.61 138.51 58.3 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-O 121.066 0.46 . . . . 0.0 110.402 -179.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.62 118.46 14.81 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.919 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 64.5 mt -89.02 -54.73 3.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.017 0.436 . . . . 0.0 110.334 179.81 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 46.6 mt -142.79 147.02 21.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.321 179.796 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.2 mtpt -96.22 127.21 42.02 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.339 179.963 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 36.1 mm -109.17 145.03 16.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.552 -179.883 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 117.976 -1.458 . . . . 0.0 110.777 179.971 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -178.74 122.89 0.83 Allowed Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.942 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -143.23 -49.13 0.32 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.047 0.451 . . . . 0.0 110.346 -179.956 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -99.53 128.62 9.63 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.784 -0.927 . . . . 0.0 110.784 179.972 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 19.1 mttm -109.32 41.14 1.7 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.368 0.604 . . . . 0.0 110.429 179.97 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -147.63 94.97 2.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.396 179.848 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -86.58 -90.58 0.96 Allowed Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.756 -0.937 . . . . 0.0 110.756 179.944 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -110.79 129.15 55.93 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.108 0.48 . . . . 0.0 110.383 179.935 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.69 -53.12 0.84 Allowed Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 -179.908 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -82.82 128.28 34.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.08 0.467 . . . . 0.0 110.359 -179.959 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.2 mt -79.64 111.36 20.54 Favored Pre-proline 0 CA--C 1.535 0.383 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.258 179.993 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -71.22 131.31 18.97 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 121.962 1.775 . . . . 0.0 112.302 -179.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.19 145.17 97.41 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.352 179.976 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.34 -28.03 12.78 Favored 'Trans proline' 0 CA--C 1.528 0.222 0 C-N-CA 122.22 1.946 . . . . 0.0 112.276 -179.963 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -159.59 162.87 35.39 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.357 179.971 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.35 113.81 21.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.332 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -137.75 -140.7 4.08 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -179.92 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 19.7 m -136.46 139.71 42.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.067 0.46 . . . . 0.0 110.435 179.988 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.3 t -71.09 126.59 31.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.999 179.982 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 8.2 t -101.24 -54.47 2.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.665 -179.828 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.2 tptm -157.2 140.27 15.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.602 -179.819 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 31.3 mt -94.38 140.26 16.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.995 179.719 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 22.6 mt -104.84 -37.89 6.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.631 -179.793 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.404 ' CG1' ' CG1' ' A' ' 76' ' ' VAL . 33.1 m -110.88 148.12 14.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.801 -179.927 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -139.62 166.77 23.7 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.213 179.897 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -58.1 108.91 0.66 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.702 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.04 -31.4 2.81 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -93.19 151.38 19.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.061 0.458 . . . . 0.0 110.481 179.975 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -100.68 148.65 24.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.238 179.879 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.404 ' CG1' ' CG1' ' A' ' 70' ' ' VAL . 31.6 m -124.99 165.96 21.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.58 -179.824 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.8 tppt? -124.78 153.91 41.74 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.251 179.894 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.43 97.97 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.541 -179.87 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.16 -36.64 2.11 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.904 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -62.88 139.46 58.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.496 . . . . 0.0 110.563 -179.959 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.9 m -67.07 141.87 57.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.282 -179.997 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 31.5 m -113.58 -27.04 2.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.225 -179.604 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.0 tt -168.4 150.99 5.3 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.177 0.513 . . . . 0.0 110.622 -179.619 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -102.83 135.98 37.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.955 179.622 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 17.8 mt -115.2 163.3 15.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.587 -179.681 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -135.64 106.7 6.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.267 179.972 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -147.48 147.89 30.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.518 -179.965 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 39.3 mmm 60.41 32.62 20.65 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.54 179.986 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 35.2 mtmt 60.03 33.78 21.35 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.618 179.946 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 4.5 ttt -144.69 147.21 32.75 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.521 -179.87 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -92.22 124.48 36.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.378 179.995 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 19.6 m -121.01 125.91 48.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.418 -179.956 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -87.38 143.01 27.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.475 -179.96 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.447 HG21 HD12 ' A' ' 94' ' ' ILE . 38.7 mm -105.56 112.06 37.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.373 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -98.48 140.54 32.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.378 -179.945 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.41 142.38 96.27 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.341 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.24 -35.29 5.21 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.16 1.907 . . . . 0.0 112.357 179.95 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -146.8 162.34 38.79 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.337 -179.968 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -66.67 143.34 57.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.396 179.901 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.43 -160.86 31.45 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.972 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 28.6 tttp -130.23 147.23 51.93 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.032 0.444 . . . . 0.0 110.526 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 21.3 t -75.67 109.12 8.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.293 179.898 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -93.93 -29.91 15.03 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.76 -179.892 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 29.8 tttt -157.47 128.09 6.49 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.163 0.506 . . . . 0.0 110.642 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 29.0 t -102.59 102.45 13.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.224 179.824 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 12.5 mt -76.25 -32.22 58.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.213 179.716 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 34.8 m -77.86 142.01 14.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.632 -179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 12.7 mmmt -139.82 158.45 44.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.994 179.676 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -55.81 161.72 2.08 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.976 -179.794 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 37.18 41.24 0.21 Allowed 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.486 -179.737 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -128.99 142.16 51.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.265 179.882 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -93.51 136.99 33.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.623 -179.781 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.1 m -118.8 161.29 17.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.312 179.781 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 -102.06 143.21 32.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.438 -179.998 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.2 108.66 2.02 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.962 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.14 -26.28 10.59 Favored Glycine 0 CA--C 1.528 0.859 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 -179.798 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -58.44 144.73 41.12 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-O 121.134 0.492 . . . . 0.0 110.787 -179.966 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.96 120.74 24.1 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.962 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 89.3 mt -88.01 -59.61 2.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.105 0.478 . . . . 0.0 110.453 -179.96 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 55.0 mt -140.85 145.2 25.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.377 -179.988 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -91.4 121.56 33.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.167 179.797 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.2 mm -104.29 141.44 19.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.455 -179.957 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.75 0 CA-C-O 117.953 -1.471 . . . . 0.0 110.765 179.988 . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 . . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -177.8 -42.6 0.06 OUTLIER Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 179.951 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -62.82 -177.38 0.15 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.076 0.465 . . . . 0.0 110.448 179.976 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 66.07 -82.64 0.09 OUTLIER Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.996 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -76.79 141.5 40.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.069 0.462 . . . . 0.0 110.443 -179.976 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -78.22 179.46 6.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.377 -179.998 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 142.21 -35.47 1.75 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.636 -0.985 . . . . 0.0 110.636 179.983 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -89.88 56.48 3.5 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.468 0.651 . . . . 0.0 110.373 179.983 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.77 -30.22 10.14 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.909 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -76.57 140.09 40.94 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.212 0.53 . . . . 0.0 110.75 -179.78 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.432 HG21 HD11 ' A' ' 57' ' ' ILE . 51.3 mt -81.03 117.1 66.63 Favored Pre-proline 0 CA--C 1.533 0.31 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.14 179.86 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -71.92 137.23 29.04 Favored 'Trans proline' 0 N--CA 1.472 0.228 0 C-N-CA 121.932 1.755 . . . . 0.0 112.315 -179.984 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -61.44 146.69 89.06 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.389 -179.879 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -72.13 -28.69 15.45 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.2 1.934 . . . . 0.0 112.263 179.928 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -165.32 166.9 18.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.41 -179.965 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.43 85.1 6.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.449 179.949 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.35 -160.94 10.86 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -179.93 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.3 m -114.41 140.62 48.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.122 0.487 . . . . 0.0 110.56 -179.969 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 29.6 t -64.94 127.67 26.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.194 179.908 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.3 -61.27 1.42 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.703 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.6 mttt -149.97 145.68 26.59 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.11 0.481 . . . . 0.0 110.654 -179.812 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.5 mt -101.04 125.24 55.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.721 179.443 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 19.8 mt -96.31 -31.21 13.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.979 -179.429 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 35.6 m -111.62 147.18 15.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.201 0.524 . . . . 0.0 110.732 -179.719 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.5 163.96 29.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.154 179.795 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -59.34 102.45 0.14 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.699 -179.919 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.03 -30.31 2.37 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.974 -0.851 . . . . 0.0 110.974 179.969 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.84 150.91 20.3 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.175 0.512 . . . . 0.0 110.586 -179.866 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.5 m -96.02 148.14 22.97 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.297 179.931 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 29.8 m -119.13 166.3 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.513 -179.97 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 32.1 mmtm -128.88 147.84 50.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.24 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.81 90.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.779 -179.877 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.53 -31.34 2.6 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.827 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -64.1 141.15 58.87 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.171 0.51 . . . . 0.0 110.668 -179.769 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 6.4 m -65.97 137.01 56.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.082 179.788 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 31.1 m -121.68 -32.19 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.66 -179.318 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 16.3 tp -158.97 151.8 22.02 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.083 0.468 . . . . 0.0 110.816 -179.124 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.2 t -113.9 144.08 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.769 179.323 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 16.6 mt -120.62 158.81 26.58 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.168 0.509 . . . . 0.0 110.789 -179.64 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 -135.84 111.19 9.09 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.385 -179.916 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.51 138.65 24.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.543 179.936 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 12.6 mmt 60.56 32.65 20.47 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.541 179.986 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 42.5 mttt 60.62 33.94 20.26 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.514 -179.998 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 27.2 ttm -137.77 109.67 7.18 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.481 -179.994 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -67.55 127.11 31.5 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.363 179.981 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -123.33 113.24 18.58 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.406 179.968 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -79.5 139.31 37.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.601 -179.889 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 5.1 mp -110.27 155.88 11.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.729 179.902 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 11.3 m-80 -139.5 152.57 47.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.543 -179.918 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.16 139.75 96.1 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.305 180.0 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -73.77 -35.47 4.46 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.114 1.876 . . . . 0.0 112.153 179.977 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 24.0 p -144.96 163.17 34.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.343 179.944 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -65.28 140.87 58.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.337 179.859 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.34 -159.6 29.74 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.919 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 22.8 ttmt -135.21 148.76 49.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.078 0.466 . . . . 0.0 110.421 -179.901 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 22.4 t -78.16 110.4 13.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.197 179.929 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -92.97 -27.54 16.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.884 -179.931 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -157.35 130.82 7.92 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.093 0.473 . . . . 0.0 110.653 -179.773 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.7 t -101.32 102.98 14.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.132 179.806 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 14.0 mt -88.31 10.38 19.96 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.531 179.862 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 31.3 m -123.76 135.42 63.49 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.074 0 CA-C-O 121.177 0.513 . . . . 0.0 110.212 179.705 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 9.7 tttp -123.5 152.9 41.26 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.277 -179.943 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -59.98 146.29 43.07 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.598 -179.967 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 20.8 mtm180 61.02 34.19 19.39 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.505 -179.943 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -120.14 149.74 41.74 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.346 179.819 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.11 135.9 33.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.566 -179.981 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.4 m -121.71 -179.99 2.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.273 179.906 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -138.55 144.7 40.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.423 -179.994 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.51 111.14 3.43 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.962 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 111.86 -28.77 9.06 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.88 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.0 tt0 -59.49 135.89 57.81 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.075 0.464 . . . . 0.0 110.573 -179.899 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.25 116.1 8.85 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.946 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 71.8 mt -88.77 -54.58 4.08 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.017 0.436 . . . . 0.0 110.472 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 49.5 mt -142.7 145.0 23.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.391 -179.975 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 25.1 tttt -98.06 129.0 44.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.453 179.869 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.1 mm -103.54 145.54 12.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.475 -179.782 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.75 0 CA-C-O 118.016 -1.436 . . . . 0.0 110.753 179.891 . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 . . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -166.76 98.75 0.15 Allowed Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.9 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -107.72 127.82 54.02 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.076 0.465 . . . . 0.0 110.439 179.982 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 179.74 137.72 3.1 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 -179.998 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.7 tttt 60.65 109.19 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.066 0.46 . . . . 0.0 110.536 179.961 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.65 178.17 0.46 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.501 179.969 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -160.19 -73.34 0.02 OUTLIER Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.957 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -135.82 111.57 9.39 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.029 0.442 . . . . 0.0 110.453 -179.917 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 115.16 -48.35 0.95 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.946 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -84.19 135.99 34.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.122 0.487 . . . . 0.0 110.435 -179.927 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.5 mt -78.89 112.45 27.45 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.156 179.937 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.09 141.62 40.27 Favored 'Trans proline' 0 N--CA 1.472 0.262 0 C-N-CA 122.115 1.877 . . . . 0.0 112.395 -179.932 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.2 148.59 71.38 Favored Pre-proline 0 CA--C 1.531 0.235 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.423 179.911 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -72.2 -27.45 16.67 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.31 2.007 . . . . 0.0 112.365 -179.949 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -158.61 171.08 20.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.321 179.968 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -91.07 83.43 5.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.415 179.998 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -109.7 -136.16 7.4 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.946 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.0 m -139.08 138.55 37.2 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.173 0.511 . . . . 0.0 110.488 179.933 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.9 t -66.82 124.0 21.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.284 179.991 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.2 t -98.58 -60.31 1.57 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.478 -179.957 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.8 mttt -148.69 147.3 28.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.461 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 24.0 mt -106.04 118.02 52.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.923 179.899 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.5 mt -95.12 21.79 7.41 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.385 -179.525 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 25.2 m -150.0 148.29 15.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 121.239 0.543 . . . . 0.0 110.524 179.812 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 12.0 mtpp -132.17 157.36 44.48 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.185 179.874 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 27.0 mt-10 -59.11 95.33 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.516 179.989 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.15 -30.41 2.35 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.777 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 59.8 m-20 -73.13 146.39 45.72 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.062 0.458 . . . . 0.0 110.319 179.963 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.4 m -98.45 127.68 44.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.423 179.928 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 22.7 m -112.56 151.79 14.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.409 179.971 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.5 mttp -112.99 149.05 33.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.324 179.908 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -57.98 95.56 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.803 -179.854 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.39 -33.92 2.24 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.4 tt0 -69.34 140.17 54.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.083 0.468 . . . . 0.0 110.481 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.6 m -60.43 137.82 58.09 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.488 179.905 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 34.6 m -113.95 -33.65 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.947 -179.609 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 83' ' ' LEU . . . . . . . . . . . . . 7.9 tt -161.17 149.61 15.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.583 -179.558 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -104.46 140.69 21.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.183 179.836 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.6 mt -117.75 171.41 8.06 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.44 -179.848 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 -131.14 113.54 14.01 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.422 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -145.7 139.86 26.83 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.338 179.974 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 7.7 mtp 60.77 33.01 20.22 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.55 179.992 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 60.92 33.16 19.95 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.329 179.912 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.7 mtt -139.41 160.4 39.93 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.315 -179.999 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -93.19 131.56 38.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.541 179.971 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.6 m -120.76 121.06 37.4 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.212 179.961 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -84.8 131.98 34.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.57 -179.894 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.8 mm -102.25 124.87 56.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.167 179.767 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -103.64 140.94 36.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.345 -179.934 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.29 142.31 93.66 Favored Pre-proline 0 CA--C 1.532 0.26 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.403 -179.872 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.77 -36.8 4.36 Favored 'Trans proline' 0 N--CA 1.471 0.194 0 C-N-CA 122.109 1.873 . . . . 0.0 112.352 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 23.0 p -149.48 157.48 43.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.321 -179.989 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -63.53 140.85 58.91 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.358 179.91 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.81 -155.99 19.64 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.983 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 5.8 ttmt -136.93 142.23 42.68 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.143 0.497 . . . . 0.0 110.631 -179.931 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 31.3 t -74.12 112.17 10.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.246 179.9 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -96.11 -30.41 13.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.584 179.972 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 29.5 ttmt -158.97 133.77 8.14 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.468 179.954 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.1 t -99.93 109.2 24.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.237 -179.977 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.7 mt -90.12 30.34 1.11 Allowed 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.688 179.971 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 26.7 m -155.46 138.34 7.15 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-O 120.987 0.423 . . . . 0.0 110.261 -179.999 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 21.2 mttt -124.55 162.48 23.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.364 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 53.3 mt-10 -61.22 149.96 36.04 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.445 179.911 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 61.18 32.56 19.5 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.255 -179.803 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -120.18 148.42 43.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.378 179.9 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.47 140.58 29.61 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.472 -179.995 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.8 m -120.35 -179.99 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.5 -179.986 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.5 144.68 42.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.432 179.897 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.76 107.95 1.64 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.969 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.12 -27.96 9.7 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -60.64 137.14 58.21 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 121.199 0.523 . . . . 0.0 110.562 -179.85 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.96 119.19 17.73 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.968 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 59.5 mt -89.96 -49.75 6.42 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.091 0.472 . . . . 0.0 110.573 -179.873 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 47.8 mt -141.1 138.4 33.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.343 -179.918 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -91.13 130.22 37.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.394 179.887 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.4 mm -108.51 140.75 25.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.408 -179.996 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.834 0 CA-C-O 117.967 -1.463 . . . . 0.0 110.788 179.966 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 . . . . . 0 C--O 1.231 0.122 0 CA-C-O 121.145 0.498 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 51.8 mt -81.7 111.45 26.12 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.242 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.45 136.98 29.76 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.047 1.832 . . . . 0.0 112.305 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.772 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -72.18 147.17 90.48 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.516 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.89 -25.89 16.15 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.252 1.968 . . . . 0.0 112.464 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 pp -165.98 179.32 5.89 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.451 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.34 102.69 9.72 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.437 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.418 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -127.87 171.1 19.22 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.0 m -105.37 135.25 47.09 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.136 0.494 . . . . 0.0 110.416 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.611 HG23 ' O ' ' A' ' 111' ' ' ASP . 26.0 t -69.93 122.14 20.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.129 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -101.03 -54.42 2.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.576 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.3 ttpm? -151.66 145.85 25.37 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.487 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 3.4 mp -105.36 133.7 48.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.115 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.8 mp -98.15 -44.83 6.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.648 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.784 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.9 m -88.67 150.49 3.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.743 -179.708 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 3.5 ptpt -136.08 161.37 35.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.181 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -61.22 98.6 0.08 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.526 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -29.98 2.38 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.49 148.04 26.74 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.125 0.488 . . . . 0.0 110.578 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 24.5 m -95.2 142.17 27.95 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.192 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.708 HG11 HG11 ' A' ' 70' ' ' VAL . 23.8 m -120.19 163.73 17.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.638 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.1 mttp -123.04 147.47 46.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.153 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.659 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.11 92.9 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.693 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.2 -35.37 2.03 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -63.36 143.51 57.74 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.135 0.493 . . . . 0.0 110.614 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.7 m -66.87 137.2 56.4 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.219 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.514 ' HA ' HG13 ' A' ' 70' ' ' VAL . 30.7 m -115.17 -30.24 2.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.206 -179.51 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.62 HD13 HG21 ' A' ' 107' ' ' VAL . 9.0 tt -163.27 150.14 12.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.127 0.489 . . . . 0.0 110.855 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 t -102.13 130.59 51.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.998 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.446 HD12 ' CD1' ' A' ' 94' ' ' ILE . 9.6 mt -119.1 132.23 55.98 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.664 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.054 179.547 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 . . . . . 0 N--CA 1.462 0.137 0 CA-C-O 121.14 0.495 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.9 m -118.45 127.67 53.87 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.32 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -84.07 130.85 34.85 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.643 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.446 ' CD1' HD12 ' A' ' 85' ' ' LEU . 38.3 mm -104.94 116.22 48.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.124 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 82.5 m-20 -103.03 143.71 32.22 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.426 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.6 143.3 96.47 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.358 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -73.15 -37.65 3.28 Favored 'Trans proline' 0 CA--C 1.527 0.17 0 C-N-CA 122.072 1.848 . . . . 0.0 112.24 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.659 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 15.6 p -145.78 162.2 38.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.387 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -67.76 142.3 56.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.456 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.57 -157.25 27.52 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.1 ttmt -133.91 147.25 51.09 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.142 0.496 . . . . 0.0 110.544 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.784 HG21 ' HB ' ' A' ' 70' ' ' VAL . 35.2 t -75.32 107.26 5.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.301 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -93.39 -28.04 16.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.65 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -158.56 130.93 6.9 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.077 0.465 . . . . 0.0 110.396 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.427 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.4 t -97.96 109.39 23.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.31 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.2 mt -90.29 30.37 1.13 Allowed 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.641 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.62 HG21 HD13 ' A' ' 83' ' ' LEU . 25.6 m -155.47 137.47 6.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 121.073 0.463 . . . . 0.0 110.252 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 24.9 mmtt -128.9 167.01 18.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.385 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -62.27 147.61 47.53 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.426 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 11.0 mmp_? 60.69 32.32 20.26 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.598 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.611 ' O ' HG23 ' A' ' 65' ' ' VAL . 4.2 t70 -122.74 136.43 54.87 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.354 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.28 136.68 32.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.487 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 63' ' ' GLY . 30.5 m -119.18 150.73 21.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.394 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -98.15 149.28 22.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.449 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.92 117.3 11.16 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 105.84 -28.12 15.18 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 -59.57 138.33 57.74 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 121.041 0.448 . . . . 0.0 110.586 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.68 121.43 26.58 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.772 HD21 ' HB2' ' A' ' 59' ' ' ALA . 24.5 mt -88.92 -51.81 5.43 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.073 0.463 . . . . 0.0 110.404 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 48.4 mt -142.82 144.78 23.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.407 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -96.51 125.29 40.89 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.238 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.6 mm -106.06 143.87 16.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.536 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.772 0 CA-C-O 117.989 -1.45 . . . . 0.0 110.716 179.956 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 121.078 0.466 . . . . 0.0 110.481 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.507 HD11 HD11 ' A' ' 122' ' ' ILE . 28.5 mt -79.01 115.01 49.21 Favored Pre-proline 0 CA--C 1.535 0.386 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.006 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.84 140.04 37.76 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 121.963 1.775 . . . . 0.0 112.329 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.67 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -75.25 146.53 81.74 Favored Pre-proline 0 CA--C 1.531 0.219 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.454 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.612 ' HG2' HD23 ' A' ' 61' ' ' LEU . 49.0 Cg_endo -72.71 -24.34 18.42 Favored 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 122.232 1.954 . . . . 0.0 112.47 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.612 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.7 OUTLIER -161.08 175.23 12.65 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.457 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -87.83 110.26 20.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.402 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.451 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -138.09 177.85 19.69 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 18.9 m -104.75 136.58 43.99 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.142 0.496 . . . . 0.0 110.481 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.859 HG13 HD11 ' A' ' 83' ' ' LEU . 32.0 t -70.28 117.83 13.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.25 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.8 p -99.61 -51.86 3.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.525 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.3 ptpt -151.73 145.28 24.9 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.528 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.704 HG12 HD12 ' A' ' 83' ' ' LEU . 10.7 mt -100.77 141.23 17.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.009 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.474 HD13 ' HA ' ' A' ' 69' ' ' LEU . 3.9 mm? -101.6 -30.44 11.37 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.109 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.717 HG11 ' CG1' ' A' ' 76' ' ' VAL . 34.5 m -124.91 133.65 68.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.244 0.545 . . . . 0.0 110.854 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.75 149.3 37.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.853 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.8 121.06 5.96 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.387 0.613 . . . . 0.0 111.108 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.17 -28.83 4.48 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.51 158.82 15.37 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-O 121.054 0.454 . . . . 0.0 110.425 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -97.91 141.22 31.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.428 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.717 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.2 m -123.83 158.31 29.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.485 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 32.3 mttm -117.68 157.83 25.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.35 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.615 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -62.42 106.84 0.82 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.515 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.3 -31.47 4.66 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 -62.77 140.62 58.76 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.125 0.488 . . . . 0.0 110.532 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 7.5 m -67.54 139.38 56.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.305 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CA ' HG22 ' A' ' 70' ' ' VAL . 29.4 m -114.43 -31.54 2.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.053 -179.606 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.859 HD11 HG13 ' A' ' 65' ' ' VAL . 8.5 tt -166.41 146.9 6.19 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.103 0.478 . . . . 0.0 110.841 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.1 t -103.08 135.88 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.131 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.877 HD12 HD11 ' A' ' 94' ' ' ILE . 51.9 mt -118.32 166.27 12.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.706 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.336 179.911 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 21.5 mt-10 . . . . . 0 C--O 1.23 0.071 0 CA-C-O 121.056 0.455 . . . . 0.0 110.433 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.0 m -117.45 109.04 16.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.276 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -77.97 140.64 39.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.604 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.877 HD11 HD12 ' A' ' 85' ' ' LEU . 37.2 mm -103.68 140.67 21.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.057 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 38.3 m-20 -128.76 143.48 50.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.665 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.25 138.62 96.18 Favored Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.259 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.99 -31.86 11.87 Favored 'Trans proline' 0 N--CA 1.472 0.209 0 C-N-CA 122.09 1.86 . . . . 0.0 112.416 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.615 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 40.9 p -147.17 164.95 31.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.483 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -66.42 143.61 57.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.399 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.48 -160.43 27.98 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -135.02 136.87 42.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.139 0.495 . . . . 0.0 110.431 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.633 HG13 ' CG2' ' A' ' 120' ' ' ILE . 4.2 t -73.16 107.26 3.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.86 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -87.68 -29.39 21.17 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.001 -179.583 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 13.7 tttt -163.95 138.13 5.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.407 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 107' ' ' VAL . 21.6 t -107.92 110.49 32.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.416 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.8 mt -79.24 -31.59 43.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.394 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.571 HG21 HD13 ' A' ' 83' ' ' LEU . 27.3 m -82.56 142.84 13.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.501 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 54.2 mttt -136.47 163.11 31.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.246 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -60.79 147.29 43.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.519 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 5.5 tpt180 61.13 35.45 18.58 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.479 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.569 ' O ' HG23 ' A' ' 65' ' ' VAL . 8.0 t0 -127.98 140.32 52.05 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.388 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.51 136.24 33.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.517 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 63' ' ' GLY . 26.0 m -120.24 152.06 23.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.341 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -97.36 140.19 32.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.501 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.7 87.92 0.04 OUTLIER Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 137.54 -28.08 2.79 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -61.59 146.93 47.3 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.157 0.503 . . . . 0.0 110.515 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.56 118.87 16.16 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.67 HD21 ' HB2' ' A' ' 59' ' ' ALA . 71.8 mt -87.14 -53.15 5.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.082 0.468 . . . . 0.0 110.485 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.633 ' CG2' HG13 ' A' ' 102' ' ' VAL . 55.5 mt -140.9 151.59 20.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.477 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -97.22 133.99 41.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.209 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.507 HD11 HD11 ' A' ' 57' ' ' ILE . 35.9 mm -114.25 145.18 20.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.438 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.781 0 CA-C-O 118.011 -1.438 . . . . 0.0 110.774 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.998 0.428 . . . . 0.0 110.499 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.772 HD12 ' HD2' ' A' ' 97' ' ' PRO . 46.1 mm -80.22 120.6 80.07 Favored Pre-proline 0 CA--C 1.536 0.431 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.923 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -72.05 128.0 13.47 Favored 'Trans proline' 0 N--CA 1.472 0.222 0 C-N-CA 121.892 1.728 . . . . 0.0 112.1 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.443 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -61.05 142.12 93.22 Favored Pre-proline 0 CA--C 1.532 0.28 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.471 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -73.62 -27.54 12.73 Favored 'Trans proline' 0 CA--C 1.528 0.188 0 C-N-CA 122.181 1.921 . . . . 0.0 112.374 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -161.33 159.92 29.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.472 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.59 125.39 30.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.402 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -159.06 -140.22 2.86 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.621 ' C ' HD23 ' A' ' 85' ' ' LEU . 14.8 m -136.56 139.13 41.96 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.082 0.468 . . . . 0.0 110.406 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.771 HG13 HD11 ' A' ' 83' ' ' LEU . 27.9 t -70.71 124.61 27.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.208 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.0 t -98.42 -54.23 3.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.675 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -153.67 145.02 23.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.529 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.704 HG12 HD12 ' A' ' 83' ' ' LEU . 35.7 mt -99.65 135.16 36.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.118 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.546 HD13 ' HB ' ' A' ' 81' ' ' THR . 12.3 mt -98.48 -44.13 6.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.617 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.689 HG11 ' CG1' ' A' ' 76' ' ' VAL . 34.6 m -98.83 144.69 11.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.502 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 46.1 pttt -137.3 164.28 28.94 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.206 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -57.05 102.29 0.08 Allowed 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.692 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.13 -31.97 2.22 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -90.15 152.94 20.88 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.062 0.458 . . . . 0.0 110.387 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -98.84 146.79 25.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.474 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.689 ' CG1' HG11 ' A' ' 70' ' ' VAL . 28.4 m -121.47 162.44 20.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.344 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -127.29 156.85 41.27 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.488 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.34 90.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.55 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.65 -30.36 3.0 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 16.3 tt0 -61.88 143.32 56.56 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.077 0.465 . . . . 0.0 110.672 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.546 ' HB ' HD13 ' A' ' 69' ' ' LEU . 1.9 m -68.9 138.97 55.1 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.148 179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.529 ' HA ' HG13 ' A' ' 70' ' ' VAL . 28.4 m -117.63 -33.86 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.35 -179.423 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.771 HD11 HG13 ' A' ' 65' ' ' VAL . 7.6 tt -161.52 153.15 19.02 Favored 'General case' 0 C--N 1.332 -0.175 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.167 -179.303 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.4 t -107.55 138.4 33.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.923 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.678 HD21 ' CG2' ' A' ' 113' ' ' VAL . 0.9 OUTLIER -120.26 168.53 11.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.191 0.52 . . . . 0.0 110.457 -179.808 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.357 179.961 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 121.063 0.459 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.2 m -114.4 122.34 46.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.232 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -82.52 130.22 35.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.62 -179.747 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.501 HG13 HD12 ' A' ' 85' ' ' LEU . 25.7 mm -103.19 147.45 9.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.011 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -139.27 142.38 37.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.152 0.501 . . . . 0.0 110.779 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.518 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -62.65 109.76 2.72 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.291 179.665 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.772 ' HD2' HD12 ' A' ' 57' ' ' ILE . 41.9 Cg_endo -64.93 -13.77 41.46 Favored 'Trans proline' 0 N--CA 1.476 0.46 0 C-N-CA 122.148 1.899 . . . . 0.0 112.885 179.643 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -135.94 135.96 40.04 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.097 0.475 . . . . 0.0 110.359 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -63.36 151.29 41.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.422 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 159.36 -154.66 25.73 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.0 ttmt -135.69 148.03 48.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.141 0.496 . . . . 0.0 110.448 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.653 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -75.69 111.26 11.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.208 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -95.21 -30.07 14.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.784 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.7 ttpt -162.01 130.17 4.13 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.569 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.494 HG13 HG12 ' A' ' 120' ' ' ILE . 22.0 t -103.57 113.89 41.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.295 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.0 mt -81.59 -37.17 28.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.374 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.526 HG21 HD13 ' A' ' 83' ' ' LEU . 32.9 m -77.44 147.45 7.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.574 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -133.49 163.68 28.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.075 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -62.71 138.55 58.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.394 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER 67.2 37.16 3.76 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.564 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.41 151.07 40.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.278 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -95.61 133.46 39.63 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.513 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.678 ' CG2' HD21 ' A' ' 85' ' ' LEU . 31.4 m -120.8 179.8 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.356 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 81.7 mm-40 -136.05 147.67 48.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.425 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.32 113.07 5.31 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 111.18 -30.78 7.69 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -60.18 140.33 57.02 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.138 0.494 . . . . 0.0 110.675 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.49 120.49 22.72 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.443 HD21 ' HB2' ' A' ' 59' ' ' ALA . 91.6 mt -87.06 -53.59 4.79 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.103 0.478 . . . . 0.0 110.423 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.562 ' CG2' HG13 ' A' ' 102' ' ' VAL . 52.3 mt -141.32 151.82 19.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.326 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 39.1 mttt -93.76 128.19 39.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.382 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.437 HD12 HG21 ' A' ' 76' ' ' VAL . 37.1 mm -109.87 145.76 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.37 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.748 0 CA-C-O 117.991 -1.449 . . . . 0.0 110.728 179.925 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 . . . . . 0 N--CA 1.46 0.074 0 CA-C-O 121.067 0.46 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.457 HD11 HD11 ' A' ' 122' ' ' ILE . 45.7 mt -78.9 111.45 19.86 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.127 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -70.38 142.42 45.17 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.099 1.866 . . . . 0.0 112.465 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.511 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -77.67 148.53 76.51 Favored Pre-proline 0 CA--C 1.531 0.24 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.521 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -73.11 -26.66 14.71 Favored 'Trans proline' 0 CA--C 1.528 0.212 0 C-N-CA 122.206 1.937 . . . . 0.0 112.461 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -164.63 156.98 16.37 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.472 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.0 121.92 19.07 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.423 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -150.96 -145.17 4.07 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.7 m -136.97 139.02 41.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.138 0.494 . . . . 0.0 110.413 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.629 HG13 HD11 ' A' ' 83' ' ' LEU . 25.2 t -71.98 126.23 32.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.181 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 32.7 t -96.03 -53.41 3.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.655 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.32 150.55 31.62 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.178 0.513 . . . . 0.0 110.74 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.485 HD11 ' HA ' ' A' ' 108' ' ' LYS . 32.8 mt -105.87 116.48 49.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.051 179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 64.2 mt -98.75 13.78 31.05 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.622 -179.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.756 ' HB ' HG21 ' A' ' 102' ' ' VAL . 28.4 m -148.22 133.56 11.0 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 CA-C-O 121.122 0.486 . . . . 0.0 110.691 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -116.86 161.2 19.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.195 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.21 95.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.621 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.22 -35.79 1.86 Allowed Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.52 146.77 47.59 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.093 0.473 . . . . 0.0 110.481 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -96.67 137.51 35.63 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.578 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 18.8 m -126.91 166.76 22.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.395 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -130.3 157.23 43.11 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.309 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.703 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -62.39 88.62 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.401 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.15 -33.51 2.08 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -63.15 145.66 55.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.145 0.498 . . . . 0.0 110.451 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.1 m -67.33 139.57 57.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.425 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.595 ' O ' HG22 ' A' ' 70' ' ' VAL . 28.1 m -120.14 -35.49 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.17 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.629 HD11 HG13 ' A' ' 65' ' ' VAL . 7.6 tt -162.05 152.71 17.45 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.261 0.553 . . . . 0.0 111.032 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.9 t -103.54 145.1 13.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.794 179.499 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.815 HD12 HD11 ' A' ' 94' ' ' ILE . 11.1 mt -126.67 160.3 31.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.52 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.423 179.907 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 . . . . . 0 C--O 1.231 0.09 0 CA-C-O 121.016 0.436 . . . . 0.0 110.196 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.3 m -118.75 117.58 29.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.393 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -83.04 133.82 35.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.457 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.815 HD11 HD12 ' A' ' 85' ' ' LEU . 33.7 mm -103.71 152.78 6.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.172 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 47.6 m-80 -139.88 148.08 41.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.495 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.89 139.18 95.66 Favored Pre-proline 0 CA--C 1.533 0.316 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.399 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -76.02 -28.65 7.38 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.128 1.886 . . . . 0.0 112.387 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.703 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 3.7 p -145.63 168.27 21.06 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.535 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -69.57 141.71 53.73 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.514 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 159.78 -168.16 35.48 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -129.13 168.4 16.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.229 0.538 . . . . 0.0 110.637 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.756 HG21 ' HB ' ' A' ' 70' ' ' VAL . 27.4 t -82.4 111.56 18.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.439 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -92.95 -30.13 15.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.42 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 4.9 tmtt? -159.05 128.77 5.62 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.275 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.429 HG22 HG11 ' A' ' 102' ' ' VAL . 20.7 t -101.3 105.73 18.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.117 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.0 mt -85.84 9.45 16.66 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.863 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.479 HG21 HD13 ' A' ' 83' ' ' LEU . 28.4 m -129.33 146.0 34.89 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-O 121.192 0.52 . . . . 0.0 110.629 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.485 ' HA ' HD11 ' A' ' 68' ' ' ILE . 20.5 mtpt -128.39 166.5 18.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.263 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -63.49 140.89 58.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.323 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 17.7 mmt85 65.83 36.71 5.96 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.67 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.504 ' O ' HG23 ' A' ' 65' ' ' VAL . 1.8 m-20 -121.89 137.44 54.78 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.272 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.2 134.21 34.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.521 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.2 m -120.72 156.96 23.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.367 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -97.51 144.12 27.53 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.393 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.3 108.05 1.62 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.96 -27.06 9.41 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.05 -0.82 . . . . 0.0 111.05 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 24.1 tt0 -59.83 143.52 50.96 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-O 121.126 0.489 . . . . 0.0 110.631 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.63 119.84 19.93 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.511 HD21 ' HB2' ' A' ' 59' ' ' ALA . 70.6 mt -89.67 -52.82 4.81 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.136 0.493 . . . . 0.0 110.172 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.484 ' CG2' HG13 ' A' ' 102' ' ' VAL . 46.3 mt -145.21 144.14 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.16 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 9.3 tttt -94.99 135.48 36.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.143 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.457 HD11 HD11 ' A' ' 57' ' ' ILE . 40.8 mm -109.2 142.69 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.412 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.815 0 CA-C-O 118.061 -1.41 . . . . 0.0 110.833 -179.919 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.49 ' OE2' HD11 ' A' ' 106' ' ' LEU . 7.6 mm-40 . . . . . 0 C--O 1.232 0.162 0 CA-C-O 121.09 0.471 . . . . 0.0 110.42 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.487 HD11 HD11 ' A' ' 122' ' ' ILE . 48.5 mt -78.29 118.79 74.39 Favored Pre-proline 0 CA--C 1.535 0.39 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.185 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -71.53 135.33 26.14 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 121.98 1.787 . . . . 0.0 112.331 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.764 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -65.52 148.4 98.1 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.456 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.79 -34.73 6.48 Favored 'Trans proline' 0 N--CA 1.472 0.224 0 C-N-CA 122.276 1.984 . . . . 0.0 112.236 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -162.67 159.06 23.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.411 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.77 81.91 0.19 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.288 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.411 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -115.01 -172.79 17.5 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.9 m -109.89 136.7 48.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.061 0.458 . . . . 0.0 110.388 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.507 HG13 HD21 ' A' ' 83' ' ' LEU . 24.3 t -71.73 117.02 14.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.094 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.8 t -92.93 -49.99 5.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.679 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -155.37 148.35 24.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.246 0.546 . . . . 0.0 110.608 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.422 HG22 ' O ' ' A' ' 70' ' ' VAL . 48.5 mt -103.37 130.15 54.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.95 179.696 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.588 HD11 HG23 ' A' ' 84' ' ' VAL . 5.7 mp -94.29 -30.72 14.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.854 -179.599 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.69 HG11 ' CG1' ' A' ' 76' ' ' VAL . 31.0 m -114.72 145.77 20.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.112 0.482 . . . . 0.0 110.728 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -138.88 166.87 23.32 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.331 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -56.96 104.95 0.18 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.839 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 132.1 -31.02 3.1 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -87.35 144.49 26.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.108 0.48 . . . . 0.0 110.57 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.2 m -93.51 150.45 20.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.293 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.69 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.9 m -125.14 166.9 20.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.568 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -129.48 147.51 51.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.204 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.463 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.52 92.02 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.629 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.17 -30.55 2.62 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.6 tt0 -69.25 143.04 54.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.107 0.479 . . . . 0.0 110.618 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.446 ' HB ' HD22 ' A' ' 69' ' ' LEU . 27.1 m -65.02 138.21 58.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.206 179.784 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.694 HG22 ' O ' ' A' ' 94' ' ' ILE . 29.6 m -115.7 -26.38 2.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.449 -179.494 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.507 HD21 HG13 ' A' ' 65' ' ' VAL . 9.1 tt -165.26 150.02 9.0 Favored 'General case' 0 C--N 1.332 -0.166 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.966 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.588 HG23 HD11 ' A' ' 69' ' ' LEU . 22.0 t -106.74 137.91 35.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.017 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.46 HD23 ' HA ' ' A' ' 85' ' ' LEU . 11.8 mt -115.66 164.75 13.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.184 0.516 . . . . 0.0 110.595 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.363 179.959 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 . . . . . 0 N--CA 1.461 0.108 0 CA-C-O 121.128 0.49 . . . . 0.0 110.55 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.7 m -122.02 112.61 18.48 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.233 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.443 ' HG3' HG22 ' A' ' 84' ' ' VAL . 1.7 mp0 -87.4 143.0 27.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.487 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.694 ' O ' HG22 ' A' ' 82' ' ' VAL . 4.8 mp -116.52 126.24 73.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.123 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -101.07 153.95 19.13 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.261 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.06 141.37 95.77 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.325 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.26 -32.72 7.98 Favored 'Trans proline' 0 N--CA 1.472 0.208 0 C-N-CA 122.133 1.889 . . . . 0.0 112.212 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.463 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 73.1 p -148.16 155.92 41.97 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.348 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -63.73 142.85 58.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.393 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 169.34 -156.38 27.43 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -134.35 150.97 50.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.092 0.472 . . . . 0.0 110.372 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.656 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -78.3 111.03 14.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.276 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -93.55 -30.94 14.74 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.646 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.61 151.74 27.88 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.221 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.495 HG13 HG12 ' A' ' 120' ' ' ILE . 21.9 t -131.95 113.26 21.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.304 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.49 HD11 ' OE2' ' A' ' 56' ' ' GLU . 2.1 mt -84.63 -33.07 23.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.348 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.417 ' O ' HG12 ' A' ' 105' ' ' VAL . 32.7 m -80.46 144.24 11.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.585 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -133.36 164.19 27.67 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.247 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 -61.28 144.35 54.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.458 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 2.5 ttt-85 61.48 35.02 17.78 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.44 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.459 ' O ' HG23 ' A' ' 65' ' ' VAL . 17.2 t0 -124.62 148.04 48.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.428 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.3 141.33 28.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.469 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 63' ' ' GLY . 30.8 m -122.41 156.18 27.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.379 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -100.58 140.18 35.21 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.346 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.51 98.97 0.16 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.3 -27.55 6.32 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.7 tt0 -59.56 142.63 52.28 Favored 'General case' 0 N--CA 1.462 0.127 0 CA-C-O 121.062 0.458 . . . . 0.0 110.656 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.26 121.64 26.03 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.761 -0.935 . . . . 0.0 110.761 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.764 HD21 ' HB2' ' A' ' 59' ' ' ALA . 79.6 mt -87.78 -54.46 4.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.075 0.464 . . . . 0.0 110.394 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.581 ' CG2' HG13 ' A' ' 102' ' ' VAL . 52.9 mt -141.24 149.39 20.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.312 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 14.8 tttp -98.14 126.75 43.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.343 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.487 HD11 HD11 ' A' ' 57' ' ' ILE . 36.7 mm -102.62 145.68 11.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.331 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.689 0 CA-C-O 117.988 -1.451 . . . . 0.0 110.784 179.967 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 121.132 0.492 . . . . 0.0 110.3 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.44 HD11 HD11 ' A' ' 122' ' ' ILE . 54.5 mt -78.04 113.67 35.27 Favored Pre-proline 0 CA--C 1.535 0.395 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.068 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.08 132.71 23.37 Favored 'Trans proline' 0 N--CA 1.472 0.249 0 C-N-CA 122.08 1.853 . . . . 0.0 112.297 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.503 ' HB3' ' O ' ' A' ' 114' ' ' GLN . . . -65.94 147.97 98.54 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.584 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.681 ' HB2' HD23 ' A' ' 61' ' ' LEU . 49.6 Cg_endo -73.33 -29.01 11.77 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.256 1.971 . . . . 0.0 112.314 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.681 HD23 ' HB2' ' A' ' 60' ' ' PRO . 0.2 OUTLIER -163.81 -179.85 6.61 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.528 179.83 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.19 98.45 9.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.42 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.57 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -132.76 -177.55 14.99 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.3 m -113.63 141.27 47.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.132 0.492 . . . . 0.0 110.418 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.706 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -70.89 126.02 30.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.293 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.1 t -100.65 -52.28 3.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.58 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 7.2 ttmm -150.52 148.56 28.85 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.654 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.422 HD11 ' HA ' ' A' ' 108' ' ' LYS . 44.8 mt -102.66 131.71 50.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.019 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.9 mt -99.79 -36.37 9.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.786 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.739 HG11 ' CG1' ' A' ' 76' ' ' VAL . 33.6 m -110.47 146.92 15.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 121.172 0.511 . . . . 0.0 110.835 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.3 pttt -137.3 165.6 25.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.182 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.485 ' HG3' HG23 ' A' ' 105' ' ' VAL . 36.8 mt-10 -58.42 101.74 0.09 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.606 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.07 -32.6 2.17 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -88.54 146.28 25.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.129 0.49 . . . . 0.0 110.392 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.507 HG22 ' O ' ' A' ' 100' ' ' GLY . 0.8 OUTLIER -96.28 148.33 22.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.32 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.739 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.9 m -125.77 169.79 16.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.52 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 43.6 tttt -132.37 153.97 50.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.31 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.656 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.94 97.97 0.07 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.595 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.27 -36.75 2.19 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 14.9 tt0 -62.49 139.08 58.59 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.056 0.455 . . . . 0.0 110.67 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.6 m -65.86 137.11 56.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.206 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.472 ' HA ' HG13 ' A' ' 70' ' ' VAL . 24.3 m -115.67 -31.39 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.229 -179.502 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.706 HD11 HG13 ' A' ' 65' ' ' VAL . 7.5 tt -161.35 153.0 19.18 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.177 0.513 . . . . 0.0 110.86 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -101.35 140.55 19.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.038 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.653 HD12 HD11 ' A' ' 94' ' ' ILE . 12.5 mt -122.78 139.24 54.21 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.161 0.505 . . . . 0.0 110.643 -179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.373 179.931 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.461 0.097 0 CA-C-O 121.117 0.484 . . . . 0.0 110.507 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.6 m -113.5 123.36 49.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.312 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -84.64 130.65 34.69 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.523 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.653 HD11 HD12 ' A' ' 85' ' ' LEU . 35.6 mm -106.23 114.9 46.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.184 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -102.11 146.91 27.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.289 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.09 141.53 95.79 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.322 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.62 -34.78 6.77 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.077 1.852 . . . . 0.0 112.211 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.656 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 17.4 p -147.85 162.57 38.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.271 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -68.19 141.18 56.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.328 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.507 ' O ' HG22 ' A' ' 75' ' ' THR . . . 171.47 -158.34 29.4 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 5.6 ttpm? -132.95 149.7 52.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.976 0.417 . . . . 0.0 110.336 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.66 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -75.99 110.16 10.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.21 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -92.77 -29.97 15.74 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.582 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 27.6 tttm -159.2 129.65 5.85 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.157 0.503 . . . . 0.0 110.486 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.485 HG23 ' HG3' ' A' ' 72' ' ' GLU . 33.2 t -100.19 102.84 13.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.168 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.2 mt -85.24 6.38 26.29 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.64 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.647 HG21 HD13 ' A' ' 83' ' ' LEU . 26.7 m -120.89 136.23 58.54 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.109 0 CA-C-O 121.181 0.515 . . . . 0.0 110.312 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.422 ' HA ' HD11 ' A' ' 68' ' ' ILE . 83.3 mttt -126.23 164.41 21.04 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.313 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -62.1 145.33 53.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.38 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 36.6 mtt180 60.13 35.6 21.18 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.588 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -114.64 141.68 47.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.373 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.61 129.27 38.59 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.572 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.57 HG22 ' O ' ' A' ' 63' ' ' GLY . 27.5 m -119.09 179.7 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.259 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' GLN . . . . . 0.503 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 64.3 mt-30 -140.68 152.45 45.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.512 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.82 105.09 0.83 Allowed Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.9 -31.39 4.97 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -60.05 135.32 57.68 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.131 0.491 . . . . 0.0 110.541 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.81 121.07 25.4 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.492 ' O ' HG13 ' A' ' 107' ' ' VAL . 62.3 mt -87.36 -56.51 3.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.012 0.434 . . . . 0.0 110.296 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.542 ' CG2' HG13 ' A' ' 102' ' ' VAL . 49.1 mt -143.15 150.89 17.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.126 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -96.2 125.7 40.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.265 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.44 HD11 HD11 ' A' ' 57' ' ' ILE . 37.8 mm -106.46 143.36 17.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.516 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.697 0 CA-C-O 117.951 -1.471 . . . . 0.0 110.767 179.977 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 . . . . . 0 N--CA 1.461 0.101 0 CA-C-O 121.026 0.441 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.465 HG23 ' HD3' ' A' ' 97' ' ' PRO . 54.3 mt -82.11 111.06 24.26 Favored Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.282 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -71.57 142.67 40.71 Favored 'Trans proline' 0 N--CA 1.472 0.263 0 C-N-CA 122.0 1.8 . . . . 0.0 112.295 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.483 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -74.7 147.14 84.15 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.397 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -72.49 -26.51 16.77 Favored 'Trans proline' 0 N--CA 1.471 0.199 0 C-N-CA 122.182 1.921 . . . . 0.0 112.366 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -164.55 157.57 17.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.362 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.502 ' HB2' ' H ' ' A' ' 115' ' ' GLY . . . -73.52 97.15 2.53 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.43 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.86 -144.55 6.22 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 3.9 m -136.54 132.18 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.095 0.474 . . . . 0.0 110.358 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.635 ' CG1' HD11 ' A' ' 83' ' ' LEU . 21.8 t -67.71 130.5 33.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.254 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 4.8 p -101.6 -53.98 2.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.542 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 23.8 ttpt -152.82 147.26 25.82 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.588 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.556 HG12 HD12 ' A' ' 83' ' ' LEU . 47.3 mt -100.23 133.48 43.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.116 179.761 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.425 HD12 HG22 ' A' ' 81' ' ' THR . 25.7 mt -98.64 -31.3 12.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.638 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.786 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.0 m -104.51 149.95 7.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.701 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 67.7 mttt -137.19 163.43 30.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.206 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -62.36 97.0 0.08 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.258 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.19 -29.19 2.43 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -85.43 147.82 26.3 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.082 0.467 . . . . 0.0 110.442 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.442 HG22 ' O ' ' A' ' 100' ' ' GLY . 0.7 OUTLIER -96.88 150.21 20.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.147 179.878 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.756 HG11 HG11 ' A' ' 70' ' ' VAL . 31.6 m -128.54 170.02 18.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.653 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.5 mmtt -131.38 146.26 52.2 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.22 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.707 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -58.84 96.51 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.717 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.16 -34.5 2.3 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 23.6 tt0 -67.84 144.46 55.3 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.14 0.495 . . . . 0.0 110.515 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.425 HG22 HD12 ' A' ' 69' ' ' LEU . 3.5 m -65.13 136.73 57.05 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.315 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.457 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.3 m -112.73 -33.09 2.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.921 -179.674 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.635 HD11 ' CG1' ' A' ' 65' ' ' VAL . 7.5 tt -160.4 150.75 18.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.686 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.2 t -102.55 136.64 33.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.184 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.695 HD11 HG21 ' A' ' 113' ' ' VAL . 0.7 OUTLIER -117.16 164.1 15.28 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.519 -179.793 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.28 179.985 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 121.068 0.461 . . . . 0.0 110.459 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 24.1 m -116.47 124.64 50.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.388 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -85.01 134.14 34.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.486 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.3 mm -102.66 126.1 56.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.242 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 13.7 p30 -110.25 140.06 44.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.314 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.11 139.24 96.03 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.311 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.465 ' HD3' HG23 ' A' ' 57' ' ' ILE . 49.8 Cg_endo -73.81 -31.04 8.75 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.166 1.911 . . . . 0.0 112.227 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.707 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 78.2 p -147.01 151.31 36.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.344 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -66.78 142.67 57.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.352 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.442 ' O ' HG22 ' A' ' 75' ' ' THR . . . 176.62 -147.93 8.76 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -140.88 145.47 36.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.076 0.465 . . . . 0.0 110.316 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.786 HG21 ' HB ' ' A' ' 70' ' ' VAL . 24.7 t -77.8 107.45 9.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.327 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -91.92 -28.42 17.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.729 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 17.8 ttpt -160.75 130.89 5.14 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.099 0.476 . . . . 0.0 110.544 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.435 HG13 HG12 ' A' ' 120' ' ' ILE . 21.9 t -105.49 109.52 28.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.347 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.6 mt -78.92 -31.8 45.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.476 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.424 HG11 HD23 ' A' ' 119' ' ' LEU . 31.5 m -80.18 152.84 4.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.593 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -135.79 155.11 50.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.268 179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -59.01 141.99 52.44 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.632 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER 60.75 36.39 19.34 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.499 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -119.45 151.11 39.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.286 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -93.64 133.4 37.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.491 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.695 HG21 HD11 ' A' ' 85' ' ' LEU . 29.7 m -120.39 152.01 23.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.453 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -100.17 144.93 28.62 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.354 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.502 ' H ' ' HB2' ' A' ' 62' ' ' ALA . . . -61.62 105.63 0.96 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 117.91 -28.04 7.19 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 37.3 tt0 -59.85 139.96 56.96 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 121.127 0.489 . . . . 0.0 110.597 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.36 126.58 40.3 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.483 HD11 ' HA ' ' A' ' 59' ' ' ALA . 41.5 mt -89.43 -58.94 2.35 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.153 0.501 . . . . 0.0 110.567 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.495 ' CG2' HG13 ' A' ' 102' ' ' VAL . 58.4 mt -140.95 145.57 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.164 -179.733 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -93.41 123.76 36.94 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.536 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.1 mm -101.23 145.07 12.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.274 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.678 0 CA-C-O 117.947 -1.474 . . . . 0.0 110.875 -179.996 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 . . . . . 0 C--O 1.232 0.145 0 CA-C-O 121.072 0.463 . . . . 0.0 110.453 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.405 HD11 HD11 ' A' ' 122' ' ' ILE . 43.4 mt -79.27 120.22 79.77 Favored Pre-proline 0 CA--C 1.534 0.335 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.157 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.22 138.72 31.01 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 121.998 1.799 . . . . 0.0 112.375 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -75.2 147.92 83.44 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.42 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -72.27 -28.53 15.21 Favored 'Trans proline' 0 CA--C 1.527 0.156 0 C-N-CA 122.324 2.016 . . . . 0.0 112.409 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.6 pp -163.25 163.2 25.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.436 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.16 98.17 5.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.437 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -123.65 -148.04 7.43 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.742 -0.943 . . . . 0.0 110.742 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.1 m -136.4 140.21 43.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.064 0.459 . . . . 0.0 110.439 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.698 HG13 HD11 ' A' ' 83' ' ' LEU . 24.7 t -72.28 120.12 20.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.16 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -96.82 -51.28 4.33 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.693 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -152.97 144.08 23.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.64 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 33.3 mt -97.45 131.46 44.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.0 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.507 HD22 ' HB ' ' A' ' 81' ' ' THR . 5.3 mp -100.11 -29.44 12.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.884 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.877 HG11 HG11 ' A' ' 76' ' ' VAL . 28.3 m -118.71 145.76 24.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-O 121.255 0.55 . . . . 0.0 110.685 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.3 pttm -136.52 167.04 22.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.175 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 9.1 mp0 -60.51 105.27 0.42 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.49 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -31.55 2.26 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 50.4 m-20 -93.82 149.49 21.19 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.064 0.459 . . . . 0.0 110.497 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.57 HG23 ' HB2' ' A' ' 101' ' ' LYS . 0.4 OUTLIER -102.18 143.44 31.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.286 179.941 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.877 HG11 HG11 ' A' ' 70' ' ' VAL . 22.9 m -122.03 162.1 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.551 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -122.98 158.07 31.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.265 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.612 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.47 101.83 0.2 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.518 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.29 -36.09 2.31 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -65.45 137.97 57.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.054 0.454 . . . . 0.0 110.563 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.507 ' HB ' HD22 ' A' ' 69' ' ' LEU . 11.1 m -64.13 139.38 58.76 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.172 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.44 HG22 ' O ' ' A' ' 94' ' ' ILE . 33.1 m -113.96 -30.53 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.19 -179.58 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.698 HD11 HG13 ' A' ' 65' ' ' VAL . 8.9 tt -164.66 151.64 11.17 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.088 0.47 . . . . 0.0 110.782 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.452 HG23 ' CD1' ' A' ' 69' ' ' LEU . 21.9 t -104.21 136.84 35.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.077 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.736 HD12 HD11 ' A' ' 94' ' ' ILE . 16.0 mt -118.07 159.79 22.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.651 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 . . . . . 0 C--N 1.33 -0.242 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.376 179.897 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 . . . . . 0 C--O 1.232 0.164 0 CA-C-O 121.028 0.442 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 24.7 m -116.08 124.41 50.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.341 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -82.17 132.26 35.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.479 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.736 HD11 HD12 ' A' ' 85' ' ' LEU . 36.2 mm -102.15 121.49 53.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.248 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -109.73 143.65 39.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.352 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.57 143.5 93.49 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.407 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -72.67 -35.54 5.85 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.118 1.879 . . . . 0.0 112.223 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.612 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 19.6 p -148.7 166.1 29.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.365 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -66.65 141.59 57.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.471 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.531 ' O ' HG22 ' A' ' 75' ' ' THR . . . 174.04 -162.35 32.91 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' LYS . . . . . 0.57 ' HB2' HG23 ' A' ' 75' ' ' THR . 6.8 ttpm? -133.07 147.53 52.18 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.034 0.445 . . . . 0.0 110.465 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.575 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.8 t -77.75 111.08 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.166 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -94.86 -30.07 14.38 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.638 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.7 tttp -159.02 131.01 6.54 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.345 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.434 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.3 t -96.66 110.68 25.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.312 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 29.8 mt -90.27 30.24 1.14 Allowed 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.633 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.434 ' H ' HG12 ' A' ' 105' ' ' VAL . 23.2 m -155.59 139.24 8.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-O 121.02 0.438 . . . . 0.0 110.259 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.67 165.13 18.45 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.134 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -60.91 147.19 43.96 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.555 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 60.99 35.76 18.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.505 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.42 ' O ' HG23 ' A' ' 65' ' ' VAL . 6.9 t0 -121.36 137.72 54.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.412 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -89.24 134.75 33.91 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.432 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.0 m -122.39 155.91 27.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.417 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -100.23 145.88 27.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.453 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.17 112.36 4.65 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 109.85 -27.8 11.51 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -57.45 145.33 33.36 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 121.07 0.462 . . . . 0.0 110.779 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.01 122.02 28.37 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 97.8 mt -90.42 -56.77 3.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.114 0.483 . . . . 0.0 110.523 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.482 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.5 mt -140.94 145.74 24.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.301 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 7.2 ttmt -92.46 124.44 36.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.365 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.405 HD11 HD11 ' A' ' 57' ' ' ILE . 37.6 mm -103.46 145.1 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.448 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.218 -0.848 0 CA-C-O 118.076 -1.402 . . . . 0.0 110.701 179.952 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.23 0.073 0 CA-C-O 121.02 0.438 . . . . 0.0 110.382 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 55.3 mt -80.25 111.22 20.53 Favored Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.053 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -70.68 141.86 42.51 Favored 'Trans proline' 0 N--CA 1.472 0.262 0 C-N-CA 122.032 1.821 . . . . 0.0 112.292 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.674 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -75.85 144.89 77.06 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.475 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.684 ' HG2' HD23 ' A' ' 61' ' ' LEU . 50.5 Cg_endo -73.71 -24.74 15.43 Favored 'Trans proline' 0 N--CA 1.472 0.217 0 C-N-CA 122.188 1.925 . . . . 0.0 112.59 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.684 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.9 OUTLIER -161.55 167.54 25.2 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.454 -179.913 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -91.7 95.49 9.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.369 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -122.83 -139.67 5.56 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.9 m -136.12 134.61 38.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.083 0.468 . . . . 0.0 110.406 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.606 HG13 HD11 ' A' ' 83' ' ' LEU . 26.4 t -71.34 125.61 30.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.279 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.9 t -95.7 -54.79 3.23 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.578 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -152.43 149.52 28.67 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.523 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.415 HG12 HD12 ' A' ' 83' ' ' LEU . 48.9 mt -102.27 133.39 46.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.221 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.9 mp -98.82 -31.5 11.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.618 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.687 HG11 ' CG1' ' A' ' 76' ' ' VAL . 33.2 m -114.79 144.91 21.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.681 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.85 165.54 25.39 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.26 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -59.33 101.52 0.1 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.598 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.09 -31.81 2.24 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -90.11 150.03 22.23 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.089 0.471 . . . . 0.0 110.486 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.503 HG22 ' O ' ' A' ' 100' ' ' GLY . 1.0 OUTLIER -96.23 149.43 21.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.332 179.925 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.687 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.3 m -122.73 168.33 15.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.464 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 21.4 ttpt -128.34 148.49 50.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.346 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.637 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.05 100.83 0.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.612 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.11 -31.31 4.75 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.1 tt0 -64.08 143.73 57.65 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.057 0.456 . . . . 0.0 110.67 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 21.4 m -65.44 138.84 58.38 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.219 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.431 ' HA ' HG13 ' A' ' 70' ' ' VAL . 28.4 m -118.49 -32.2 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.384 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.606 HD11 HG13 ' A' ' 65' ' ' VAL . 7.5 tt -161.04 152.28 18.91 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.311 0.577 . . . . 0.0 111.296 -179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.539 HG13 ' O ' ' A' ' 92' ' ' THR . 19.7 t -103.45 147.32 9.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.557 179.33 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.849 HD12 HD11 ' A' ' 94' ' ' ILE . 7.4 mt -127.48 170.44 12.57 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.156 0.503 . . . . 0.0 110.785 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 . . . . . 0 C--N 1.33 -0.244 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.478 -179.832 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.173 0.511 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.539 ' O ' HG13 ' A' ' 84' ' ' VAL . 0.5 OUTLIER -112.13 176.19 5.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.656 179.594 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.535 ' H ' HG22 ' A' ' 92' ' ' THR . 50.6 mt-10 -146.02 134.87 22.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.28 0.562 . . . . 0.0 110.648 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.849 HD11 HD12 ' A' ' 85' ' ' LEU . 37.3 mm -102.57 153.7 5.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.146 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -136.91 141.45 42.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.353 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.93 135.52 94.65 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.309 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -73.85 -31.64 8.09 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.073 1.849 . . . . 0.0 112.268 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.637 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 25.1 p -146.13 157.57 43.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.411 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -65.86 141.81 58.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.279 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.503 ' O ' HG22 ' A' ' 75' ' ' THR . . . 174.66 -158.52 26.69 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 26.5 ttpt -133.74 148.54 51.42 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.144 0.497 . . . . 0.0 110.413 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.646 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.7 t -75.47 105.83 4.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.27 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -92.49 -26.67 17.85 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.859 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' LYS . . . . . 0.695 ' HD2' HD21 ' A' ' 106' ' ' LEU . 27.9 ttmt -158.93 129.08 5.81 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.098 0.475 . . . . 0.0 110.635 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 24.9 t -102.29 106.13 19.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.194 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.695 HD21 ' HD2' ' A' ' 104' ' ' LYS . 18.1 mt -89.5 13.33 14.11 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.632 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.441 HG21 HD13 ' A' ' 83' ' ' LEU . 30.7 m -130.12 143.77 40.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 CA-C-O 121.079 0.466 . . . . 0.0 110.312 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 13.6 mtmm -126.08 168.01 14.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.387 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -72.29 143.25 48.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.338 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 16.3 mtm180 61.42 38.5 15.98 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.514 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -126.45 148.04 49.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.336 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.83 140.0 30.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.56 -179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.9 m -122.8 156.02 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.274 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 39.0 mm-40 -101.94 142.39 33.31 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.337 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.38 111.38 3.38 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 108.72 -25.02 20.52 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -59.9 140.97 56.3 Favored 'General case' 0 N--CA 1.462 0.15 0 CA-C-O 121.017 0.437 . . . . 0.0 110.791 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.48 118.37 14.6 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.674 HD21 ' HB2' ' A' ' 59' ' ' ALA . 33.2 mt -88.58 -54.02 4.37 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.124 0.487 . . . . 0.0 110.497 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 52.2 mt -142.4 142.74 26.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.325 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.0 122.49 38.88 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.097 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.0 mm -100.66 142.46 15.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.479 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.667 0 CA-C-O 117.972 -1.46 . . . . 0.0 110.758 179.931 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 121.079 0.466 . . . . 0.0 110.542 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.505 HD11 HD11 ' A' ' 122' ' ' ILE . 48.5 mt -79.49 120.28 79.79 Favored Pre-proline 0 CA--C 1.534 0.348 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.081 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -72.19 146.06 45.27 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 121.996 1.797 . . . . 0.0 112.352 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.62 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -74.55 148.47 85.58 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.41 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.85 -28.5 13.43 Favored 'Trans proline' 0 N--CA 1.472 0.207 0 C-N-CA 122.207 1.938 . . . . 0.0 112.345 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.7 pp -166.27 165.3 17.49 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.494 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.69 84.21 3.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.396 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.448 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -120.92 -166.57 13.06 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.8 m -112.28 135.78 52.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.132 0.492 . . . . 0.0 110.357 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.563 HG13 HD11 ' A' ' 83' ' ' LEU . 25.1 t -70.79 126.11 30.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.247 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 4.5 p -97.82 -61.63 1.36 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.604 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 9.1 mmmt -141.47 150.23 41.97 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.607 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.502 HG22 ' H ' ' A' ' 70' ' ' VAL . 33.6 mt -110.22 120.55 61.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.842 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.4 mt -96.82 27.66 3.85 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.344 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.829 ' HB ' HG21 ' A' ' 102' ' ' VAL . 31.5 m -155.5 151.18 10.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 121.195 0.521 . . . . 0.0 110.483 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.9 pttt -141.6 160.33 40.39 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.054 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -60.34 95.05 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.431 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.18 -26.63 2.57 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -80.64 149.05 29.98 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.161 0.505 . . . . 0.0 110.457 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.6 m -97.32 137.71 35.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.228 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.467 HG11 HG11 ' A' ' 70' ' ' VAL . 34.6 m -119.78 145.03 26.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.556 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 mtmt -108.74 147.53 31.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.235 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.673 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -58.5 102.04 0.1 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.812 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.01 -32.72 3.38 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 12.7 tt0 -65.15 143.9 57.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.055 0.455 . . . . 0.0 110.501 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.9 m -66.95 138.45 57.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.221 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 32.3 m -119.37 -31.29 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.531 -179.59 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.563 HD11 HG13 ' A' ' 65' ' ' VAL . 9.9 tt -162.37 146.23 11.85 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.129 0.49 . . . . 0.0 111.032 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.471 HG22 ' OE2' ' A' ' 93' ' ' GLU . 22.0 t -108.81 143.08 19.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.89 179.517 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.458 HD11 HG21 ' A' ' 113' ' ' VAL . 1.0 OUTLIER -124.38 163.59 21.42 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.186 0.517 . . . . 0.0 110.798 -179.6 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.2 mt-10 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.371 179.906 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 121.14 0.495 . . . . 0.0 110.52 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.9 m -113.15 116.55 30.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.22 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.471 ' OE2' HG22 ' A' ' 84' ' ' VAL . 10.2 mm-40 -91.78 125.91 36.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.526 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.494 ' N ' HD12 ' A' ' 94' ' ' ILE . 5.3 mp -108.72 148.46 12.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.954 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -135.89 156.12 49.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.165 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.56 135.58 95.61 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.337 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.37 -32.47 8.05 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.044 1.829 . . . . 0.0 112.224 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.673 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 1.1 p -145.61 159.33 43.3 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.315 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -63.64 140.03 58.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.339 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.17 -161.69 32.78 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.3 ttmp? -135.62 146.75 48.22 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.062 0.458 . . . . 0.0 110.444 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.829 HG21 ' HB ' ' A' ' 70' ' ' VAL . 30.3 t -75.99 114.07 15.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.147 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -94.94 -30.02 14.36 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.778 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 77.6 tttt -159.98 128.91 5.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.546 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 120' ' ' ILE . 22.1 t -107.62 108.71 25.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.271 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 mt -79.21 -31.62 43.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.447 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.44 ' O ' HG12 ' A' ' 105' ' ' VAL . 27.6 m -80.77 145.27 9.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.567 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -130.36 157.67 41.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.21 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 66.5 mt-10 -59.27 143.21 49.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.668 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 24.4 ttt180 61.76 32.84 18.15 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.305 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -116.24 151.06 36.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.427 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.83 135.51 34.06 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.442 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.458 HG21 HD11 ' A' ' 85' ' ' LEU . 30.8 m -120.53 179.67 2.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.43 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -135.42 145.29 47.11 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.366 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.45 109.43 2.48 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.0 -29.32 8.13 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.3 tt0 -60.11 140.82 56.65 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 121.146 0.498 . . . . 0.0 110.609 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.38 122.04 28.06 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.62 HD11 ' HA ' ' A' ' 59' ' ' ALA . 87.7 mt -89.22 -61.63 1.66 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.132 0.491 . . . . 0.0 110.503 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.559 HG12 HG13 ' A' ' 105' ' ' VAL . 55.4 mt -140.96 151.83 20.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.362 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 33.0 tttm -98.63 134.63 41.3 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.386 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.505 HD11 HD11 ' A' ' 57' ' ' ILE . 35.4 mm -108.06 146.87 13.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.424 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.779 0 CA-C-O 118.049 -1.417 . . . . 0.0 110.786 179.958 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 . . . . . 0 C--O 1.231 0.081 0 CA-C-O 121.015 0.435 . . . . 0.0 110.272 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 54.8 mt -80.1 111.41 21.8 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.17 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -71.1 153.41 62.68 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.011 1.807 . . . . 0.0 112.218 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.695 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -78.97 143.05 60.92 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.468 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -74.13 -27.91 11.33 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.121 1.881 . . . . 0.0 112.309 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -163.9 162.91 23.75 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.364 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.56 92.07 5.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.39 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -126.16 -141.85 5.59 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 19.8 m -138.04 138.3 38.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.003 0.43 . . . . 0.0 110.459 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.523 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -70.66 125.31 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.208 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.1 t -98.24 -46.42 5.83 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.564 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 36.0 mtmt -149.16 169.84 19.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.606 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 51.7 mt -129.8 125.81 61.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.946 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.478 HD12 HG22 ' A' ' 81' ' ' THR . 20.4 mt -97.24 -28.11 14.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.12 -179.383 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.872 ' HB ' HG21 ' A' ' 102' ' ' VAL . 32.9 m -101.47 156.77 4.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.346 0.593 . . . . 0.0 111.218 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 22.5 mttp -135.96 151.9 50.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.843 179.664 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.561 ' HG3' HG23 ' A' ' 105' ' ' VAL . 16.6 mt-10 -60.78 90.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.52 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.09 -25.86 2.63 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 63.8 m-20 -78.72 148.66 32.96 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.143 0.497 . . . . 0.0 110.5 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 5.3 m -97.02 140.04 32.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.184 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.57 HG11 HG11 ' A' ' 70' ' ' VAL . 30.0 m -121.91 171.26 10.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.66 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -127.42 138.66 53.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.191 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.696 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -56.11 100.25 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.029 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.86 -38.84 1.63 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 45.3 tt0 -69.35 144.82 53.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.065 0.459 . . . . 0.0 110.599 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.478 HG22 HD12 ' A' ' 69' ' ' LEU . 17.6 m -65.02 139.11 58.71 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.317 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.587 HG22 ' O ' ' A' ' 94' ' ' ILE . 35.1 m -115.05 -25.88 3.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.397 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.523 HD11 HG13 ' A' ' 65' ' ' VAL . 7.7 tt -166.58 146.52 5.86 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 121.052 0.453 . . . . 0.0 110.702 -179.471 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -105.1 141.26 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.133 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 85' ' ' LEU . 12.1 mt -120.11 158.28 27.22 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.553 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 . . . . . 0 C--N 1.33 -0.251 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.397 179.94 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 . . . . . 0 N--CA 1.461 0.122 0 CA-C-O 121.171 0.51 . . . . 0.0 110.41 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.8 m -129.0 113.0 14.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.131 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -87.22 142.98 27.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.717 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.649 ' N ' HD12 ' A' ' 94' ' ' ILE . 4.6 mp -115.21 127.08 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.907 179.748 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 42.4 m-20 -102.5 153.31 20.19 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.207 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.85 136.22 94.84 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.345 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -72.62 -35.25 6.23 Favored 'Trans proline' 0 N--CA 1.471 0.2 0 C-N-CA 122.09 1.86 . . . . 0.0 112.172 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.696 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 2.5 p -147.36 155.32 41.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.296 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -64.49 140.43 58.87 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.384 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.21 -157.94 26.14 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 15.7 ttmm -132.31 143.7 50.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.065 0.459 . . . . 0.0 110.468 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.872 HG21 ' HB ' ' A' ' 70' ' ' VAL . 36.0 t -78.78 110.08 14.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.171 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.09 -29.65 16.43 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.84 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 8.0 ttpt -157.86 131.03 7.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.448 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.561 HG23 ' HG3' ' A' ' 72' ' ' GLU . 21.8 t -101.06 115.46 42.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.243 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.408 ' O ' HG13 ' A' ' 107' ' ' VAL . 19.9 mt -89.95 28.52 1.36 Allowed 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.698 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.503 ' H ' HG12 ' A' ' 105' ' ' VAL . 19.2 m -155.69 142.5 11.3 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 121.038 0.447 . . . . 0.0 110.378 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.5 tttt -125.89 165.03 19.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.188 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -59.61 143.05 51.51 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.615 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 30.2 mtm180 60.14 34.01 21.15 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.558 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -114.21 149.16 36.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.338 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.92 134.98 34.29 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.526 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.6 m -122.38 149.91 25.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.331 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 55.9 mt-30 -99.68 144.1 29.15 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.416 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.42 110.07 2.71 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.739 -0.945 . . . . 0.0 110.739 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 110.24 -27.29 11.85 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -59.64 139.77 56.94 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.056 0.455 . . . . 0.0 110.668 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.12 123.08 31.53 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.695 HD11 ' HA ' ' A' ' 59' ' ' ALA . 65.8 mt -87.57 -54.01 4.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.032 0.444 . . . . 0.0 110.405 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.626 ' CG2' HG13 ' A' ' 102' ' ' VAL . 50.2 mt -141.5 149.64 20.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.426 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.0 tttm -99.25 130.51 45.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.299 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.2 mm -107.63 144.71 15.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.506 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.797 0 CA-C-O 117.964 -1.464 . . . . 0.0 110.806 179.969 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.1 0.476 . . . . 0.0 110.477 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.51 HD11 HD11 ' A' ' 122' ' ' ILE . 45.0 mt -78.82 111.76 22.04 Favored Pre-proline 0 CA--C 1.534 0.363 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.212 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.94 137.82 32.82 Favored 'Trans proline' 0 N--CA 1.473 0.267 0 C-N-CA 122.084 1.856 . . . . 0.0 112.374 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.721 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -68.72 149.13 98.02 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.465 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.52 -27.55 15.53 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.253 1.969 . . . . 0.0 112.414 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 pp -164.79 165.22 20.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.443 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.34 96.49 5.32 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.363 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -128.4 -141.11 5.14 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.776 -0.929 . . . . 0.0 110.776 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.1 m -136.71 141.51 43.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.002 0.43 . . . . 0.0 110.46 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.76 HG13 HD11 ' A' ' 83' ' ' LEU . 23.1 t -71.21 128.64 34.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.218 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 t -98.67 -62.0 1.3 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.518 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 9.8 mtpt -150.16 144.81 25.92 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.457 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.653 HG12 HD12 ' A' ' 83' ' ' LEU . 42.2 mt -99.24 128.85 50.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.039 179.691 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.9 mp -97.67 -36.03 10.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.829 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.688 HG11 HG12 ' A' ' 76' ' ' VAL . 33.7 m -115.17 139.26 42.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.263 0.554 . . . . 0.0 110.78 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 20.9 pttt -135.91 162.75 31.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.793 179.514 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -54.61 108.64 0.41 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.279 0.561 . . . . 0.0 110.783 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.42 -29.98 2.35 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -102.53 155.12 18.49 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.974 0.416 . . . . 0.0 110.396 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.4 m -96.91 150.43 20.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.43 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.688 HG12 HG11 ' A' ' 70' ' ' VAL . 30.3 m -123.97 168.28 16.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.498 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 28.4 mmtm -129.69 155.28 46.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.448 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.511 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -62.2 105.76 0.64 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.453 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.25 -29.37 7.07 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -61.32 142.7 56.7 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.104 0.478 . . . . 0.0 110.564 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.9 m -67.1 138.14 56.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.271 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.4 m -118.17 -34.26 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.208 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.76 HD11 HG13 ' A' ' 65' ' ' VAL . 6.5 tt -162.11 152.02 16.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.134 0.492 . . . . 0.0 111.078 -179.315 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.682 HG22 ' OE1' ' A' ' 93' ' ' GLU . 22.8 t -102.89 143.15 15.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.654 179.245 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.7 HD11 HG21 ' A' ' 113' ' ' VAL . 0.3 OUTLIER -119.49 167.69 11.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.229 0.538 . . . . 0.0 110.782 -179.559 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.365 179.897 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 . . . . . 0 N--CA 1.461 0.109 0 CA-C-O 121.14 0.495 . . . . 0.0 110.403 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 14.0 m -118.47 123.09 44.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.33 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.682 ' OE1' HG22 ' A' ' 84' ' ' VAL . 6.4 mm-40 -84.51 132.26 34.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.59 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 30.8 mm -105.45 148.72 9.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.049 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -139.29 150.83 45.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.612 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.63 143.73 96.35 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.399 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -72.62 -34.42 7.21 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.186 1.924 . . . . 0.0 112.26 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.511 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 14.3 p -146.95 168.45 21.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.312 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -68.82 142.26 54.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.463 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.1 -161.25 32.27 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.2 ttpt -133.62 138.91 46.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.062 0.458 . . . . 0.0 110.464 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.647 HG13 ' CG2' ' A' ' 120' ' ' ILE . 22.3 t -74.22 123.73 30.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.238 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -99.03 -33.17 10.92 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.588 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' LYS . . . . . 0.534 ' NZ ' HD23 ' A' ' 106' ' ' LEU . 0.2 OUTLIER -160.88 147.82 15.29 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.412 -179.948 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.506 HG12 ' H ' ' A' ' 107' ' ' VAL . 11.9 t -101.29 119.0 48.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.008 179.784 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.534 HD23 ' NZ ' ' A' ' 104' ' ' LYS . 6.9 mt -89.53 21.56 3.36 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.919 -179.638 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.506 ' H ' HG12 ' A' ' 105' ' ' VAL . 30.6 m -154.56 156.3 5.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-O 121.093 0.473 . . . . 0.0 110.673 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.5 mtmp? -130.85 159.03 38.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.25 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 64.4 mt-10 -60.51 151.26 28.99 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.513 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? 60.99 32.33 19.92 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.521 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -122.91 150.9 42.31 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.452 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.01 137.56 32.27 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.348 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.7 HG21 HD11 ' A' ' 85' ' ' LEU . 30.5 m -121.12 148.71 24.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.432 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -98.1 140.66 32.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.259 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.54 96.28 0.09 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 127.51 -27.87 4.61 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -59.31 142.71 51.39 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.086 0.47 . . . . 0.0 110.704 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.22 120.93 24.71 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.721 HD11 ' HA ' ' A' ' 59' ' ' ALA . 14.1 mt -89.78 -50.2 6.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.079 0.466 . . . . 0.0 110.418 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.647 ' CG2' HG13 ' A' ' 102' ' ' VAL . 45.9 mt -145.27 147.82 18.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.297 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.5 mttp -95.43 130.34 42.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.158 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.51 HD11 HD11 ' A' ' 57' ' ' ILE . 37.5 mm -110.39 144.67 18.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.357 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.711 0 CA-C-O 117.974 -1.459 . . . . 0.0 110.76 -179.997 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 . . . . . 0 C--O 1.231 0.083 0 CA-C-O 121.107 0.48 . . . . 0.0 110.459 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.636 HD11 HD11 ' A' ' 122' ' ' ILE . 35.5 mt -81.81 112.22 32.93 Favored Pre-proline 0 CA--C 1.535 0.366 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.167 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -70.73 128.56 15.3 Favored 'Trans proline' 0 N--CA 1.472 0.233 0 C-N-CA 122.017 1.811 . . . . 0.0 112.363 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.574 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -61.95 148.64 87.75 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.49 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.99 -26.82 18.08 Favored 'Trans proline' 0 N--CA 1.471 0.15 0 C-N-CA 122.283 1.989 . . . . 0.0 112.509 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -163.75 168.54 19.58 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.423 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.75 102.83 13.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.499 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -133.98 -140.73 4.37 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 16.0 m -137.15 142.1 42.23 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.104 0.478 . . . . 0.0 110.369 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 111' ' ' ASP . 23.1 t -71.96 131.99 33.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.122 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -101.37 -54.17 2.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.502 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 33.5 tttt -155.74 147.0 22.59 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.594 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.483 HD11 ' HA ' ' A' ' 108' ' ' LYS . 8.8 mt -100.43 130.78 49.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.972 179.662 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.1 mt -101.56 -41.88 6.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.691 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.795 ' HB ' HG21 ' A' ' 102' ' ' VAL . 29.5 m -93.54 149.88 4.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.761 -179.784 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -135.11 162.22 33.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.255 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.46 ' OE1' HG23 ' A' ' 105' ' ' VAL . 2.6 mp0 -60.94 96.6 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.543 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.0 -31.22 2.3 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -79.78 147.07 31.99 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.127 0.489 . . . . 0.0 110.449 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 6.7 m -95.9 141.12 29.7 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.382 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.707 HG11 HG11 ' A' ' 70' ' ' VAL . 29.9 m -120.06 160.93 20.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.555 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 tttt -120.08 146.97 45.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.311 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.65 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.84 93.46 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.69 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.42 -32.43 2.55 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -67.84 141.12 56.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.976 0.417 . . . . 0.0 110.52 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.0 m -63.34 137.22 58.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.189 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.528 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.6 m -114.01 -35.1 2.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.781 -179.691 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.567 HD13 HG21 ' A' ' 107' ' ' VAL . 7.0 tt -159.18 151.49 21.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.449 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.2 t -102.9 143.44 15.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.042 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -124.06 164.75 18.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.582 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.338 179.989 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 . . . . . 0 N--CA 1.461 0.102 0 CA-C-O 121.167 0.508 . . . . 0.0 110.43 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.5 m -119.41 120.42 36.8 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.425 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -85.09 129.98 34.7 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.514 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 33.6 mm -103.13 124.55 57.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.327 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -110.29 147.76 33.23 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.376 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.78 138.42 96.96 Favored Pre-proline 0 CA--C 1.532 0.282 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.346 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.65 -32.87 7.18 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.087 1.858 . . . . 0.0 112.162 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.65 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 5.7 p -149.63 155.03 39.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.345 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -61.85 141.96 57.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.443 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 170.07 -157.37 28.75 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.1 ttmp? -134.82 148.07 50.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.129 0.49 . . . . 0.0 110.523 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.795 HG21 ' HB ' ' A' ' 70' ' ' VAL . 26.2 t -77.06 113.54 16.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.326 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -93.26 -30.83 14.97 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.699 -179.769 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 13.1 ttpt -159.45 133.57 7.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.569 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.46 HG23 ' OE1' ' A' ' 72' ' ' GLU . 21.6 t -101.92 108.11 23.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.144 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mt -89.58 13.13 14.77 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.578 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.567 HG21 HD13 ' A' ' 83' ' ' LEU . 26.3 m -130.72 136.59 57.92 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-O 121.123 0.487 . . . . 0.0 110.186 179.752 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.483 ' HA ' HD11 ' A' ' 68' ' ' ILE . 0.2 OUTLIER -125.49 172.16 9.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.226 -179.782 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -72.05 150.63 43.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.311 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 37.3 mtt-85 61.45 30.89 19.07 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.664 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.515 ' O ' HG23 ' A' ' 65' ' ' VAL . 5.8 m-20 -125.88 139.33 53.56 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.285 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.17 141.57 28.44 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.449 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.2 m -121.09 156.95 24.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.391 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -99.22 144.6 28.15 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.373 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.12 106.08 1.03 Allowed Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 117.56 -28.51 7.08 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.0 tt0 -59.21 137.7 57.87 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.126 0.489 . . . . 0.0 110.713 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.15 123.25 31.96 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.574 HD11 ' HA ' ' A' ' 59' ' ' ALA . 17.1 mt -86.5 -55.85 3.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.191 0.52 . . . . 0.0 110.534 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.655 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.8 mt -140.88 152.31 20.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.336 -179.779 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -96.92 132.52 42.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.476 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.636 HD11 HD11 ' A' ' 57' ' ' ILE . 36.9 mm -109.52 145.18 16.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.303 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.791 0 CA-C-O 118.095 -1.392 . . . . 0.0 110.757 -179.953 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 121.066 0.46 . . . . 0.0 110.354 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.564 HD11 HD11 ' A' ' 122' ' ' ILE . 45.4 mt -79.74 111.63 22.9 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.263 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -72.48 129.8 15.25 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 121.982 1.788 . . . . 0.0 112.217 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.441 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -62.09 139.43 96.0 Favored Pre-proline 0 CA--C 1.532 0.274 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.274 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.409 ' HG2' HD12 ' A' ' 61' ' ' LEU . 48.0 Cg_endo -75.43 -12.0 20.7 Favored 'Trans proline' 0 CA--C 1.533 0.445 0 C-N-CA 122.091 1.861 . . . . 0.0 113.038 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.699 HD22 ' N ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -160.73 179.55 8.44 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-O 121.099 0.476 . . . . 0.0 110.48 179.901 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.699 ' N ' HD22 ' A' ' 61' ' ' LEU . . . -109.76 113.34 26.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.401 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -149.5 -138.87 3.0 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.512 ' C ' HD23 ' A' ' 85' ' ' LEU . 12.3 m -135.82 139.36 43.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.103 0.478 . . . . 0.0 110.411 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.554 HG13 HD11 ' A' ' 83' ' ' LEU . 28.1 t -70.48 126.5 30.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.18 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t -97.04 -55.06 2.98 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.574 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 ttpt -153.08 149.09 27.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.521 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.531 HD11 ' HA ' ' A' ' 108' ' ' LYS . 41.7 mt -103.01 135.66 39.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.059 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.477 HD22 ' HB ' ' A' ' 81' ' ' THR . 9.7 mp -99.72 -45.08 5.88 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.818 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.734 ' HB ' HG21 ' A' ' 102' ' ' VAL . 34.8 m -97.2 148.16 5.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.218 0.532 . . . . 0.0 110.876 -179.688 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 pttt -137.24 163.66 30.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.195 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.425 ' HG3' HG23 ' A' ' 105' ' ' VAL . 14.2 mt-10 -59.64 102.59 0.15 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.584 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.51 2.26 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -91.91 151.45 20.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.119 0.485 . . . . 0.0 110.492 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.562 HG22 ' O ' ' A' ' 100' ' ' GLY . 0.7 OUTLIER -96.58 153.67 17.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.312 179.916 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.712 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.9 m -126.14 167.67 20.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.562 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 mttm -129.05 148.05 50.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.37 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.594 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.16 93.14 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.715 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.88 -34.8 2.17 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -64.0 143.95 57.46 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.086 0.469 . . . . 0.0 110.582 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.477 ' HB ' HD22 ' A' ' 69' ' ' LEU . 9.0 m -66.92 139.58 57.72 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.336 179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 35.6 m -114.11 -32.68 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.939 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.695 HD13 HG21 ' A' ' 107' ' ' VAL . 7.9 tt -161.49 148.38 14.52 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.106 0.479 . . . . 0.0 110.797 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -103.4 140.37 21.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.113 179.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.66 HD21 HG21 ' A' ' 113' ' ' VAL . 2.1 mt -119.83 172.09 7.95 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.56 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.444 179.995 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 121.06 0.457 . . . . 0.0 110.569 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.5 m -112.41 117.54 32.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.283 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -84.99 135.52 33.99 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.56 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.634 HD11 HD12 ' A' ' 85' ' ' LEU . 41.1 mm -106.7 122.33 60.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.255 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -104.95 142.81 34.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.362 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.13 144.11 91.53 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -72.57 -38.95 2.94 Favored 'Trans proline' 0 CA--C 1.528 0.216 0 C-N-CA 122.175 1.917 . . . . 0.0 112.168 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.594 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 2.8 p -148.39 165.14 31.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.309 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -66.6 141.43 57.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.393 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.562 ' O ' HG22 ' A' ' 75' ' ' THR . . . 172.82 -157.37 26.58 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 17.7 ttmt -136.11 146.69 47.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.104 0.478 . . . . 0.0 110.488 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.734 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.0 t -74.7 108.72 6.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.186 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -91.52 -29.12 17.15 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.809 -179.809 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.4 ttmm -159.33 130.27 6.0 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.095 0.474 . . . . 0.0 110.53 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.425 HG23 ' HG3' ' A' ' 72' ' ' GLU . 32.3 t -102.19 105.72 18.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.184 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.4 mt -88.0 10.21 19.74 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.67 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.695 HG21 HD13 ' A' ' 83' ' ' LEU . 23.7 m -125.59 136.13 61.81 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.062 0 CA-C-O 121.11 0.481 . . . . 0.0 110.258 179.675 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.531 ' HA ' HD11 ' A' ' 68' ' ' ILE . 2.8 ttpm? -122.56 169.36 11.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.391 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 -66.65 142.5 57.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.356 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER 63.17 38.14 10.82 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.66 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -117.8 142.36 47.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.319 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.91 131.61 36.43 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.427 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.66 HG21 HD21 ' A' ' 85' ' ' LEU . 30.8 m -119.59 179.82 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.452 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -141.46 149.35 40.84 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.427 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.55 104.4 0.7 Allowed Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.64 -31.49 4.57 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -61.64 135.9 57.81 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.091 0.472 . . . . 0.0 110.445 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -63.01 118.89 15.27 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.441 HD21 ' HB2' ' A' ' 59' ' ' ALA . 69.3 mt -88.38 -56.21 3.41 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.074 0.464 . . . . 0.0 110.392 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.528 ' CG2' HG13 ' A' ' 102' ' ' VAL . 50.9 mt -142.26 144.94 24.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.323 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.7 tttt -96.55 132.76 41.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.333 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.564 HD11 HD11 ' A' ' 57' ' ' ILE . 39.2 mm -107.25 144.88 15.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.416 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.738 0 CA-C-O 117.958 -1.468 . . . . 0.0 110.813 -179.992 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 121.104 0.478 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.41 HD11 ' CG1' ' A' ' 122' ' ' ILE . 52.6 mt -77.84 111.67 19.51 Favored Pre-proline 0 CA--C 1.534 0.364 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.175 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -70.83 145.02 49.89 Favored 'Trans proline' 0 N--CA 1.472 0.248 0 C-N-CA 122.035 1.823 . . . . 0.0 112.394 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -82.11 147.52 57.73 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.468 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.661 ' HG2' HD23 ' A' ' 61' ' ' LEU . 48.7 Cg_endo -71.82 -23.26 22.59 Favored 'Trans proline' 0 N--CA 1.472 0.251 0 C-N-CA 122.278 1.986 . . . . 0.0 112.658 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.661 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.8 OUTLIER -161.68 173.38 14.77 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.089 0.471 . . . . 0.0 110.486 -179.991 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.55 91.81 5.23 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.411 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.721 ' HA3' HD23 ' A' ' 85' ' ' LEU . . . -103.42 175.15 23.44 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.4 m -105.81 7.17 32.23 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.639 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t 63.15 117.75 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 CA-C-O 121.075 0.464 . . . . 0.0 110.322 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.5 t -95.89 -57.37 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.577 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 34.4 tttm -155.11 146.38 22.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.59 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.637 HG12 HD12 ' A' ' 83' ' ' LEU . 23.7 mt -105.09 120.82 56.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.867 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 16.8 mt -98.39 25.49 6.26 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.303 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.685 ' HB ' HG21 ' A' ' 102' ' ' VAL . 30.6 m -153.16 147.73 14.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.133 0.492 . . . . 0.0 110.644 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.3 pttt -135.05 161.3 35.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.151 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 51.5 mt-10 -60.07 99.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.519 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -30.45 2.35 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -77.36 151.89 34.68 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.11 0.481 . . . . 0.0 110.412 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 5.1 m -100.77 132.52 46.12 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.488 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.3 m -115.68 150.56 17.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.409 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -111.62 153.62 26.07 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.383 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.609 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.85 100.62 0.11 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.603 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.89 -31.45 4.11 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 5.6 tt0 -63.66 143.81 57.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.117 0.484 . . . . 0.0 110.524 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.2 m -66.27 136.34 55.7 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.334 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.605 ' O ' HG22 ' A' ' 70' ' ' VAL . 27.6 m -119.1 -35.38 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.213 -179.51 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.637 HD12 HG12 ' A' ' 68' ' ' ILE . 7.1 tt -159.64 149.74 18.74 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.838 -179.315 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.418 HG12 ' N ' ' A' ' 85' ' ' LEU . 21.9 t -107.94 154.99 8.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.898 179.471 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.721 HD23 ' HA3' ' A' ' 63' ' ' GLY . 3.5 mp -123.78 173.12 8.36 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.196 0.522 . . . . 0.0 110.636 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 . . . . . 0 C--N 1.33 -0.261 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.308 179.953 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 . . . . . 0 C--O 1.23 0.064 0 CA-C-O 121.134 0.492 . . . . 0.0 110.413 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.21 103.44 9.84 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.291 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -79.85 143.44 34.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.646 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.482 ' CG1' HD13 ' A' ' 85' ' ' LEU . 40.7 mm -105.93 156.31 6.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.052 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.435 ' N ' HG22 ' A' ' 94' ' ' ILE . 12.9 m120 -134.24 143.07 47.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.47 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.11 142.0 98.17 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.318 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.5 -36.02 4.28 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.12 1.88 . . . . 0.0 112.288 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.609 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 1.7 p -145.76 161.47 39.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.433 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -65.27 142.51 58.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.322 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.8 -158.4 25.32 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.5 ttmt -135.5 145.88 47.55 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.05 0.453 . . . . 0.0 110.549 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.685 HG21 ' HB ' ' A' ' 70' ' ' VAL . 26.2 t -74.33 110.25 8.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.245 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -95.24 -29.54 14.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.723 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -160.51 135.39 7.67 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.517 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.417 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.1 t -101.37 109.27 25.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.21 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 29.4 mt -90.08 29.66 1.19 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.639 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.562 HG21 HD13 ' A' ' 83' ' ' LEU . 29.6 m -155.2 145.17 13.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 121.055 0.455 . . . . 0.0 110.361 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.4 mmtm -127.25 160.85 30.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.259 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -60.02 142.99 52.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.524 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 3.1 ttm180 61.35 34.35 18.45 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.492 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -114.18 140.15 48.77 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.388 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -88.63 126.11 35.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.531 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.7 m -122.11 157.79 26.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.395 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -96.57 143.69 27.33 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.414 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.32 92.64 0.07 OUTLIER Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.6 -27.81 2.92 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -60.94 141.35 57.33 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-O 121.031 0.444 . . . . 0.0 110.54 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.08 123.81 33.6 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.442 ' O ' HG22 ' A' ' 107' ' ' VAL . 92.3 mt -86.61 -51.83 5.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.055 0.455 . . . . 0.0 110.539 -179.802 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.5 mt -140.88 150.23 20.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.395 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -97.78 128.4 44.4 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.309 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.41 ' CG1' HD11 ' A' ' 57' ' ' ILE . 37.6 mm -107.17 143.61 17.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.478 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.749 0 CA-C-O 117.982 -1.455 . . . . 0.0 110.781 179.975 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 121.08 0.467 . . . . 0.0 110.571 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.598 HD11 HD11 ' A' ' 122' ' ' ILE . 38.5 mt -80.72 111.2 21.21 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.131 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -70.61 135.64 28.89 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 122.085 1.857 . . . . 0.0 112.387 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.591 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -73.02 153.39 90.85 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.398 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.62 -27.9 14.8 Favored 'Trans proline' 0 CA--C 1.528 0.2 0 C-N-CA 122.211 1.941 . . . . 0.0 112.404 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.9 pp -165.95 165.71 17.9 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.418 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.496 ' HB2' ' H ' ' A' ' 115' ' ' GLY . . . -79.76 104.73 10.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.286 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.22 -142.43 4.91 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.9 m -135.78 134.22 38.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.068 0.461 . . . . 0.0 110.468 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.602 ' CG1' HD11 ' A' ' 83' ' ' LEU . 24.9 t -72.14 127.94 34.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.126 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.31 -53.54 3.32 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.68 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 16.8 tttp -152.03 147.19 26.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.598 -179.749 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.571 HG12 HD12 ' A' ' 83' ' ' LEU . 47.9 mt -100.82 133.14 44.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.992 179.621 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.3 mp -99.6 -29.85 12.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.929 -179.599 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.777 ' HB ' HG21 ' A' ' 102' ' ' VAL . 34.9 m -110.7 148.66 13.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 121.241 0.543 . . . . 0.0 110.878 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.8 ptpp? -135.13 163.96 28.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.14 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -61.87 99.08 0.11 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.502 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.62 -30.9 2.36 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -84.73 147.53 26.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.14 0.495 . . . . 0.0 110.455 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.5 m -96.38 145.95 25.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.294 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.685 HG11 HG11 ' A' ' 70' ' ' VAL . 26.8 m -120.88 170.42 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.655 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 35.5 mttt -130.19 147.11 51.88 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.199 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.635 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.7 95.89 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.74 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.05 -34.21 2.48 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 11.0 tt0 -66.46 139.25 57.96 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.082 0.467 . . . . 0.0 110.527 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 19.4 m -62.76 137.68 58.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.313 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.455 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.1 m -112.83 -32.27 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.952 -179.653 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.602 HD11 ' CG1' ' A' ' 65' ' ' VAL . 7.1 tt -162.74 150.21 13.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.159 0.504 . . . . 0.0 110.624 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.1 t -103.49 143.57 15.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.119 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.5 tp -124.66 165.81 17.25 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.631 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.321 -179.978 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 . . . . . 0 C--O 1.231 0.095 0 CA-C-O 121.046 0.45 . . . . 0.0 110.423 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.9 m -119.19 115.65 24.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.383 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -83.7 129.93 34.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.489 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 37.3 mm -104.14 122.51 57.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.306 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -109.84 144.01 38.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.253 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.51 141.88 94.4 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.42 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.39 -37.9 3.97 Favored 'Trans proline' 0 N--CA 1.471 0.178 0 C-N-CA 122.125 1.883 . . . . 0.0 112.302 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.635 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 3.0 p -147.19 159.93 43.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.403 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -62.7 141.36 58.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.351 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.3 -157.0 25.47 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -137.95 147.03 43.91 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.081 0.467 . . . . 0.0 110.416 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.777 HG21 ' HB ' ' A' ' 70' ' ' VAL . 25.0 t -76.88 112.61 14.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.191 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -95.31 -30.07 14.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.741 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.2 tttm -159.75 127.43 4.74 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.604 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.483 HG13 HG12 ' A' ' 120' ' ' ILE . 24.1 t -104.16 114.85 44.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.255 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mt -82.31 -39.06 23.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.405 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.549 HG21 HD13 ' A' ' 83' ' ' LEU . 33.2 m -74.64 150.27 7.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.545 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 43.4 mttt -133.6 161.13 35.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.316 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -61.56 139.98 58.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.458 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.44 37.52 16.62 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.354 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -123.92 146.98 48.08 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.386 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.18 138.14 31.78 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.519 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.2 m -122.33 162.39 22.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.336 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 13.6 mt-30 -103.12 141.06 36.49 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.293 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.496 ' H ' ' HB2' ' A' ' 62' ' ' ALA . . . -60.38 105.95 0.92 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.03 -26.97 9.99 Favored Glycine 0 CA--C 1.527 0.831 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 -58.15 148.89 25.3 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-O 121.109 0.48 . . . . 0.0 110.773 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.16 122.85 30.81 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.591 HD21 ' HB2' ' A' ' 59' ' ' ALA . 92.3 mt -89.61 -60.86 1.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.086 0.469 . . . . 0.0 110.423 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.582 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.4 mt -140.95 152.52 20.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.243 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 55.3 mttt -95.86 127.38 41.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.415 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.598 HD11 HD11 ' A' ' 57' ' ' ILE . 37.1 mm -107.15 145.16 14.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.396 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.027 -1.429 . . . . 0.0 110.798 -179.998 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 121.119 0.485 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.489 HD11 HD11 ' A' ' 122' ' ' ILE . 52.4 mt -78.22 111.66 20.16 Favored Pre-proline 0 CA--C 1.535 0.372 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.237 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -71.32 138.39 32.88 Favored 'Trans proline' 0 N--CA 1.472 0.221 0 C-N-CA 121.997 1.798 . . . . 0.0 112.348 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.66 146.66 99.09 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.404 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.81 -27.73 14.4 Favored 'Trans proline' 0 CA--C 1.528 0.196 0 C-N-CA 122.254 1.97 . . . . 0.0 112.291 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -164.64 171.02 14.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.46 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.71 93.53 6.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.447 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.95 -148.76 7.41 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.1 m -136.46 138.0 41.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.071 0.462 . . . . 0.0 110.551 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.571 HG13 HD21 ' A' ' 83' ' ' LEU . 19.5 t -71.05 116.72 13.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.2 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 t -98.61 -48.65 4.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.622 -179.804 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -150.4 144.67 25.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.622 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.622 HD11 ' HA ' ' A' ' 108' ' ' LYS . 21.8 mt -105.35 135.12 44.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.905 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.786 HD22 ' HB ' ' A' ' 81' ' ' THR . 3.6 mp -97.14 -30.62 12.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.846 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.701 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.3 m -119.47 145.7 25.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.187 0.518 . . . . 0.0 110.742 -179.704 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.9 pttm -133.6 164.21 27.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.252 179.879 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -60.54 103.82 0.28 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.452 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.04 -29.68 2.41 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -94.94 153.15 17.8 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.098 0.475 . . . . 0.0 110.475 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.4 m -96.69 153.08 18.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.311 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.701 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.4 m -128.61 168.64 21.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.73 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.4 mtpp -129.96 151.69 50.24 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.19 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.646 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.57 102.16 0.17 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.71 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.85 -37.74 2.05 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 32.3 tt0 -62.55 140.57 58.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.12 0.486 . . . . 0.0 110.692 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.786 ' HB ' HD22 ' A' ' 69' ' ' LEU . 9.2 m -67.34 141.07 57.26 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.227 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.781 HG22 ' O ' ' A' ' 94' ' ' ILE . 34.9 m -115.61 -24.25 3.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.592 -179.405 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.571 HD21 HG13 ' A' ' 65' ' ' VAL . 8.3 tt -166.26 152.94 9.29 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.211 0.529 . . . . 0.0 110.885 -179.668 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.566 ' N ' HD23 ' A' ' 83' ' ' LEU . 21.8 t -114.9 134.7 57.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.042 179.702 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.45 HD12 HD11 ' A' ' 94' ' ' ILE . 55.8 mt -115.47 161.59 18.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.611 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.132 179.889 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 121.112 0.482 . . . . 0.0 110.569 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.9 m -115.07 123.6 49.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.224 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 14.8 mt-10 -94.07 129.91 40.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.788 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.781 ' O ' HG22 ' A' ' 82' ' ' VAL . 4.4 mp -115.5 112.37 39.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.633 179.489 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -99.48 153.97 18.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.419 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.98 142.54 95.19 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.293 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.33 -36.22 5.67 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.175 1.917 . . . . 0.0 112.196 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.646 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -146.12 168.83 20.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.299 179.846 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -68.55 141.9 55.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.334 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.24 -161.16 31.12 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 74.9 tttt -134.51 148.12 50.47 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.096 0.474 . . . . 0.0 110.429 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.618 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.6 t -74.75 103.7 2.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.202 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -90.39 -29.29 18.11 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.774 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.5 tttt -158.32 123.53 4.37 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.139 0.495 . . . . 0.0 110.518 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.506 HG13 HG12 ' A' ' 120' ' ' ILE . 24.5 t -100.37 106.79 19.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.332 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.41 ' O ' HG13 ' A' ' 107' ' ' VAL . 5.4 mt -90.48 33.76 0.9 Allowed 'General case' 0 CA--C 1.533 0.326 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.421 179.678 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.43 HG22 ' O ' ' A' ' 119' ' ' LEU . 19.2 m -156.4 137.26 4.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 121.031 0.443 . . . . 0.0 110.101 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.622 ' HA ' HD11 ' A' ' 68' ' ' ILE . 1.4 mptp? -125.85 175.82 7.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.272 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -72.2 147.63 46.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.401 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 63.16 34.51 13.51 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.537 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -121.87 145.0 48.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.26 179.754 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.24 136.99 32.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.629 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 20.7 m -120.23 179.73 2.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.383 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -133.05 141.97 48.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.367 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.8 102.36 0.33 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.849 -0.901 . . . . 0.0 110.849 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.33 -31.32 4.7 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -60.24 142.5 54.44 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.093 0.473 . . . . 0.0 110.583 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -65.45 126.64 30.77 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.43 ' O ' HG22 ' A' ' 107' ' ' VAL . 92.6 mt -89.98 -55.49 3.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.993 0.425 . . . . 0.0 110.271 179.88 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.538 ' CG2' HG13 ' A' ' 102' ' ' VAL . 45.6 mt -143.51 149.25 18.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.333 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.2 ttmt -96.44 130.84 43.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.276 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.489 HD11 HD11 ' A' ' 57' ' ' ILE . 37.6 mm -107.22 144.17 16.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.49 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.758 0 CA-C-O 117.998 -1.446 . . . . 0.0 110.737 179.991 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 121.116 0.484 . . . . 0.0 110.341 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.427 HD11 HD11 ' A' ' 122' ' ' ILE . 47.4 mt -82.5 114.85 54.6 Favored Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.24 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.38 148.98 55.9 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.054 1.836 . . . . 0.0 112.278 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.586 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -81.13 145.26 56.04 Favored Pre-proline 0 CA--C 1.532 0.25 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.431 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -73.44 -27.34 13.29 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.238 1.958 . . . . 0.0 112.399 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.7 pp -162.57 158.26 23.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.472 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -75.19 91.28 2.61 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.337 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -121.03 -170.24 13.99 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.474 ' C ' HD23 ' A' ' 85' ' ' LEU . 18.9 m -106.93 134.98 49.28 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.057 0.456 . . . . 0.0 110.408 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.756 HG13 HD11 ' A' ' 83' ' ' LEU . 32.6 t -69.59 121.49 19.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.15 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t -95.66 -60.14 1.72 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.398 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -150.32 146.52 26.8 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.465 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.722 HG12 HD12 ' A' ' 83' ' ' LEU . 32.8 mt -102.46 124.05 56.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.922 179.773 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.635 HD22 ' HB ' ' A' ' 81' ' ' THR . 8.4 mp -97.61 27.88 4.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.991 -179.561 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.767 ' HB ' HG21 ' A' ' 102' ' ' VAL . 26.3 m -153.9 154.85 6.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 121.178 0.514 . . . . 0.0 110.486 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -141.6 158.2 44.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.122 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -60.52 92.5 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.45 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.19 -27.06 2.55 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -78.42 144.62 35.7 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.077 0.465 . . . . 0.0 110.489 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -95.54 135.45 37.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.355 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.602 HG11 HG11 ' A' ' 70' ' ' VAL . 26.6 m -115.4 160.28 14.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.573 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 23.8 mttm -118.52 142.91 47.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.286 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.601 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -57.76 95.7 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.761 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.19 -31.88 2.64 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.8 tt0 -68.01 151.17 47.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.137 0.494 . . . . 0.0 110.399 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.635 ' HB ' HD22 ' A' ' 69' ' ' LEU . 4.5 m -69.76 136.65 51.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.401 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.1 m -113.6 -32.11 2.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.901 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.756 HD11 HG13 ' A' ' 65' ' ' VAL . 8.3 tt -160.75 146.76 14.9 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.111 0.482 . . . . 0.0 110.705 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -101.85 137.1 30.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.094 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.737 HD12 HD11 ' A' ' 94' ' ' ILE . 12.8 mt -120.4 165.73 14.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.496 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.3 mt-10 . . . . . 0 C--N 1.331 -0.212 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.327 179.955 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.061 0.458 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.8 m -113.07 120.21 40.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.333 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 -84.65 135.84 34.0 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.492 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.737 HD11 HD12 ' A' ' 85' ' ' LEU . 37.8 mm -104.85 126.85 59.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.296 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -108.73 141.23 41.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.427 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.32 143.17 95.79 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.324 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -73.08 -37.99 3.11 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.121 1.88 . . . . 0.0 112.273 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.601 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 21.2 p -145.01 155.71 43.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.302 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -65.64 141.45 58.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.375 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 178.15 -155.31 16.68 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -134.83 143.44 47.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.023 0.44 . . . . 0.0 110.38 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.767 HG21 ' HB ' ' A' ' 70' ' ' VAL . 26.0 t -79.04 114.13 19.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.139 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -95.44 -30.37 13.92 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.606 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.3 ttpt -158.0 131.89 7.94 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.464 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 26.8 t -108.72 102.22 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.267 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.1 mt -74.32 -33.61 63.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.446 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 119' ' ' LEU . 29.9 m -73.52 150.68 7.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.346 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -140.88 157.29 45.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.473 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 61.7 mt-10 -61.17 145.62 50.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.51 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.14 37.54 17.55 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.33 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.543 ' O ' HG23 ' A' ' 65' ' ' VAL . 15.0 t70 -127.28 145.0 50.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.454 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.9 137.46 32.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.493 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.1 m -121.32 156.12 25.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.376 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 13.6 mt-30 -101.6 144.57 30.17 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.376 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.31 107.18 1.36 Allowed Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.84 -27.64 8.17 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -59.75 141.72 54.67 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.054 0.454 . . . . 0.0 110.645 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.35 127.11 41.55 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.586 HD21 ' HB2' ' A' ' 59' ' ' ALA . 91.7 mt -91.17 -56.29 3.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.086 0.469 . . . . 0.0 110.459 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.578 ' CG2' HG13 ' A' ' 102' ' ' VAL . 53.5 mt -141.12 151.28 19.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.342 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.0 tttt -97.36 126.63 42.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.42 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.427 HD11 HD11 ' A' ' 57' ' ' ILE . 37.5 mm -105.24 145.64 13.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.397 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.82 0 CA-C-O 118.002 -1.443 . . . . 0.0 110.813 179.968 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 . . . . . 0 C--O 1.232 0.169 0 CA-C-O 121.096 0.474 . . . . 0.0 110.506 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.6 mt -79.01 116.69 61.95 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.159 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -71.6 137.62 30.62 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 121.991 1.794 . . . . 0.0 112.279 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.527 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -71.0 148.17 94.3 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.404 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.551 ' HD3' HD12 ' A' ' 94' ' ' ILE . 47.9 Cg_endo -72.58 -28.75 13.96 Favored 'Trans proline' 0 CA--C 1.528 0.194 0 C-N-CA 122.238 1.959 . . . . 0.0 112.216 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.5 pp -162.34 173.51 14.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.511 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -86.67 95.8 9.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.384 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.22 -145.39 6.52 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.534 ' C ' HD23 ' A' ' 85' ' ' LEU . 13.8 m -136.33 139.72 42.79 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.128 0.49 . . . . 0.0 110.512 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.707 HG13 HD11 ' A' ' 83' ' ' LEU . 21.8 t -68.66 121.96 19.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.097 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 92.7 p -99.45 -53.15 3.29 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.627 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.3 tptt -152.33 144.77 24.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.558 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.409 HG12 HD12 ' A' ' 83' ' ' LEU . 21.8 mt -103.14 133.19 47.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.989 179.716 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.412 HD13 ' HB ' ' A' ' 81' ' ' THR . 12.3 mt -99.77 -29.57 12.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.952 -179.648 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.813 HG11 HG11 ' A' ' 76' ' ' VAL . 32.6 m -110.98 147.87 14.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.249 0.547 . . . . 0.0 110.765 -179.726 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.8 pttt -136.18 166.01 24.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.244 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.5 ' HG3' HG23 ' A' ' 105' ' ' VAL . 14.8 mt-10 -61.79 100.03 0.14 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.495 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.06 -31.98 2.23 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -85.42 147.15 26.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.068 0.461 . . . . 0.0 110.461 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.1 m -98.29 146.8 25.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.348 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.813 HG11 HG11 ' A' ' 70' ' ' VAL . 24.9 m -126.75 165.52 25.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.614 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 22.2 pttt -127.2 150.51 49.49 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.285 179.768 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.743 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -58.62 98.23 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.748 -179.759 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.31 -37.91 1.83 Allowed Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 21.1 tt0 -65.18 143.82 57.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.072 0.463 . . . . 0.0 110.639 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.412 ' HB ' HD13 ' A' ' 69' ' ' LEU . 4.1 m -67.37 138.93 57.11 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.204 179.85 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.431 ' HA ' HG13 ' A' ' 70' ' ' VAL . 34.8 m -113.75 -34.38 2.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.84 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.707 HD11 HG13 ' A' ' 65' ' ' VAL . 7.9 tt -160.45 147.34 15.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.788 -179.415 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -104.97 139.43 25.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.001 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.634 HD21 HG21 ' A' ' 113' ' ' VAL . 2.4 mt -120.02 165.36 14.8 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.19 0.519 . . . . 0.0 110.691 -179.707 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 . . . . . 0 C--N 1.331 -0.22 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.532 -179.833 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 121.14 0.495 . . . . 0.0 110.412 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.2 m -119.85 114.52 22.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.437 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -82.4 143.5 31.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.579 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.551 HD12 ' HD3' ' A' ' 60' ' ' PRO . 39.7 mm -105.14 127.62 59.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.162 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -105.42 142.16 35.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.341 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.86 132.2 91.76 Favored Pre-proline 0 CA--C 1.534 0.33 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.371 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -72.79 -32.19 9.5 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 121.99 1.793 . . . . 0.0 112.243 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.743 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 4.6 p -146.68 156.91 43.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.419 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -68.32 142.73 55.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.44 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 172.19 -156.77 26.1 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -135.43 146.46 48.26 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.057 0.456 . . . . 0.0 110.415 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.69 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.0 t -74.86 107.75 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.271 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' GLU . . . . . 0.402 ' HG3' ' N ' ' A' ' 104' ' ' LYS . 7.3 pt-20 -90.59 -30.98 16.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.563 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' LYS . . . . . 0.402 ' N ' ' HG3' ' A' ' 103' ' ' GLU . 1.5 tptm -156.11 130.57 8.87 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.586 -179.787 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.5 HG23 ' HG3' ' A' ' 72' ' ' GLU . 25.4 t -98.92 106.1 18.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.347 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.2 mt -89.59 12.06 17.82 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.511 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.688 HG21 HD13 ' A' ' 83' ' ' LEU . 28.3 m -127.33 136.16 61.38 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.095 0 CA-C-O 121.121 0.486 . . . . 0.0 110.122 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 40.1 tttt -128.5 156.21 43.62 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.373 -179.787 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -60.7 150.22 32.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.487 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 61.45 31.79 19.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.443 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -124.36 142.78 51.01 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.264 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.5 136.84 32.83 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.609 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.634 HG21 HD21 ' A' ' 85' ' ' LEU . 30.4 m -120.69 157.16 23.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.306 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 -100.14 142.19 31.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.504 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.07 107.64 1.41 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.61 -28.32 8.65 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.4 tt0 -57.62 147.14 28.19 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.087 0.47 . . . . 0.0 110.76 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -63.33 121.85 25.38 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.941 -0.863 . . . . 0.0 110.941 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.671 ' O ' HG13 ' A' ' 107' ' ' VAL . 56.5 mt -87.25 -52.56 5.33 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.056 0.455 . . . . 0.0 110.501 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' HG13 ' A' ' 102' ' ' VAL . 48.9 mt -142.31 148.3 20.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.35 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -95.75 128.04 42.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.345 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.4 mm -107.68 145.34 15.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.484 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.798 0 CA-C-O 117.984 -1.454 . . . . 0.0 110.824 179.999 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 . . . . . 0 C--O 1.23 0.071 0 CA-C-O 121.066 0.46 . . . . 0.0 110.357 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.568 HD11 HD11 ' A' ' 122' ' ' ILE . 53.0 mt -79.39 111.45 20.8 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.144 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.33 141.98 40.18 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.016 1.811 . . . . 0.0 112.288 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.411 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -76.75 144.49 73.15 Favored Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.275 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.73 -22.35 20.6 Favored 'Trans proline' 0 CA--C 1.529 0.241 0 C-N-CA 122.181 1.921 . . . . 0.0 112.702 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.5 pp -161.7 167.38 25.19 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.128 0.489 . . . . 0.0 110.457 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -86.37 119.67 26.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.455 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -152.04 -141.4 3.31 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.522 ' C ' HD23 ' A' ' 85' ' ' LEU . 6.6 m -137.56 143.42 41.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.139 0.495 . . . . 0.0 110.439 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.796 HG13 HD11 ' A' ' 83' ' ' LEU . 37.3 t -68.17 128.63 31.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.172 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.6 m -98.18 -59.75 1.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.683 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 12.6 mtpt -149.49 147.18 27.9 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.541 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.474 HD11 ' HA ' ' A' ' 108' ' ' LYS . 51.8 mt -102.87 123.25 56.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.075 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.6 mp -94.09 -46.04 7.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.657 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.683 ' HB ' HG21 ' A' ' 102' ' ' VAL . 33.4 m -95.23 143.9 10.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.694 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 3.5 pttt -133.36 165.33 25.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.182 179.76 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -59.31 102.03 0.12 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.666 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 137.91 -31.89 2.42 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -84.9 149.99 25.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.09 0.471 . . . . 0.0 110.501 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 9.3 m -96.64 142.98 28.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.352 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.674 ' CG1' HG11 ' A' ' 70' ' ' VAL . 31.5 m -120.7 154.22 24.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.548 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 13.0 tptt -116.57 151.22 36.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.192 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.08 96.69 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.647 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.62 -30.81 3.35 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -64.79 139.52 58.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.082 0.468 . . . . 0.0 110.602 -179.857 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.0 m -65.57 136.16 56.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.187 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.493 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.0 m -115.09 -29.57 2.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.294 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.796 HD11 HG13 ' A' ' 65' ' ' VAL . 7.2 tt -165.29 152.22 10.47 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.133 0.492 . . . . 0.0 110.778 -179.451 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -107.66 139.81 28.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.153 179.751 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.712 HD21 HG21 ' A' ' 113' ' ' VAL . 1.8 mt -120.58 160.78 22.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.497 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.232 179.916 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 . . . . . 0 C--O 1.232 0.148 0 CA-C-O 121.053 0.454 . . . . 0.0 110.372 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.1 m -119.76 126.18 50.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.367 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -82.7 129.9 35.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.361 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.526 HG13 HD12 ' A' ' 85' ' ' LEU . 23.6 mm -106.39 118.2 53.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.188 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 22.9 p30 -110.65 152.18 26.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.333 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.23 142.19 95.91 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.359 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -73.54 -32.97 7.26 Favored 'Trans proline' 0 N--CA 1.471 0.173 0 C-N-CA 122.171 1.914 . . . . 0.0 112.232 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.583 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 1.0 OUTLIER -148.64 161.08 42.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.385 179.999 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -64.24 142.79 58.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.407 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.21 -153.02 19.63 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 26.3 ttmt -139.84 147.07 40.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.103 0.478 . . . . 0.0 110.428 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.683 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -74.74 107.91 5.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.315 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -91.85 -27.74 17.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.865 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -161.4 136.1 7.24 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.07 0.462 . . . . 0.0 110.481 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.417 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.8 t -103.05 108.61 24.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.269 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.6 mt -90.5 31.1 1.06 Allowed 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.605 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.417 ' H ' HG12 ' A' ' 105' ' ' VAL . 25.8 m -155.54 144.54 12.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 121.032 0.444 . . . . 0.0 110.342 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.474 ' HA ' HD11 ' A' ' 68' ' ' ILE . 8.4 mptt -130.52 165.85 21.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.277 179.824 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -60.99 145.41 50.74 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.472 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 14.2 mmt85 60.64 37.12 19.43 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.507 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -117.93 144.7 45.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.351 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.01 129.24 38.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.457 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.712 HG21 HD21 ' A' ' 85' ' ' LEU . 27.8 m -122.09 150.38 25.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.475 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 -99.44 148.4 24.26 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.432 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -63.59 103.26 0.65 Allowed Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.48 -28.66 5.69 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -59.51 137.89 57.87 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.109 0.481 . . . . 0.0 110.665 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.23 119.73 19.8 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.411 HD21 ' HB2' ' A' ' 59' ' ' ALA . 44.8 mt -87.2 -54.74 4.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.133 0.492 . . . . 0.0 110.484 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.529 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.1 mt -140.99 143.76 27.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.226 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 7.2 tttt -95.16 129.99 42.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.517 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.568 HD11 HD11 ' A' ' 57' ' ' ILE . 37.2 mm -104.62 145.57 13.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.32 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.731 0 CA-C-O 118.011 -1.438 . . . . 0.0 110.768 179.97 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.413 ' OE2' HD11 ' A' ' 106' ' ' LEU . 66.2 mt-10 . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.915 0.388 . . . . 0.0 110.146 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.736 HD12 ' HD2' ' A' ' 97' ' ' PRO . 41.5 mm -83.16 110.49 24.02 Favored Pre-proline 0 CA--C 1.534 0.338 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.068 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -71.57 131.02 18.0 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 121.972 1.782 . . . . 0.0 112.101 -179.741 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.639 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -59.61 145.9 81.75 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.64 -179.867 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -75.62 -29.75 6.98 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.292 1.995 . . . . 0.0 112.5 -179.86 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.429 HD12 ' C ' ' A' ' 61' ' ' LEU . 4.4 pp -157.5 164.43 37.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.552 -179.681 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.9 108.02 13.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.437 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -134.65 -146.63 5.43 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.588 ' O ' HD23 ' A' ' 85' ' ' LEU . 1.8 m -136.33 138.18 41.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.095 0.474 . . . . 0.0 110.401 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.827 HG13 HD11 ' A' ' 83' ' ' LEU . 29.2 t -70.42 118.57 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.039 179.867 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.7 p -96.25 -53.67 3.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.845 -179.749 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 37.9 mttt -148.64 145.28 27.68 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 121.108 0.48 . . . . 0.0 110.703 -179.607 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.522 HD11 ' HA ' ' A' ' 108' ' ' LYS . 38.9 mt -101.78 128.81 53.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.986 179.507 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.429 HD12 HG22 ' A' ' 81' ' ' THR . 15.4 mt -97.64 -49.04 5.0 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.819 -179.592 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.697 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.6 m -93.73 146.04 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.217 0.532 . . . . 0.0 110.797 -179.831 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.8 pttp -135.31 162.72 31.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.034 179.789 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -59.26 103.19 0.16 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.54 -179.971 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.4 2.27 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.881 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -89.79 149.61 22.63 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.135 0.493 . . . . 0.0 110.445 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.4 m -97.22 141.51 30.25 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.444 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.697 ' CG1' HG11 ' A' ' 70' ' ' VAL . 27.1 m -117.43 156.33 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.464 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -117.53 157.03 27.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.438 179.864 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.81 96.48 0.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.557 -179.888 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.52 -28.24 4.52 Favored Glycine 0 CA--C 1.527 0.829 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.806 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -63.3 142.91 58.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.113 0.482 . . . . 0.0 110.684 -179.746 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.429 HG22 HD12 ' A' ' 69' ' ' LEU . 4.9 m -67.65 139.48 56.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.227 179.747 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.566 ' HA ' HG13 ' A' ' 70' ' ' VAL . 30.8 m -119.37 -32.62 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.399 -179.415 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.827 HD11 HG13 ' A' ' 65' ' ' VAL . 7.1 tt -163.09 152.09 14.71 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.228 0.537 . . . . 0.0 111.049 -179.297 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -106.1 139.81 26.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.857 179.574 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.588 HD23 ' O ' ' A' ' 64' ' ' THR . 12.5 mt -122.09 168.01 12.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.153 0.502 . . . . 0.0 110.759 -179.719 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 72.2 mt-10 . . . . . 0 C--N 1.331 -0.23 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.364 179.974 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 . . . . . 0 N--CA 1.461 0.103 0 CA-C-O 121.105 0.478 . . . . 0.0 110.501 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 7.0 m -113.53 115.21 27.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.241 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -80.98 128.66 33.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.525 -179.793 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.568 HD11 HD12 ' A' ' 85' ' ' LEU . 35.4 mm -101.54 144.08 13.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.06 179.707 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -138.14 134.82 35.06 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.731 -179.686 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.513 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -61.89 109.6 2.41 Favored Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.225 179.641 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.736 ' HD2' HD12 ' A' ' 57' ' ' ILE . 41.8 Cg_endo -65.0 -12.49 34.86 Favored 'Trans proline' 0 N--CA 1.475 0.425 0 C-N-CA 122.275 1.983 . . . . 0.0 113.147 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.91 134.83 39.12 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 121.014 0.435 . . . . 0.0 110.54 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -62.57 159.15 16.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.459 -179.911 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 154.29 -156.2 26.69 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.962 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 16.9 ttpt -133.02 146.78 52.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.125 0.488 . . . . 0.0 110.334 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.663 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.4 t -78.53 109.23 12.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.25 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -94.64 -30.53 14.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.59 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -157.1 130.92 8.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.449 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.468 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.2 t -97.92 112.64 30.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.259 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.413 HD11 ' OE2' ' A' ' 56' ' ' GLU . 5.6 mt -90.12 28.48 1.4 Allowed 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.737 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.468 ' H ' HG12 ' A' ' 105' ' ' VAL . 23.2 m -155.39 137.33 6.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.118 0.485 . . . . 0.0 110.336 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.522 ' HA ' HD11 ' A' ' 68' ' ' ILE . 13.8 pttm -127.5 167.01 16.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.346 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -60.09 145.76 45.49 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.77 179.993 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.05 37.41 17.94 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.354 179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.48 ' O ' HG23 ' A' ' 65' ' ' VAL . 8.4 t70 -123.36 138.62 54.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.442 179.983 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.34 131.35 36.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.493 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.0 m -120.95 154.55 24.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.419 179.97 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 19.9 mp0 -96.65 141.93 29.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.325 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.77 90.38 0.06 OUTLIER Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.848 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.3 -30.35 2.81 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -58.63 154.58 14.11 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.115 0.483 . . . . 0.0 110.681 -179.997 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.64 125.76 37.79 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 -179.681 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.639 HD21 ' HB2' ' A' ' 59' ' ' ALA . 58.4 mt -94.77 -59.41 1.93 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.151 0.5 . . . . 0.0 110.225 179.744 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.503 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.9 mt -141.33 141.95 29.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.181 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.3 tttt -88.5 127.06 35.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.433 179.972 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.5 mm -106.82 141.27 22.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.364 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.03 -1.428 . . . . 0.0 110.796 179.959 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.161 0.505 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.432 HD13 ' HD3' ' A' ' 97' ' ' PRO . 53.8 mt -79.01 111.71 22.05 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.154 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -71.09 149.09 57.85 Favored 'Trans proline' 0 N--CA 1.472 0.247 0 C-N-CA 122.074 1.849 . . . . 0.0 112.299 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.852 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -84.24 150.76 58.48 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.447 -179.963 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -72.83 -28.5 13.46 Favored 'Trans proline' 0 CA--C 1.527 0.164 0 C-N-CA 122.251 1.968 . . . . 0.0 112.311 179.971 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.8 pp -164.84 161.99 20.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.43 179.968 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.67 104.72 2.06 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.386 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.87 178.56 18.05 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.972 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.7 m -104.07 134.86 46.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.084 0.469 . . . . 0.0 110.368 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.644 ' HA ' HD23 ' A' ' 85' ' ' LEU . 24.2 t -72.04 118.66 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.102 179.878 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -100.02 -50.19 4.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.629 -179.72 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.95 140.53 21.61 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.769 -179.653 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.554 HG12 HD12 ' A' ' 83' ' ' LEU . 36.1 mt -105.41 126.15 60.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.836 179.579 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.34 28.65 3.99 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.978 -179.564 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.859 ' HB ' HG21 ' A' ' 102' ' ' VAL . 13.6 m -151.07 153.18 10.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.338 0.59 . . . . 0.0 110.897 -179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -137.26 154.82 50.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.918 179.502 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -58.18 91.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.165 0.507 . . . . 0.0 110.681 -179.881 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.88 -29.1 2.47 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -179.919 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -65.06 148.27 51.96 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.055 0.455 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.2 m -97.67 132.28 43.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.237 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.1 m -121.54 163.77 19.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.633 -179.821 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -129.63 154.18 47.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.593 -0.731 . . . . 0.0 110.184 179.74 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.652 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.01 91.21 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.482 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.07 -34.98 1.95 Allowed Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -62.56 140.03 58.63 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.028 0.442 . . . . 0.0 110.45 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.9 m -66.92 136.84 55.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.124 179.815 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.42 ' O ' HG22 ' A' ' 70' ' ' VAL . 29.8 m -116.97 -29.76 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.493 -179.382 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.644 HD11 HG13 ' A' ' 65' ' ' VAL . 10.2 tt -161.04 159.13 28.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.303 0.573 . . . . 0.0 111.016 -179.439 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.615 ' N ' HD23 ' A' ' 83' ' ' LEU . 21.7 t -125.7 131.69 71.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.809 179.513 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.644 HD23 ' HA ' ' A' ' 65' ' ' VAL . 19.8 mt -116.09 168.95 9.64 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.202 0.525 . . . . 0.0 110.747 -179.554 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.156 179.687 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 121.111 0.482 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 8.7 m -114.46 116.96 29.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.202 179.906 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -84.38 131.7 34.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.438 -179.951 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.428 HG22 ' N ' ' A' ' 95' ' ' ASN . 37.7 mm -106.4 155.95 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.293 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.428 ' N ' HG22 ' A' ' 94' ' ' ILE . 10.6 m120 -142.28 145.42 34.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.455 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.64 142.38 94.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.418 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.432 ' HD3' HD13 ' A' ' 57' ' ' ILE . 50.6 Cg_endo -74.59 -36.24 3.05 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.157 1.905 . . . . 0.0 112.375 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.652 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -146.55 170.45 16.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.413 -179.946 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -69.31 142.2 54.11 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.6 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 160.29 -166.7 35.34 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 -179.989 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 13.9 ptpt -129.17 168.8 15.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.355 0.598 . . . . 0.0 110.657 179.798 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.859 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.6 t -82.48 113.89 22.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.547 -179.72 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -94.61 -33.08 13.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.455 179.894 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.1 ttpp -160.63 123.75 3.37 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.606 179.871 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.54 HG13 HG12 ' A' ' 120' ' ' ILE . 23.1 t -102.1 109.99 27.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.325 179.799 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.4 mt -82.21 -30.43 30.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.452 179.763 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 105' ' ' VAL . 27.6 m -82.04 143.25 12.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.796 -179.824 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 20.2 mmtt -131.32 158.79 39.72 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.107 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -61.99 147.33 47.41 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.496 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 8.1 mmm180 64.16 34.43 11.03 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.759 179.85 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.522 ' O ' HG23 ' A' ' 65' ' ' VAL . 31.4 m-20 -131.98 140.81 49.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.413 179.676 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.8 140.75 29.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.554 -179.904 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.0 m -121.69 163.52 19.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.374 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 12.4 mm100 -98.35 142.63 29.75 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.299 179.966 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.96 106.28 1.06 Allowed Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.749 -0.941 . . . . 0.0 110.749 -179.972 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.63 -25.57 10.19 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -179.833 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 -59.73 143.05 51.9 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 121.102 0.477 . . . . 0.0 110.651 -179.822 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.34 124.84 36.03 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 179.954 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.852 HD21 ' HB2' ' A' ' 59' ' ' ALA . 49.2 mt -89.76 -54.9 3.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.092 0.472 . . . . 0.0 110.452 -179.979 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.54 HG12 HG13 ' A' ' 105' ' ' VAL . 47.3 mt -145.86 147.8 18.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.121 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 14.7 ttmt -95.89 136.44 36.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.153 179.774 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.8 mm -110.0 143.16 20.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.433 -179.899 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.745 0 CA-C-O 117.987 -1.452 . . . . 0.0 110.766 -179.997 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 17.0 mt-10 . . . . . 0 N--CA 1.461 0.099 0 CA-C-O 121.11 0.481 . . . . 0.0 110.465 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.515 HD11 HD11 ' A' ' 122' ' ' ILE . 55.8 mt -79.98 111.61 23.19 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.309 -179.997 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.81 131.67 18.79 Favored 'Trans proline' 0 N--CA 1.472 0.217 0 C-N-CA 122.035 1.823 . . . . 0.0 112.287 179.931 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.46 147.57 98.78 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.396 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -72.29 -27.9 15.86 Favored 'Trans proline' 0 CA--C 1.528 0.205 0 C-N-CA 122.188 1.926 . . . . 0.0 112.325 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.533 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.4 pp -163.92 159.65 21.14 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.464 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.456 ' HB2' ' H ' ' A' ' 115' ' ' GLY . . . -74.72 101.57 4.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.373 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.11 -141.26 5.07 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.94 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.0 m -137.81 135.86 36.66 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.169 0.509 . . . . 0.0 110.45 -179.859 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.753 HG13 HD11 ' A' ' 83' ' ' LEU . 21.7 t -69.64 120.06 16.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.225 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 79.2 p -97.02 -53.45 3.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.749 -179.829 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 45.6 tttt -152.06 148.37 27.6 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.603 -179.813 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.544 HG12 HD12 ' A' ' 83' ' ' LEU . 48.9 mt -104.15 134.39 45.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.061 179.756 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.587 HD12 HG22 ' A' ' 81' ' ' THR . 86.3 mt -99.22 -31.46 11.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.758 -179.694 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.705 HG11 ' CG1' ' A' ' 76' ' ' VAL . 34.5 m -113.18 145.07 19.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.229 0.538 . . . . 0.0 110.589 -179.871 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.78 163.89 30.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.211 179.771 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.438 ' HG3' HG23 ' A' ' 105' ' ' VAL . 33.6 mt-10 -58.36 102.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.582 -179.864 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.25 -28.29 2.48 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.824 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -95.69 151.81 19.02 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.1 0.476 . . . . 0.0 110.421 -179.97 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -98.46 147.58 24.59 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.392 179.894 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.705 ' CG1' HG11 ' A' ' 70' ' ' VAL . 24.9 m -121.83 169.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.498 -179.94 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.2 mmtp -130.23 155.25 46.59 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.36 -179.969 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.543 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.74 103.51 0.35 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.474 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.4 -30.79 5.66 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 179.94 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.8 tt0 -61.29 143.2 56.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.621 -179.853 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.587 HG22 HD12 ' A' ' 69' ' ' LEU . 2.5 m -67.76 138.51 56.26 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.266 179.831 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.476 ' HA ' HG13 ' A' ' 70' ' ' VAL . 28.1 m -118.68 -33.6 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.265 -179.443 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.753 HD11 HG13 ' A' ' 65' ' ' VAL . 7.4 tt -161.05 152.87 19.61 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.21 0.529 . . . . 0.0 111.017 -179.303 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.2 t -106.45 143.34 17.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.999 179.665 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.788 HD21 HG21 ' A' ' 113' ' ' VAL . 14.9 mt -120.55 163.16 18.4 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.51 -179.904 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 . . . . . 0 C--O 1.233 0.197 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.458 -179.944 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 . . . . . 0 C--O 1.23 0.068 0 CA-C-O 121.175 0.512 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 4.1 m -115.87 119.5 36.18 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.277 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 26.3 mt-10 -82.39 131.09 35.23 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.628 -179.82 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.759 HD11 HD12 ' A' ' 85' ' ' LEU . 26.9 mm -105.58 148.54 9.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.093 179.815 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 8.0 p-10 -137.23 151.06 48.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.565 -179.911 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.68 144.88 98.83 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.279 179.976 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.428 ' HD3' HG23 ' A' ' 57' ' ' ILE . 49.1 Cg_endo -73.94 -34.63 5.01 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.153 1.902 . . . . 0.0 112.252 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.543 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 32.9 p -145.65 167.46 23.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.37 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -68.77 142.97 54.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.396 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 170.15 -160.15 32.92 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -133.23 149.24 52.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.145 0.497 . . . . 0.0 110.409 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.68 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.0 t -75.1 106.86 5.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.316 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -92.95 -29.98 15.6 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.725 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.9 tttt -158.02 127.93 6.04 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.466 179.998 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.588 HG13 HG12 ' A' ' 120' ' ' ILE . 20.4 t -100.52 110.8 28.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.322 179.916 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.5 mt -90.09 29.38 1.23 Allowed 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.676 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.436 ' H ' HG12 ' A' ' 105' ' ' VAL . 24.4 m -155.44 142.12 11.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.062 0.458 . . . . 0.0 110.353 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.499 ' HA ' HD11 ' A' ' 68' ' ' ILE . 16.8 mmtt -125.86 175.37 7.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.392 179.979 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -73.06 148.34 44.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.395 179.937 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.4 34.2 18.39 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.584 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -123.09 149.91 43.86 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.329 179.838 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.17 135.22 33.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.541 -179.952 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.788 HG21 HD21 ' A' ' 85' ' ' LEU . 30.7 m -121.17 151.64 24.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.279 179.919 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -98.56 140.46 32.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.328 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 115' ' ' GLY . . . . . 0.456 ' H ' ' HB2' ' A' ' 62' ' ' ALA . . . -59.19 108.45 1.63 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 109.53 -26.55 14.31 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -179.782 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -57.63 145.24 34.69 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 121.134 0.492 . . . . 0.0 110.862 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.18 118.21 13.79 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.848 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.405 ' O ' HG22 ' A' ' 107' ' ' VAL . 94.5 mt -88.33 -54.75 4.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.169 0.509 . . . . 0.0 110.177 179.799 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.588 HG12 HG13 ' A' ' 105' ' ' VAL . 44.8 mt -143.18 149.19 18.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.145 179.819 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 42.7 tttt -97.34 130.01 44.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.319 179.885 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.515 HD11 HD11 ' A' ' 57' ' ' ILE . 37.9 mm -107.71 144.44 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.425 -179.843 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.764 0 CA-C-O 118.025 -1.431 . . . . 0.0 110.747 179.955 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.957 0.408 . . . . 0.0 110.421 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 54.3 mt -80.42 111.1 19.81 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.167 -179.984 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -72.31 135.08 23.98 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.024 1.816 . . . . 0.0 112.351 -179.893 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.572 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -70.27 148.89 95.88 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.427 179.977 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -72.31 -28.44 15.19 Favored 'Trans proline' 0 N--CA 1.472 0.207 0 C-N-CA 122.228 1.952 . . . . 0.0 112.303 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.2 pp -164.26 162.71 22.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.389 179.952 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.29 117.84 16.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.443 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -145.83 -146.87 4.49 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 25.9 m -137.18 132.6 34.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.172 0.51 . . . . 0.0 110.376 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.638 ' CG1' HD11 ' A' ' 83' ' ' LEU . 21.4 t -70.23 132.31 33.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.301 179.907 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.0 t -101.52 -57.61 2.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.586 -179.958 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 32.2 ttpt -150.2 146.58 26.93 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.492 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.471 HG12 HD12 ' A' ' 83' ' ' LEU . 21.6 mt -98.92 133.95 39.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.149 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.641 HD11 HG23 ' A' ' 84' ' ' VAL . 5.6 mp -98.23 -31.57 12.01 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.617 -179.828 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.795 HG11 HG11 ' A' ' 76' ' ' VAL . 34.0 m -113.72 145.92 18.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.207 0.527 . . . . 0.0 110.761 -179.841 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.4 ptpp? -133.67 167.13 21.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.042 179.605 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -57.58 113.14 1.67 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.623 -179.972 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.39 21.06 5.29 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.588 -179.989 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -135.01 141.1 46.12 Favored 'General case' 0 C--O 1.231 0.081 0 CA-C-O 121.094 0.474 . . . . 0.0 110.138 179.601 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -95.29 132.02 40.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.611 -179.711 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.795 HG11 HG11 ' A' ' 70' ' ' VAL . 19.9 m -114.5 168.08 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.312 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 7.8 mmmt -121.65 139.91 52.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.258 179.829 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.656 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -56.27 97.95 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.972 -179.81 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.96 -37.39 1.9 Allowed Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.9 tt0 -66.07 149.12 50.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.033 0.444 . . . . 0.0 110.526 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -67.13 136.51 55.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.295 179.971 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.464 HG11 ' HB2' ' A' ' 96' ' ' ALA . 25.6 m -114.77 -31.5 2.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.124 -179.739 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.638 HD11 ' CG1' ' A' ' 65' ' ' VAL . 7.7 tt -160.67 151.83 19.01 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -179.674 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.641 HG23 HD11 ' A' ' 69' ' ' LEU . 22.0 t -102.87 128.26 55.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.055 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.437 HD11 HG21 ' A' ' 113' ' ' VAL . 1.0 OUTLIER -111.76 159.41 18.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.643 -179.771 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.301 179.867 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 . . . . . 0 C--O 1.231 0.081 0 CA-C-O 121.064 0.459 . . . . 0.0 110.474 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 20.2 m -120.29 139.55 52.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.343 179.894 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -85.92 135.09 33.81 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.481 -179.862 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.1 mm -107.82 119.24 57.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.237 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 14.0 p-10 -104.2 142.36 34.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.457 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.464 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -60.82 141.62 92.79 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.492 -179.963 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -73.55 -36.45 3.86 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.198 1.932 . . . . 0.0 112.172 179.932 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.656 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 69.4 p -147.24 153.92 40.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.345 -179.974 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -65.38 141.89 58.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.415 179.863 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.67 -155.34 19.6 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.967 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.7 ttpt -133.48 143.81 49.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.174 0.511 . . . . 0.0 110.593 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.54 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.0 t -75.97 111.23 12.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.079 179.828 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -95.69 -32.49 12.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.82 -179.662 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -161.03 129.84 4.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.117 0.484 . . . . 0.0 110.285 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.715 HG13 HG12 ' A' ' 120' ' ' ILE . 21.8 t -103.85 112.64 38.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.263 179.896 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.3 mt -79.81 -31.62 40.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.562 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.463 HG13 ' HA ' ' A' ' 119' ' ' LEU . 27.0 m -83.76 146.92 6.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.615 -179.801 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 18.9 mttm -129.36 172.15 11.79 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.252 179.943 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.41 139.27 54.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.247 -179.983 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 60.78 40.85 15.54 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.57 179.965 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -121.94 145.83 47.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.404 179.846 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.86 131.12 37.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.381 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.437 HG21 HD11 ' A' ' 85' ' ' LEU . 31.3 m -120.3 153.26 23.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.37 179.924 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -98.86 145.84 26.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.36 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.9 110.24 2.91 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.998 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.55 -28.73 8.36 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.906 -0.877 . . . . 0.0 110.906 -179.83 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -58.02 141.01 51.19 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 121.128 0.49 . . . . 0.0 110.815 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.3 125.85 36.77 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.87 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.572 HD21 ' HB2' ' A' ' 59' ' ' ALA . 89.9 mt -88.96 -57.23 2.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.009 0.433 . . . . 0.0 110.4 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.715 HG12 HG13 ' A' ' 105' ' ' VAL . 53.2 mt -141.29 151.3 19.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.431 179.926 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.7 mttt -94.02 121.68 35.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.132 179.813 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.3 mm -104.01 142.55 17.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.486 -179.845 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.771 0 CA-C-O 117.97 -1.461 . . . . 0.0 110.777 -179.981 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 . . . . . 0 N--CA 1.461 0.096 0 CA-C-O 121.088 0.47 . . . . 0.0 110.473 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.3 mt -79.15 118.5 72.84 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.213 -179.942 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -71.81 138.03 30.83 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 122.057 1.838 . . . . 0.0 112.343 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.556 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -71.66 147.76 92.28 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.405 179.934 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.29 -26.47 17.48 Favored 'Trans proline' 0 CA--C 1.528 0.207 0 C-N-CA 122.232 1.954 . . . . 0.0 112.451 179.913 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.9 pp -163.07 175.27 11.25 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.485 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -89.79 93.01 9.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.428 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.66 -145.41 6.61 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.5 m -137.03 140.71 42.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.122 0.487 . . . . 0.0 110.415 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.59 HG13 HD11 ' A' ' 83' ' ' LEU . 22.8 t -70.79 127.98 33.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.156 179.949 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 7.9 p -99.55 -54.5 2.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.623 -179.84 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.6 tttt -151.05 147.98 27.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.564 -179.804 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.643 HD11 ' HA ' ' A' ' 108' ' ' LYS . 38.1 mt -102.4 133.15 46.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.151 179.792 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.551 HD12 HG22 ' A' ' 81' ' ' THR . 50.3 mt -99.16 -47.73 5.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.686 -179.809 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.772 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.3 m -99.98 146.91 8.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.552 -179.88 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -137.15 164.21 29.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.119 179.749 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -58.5 106.01 0.35 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.61 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.99 2.22 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -96.63 151.08 19.95 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.129 0.49 . . . . 0.0 110.361 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.546 HG22 ' O ' ' A' ' 100' ' ' GLY . 1.1 m -96.44 151.65 19.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.46 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.772 ' CG1' HG11 ' A' ' 70' ' ' VAL . 26.7 m -125.75 168.22 18.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.49 -179.951 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.1 ttpt -129.57 153.84 47.66 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.322 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.672 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.76 100.8 0.16 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.503 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.19 -32.89 3.47 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.87 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.4 tt0 -63.99 143.12 58.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.038 0.447 . . . . 0.0 110.513 -179.84 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.551 HG22 HD12 ' A' ' 69' ' ' LEU . 2.2 m -67.51 137.57 55.88 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.196 179.838 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.0 m -117.13 -34.02 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.124 -179.497 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.59 HD11 HG13 ' A' ' 65' ' ' VAL . 7.6 tt -161.72 153.62 19.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.227 0.537 . . . . 0.0 110.952 -179.453 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -108.55 143.09 19.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.932 179.52 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.426 HD11 HG21 ' A' ' 113' ' ' VAL . 1.4 tp -122.49 170.63 9.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.675 -179.693 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.466 179.997 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 . . . . . 0 N--CA 1.46 0.061 0 CA-C-O 121.115 0.483 . . . . 0.0 110.539 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -114.72 111.25 20.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.201 179.956 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -81.72 127.94 33.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.586 -179.829 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 34.4 mm -103.97 144.63 13.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.128 179.689 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -135.29 148.87 49.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.426 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.79 138.39 97.37 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.273 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -74.38 -31.2 7.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.052 1.835 . . . . 0.0 112.258 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.672 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 15.9 p -145.74 163.9 33.5 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.435 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -68.11 142.7 55.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.363 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.546 ' O ' HG22 ' A' ' 75' ' ' THR . . . 171.76 -161.41 33.54 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.7 ttpt -132.27 147.25 52.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.412 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.61 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.7 t -75.2 106.68 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.198 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -92.12 -29.13 16.68 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.776 -179.846 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 5.6 tttt -160.07 131.02 5.72 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.112 0.482 . . . . 0.0 110.508 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.423 HG12 ' H ' ' A' ' 107' ' ' VAL . 22.3 t -100.8 109.01 24.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.198 179.897 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 23.5 mt -90.13 31.02 1.02 Allowed 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.65 -179.99 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.449 HG21 HD13 ' A' ' 83' ' ' LEU . 24.6 m -155.58 137.11 5.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-O 121.061 0.458 . . . . 0.0 110.174 -179.993 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.643 ' HA ' HD11 ' A' ' 68' ' ' ILE . 34.1 mtmt -123.63 177.56 5.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.379 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -68.93 144.64 54.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.491 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 34.1 mtt180 60.12 33.25 21.17 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.619 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -111.49 142.86 43.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.36 -179.978 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.75 134.28 34.54 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.5 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.426 HG21 HD11 ' A' ' 85' ' ' LEU . 30.3 m -120.77 -179.92 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.398 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -140.84 147.94 39.77 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.397 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.02 106.43 1.11 Allowed Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 179.962 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 119.82 -31.79 5.22 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 -179.938 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -60.61 134.49 57.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.064 0.459 . . . . 0.0 110.571 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.14 123.06 31.47 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.781 -0.927 . . . . 0.0 110.781 179.961 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.556 HD21 ' HB2' ' A' ' 59' ' ' ALA . 62.7 mt -88.67 -54.88 3.95 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.068 0.461 . . . . 0.0 110.467 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.525 ' CG2' HG13 ' A' ' 102' ' ' VAL . 52.9 mt -140.93 148.91 21.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.368 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.8 mttt -95.35 127.15 41.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.335 179.885 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.3 mm -108.02 143.52 18.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.359 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.698 0 CA-C-O 117.982 -1.454 . . . . 0.0 110.761 -179.984 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 . . . . . 0 N--CA 1.461 0.105 0 CA-C-O 121.085 0.469 . . . . 0.0 110.427 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.743 HD11 HD11 ' A' ' 122' ' ' ILE . 42.7 mt -80.8 111.13 20.71 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.284 179.885 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -71.02 137.27 31.46 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.079 1.852 . . . . 0.0 112.33 -179.854 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.32 151.01 97.57 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.458 179.994 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.66 ' HB2' HD23 ' A' ' 61' ' ' LEU . 48.9 Cg_endo -72.7 -27.5 15.0 Favored 'Trans proline' 0 CA--C 1.529 0.23 0 C-N-CA 122.212 1.941 . . . . 0.0 112.35 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.66 HD23 ' HB2' ' A' ' 60' ' ' PRO . 0.2 OUTLIER -164.23 172.47 13.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.368 179.97 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.8 92.3 7.22 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.31 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -123.81 -146.16 6.94 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.931 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.3 m -135.79 137.57 41.73 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.102 0.477 . . . . 0.0 110.362 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.774 HG13 HD11 ' A' ' 83' ' ' LEU . 22.1 t -68.22 128.27 31.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.319 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -97.72 -61.55 1.37 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.428 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -149.71 145.87 26.92 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.403 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.565 HG12 HD12 ' A' ' 83' ' ' LEU . 49.5 mt -97.76 129.42 47.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.079 179.789 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.585 HD12 HG22 ' A' ' 81' ' ' THR . 22.3 mt -97.41 -43.54 7.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.818 -179.703 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.769 HG11 ' CG1' ' A' ' 76' ' ' VAL . 31.4 m -104.2 145.83 12.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.216 0.531 . . . . 0.0 110.781 -179.691 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.1 pttt -137.24 161.93 34.89 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.945 179.718 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -57.16 107.88 0.47 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.766 -179.926 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -31.02 2.31 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -179.686 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -98.83 152.71 19.43 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.972 0.415 . . . . 0.0 110.36 179.86 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.522 HG23 ' HB2' ' A' ' 101' ' ' LYS . 0.7 OUTLIER -96.61 151.07 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.45 179.995 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.769 ' CG1' HG11 ' A' ' 70' ' ' VAL . 23.5 m -127.81 169.97 18.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.41 -179.929 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 17.4 mmmt -132.49 153.75 50.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.409 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.514 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.79 104.47 0.36 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.577 -179.845 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 126.35 -34.69 3.14 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.857 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 -64.43 140.43 58.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.116 0.484 . . . . 0.0 110.513 -179.908 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.585 HG22 HD12 ' A' ' 69' ' ' LEU . 11.1 m -67.42 136.55 54.88 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.333 179.915 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 94' ' ' ILE . 30.0 m -112.82 -29.23 2.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.042 -179.737 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.774 HD11 HG13 ' A' ' 65' ' ' VAL . 7.7 tt -163.99 147.53 9.8 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 121.12 0.486 . . . . 0.0 110.86 -179.516 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -98.86 134.15 38.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.961 179.593 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.716 HD11 HG21 ' A' ' 113' ' ' VAL . 1.0 OUTLIER -116.04 167.71 10.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.542 -179.729 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 . . . . . 0 C--N 1.331 -0.239 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.493 179.962 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 121.136 0.493 . . . . 0.0 110.314 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 11.8 m -116.04 128.14 55.47 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.493 -179.931 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -85.51 133.31 34.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.445 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.425 ' O ' HG22 ' A' ' 82' ' ' VAL . 38.2 mm -102.38 118.3 49.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.223 179.869 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -104.24 143.93 32.29 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.315 -179.887 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.21 140.31 91.23 Favored Pre-proline 0 CA--C 1.533 0.32 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.556 -179.983 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -73.25 -33.33 7.33 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.186 1.924 . . . . 0.0 112.338 -179.975 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.514 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 81.1 p -147.84 163.44 36.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.354 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -67.98 142.91 55.82 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.531 179.92 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.503 ' O ' HG22 ' A' ' 75' ' ' THR . . . 171.51 -159.97 31.8 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.995 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 101' ' ' LYS . . . . . 0.522 ' HB2' HG23 ' A' ' 75' ' ' THR . 13.3 ttmt -136.55 141.61 43.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.105 0.479 . . . . 0.0 110.517 -179.911 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.644 HG13 ' CG2' ' A' ' 120' ' ' ILE . 22.0 t -72.03 125.9 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.262 179.856 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -102.63 -31.23 10.48 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.783 -179.915 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 2.2 ttmt -164.4 139.08 5.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.674 -179.772 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 107' ' ' VAL . 22.0 t -106.67 109.01 26.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.128 179.807 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.4 mt -80.01 -31.81 39.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.302 179.898 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.429 ' O ' HG12 ' A' ' 105' ' ' VAL . 29.0 m -79.85 147.7 6.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.49 -179.965 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 24.3 mttp -127.83 164.1 22.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.149 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -65.95 142.38 57.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.397 179.997 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 63.54 37.77 10.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.619 179.885 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -121.64 152.16 39.63 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.389 179.681 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.97 134.52 34.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.476 -179.909 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.716 HG21 HD11 ' A' ' 85' ' ' LEU . 30.7 m -120.42 150.24 23.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.456 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 21.8 mt-30 -101.17 139.44 36.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.336 179.919 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.38 92.11 0.05 OUTLIER Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 132.81 -28.47 3.37 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.867 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -60.0 144.9 48.13 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 121.108 0.48 . . . . 0.0 110.645 -179.95 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.87 122.88 28.97 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.885 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 88.6 mt -88.18 -59.44 2.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.061 0.458 . . . . 0.0 110.385 179.853 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.644 ' CG2' HG13 ' A' ' 102' ' ' VAL . 49.7 mt -141.77 149.21 20.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.358 179.803 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -94.04 131.41 39.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.332 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.743 HD11 HD11 ' A' ' 57' ' ' ILE . 35.7 mm -107.7 146.02 14.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.397 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.718 0 CA-C-O 118.002 -1.443 . . . . 0.0 110.746 179.903 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.466 ' OE2' HD11 ' A' ' 106' ' ' LEU . 33.7 mt-10 . . . . . 0 N--CA 1.462 0.159 0 CA-C-O 121.215 0.531 . . . . 0.0 110.677 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.9 mt -80.45 125.92 79.85 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.341 -179.835 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -74.85 156.65 43.65 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 121.885 1.723 . . . . 0.0 112.247 179.737 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.493 ' HB3' ' H ' ' A' ' 116' ' ' GLY . . . -84.89 143.36 40.15 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.305 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -73.89 -27.93 11.79 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.225 1.95 . . . . 0.0 112.484 -179.97 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -163.65 172.49 14.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.51 -179.908 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.3 98.64 11.7 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.506 179.925 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.68 -144.31 5.62 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 8.9 m -137.71 135.9 36.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.149 0.499 . . . . 0.0 110.458 179.926 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.652 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -71.1 125.89 30.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.24 179.86 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.5 p -98.99 -57.54 2.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.74 -179.707 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.43 ' HD2' HG21 ' A' ' 84' ' ' VAL . 5.6 ptpt -149.52 146.37 27.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.679 -179.728 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.681 HG12 HD12 ' A' ' 83' ' ' LEU . 30.8 mt -101.62 136.83 31.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.16 179.74 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.587 HD12 HG22 ' A' ' 81' ' ' THR . 46.3 mt -100.0 -40.21 7.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.576 -179.847 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.628 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.0 m -100.73 138.15 25.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.148 0.499 . . . . 0.0 110.581 -179.873 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 10.2 pttp -122.7 163.26 20.45 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.044 179.825 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -60.47 104.02 0.3 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.569 -179.895 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 137.56 -31.82 2.46 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -83.17 154.99 23.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.052 0.453 . . . . 0.0 110.557 179.969 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.5 m -98.47 144.78 27.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.322 179.952 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.578 ' CG1' HG11 ' A' ' 70' ' ' VAL . 31.1 m -120.78 158.12 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.511 -179.914 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 41.6 mttt -122.7 151.12 41.87 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.261 179.832 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.458 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.29 90.99 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.694 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.53 -30.36 3.01 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.921 -0.871 . . . . 0.0 110.921 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -61.85 142.8 57.14 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.158 0.504 . . . . 0.0 110.571 -179.855 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.587 HG22 HD12 ' A' ' 69' ' ' LEU . 2.1 m -67.22 140.53 57.42 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.123 179.779 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.599 ' HA ' HG13 ' A' ' 70' ' ' VAL . 32.4 m -121.76 -32.49 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.631 -179.459 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.681 HD12 HG12 ' A' ' 68' ' ' ILE . 8.0 tt -161.23 152.84 19.21 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 120.169 -0.612 . . . . 0.0 111.557 -179.244 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.43 HG21 ' HD2' ' A' ' 67' ' ' LYS . 21.6 t -103.96 137.64 31.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.638 179.405 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.1 tp -121.0 165.7 14.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.176 0.512 . . . . 0.0 110.656 -179.776 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.463 -179.949 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 121.082 0.468 . . . . 0.0 110.288 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.2 m -121.71 129.54 52.8 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.368 -179.987 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -84.29 138.04 33.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.564 -179.902 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.2 mm -103.21 150.48 6.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.077 179.853 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -138.05 142.15 40.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.507 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.11 139.79 96.02 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.293 -179.98 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.1 -30.35 10.8 Favored 'Trans proline' 0 N--CA 1.472 0.223 0 C-N-CA 122.061 1.841 . . . . 0.0 112.081 179.894 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.458 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 6.0 p -147.01 162.79 38.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.198 179.879 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 11.6 p30 -67.54 147.71 52.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.204 0.526 . . . . 0.0 110.315 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 169.92 -160.04 32.87 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -179.832 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -135.58 142.89 45.38 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.068 0.461 . . . . 0.0 110.455 -179.915 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.628 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.6 t -75.59 111.48 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.905 179.699 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -97.36 -31.21 12.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.833 -179.488 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -161.77 132.01 4.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.148 0.499 . . . . 0.0 110.786 -179.878 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.483 HG13 HG12 ' A' ' 120' ' ' ILE . 22.0 t -102.71 123.78 56.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.923 179.685 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.466 HD11 ' OE2' ' A' ' 56' ' ' GLU . 35.3 mt -82.77 -29.92 29.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.98 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.413 ' O ' HG12 ' A' ' 105' ' ' VAL . 35.3 m -95.97 158.82 3.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 121.213 0.53 . . . . 0.0 110.936 -179.677 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 37.2 mttt -132.08 163.53 28.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.167 179.65 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -60.72 141.42 56.89 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.544 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? 61.43 39.11 15.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.393 179.988 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -123.88 151.38 43.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.327 179.852 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.63 144.21 25.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.473 -179.912 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.416 HG13 HG23 ' A' ' 65' ' ' VAL . 33.7 m -126.75 179.53 3.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.37 179.801 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -130.04 140.88 50.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.323 179.937 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -58.78 105.93 0.77 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.837 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.493 ' H ' ' HB3' ' A' ' 59' ' ' ALA . . . 115.99 -31.05 6.24 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.995 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.1 tt0 -58.4 140.61 53.43 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 121.141 0.496 . . . . 0.0 110.763 -179.909 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.71 124.01 34.43 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 179.934 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 90.1 mt -90.38 -49.31 6.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.036 0.446 . . . . 0.0 110.844 -179.585 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.483 HG12 HG13 ' A' ' 105' ' ' VAL . 50.7 mt -142.33 153.61 18.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.576 -179.852 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.403 ' N ' HG22 ' A' ' 120' ' ' ILE . 23.4 tttt -98.19 125.21 43.14 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.354 179.835 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 39.4 mm -108.37 140.4 27.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.397 -179.93 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.701 0 CA-C-O 117.979 -1.456 . . . . 0.0 110.943 179.93 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 . . . . . 0 N--CA 1.462 0.129 0 CA-C-O 121.106 0.479 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.764 HD12 ' HD2' ' A' ' 97' ' ' PRO . 42.9 mm -79.09 124.48 84.6 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.051 179.879 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.9 132.77 17.42 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 121.924 1.749 . . . . 0.0 112.223 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 114' ' ' GLN . . . -65.34 146.16 98.98 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.427 -179.938 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -72.9 -29.95 11.7 Favored 'Trans proline' 0 N--CA 1.471 0.2 0 C-N-CA 122.191 1.927 . . . . 0.0 112.295 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.454 HD12 ' C ' ' A' ' 61' ' ' LEU . 4.2 pp -163.67 166.38 22.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.393 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.1 101.82 6.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.339 179.929 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.63 -149.91 6.33 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.989 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.8 m -136.21 140.6 43.65 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.149 0.5 . . . . 0.0 110.437 179.933 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.974 HG13 HD11 ' A' ' 83' ' ' LEU . 23.2 t -73.24 121.69 24.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.252 179.918 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -99.49 -49.69 4.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.555 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 17.2 ttpt -152.56 146.51 25.28 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.535 -179.735 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.487 HD12 ' HG2' ' A' ' 109' ' ' GLU . 2.9 mp -105.59 135.82 42.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.09 179.7 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.511 HD11 HG23 ' A' ' 84' ' ' VAL . 7.1 mp -100.03 -36.34 9.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.653 -179.783 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.763 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.0 m -101.16 143.2 14.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.72 -179.819 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.4 pttp -133.47 162.67 31.23 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.063 179.81 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -59.16 101.12 0.09 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.534 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.22 -29.6 2.4 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.836 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -90.7 148.03 22.87 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.093 0.473 . . . . 0.0 110.43 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.6 m -95.72 144.72 25.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.396 179.972 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.668 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.4 m -119.78 160.68 19.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.505 -179.965 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 88.2 mttt -125.06 154.32 41.52 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.327 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.36 97.61 0.05 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.732 -179.802 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.83 -30.66 3.69 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 28.2 tt0 -63.94 141.24 58.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.101 0.477 . . . . 0.0 110.735 -179.816 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.2 m -65.45 138.6 58.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.235 179.744 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.663 HG11 ' HB2' ' A' ' 96' ' ' ALA . 31.4 m -117.91 -32.95 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.247 -179.373 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.974 HD11 HG13 ' A' ' 65' ' ' VAL . 7.8 tt -161.47 153.51 19.61 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.284 0.564 . . . . 0.0 111.111 -179.268 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.511 HG23 HD11 ' A' ' 69' ' ' LEU . 21.3 t -107.01 137.3 38.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.911 179.504 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.573 HD12 HD11 ' A' ' 94' ' ' ILE . 15.3 mt -115.36 162.61 16.88 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.28 0.562 . . . . 0.0 110.782 -179.657 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.274 179.804 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 121.108 0.48 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 11.1 m -112.09 119.58 38.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.318 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -82.1 129.11 34.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.852 -179.587 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.573 HD11 HD12 ' A' ' 85' ' ' LEU . 39.0 mm -101.35 149.45 6.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.997 179.569 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 67.9 m-20 -139.2 134.34 32.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.161 0.505 . . . . 0.0 110.863 -179.665 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.663 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -63.13 110.46 3.56 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.946 179.363 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.764 ' HD2' HD12 ' A' ' 57' ' ' ILE . 40.6 Cg_endo -64.27 -15.13 47.85 Favored 'Trans proline' 0 N--CA 1.476 0.484 0 C-N-CA 122.182 1.921 . . . . 0.0 113.105 179.834 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 61.1 p -135.9 136.66 40.68 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-O 121.145 0.498 . . . . 0.0 110.425 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -64.02 163.31 12.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.468 -179.976 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 149.03 -155.93 26.58 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.5 ttmt -134.55 147.89 50.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.084 0.469 . . . . 0.0 110.506 -179.833 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.763 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.1 t -77.44 111.81 14.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.165 179.802 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -95.94 -27.59 15.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.987 -179.774 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -162.69 127.38 3.14 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.064 0.459 . . . . 0.0 110.453 -179.864 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.503 HG12 ' O ' ' A' ' 107' ' ' VAL . 21.5 t -102.62 112.5 36.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.307 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.5 mt -80.05 -31.44 39.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.503 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.503 ' O ' HG12 ' A' ' 105' ' ' VAL . 33.6 m -87.08 141.56 14.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.71 -179.918 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -128.39 171.54 11.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.438 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 109' ' ' GLU . . . . . 0.487 ' HG2' HD12 ' A' ' 68' ' ' ILE . 28.5 mt-10 -63.29 137.74 58.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.414 179.995 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.76 38.88 6.57 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.618 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -118.79 144.82 46.06 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.224 179.635 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.98 134.99 34.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.485 -179.955 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.7 m -122.32 179.9 2.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.319 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 114' ' ' GLN . . . . . 0.452 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 93.8 mt-30 -137.19 147.81 46.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.416 179.891 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.74 114.31 6.45 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.88 -30.37 9.14 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.928 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.4 tt0 -60.9 137.06 58.24 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.034 0.445 . . . . 0.0 110.567 -179.967 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.86 119.19 17.15 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 41.3 mt -88.92 -51.04 5.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.109 0.48 . . . . 0.0 110.378 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.478 ' CG2' HG13 ' A' ' 102' ' ' VAL . 53.5 mt -140.91 144.91 26.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 8.1 tttt -93.94 129.75 40.29 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.357 179.947 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 36.6 mm -106.44 148.82 10.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.426 -179.776 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.739 0 CA-C-O 118.015 -1.436 . . . . 0.0 110.85 -179.991 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 121.187 0.517 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.576 HD11 ' CG1' ' A' ' 122' ' ' ILE . 32.7 mt -80.11 119.93 78.09 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.138 179.756 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -72.19 139.47 32.44 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 122.0 1.8 . . . . 0.0 112.277 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.635 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -71.8 146.77 91.12 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.373 179.948 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -72.85 -27.14 14.91 Favored 'Trans proline' 0 N--CA 1.471 0.184 0 C-N-CA 122.227 1.951 . . . . 0.0 112.393 179.972 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.2 pp -162.18 174.58 12.71 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.394 -179.941 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -90.24 82.21 6.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.306 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -109.26 -144.47 10.63 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.7 m -136.99 138.8 40.92 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.062 0.458 . . . . 0.0 110.525 -179.943 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.775 HG13 HD21 ' A' ' 83' ' ' LEU . 25.7 t -70.95 124.18 26.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.077 179.897 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.3 t -101.9 -59.12 1.75 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.787 -179.7 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 tptt -149.81 138.79 21.08 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.738 -179.583 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 38.9 mt -95.92 135.52 29.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.965 179.532 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.651 HD13 ' HB ' ' A' ' 81' ' ' THR . 11.5 mt -100.91 -30.82 11.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.93 -179.556 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.691 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.3 m -108.49 149.81 11.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.144 0.497 . . . . 0.0 110.733 -179.854 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 12.6 ptpt -137.66 164.16 29.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.164 179.856 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.424 ' HG3' HG23 ' A' ' 105' ' ' VAL . 39.4 mt-10 -60.58 102.97 0.21 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.5 -179.985 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 138.55 -31.48 2.41 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 23.8 m-20 -88.18 147.6 24.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.108 0.48 . . . . 0.0 110.482 -179.946 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 19.6 m -95.52 142.93 27.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.303 179.914 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.691 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.4 m -119.42 156.63 21.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.53 -179.883 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.4 mptt -117.79 152.58 35.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.288 179.888 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.558 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.24 93.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.644 -179.916 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.23 -31.49 2.78 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 17.7 tt0 -62.42 141.96 58.1 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.078 0.466 . . . . 0.0 110.562 -179.98 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.651 ' HB ' HD13 ' A' ' 69' ' ' LEU . 3.9 m -68.12 138.84 56.03 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.212 179.819 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.53 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.4 m -121.07 -32.42 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.657 -179.243 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.775 HD21 HG13 ' A' ' 65' ' ' VAL . 1.5 tm? -160.34 136.74 8.76 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.863 -179.11 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.757 ' N ' HD22 ' A' ' 83' ' ' LEU . 20.1 t -102.3 136.35 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.459 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.502 HD23 ' HA ' ' A' ' 65' ' ' VAL . 88.4 mt -114.12 166.56 11.5 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.584 -179.874 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.316 179.899 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 . . . . . 0 C--O 1.232 0.137 0 CA-C-O 121.152 0.501 . . . . 0.0 110.526 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 23.9 m -117.44 112.64 20.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.353 179.983 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -80.64 132.97 35.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.765 -179.724 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.424 HG22 ' N ' ' A' ' 95' ' ' ASN . 35.7 mm -101.88 155.91 4.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.066 179.648 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.424 ' N ' HG22 ' A' ' 94' ' ' ILE . 2.1 p30 -136.84 149.34 47.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.568 179.959 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.71 139.8 97.06 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.242 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.65 -30.99 11.25 Favored 'Trans proline' 0 N--CA 1.472 0.226 0 C-N-CA 122.087 1.858 . . . . 0.0 112.197 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.558 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -147.07 163.61 35.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.313 179.943 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -68.17 141.94 55.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.352 179.969 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.48 -159.48 27.43 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 10.1 ttpt -133.36 143.71 49.14 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.045 0.45 . . . . 0.0 110.338 -179.849 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.678 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -75.72 111.71 12.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.224 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -92.75 -29.72 15.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.69 -179.85 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.5 ttpt -158.79 134.03 8.48 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.127 0.489 . . . . 0.0 110.575 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 107' ' ' VAL . 26.9 t -101.19 107.91 22.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.346 179.96 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.7 mt -80.07 -32.2 39.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.222 179.697 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.44 HG13 ' HA ' ' A' ' 119' ' ' LEU . 31.4 m -77.3 143.63 12.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.416 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 10.6 mmmt -135.05 151.86 51.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.156 179.81 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 16.4 mp0 -58.41 137.74 57.07 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.781 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 8.2 ttp-105 63.41 39.08 9.55 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.344 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.418 ' O ' HG23 ' A' ' 65' ' ' VAL . 5.0 t70 -125.09 144.63 50.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.289 179.815 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.79 140.13 30.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.558 -179.99 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.9 m -121.14 179.93 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.371 179.978 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 114' ' ' GLN . . . . . 0.448 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 9.3 mt-30 -141.06 146.86 37.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.412 179.976 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.23 103.4 0.53 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.03 -29.78 5.45 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 -179.889 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -61.61 138.51 58.3 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-O 121.066 0.46 . . . . 0.0 110.402 -179.971 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.62 118.46 14.81 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.919 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.635 HD11 ' HA ' ' A' ' 59' ' ' ALA . 64.5 mt -89.02 -54.73 3.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.017 0.436 . . . . 0.0 110.334 179.81 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.509 ' CG2' HG13 ' A' ' 102' ' ' VAL . 46.6 mt -142.79 147.02 21.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.321 179.796 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.2 mtpt -96.22 127.21 42.02 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.339 179.963 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.576 ' CG1' HD11 ' A' ' 57' ' ' ILE . 36.1 mm -109.17 145.03 16.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.552 -179.883 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 117.976 -1.458 . . . . 0.0 110.777 179.971 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 . . . . . 0 C--O 1.23 0.07 0 CA-C-O 121.08 0.467 . . . . 0.0 110.359 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.2 mt -79.64 111.36 20.54 Favored Pre-proline 0 CA--C 1.535 0.383 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.258 179.993 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -71.22 131.31 18.97 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 121.962 1.775 . . . . 0.0 112.302 -179.963 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.64 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -68.19 145.17 97.41 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.352 179.976 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.607 ' HG2' HD23 ' A' ' 61' ' ' LEU . 50.3 Cg_endo -73.34 -28.03 12.78 Favored 'Trans proline' 0 CA--C 1.528 0.222 0 C-N-CA 122.22 1.946 . . . . 0.0 112.276 -179.963 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.607 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.7 OUTLIER -159.59 162.87 35.39 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.357 179.971 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.35 113.81 21.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.332 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -137.75 -140.7 4.08 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -179.92 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 19.7 m -136.46 139.71 42.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.067 0.46 . . . . 0.0 110.435 179.988 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.716 HG13 HD11 ' A' ' 83' ' ' LEU . 22.3 t -71.09 126.59 31.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.999 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 8.2 t -101.24 -54.47 2.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.665 -179.828 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.2 tptm -157.2 140.27 15.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.602 -179.819 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.742 HG12 HD12 ' A' ' 83' ' ' LEU . 31.3 mt -94.38 140.26 16.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.995 179.719 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.481 HD13 ' HB ' ' A' ' 81' ' ' THR . 22.6 mt -104.84 -37.89 6.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.631 -179.793 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.771 HG11 ' CG1' ' A' ' 76' ' ' VAL . 33.1 m -110.88 148.12 14.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.801 -179.927 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -139.62 166.77 23.7 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.213 179.897 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -58.1 108.91 0.66 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.702 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.04 -31.4 2.81 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -93.19 151.38 19.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.061 0.458 . . . . 0.0 110.481 179.975 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 75' ' ' THR . . . . . 0.435 HG22 ' O ' ' A' ' 100' ' ' GLY . 1.2 m -100.68 148.65 24.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.238 179.879 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.771 ' CG1' HG11 ' A' ' 70' ' ' VAL . 31.6 m -124.99 165.96 21.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.58 -179.824 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.8 tppt? -124.78 153.91 41.74 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.251 179.894 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.617 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.43 97.97 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.541 -179.87 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.16 -36.64 2.11 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.904 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -62.88 139.46 58.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.496 . . . . 0.0 110.563 -179.959 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.481 ' HB ' HD13 ' A' ' 69' ' ' LEU . 6.9 m -67.07 141.87 57.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.282 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.743 HG22 ' O ' ' A' ' 94' ' ' ILE . 31.5 m -113.58 -27.04 2.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.225 -179.604 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.742 HD12 HG12 ' A' ' 68' ' ' ILE . 7.0 tt -168.4 150.99 5.3 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.177 0.513 . . . . 0.0 110.622 -179.619 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -102.83 135.98 37.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.955 179.622 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 1.0 HD12 HD11 ' A' ' 94' ' ' ILE . 17.8 mt -115.2 163.3 15.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.587 -179.681 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.267 179.972 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 121.14 0.495 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 19.6 m -121.01 125.91 48.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.418 -179.956 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -87.38 143.01 27.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.475 -179.96 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 1.0 HD11 HD12 ' A' ' 85' ' ' LEU . 38.7 mm -105.56 112.06 37.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.373 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -98.48 140.54 32.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.378 -179.945 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.41 142.38 96.27 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.341 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.24 -35.29 5.21 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.16 1.907 . . . . 0.0 112.357 179.95 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.617 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -146.8 162.34 38.79 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.337 -179.968 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -66.67 143.34 57.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.396 179.901 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 100' ' ' GLY . . . . . 0.435 ' O ' HG22 ' A' ' 75' ' ' THR . . . 173.43 -160.86 31.45 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.972 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 28.6 tttp -130.23 147.23 51.93 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.032 0.444 . . . . 0.0 110.526 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.566 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.3 t -75.67 109.12 8.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.293 179.898 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -93.93 -29.91 15.03 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.76 -179.892 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 29.8 tttt -157.47 128.09 6.49 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.163 0.506 . . . . 0.0 110.642 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.46 HG12 ' O ' ' A' ' 107' ' ' VAL . 29.0 t -102.59 102.45 13.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.224 179.824 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 12.5 mt -76.25 -32.22 58.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.213 179.716 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.633 HG21 HD13 ' A' ' 83' ' ' LEU . 34.8 m -77.86 142.01 14.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.632 -179.978 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.443 ' HA ' HD11 ' A' ' 68' ' ' ILE . 12.7 mmmt -139.82 158.45 44.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.994 179.676 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 109' ' ' GLU . . . . . 0.417 ' O ' ' HG3' ' A' ' 110' ' ' ARG . 13.7 mt-10 -55.81 161.72 2.08 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.976 -179.794 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 110' ' ' ARG . . . . . 0.417 ' HG3' ' O ' ' A' ' 109' ' ' GLU . 0.0 OUTLIER 37.18 41.24 0.21 Allowed 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.486 -179.737 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.692 ' O ' HG23 ' A' ' 65' ' ' VAL . 3.7 t70 -128.99 142.16 51.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.265 179.882 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -93.51 136.99 33.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.623 -179.781 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.1 m -118.8 161.29 17.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.312 179.781 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 -102.06 143.21 32.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.438 -179.998 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.2 108.66 2.02 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.962 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.14 -26.28 10.59 Favored Glycine 0 CA--C 1.528 0.859 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 -179.798 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -58.44 144.73 41.12 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-O 121.134 0.492 . . . . 0.0 110.787 -179.966 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.96 120.74 24.1 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.962 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.64 HD21 ' HB2' ' A' ' 59' ' ' ALA . 89.3 mt -88.01 -59.61 2.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.105 0.478 . . . . 0.0 110.453 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.475 ' CG2' HG13 ' A' ' 102' ' ' VAL . 55.0 mt -140.85 145.2 25.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.377 -179.988 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -91.4 121.56 33.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.167 179.797 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.2 mm -104.29 141.44 19.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.455 -179.957 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.75 0 CA-C-O 117.953 -1.471 . . . . 0.0 110.765 179.988 . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 . . . . . 0 N--CA 1.462 0.127 0 CA-C-O 121.212 0.53 . . . . 0.0 110.75 . . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 51.3 mt -81.03 117.1 66.63 Favored Pre-proline 0 CA--C 1.533 0.31 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.14 179.86 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -71.92 137.23 29.04 Favored 'Trans proline' 0 N--CA 1.472 0.228 0 C-N-CA 121.932 1.755 . . . . 0.0 112.315 -179.984 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.664 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -61.44 146.69 89.06 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.389 -179.879 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -72.13 -28.69 15.45 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.2 1.934 . . . . 0.0 112.263 179.928 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -165.32 166.9 18.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.41 -179.965 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.43 85.1 6.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.449 179.949 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.449 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -125.35 -160.94 10.86 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -179.93 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.3 m -114.41 140.62 48.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.122 0.487 . . . . 0.0 110.56 -179.969 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.92 HG13 HD11 ' A' ' 83' ' ' LEU . 29.6 t -64.94 127.67 26.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.194 179.908 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.3 -61.27 1.42 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.703 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.702 ' O ' HD12 ' A' ' 83' ' ' LEU . 40.6 mttt -149.97 145.68 26.59 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.11 0.481 . . . . 0.0 110.654 -179.812 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.5 mt -101.04 125.24 55.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.721 179.443 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.654 HD12 HG22 ' A' ' 81' ' ' THR . 19.8 mt -96.31 -31.21 13.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.979 -179.429 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.735 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.6 m -111.62 147.18 15.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.201 0.524 . . . . 0.0 110.732 -179.719 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.5 163.96 29.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.154 179.795 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.665 ' HG3' HG23 ' A' ' 105' ' ' VAL . 24.6 mt-10 -59.34 102.45 0.14 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.699 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.03 -30.31 2.37 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.974 -0.851 . . . . 0.0 110.974 179.969 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.84 150.91 20.3 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.175 0.512 . . . . 0.0 110.586 -179.866 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.5 m -96.02 148.14 22.97 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.297 179.931 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.673 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.8 m -119.13 166.3 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.513 -179.97 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 32.1 mmtm -128.88 147.84 50.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.24 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.61 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.81 90.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.779 -179.877 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.53 -31.34 2.6 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.827 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -64.1 141.15 58.87 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.171 0.51 . . . . 0.0 110.668 -179.769 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.654 HG22 HD12 ' A' ' 69' ' ' LEU . 6.4 m -65.97 137.01 56.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.082 179.788 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.477 HG12 HG11 ' A' ' 70' ' ' VAL . 31.1 m -121.68 -32.19 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.66 -179.318 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.92 HD11 HG13 ' A' ' 65' ' ' VAL . 16.3 tp -158.97 151.8 22.02 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.083 0.468 . . . . 0.0 110.816 -179.124 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.2 t -113.9 144.08 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.769 179.323 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.712 HD21 HG21 ' A' ' 113' ' ' VAL . 16.6 mt -120.62 158.81 26.58 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.168 0.509 . . . . 0.0 110.789 -179.64 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 . . . . . 0 C--N 1.331 -0.219 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.385 -179.916 . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 121.088 0.47 . . . . 0.0 110.363 . . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -123.33 113.24 18.58 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.406 179.968 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -79.5 139.31 37.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.601 -179.889 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.427 ' N ' HD12 ' A' ' 94' ' ' ILE . 5.1 mp -110.27 155.88 11.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.729 179.902 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.416 ' N ' HG22 ' A' ' 94' ' ' ILE . 11.3 m-80 -139.5 152.57 47.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.543 -179.918 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.16 139.75 96.1 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.305 180.0 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -73.77 -35.47 4.46 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.114 1.876 . . . . 0.0 112.153 179.977 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.61 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 24.0 p -144.96 163.17 34.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.343 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -65.28 140.87 58.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.337 179.859 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.34 -159.6 29.74 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.919 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 22.8 ttmt -135.21 148.76 49.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.078 0.466 . . . . 0.0 110.421 -179.901 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.735 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.4 t -78.16 110.4 13.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.197 179.929 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -92.97 -27.54 16.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.884 -179.931 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -157.35 130.82 7.92 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.093 0.473 . . . . 0.0 110.653 -179.773 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.665 HG23 ' HG3' ' A' ' 72' ' ' GLU . 42.7 t -101.32 102.98 14.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.132 179.806 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 14.0 mt -88.31 10.38 19.96 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.531 179.862 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.465 HG21 HD22 ' A' ' 83' ' ' LEU . 31.3 m -123.76 135.42 63.49 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.074 0 CA-C-O 121.177 0.513 . . . . 0.0 110.212 179.705 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 9.7 tttp -123.5 152.9 41.26 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.277 -179.943 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -59.98 146.29 43.07 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.598 -179.967 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 20.8 mtm180 61.02 34.19 19.39 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.505 -179.943 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -120.14 149.74 41.74 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.346 179.819 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.11 135.9 33.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.566 -179.981 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.712 HG21 HD21 ' A' ' 85' ' ' LEU . 27.4 m -121.71 -179.99 2.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.273 179.906 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 11.6 mp0 -138.55 144.7 40.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.423 -179.994 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.51 111.14 3.43 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.962 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 111.86 -28.77 9.06 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.88 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -59.49 135.89 57.81 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.075 0.464 . . . . 0.0 110.573 -179.899 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.25 116.1 8.85 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.946 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.664 HD11 ' HA ' ' A' ' 59' ' ' ALA . 71.8 mt -88.77 -54.58 4.08 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.017 0.436 . . . . 0.0 110.472 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.615 ' CG2' HG13 ' A' ' 102' ' ' VAL . 49.5 mt -142.7 145.0 23.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.391 -179.975 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 25.1 tttt -98.06 129.0 44.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.453 179.869 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.1 mm -103.54 145.54 12.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.475 -179.782 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.75 0 CA-C-O 118.016 -1.436 . . . . 0.0 110.753 179.891 . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 121.122 0.487 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.454 HD11 HD11 ' A' ' 122' ' ' ILE . 52.5 mt -78.89 112.45 27.45 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.156 179.937 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.09 141.62 40.27 Favored 'Trans proline' 0 N--CA 1.472 0.262 0 C-N-CA 122.115 1.877 . . . . 0.0 112.395 -179.932 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.851 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -79.2 148.59 71.38 Favored Pre-proline 0 CA--C 1.531 0.235 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.423 179.911 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.545 ' HG2' HD23 ' A' ' 61' ' ' LEU . 50.5 Cg_endo -72.2 -27.45 16.67 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.31 2.007 . . . . 0.0 112.365 -179.949 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.545 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.6 OUTLIER -158.61 171.08 20.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.321 179.968 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -91.07 83.43 5.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.415 179.998 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -109.7 -136.16 7.4 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.946 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.402 ' C ' HD23 ' A' ' 85' ' ' LEU . 2.0 m -139.08 138.55 37.2 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.173 0.511 . . . . 0.0 110.488 179.933 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.615 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -66.82 124.0 21.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.284 179.991 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.2 t -98.58 -60.31 1.57 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.478 -179.957 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.8 mttt -148.69 147.3 28.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.461 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.508 HG22 ' H ' ' A' ' 70' ' ' VAL . 24.0 mt -106.04 118.02 52.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.923 179.899 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.5 mt -95.12 21.79 7.41 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.385 -179.525 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.762 ' HB ' HG21 ' A' ' 102' ' ' VAL . 25.2 m -150.0 148.29 15.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 121.239 0.543 . . . . 0.0 110.524 179.812 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 12.0 mtpp -132.17 157.36 44.48 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.185 179.874 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.463 ' HG3' HG23 ' A' ' 105' ' ' VAL . 27.0 mt-10 -59.11 95.33 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.516 179.989 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.15 -30.41 2.35 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.777 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 59.8 m-20 -73.13 146.39 45.72 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.062 0.458 . . . . 0.0 110.319 179.963 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.4 m -98.45 127.68 44.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.423 179.928 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.686 HG11 HG11 ' A' ' 70' ' ' VAL . 22.7 m -112.56 151.79 14.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.409 179.971 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.5 mttp -112.99 149.05 33.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.324 179.908 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.685 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -57.98 95.56 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.803 -179.854 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.39 -33.92 2.24 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.4 tt0 -69.34 140.17 54.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.083 0.468 . . . . 0.0 110.481 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.6 m -60.43 137.82 58.09 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.488 179.905 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.583 ' O ' HG22 ' A' ' 70' ' ' VAL . 34.6 m -113.95 -33.65 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.947 -179.609 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 83' ' ' LEU . . . . . 0.615 HD11 HG13 ' A' ' 65' ' ' VAL . 7.9 tt -161.17 149.61 15.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.583 -179.558 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -104.46 140.69 21.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.183 179.836 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.791 HD12 HD11 ' A' ' 94' ' ' ILE . 3.6 mt -117.75 171.41 8.06 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.44 -179.848 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.422 179.994 . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 . . . . . 0 C--O 1.231 0.084 0 CA-C-O 121.094 0.473 . . . . 0.0 110.541 . . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.6 m -120.76 121.06 37.4 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.212 179.961 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -84.8 131.98 34.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.57 -179.894 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.791 HD11 HD12 ' A' ' 85' ' ' LEU . 38.8 mm -102.25 124.87 56.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.167 179.767 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -103.64 140.94 36.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.345 -179.934 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.464 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . . . -61.29 142.31 93.66 Favored Pre-proline 0 CA--C 1.532 0.26 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.403 -179.872 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.408 ' HD3' HG23 ' A' ' 57' ' ' ILE . 49.1 Cg_endo -72.77 -36.8 4.36 Favored 'Trans proline' 0 N--CA 1.471 0.194 0 C-N-CA 122.109 1.873 . . . . 0.0 112.352 -179.978 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.685 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 23.0 p -149.48 157.48 43.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.321 -179.989 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -63.53 140.85 58.91 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.358 179.91 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.81 -155.99 19.64 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.983 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 5.8 ttmt -136.93 142.23 42.68 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.143 0.497 . . . . 0.0 110.631 -179.931 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.762 HG21 ' HB ' ' A' ' 70' ' ' VAL . 31.3 t -74.12 112.17 10.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.246 179.9 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -96.11 -30.41 13.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.584 179.972 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 29.5 ttmt -158.97 133.77 8.14 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.468 179.954 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.463 HG23 ' HG3' ' A' ' 72' ' ' GLU . 21.1 t -99.93 109.2 24.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.237 -179.977 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.7 mt -90.12 30.34 1.11 Allowed 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.688 179.971 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.459 HG21 HD13 ' A' ' 83' ' ' LEU . 26.7 m -155.46 138.34 7.15 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-O 120.987 0.423 . . . . 0.0 110.261 -179.999 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 21.2 mttt -124.55 162.48 23.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.364 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 53.3 mt-10 -61.22 149.96 36.04 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.445 179.911 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 61.18 32.56 19.5 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.255 -179.803 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -120.18 148.42 43.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.378 179.9 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.47 140.58 29.61 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.472 -179.995 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.782 HG21 HD21 ' A' ' 85' ' ' LEU . 27.8 m -120.35 -179.99 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.5 -179.986 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 5.9 mm-40 -137.5 144.68 42.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.432 179.897 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.76 107.95 1.64 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.969 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.12 -27.96 9.7 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -60.64 137.14 58.21 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 121.199 0.523 . . . . 0.0 110.562 -179.85 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.96 119.19 17.73 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.968 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.851 HD21 ' HB2' ' A' ' 59' ' ' ALA . 59.5 mt -89.96 -49.75 6.42 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.091 0.472 . . . . 0.0 110.573 -179.873 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.494 HD13 HG21 ' A' ' 70' ' ' VAL . 47.8 mt -141.1 138.4 33.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.343 -179.918 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -91.13 130.22 37.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.394 179.887 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.454 HD11 HD11 ' A' ' 57' ' ' ILE . 38.4 mm -108.51 140.75 25.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.408 -179.996 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.834 0 CA-C-O 117.967 -1.463 . . . . 0.0 110.788 179.966 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 143.31 100.07 0.33 Allowed Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -117.61 156.28 28.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.107 0.48 . . . . 0.0 110.372 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 110.01 51.69 0.63 Allowed Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -171.05 151.66 3.31 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.073 0.463 . . . . 0.0 110.415 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.653 ' HB3' ' HB3' ' A' ' 58' ' ' PRO . . . -88.77 169.74 11.37 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.345 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 154.19 -32.97 0.72 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -90.32 52.27 2.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.308 0.575 . . . . 0.0 110.578 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 94.64 -22.47 37.42 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 120.899 -0.667 . . . . 0.0 111.551 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.636 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 13.8 mt-10 -76.54 139.09 40.59 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-O 121.145 0.498 . . . . 0.0 110.851 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 51.8 mt -81.7 111.45 26.12 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.242 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.653 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.9 Cg_endo -71.45 136.98 29.76 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.047 1.832 . . . . 0.0 112.305 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.772 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -72.18 147.17 90.48 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.516 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.89 -25.89 16.15 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.252 1.968 . . . . 0.0 112.464 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 pp -165.98 179.32 5.89 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.451 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.34 102.69 9.72 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.437 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.418 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -127.87 171.1 19.22 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.0 m -105.37 135.25 47.09 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.136 0.494 . . . . 0.0 110.416 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.611 HG23 ' O ' ' A' ' 111' ' ' ASP . 26.0 t -69.93 122.14 20.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.129 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -101.03 -54.42 2.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.576 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.3 ttpm? -151.66 145.85 25.37 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.487 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 3.4 mp -105.36 133.7 48.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.115 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.8 mp -98.15 -44.83 6.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.648 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.784 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.9 m -88.67 150.49 3.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.743 -179.708 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 3.5 ptpt -136.08 161.37 35.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.181 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -61.22 98.6 0.08 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.526 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -29.98 2.38 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.49 148.04 26.74 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.125 0.488 . . . . 0.0 110.578 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 24.5 m -95.2 142.17 27.95 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.192 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.708 HG11 HG11 ' A' ' 70' ' ' VAL . 23.8 m -120.19 163.73 17.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.638 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.1 mttp -123.04 147.47 46.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.153 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.659 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.11 92.9 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.693 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.2 -35.37 2.03 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -63.36 143.51 57.74 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.135 0.493 . . . . 0.0 110.614 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.7 m -66.87 137.2 56.4 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.219 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.514 ' HA ' HG13 ' A' ' 70' ' ' VAL . 30.7 m -115.17 -30.24 2.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.206 -179.51 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.62 HD13 HG21 ' A' ' 107' ' ' VAL . 9.0 tt -163.27 150.14 12.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.127 0.489 . . . . 0.0 110.855 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 t -102.13 130.59 51.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.998 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.446 HD12 ' CD1' ' A' ' 94' ' ' ILE . 9.6 mt -119.1 132.23 55.98 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.664 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -100.4 86.94 3.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.054 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -96.95 117.81 31.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.081 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 41.0 mtm 61.5 56.08 2.65 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.438 0.637 . . . . 0.0 109.487 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 17.5 pttp 43.79 40.17 2.96 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 115.033 -0.985 . . . . 0.0 111.449 -179.14 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.0 ttp -136.23 125.93 25.5 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.358 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -70.79 119.24 14.65 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.411 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.9 m -118.45 127.67 53.87 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.32 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -84.07 130.85 34.85 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.643 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.446 ' CD1' HD12 ' A' ' 85' ' ' LEU . 38.3 mm -104.94 116.22 48.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.124 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 82.5 m-20 -103.03 143.71 32.22 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.426 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.6 143.3 96.47 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.358 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -73.15 -37.65 3.28 Favored 'Trans proline' 0 CA--C 1.527 0.17 0 C-N-CA 122.072 1.848 . . . . 0.0 112.24 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.659 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 15.6 p -145.78 162.2 38.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.387 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -67.76 142.3 56.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.456 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.57 -157.25 27.52 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.1 ttmt -133.91 147.25 51.09 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.142 0.496 . . . . 0.0 110.544 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.784 HG21 ' HB ' ' A' ' 70' ' ' VAL . 35.2 t -75.32 107.26 5.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.301 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -93.39 -28.04 16.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.65 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -158.56 130.93 6.9 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.077 0.465 . . . . 0.0 110.396 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.427 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.4 t -97.96 109.39 23.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.31 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.2 mt -90.29 30.37 1.13 Allowed 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.641 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.62 HG21 HD13 ' A' ' 83' ' ' LEU . 25.6 m -155.47 137.47 6.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 121.073 0.463 . . . . 0.0 110.252 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 24.9 mmtt -128.9 167.01 18.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.385 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -62.27 147.61 47.53 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.426 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 11.0 mmp_? 60.69 32.32 20.26 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.598 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.611 ' O ' HG23 ' A' ' 65' ' ' VAL . 4.2 t70 -122.74 136.43 54.87 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.354 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.28 136.68 32.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.487 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 63' ' ' GLY . 30.5 m -119.18 150.73 21.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.394 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -98.15 149.28 22.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.449 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.92 117.3 11.16 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 105.84 -28.12 15.18 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 -59.57 138.33 57.74 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 121.041 0.448 . . . . 0.0 110.586 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.618 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -60.68 121.43 26.58 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.772 HD21 ' HB2' ' A' ' 59' ' ' ALA . 24.5 mt -88.92 -51.81 5.43 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.073 0.463 . . . . 0.0 110.404 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 48.4 mt -142.82 144.78 23.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.407 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -96.51 125.29 40.89 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.238 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.6 mm -106.06 143.87 16.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.536 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.772 0 CA-C-O 117.989 -1.45 . . . . 0.0 110.716 179.956 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 124.86 94.58 1.03 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -63.93 -37.13 86.29 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.05 0.452 . . . . 0.0 110.412 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.97 140.14 0.02 OUTLIER Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -99.24 40.73 1.19 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.256 0.55 . . . . 0.0 110.373 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.649 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -143.84 111.34 5.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.394 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -168.63 48.1 0.22 Allowed Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.3 tt0 -165.53 33.39 0.06 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.154 0.502 . . . . 0.0 110.397 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 122.83 -32.15 4.52 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -78.29 134.55 37.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.078 0.466 . . . . 0.0 110.481 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.507 HD11 HD11 ' A' ' 122' ' ' ILE . 28.5 mt -79.01 115.01 49.21 Favored Pre-proline 0 CA--C 1.535 0.386 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.006 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.551 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 46.8 Cg_endo -70.84 140.04 37.76 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 121.963 1.775 . . . . 0.0 112.329 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.67 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -75.25 146.53 81.74 Favored Pre-proline 0 CA--C 1.531 0.219 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.454 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.612 ' HG2' HD23 ' A' ' 61' ' ' LEU . 49.0 Cg_endo -72.71 -24.34 18.42 Favored 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 122.232 1.954 . . . . 0.0 112.47 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.612 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.7 OUTLIER -161.08 175.23 12.65 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.457 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -87.83 110.26 20.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.402 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.451 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -138.09 177.85 19.69 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 18.9 m -104.75 136.58 43.99 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.142 0.496 . . . . 0.0 110.481 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.859 HG13 HD11 ' A' ' 83' ' ' LEU . 32.0 t -70.28 117.83 13.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.25 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.8 p -99.61 -51.86 3.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.525 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.3 ptpt -151.73 145.28 24.9 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.528 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.704 HG12 HD12 ' A' ' 83' ' ' LEU . 10.7 mt -100.77 141.23 17.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.009 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.474 HD13 ' HA ' ' A' ' 69' ' ' LEU . 3.9 mm? -101.6 -30.44 11.37 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.109 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.717 HG11 ' CG1' ' A' ' 76' ' ' VAL . 34.5 m -124.91 133.65 68.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.244 0.545 . . . . 0.0 110.854 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.75 149.3 37.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.853 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.8 121.06 5.96 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.387 0.613 . . . . 0.0 111.108 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.17 -28.83 4.48 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.51 158.82 15.37 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-O 121.054 0.454 . . . . 0.0 110.425 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -97.91 141.22 31.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.428 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.717 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.2 m -123.83 158.31 29.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.485 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 32.3 mttm -117.68 157.83 25.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.35 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.615 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -62.42 106.84 0.82 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.515 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.3 -31.47 4.66 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 -62.77 140.62 58.76 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.125 0.488 . . . . 0.0 110.532 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 7.5 m -67.54 139.38 56.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.305 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CA ' HG22 ' A' ' 70' ' ' VAL . 29.4 m -114.43 -31.54 2.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.053 -179.606 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.859 HD11 HG13 ' A' ' 65' ' ' VAL . 8.5 tt -166.41 146.9 6.19 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.103 0.478 . . . . 0.0 110.841 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.1 t -103.08 135.88 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.131 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.877 HD12 HD11 ' A' ' 94' ' ' ILE . 51.9 mt -118.32 166.27 12.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.706 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -141.38 82.63 1.83 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.336 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.41 ' HB2' ' CA ' ' A' ' 63' ' ' GLY . . . -97.11 120.52 37.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.457 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 22.4 mmt 62.35 43.11 8.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.413 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.5 mttp 59.81 38.52 21.39 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.628 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 82.8 mtp -131.71 110.54 10.96 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.459 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 21.5 mt-10 -66.08 109.14 2.47 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.433 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.0 m -117.45 109.04 16.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.276 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -77.97 140.64 39.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.604 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.877 HD11 HD12 ' A' ' 85' ' ' LEU . 37.2 mm -103.68 140.67 21.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.057 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 38.3 m-20 -128.76 143.48 50.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.665 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.25 138.62 96.18 Favored Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.259 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.99 -31.86 11.87 Favored 'Trans proline' 0 N--CA 1.472 0.209 0 C-N-CA 122.09 1.86 . . . . 0.0 112.416 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.615 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 40.9 p -147.17 164.95 31.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.483 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -66.42 143.61 57.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.399 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.48 -160.43 27.98 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -135.02 136.87 42.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.139 0.495 . . . . 0.0 110.431 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.633 HG13 ' CG2' ' A' ' 120' ' ' ILE . 4.2 t -73.16 107.26 3.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.86 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -87.68 -29.39 21.17 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.001 -179.583 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 13.7 tttt -163.95 138.13 5.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.407 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 107' ' ' VAL . 21.6 t -107.92 110.49 32.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.416 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.8 mt -79.24 -31.59 43.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.394 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.571 HG21 HD13 ' A' ' 83' ' ' LEU . 27.3 m -82.56 142.84 13.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.501 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 54.2 mttt -136.47 163.11 31.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.246 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -60.79 147.29 43.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.519 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 5.5 tpt180 61.13 35.45 18.58 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.479 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.569 ' O ' HG23 ' A' ' 65' ' ' VAL . 8.0 t0 -127.98 140.32 52.05 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.388 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.51 136.24 33.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.517 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 63' ' ' GLY . 26.0 m -120.24 152.06 23.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.341 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -97.36 140.19 32.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.501 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.7 87.92 0.04 OUTLIER Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 137.54 -28.08 2.79 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -61.59 146.93 47.3 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.157 0.503 . . . . 0.0 110.515 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.649 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.56 118.87 16.16 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.67 HD21 ' HB2' ' A' ' 59' ' ' ALA . 71.8 mt -87.14 -53.15 5.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.082 0.468 . . . . 0.0 110.485 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.633 ' CG2' HG13 ' A' ' 102' ' ' VAL . 55.5 mt -140.9 151.59 20.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.477 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -97.22 133.99 41.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.209 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.507 HD11 HD11 ' A' ' 57' ' ' ILE . 35.9 mm -114.25 145.18 20.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.438 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.781 0 CA-C-O 118.011 -1.438 . . . . 0.0 110.774 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -159.28 110.78 0.46 Allowed Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -149.75 37.31 0.72 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.28 0.562 . . . . 0.0 110.379 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.85 148.38 45.57 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 39.8 tttm -130.18 159.43 36.85 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.146 0.498 . . . . 0.0 110.394 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.767 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -109.1 179.12 4.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.474 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 151.72 -46.09 0.6 Allowed Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -112.77 96.2 5.84 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.116 0.484 . . . . 0.0 110.513 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 93.79 -52.66 2.3 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.702 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 0.6 OUTLIER -82.31 134.8 35.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.998 0.428 . . . . 0.0 110.499 179.991 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.772 HD12 ' HD2' ' A' ' 97' ' ' PRO . 46.1 mm -80.22 120.6 80.07 Favored Pre-proline 0 CA--C 1.536 0.431 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.923 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.576 ' CA ' ' HB3' ' A' ' 52' ' ' ALA . 47.9 Cg_endo -72.05 128.0 13.47 Favored 'Trans proline' 0 N--CA 1.472 0.222 0 C-N-CA 121.892 1.728 . . . . 0.0 112.1 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.443 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -61.05 142.12 93.22 Favored Pre-proline 0 CA--C 1.532 0.28 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.471 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -73.62 -27.54 12.73 Favored 'Trans proline' 0 CA--C 1.528 0.188 0 C-N-CA 122.181 1.921 . . . . 0.0 112.374 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -161.33 159.92 29.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.472 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.59 125.39 30.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.402 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -159.06 -140.22 2.86 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.621 ' C ' HD23 ' A' ' 85' ' ' LEU . 14.8 m -136.56 139.13 41.96 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.082 0.468 . . . . 0.0 110.406 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.771 HG13 HD11 ' A' ' 83' ' ' LEU . 27.9 t -70.71 124.61 27.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.208 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.0 t -98.42 -54.23 3.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.675 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -153.67 145.02 23.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.529 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.704 HG12 HD12 ' A' ' 83' ' ' LEU . 35.7 mt -99.65 135.16 36.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.118 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.546 HD13 ' HB ' ' A' ' 81' ' ' THR . 12.3 mt -98.48 -44.13 6.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.617 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.689 HG11 ' CG1' ' A' ' 76' ' ' VAL . 34.6 m -98.83 144.69 11.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.502 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 46.1 pttt -137.3 164.28 28.94 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.206 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -57.05 102.29 0.08 Allowed 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.692 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.13 -31.97 2.22 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -90.15 152.94 20.88 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.062 0.458 . . . . 0.0 110.387 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -98.84 146.79 25.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.474 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.689 ' CG1' HG11 ' A' ' 70' ' ' VAL . 28.4 m -121.47 162.44 20.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.344 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -127.29 156.85 41.27 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.488 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.34 90.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.55 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.65 -30.36 3.0 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 16.3 tt0 -61.88 143.32 56.56 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.077 0.465 . . . . 0.0 110.672 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.546 ' HB ' HD13 ' A' ' 69' ' ' LEU . 1.9 m -68.9 138.97 55.1 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.148 179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.529 ' HA ' HG13 ' A' ' 70' ' ' VAL . 28.4 m -117.63 -33.86 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.35 -179.423 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.771 HD11 HG13 ' A' ' 65' ' ' VAL . 7.6 tt -161.52 153.15 19.02 Favored 'General case' 0 C--N 1.332 -0.175 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.167 -179.303 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.4 t -107.55 138.4 33.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.923 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.678 HD21 ' CG2' ' A' ' 113' ' ' VAL . 0.9 OUTLIER -120.26 168.53 11.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.191 0.52 . . . . 0.0 110.457 -179.808 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -133.6 115.38 14.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.357 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.52 142.82 25.17 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.509 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 56.8 mtp 60.36 32.71 20.74 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.6 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.4 33.04 20.76 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.55 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 14.8 ttm -146.69 120.51 9.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.441 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -66.0 128.1 34.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.613 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.2 m -114.4 122.34 46.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.232 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -82.52 130.22 35.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.62 -179.747 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.501 HG13 HD12 ' A' ' 85' ' ' LEU . 25.7 mm -103.19 147.45 9.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.011 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -139.27 142.38 37.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.152 0.501 . . . . 0.0 110.779 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.518 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -62.65 109.76 2.72 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.291 179.665 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.772 ' HD2' HD12 ' A' ' 57' ' ' ILE . 41.9 Cg_endo -64.93 -13.77 41.46 Favored 'Trans proline' 0 N--CA 1.476 0.46 0 C-N-CA 122.148 1.899 . . . . 0.0 112.885 179.643 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -135.94 135.96 40.04 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.097 0.475 . . . . 0.0 110.359 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -63.36 151.29 41.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.422 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 159.36 -154.66 25.73 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.0 ttmt -135.69 148.03 48.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.141 0.496 . . . . 0.0 110.448 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.653 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -75.69 111.26 11.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.208 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -95.21 -30.07 14.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.784 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.7 ttpt -162.01 130.17 4.13 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.569 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.494 HG13 HG12 ' A' ' 120' ' ' ILE . 22.0 t -103.57 113.89 41.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.295 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.0 mt -81.59 -37.17 28.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.374 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.526 HG21 HD13 ' A' ' 83' ' ' LEU . 32.9 m -77.44 147.45 7.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.574 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -133.49 163.68 28.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.075 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -62.71 138.55 58.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.394 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER 67.2 37.16 3.76 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.564 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.41 151.07 40.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.278 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -95.61 133.46 39.63 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.513 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.678 ' CG2' HD21 ' A' ' 85' ' ' LEU . 31.4 m -120.8 179.8 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.356 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 81.7 mm-40 -136.05 147.67 48.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.425 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.32 113.07 5.31 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 111.18 -30.78 7.69 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -60.18 140.33 57.02 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.138 0.494 . . . . 0.0 110.675 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.767 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.49 120.49 22.72 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.443 HD21 ' HB2' ' A' ' 59' ' ' ALA . 91.6 mt -87.06 -53.59 4.79 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.103 0.478 . . . . 0.0 110.423 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.562 ' CG2' HG13 ' A' ' 102' ' ' VAL . 52.3 mt -141.32 151.82 19.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.326 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 39.1 mttt -93.76 128.19 39.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.382 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.437 HD12 HG21 ' A' ' 76' ' ' VAL . 37.1 mm -109.87 145.76 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.37 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.748 0 CA-C-O 117.991 -1.449 . . . . 0.0 110.728 179.925 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 144.79 -40.99 1.11 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -117.45 -70.1 0.81 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.033 0.444 . . . . 0.0 110.359 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -96.55 -160.22 32.1 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -163.71 40.37 0.09 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.266 0.555 . . . . 0.0 110.27 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.776 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -154.84 178.31 10.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.334 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 138.44 -45.84 1.02 Allowed Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -105.38 80.69 1.61 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.259 0.552 . . . . 0.0 110.495 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.99 -48.4 1.01 Allowed Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.724 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 6.8 mt-10 -83.69 128.94 34.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.067 0.46 . . . . 0.0 110.503 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.457 HD11 HD11 ' A' ' 122' ' ' ILE . 45.7 mt -78.9 111.45 19.86 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.127 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.6 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 46.2 Cg_endo -70.38 142.42 45.17 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.099 1.866 . . . . 0.0 112.465 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.511 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -77.67 148.53 76.51 Favored Pre-proline 0 CA--C 1.531 0.24 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.521 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -73.11 -26.66 14.71 Favored 'Trans proline' 0 CA--C 1.528 0.212 0 C-N-CA 122.206 1.937 . . . . 0.0 112.461 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -164.63 156.98 16.37 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.472 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.0 121.92 19.07 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.423 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -150.96 -145.17 4.07 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.7 m -136.97 139.02 41.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.138 0.494 . . . . 0.0 110.413 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.629 HG13 HD11 ' A' ' 83' ' ' LEU . 25.2 t -71.98 126.23 32.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.181 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 32.7 t -96.03 -53.41 3.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.655 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.32 150.55 31.62 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.178 0.513 . . . . 0.0 110.74 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.485 HD11 ' HA ' ' A' ' 108' ' ' LYS . 32.8 mt -105.87 116.48 49.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.051 179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 64.2 mt -98.75 13.78 31.05 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.622 -179.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.756 ' HB ' HG21 ' A' ' 102' ' ' VAL . 28.4 m -148.22 133.56 11.0 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 CA-C-O 121.122 0.486 . . . . 0.0 110.691 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -116.86 161.2 19.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.195 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.21 95.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.621 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.22 -35.79 1.86 Allowed Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.52 146.77 47.59 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.093 0.473 . . . . 0.0 110.481 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -96.67 137.51 35.63 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.578 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 18.8 m -126.91 166.76 22.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.395 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -130.3 157.23 43.11 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.309 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.703 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -62.39 88.62 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.401 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.15 -33.51 2.08 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -63.15 145.66 55.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.145 0.498 . . . . 0.0 110.451 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.1 m -67.33 139.57 57.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.425 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.595 ' O ' HG22 ' A' ' 70' ' ' VAL . 28.1 m -120.14 -35.49 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.17 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.629 HD11 HG13 ' A' ' 65' ' ' VAL . 7.6 tt -162.05 152.71 17.45 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.261 0.553 . . . . 0.0 111.032 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.9 t -103.54 145.1 13.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.794 179.499 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.815 HD12 HD11 ' A' ' 94' ' ' ILE . 11.1 mt -126.67 160.3 31.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.52 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -131.13 114.37 15.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.423 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.57 140.6 22.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.299 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 34.3 mtt 60.91 32.01 20.0 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.572 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 33.3 mtmt 59.61 31.99 21.27 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.702 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 6.9 mtt -139.82 121.1 14.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.509 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -64.01 127.66 32.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.196 179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.3 m -118.75 117.58 29.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.393 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -83.04 133.82 35.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.457 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.815 HD11 HD12 ' A' ' 85' ' ' LEU . 33.7 mm -103.71 152.78 6.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.172 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 47.6 m-80 -139.88 148.08 41.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.495 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.89 139.18 95.66 Favored Pre-proline 0 CA--C 1.533 0.316 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.399 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -76.02 -28.65 7.38 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.128 1.886 . . . . 0.0 112.387 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.703 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 3.7 p -145.63 168.27 21.06 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.535 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -69.57 141.71 53.73 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.514 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 159.78 -168.16 35.48 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -129.13 168.4 16.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.229 0.538 . . . . 0.0 110.637 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.756 HG21 ' HB ' ' A' ' 70' ' ' VAL . 27.4 t -82.4 111.56 18.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.439 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -92.95 -30.13 15.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.42 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 4.9 tmtt? -159.05 128.77 5.62 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.275 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.429 HG22 HG11 ' A' ' 102' ' ' VAL . 20.7 t -101.3 105.73 18.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.117 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.0 mt -85.84 9.45 16.66 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.863 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.479 HG21 HD13 ' A' ' 83' ' ' LEU . 28.4 m -129.33 146.0 34.89 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-O 121.192 0.52 . . . . 0.0 110.629 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.485 ' HA ' HD11 ' A' ' 68' ' ' ILE . 20.5 mtpt -128.39 166.5 18.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.263 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -63.49 140.89 58.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.323 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 17.7 mmt85 65.83 36.71 5.96 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.67 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.504 ' O ' HG23 ' A' ' 65' ' ' VAL . 1.8 m-20 -121.89 137.44 54.78 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.272 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.2 134.21 34.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.521 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.2 m -120.72 156.96 23.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.367 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -97.51 144.12 27.53 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.393 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.3 108.05 1.62 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.96 -27.06 9.41 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.05 -0.82 . . . . 0.0 111.05 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 24.1 tt0 -59.83 143.52 50.96 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-O 121.126 0.489 . . . . 0.0 110.631 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.776 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.63 119.84 19.93 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.511 HD21 ' HB2' ' A' ' 59' ' ' ALA . 70.6 mt -89.67 -52.82 4.81 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.136 0.493 . . . . 0.0 110.172 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.484 ' CG2' HG13 ' A' ' 102' ' ' VAL . 46.3 mt -145.21 144.14 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.16 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 9.3 tttt -94.99 135.48 36.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.143 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.457 HD11 HD11 ' A' ' 57' ' ' ILE . 40.8 mm -109.2 142.69 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.412 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.815 0 CA-C-O 118.061 -1.41 . . . . 0.0 110.833 -179.919 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.26 174.06 15.25 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.94 -36.67 19.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.17 0.51 . . . . 0.0 110.492 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 68.8 -134.56 27.82 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 63.8 mttt -132.21 40.88 3.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.325 0.584 . . . . 0.0 110.471 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.741 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -148.72 176.69 10.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.456 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.44 -35.8 2.96 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -92.23 52.01 1.88 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.409 0.624 . . . . 0.0 110.437 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 114.76 -40.02 2.6 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.637 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 7.6 mm-40 -85.35 136.56 33.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.09 0.471 . . . . 0.0 110.42 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.487 HD11 HD11 ' A' ' 122' ' ' ILE . 48.5 mt -78.29 118.79 74.39 Favored Pre-proline 0 CA--C 1.535 0.39 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.185 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.498 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 48.4 Cg_endo -71.53 135.33 26.14 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 121.98 1.787 . . . . 0.0 112.331 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.764 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -65.52 148.4 98.1 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.456 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.79 -34.73 6.48 Favored 'Trans proline' 0 N--CA 1.472 0.224 0 C-N-CA 122.276 1.984 . . . . 0.0 112.236 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -162.67 159.06 23.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.411 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.77 81.91 0.19 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.288 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.411 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -115.01 -172.79 17.5 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.9 m -109.89 136.7 48.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.061 0.458 . . . . 0.0 110.388 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.507 HG13 HD21 ' A' ' 83' ' ' LEU . 24.3 t -71.73 117.02 14.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.094 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.8 t -92.93 -49.99 5.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.679 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -155.37 148.35 24.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.246 0.546 . . . . 0.0 110.608 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.422 HG22 ' O ' ' A' ' 70' ' ' VAL . 48.5 mt -103.37 130.15 54.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.95 179.696 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.588 HD11 HG23 ' A' ' 84' ' ' VAL . 5.7 mp -94.29 -30.72 14.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.854 -179.599 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.69 HG11 ' CG1' ' A' ' 76' ' ' VAL . 31.0 m -114.72 145.77 20.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.112 0.482 . . . . 0.0 110.728 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -138.88 166.87 23.32 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.331 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -56.96 104.95 0.18 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.839 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 132.1 -31.02 3.1 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -87.35 144.49 26.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.108 0.48 . . . . 0.0 110.57 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.2 m -93.51 150.45 20.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.293 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.69 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.9 m -125.14 166.9 20.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.568 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -129.48 147.51 51.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.204 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.463 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.52 92.02 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.629 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.17 -30.55 2.62 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.6 tt0 -69.25 143.04 54.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.107 0.479 . . . . 0.0 110.618 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.446 ' HB ' HD22 ' A' ' 69' ' ' LEU . 27.1 m -65.02 138.21 58.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.206 179.784 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.694 HG22 ' O ' ' A' ' 94' ' ' ILE . 29.6 m -115.7 -26.38 2.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.449 -179.494 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.507 HD21 HG13 ' A' ' 65' ' ' VAL . 9.1 tt -165.26 150.02 9.0 Favored 'General case' 0 C--N 1.332 -0.166 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.966 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.588 HG23 HD11 ' A' ' 69' ' ' LEU . 22.0 t -106.74 137.91 35.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.017 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.46 HD23 ' HA ' ' A' ' 85' ' ' LEU . 11.8 mt -115.66 164.75 13.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.184 0.516 . . . . 0.0 110.595 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -135.1 101.07 4.75 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.363 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -147.11 150.94 36.0 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.445 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 67.4 mtt 60.17 29.4 18.97 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.872 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 35.0 mtpt 59.46 31.76 21.26 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.886 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.1 ptp -146.16 139.49 25.96 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.461 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -76.91 125.98 30.21 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.55 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.7 m -122.02 112.61 18.48 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.233 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.443 ' HG3' HG22 ' A' ' 84' ' ' VAL . 1.7 mp0 -87.4 143.0 27.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.487 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.694 ' O ' HG22 ' A' ' 82' ' ' VAL . 4.8 mp -116.52 126.24 73.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.123 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -101.07 153.95 19.13 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.261 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.06 141.37 95.77 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.325 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.26 -32.72 7.98 Favored 'Trans proline' 0 N--CA 1.472 0.208 0 C-N-CA 122.133 1.889 . . . . 0.0 112.212 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.463 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 73.1 p -148.16 155.92 41.97 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.348 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -63.73 142.85 58.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.393 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 169.34 -156.38 27.43 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -134.35 150.97 50.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.092 0.472 . . . . 0.0 110.372 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.656 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -78.3 111.03 14.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.276 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -93.55 -30.94 14.74 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.646 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.61 151.74 27.88 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.221 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.495 HG13 HG12 ' A' ' 120' ' ' ILE . 21.9 t -131.95 113.26 21.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.304 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.49 HD11 ' OE2' ' A' ' 56' ' ' GLU . 2.1 mt -84.63 -33.07 23.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.348 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.417 ' O ' HG12 ' A' ' 105' ' ' VAL . 32.7 m -80.46 144.24 11.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.585 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -133.36 164.19 27.67 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.247 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 -61.28 144.35 54.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.458 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 2.5 ttt-85 61.48 35.02 17.78 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.44 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.459 ' O ' HG23 ' A' ' 65' ' ' VAL . 17.2 t0 -124.62 148.04 48.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.428 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.3 141.33 28.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.469 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 63' ' ' GLY . 30.8 m -122.41 156.18 27.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.379 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -100.58 140.18 35.21 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.346 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.51 98.97 0.16 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.3 -27.55 6.32 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.7 tt0 -59.56 142.63 52.28 Favored 'General case' 0 N--CA 1.462 0.127 0 CA-C-O 121.062 0.458 . . . . 0.0 110.656 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.741 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -62.26 121.64 26.03 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.761 -0.935 . . . . 0.0 110.761 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.764 HD21 ' HB2' ' A' ' 59' ' ' ALA . 79.6 mt -87.78 -54.46 4.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.075 0.464 . . . . 0.0 110.394 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.581 ' CG2' HG13 ' A' ' 102' ' ' VAL . 52.9 mt -141.24 149.39 20.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.312 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 14.8 tttp -98.14 126.75 43.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.343 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.487 HD11 HD11 ' A' ' 57' ' ' ILE . 36.7 mm -102.62 145.68 11.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.331 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.689 0 CA-C-O 117.988 -1.451 . . . . 0.0 110.784 179.967 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -76.77 -91.19 0.25 Allowed Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -121.2 -59.03 1.75 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.164 0.506 . . . . 0.0 110.494 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 98.94 131.87 7.46 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.804 -0.919 . . . . 0.0 110.804 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 17.2 pttt -150.41 151.45 32.81 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.133 0.492 . . . . 0.0 110.474 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.512 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -61.63 173.09 1.04 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.284 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -178.89 -50.71 0.08 OUTLIER Glycine 0 CA--C 1.526 0.738 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.308 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -61.92 -82.37 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.027 0.441 . . . . 0.0 110.709 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -137.64 19.2 3.36 Favored Glycine 0 CA--C 1.528 0.862 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.586 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.494 ' HB2' ' HB1' ' A' ' 52' ' ' ALA . 44.8 mt-10 -92.16 139.41 30.65 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 121.132 0.492 . . . . 0.0 110.3 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.44 HD11 HD11 ' A' ' 122' ' ' ILE . 54.5 mt -78.04 113.67 35.27 Favored Pre-proline 0 CA--C 1.535 0.395 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.068 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.08 132.71 23.37 Favored 'Trans proline' 0 N--CA 1.472 0.249 0 C-N-CA 122.08 1.853 . . . . 0.0 112.297 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.503 ' HB3' ' O ' ' A' ' 114' ' ' GLN . . . -65.94 147.97 98.54 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.584 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.681 ' HB2' HD23 ' A' ' 61' ' ' LEU . 49.6 Cg_endo -73.33 -29.01 11.77 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.256 1.971 . . . . 0.0 112.314 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.681 HD23 ' HB2' ' A' ' 60' ' ' PRO . 0.2 OUTLIER -163.81 -179.85 6.61 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.528 179.83 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.19 98.45 9.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.42 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.57 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -132.76 -177.55 14.99 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.3 m -113.63 141.27 47.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.132 0.492 . . . . 0.0 110.418 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.706 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -70.89 126.02 30.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.293 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.1 t -100.65 -52.28 3.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.58 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 7.2 ttmm -150.52 148.56 28.85 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.654 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.422 HD11 ' HA ' ' A' ' 108' ' ' LYS . 44.8 mt -102.66 131.71 50.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.019 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.9 mt -99.79 -36.37 9.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.786 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.739 HG11 ' CG1' ' A' ' 76' ' ' VAL . 33.6 m -110.47 146.92 15.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 121.172 0.511 . . . . 0.0 110.835 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.3 pttt -137.3 165.6 25.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.182 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.485 ' HG3' HG23 ' A' ' 105' ' ' VAL . 36.8 mt-10 -58.42 101.74 0.09 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.606 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.07 -32.6 2.17 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -88.54 146.28 25.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.129 0.49 . . . . 0.0 110.392 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.507 HG22 ' O ' ' A' ' 100' ' ' GLY . 0.8 OUTLIER -96.28 148.33 22.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.32 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.739 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.9 m -125.77 169.79 16.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.52 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 43.6 tttt -132.37 153.97 50.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.31 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.656 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.94 97.97 0.07 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.595 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.27 -36.75 2.19 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 14.9 tt0 -62.49 139.08 58.59 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.056 0.455 . . . . 0.0 110.67 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.6 m -65.86 137.11 56.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.206 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.472 ' HA ' HG13 ' A' ' 70' ' ' VAL . 24.3 m -115.67 -31.39 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.229 -179.502 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.706 HD11 HG13 ' A' ' 65' ' ' VAL . 7.5 tt -161.35 153.0 19.18 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.177 0.513 . . . . 0.0 110.86 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -101.35 140.55 19.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.038 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.653 HD12 HD11 ' A' ' 94' ' ' ILE . 12.5 mt -122.78 139.24 54.21 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.161 0.505 . . . . 0.0 110.643 -179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -102.69 107.74 18.74 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.373 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.1 149.47 31.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.476 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 24.4 mmm 60.38 31.07 20.28 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.686 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 38.6 mmtt 59.11 29.28 18.8 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.901 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 20.0 ptp -145.34 161.17 40.27 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.477 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -86.24 127.67 34.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.507 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.6 m -113.5 123.36 49.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.312 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -84.64 130.65 34.69 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.523 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.653 HD11 HD12 ' A' ' 85' ' ' LEU . 35.6 mm -106.23 114.9 46.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.184 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -102.11 146.91 27.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.289 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.09 141.53 95.79 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.322 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.62 -34.78 6.77 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.077 1.852 . . . . 0.0 112.211 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.656 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 17.4 p -147.85 162.57 38.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.271 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -68.19 141.18 56.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.328 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.507 ' O ' HG22 ' A' ' 75' ' ' THR . . . 171.47 -158.34 29.4 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 5.6 ttpm? -132.95 149.7 52.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.976 0.417 . . . . 0.0 110.336 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.66 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -75.99 110.16 10.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.21 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -92.77 -29.97 15.74 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.582 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 27.6 tttm -159.2 129.65 5.85 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.157 0.503 . . . . 0.0 110.486 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.485 HG23 ' HG3' ' A' ' 72' ' ' GLU . 33.2 t -100.19 102.84 13.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.168 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.2 mt -85.24 6.38 26.29 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.64 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.647 HG21 HD13 ' A' ' 83' ' ' LEU . 26.7 m -120.89 136.23 58.54 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.109 0 CA-C-O 121.181 0.515 . . . . 0.0 110.312 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.422 ' HA ' HD11 ' A' ' 68' ' ' ILE . 83.3 mttt -126.23 164.41 21.04 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.313 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -62.1 145.33 53.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.38 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 36.6 mtt180 60.13 35.6 21.18 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.588 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -114.64 141.68 47.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.373 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.61 129.27 38.59 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.572 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.57 HG22 ' O ' ' A' ' 63' ' ' GLY . 27.5 m -119.09 179.7 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.259 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLN . . . . . 0.503 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 64.3 mt-30 -140.68 152.45 45.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.512 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.82 105.09 0.83 Allowed Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.9 -31.39 4.97 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -60.05 135.32 57.68 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.131 0.491 . . . . 0.0 110.541 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.512 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -60.81 121.07 25.4 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.492 ' O ' HG13 ' A' ' 107' ' ' VAL . 62.3 mt -87.36 -56.51 3.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.012 0.434 . . . . 0.0 110.296 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.542 ' CG2' HG13 ' A' ' 102' ' ' VAL . 49.1 mt -143.15 150.89 17.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.126 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -96.2 125.7 40.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.265 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.44 HD11 HD11 ' A' ' 57' ' ' ILE . 37.8 mm -106.46 143.36 17.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.516 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.697 0 CA-C-O 117.951 -1.471 . . . . 0.0 110.767 179.977 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -78.19 73.18 2.21 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -131.42 104.29 6.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.135 0.493 . . . . 0.0 110.41 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -179.59 -68.64 0.07 OUTLIER Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -147.35 132.15 17.99 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.07 0.462 . . . . 0.0 110.416 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.662 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -64.59 178.81 0.7 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.416 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -167.6 -69.62 0.03 OUTLIER Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -127.06 114.13 17.35 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.023 0.44 . . . . 0.0 110.378 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 106.69 -52.65 0.66 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -83.34 134.64 34.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.026 0.441 . . . . 0.0 110.38 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.465 HG23 ' HD3' ' A' ' 97' ' ' PRO . 54.3 mt -82.11 111.06 24.26 Favored Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.282 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.449 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 48.1 Cg_endo -71.57 142.67 40.71 Favored 'Trans proline' 0 N--CA 1.472 0.263 0 C-N-CA 122.0 1.8 . . . . 0.0 112.295 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.483 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -74.7 147.14 84.15 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.397 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -72.49 -26.51 16.77 Favored 'Trans proline' 0 N--CA 1.471 0.199 0 C-N-CA 122.182 1.921 . . . . 0.0 112.366 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -164.55 157.57 17.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.362 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.502 ' HB2' ' H ' ' A' ' 115' ' ' GLY . . . -73.52 97.15 2.53 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.43 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.86 -144.55 6.22 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 3.9 m -136.54 132.18 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.095 0.474 . . . . 0.0 110.358 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.635 ' CG1' HD11 ' A' ' 83' ' ' LEU . 21.8 t -67.71 130.5 33.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.254 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 4.8 p -101.6 -53.98 2.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.542 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 23.8 ttpt -152.82 147.26 25.82 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.588 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.556 HG12 HD12 ' A' ' 83' ' ' LEU . 47.3 mt -100.23 133.48 43.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.116 179.761 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.425 HD12 HG22 ' A' ' 81' ' ' THR . 25.7 mt -98.64 -31.3 12.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.638 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.786 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.0 m -104.51 149.95 7.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.701 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 67.7 mttt -137.19 163.43 30.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.206 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -62.36 97.0 0.08 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.258 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.19 -29.19 2.43 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -85.43 147.82 26.3 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.082 0.467 . . . . 0.0 110.442 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.442 HG22 ' O ' ' A' ' 100' ' ' GLY . 0.7 OUTLIER -96.88 150.21 20.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.147 179.878 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.756 HG11 HG11 ' A' ' 70' ' ' VAL . 31.6 m -128.54 170.02 18.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.653 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.5 mmtt -131.38 146.26 52.2 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.22 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.707 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -58.84 96.51 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.717 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.16 -34.5 2.3 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 23.6 tt0 -67.84 144.46 55.3 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.14 0.495 . . . . 0.0 110.515 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.425 HG22 HD12 ' A' ' 69' ' ' LEU . 3.5 m -65.13 136.73 57.05 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.315 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.457 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.3 m -112.73 -33.09 2.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.921 -179.674 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.635 HD11 ' CG1' ' A' ' 65' ' ' VAL . 7.5 tt -160.4 150.75 18.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.686 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.2 t -102.55 136.64 33.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.184 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.695 HD11 HG21 ' A' ' 113' ' ' VAL . 0.7 OUTLIER -117.16 164.1 15.28 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.519 -179.793 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -135.97 112.84 10.25 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.28 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -145.84 138.61 25.78 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.49 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 12.2 mmt 60.68 32.68 20.31 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.512 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 61.11 33.26 19.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.374 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 28.1 ttm -140.03 121.81 15.42 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.496 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -69.98 125.09 25.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.459 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 24.1 m -116.47 124.64 50.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.388 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -85.01 134.14 34.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.486 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.3 mm -102.66 126.1 56.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.242 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 13.7 p30 -110.25 140.06 44.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.314 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.11 139.24 96.03 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.311 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.465 ' HD3' HG23 ' A' ' 57' ' ' ILE . 49.8 Cg_endo -73.81 -31.04 8.75 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.166 1.911 . . . . 0.0 112.227 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.707 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 78.2 p -147.01 151.31 36.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.344 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -66.78 142.67 57.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.352 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.442 ' O ' HG22 ' A' ' 75' ' ' THR . . . 176.62 -147.93 8.76 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -140.88 145.47 36.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.076 0.465 . . . . 0.0 110.316 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.786 HG21 ' HB ' ' A' ' 70' ' ' VAL . 24.7 t -77.8 107.45 9.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.327 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -91.92 -28.42 17.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.729 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 17.8 ttpt -160.75 130.89 5.14 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.099 0.476 . . . . 0.0 110.544 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.435 HG13 HG12 ' A' ' 120' ' ' ILE . 21.9 t -105.49 109.52 28.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.347 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.6 mt -78.92 -31.8 45.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.476 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.424 HG11 HD23 ' A' ' 119' ' ' LEU . 31.5 m -80.18 152.84 4.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.593 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -135.79 155.11 50.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.268 179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -59.01 141.99 52.44 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.632 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER 60.75 36.39 19.34 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.499 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -119.45 151.11 39.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.286 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -93.64 133.4 37.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.491 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.695 HG21 HD11 ' A' ' 85' ' ' LEU . 29.7 m -120.39 152.01 23.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.453 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -100.17 144.93 28.62 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.354 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.502 ' H ' ' HB2' ' A' ' 62' ' ' ALA . . . -61.62 105.63 0.96 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 117.91 -28.04 7.19 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 37.3 tt0 -59.85 139.96 56.96 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 121.127 0.489 . . . . 0.0 110.597 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.662 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.36 126.58 40.3 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.483 HD11 ' HA ' ' A' ' 59' ' ' ALA . 41.5 mt -89.43 -58.94 2.35 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.153 0.501 . . . . 0.0 110.567 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.495 ' CG2' HG13 ' A' ' 102' ' ' VAL . 58.4 mt -140.95 145.57 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.164 -179.733 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -93.41 123.76 36.94 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.536 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.1 mm -101.23 145.07 12.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.274 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.678 0 CA-C-O 117.947 -1.474 . . . . 0.0 110.875 -179.996 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.89 94.56 2.36 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.729 -0.948 . . . . 0.0 110.729 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.49 84.3 6.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.001 0.429 . . . . 0.0 110.457 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 159.83 -175.85 36.62 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 46.0 mttt -143.61 40.05 1.41 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.338 0.59 . . . . 0.0 110.322 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.68 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -145.66 135.22 23.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.426 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -141.18 -95.34 0.25 Allowed Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.846 -0.902 . . . . 0.0 110.846 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -92.86 114.24 26.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.158 0.504 . . . . 0.0 110.438 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.04 -60.36 0.34 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -83.89 128.35 34.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.072 0.463 . . . . 0.0 110.453 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.405 HD11 HD11 ' A' ' 122' ' ' ILE . 43.4 mt -79.27 120.22 79.77 Favored Pre-proline 0 CA--C 1.534 0.335 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.157 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.424 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 48.6 Cg_endo -72.22 138.72 31.01 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 121.998 1.799 . . . . 0.0 112.375 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -75.2 147.92 83.44 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.42 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -72.27 -28.53 15.21 Favored 'Trans proline' 0 CA--C 1.527 0.156 0 C-N-CA 122.324 2.016 . . . . 0.0 112.409 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.6 pp -163.25 163.2 25.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.436 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.16 98.17 5.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.437 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -123.65 -148.04 7.43 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.742 -0.943 . . . . 0.0 110.742 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.1 m -136.4 140.21 43.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.064 0.459 . . . . 0.0 110.439 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.698 HG13 HD11 ' A' ' 83' ' ' LEU . 24.7 t -72.28 120.12 20.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.16 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -96.82 -51.28 4.33 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.693 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -152.97 144.08 23.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.64 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 33.3 mt -97.45 131.46 44.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.0 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.507 HD22 ' HB ' ' A' ' 81' ' ' THR . 5.3 mp -100.11 -29.44 12.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.884 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.877 HG11 HG11 ' A' ' 76' ' ' VAL . 28.3 m -118.71 145.76 24.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-O 121.255 0.55 . . . . 0.0 110.685 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.3 pttm -136.52 167.04 22.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.175 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 9.1 mp0 -60.51 105.27 0.42 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.49 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -31.55 2.26 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 50.4 m-20 -93.82 149.49 21.19 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.064 0.459 . . . . 0.0 110.497 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.57 HG23 ' HB2' ' A' ' 101' ' ' LYS . 0.4 OUTLIER -102.18 143.44 31.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.286 179.941 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.877 HG11 HG11 ' A' ' 70' ' ' VAL . 22.9 m -122.03 162.1 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.551 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -122.98 158.07 31.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.265 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.612 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.47 101.83 0.2 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.518 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.29 -36.09 2.31 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -65.45 137.97 57.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.054 0.454 . . . . 0.0 110.563 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.507 ' HB ' HD22 ' A' ' 69' ' ' LEU . 11.1 m -64.13 139.38 58.76 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.172 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.44 HG22 ' O ' ' A' ' 94' ' ' ILE . 33.1 m -113.96 -30.53 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.19 -179.58 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.698 HD11 HG13 ' A' ' 65' ' ' VAL . 8.9 tt -164.66 151.64 11.17 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.088 0.47 . . . . 0.0 110.782 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.452 HG23 ' CD1' ' A' ' 69' ' ' LEU . 21.9 t -104.21 136.84 35.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.077 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.736 HD12 HD11 ' A' ' 94' ' ' ILE . 16.0 mt -118.07 159.79 22.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.651 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -132.87 111.11 10.8 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.376 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -145.56 143.95 30.22 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.465 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 42.7 mmm 60.5 33.17 20.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.473 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.85 33.8 19.86 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.511 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 2.7 ttt -143.96 136.19 26.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.444 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -82.16 126.17 31.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.517 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 24.7 m -116.08 124.41 50.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.341 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -82.17 132.26 35.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.479 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.736 HD11 HD12 ' A' ' 85' ' ' LEU . 36.2 mm -102.15 121.49 53.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.248 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -109.73 143.65 39.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.352 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.57 143.5 93.49 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.407 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -72.67 -35.54 5.85 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.118 1.879 . . . . 0.0 112.223 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.612 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 19.6 p -148.7 166.1 29.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.365 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -66.65 141.59 57.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.471 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.531 ' O ' HG22 ' A' ' 75' ' ' THR . . . 174.04 -162.35 32.91 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' LYS . . . . . 0.57 ' HB2' HG23 ' A' ' 75' ' ' THR . 6.8 ttpm? -133.07 147.53 52.18 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.034 0.445 . . . . 0.0 110.465 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.575 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.8 t -77.75 111.08 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.166 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -94.86 -30.07 14.38 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.638 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.7 tttp -159.02 131.01 6.54 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.345 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.434 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.3 t -96.66 110.68 25.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.312 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 29.8 mt -90.27 30.24 1.14 Allowed 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.633 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.434 ' H ' HG12 ' A' ' 105' ' ' VAL . 23.2 m -155.59 139.24 8.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-O 121.02 0.438 . . . . 0.0 110.259 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.67 165.13 18.45 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.134 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -60.91 147.19 43.96 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.555 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 60.99 35.76 18.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.505 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.42 ' O ' HG23 ' A' ' 65' ' ' VAL . 6.9 t0 -121.36 137.72 54.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.412 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -89.24 134.75 33.91 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.432 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.0 m -122.39 155.91 27.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.417 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -100.23 145.88 27.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.453 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.17 112.36 4.65 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 109.85 -27.8 11.51 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -57.45 145.33 33.36 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 121.07 0.462 . . . . 0.0 110.779 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.68 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.01 122.02 28.37 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 97.8 mt -90.42 -56.77 3.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.114 0.483 . . . . 0.0 110.523 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.482 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.5 mt -140.94 145.74 24.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.301 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 7.2 ttmt -92.46 124.44 36.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.365 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.405 HD11 HD11 ' A' ' 57' ' ' ILE . 37.6 mm -103.46 145.1 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.448 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.218 -0.848 0 CA-C-O 118.076 -1.402 . . . . 0.0 110.701 179.952 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 118.95 -43.87 1.51 Allowed Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.91 110.17 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.114 0.483 . . . . 0.0 110.553 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 178.61 -153.41 12.66 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 21.5 mmtt -135.24 39.57 2.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.258 0.552 . . . . 0.0 110.421 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.831 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -153.03 162.67 41.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.321 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 156.52 -55.74 0.39 Allowed Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.814 -0.915 . . . . 0.0 110.814 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -102.34 86.48 2.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.089 0.471 . . . . 0.0 110.492 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.04 -49.65 0.92 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.543 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 0.9 OUTLIER -82.92 130.27 35.12 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.02 0.438 . . . . 0.0 110.382 -179.879 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 55.3 mt -80.25 111.22 20.53 Favored Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.053 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.656 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.6 Cg_endo -70.68 141.86 42.51 Favored 'Trans proline' 0 N--CA 1.472 0.262 0 C-N-CA 122.032 1.821 . . . . 0.0 112.292 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.674 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -75.85 144.89 77.06 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.475 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.684 ' HG2' HD23 ' A' ' 61' ' ' LEU . 50.5 Cg_endo -73.71 -24.74 15.43 Favored 'Trans proline' 0 N--CA 1.472 0.217 0 C-N-CA 122.188 1.925 . . . . 0.0 112.59 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.684 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.9 OUTLIER -161.55 167.54 25.2 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.454 -179.913 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -91.7 95.49 9.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.369 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -122.83 -139.67 5.56 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.9 m -136.12 134.61 38.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.083 0.468 . . . . 0.0 110.406 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.606 HG13 HD11 ' A' ' 83' ' ' LEU . 26.4 t -71.34 125.61 30.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.279 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.9 t -95.7 -54.79 3.23 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.578 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -152.43 149.52 28.67 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.523 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.415 HG12 HD12 ' A' ' 83' ' ' LEU . 48.9 mt -102.27 133.39 46.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.221 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.9 mp -98.82 -31.5 11.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.618 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.687 HG11 ' CG1' ' A' ' 76' ' ' VAL . 33.2 m -114.79 144.91 21.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.681 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.85 165.54 25.39 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.26 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -59.33 101.52 0.1 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.598 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.09 -31.81 2.24 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -90.11 150.03 22.23 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.089 0.471 . . . . 0.0 110.486 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.503 HG22 ' O ' ' A' ' 100' ' ' GLY . 1.0 OUTLIER -96.23 149.43 21.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.332 179.925 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.687 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.3 m -122.73 168.33 15.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.464 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 21.4 ttpt -128.34 148.49 50.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.346 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.637 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.05 100.83 0.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.612 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.11 -31.31 4.75 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.1 tt0 -64.08 143.73 57.65 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.057 0.456 . . . . 0.0 110.67 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 21.4 m -65.44 138.84 58.38 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.219 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.431 ' HA ' HG13 ' A' ' 70' ' ' VAL . 28.4 m -118.49 -32.2 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.384 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.606 HD11 HG13 ' A' ' 65' ' ' VAL . 7.5 tt -161.04 152.28 18.91 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.311 0.577 . . . . 0.0 111.296 -179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.539 HG13 ' O ' ' A' ' 92' ' ' THR . 19.7 t -103.45 147.32 9.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.557 179.33 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.849 HD12 HD11 ' A' ' 94' ' ' ILE . 7.4 mt -127.48 170.44 12.57 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.156 0.503 . . . . 0.0 110.785 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -139.28 110.92 7.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.478 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -145.88 142.68 29.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.486 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 24.9 mmt 60.52 32.36 20.46 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.572 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 52.4 mttt 60.61 32.69 20.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.476 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -141.28 127.75 20.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.412 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -68.58 129.23 39.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.565 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.539 ' O ' HG13 ' A' ' 84' ' ' VAL . 0.5 OUTLIER -112.13 176.19 5.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.656 179.594 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.535 ' H ' HG22 ' A' ' 92' ' ' THR . 50.6 mt-10 -146.02 134.87 22.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.28 0.562 . . . . 0.0 110.648 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.849 HD11 HD12 ' A' ' 85' ' ' LEU . 37.3 mm -102.57 153.7 5.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.146 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -136.91 141.45 42.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.353 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.93 135.52 94.65 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.309 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -73.85 -31.64 8.09 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.073 1.849 . . . . 0.0 112.268 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.637 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 25.1 p -146.13 157.57 43.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.411 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -65.86 141.81 58.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.279 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.503 ' O ' HG22 ' A' ' 75' ' ' THR . . . 174.66 -158.52 26.69 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 26.5 ttpt -133.74 148.54 51.42 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.144 0.497 . . . . 0.0 110.413 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.646 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.7 t -75.47 105.83 4.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.27 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -92.49 -26.67 17.85 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.859 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' LYS . . . . . 0.695 ' HD2' HD21 ' A' ' 106' ' ' LEU . 27.9 ttmt -158.93 129.08 5.81 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.098 0.475 . . . . 0.0 110.635 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 24.9 t -102.29 106.13 19.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.194 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.695 HD21 ' HD2' ' A' ' 104' ' ' LYS . 18.1 mt -89.5 13.33 14.11 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.632 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.441 HG21 HD13 ' A' ' 83' ' ' LEU . 30.7 m -130.12 143.77 40.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 CA-C-O 121.079 0.466 . . . . 0.0 110.312 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 13.6 mtmm -126.08 168.01 14.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.387 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -72.29 143.25 48.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.338 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 16.3 mtm180 61.42 38.5 15.98 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.514 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -126.45 148.04 49.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.336 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.83 140.0 30.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.56 -179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.9 m -122.8 156.02 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.274 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 39.0 mm-40 -101.94 142.39 33.31 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.337 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.38 111.38 3.38 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 108.72 -25.02 20.52 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -59.9 140.97 56.3 Favored 'General case' 0 N--CA 1.462 0.15 0 CA-C-O 121.017 0.437 . . . . 0.0 110.791 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.831 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -60.48 118.37 14.6 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.674 HD21 ' HB2' ' A' ' 59' ' ' ALA . 33.2 mt -88.58 -54.02 4.37 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.124 0.487 . . . . 0.0 110.497 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 52.2 mt -142.4 142.74 26.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.325 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.0 122.49 38.88 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.097 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.0 mm -100.66 142.46 15.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.479 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.667 0 CA-C-O 117.972 -1.46 . . . . 0.0 110.758 179.931 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -144.79 170.46 26.32 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.801 -0.919 . . . . 0.0 110.801 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -133.65 113.15 12.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.1 0.476 . . . . 0.0 110.468 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 111.89 39.27 1.31 Allowed Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt -126.02 154.52 42.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.107 0.479 . . . . 0.0 110.464 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.666 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -84.54 169.89 13.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.417 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 141.01 47.25 0.05 OUTLIER Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -167.52 33.82 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.099 0.476 . . . . 0.0 110.391 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 117.11 -32.42 5.45 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -77.28 140.48 40.06 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.079 0.466 . . . . 0.0 110.542 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.505 HD11 HD11 ' A' ' 122' ' ' ILE . 48.5 mt -79.49 120.28 79.79 Favored Pre-proline 0 CA--C 1.534 0.348 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.081 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -72.19 146.06 45.27 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 121.996 1.797 . . . . 0.0 112.352 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.62 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -74.55 148.47 85.58 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.41 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.85 -28.5 13.43 Favored 'Trans proline' 0 N--CA 1.472 0.207 0 C-N-CA 122.207 1.938 . . . . 0.0 112.345 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.7 pp -166.27 165.3 17.49 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.494 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.69 84.21 3.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.396 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.521 ' CA ' ' HB2' ' A' ' 87' ' ' ALA . . . -120.92 -166.57 13.06 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.8 m -112.28 135.78 52.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.132 0.492 . . . . 0.0 110.357 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.563 HG13 HD11 ' A' ' 83' ' ' LEU . 25.1 t -70.79 126.11 30.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.247 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 4.5 p -97.82 -61.63 1.36 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.604 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 9.1 mmmt -141.47 150.23 41.97 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.607 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.502 HG22 ' H ' ' A' ' 70' ' ' VAL . 33.6 mt -110.22 120.55 61.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.842 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.4 mt -96.82 27.66 3.85 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.344 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.829 ' HB ' HG21 ' A' ' 102' ' ' VAL . 31.5 m -155.5 151.18 10.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 121.195 0.521 . . . . 0.0 110.483 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.9 pttt -141.6 160.33 40.39 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.054 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -60.34 95.05 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.431 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.18 -26.63 2.57 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -80.64 149.05 29.98 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.161 0.505 . . . . 0.0 110.457 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.6 m -97.32 137.71 35.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.228 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.467 HG11 HG11 ' A' ' 70' ' ' VAL . 34.6 m -119.78 145.03 26.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.556 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 mtmt -108.74 147.53 31.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.235 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.673 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -58.5 102.04 0.1 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.812 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.01 -32.72 3.38 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 12.7 tt0 -65.15 143.9 57.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.055 0.455 . . . . 0.0 110.501 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.9 m -66.95 138.45 57.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.221 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 32.3 m -119.37 -31.29 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.531 -179.59 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.563 HD11 HG13 ' A' ' 65' ' ' VAL . 9.9 tt -162.37 146.23 11.85 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.129 0.49 . . . . 0.0 111.032 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.471 HG22 ' OE2' ' A' ' 93' ' ' GLU . 22.0 t -108.81 143.08 19.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.89 179.517 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.458 HD11 HG21 ' A' ' 113' ' ' VAL . 1.0 OUTLIER -124.38 163.59 21.42 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.186 0.517 . . . . 0.0 110.798 -179.6 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.2 mt-10 -137.22 111.39 8.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.371 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.521 ' HB2' ' CA ' ' A' ' 63' ' ' GLY . . . -147.38 146.87 29.78 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.5 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 7.8 mmt 60.34 34.04 20.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.584 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 27.1 mtpt 60.92 33.4 19.86 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.495 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 12.9 mtm -141.75 155.81 45.61 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.399 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -98.15 128.68 44.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.52 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.9 m -113.15 116.55 30.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.22 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.471 ' OE2' HG22 ' A' ' 84' ' ' VAL . 10.2 mm-40 -91.78 125.91 36.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.526 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.494 ' N ' HD12 ' A' ' 94' ' ' ILE . 5.3 mp -108.72 148.46 12.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.954 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -135.89 156.12 49.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.165 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.56 135.58 95.61 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.337 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.37 -32.47 8.05 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.044 1.829 . . . . 0.0 112.224 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.673 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 1.1 p -145.61 159.33 43.3 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.315 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -63.64 140.03 58.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.339 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.17 -161.69 32.78 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.3 ttmp? -135.62 146.75 48.22 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.062 0.458 . . . . 0.0 110.444 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.829 HG21 ' HB ' ' A' ' 70' ' ' VAL . 30.3 t -75.99 114.07 15.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.147 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -94.94 -30.02 14.36 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.778 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 77.6 tttt -159.98 128.91 5.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.546 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 120' ' ' ILE . 22.1 t -107.62 108.71 25.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.271 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 mt -79.21 -31.62 43.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.447 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.44 ' O ' HG12 ' A' ' 105' ' ' VAL . 27.6 m -80.77 145.27 9.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.567 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -130.36 157.67 41.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.21 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 66.5 mt-10 -59.27 143.21 49.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.668 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 24.4 ttt180 61.76 32.84 18.15 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.305 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -116.24 151.06 36.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.427 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.83 135.51 34.06 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.442 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.458 HG21 HD11 ' A' ' 85' ' ' LEU . 30.8 m -120.53 179.67 2.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.43 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -135.42 145.29 47.11 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.366 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.45 109.43 2.48 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.0 -29.32 8.13 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.3 tt0 -60.11 140.82 56.65 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 121.146 0.498 . . . . 0.0 110.609 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.666 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.38 122.04 28.06 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.62 HD11 ' HA ' ' A' ' 59' ' ' ALA . 87.7 mt -89.22 -61.63 1.66 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.132 0.491 . . . . 0.0 110.503 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.559 HG12 HG13 ' A' ' 105' ' ' VAL . 55.4 mt -140.96 151.83 20.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.362 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 33.0 tttm -98.63 134.63 41.3 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.386 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.505 HD11 HD11 ' A' ' 57' ' ' ILE . 35.4 mm -108.06 146.87 13.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.424 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.779 0 CA-C-O 118.049 -1.417 . . . . 0.0 110.786 179.958 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -149.21 -152.88 5.85 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.62 161.99 0.06 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.12 0.486 . . . . 0.0 110.518 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 88.4 -78.63 1.73 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 16.5 ttmt -142.22 142.26 32.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.108 0.48 . . . . 0.0 110.353 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.491 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -64.75 175.47 1.45 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.382 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -175.59 -43.9 0.06 OUTLIER Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -63.72 -149.85 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.472 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.392 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -87.98 18.12 42.07 Favored Glycine 0 CA--C 1.534 1.272 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.907 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -81.84 152.41 26.9 Favored 'General case' 0 C--O 1.231 0.081 0 CA-C-O 121.015 0.435 . . . . 0.0 110.272 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 54.8 mt -80.1 111.41 21.8 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.17 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -71.1 153.41 62.68 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.011 1.807 . . . . 0.0 112.218 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.695 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -78.97 143.05 60.92 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.468 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -74.13 -27.91 11.33 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.121 1.881 . . . . 0.0 112.309 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -163.9 162.91 23.75 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.364 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.56 92.07 5.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.39 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.545 ' HA3' ' HB2' ' A' ' 87' ' ' ALA . . . -126.16 -141.85 5.59 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 19.8 m -138.04 138.3 38.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.003 0.43 . . . . 0.0 110.459 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.523 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -70.66 125.31 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.208 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.1 t -98.24 -46.42 5.83 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.564 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 36.0 mtmt -149.16 169.84 19.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.606 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 51.7 mt -129.8 125.81 61.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.946 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.478 HD12 HG22 ' A' ' 81' ' ' THR . 20.4 mt -97.24 -28.11 14.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.12 -179.383 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.872 ' HB ' HG21 ' A' ' 102' ' ' VAL . 32.9 m -101.47 156.77 4.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.346 0.593 . . . . 0.0 111.218 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 22.5 mttp -135.96 151.9 50.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.843 179.664 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.561 ' HG3' HG23 ' A' ' 105' ' ' VAL . 16.6 mt-10 -60.78 90.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.52 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.09 -25.86 2.63 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 63.8 m-20 -78.72 148.66 32.96 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.143 0.497 . . . . 0.0 110.5 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 5.3 m -97.02 140.04 32.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.184 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.57 HG11 HG11 ' A' ' 70' ' ' VAL . 30.0 m -121.91 171.26 10.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.66 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -127.42 138.66 53.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.191 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.696 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -56.11 100.25 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.029 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.86 -38.84 1.63 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 45.3 tt0 -69.35 144.82 53.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.065 0.459 . . . . 0.0 110.599 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.478 HG22 HD12 ' A' ' 69' ' ' LEU . 17.6 m -65.02 139.11 58.71 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.317 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.587 HG22 ' O ' ' A' ' 94' ' ' ILE . 35.1 m -115.05 -25.88 3.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.397 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.523 HD11 HG13 ' A' ' 65' ' ' VAL . 7.7 tt -166.58 146.52 5.86 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 121.052 0.453 . . . . 0.0 110.702 -179.471 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -105.1 141.26 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.133 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 85' ' ' LEU . 12.1 mt -120.11 158.28 27.22 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.553 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -137.53 114.89 11.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.397 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.545 ' HB2' ' HA3' ' A' ' 63' ' ' GLY . . . -149.76 136.76 19.58 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 69.0 mtp 60.68 32.22 20.26 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.537 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 11.5 mtmm 60.53 32.68 20.51 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.568 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.1 ttt -135.71 104.74 5.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.381 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -62.04 128.52 36.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.41 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.8 m -129.0 113.0 14.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.131 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -87.22 142.98 27.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.717 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.649 ' N ' HD12 ' A' ' 94' ' ' ILE . 4.6 mp -115.21 127.08 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.907 179.748 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 42.4 m-20 -102.5 153.31 20.19 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.207 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.85 136.22 94.84 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.345 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -72.62 -35.25 6.23 Favored 'Trans proline' 0 N--CA 1.471 0.2 0 C-N-CA 122.09 1.86 . . . . 0.0 112.172 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.696 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 2.5 p -147.36 155.32 41.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.296 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -64.49 140.43 58.87 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.384 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.21 -157.94 26.14 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 15.7 ttmm -132.31 143.7 50.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.065 0.459 . . . . 0.0 110.468 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.872 HG21 ' HB ' ' A' ' 70' ' ' VAL . 36.0 t -78.78 110.08 14.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.171 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.09 -29.65 16.43 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.84 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 8.0 ttpt -157.86 131.03 7.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.448 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.561 HG23 ' HG3' ' A' ' 72' ' ' GLU . 21.8 t -101.06 115.46 42.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.243 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.408 ' O ' HG13 ' A' ' 107' ' ' VAL . 19.9 mt -89.95 28.52 1.36 Allowed 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.698 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.503 ' H ' HG12 ' A' ' 105' ' ' VAL . 19.2 m -155.69 142.5 11.3 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 121.038 0.447 . . . . 0.0 110.378 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.5 tttt -125.89 165.03 19.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.188 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -59.61 143.05 51.51 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.615 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 30.2 mtm180 60.14 34.01 21.15 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.558 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -114.21 149.16 36.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.338 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.92 134.98 34.29 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.526 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.6 m -122.38 149.91 25.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.331 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 55.9 mt-30 -99.68 144.1 29.15 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.416 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.42 110.07 2.71 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.739 -0.945 . . . . 0.0 110.739 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 110.24 -27.29 11.85 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -59.64 139.77 56.94 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.056 0.455 . . . . 0.0 110.668 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.491 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.12 123.08 31.53 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.695 HD11 ' HA ' ' A' ' 59' ' ' ALA . 65.8 mt -87.57 -54.01 4.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.032 0.444 . . . . 0.0 110.405 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.626 ' CG2' HG13 ' A' ' 102' ' ' VAL . 50.2 mt -141.5 149.64 20.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.426 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.0 tttm -99.25 130.51 45.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.299 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.2 mm -107.63 144.71 15.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.506 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.797 0 CA-C-O 117.964 -1.464 . . . . 0.0 110.806 179.969 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -99.87 117.01 5.74 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -162.21 89.25 0.69 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.096 0.474 . . . . 0.0 110.41 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 134.98 139.06 4.0 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 46.6 mttp -120.43 40.73 3.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.326 0.584 . . . . 0.0 110.394 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.708 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -151.44 179.51 8.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.433 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.71 -49.03 0.93 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.716 -0.953 . . . . 0.0 110.716 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -92.46 75.55 5.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.273 0.559 . . . . 0.0 110.408 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 99.78 -41.51 2.17 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.605 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 32.9 mt-10 -83.92 130.04 34.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.1 0.476 . . . . 0.0 110.477 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.51 HD11 HD11 ' A' ' 122' ' ' ILE . 45.0 mt -78.82 111.76 22.04 Favored Pre-proline 0 CA--C 1.534 0.363 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.212 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.541 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.3 Cg_endo -70.94 137.82 32.82 Favored 'Trans proline' 0 N--CA 1.473 0.267 0 C-N-CA 122.084 1.856 . . . . 0.0 112.374 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.721 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -68.72 149.13 98.02 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.465 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.52 -27.55 15.53 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.253 1.969 . . . . 0.0 112.414 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 pp -164.79 165.22 20.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.443 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.34 96.49 5.32 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.363 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -128.4 -141.11 5.14 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.776 -0.929 . . . . 0.0 110.776 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.1 m -136.71 141.51 43.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.002 0.43 . . . . 0.0 110.46 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.76 HG13 HD11 ' A' ' 83' ' ' LEU . 23.1 t -71.21 128.64 34.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.218 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 t -98.67 -62.0 1.3 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.518 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 9.8 mtpt -150.16 144.81 25.92 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.457 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.653 HG12 HD12 ' A' ' 83' ' ' LEU . 42.2 mt -99.24 128.85 50.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.039 179.691 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.9 mp -97.67 -36.03 10.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.829 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.688 HG11 HG12 ' A' ' 76' ' ' VAL . 33.7 m -115.17 139.26 42.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.263 0.554 . . . . 0.0 110.78 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 20.9 pttt -135.91 162.75 31.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.793 179.514 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -54.61 108.64 0.41 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.279 0.561 . . . . 0.0 110.783 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.42 -29.98 2.35 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -102.53 155.12 18.49 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.974 0.416 . . . . 0.0 110.396 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.4 m -96.91 150.43 20.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.43 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.688 HG12 HG11 ' A' ' 70' ' ' VAL . 30.3 m -123.97 168.28 16.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.498 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 28.4 mmtm -129.69 155.28 46.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.448 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.511 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -62.2 105.76 0.64 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.453 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.25 -29.37 7.07 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -61.32 142.7 56.7 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.104 0.478 . . . . 0.0 110.564 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.9 m -67.1 138.14 56.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.271 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.4 m -118.17 -34.26 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.208 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.76 HD11 HG13 ' A' ' 65' ' ' VAL . 6.5 tt -162.11 152.02 16.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.134 0.492 . . . . 0.0 111.078 -179.315 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.682 HG22 ' OE1' ' A' ' 93' ' ' GLU . 22.8 t -102.89 143.15 15.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.654 179.245 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.7 HD11 HG21 ' A' ' 113' ' ' VAL . 0.3 OUTLIER -119.49 167.69 11.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.229 0.538 . . . . 0.0 110.782 -179.559 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -138.33 109.21 6.7 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.365 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.57 133.72 17.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.333 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 66.9 mtm 61.06 50.71 4.84 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.26 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.2 ptpp? 41.41 32.22 0.21 Allowed 'General case' 0 N--CA 1.474 0.739 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.984 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 19.5 ttm -139.52 112.3 7.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.424 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -61.8 130.75 47.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.403 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 14.0 m -118.47 123.09 44.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.33 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.682 ' OE1' HG22 ' A' ' 84' ' ' VAL . 6.4 mm-40 -84.51 132.26 34.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.59 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 30.8 mm -105.45 148.72 9.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.049 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -139.29 150.83 45.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.612 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.63 143.73 96.35 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.399 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -72.62 -34.42 7.21 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.186 1.924 . . . . 0.0 112.26 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.511 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 14.3 p -146.95 168.45 21.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.312 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -68.82 142.26 54.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.463 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.1 -161.25 32.27 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.2 ttpt -133.62 138.91 46.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.062 0.458 . . . . 0.0 110.464 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.647 HG13 ' CG2' ' A' ' 120' ' ' ILE . 22.3 t -74.22 123.73 30.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.238 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -99.03 -33.17 10.92 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.588 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' LYS . . . . . 0.534 ' NZ ' HD23 ' A' ' 106' ' ' LEU . 0.2 OUTLIER -160.88 147.82 15.29 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.412 -179.948 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.506 HG12 ' H ' ' A' ' 107' ' ' VAL . 11.9 t -101.29 119.0 48.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.008 179.784 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.534 HD23 ' NZ ' ' A' ' 104' ' ' LYS . 6.9 mt -89.53 21.56 3.36 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.919 -179.638 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.506 ' H ' HG12 ' A' ' 105' ' ' VAL . 30.6 m -154.56 156.3 5.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-O 121.093 0.473 . . . . 0.0 110.673 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.5 mtmp? -130.85 159.03 38.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.25 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 64.4 mt-10 -60.51 151.26 28.99 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.513 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? 60.99 32.33 19.92 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.521 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -122.91 150.9 42.31 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.452 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.01 137.56 32.27 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.348 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.7 HG21 HD11 ' A' ' 85' ' ' LEU . 30.5 m -121.12 148.71 24.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.432 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -98.1 140.66 32.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.259 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.54 96.28 0.09 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 127.51 -27.87 4.61 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -59.31 142.71 51.39 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.086 0.47 . . . . 0.0 110.704 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.708 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.22 120.93 24.71 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.721 HD11 ' HA ' ' A' ' 59' ' ' ALA . 14.1 mt -89.78 -50.2 6.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.079 0.466 . . . . 0.0 110.418 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.647 ' CG2' HG13 ' A' ' 102' ' ' VAL . 45.9 mt -145.27 147.82 18.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.297 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.5 mttp -95.43 130.34 42.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.158 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.51 HD11 HD11 ' A' ' 57' ' ' ILE . 37.5 mm -110.39 144.67 18.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.357 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.711 0 CA-C-O 117.974 -1.459 . . . . 0.0 110.76 -179.997 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 143.97 -33.04 1.76 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -176.75 116.86 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.047 0.451 . . . . 0.0 110.435 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 68.27 -163.11 48.91 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 2.4 mtpm? -160.88 40.74 0.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.301 0.572 . . . . 0.0 110.494 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.727 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -145.42 99.12 3.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.344 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -104.6 -75.19 1.01 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.836 -0.905 . . . . 0.0 110.836 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -123.82 100.46 6.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.101 0.477 . . . . 0.0 110.443 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 130.17 -57.93 0.71 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.687 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 24.8 mt-10 -83.97 137.06 33.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.107 0.48 . . . . 0.0 110.459 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.636 HD11 HD11 ' A' ' 122' ' ' ILE . 35.5 mt -81.81 112.22 32.93 Favored Pre-proline 0 CA--C 1.535 0.366 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.167 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.705 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 46.9 Cg_endo -70.73 128.56 15.3 Favored 'Trans proline' 0 N--CA 1.472 0.233 0 C-N-CA 122.017 1.811 . . . . 0.0 112.363 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.574 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -61.95 148.64 87.75 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.49 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.99 -26.82 18.08 Favored 'Trans proline' 0 N--CA 1.471 0.15 0 C-N-CA 122.283 1.989 . . . . 0.0 112.509 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -163.75 168.54 19.58 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.423 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.75 102.83 13.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.499 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -133.98 -140.73 4.37 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 16.0 m -137.15 142.1 42.23 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.104 0.478 . . . . 0.0 110.369 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 111' ' ' ASP . 23.1 t -71.96 131.99 33.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.122 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -101.37 -54.17 2.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.502 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 33.5 tttt -155.74 147.0 22.59 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.594 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.483 HD11 ' HA ' ' A' ' 108' ' ' LYS . 8.8 mt -100.43 130.78 49.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.972 179.662 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.1 mt -101.56 -41.88 6.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.691 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.795 ' HB ' HG21 ' A' ' 102' ' ' VAL . 29.5 m -93.54 149.88 4.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.761 -179.784 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -135.11 162.22 33.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.255 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.46 ' OE1' HG23 ' A' ' 105' ' ' VAL . 2.6 mp0 -60.94 96.6 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.543 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.0 -31.22 2.3 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -79.78 147.07 31.99 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.127 0.489 . . . . 0.0 110.449 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 6.7 m -95.9 141.12 29.7 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.382 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.707 HG11 HG11 ' A' ' 70' ' ' VAL . 29.9 m -120.06 160.93 20.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.555 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 tttt -120.08 146.97 45.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.311 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.65 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.84 93.46 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.69 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.42 -32.43 2.55 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -67.84 141.12 56.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.976 0.417 . . . . 0.0 110.52 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.0 m -63.34 137.22 58.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.189 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.528 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.6 m -114.01 -35.1 2.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.781 -179.691 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.567 HD13 HG21 ' A' ' 107' ' ' VAL . 7.0 tt -159.18 151.49 21.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.449 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.2 t -102.9 143.44 15.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.042 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -124.06 164.75 18.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.582 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -137.38 115.42 11.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.338 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.65 136.95 23.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.391 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 15.7 mtt 60.83 32.93 20.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.514 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.9 mptt 60.95 35.14 19.21 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.477 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.7 mtt -139.43 126.77 21.43 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.461 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -71.05 128.68 36.75 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.43 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.5 m -119.41 120.42 36.8 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.425 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -85.09 129.98 34.7 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.514 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 33.6 mm -103.13 124.55 57.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.327 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -110.29 147.76 33.23 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.376 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.78 138.42 96.96 Favored Pre-proline 0 CA--C 1.532 0.282 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.346 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.65 -32.87 7.18 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.087 1.858 . . . . 0.0 112.162 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.65 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 5.7 p -149.63 155.03 39.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.345 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -61.85 141.96 57.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.443 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 170.07 -157.37 28.75 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.1 ttmp? -134.82 148.07 50.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.129 0.49 . . . . 0.0 110.523 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.795 HG21 ' HB ' ' A' ' 70' ' ' VAL . 26.2 t -77.06 113.54 16.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.326 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -93.26 -30.83 14.97 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.699 -179.769 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 13.1 ttpt -159.45 133.57 7.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.569 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.46 HG23 ' OE1' ' A' ' 72' ' ' GLU . 21.6 t -101.92 108.11 23.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.144 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mt -89.58 13.13 14.77 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.578 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.567 HG21 HD13 ' A' ' 83' ' ' LEU . 26.3 m -130.72 136.59 57.92 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-O 121.123 0.487 . . . . 0.0 110.186 179.752 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.483 ' HA ' HD11 ' A' ' 68' ' ' ILE . 0.2 OUTLIER -125.49 172.16 9.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.226 -179.782 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -72.05 150.63 43.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.311 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 37.3 mtt-85 61.45 30.89 19.07 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.664 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.515 ' O ' HG23 ' A' ' 65' ' ' VAL . 5.8 m-20 -125.88 139.33 53.56 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.285 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.17 141.57 28.44 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.449 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.2 m -121.09 156.95 24.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.391 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -99.22 144.6 28.15 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.373 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.12 106.08 1.03 Allowed Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 117.56 -28.51 7.08 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.0 tt0 -59.21 137.7 57.87 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.126 0.489 . . . . 0.0 110.713 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.727 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.15 123.25 31.96 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.574 HD11 ' HA ' ' A' ' 59' ' ' ALA . 17.1 mt -86.5 -55.85 3.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.191 0.52 . . . . 0.0 110.534 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.655 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.8 mt -140.88 152.31 20.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.336 -179.779 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -96.92 132.52 42.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.476 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.636 HD11 HD11 ' A' ' 57' ' ' ILE . 36.9 mm -109.52 145.18 16.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.303 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.791 0 CA-C-O 118.095 -1.392 . . . . 0.0 110.757 -179.953 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 176.54 90.79 0.08 OUTLIER Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -97.77 145.37 26.43 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.127 0.489 . . . . 0.0 110.433 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -95.18 -55.17 1.4 Allowed Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 11.3 ptmt -152.46 145.06 24.19 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.08 0.466 . . . . 0.0 110.424 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.571 ' HB1' ' HB2' ' A' ' 56' ' ' GLU . . . -70.74 178.18 3.2 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.483 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -179.05 95.89 0.1 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 59.2 101.6 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.132 0.491 . . . . 0.0 110.731 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 118.2 -61.17 0.46 Allowed Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.571 ' HB2' ' HB1' ' A' ' 52' ' ' ALA . 16.5 mt-10 -83.51 136.76 34.16 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.066 0.46 . . . . 0.0 110.354 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.564 HD11 HD11 ' A' ' 122' ' ' ILE . 45.4 mt -79.74 111.63 22.9 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.263 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -72.48 129.8 15.25 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 121.982 1.788 . . . . 0.0 112.217 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.441 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -62.09 139.43 96.0 Favored Pre-proline 0 CA--C 1.532 0.274 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.274 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.409 ' HG2' HD12 ' A' ' 61' ' ' LEU . 48.0 Cg_endo -75.43 -12.0 20.7 Favored 'Trans proline' 0 CA--C 1.533 0.445 0 C-N-CA 122.091 1.861 . . . . 0.0 113.038 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.699 HD22 ' N ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -160.73 179.55 8.44 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-O 121.099 0.476 . . . . 0.0 110.48 179.901 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.699 ' N ' HD22 ' A' ' 61' ' ' LEU . . . -109.76 113.34 26.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.401 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -149.5 -138.87 3.0 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.512 ' C ' HD23 ' A' ' 85' ' ' LEU . 12.3 m -135.82 139.36 43.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.103 0.478 . . . . 0.0 110.411 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.554 HG13 HD11 ' A' ' 83' ' ' LEU . 28.1 t -70.48 126.5 30.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.18 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t -97.04 -55.06 2.98 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.574 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 ttpt -153.08 149.09 27.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.521 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.531 HD11 ' HA ' ' A' ' 108' ' ' LYS . 41.7 mt -103.01 135.66 39.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.059 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.477 HD22 ' HB ' ' A' ' 81' ' ' THR . 9.7 mp -99.72 -45.08 5.88 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.818 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.734 ' HB ' HG21 ' A' ' 102' ' ' VAL . 34.8 m -97.2 148.16 5.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.218 0.532 . . . . 0.0 110.876 -179.688 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 pttt -137.24 163.66 30.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.195 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.425 ' HG3' HG23 ' A' ' 105' ' ' VAL . 14.2 mt-10 -59.64 102.59 0.15 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.584 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.51 2.26 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -91.91 151.45 20.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.119 0.485 . . . . 0.0 110.492 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.562 HG22 ' O ' ' A' ' 100' ' ' GLY . 0.7 OUTLIER -96.58 153.67 17.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.312 179.916 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.712 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.9 m -126.14 167.67 20.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.562 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 mttm -129.05 148.05 50.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.37 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.594 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.16 93.14 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.715 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.88 -34.8 2.17 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -64.0 143.95 57.46 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.086 0.469 . . . . 0.0 110.582 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.477 ' HB ' HD22 ' A' ' 69' ' ' LEU . 9.0 m -66.92 139.58 57.72 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.336 179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 35.6 m -114.11 -32.68 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.939 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.695 HD13 HG21 ' A' ' 107' ' ' VAL . 7.9 tt -161.49 148.38 14.52 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.106 0.479 . . . . 0.0 110.797 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -103.4 140.37 21.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.113 179.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.66 HD21 HG21 ' A' ' 113' ' ' VAL . 2.1 mt -119.83 172.09 7.95 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.56 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -135.09 106.71 6.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.444 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.92 152.26 34.72 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.465 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 16.4 mtt 60.02 30.5 19.98 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.648 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 52.5 mttt 59.81 31.54 20.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.684 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 14.8 ptp -148.72 153.41 38.17 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.352 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -80.79 128.24 33.43 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.569 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.5 m -112.41 117.54 32.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.283 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -84.99 135.52 33.99 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.56 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.634 HD11 HD12 ' A' ' 85' ' ' LEU . 41.1 mm -106.7 122.33 60.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.255 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -104.95 142.81 34.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.362 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.13 144.11 91.53 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -72.57 -38.95 2.94 Favored 'Trans proline' 0 CA--C 1.528 0.216 0 C-N-CA 122.175 1.917 . . . . 0.0 112.168 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.594 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 2.8 p -148.39 165.14 31.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.309 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -66.6 141.43 57.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.393 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.562 ' O ' HG22 ' A' ' 75' ' ' THR . . . 172.82 -157.37 26.58 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 17.7 ttmt -136.11 146.69 47.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.104 0.478 . . . . 0.0 110.488 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.734 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.0 t -74.7 108.72 6.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.186 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -91.52 -29.12 17.15 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.809 -179.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.4 ttmm -159.33 130.27 6.0 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.095 0.474 . . . . 0.0 110.53 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.425 HG23 ' HG3' ' A' ' 72' ' ' GLU . 32.3 t -102.19 105.72 18.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.184 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.4 mt -88.0 10.21 19.74 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.67 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.695 HG21 HD13 ' A' ' 83' ' ' LEU . 23.7 m -125.59 136.13 61.81 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.062 0 CA-C-O 121.11 0.481 . . . . 0.0 110.258 179.675 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.531 ' HA ' HD11 ' A' ' 68' ' ' ILE . 2.8 ttpm? -122.56 169.36 11.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.391 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 -66.65 142.5 57.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.356 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER 63.17 38.14 10.82 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.66 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -117.8 142.36 47.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.319 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.91 131.61 36.43 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.427 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.66 HG21 HD21 ' A' ' 85' ' ' LEU . 30.8 m -119.59 179.82 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.452 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -141.46 149.35 40.84 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.427 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.55 104.4 0.7 Allowed Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.64 -31.49 4.57 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -61.64 135.9 57.81 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.091 0.472 . . . . 0.0 110.445 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.471 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -63.01 118.89 15.27 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.441 HD21 ' HB2' ' A' ' 59' ' ' ALA . 69.3 mt -88.38 -56.21 3.41 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.074 0.464 . . . . 0.0 110.392 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.528 ' CG2' HG13 ' A' ' 102' ' ' VAL . 50.9 mt -142.26 144.94 24.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.323 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.7 tttt -96.55 132.76 41.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.333 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.564 HD11 HD11 ' A' ' 57' ' ' ILE . 39.2 mm -107.25 144.88 15.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.416 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.738 0 CA-C-O 117.958 -1.468 . . . . 0.0 110.813 -179.992 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 99.95 -98.97 1.98 Allowed Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.69 95.68 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.105 0.479 . . . . 0.0 110.501 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -101.55 143.32 16.03 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 14.5 pttm -162.67 142.48 9.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.085 0.469 . . . . 0.0 110.453 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.557 ' HB2' ' N ' ' A' ' 118' ' ' GLY . . . -63.43 178.77 0.51 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.391 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.87 -88.72 0.07 OUTLIER Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.0 tm-20 -128.59 124.15 35.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.111 0.482 . . . . 0.0 110.458 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 107.93 -49.73 0.84 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -84.26 136.39 33.95 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.104 0.478 . . . . 0.0 110.438 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.41 HD11 ' CG1' ' A' ' 122' ' ' ILE . 52.6 mt -77.84 111.67 19.51 Favored Pre-proline 0 CA--C 1.534 0.364 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.175 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.513 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.9 Cg_endo -70.83 145.02 49.89 Favored 'Trans proline' 0 N--CA 1.472 0.248 0 C-N-CA 122.035 1.823 . . . . 0.0 112.394 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -82.11 147.52 57.73 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.468 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.661 ' HG2' HD23 ' A' ' 61' ' ' LEU . 48.7 Cg_endo -71.82 -23.26 22.59 Favored 'Trans proline' 0 N--CA 1.472 0.251 0 C-N-CA 122.278 1.986 . . . . 0.0 112.658 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.661 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.8 OUTLIER -161.68 173.38 14.77 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.089 0.471 . . . . 0.0 110.486 -179.991 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.55 91.81 5.23 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.411 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.721 ' HA3' HD23 ' A' ' 85' ' ' LEU . . . -103.42 175.15 23.44 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.4 m -105.81 7.17 32.23 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.639 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t 63.15 117.75 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 CA-C-O 121.075 0.464 . . . . 0.0 110.322 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.5 t -95.89 -57.37 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.577 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 34.4 tttm -155.11 146.38 22.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.59 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.637 HG12 HD12 ' A' ' 83' ' ' LEU . 23.7 mt -105.09 120.82 56.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.867 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 16.8 mt -98.39 25.49 6.26 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.303 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.685 ' HB ' HG21 ' A' ' 102' ' ' VAL . 30.6 m -153.16 147.73 14.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.133 0.492 . . . . 0.0 110.644 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.3 pttt -135.05 161.3 35.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.151 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 51.5 mt-10 -60.07 99.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.519 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -30.45 2.35 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -77.36 151.89 34.68 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.11 0.481 . . . . 0.0 110.412 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 5.1 m -100.77 132.52 46.12 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.488 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.3 m -115.68 150.56 17.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.409 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -111.62 153.62 26.07 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.383 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.609 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.85 100.62 0.11 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.603 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.89 -31.45 4.11 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 5.6 tt0 -63.66 143.81 57.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.117 0.484 . . . . 0.0 110.524 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.2 m -66.27 136.34 55.7 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.334 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.605 ' O ' HG22 ' A' ' 70' ' ' VAL . 27.6 m -119.1 -35.38 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.213 -179.51 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.637 HD12 HG12 ' A' ' 68' ' ' ILE . 7.1 tt -159.64 149.74 18.74 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.838 -179.315 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.418 HG12 ' N ' ' A' ' 85' ' ' LEU . 21.9 t -107.94 154.99 8.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.898 179.471 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.721 HD23 ' HA3' ' A' ' 63' ' ' GLY . 3.5 mp -123.78 173.12 8.36 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.196 0.522 . . . . 0.0 110.636 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -137.52 106.72 6.04 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.308 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.93 135.71 22.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.49 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 26.8 mtt 60.15 29.29 18.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.704 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt 59.42 35.46 22.98 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.712 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 10.7 mmm -133.61 130.81 38.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.546 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -70.9 117.49 12.48 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.413 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.21 103.44 9.84 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.291 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -79.85 143.44 34.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.646 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.482 ' CG1' HD13 ' A' ' 85' ' ' LEU . 40.7 mm -105.93 156.31 6.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.052 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.435 ' N ' HG22 ' A' ' 94' ' ' ILE . 12.9 m120 -134.24 143.07 47.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.47 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.11 142.0 98.17 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.318 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.5 -36.02 4.28 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.12 1.88 . . . . 0.0 112.288 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.609 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 1.7 p -145.76 161.47 39.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.433 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -65.27 142.51 58.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.322 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.8 -158.4 25.32 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.5 ttmt -135.5 145.88 47.55 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.05 0.453 . . . . 0.0 110.549 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.685 HG21 ' HB ' ' A' ' 70' ' ' VAL . 26.2 t -74.33 110.25 8.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.245 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -95.24 -29.54 14.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.723 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -160.51 135.39 7.67 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.517 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.417 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.1 t -101.37 109.27 25.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.21 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 29.4 mt -90.08 29.66 1.19 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.639 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.562 HG21 HD13 ' A' ' 83' ' ' LEU . 29.6 m -155.2 145.17 13.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 121.055 0.455 . . . . 0.0 110.361 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.4 mmtm -127.25 160.85 30.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.259 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -60.02 142.99 52.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.524 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 3.1 ttm180 61.35 34.35 18.45 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.492 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -114.18 140.15 48.77 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.388 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -88.63 126.11 35.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.531 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.7 m -122.11 157.79 26.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.395 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -96.57 143.69 27.33 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.414 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.32 92.64 0.07 OUTLIER Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.6 -27.81 2.92 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -60.94 141.35 57.33 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-O 121.031 0.444 . . . . 0.0 110.54 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.557 ' N ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.08 123.81 33.6 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.442 ' O ' HG22 ' A' ' 107' ' ' VAL . 92.3 mt -86.61 -51.83 5.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.055 0.455 . . . . 0.0 110.539 -179.802 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.5 mt -140.88 150.23 20.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.395 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -97.78 128.4 44.4 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.309 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.41 ' CG1' HD11 ' A' ' 57' ' ' ILE . 37.6 mm -107.17 143.61 17.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.478 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.749 0 CA-C-O 117.982 -1.455 . . . . 0.0 110.781 179.975 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -102.91 -138.48 9.98 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -98.31 114.33 26.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.101 0.477 . . . . 0.0 110.434 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 114.49 179.36 18.85 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.1 mtmt -141.93 41.96 1.68 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.338 0.59 . . . . 0.0 110.332 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.765 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -147.35 179.23 7.8 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.432 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 154.9 -85.59 0.14 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.791 -0.923 . . . . 0.0 110.791 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -83.79 96.19 8.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.035 0.445 . . . . 0.0 110.574 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.6 -54.92 0.65 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.659 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 23.8 mt-10 -82.28 124.85 30.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.08 0.467 . . . . 0.0 110.571 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.598 HD11 HD11 ' A' ' 122' ' ' ILE . 38.5 mt -80.72 111.2 21.21 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.131 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.597 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 46.2 Cg_endo -70.61 135.64 28.89 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 122.085 1.857 . . . . 0.0 112.387 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.591 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -73.02 153.39 90.85 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.398 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.62 -27.9 14.8 Favored 'Trans proline' 0 CA--C 1.528 0.2 0 C-N-CA 122.211 1.941 . . . . 0.0 112.404 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.561 HD11 ' CB ' ' A' ' 87' ' ' ALA . 3.9 pp -165.95 165.71 17.9 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.418 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.496 ' HB2' ' H ' ' A' ' 115' ' ' GLY . . . -79.76 104.73 10.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.286 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.22 -142.43 4.91 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.9 m -135.78 134.22 38.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.068 0.461 . . . . 0.0 110.468 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.602 ' CG1' HD11 ' A' ' 83' ' ' LEU . 24.9 t -72.14 127.94 34.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.126 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.31 -53.54 3.32 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.68 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 16.8 tttp -152.03 147.19 26.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.598 -179.749 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.571 HG12 HD12 ' A' ' 83' ' ' LEU . 47.9 mt -100.82 133.14 44.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.992 179.621 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.3 mp -99.6 -29.85 12.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.929 -179.599 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.777 ' HB ' HG21 ' A' ' 102' ' ' VAL . 34.9 m -110.7 148.66 13.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 121.241 0.543 . . . . 0.0 110.878 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.8 ptpp? -135.13 163.96 28.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.14 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -61.87 99.08 0.11 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.502 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.62 -30.9 2.36 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -84.73 147.53 26.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.14 0.495 . . . . 0.0 110.455 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.5 m -96.38 145.95 25.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.294 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.685 HG11 HG11 ' A' ' 70' ' ' VAL . 26.8 m -120.88 170.42 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.655 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 35.5 mttt -130.19 147.11 51.88 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.199 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.635 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.7 95.89 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.74 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.05 -34.21 2.48 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 11.0 tt0 -66.46 139.25 57.96 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.082 0.467 . . . . 0.0 110.527 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 19.4 m -62.76 137.68 58.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.313 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.455 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.1 m -112.83 -32.27 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.952 -179.653 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.602 HD11 ' CG1' ' A' ' 65' ' ' VAL . 7.1 tt -162.74 150.21 13.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.159 0.504 . . . . 0.0 110.624 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.1 t -103.49 143.57 15.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.119 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.5 tp -124.66 165.81 17.25 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.631 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -132.54 118.75 19.64 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.321 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.561 ' CB ' HD11 ' A' ' 61' ' ' LEU . . . -148.0 151.74 36.28 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.545 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 2.5 ptt? 41.8 39.92 1.36 Allowed 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 115.598 -0.728 . . . . 0.0 112.069 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.6 mttt 59.79 39.41 20.75 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.608 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.4 ttt -148.7 140.17 23.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.436 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -78.65 133.1 37.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.423 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.9 m -119.19 115.65 24.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.383 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -83.7 129.93 34.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.489 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 37.3 mm -104.14 122.51 57.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.306 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -109.84 144.01 38.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.253 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.51 141.88 94.4 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.42 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.39 -37.9 3.97 Favored 'Trans proline' 0 N--CA 1.471 0.178 0 C-N-CA 122.125 1.883 . . . . 0.0 112.302 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.635 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 3.0 p -147.19 159.93 43.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.403 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -62.7 141.36 58.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.351 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.3 -157.0 25.47 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -137.95 147.03 43.91 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.081 0.467 . . . . 0.0 110.416 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.777 HG21 ' HB ' ' A' ' 70' ' ' VAL . 25.0 t -76.88 112.61 14.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.191 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -95.31 -30.07 14.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.741 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.2 tttm -159.75 127.43 4.74 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.604 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.483 HG13 HG12 ' A' ' 120' ' ' ILE . 24.1 t -104.16 114.85 44.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.255 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mt -82.31 -39.06 23.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.405 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.549 HG21 HD13 ' A' ' 83' ' ' LEU . 33.2 m -74.64 150.27 7.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.545 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 43.4 mttt -133.6 161.13 35.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.316 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -61.56 139.98 58.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.458 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.44 37.52 16.62 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.354 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -123.92 146.98 48.08 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.386 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.18 138.14 31.78 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.519 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.2 m -122.33 162.39 22.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.336 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 13.6 mt-30 -103.12 141.06 36.49 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.293 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.496 ' H ' ' HB2' ' A' ' 62' ' ' ALA . . . -60.38 105.95 0.92 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.03 -26.97 9.99 Favored Glycine 0 CA--C 1.527 0.831 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 -58.15 148.89 25.3 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-O 121.109 0.48 . . . . 0.0 110.773 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.765 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.16 122.85 30.81 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.591 HD21 ' HB2' ' A' ' 59' ' ' ALA . 92.3 mt -89.61 -60.86 1.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.086 0.469 . . . . 0.0 110.423 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.582 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.4 mt -140.95 152.52 20.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.243 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 55.3 mttt -95.86 127.38 41.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.415 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.598 HD11 HD11 ' A' ' 57' ' ' ILE . 37.1 mm -107.15 145.16 14.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.396 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.027 -1.429 . . . . 0.0 110.798 -179.998 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -166.94 116.69 0.69 Allowed Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.809 -0.917 . . . . 0.0 110.809 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -145.05 32.69 1.11 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.057 0.456 . . . . 0.0 110.45 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.51 84.55 0.19 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 3.1 ttpt -174.81 128.85 0.31 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.071 0.462 . . . . 0.0 110.443 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.526 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -72.81 179.24 3.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.503 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.79 -103.87 0.4 Allowed Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.742 -0.943 . . . . 0.0 110.742 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 65.4 mt-10 -113.28 120.65 41.91 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.062 0.458 . . . . 0.0 110.398 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 110.62 -48.46 0.93 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -84.03 133.59 34.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.119 0.485 . . . . 0.0 110.405 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.489 HD11 HD11 ' A' ' 122' ' ' ILE . 52.4 mt -78.22 111.66 20.16 Favored Pre-proline 0 CA--C 1.535 0.372 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.237 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.435 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 48.1 Cg_endo -71.32 138.39 32.88 Favored 'Trans proline' 0 N--CA 1.472 0.221 0 C-N-CA 121.997 1.798 . . . . 0.0 112.348 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.66 146.66 99.09 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.404 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.81 -27.73 14.4 Favored 'Trans proline' 0 CA--C 1.528 0.196 0 C-N-CA 122.254 1.97 . . . . 0.0 112.291 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -164.64 171.02 14.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.46 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.71 93.53 6.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.447 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.95 -148.76 7.41 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.1 m -136.46 138.0 41.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.071 0.462 . . . . 0.0 110.551 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.571 HG13 HD21 ' A' ' 83' ' ' LEU . 19.5 t -71.05 116.72 13.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.2 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 t -98.61 -48.65 4.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.622 -179.804 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -150.4 144.67 25.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.622 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.622 HD11 ' HA ' ' A' ' 108' ' ' LYS . 21.8 mt -105.35 135.12 44.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.905 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.786 HD22 ' HB ' ' A' ' 81' ' ' THR . 3.6 mp -97.14 -30.62 12.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.846 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.701 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.3 m -119.47 145.7 25.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.187 0.518 . . . . 0.0 110.742 -179.704 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.9 pttm -133.6 164.21 27.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.252 179.879 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -60.54 103.82 0.28 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.452 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.04 -29.68 2.41 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -94.94 153.15 17.8 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.098 0.475 . . . . 0.0 110.475 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.4 m -96.69 153.08 18.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.311 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.701 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.4 m -128.61 168.64 21.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.73 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.4 mtpp -129.96 151.69 50.24 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.19 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.646 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.57 102.16 0.17 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.71 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.85 -37.74 2.05 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 32.3 tt0 -62.55 140.57 58.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.12 0.486 . . . . 0.0 110.692 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.786 ' HB ' HD22 ' A' ' 69' ' ' LEU . 9.2 m -67.34 141.07 57.26 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.227 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.781 HG22 ' O ' ' A' ' 94' ' ' ILE . 34.9 m -115.61 -24.25 3.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.592 -179.405 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.571 HD21 HG13 ' A' ' 65' ' ' VAL . 8.3 tt -166.26 152.94 9.29 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.211 0.529 . . . . 0.0 110.885 -179.668 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.566 ' N ' HD23 ' A' ' 83' ' ' LEU . 21.8 t -114.9 134.7 57.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.042 179.702 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.45 HD12 HD11 ' A' ' 94' ' ' ILE . 55.8 mt -115.47 161.59 18.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.611 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -139.11 82.33 1.89 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.132 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -92.66 104.75 17.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.245 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 55.1 mtp 64.95 48.24 2.38 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.339 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.4 mtpt 60.96 39.45 16.56 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.625 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 13.6 tpp -127.72 101.06 6.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.46 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.12 113.53 3.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.569 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.9 m -115.07 123.6 49.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.224 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 14.8 mt-10 -94.07 129.91 40.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.788 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.781 ' O ' HG22 ' A' ' 82' ' ' VAL . 4.4 mp -115.5 112.37 39.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.633 179.489 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -99.48 153.97 18.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.419 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.98 142.54 95.19 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.293 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.33 -36.22 5.67 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.175 1.917 . . . . 0.0 112.196 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.646 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -146.12 168.83 20.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.299 179.846 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -68.55 141.9 55.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.334 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.24 -161.16 31.12 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 74.9 tttt -134.51 148.12 50.47 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.096 0.474 . . . . 0.0 110.429 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.618 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.6 t -74.75 103.7 2.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.202 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -90.39 -29.29 18.11 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.774 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.5 tttt -158.32 123.53 4.37 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.139 0.495 . . . . 0.0 110.518 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.506 HG13 HG12 ' A' ' 120' ' ' ILE . 24.5 t -100.37 106.79 19.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.332 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.41 ' O ' HG13 ' A' ' 107' ' ' VAL . 5.4 mt -90.48 33.76 0.9 Allowed 'General case' 0 CA--C 1.533 0.326 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.421 179.678 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.43 HG22 ' O ' ' A' ' 119' ' ' LEU . 19.2 m -156.4 137.26 4.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 121.031 0.443 . . . . 0.0 110.101 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.622 ' HA ' HD11 ' A' ' 68' ' ' ILE . 1.4 mptp? -125.85 175.82 7.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.272 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -72.2 147.63 46.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.401 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 63.16 34.51 13.51 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.537 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -121.87 145.0 48.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.26 179.754 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.24 136.99 32.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.629 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 20.7 m -120.23 179.73 2.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.383 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -133.05 141.97 48.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.367 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.8 102.36 0.33 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.849 -0.901 . . . . 0.0 110.849 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.33 -31.32 4.7 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -60.24 142.5 54.44 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.093 0.473 . . . . 0.0 110.583 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.526 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -65.45 126.64 30.77 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.43 ' O ' HG22 ' A' ' 107' ' ' VAL . 92.6 mt -89.98 -55.49 3.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.993 0.425 . . . . 0.0 110.271 179.88 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.538 ' CG2' HG13 ' A' ' 102' ' ' VAL . 45.6 mt -143.51 149.25 18.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.333 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.2 ttmt -96.44 130.84 43.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.276 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.489 HD11 HD11 ' A' ' 57' ' ' ILE . 37.6 mm -107.22 144.17 16.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.49 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.758 0 CA-C-O 117.998 -1.446 . . . . 0.0 110.737 179.991 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -91.98 -163.55 38.15 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -123.36 -69.64 0.81 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.141 0.496 . . . . 0.0 110.502 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 160.33 -43.2 0.43 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 26.8 pttt -175.03 130.6 0.3 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.067 0.46 . . . . 0.0 110.494 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.652 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -69.92 179.13 2.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.414 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 140.68 46.67 0.06 OUTLIER Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -172.51 36.22 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.122 0.487 . . . . 0.0 110.386 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 116.21 -31.81 5.87 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -78.29 142.54 37.71 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.116 0.484 . . . . 0.0 110.341 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.427 HD11 HD11 ' A' ' 122' ' ' ILE . 47.4 mt -82.5 114.85 54.6 Favored Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.24 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.38 148.98 55.9 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.054 1.836 . . . . 0.0 112.278 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.586 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -81.13 145.26 56.04 Favored Pre-proline 0 CA--C 1.532 0.25 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.431 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -73.44 -27.34 13.29 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.238 1.958 . . . . 0.0 112.399 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.7 pp -162.57 158.26 23.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.472 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -75.19 91.28 2.61 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.337 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -121.03 -170.24 13.99 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.474 ' C ' HD23 ' A' ' 85' ' ' LEU . 18.9 m -106.93 134.98 49.28 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.057 0.456 . . . . 0.0 110.408 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.756 HG13 HD11 ' A' ' 83' ' ' LEU . 32.6 t -69.59 121.49 19.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.15 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t -95.66 -60.14 1.72 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.398 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -150.32 146.52 26.8 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.465 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.722 HG12 HD12 ' A' ' 83' ' ' LEU . 32.8 mt -102.46 124.05 56.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.922 179.773 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.635 HD22 ' HB ' ' A' ' 81' ' ' THR . 8.4 mp -97.61 27.88 4.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.991 -179.561 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.767 ' HB ' HG21 ' A' ' 102' ' ' VAL . 26.3 m -153.9 154.85 6.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 121.178 0.514 . . . . 0.0 110.486 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -141.6 158.2 44.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.122 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -60.52 92.5 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.45 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.19 -27.06 2.55 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -78.42 144.62 35.7 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.077 0.465 . . . . 0.0 110.489 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -95.54 135.45 37.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.355 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.602 HG11 HG11 ' A' ' 70' ' ' VAL . 26.6 m -115.4 160.28 14.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.573 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 23.8 mttm -118.52 142.91 47.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.286 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.601 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -57.76 95.7 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.761 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.19 -31.88 2.64 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.8 tt0 -68.01 151.17 47.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.137 0.494 . . . . 0.0 110.399 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.635 ' HB ' HD22 ' A' ' 69' ' ' LEU . 4.5 m -69.76 136.65 51.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.401 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.1 m -113.6 -32.11 2.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.901 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.756 HD11 HG13 ' A' ' 65' ' ' VAL . 8.3 tt -160.75 146.76 14.9 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.111 0.482 . . . . 0.0 110.705 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -101.85 137.1 30.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.094 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.737 HD12 HD11 ' A' ' 94' ' ' ILE . 12.8 mt -120.4 165.73 14.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.496 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.3 mt-10 -131.07 110.94 11.56 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.327 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.49 141.62 30.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.374 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 68.5 mtp 60.6 32.66 20.41 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.601 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.1 mmmt 60.87 33.1 20.05 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.557 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -142.0 142.89 32.96 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.403 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -81.1 122.78 27.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.394 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.8 m -113.07 120.21 40.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.333 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 -84.65 135.84 34.0 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.492 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.737 HD11 HD12 ' A' ' 85' ' ' LEU . 37.8 mm -104.85 126.85 59.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.296 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -108.73 141.23 41.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.427 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.32 143.17 95.79 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.324 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -73.08 -37.99 3.11 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.121 1.88 . . . . 0.0 112.273 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.601 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 21.2 p -145.01 155.71 43.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.302 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -65.64 141.45 58.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.375 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 178.15 -155.31 16.68 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -134.83 143.44 47.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.023 0.44 . . . . 0.0 110.38 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.767 HG21 ' HB ' ' A' ' 70' ' ' VAL . 26.0 t -79.04 114.13 19.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.139 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -95.44 -30.37 13.92 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.606 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.3 ttpt -158.0 131.89 7.94 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.464 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 26.8 t -108.72 102.22 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.267 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.1 mt -74.32 -33.61 63.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.446 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 119' ' ' LEU . 29.9 m -73.52 150.68 7.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.346 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -140.88 157.29 45.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.473 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 61.7 mt-10 -61.17 145.62 50.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.51 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.14 37.54 17.55 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.33 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.543 ' O ' HG23 ' A' ' 65' ' ' VAL . 15.0 t70 -127.28 145.0 50.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.454 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.9 137.46 32.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.493 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.1 m -121.32 156.12 25.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.376 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 13.6 mt-30 -101.6 144.57 30.17 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.376 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.31 107.18 1.36 Allowed Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.84 -27.64 8.17 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -59.75 141.72 54.67 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.054 0.454 . . . . 0.0 110.645 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.652 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.35 127.11 41.55 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.586 HD21 ' HB2' ' A' ' 59' ' ' ALA . 91.7 mt -91.17 -56.29 3.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.086 0.469 . . . . 0.0 110.459 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.578 ' CG2' HG13 ' A' ' 102' ' ' VAL . 53.5 mt -141.12 151.28 19.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.342 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.0 tttt -97.36 126.63 42.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.42 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.427 HD11 HD11 ' A' ' 57' ' ' ILE . 37.5 mm -105.24 145.64 13.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.397 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.82 0 CA-C-O 118.002 -1.443 . . . . 0.0 110.813 179.968 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -172.32 -76.37 0.05 OUTLIER Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.59 97.87 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.119 0.485 . . . . 0.0 110.528 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 173.99 76.86 0.05 OUTLIER Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 33.1 mttt -129.61 134.29 47.63 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.157 0.503 . . . . 0.0 110.374 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.632 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -62.42 176.62 0.6 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.445 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.79 46.54 0.07 OUTLIER Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -169.74 35.01 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.18 0.514 . . . . 0.0 110.369 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 116.4 -32.98 5.33 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -80.09 143.33 34.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.096 0.474 . . . . 0.0 110.506 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.6 mt -79.01 116.69 61.95 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.159 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.611 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 48.4 Cg_endo -71.6 137.62 30.62 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 121.991 1.794 . . . . 0.0 112.279 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.527 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -71.0 148.17 94.3 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.404 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.551 ' HD3' HD12 ' A' ' 94' ' ' ILE . 47.9 Cg_endo -72.58 -28.75 13.96 Favored 'Trans proline' 0 CA--C 1.528 0.194 0 C-N-CA 122.238 1.959 . . . . 0.0 112.216 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.5 pp -162.34 173.51 14.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.511 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -86.67 95.8 9.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.384 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.22 -145.39 6.52 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.534 ' C ' HD23 ' A' ' 85' ' ' LEU . 13.8 m -136.33 139.72 42.79 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.128 0.49 . . . . 0.0 110.512 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.707 HG13 HD11 ' A' ' 83' ' ' LEU . 21.8 t -68.66 121.96 19.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.097 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 92.7 p -99.45 -53.15 3.29 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.627 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.3 tptt -152.33 144.77 24.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.558 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.409 HG12 HD12 ' A' ' 83' ' ' LEU . 21.8 mt -103.14 133.19 47.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.989 179.716 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.412 HD13 ' HB ' ' A' ' 81' ' ' THR . 12.3 mt -99.77 -29.57 12.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.952 -179.648 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.813 HG11 HG11 ' A' ' 76' ' ' VAL . 32.6 m -110.98 147.87 14.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.249 0.547 . . . . 0.0 110.765 -179.726 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.8 pttt -136.18 166.01 24.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.244 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.5 ' HG3' HG23 ' A' ' 105' ' ' VAL . 14.8 mt-10 -61.79 100.03 0.14 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.495 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.06 -31.98 2.23 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -85.42 147.15 26.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.068 0.461 . . . . 0.0 110.461 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.1 m -98.29 146.8 25.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.348 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.813 HG11 HG11 ' A' ' 70' ' ' VAL . 24.9 m -126.75 165.52 25.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.614 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 22.2 pttt -127.2 150.51 49.49 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.285 179.768 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.743 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -58.62 98.23 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.748 -179.759 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.31 -37.91 1.83 Allowed Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 21.1 tt0 -65.18 143.82 57.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.072 0.463 . . . . 0.0 110.639 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.412 ' HB ' HD13 ' A' ' 69' ' ' LEU . 4.1 m -67.37 138.93 57.11 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.204 179.85 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.431 ' HA ' HG13 ' A' ' 70' ' ' VAL . 34.8 m -113.75 -34.38 2.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.84 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.707 HD11 HG13 ' A' ' 65' ' ' VAL . 7.9 tt -160.45 147.34 15.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.788 -179.415 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -104.97 139.43 25.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.001 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.634 HD21 HG21 ' A' ' 113' ' ' VAL . 2.4 mt -120.02 165.36 14.8 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.19 0.519 . . . . 0.0 110.691 -179.707 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -135.36 112.81 10.65 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.532 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.31 142.06 27.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.388 179.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 4.5 mtp 60.54 33.72 20.44 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.528 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.3 mttt 60.91 34.45 19.53 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.465 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.1 tpp -140.26 141.61 35.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.49 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -89.8 122.36 32.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.412 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.2 m -119.85 114.52 22.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.437 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -82.4 143.5 31.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.579 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.551 HD12 ' HD3' ' A' ' 60' ' ' PRO . 39.7 mm -105.14 127.62 59.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.162 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -105.42 142.16 35.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.341 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.86 132.2 91.76 Favored Pre-proline 0 CA--C 1.534 0.33 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.371 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -72.79 -32.19 9.5 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 121.99 1.793 . . . . 0.0 112.243 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.743 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 4.6 p -146.68 156.91 43.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.419 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -68.32 142.73 55.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.44 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 172.19 -156.77 26.1 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -135.43 146.46 48.26 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.057 0.456 . . . . 0.0 110.415 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.69 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.0 t -74.86 107.75 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.271 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' GLU . . . . . 0.402 ' HG3' ' N ' ' A' ' 104' ' ' LYS . 7.3 pt-20 -90.59 -30.98 16.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.563 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' LYS . . . . . 0.402 ' N ' ' HG3' ' A' ' 103' ' ' GLU . 1.5 tptm -156.11 130.57 8.87 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.586 -179.787 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.5 HG23 ' HG3' ' A' ' 72' ' ' GLU . 25.4 t -98.92 106.1 18.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.347 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.2 mt -89.59 12.06 17.82 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.511 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.688 HG21 HD13 ' A' ' 83' ' ' LEU . 28.3 m -127.33 136.16 61.38 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.095 0 CA-C-O 121.121 0.486 . . . . 0.0 110.122 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 40.1 tttt -128.5 156.21 43.62 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.373 -179.787 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -60.7 150.22 32.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.487 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 61.45 31.79 19.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.443 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -124.36 142.78 51.01 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.264 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.5 136.84 32.83 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.609 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.634 HG21 HD21 ' A' ' 85' ' ' LEU . 30.4 m -120.69 157.16 23.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.306 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 -100.14 142.19 31.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.504 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.07 107.64 1.41 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.61 -28.32 8.65 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.4 tt0 -57.62 147.14 28.19 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.087 0.47 . . . . 0.0 110.76 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.632 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -63.33 121.85 25.38 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.941 -0.863 . . . . 0.0 110.941 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.671 ' O ' HG13 ' A' ' 107' ' ' VAL . 56.5 mt -87.25 -52.56 5.33 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.056 0.455 . . . . 0.0 110.501 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' HG13 ' A' ' 102' ' ' VAL . 48.9 mt -142.31 148.3 20.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.35 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -95.75 128.04 42.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.345 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.4 mm -107.68 145.34 15.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.484 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.798 0 CA-C-O 117.984 -1.454 . . . . 0.0 110.824 179.999 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.72 79.13 1.24 Allowed Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -158.92 173.47 16.46 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.107 0.48 . . . . 0.0 110.444 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -171.13 158.96 30.71 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 19.1 mtpt 60.65 161.27 0.05 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.111 0.481 . . . . 0.0 110.503 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.521 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -115.31 178.05 4.44 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.422 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -158.69 -105.04 0.21 Allowed Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -108.17 120.89 43.63 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.08 0.467 . . . . 0.0 110.382 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 107.41 -48.5 0.94 Allowed Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -83.62 131.86 34.93 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.066 0.46 . . . . 0.0 110.357 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.568 HD11 HD11 ' A' ' 122' ' ' ILE . 53.0 mt -79.39 111.45 20.8 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.144 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.483 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.7 Cg_endo -71.33 141.98 40.18 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.016 1.811 . . . . 0.0 112.288 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.411 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -76.75 144.49 73.15 Favored Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.275 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.73 -22.35 20.6 Favored 'Trans proline' 0 CA--C 1.529 0.241 0 C-N-CA 122.181 1.921 . . . . 0.0 112.702 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.5 pp -161.7 167.38 25.19 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.128 0.489 . . . . 0.0 110.457 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -86.37 119.67 26.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.455 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -152.04 -141.4 3.31 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.522 ' C ' HD23 ' A' ' 85' ' ' LEU . 6.6 m -137.56 143.42 41.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.139 0.495 . . . . 0.0 110.439 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.796 HG13 HD11 ' A' ' 83' ' ' LEU . 37.3 t -68.17 128.63 31.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.172 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.6 m -98.18 -59.75 1.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.683 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 12.6 mtpt -149.49 147.18 27.9 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.541 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.474 HD11 ' HA ' ' A' ' 108' ' ' LYS . 51.8 mt -102.87 123.25 56.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.075 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.6 mp -94.09 -46.04 7.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.657 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.683 ' HB ' HG21 ' A' ' 102' ' ' VAL . 33.4 m -95.23 143.9 10.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.694 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 3.5 pttt -133.36 165.33 25.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.182 179.76 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -59.31 102.03 0.12 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.666 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 137.91 -31.89 2.42 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -84.9 149.99 25.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.09 0.471 . . . . 0.0 110.501 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 9.3 m -96.64 142.98 28.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.352 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.674 ' CG1' HG11 ' A' ' 70' ' ' VAL . 31.5 m -120.7 154.22 24.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.548 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 13.0 tptt -116.57 151.22 36.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.192 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.08 96.69 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.647 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.62 -30.81 3.35 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -64.79 139.52 58.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.082 0.468 . . . . 0.0 110.602 -179.857 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.0 m -65.57 136.16 56.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.187 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.493 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.0 m -115.09 -29.57 2.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.294 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.796 HD11 HG13 ' A' ' 65' ' ' VAL . 7.2 tt -165.29 152.22 10.47 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.133 0.492 . . . . 0.0 110.778 -179.451 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -107.66 139.81 28.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.153 179.751 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.712 HD21 HG21 ' A' ' 113' ' ' VAL . 1.8 mt -120.58 160.78 22.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.497 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -133.16 120.53 21.32 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.232 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.08 146.33 30.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.287 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 6.8 ptm 41.77 40.6 1.53 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.968 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 19.5 mtpp 61.11 40.28 15.11 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.599 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 35.3 ttp -144.71 121.7 11.37 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.501 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -79.44 127.6 32.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.372 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.1 m -119.76 126.18 50.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.367 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -82.7 129.9 35.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.361 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.526 HG13 HD12 ' A' ' 85' ' ' LEU . 23.6 mm -106.39 118.2 53.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.188 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 22.9 p30 -110.65 152.18 26.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.333 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.23 142.19 95.91 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.359 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -73.54 -32.97 7.26 Favored 'Trans proline' 0 N--CA 1.471 0.173 0 C-N-CA 122.171 1.914 . . . . 0.0 112.232 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.583 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 1.0 OUTLIER -148.64 161.08 42.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.385 179.999 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -64.24 142.79 58.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.407 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.21 -153.02 19.63 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 26.3 ttmt -139.84 147.07 40.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.103 0.478 . . . . 0.0 110.428 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.683 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -74.74 107.91 5.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.315 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -91.85 -27.74 17.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.865 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -161.4 136.1 7.24 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.07 0.462 . . . . 0.0 110.481 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.417 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.8 t -103.05 108.61 24.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.269 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.6 mt -90.5 31.1 1.06 Allowed 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.605 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.417 ' H ' HG12 ' A' ' 105' ' ' VAL . 25.8 m -155.54 144.54 12.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 121.032 0.444 . . . . 0.0 110.342 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.474 ' HA ' HD11 ' A' ' 68' ' ' ILE . 8.4 mptt -130.52 165.85 21.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.277 179.824 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -60.99 145.41 50.74 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.472 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 14.2 mmt85 60.64 37.12 19.43 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.507 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -117.93 144.7 45.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.351 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.01 129.24 38.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.457 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.712 HG21 HD21 ' A' ' 85' ' ' LEU . 27.8 m -122.09 150.38 25.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.475 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 -99.44 148.4 24.26 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.432 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -63.59 103.26 0.65 Allowed Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.48 -28.66 5.69 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -59.51 137.89 57.87 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.109 0.481 . . . . 0.0 110.665 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.521 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.23 119.73 19.8 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.411 HD21 ' HB2' ' A' ' 59' ' ' ALA . 44.8 mt -87.2 -54.74 4.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.133 0.492 . . . . 0.0 110.484 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.529 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.1 mt -140.99 143.76 27.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.226 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 7.2 tttt -95.16 129.99 42.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.517 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.568 HD11 HD11 ' A' ' 57' ' ' ILE . 37.2 mm -104.62 145.57 13.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.32 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.731 0 CA-C-O 118.011 -1.438 . . . . 0.0 110.768 179.97 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -116.54 -75.43 0.57 Allowed Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.984 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -108.1 33.57 4.05 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.191 0.52 . . . . 0.0 110.446 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.85 162.67 12.99 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 2.9 ptpt -169.43 60.55 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.334 0.588 . . . . 0.0 110.801 179.883 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.752 ' HB2' ' N ' ' A' ' 118' ' ' GLY . . . -132.19 147.24 52.41 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.44 179.692 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.39 -169.62 16.64 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.518 -1.033 . . . . 0.0 110.518 179.735 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 60.2 -145.71 0.49 Allowed 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -89.72 20.95 32.32 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.632 179.814 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.413 ' OE2' HD11 ' A' ' 106' ' ' LEU . 66.2 mt-10 -83.72 137.56 33.7 Favored 'General case' 0 C--O 1.23 0.076 0 CA-C-O 120.915 0.388 . . . . 0.0 110.146 179.725 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.736 HD12 ' HD2' ' A' ' 97' ' ' PRO . 41.5 mm -83.16 110.49 24.02 Favored Pre-proline 0 CA--C 1.534 0.338 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.068 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.483 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 48.7 Cg_endo -71.57 131.02 18.0 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 121.972 1.782 . . . . 0.0 112.101 -179.741 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.639 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -59.61 145.9 81.75 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.64 -179.867 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -75.62 -29.75 6.98 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.292 1.995 . . . . 0.0 112.5 -179.86 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.429 HD12 ' C ' ' A' ' 61' ' ' LEU . 4.4 pp -157.5 164.43 37.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.552 -179.681 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.9 108.02 13.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.437 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -134.65 -146.63 5.43 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.588 ' O ' HD23 ' A' ' 85' ' ' LEU . 1.8 m -136.33 138.18 41.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.095 0.474 . . . . 0.0 110.401 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.827 HG13 HD11 ' A' ' 83' ' ' LEU . 29.2 t -70.42 118.57 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.039 179.867 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.7 p -96.25 -53.67 3.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.845 -179.749 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 37.9 mttt -148.64 145.28 27.68 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 121.108 0.48 . . . . 0.0 110.703 -179.607 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.522 HD11 ' HA ' ' A' ' 108' ' ' LYS . 38.9 mt -101.78 128.81 53.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.986 179.507 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.429 HD12 HG22 ' A' ' 81' ' ' THR . 15.4 mt -97.64 -49.04 5.0 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.819 -179.592 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.697 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.6 m -93.73 146.04 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.217 0.532 . . . . 0.0 110.797 -179.831 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.8 pttp -135.31 162.72 31.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.034 179.789 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -59.26 103.19 0.16 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.54 -179.971 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.4 2.27 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.881 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -89.79 149.61 22.63 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.135 0.493 . . . . 0.0 110.445 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.4 m -97.22 141.51 30.25 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.444 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.697 ' CG1' HG11 ' A' ' 70' ' ' VAL . 27.1 m -117.43 156.33 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.464 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -117.53 157.03 27.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.438 179.864 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.81 96.48 0.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.557 -179.888 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.52 -28.24 4.52 Favored Glycine 0 CA--C 1.527 0.829 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.806 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -63.3 142.91 58.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.113 0.482 . . . . 0.0 110.684 -179.746 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.429 HG22 HD12 ' A' ' 69' ' ' LEU . 4.9 m -67.65 139.48 56.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.227 179.747 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.566 ' HA ' HG13 ' A' ' 70' ' ' VAL . 30.8 m -119.37 -32.62 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.399 -179.415 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.827 HD11 HG13 ' A' ' 65' ' ' VAL . 7.1 tt -163.09 152.09 14.71 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.228 0.537 . . . . 0.0 111.049 -179.297 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -106.1 139.81 26.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.857 179.574 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.588 HD23 ' O ' ' A' ' 64' ' ' THR . 12.5 mt -122.09 168.01 12.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.153 0.502 . . . . 0.0 110.759 -179.719 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 72.2 mt-10 -131.5 113.19 13.38 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.364 179.974 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -144.37 138.68 27.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.533 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 4.1 mmt 60.13 32.47 20.95 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.628 179.913 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 19.3 mttt 60.69 32.9 20.32 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.417 -179.979 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -142.4 122.24 13.54 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.19 -179.961 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -62.01 126.13 26.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.501 -179.956 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 7.0 m -113.53 115.21 27.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.241 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -80.98 128.66 33.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.525 -179.793 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.568 HD11 HD12 ' A' ' 85' ' ' LEU . 35.4 mm -101.54 144.08 13.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.06 179.707 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -138.14 134.82 35.06 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.731 -179.686 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.513 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -61.89 109.6 2.41 Favored Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.225 179.641 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.736 ' HD2' HD12 ' A' ' 57' ' ' ILE . 41.8 Cg_endo -65.0 -12.49 34.86 Favored 'Trans proline' 0 N--CA 1.475 0.425 0 C-N-CA 122.275 1.983 . . . . 0.0 113.147 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.91 134.83 39.12 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 121.014 0.435 . . . . 0.0 110.54 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -62.57 159.15 16.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.459 -179.911 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 154.29 -156.2 26.69 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.962 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 16.9 ttpt -133.02 146.78 52.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.125 0.488 . . . . 0.0 110.334 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.663 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.4 t -78.53 109.23 12.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.25 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -94.64 -30.53 14.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.59 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -157.1 130.92 8.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.449 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.468 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.2 t -97.92 112.64 30.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.259 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.413 HD11 ' OE2' ' A' ' 56' ' ' GLU . 5.6 mt -90.12 28.48 1.4 Allowed 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.737 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.468 ' H ' HG12 ' A' ' 105' ' ' VAL . 23.2 m -155.39 137.33 6.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.118 0.485 . . . . 0.0 110.336 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.522 ' HA ' HD11 ' A' ' 68' ' ' ILE . 13.8 pttm -127.5 167.01 16.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.346 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -60.09 145.76 45.49 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.77 179.993 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.05 37.41 17.94 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.354 179.974 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.48 ' O ' HG23 ' A' ' 65' ' ' VAL . 8.4 t70 -123.36 138.62 54.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.442 179.983 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.34 131.35 36.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.493 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.0 m -120.95 154.55 24.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.419 179.97 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 19.9 mp0 -96.65 141.93 29.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.325 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.77 90.38 0.06 OUTLIER Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.848 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.3 -30.35 2.81 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -58.63 154.58 14.11 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.115 0.483 . . . . 0.0 110.681 -179.997 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.752 ' N ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.64 125.76 37.79 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 -179.681 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.639 HD21 ' HB2' ' A' ' 59' ' ' ALA . 58.4 mt -94.77 -59.41 1.93 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.151 0.5 . . . . 0.0 110.225 179.744 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.503 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.9 mt -141.33 141.95 29.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.181 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.3 tttt -88.5 127.06 35.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.433 179.972 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.5 mm -106.82 141.27 22.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.364 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.03 -1.428 . . . . 0.0 110.796 179.959 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 169.5 175.73 38.87 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.957 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -87.19 -32.77 19.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.048 0.451 . . . . 0.0 110.417 179.992 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -68.23 143.24 40.74 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.918 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -137.99 41.58 2.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.356 0.598 . . . . 0.0 110.222 179.918 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.735 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -157.5 -179.46 8.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.49 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 130.98 -49.07 0.94 Allowed Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.761 -0.935 . . . . 0.0 110.761 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -80.45 63.32 4.86 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.394 0.616 . . . . 0.0 110.425 -179.86 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.25 -37.86 3.51 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 179.778 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.617 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 57.8 mt-10 -82.96 129.25 35.01 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.161 0.505 . . . . 0.0 110.554 -179.823 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.432 HD13 ' HD3' ' A' ' 97' ' ' PRO . 53.8 mt -79.01 111.71 22.05 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.154 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.626 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.1 Cg_endo -71.09 149.09 57.85 Favored 'Trans proline' 0 N--CA 1.472 0.247 0 C-N-CA 122.074 1.849 . . . . 0.0 112.299 -179.953 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.852 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -84.24 150.76 58.48 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.447 -179.963 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -72.83 -28.5 13.46 Favored 'Trans proline' 0 CA--C 1.527 0.164 0 C-N-CA 122.251 1.968 . . . . 0.0 112.311 179.971 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.8 pp -164.84 161.99 20.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.43 179.968 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.67 104.72 2.06 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.386 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.472 ' CA ' ' HB2' ' A' ' 87' ' ' ALA . . . -132.87 178.56 18.05 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.7 m -104.07 134.86 46.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.084 0.469 . . . . 0.0 110.368 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.644 ' HA ' HD23 ' A' ' 85' ' ' LEU . 24.2 t -72.04 118.66 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.102 179.878 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -100.02 -50.19 4.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.629 -179.72 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.95 140.53 21.61 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.769 -179.653 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.554 HG12 HD12 ' A' ' 83' ' ' LEU . 36.1 mt -105.41 126.15 60.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.836 179.579 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.34 28.65 3.99 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.978 -179.564 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.859 ' HB ' HG21 ' A' ' 102' ' ' VAL . 13.6 m -151.07 153.18 10.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.338 0.59 . . . . 0.0 110.897 -179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -137.26 154.82 50.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.918 179.502 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -58.18 91.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.165 0.507 . . . . 0.0 110.681 -179.881 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.88 -29.1 2.47 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -179.919 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -65.06 148.27 51.96 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.055 0.455 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.2 m -97.67 132.28 43.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.237 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.1 m -121.54 163.77 19.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.633 -179.821 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -129.63 154.18 47.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.593 -0.731 . . . . 0.0 110.184 179.74 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.652 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.01 91.21 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.482 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.07 -34.98 1.95 Allowed Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -62.56 140.03 58.63 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.028 0.442 . . . . 0.0 110.45 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.9 m -66.92 136.84 55.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.124 179.815 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.42 ' O ' HG22 ' A' ' 70' ' ' VAL . 29.8 m -116.97 -29.76 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.493 -179.382 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.644 HD11 HG13 ' A' ' 65' ' ' VAL . 10.2 tt -161.04 159.13 28.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.303 0.573 . . . . 0.0 111.016 -179.439 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.615 ' N ' HD23 ' A' ' 83' ' ' LEU . 21.7 t -125.7 131.69 71.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.809 179.513 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.644 HD23 ' HA ' ' A' ' 65' ' ' VAL . 19.8 mt -116.09 168.95 9.64 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.202 0.525 . . . . 0.0 110.747 -179.554 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -139.9 80.71 1.78 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.156 179.687 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.472 ' HB2' ' CA ' ' A' ' 63' ' ' GLY . . . -92.37 124.89 36.76 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.609 -179.675 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 13.8 mmt 60.34 39.21 19.03 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.38 179.788 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 59.9 mttt 61.67 40.15 13.55 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.238 -179.908 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 11.4 tpp -135.13 114.21 12.15 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.591 -179.915 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -63.69 118.57 8.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.446 179.822 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 8.7 m -114.46 116.96 29.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.202 179.906 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -84.38 131.7 34.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.438 -179.951 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.428 HG22 ' N ' ' A' ' 95' ' ' ASN . 37.7 mm -106.4 155.95 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.293 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.428 ' N ' HG22 ' A' ' 94' ' ' ILE . 10.6 m120 -142.28 145.42 34.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.455 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.64 142.38 94.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.418 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.432 ' HD3' HD13 ' A' ' 57' ' ' ILE . 50.6 Cg_endo -74.59 -36.24 3.05 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.157 1.905 . . . . 0.0 112.375 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.652 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -146.55 170.45 16.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.413 -179.946 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -69.31 142.2 54.11 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.6 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 160.29 -166.7 35.34 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 -179.989 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 13.9 ptpt -129.17 168.8 15.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.355 0.598 . . . . 0.0 110.657 179.798 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.859 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.6 t -82.48 113.89 22.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.547 -179.72 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -94.61 -33.08 13.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.455 179.894 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.1 ttpp -160.63 123.75 3.37 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.606 179.871 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.54 HG13 HG12 ' A' ' 120' ' ' ILE . 23.1 t -102.1 109.99 27.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.325 179.799 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.4 mt -82.21 -30.43 30.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.452 179.763 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 105' ' ' VAL . 27.6 m -82.04 143.25 12.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.796 -179.824 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 20.2 mmtt -131.32 158.79 39.72 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.107 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -61.99 147.33 47.41 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.496 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 8.1 mmm180 64.16 34.43 11.03 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.759 179.85 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.522 ' O ' HG23 ' A' ' 65' ' ' VAL . 31.4 m-20 -131.98 140.81 49.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.413 179.676 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.8 140.75 29.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.554 -179.904 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.0 m -121.69 163.52 19.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.374 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 12.4 mm100 -98.35 142.63 29.75 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.299 179.966 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.96 106.28 1.06 Allowed Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.749 -0.941 . . . . 0.0 110.749 -179.972 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.63 -25.57 10.19 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -179.833 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 -59.73 143.05 51.9 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 121.102 0.477 . . . . 0.0 110.651 -179.822 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.735 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.34 124.84 36.03 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.852 HD21 ' HB2' ' A' ' 59' ' ' ALA . 49.2 mt -89.76 -54.9 3.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.092 0.472 . . . . 0.0 110.452 -179.979 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.54 HG12 HG13 ' A' ' 105' ' ' VAL . 47.3 mt -145.86 147.8 18.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.121 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 14.7 ttmt -95.89 136.44 36.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.153 179.774 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.8 mm -110.0 143.16 20.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.433 -179.899 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.745 0 CA-C-O 117.987 -1.452 . . . . 0.0 110.766 -179.997 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 118.35 -48.23 0.96 Allowed Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.967 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.48 160.97 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.134 0.492 . . . . 0.0 110.591 -179.997 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.4 136.22 0.21 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.971 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 35.3 mttp -142.18 41.29 1.64 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.261 0.553 . . . . 0.0 110.287 179.932 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.743 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -150.54 -179.56 7.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.528 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.61 -46.16 1.09 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -93.89 72.49 4.13 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.313 0.578 . . . . 0.0 110.367 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 102.23 -41.97 2.01 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.583 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 17.0 mt-10 -83.82 134.14 34.72 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.11 0.481 . . . . 0.0 110.465 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.515 HD11 HD11 ' A' ' 122' ' ' ILE . 55.8 mt -79.98 111.61 23.19 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.309 -179.997 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.551 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.7 Cg_endo -71.81 131.67 18.79 Favored 'Trans proline' 0 N--CA 1.472 0.217 0 C-N-CA 122.035 1.823 . . . . 0.0 112.287 179.931 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.46 147.57 98.78 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.396 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -72.29 -27.9 15.86 Favored 'Trans proline' 0 CA--C 1.528 0.205 0 C-N-CA 122.188 1.926 . . . . 0.0 112.325 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.533 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.4 pp -163.92 159.65 21.14 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.464 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.456 ' HB2' ' H ' ' A' ' 115' ' ' GLY . . . -74.72 101.57 4.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.373 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.11 -141.26 5.07 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.94 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.0 m -137.81 135.86 36.66 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.169 0.509 . . . . 0.0 110.45 -179.859 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.753 HG13 HD11 ' A' ' 83' ' ' LEU . 21.7 t -69.64 120.06 16.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.225 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 79.2 p -97.02 -53.45 3.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.749 -179.829 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 45.6 tttt -152.06 148.37 27.6 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.603 -179.813 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.544 HG12 HD12 ' A' ' 83' ' ' LEU . 48.9 mt -104.15 134.39 45.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.061 179.756 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.587 HD12 HG22 ' A' ' 81' ' ' THR . 86.3 mt -99.22 -31.46 11.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.758 -179.694 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.705 HG11 ' CG1' ' A' ' 76' ' ' VAL . 34.5 m -113.18 145.07 19.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.229 0.538 . . . . 0.0 110.589 -179.871 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.78 163.89 30.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.211 179.771 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.438 ' HG3' HG23 ' A' ' 105' ' ' VAL . 33.6 mt-10 -58.36 102.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.582 -179.864 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.25 -28.29 2.48 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.824 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -95.69 151.81 19.02 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.1 0.476 . . . . 0.0 110.421 -179.97 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -98.46 147.58 24.59 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.392 179.894 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.705 ' CG1' HG11 ' A' ' 70' ' ' VAL . 24.9 m -121.83 169.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.498 -179.94 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.2 mmtp -130.23 155.25 46.59 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.36 -179.969 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.543 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.74 103.51 0.35 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.474 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.4 -30.79 5.66 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 179.94 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.8 tt0 -61.29 143.2 56.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.621 -179.853 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.587 HG22 HD12 ' A' ' 69' ' ' LEU . 2.5 m -67.76 138.51 56.26 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.266 179.831 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.476 ' HA ' HG13 ' A' ' 70' ' ' VAL . 28.1 m -118.68 -33.6 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.265 -179.443 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.753 HD11 HG13 ' A' ' 65' ' ' VAL . 7.4 tt -161.05 152.87 19.61 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.21 0.529 . . . . 0.0 111.017 -179.303 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.2 t -106.45 143.34 17.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.999 179.665 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.788 HD21 HG21 ' A' ' 113' ' ' VAL . 14.9 mt -120.55 163.16 18.4 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.51 -179.904 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -133.52 103.49 5.95 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.458 -179.944 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -148.52 153.15 38.03 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.247 179.908 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 32.1 mtp 60.54 31.06 20.18 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.699 -179.931 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.4 tttp 59.12 29.37 18.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.765 179.791 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 12.9 ptm -148.66 133.91 18.39 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.106 0.479 . . . . 0.0 110.464 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -70.51 130.61 42.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.592 -179.852 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 4.1 m -115.87 119.5 36.18 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.277 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 26.3 mt-10 -82.39 131.09 35.23 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.628 -179.82 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.759 HD11 HD12 ' A' ' 85' ' ' LEU . 26.9 mm -105.58 148.54 9.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.093 179.815 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 8.0 p-10 -137.23 151.06 48.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.565 -179.911 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.68 144.88 98.83 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.279 179.976 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.428 ' HD3' HG23 ' A' ' 57' ' ' ILE . 49.1 Cg_endo -73.94 -34.63 5.01 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.153 1.902 . . . . 0.0 112.252 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.543 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 32.9 p -145.65 167.46 23.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.37 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -68.77 142.97 54.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.396 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 170.15 -160.15 32.92 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -133.23 149.24 52.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.145 0.497 . . . . 0.0 110.409 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.68 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.0 t -75.1 106.86 5.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.316 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -92.95 -29.98 15.6 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.725 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.9 tttt -158.02 127.93 6.04 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.466 179.998 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.588 HG13 HG12 ' A' ' 120' ' ' ILE . 20.4 t -100.52 110.8 28.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.322 179.916 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.5 mt -90.09 29.38 1.23 Allowed 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.676 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.436 ' H ' HG12 ' A' ' 105' ' ' VAL . 24.4 m -155.44 142.12 11.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.062 0.458 . . . . 0.0 110.353 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.499 ' HA ' HD11 ' A' ' 68' ' ' ILE . 16.8 mmtt -125.86 175.37 7.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.392 179.979 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -73.06 148.34 44.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.395 179.937 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.4 34.2 18.39 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.584 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -123.09 149.91 43.86 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.329 179.838 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.17 135.22 33.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.541 -179.952 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.788 HG21 HD21 ' A' ' 85' ' ' LEU . 30.7 m -121.17 151.64 24.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.279 179.919 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -98.56 140.46 32.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.328 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 115' ' ' GLY . . . . . 0.456 ' H ' ' HB2' ' A' ' 62' ' ' ALA . . . -59.19 108.45 1.63 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 109.53 -26.55 14.31 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -179.782 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -57.63 145.24 34.69 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 121.134 0.492 . . . . 0.0 110.862 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.743 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -62.18 118.21 13.79 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.848 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.405 ' O ' HG22 ' A' ' 107' ' ' VAL . 94.5 mt -88.33 -54.75 4.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.169 0.509 . . . . 0.0 110.177 179.799 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.588 HG12 HG13 ' A' ' 105' ' ' VAL . 44.8 mt -143.18 149.19 18.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.145 179.819 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 42.7 tttt -97.34 130.01 44.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.319 179.885 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.515 HD11 HD11 ' A' ' 57' ' ' ILE . 37.9 mm -107.71 144.44 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.425 -179.843 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.764 0 CA-C-O 118.025 -1.431 . . . . 0.0 110.747 179.955 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 174.87 -178.12 46.73 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -89.43 -70.85 0.63 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.108 0.48 . . . . 0.0 110.438 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -65.81 -176.66 6.6 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 179.999 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.5 mttt -156.93 40.07 0.32 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.235 0.541 . . . . 0.0 110.42 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.779 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -151.63 141.36 21.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.253 179.83 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -177.63 -39.56 0.06 OUTLIER Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.164 -0.774 . . . . 0.0 111.164 179.94 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -77.9 -79.98 0.11 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.086 0.469 . . . . 0.0 110.891 -179.669 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -117.64 -4.61 15.03 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.562 179.721 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.716 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 37.2 mt-10 -92.18 132.77 36.38 Favored 'General case' 0 C--O 1.23 0.049 0 O-C-N 122.494 -0.415 . . . . 0.0 110.421 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 54.3 mt -80.42 111.1 19.81 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.167 -179.984 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.61 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 50.3 Cg_endo -72.31 135.08 23.98 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.024 1.816 . . . . 0.0 112.351 -179.893 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.572 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -70.27 148.89 95.88 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.427 179.977 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -72.31 -28.44 15.19 Favored 'Trans proline' 0 N--CA 1.472 0.207 0 C-N-CA 122.228 1.952 . . . . 0.0 112.303 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.2 pp -164.26 162.71 22.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.389 179.952 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.29 117.84 16.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.443 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -145.83 -146.87 4.49 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 25.9 m -137.18 132.6 34.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.172 0.51 . . . . 0.0 110.376 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.638 ' CG1' HD11 ' A' ' 83' ' ' LEU . 21.4 t -70.23 132.31 33.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.301 179.907 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.0 t -101.52 -57.61 2.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.586 -179.958 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 32.2 ttpt -150.2 146.58 26.93 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.492 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.471 HG12 HD12 ' A' ' 83' ' ' LEU . 21.6 mt -98.92 133.95 39.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.149 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.641 HD11 HG23 ' A' ' 84' ' ' VAL . 5.6 mp -98.23 -31.57 12.01 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.617 -179.828 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.795 HG11 HG11 ' A' ' 76' ' ' VAL . 34.0 m -113.72 145.92 18.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.207 0.527 . . . . 0.0 110.761 -179.841 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.4 ptpp? -133.67 167.13 21.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.042 179.605 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -57.58 113.14 1.67 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.623 -179.972 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.39 21.06 5.29 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.588 -179.989 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -135.01 141.1 46.12 Favored 'General case' 0 C--O 1.231 0.081 0 CA-C-O 121.094 0.474 . . . . 0.0 110.138 179.601 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -95.29 132.02 40.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.611 -179.711 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.795 HG11 HG11 ' A' ' 70' ' ' VAL . 19.9 m -114.5 168.08 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.312 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 7.8 mmmt -121.65 139.91 52.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.258 179.829 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.656 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -56.27 97.95 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.972 -179.81 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.96 -37.39 1.9 Allowed Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.9 tt0 -66.07 149.12 50.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.033 0.444 . . . . 0.0 110.526 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -67.13 136.51 55.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.295 179.971 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.464 HG11 ' HB2' ' A' ' 96' ' ' ALA . 25.6 m -114.77 -31.5 2.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.124 -179.739 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.638 HD11 ' CG1' ' A' ' 65' ' ' VAL . 7.7 tt -160.67 151.83 19.01 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -179.674 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.641 HG23 HD11 ' A' ' 69' ' ' LEU . 22.0 t -102.87 128.26 55.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.055 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.437 HD11 HG21 ' A' ' 113' ' ' VAL . 1.0 OUTLIER -111.76 159.41 18.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.643 -179.771 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -139.84 84.3 1.97 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.301 179.867 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -91.17 112.63 24.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.368 -179.836 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 35.4 mtt 63.61 46.03 4.36 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.393 0.615 . . . . 0.0 110.265 179.829 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 18.4 mtmt 61.06 39.81 15.83 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.396 179.909 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 1.2 tpt -129.34 96.4 4.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.359 179.922 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -62.44 112.23 2.36 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.474 179.967 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 20.2 m -120.29 139.55 52.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.343 179.894 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -85.92 135.09 33.81 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.481 -179.862 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.1 mm -107.82 119.24 57.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.237 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 14.0 p-10 -104.2 142.36 34.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.457 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.464 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -60.82 141.62 92.79 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.492 -179.963 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -73.55 -36.45 3.86 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.198 1.932 . . . . 0.0 112.172 179.932 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.656 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 69.4 p -147.24 153.92 40.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.345 -179.974 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -65.38 141.89 58.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.415 179.863 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.67 -155.34 19.6 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.967 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.7 ttpt -133.48 143.81 49.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.174 0.511 . . . . 0.0 110.593 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.54 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.0 t -75.97 111.23 12.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.079 179.828 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -95.69 -32.49 12.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.82 -179.662 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -161.03 129.84 4.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.117 0.484 . . . . 0.0 110.285 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.715 HG13 HG12 ' A' ' 120' ' ' ILE . 21.8 t -103.85 112.64 38.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.263 179.896 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.3 mt -79.81 -31.62 40.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.562 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.463 HG13 ' HA ' ' A' ' 119' ' ' LEU . 27.0 m -83.76 146.92 6.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.615 -179.801 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 18.9 mttm -129.36 172.15 11.79 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.252 179.943 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.41 139.27 54.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.247 -179.983 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 60.78 40.85 15.54 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.57 179.965 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -121.94 145.83 47.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.404 179.846 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.86 131.12 37.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.381 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.437 HG21 HD11 ' A' ' 85' ' ' LEU . 31.3 m -120.3 153.26 23.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.37 179.924 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -98.86 145.84 26.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.36 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.9 110.24 2.91 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.998 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.55 -28.73 8.36 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.906 -0.877 . . . . 0.0 110.906 -179.83 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -58.02 141.01 51.19 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 121.128 0.49 . . . . 0.0 110.815 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.779 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -62.3 125.85 36.77 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.87 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.572 HD21 ' HB2' ' A' ' 59' ' ' ALA . 89.9 mt -88.96 -57.23 2.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.009 0.433 . . . . 0.0 110.4 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.715 HG12 HG13 ' A' ' 105' ' ' VAL . 53.2 mt -141.29 151.3 19.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.431 179.926 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.7 mttt -94.02 121.68 35.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.132 179.813 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.3 mm -104.01 142.55 17.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.486 -179.845 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.771 0 CA-C-O 117.97 -1.461 . . . . 0.0 110.777 -179.981 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.41 -59.21 0.11 Allowed Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -141.85 78.07 1.61 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.271 0.558 . . . . 0.0 110.318 179.924 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 168.58 43.28 0.03 OUTLIER Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.871 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.8 pttt -153.64 143.56 21.99 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.051 0.453 . . . . 0.0 110.404 179.964 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 56' ' ' GLU . . . -62.04 173.74 1.03 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.492 -179.9 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -162.04 -66.92 0.02 OUTLIER Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 179.95 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -134.48 105.85 6.75 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.121 0.486 . . . . 0.0 110.451 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 116.14 -52.06 0.69 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.484 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 14.0 mt-10 -83.84 132.99 34.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.088 0.47 . . . . 0.0 110.473 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.3 mt -79.15 118.5 72.84 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.213 -179.942 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -71.81 138.03 30.83 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 122.057 1.838 . . . . 0.0 112.343 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.556 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -71.66 147.76 92.28 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.405 179.934 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.29 -26.47 17.48 Favored 'Trans proline' 0 CA--C 1.528 0.207 0 C-N-CA 122.232 1.954 . . . . 0.0 112.451 179.913 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.9 pp -163.07 175.27 11.25 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.485 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -89.79 93.01 9.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.428 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.66 -145.41 6.61 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.5 m -137.03 140.71 42.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.122 0.487 . . . . 0.0 110.415 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.59 HG13 HD11 ' A' ' 83' ' ' LEU . 22.8 t -70.79 127.98 33.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.156 179.949 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 7.9 p -99.55 -54.5 2.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.623 -179.84 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.6 tttt -151.05 147.98 27.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.564 -179.804 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.643 HD11 ' HA ' ' A' ' 108' ' ' LYS . 38.1 mt -102.4 133.15 46.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.151 179.792 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.551 HD12 HG22 ' A' ' 81' ' ' THR . 50.3 mt -99.16 -47.73 5.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.686 -179.809 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.772 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.3 m -99.98 146.91 8.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.552 -179.88 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -137.15 164.21 29.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.119 179.749 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -58.5 106.01 0.35 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.61 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.99 2.22 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -96.63 151.08 19.95 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.129 0.49 . . . . 0.0 110.361 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.546 HG22 ' O ' ' A' ' 100' ' ' GLY . 1.1 m -96.44 151.65 19.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.46 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.772 ' CG1' HG11 ' A' ' 70' ' ' VAL . 26.7 m -125.75 168.22 18.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.49 -179.951 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.1 ttpt -129.57 153.84 47.66 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.322 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.672 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.76 100.8 0.16 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.503 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.19 -32.89 3.47 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.87 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.4 tt0 -63.99 143.12 58.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.038 0.447 . . . . 0.0 110.513 -179.84 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.551 HG22 HD12 ' A' ' 69' ' ' LEU . 2.2 m -67.51 137.57 55.88 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.196 179.838 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.0 m -117.13 -34.02 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.124 -179.497 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.59 HD11 HG13 ' A' ' 65' ' ' VAL . 7.6 tt -161.72 153.62 19.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.227 0.537 . . . . 0.0 110.952 -179.453 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -108.55 143.09 19.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.932 179.52 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.426 HD11 HG21 ' A' ' 113' ' ' VAL . 1.4 tp -122.49 170.63 9.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.675 -179.693 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -137.83 117.6 13.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.466 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -148.96 133.7 17.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.399 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 12.5 mtt 60.66 33.2 20.33 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.468 -179.99 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 28.3 mmtt 60.23 33.96 20.99 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.609 -179.946 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 4.2 mmt -136.99 122.43 19.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.419 179.958 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -62.9 128.33 35.38 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.539 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -114.72 111.25 20.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.201 179.956 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -81.72 127.94 33.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.586 -179.829 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 34.4 mm -103.97 144.63 13.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.128 179.689 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -135.29 148.87 49.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.426 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.79 138.39 97.37 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.273 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -74.38 -31.2 7.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.052 1.835 . . . . 0.0 112.258 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.672 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 15.9 p -145.74 163.9 33.5 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.435 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -68.11 142.7 55.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.363 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.546 ' O ' HG22 ' A' ' 75' ' ' THR . . . 171.76 -161.41 33.54 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.7 ttpt -132.27 147.25 52.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.412 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.61 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.7 t -75.2 106.68 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.198 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -92.12 -29.13 16.68 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.776 -179.846 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 5.6 tttt -160.07 131.02 5.72 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.112 0.482 . . . . 0.0 110.508 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.423 HG12 ' H ' ' A' ' 107' ' ' VAL . 22.3 t -100.8 109.01 24.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.198 179.897 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 23.5 mt -90.13 31.02 1.02 Allowed 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.65 -179.99 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.449 HG21 HD13 ' A' ' 83' ' ' LEU . 24.6 m -155.58 137.11 5.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-O 121.061 0.458 . . . . 0.0 110.174 -179.993 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.643 ' HA ' HD11 ' A' ' 68' ' ' ILE . 34.1 mtmt -123.63 177.56 5.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.379 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -68.93 144.64 54.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.491 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 34.1 mtt180 60.12 33.25 21.17 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.619 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -111.49 142.86 43.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.36 -179.978 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.75 134.28 34.54 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.5 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.426 HG21 HD11 ' A' ' 85' ' ' LEU . 30.3 m -120.77 -179.92 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.398 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -140.84 147.94 39.77 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.397 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.02 106.43 1.11 Allowed Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 179.962 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 119.82 -31.79 5.22 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 -179.938 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -60.61 134.49 57.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.064 0.459 . . . . 0.0 110.571 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.472 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.14 123.06 31.47 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.781 -0.927 . . . . 0.0 110.781 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.556 HD21 ' HB2' ' A' ' 59' ' ' ALA . 62.7 mt -88.67 -54.88 3.95 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.068 0.461 . . . . 0.0 110.467 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.525 ' CG2' HG13 ' A' ' 102' ' ' VAL . 52.9 mt -140.93 148.91 21.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.368 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.8 mttt -95.35 127.15 41.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.335 179.885 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.3 mm -108.02 143.52 18.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.359 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.698 0 CA-C-O 117.982 -1.454 . . . . 0.0 110.761 -179.984 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -178.57 68.74 0.08 OUTLIER Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.55 89.91 5.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.121 0.486 . . . . 0.0 110.394 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 138.76 -146.79 18.62 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 58.1 mttm -153.68 40.5 0.51 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.235 0.54 . . . . 0.0 110.418 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.799 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -148.47 132.98 17.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.353 179.837 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -141.86 -91.41 0.17 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 35.5 mt-10 -99.89 93.88 6.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.057 0.456 . . . . 0.0 110.529 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 128.88 -56.9 0.73 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.758 -0.937 . . . . 0.0 110.758 179.936 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.65 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 7.7 mt-10 -84.62 129.67 34.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.085 0.469 . . . . 0.0 110.427 179.992 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.743 HD11 HD11 ' A' ' 122' ' ' ILE . 42.7 mt -80.8 111.13 20.71 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.284 179.885 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.606 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.1 Cg_endo -71.02 137.27 31.46 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.079 1.852 . . . . 0.0 112.33 -179.854 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.32 151.01 97.57 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.458 179.994 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.66 ' HB2' HD23 ' A' ' 61' ' ' LEU . 48.9 Cg_endo -72.7 -27.5 15.0 Favored 'Trans proline' 0 CA--C 1.529 0.23 0 C-N-CA 122.212 1.941 . . . . 0.0 112.35 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.66 HD23 ' HB2' ' A' ' 60' ' ' PRO . 0.2 OUTLIER -164.23 172.47 13.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.368 179.97 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.8 92.3 7.22 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.31 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -123.81 -146.16 6.94 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.931 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.3 m -135.79 137.57 41.73 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.102 0.477 . . . . 0.0 110.362 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.774 HG13 HD11 ' A' ' 83' ' ' LEU . 22.1 t -68.22 128.27 31.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.319 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -97.72 -61.55 1.37 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.428 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -149.71 145.87 26.92 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.403 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.565 HG12 HD12 ' A' ' 83' ' ' LEU . 49.5 mt -97.76 129.42 47.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.079 179.789 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.585 HD12 HG22 ' A' ' 81' ' ' THR . 22.3 mt -97.41 -43.54 7.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.818 -179.703 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.769 HG11 ' CG1' ' A' ' 76' ' ' VAL . 31.4 m -104.2 145.83 12.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.216 0.531 . . . . 0.0 110.781 -179.691 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.1 pttt -137.24 161.93 34.89 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.945 179.718 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -57.16 107.88 0.47 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.766 -179.926 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -31.02 2.31 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -179.686 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -98.83 152.71 19.43 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.972 0.415 . . . . 0.0 110.36 179.86 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.522 HG23 ' HB2' ' A' ' 101' ' ' LYS . 0.7 OUTLIER -96.61 151.07 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.45 179.995 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.769 ' CG1' HG11 ' A' ' 70' ' ' VAL . 23.5 m -127.81 169.97 18.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.41 -179.929 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 17.4 mmmt -132.49 153.75 50.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.409 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.514 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.79 104.47 0.36 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.577 -179.845 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 126.35 -34.69 3.14 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.857 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 -64.43 140.43 58.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.116 0.484 . . . . 0.0 110.513 -179.908 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.585 HG22 HD12 ' A' ' 69' ' ' LEU . 11.1 m -67.42 136.55 54.88 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.333 179.915 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 94' ' ' ILE . 30.0 m -112.82 -29.23 2.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.042 -179.737 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.774 HD11 HG13 ' A' ' 65' ' ' VAL . 7.7 tt -163.99 147.53 9.8 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 121.12 0.486 . . . . 0.0 110.86 -179.516 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -98.86 134.15 38.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.961 179.593 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.716 HD11 HG21 ' A' ' 113' ' ' VAL . 1.0 OUTLIER -116.04 167.71 10.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.542 -179.729 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -136.33 110.93 8.61 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.493 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -147.27 143.35 28.05 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.49 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 9.5 mmt 60.43 31.72 20.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.682 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.7 mmtp 59.78 34.56 21.94 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.464 -179.944 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.2 mtt -147.28 118.08 7.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.482 -179.87 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -62.95 127.07 29.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.314 179.939 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 11.8 m -116.04 128.14 55.47 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.493 -179.931 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -85.51 133.31 34.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.445 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.425 ' O ' HG22 ' A' ' 82' ' ' VAL . 38.2 mm -102.38 118.3 49.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.223 179.869 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -104.24 143.93 32.29 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.315 -179.887 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.21 140.31 91.23 Favored Pre-proline 0 CA--C 1.533 0.32 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.556 -179.983 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -73.25 -33.33 7.33 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.186 1.924 . . . . 0.0 112.338 -179.975 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.514 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 81.1 p -147.84 163.44 36.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.354 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -67.98 142.91 55.82 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.531 179.92 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.503 ' O ' HG22 ' A' ' 75' ' ' THR . . . 171.51 -159.97 31.8 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.995 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 101' ' ' LYS . . . . . 0.522 ' HB2' HG23 ' A' ' 75' ' ' THR . 13.3 ttmt -136.55 141.61 43.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.105 0.479 . . . . 0.0 110.517 -179.911 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.644 HG13 ' CG2' ' A' ' 120' ' ' ILE . 22.0 t -72.03 125.9 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.262 179.856 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -102.63 -31.23 10.48 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.783 -179.915 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 2.2 ttmt -164.4 139.08 5.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.674 -179.772 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 107' ' ' VAL . 22.0 t -106.67 109.01 26.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.128 179.807 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.4 mt -80.01 -31.81 39.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.302 179.898 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.429 ' O ' HG12 ' A' ' 105' ' ' VAL . 29.0 m -79.85 147.7 6.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.49 -179.965 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 24.3 mttp -127.83 164.1 22.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.149 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -65.95 142.38 57.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.397 179.997 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 63.54 37.77 10.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.619 179.885 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -121.64 152.16 39.63 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.389 179.681 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.97 134.52 34.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.476 -179.909 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.716 HG21 HD11 ' A' ' 85' ' ' LEU . 30.7 m -120.42 150.24 23.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.456 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 21.8 mt-30 -101.17 139.44 36.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.336 179.919 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.38 92.11 0.05 OUTLIER Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 132.81 -28.47 3.37 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.867 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -60.0 144.9 48.13 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 121.108 0.48 . . . . 0.0 110.645 -179.95 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.799 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -62.87 122.88 28.97 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.885 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 88.6 mt -88.18 -59.44 2.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.061 0.458 . . . . 0.0 110.385 179.853 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.644 ' CG2' HG13 ' A' ' 102' ' ' VAL . 49.7 mt -141.77 149.21 20.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.358 179.803 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -94.04 131.41 39.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.332 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.743 HD11 HD11 ' A' ' 57' ' ' ILE . 35.7 mm -107.7 146.02 14.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.397 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.718 0 CA-C-O 118.002 -1.443 . . . . 0.0 110.746 179.903 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.54 58.56 0.39 Allowed Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.931 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -174.79 119.45 0.21 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.072 0.463 . . . . 0.0 110.349 179.966 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -153.35 165.1 31.25 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 179.952 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 12.5 pttm -140.96 149.23 41.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.136 0.493 . . . . 0.0 110.386 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.588 ' HB3' ' HB3' ' A' ' 58' ' ' PRO . . . -61.79 -179.96 0.23 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.487 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 172.88 -45.06 0.17 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 -179.965 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -66.32 -148.86 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.525 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -70.91 -7.09 61.35 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.17 -179.83 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.466 ' OE2' HD11 ' A' ' 106' ' ' LEU . 33.7 mt-10 -76.61 143.18 40.38 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 121.215 0.531 . . . . 0.0 110.677 -179.621 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.9 mt -80.45 125.92 79.85 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.341 -179.835 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.588 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 51.8 Cg_endo -74.85 156.65 43.65 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 121.885 1.723 . . . . 0.0 112.247 179.737 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.493 ' HB3' ' H ' ' A' ' 116' ' ' GLY . . . -84.89 143.36 40.15 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.305 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -73.89 -27.93 11.79 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.225 1.95 . . . . 0.0 112.484 -179.97 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -163.65 172.49 14.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.51 -179.908 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.3 98.64 11.7 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.506 179.925 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.68 -144.31 5.62 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 8.9 m -137.71 135.9 36.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.149 0.499 . . . . 0.0 110.458 179.926 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.652 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -71.1 125.89 30.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.24 179.86 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.5 p -98.99 -57.54 2.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.74 -179.707 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.43 ' HD2' HG21 ' A' ' 84' ' ' VAL . 5.6 ptpt -149.52 146.37 27.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.679 -179.728 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.681 HG12 HD12 ' A' ' 83' ' ' LEU . 30.8 mt -101.62 136.83 31.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.16 179.74 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.587 HD12 HG22 ' A' ' 81' ' ' THR . 46.3 mt -100.0 -40.21 7.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.576 -179.847 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.628 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.0 m -100.73 138.15 25.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.148 0.499 . . . . 0.0 110.581 -179.873 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 10.2 pttp -122.7 163.26 20.45 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.044 179.825 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -60.47 104.02 0.3 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.569 -179.895 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 137.56 -31.82 2.46 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -83.17 154.99 23.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.052 0.453 . . . . 0.0 110.557 179.969 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.5 m -98.47 144.78 27.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.322 179.952 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.578 ' CG1' HG11 ' A' ' 70' ' ' VAL . 31.1 m -120.78 158.12 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.511 -179.914 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 41.6 mttt -122.7 151.12 41.87 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.261 179.832 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.458 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.29 90.99 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.694 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.53 -30.36 3.01 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.921 -0.871 . . . . 0.0 110.921 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -61.85 142.8 57.14 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.158 0.504 . . . . 0.0 110.571 -179.855 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.587 HG22 HD12 ' A' ' 69' ' ' LEU . 2.1 m -67.22 140.53 57.42 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.123 179.779 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.599 ' HA ' HG13 ' A' ' 70' ' ' VAL . 32.4 m -121.76 -32.49 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.631 -179.459 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.681 HD12 HG12 ' A' ' 68' ' ' ILE . 8.0 tt -161.23 152.84 19.21 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 120.169 -0.612 . . . . 0.0 111.557 -179.244 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.43 HG21 ' HD2' ' A' ' 67' ' ' LYS . 21.6 t -103.96 137.64 31.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.638 179.405 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.1 tp -121.0 165.7 14.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.176 0.512 . . . . 0.0 110.656 -179.776 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -138.24 120.11 15.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.463 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -150.63 138.61 20.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.397 179.983 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 44.8 mtp 60.73 36.12 19.46 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.598 -179.954 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 60.52 31.21 20.23 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.53 179.983 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 9.4 ttt -141.01 121.12 13.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.568 179.991 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -73.48 130.38 39.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.288 179.917 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.2 m -121.71 129.54 52.8 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.368 -179.987 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -84.29 138.04 33.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.564 -179.902 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.2 mm -103.21 150.48 6.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.077 179.853 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -138.05 142.15 40.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.507 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.11 139.79 96.02 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.293 -179.98 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.1 -30.35 10.8 Favored 'Trans proline' 0 N--CA 1.472 0.223 0 C-N-CA 122.061 1.841 . . . . 0.0 112.081 179.894 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.458 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 6.0 p -147.01 162.79 38.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.198 179.879 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 11.6 p30 -67.54 147.71 52.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.204 0.526 . . . . 0.0 110.315 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 169.92 -160.04 32.87 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -179.832 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -135.58 142.89 45.38 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.068 0.461 . . . . 0.0 110.455 -179.915 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.628 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.6 t -75.59 111.48 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.905 179.699 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -97.36 -31.21 12.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.833 -179.488 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -161.77 132.01 4.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.148 0.499 . . . . 0.0 110.786 -179.878 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.483 HG13 HG12 ' A' ' 120' ' ' ILE . 22.0 t -102.71 123.78 56.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.923 179.685 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.466 HD11 ' OE2' ' A' ' 56' ' ' GLU . 35.3 mt -82.77 -29.92 29.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.98 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.413 ' O ' HG12 ' A' ' 105' ' ' VAL . 35.3 m -95.97 158.82 3.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 121.213 0.53 . . . . 0.0 110.936 -179.677 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 37.2 mttt -132.08 163.53 28.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.167 179.65 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -60.72 141.42 56.89 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.544 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? 61.43 39.11 15.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.393 179.988 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -123.88 151.38 43.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.327 179.852 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.63 144.21 25.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.473 -179.912 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.416 HG13 HG23 ' A' ' 65' ' ' VAL . 33.7 m -126.75 179.53 3.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.37 179.801 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -130.04 140.88 50.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.323 179.937 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -58.78 105.93 0.77 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.837 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.493 ' H ' ' HB3' ' A' ' 59' ' ' ALA . . . 115.99 -31.05 6.24 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.995 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.1 tt0 -58.4 140.61 53.43 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 121.141 0.496 . . . . 0.0 110.763 -179.909 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.528 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -60.71 124.01 34.43 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 179.934 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 90.1 mt -90.38 -49.31 6.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.036 0.446 . . . . 0.0 110.844 -179.585 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.483 HG12 HG13 ' A' ' 105' ' ' VAL . 50.7 mt -142.33 153.61 18.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.576 -179.852 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.403 ' N ' HG22 ' A' ' 120' ' ' ILE . 23.4 tttt -98.19 125.21 43.14 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.354 179.835 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 39.4 mm -108.37 140.4 27.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.397 -179.93 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.701 0 CA-C-O 117.979 -1.456 . . . . 0.0 110.943 179.93 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -127.13 84.71 0.34 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.994 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.64 104.07 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.07 0.462 . . . . 0.0 110.567 -179.913 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -125.3 58.72 0.66 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 -179.927 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.3 mtmt -147.43 166.77 26.22 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.003 0.43 . . . . 0.0 110.439 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.634 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -118.07 128.64 54.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.399 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -176.53 42.89 0.11 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.706 -0.958 . . . . 0.0 110.706 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -164.02 32.2 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.106 0.479 . . . . 0.0 110.503 -179.966 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 122.53 -32.26 4.54 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.995 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.607 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 13.8 mt-10 -80.45 139.98 36.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.106 0.479 . . . . 0.0 110.509 -179.846 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.764 HD12 ' HD2' ' A' ' 97' ' ' PRO . 42.9 mm -79.09 124.48 84.6 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.051 179.879 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.9 132.77 17.42 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 121.924 1.749 . . . . 0.0 112.223 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 114' ' ' GLN . . . -65.34 146.16 98.98 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.427 -179.938 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -72.9 -29.95 11.7 Favored 'Trans proline' 0 N--CA 1.471 0.2 0 C-N-CA 122.191 1.927 . . . . 0.0 112.295 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.454 HD12 ' C ' ' A' ' 61' ' ' LEU . 4.2 pp -163.67 166.38 22.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.393 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.1 101.82 6.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.339 179.929 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.63 -149.91 6.33 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.989 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.8 m -136.21 140.6 43.65 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.149 0.5 . . . . 0.0 110.437 179.933 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.974 HG13 HD11 ' A' ' 83' ' ' LEU . 23.2 t -73.24 121.69 24.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.252 179.918 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -99.49 -49.69 4.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.555 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 17.2 ttpt -152.56 146.51 25.28 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.535 -179.735 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.487 HD12 ' HG2' ' A' ' 109' ' ' GLU . 2.9 mp -105.59 135.82 42.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.09 179.7 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.511 HD11 HG23 ' A' ' 84' ' ' VAL . 7.1 mp -100.03 -36.34 9.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.653 -179.783 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.763 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.0 m -101.16 143.2 14.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.72 -179.819 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.4 pttp -133.47 162.67 31.23 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.063 179.81 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -59.16 101.12 0.09 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.534 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.22 -29.6 2.4 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.836 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -90.7 148.03 22.87 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.093 0.473 . . . . 0.0 110.43 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.6 m -95.72 144.72 25.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.396 179.972 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.668 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.4 m -119.78 160.68 19.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.505 -179.965 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 88.2 mttt -125.06 154.32 41.52 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.327 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.36 97.61 0.05 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.732 -179.802 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.83 -30.66 3.69 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 28.2 tt0 -63.94 141.24 58.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.101 0.477 . . . . 0.0 110.735 -179.816 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.2 m -65.45 138.6 58.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.235 179.744 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.663 HG11 ' HB2' ' A' ' 96' ' ' ALA . 31.4 m -117.91 -32.95 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.247 -179.373 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.974 HD11 HG13 ' A' ' 65' ' ' VAL . 7.8 tt -161.47 153.51 19.61 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.284 0.564 . . . . 0.0 111.111 -179.268 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.511 HG23 HD11 ' A' ' 69' ' ' LEU . 21.3 t -107.01 137.3 38.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.911 179.504 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.573 HD12 HD11 ' A' ' 94' ' ' ILE . 15.3 mt -115.36 162.61 16.88 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.28 0.562 . . . . 0.0 110.782 -179.657 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -140.14 79.68 1.72 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.274 179.804 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -94.8 119.83 34.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.436 -179.854 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 37.0 mtt 62.66 39.64 11.06 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.361 179.846 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.2 mtmt 62.06 40.03 12.49 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.588 179.742 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 6.5 mmt -131.96 113.17 13.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.246 179.654 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -65.71 109.96 2.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.721 -179.845 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 11.1 m -112.09 119.58 38.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.318 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -82.1 129.11 34.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.852 -179.587 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.573 HD11 HD12 ' A' ' 85' ' ' LEU . 39.0 mm -101.35 149.45 6.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.997 179.569 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 67.9 m-20 -139.2 134.34 32.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.161 0.505 . . . . 0.0 110.863 -179.665 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.663 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -63.13 110.46 3.56 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.946 179.363 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.764 ' HD2' HD12 ' A' ' 57' ' ' ILE . 40.6 Cg_endo -64.27 -15.13 47.85 Favored 'Trans proline' 0 N--CA 1.476 0.484 0 C-N-CA 122.182 1.921 . . . . 0.0 113.105 179.834 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 61.1 p -135.9 136.66 40.68 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-O 121.145 0.498 . . . . 0.0 110.425 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -64.02 163.31 12.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.468 -179.976 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 149.03 -155.93 26.58 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.5 ttmt -134.55 147.89 50.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.084 0.469 . . . . 0.0 110.506 -179.833 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.763 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.1 t -77.44 111.81 14.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.165 179.802 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -95.94 -27.59 15.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.987 -179.774 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -162.69 127.38 3.14 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.064 0.459 . . . . 0.0 110.453 -179.864 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.503 HG12 ' O ' ' A' ' 107' ' ' VAL . 21.5 t -102.62 112.5 36.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.307 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.5 mt -80.05 -31.44 39.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.503 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.503 ' O ' HG12 ' A' ' 105' ' ' VAL . 33.6 m -87.08 141.56 14.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.71 -179.918 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -128.39 171.54 11.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.438 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 109' ' ' GLU . . . . . 0.487 ' HG2' HD12 ' A' ' 68' ' ' ILE . 28.5 mt-10 -63.29 137.74 58.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.414 179.995 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.76 38.88 6.57 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.618 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -118.79 144.82 46.06 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.224 179.635 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.98 134.99 34.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.485 -179.955 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.7 m -122.32 179.9 2.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.319 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 114' ' ' GLN . . . . . 0.452 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 93.8 mt-30 -137.19 147.81 46.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.416 179.891 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.74 114.31 6.45 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.88 -30.37 9.14 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.928 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.4 tt0 -60.9 137.06 58.24 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.034 0.445 . . . . 0.0 110.567 -179.967 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.634 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.86 119.19 17.15 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.988 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 41.3 mt -88.92 -51.04 5.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.109 0.48 . . . . 0.0 110.378 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.478 ' CG2' HG13 ' A' ' 102' ' ' VAL . 53.5 mt -140.91 144.91 26.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 8.1 tttt -93.94 129.75 40.29 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.357 179.947 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 36.6 mm -106.44 148.82 10.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.426 -179.776 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.739 0 CA-C-O 118.015 -1.436 . . . . 0.0 110.85 -179.991 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 63.79 -100.73 0.4 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -159.79 89.27 0.87 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.078 0.466 . . . . 0.0 110.41 179.956 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 165.67 -156.31 28.18 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? 60.63 177.44 0.1 Allowed 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.1 0.476 . . . . 0.0 110.538 -179.917 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.615 ' HB1' ' O ' ' A' ' 56' ' ' GLU . . . -131.32 179.39 6.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.355 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 133.95 -33.24 2.56 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.992 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -91.12 51.91 2.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.265 0.555 . . . . 0.0 110.548 -179.836 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.44 -28.17 15.37 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 179.828 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.615 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 7.2 mt-10 -76.6 138.44 40.12 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.187 0.517 . . . . 0.0 110.698 -179.694 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.576 HD11 ' CG1' ' A' ' 122' ' ' ILE . 32.7 mt -80.11 119.93 78.09 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.138 179.756 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.499 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.6 Cg_endo -72.19 139.47 32.44 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 122.0 1.8 . . . . 0.0 112.277 -179.965 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.635 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -71.8 146.77 91.12 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.373 179.948 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -72.85 -27.14 14.91 Favored 'Trans proline' 0 N--CA 1.471 0.184 0 C-N-CA 122.227 1.951 . . . . 0.0 112.393 179.972 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.2 pp -162.18 174.58 12.71 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.394 -179.941 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -90.24 82.21 6.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.306 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.424 ' HA3' ' HB2' ' A' ' 87' ' ' ALA . . . -109.26 -144.47 10.63 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.964 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.7 m -136.99 138.8 40.92 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.062 0.458 . . . . 0.0 110.525 -179.943 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.775 HG13 HD21 ' A' ' 83' ' ' LEU . 25.7 t -70.95 124.18 26.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.077 179.897 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.3 t -101.9 -59.12 1.75 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.787 -179.7 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 tptt -149.81 138.79 21.08 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.738 -179.583 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 38.9 mt -95.92 135.52 29.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.965 179.532 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.651 HD13 ' HB ' ' A' ' 81' ' ' THR . 11.5 mt -100.91 -30.82 11.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.93 -179.556 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.691 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.3 m -108.49 149.81 11.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.144 0.497 . . . . 0.0 110.733 -179.854 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 12.6 ptpt -137.66 164.16 29.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.164 179.856 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.424 ' HG3' HG23 ' A' ' 105' ' ' VAL . 39.4 mt-10 -60.58 102.97 0.21 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.5 -179.985 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 138.55 -31.48 2.41 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 23.8 m-20 -88.18 147.6 24.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.108 0.48 . . . . 0.0 110.482 -179.946 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 19.6 m -95.52 142.93 27.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.303 179.914 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.691 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.4 m -119.42 156.63 21.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.53 -179.883 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.4 mptt -117.79 152.58 35.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.288 179.888 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.558 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.24 93.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.644 -179.916 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.23 -31.49 2.78 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 17.7 tt0 -62.42 141.96 58.1 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.078 0.466 . . . . 0.0 110.562 -179.98 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.651 ' HB ' HD13 ' A' ' 69' ' ' LEU . 3.9 m -68.12 138.84 56.03 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.212 179.819 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.53 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.4 m -121.07 -32.42 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.657 -179.243 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.775 HD21 HG13 ' A' ' 65' ' ' VAL . 1.5 tm? -160.34 136.74 8.76 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.863 -179.11 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.757 ' N ' HD22 ' A' ' 83' ' ' LEU . 20.1 t -102.3 136.35 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.459 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.502 HD23 ' HA ' ' A' ' 65' ' ' VAL . 88.4 mt -114.12 166.56 11.5 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.584 -179.874 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -142.19 80.81 1.72 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.316 179.899 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.424 ' HB2' ' HA3' ' A' ' 63' ' ' GLY . . . -92.24 115.04 27.74 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.349 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 8.5 mtp 62.73 46.03 5.5 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.237 179.94 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 50.2 mttt 60.35 30.97 20.24 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.553 -179.823 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 9.0 tpt -118.44 95.93 5.08 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.41 -179.989 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -61.39 107.75 0.83 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.526 -179.898 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 23.9 m -117.44 112.64 20.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.353 179.983 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -80.64 132.97 35.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.765 -179.724 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.424 HG22 ' N ' ' A' ' 95' ' ' ASN . 35.7 mm -101.88 155.91 4.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.066 179.648 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.424 ' N ' HG22 ' A' ' 94' ' ' ILE . 2.1 p30 -136.84 149.34 47.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.568 179.959 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.71 139.8 97.06 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.242 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.65 -30.99 11.25 Favored 'Trans proline' 0 N--CA 1.472 0.226 0 C-N-CA 122.087 1.858 . . . . 0.0 112.197 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.558 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -147.07 163.61 35.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.313 179.943 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -68.17 141.94 55.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.352 179.969 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.48 -159.48 27.43 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 10.1 ttpt -133.36 143.71 49.14 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.045 0.45 . . . . 0.0 110.338 -179.849 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.678 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -75.72 111.71 12.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.224 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -92.75 -29.72 15.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.69 -179.85 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.5 ttpt -158.79 134.03 8.48 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.127 0.489 . . . . 0.0 110.575 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 107' ' ' VAL . 26.9 t -101.19 107.91 22.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.346 179.96 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.7 mt -80.07 -32.2 39.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.222 179.697 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.44 HG13 ' HA ' ' A' ' 119' ' ' LEU . 31.4 m -77.3 143.63 12.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.416 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 10.6 mmmt -135.05 151.86 51.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.156 179.81 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 16.4 mp0 -58.41 137.74 57.07 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.781 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 8.2 ttp-105 63.41 39.08 9.55 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.344 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.418 ' O ' HG23 ' A' ' 65' ' ' VAL . 5.0 t70 -125.09 144.63 50.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.289 179.815 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.79 140.13 30.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.558 -179.99 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.9 m -121.14 179.93 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.371 179.978 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 114' ' ' GLN . . . . . 0.448 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 9.3 mt-30 -141.06 146.86 37.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.412 179.976 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.23 103.4 0.53 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.03 -29.78 5.45 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 -179.889 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -61.61 138.51 58.3 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-O 121.066 0.46 . . . . 0.0 110.402 -179.971 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.62 118.46 14.81 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.919 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.635 HD11 ' HA ' ' A' ' 59' ' ' ALA . 64.5 mt -89.02 -54.73 3.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.017 0.436 . . . . 0.0 110.334 179.81 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.509 ' CG2' HG13 ' A' ' 102' ' ' VAL . 46.6 mt -142.79 147.02 21.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.321 179.796 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.2 mtpt -96.22 127.21 42.02 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.339 179.963 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.576 ' CG1' HD11 ' A' ' 57' ' ' ILE . 36.1 mm -109.17 145.03 16.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.552 -179.883 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 117.976 -1.458 . . . . 0.0 110.777 179.971 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -178.74 122.89 0.83 Allowed Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.942 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -143.23 -49.13 0.32 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.047 0.451 . . . . 0.0 110.346 -179.956 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -99.53 128.62 9.63 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.784 -0.927 . . . . 0.0 110.784 179.972 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 19.1 mttm -109.32 41.14 1.7 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.368 0.604 . . . . 0.0 110.429 179.97 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.713 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -147.63 94.97 2.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.396 179.848 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -86.58 -90.58 0.96 Allowed Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.756 -0.937 . . . . 0.0 110.756 179.944 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -110.79 129.15 55.93 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.108 0.48 . . . . 0.0 110.383 179.935 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.69 -53.12 0.84 Allowed Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 -179.908 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.504 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 20.5 mt-10 -82.82 128.28 34.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.08 0.467 . . . . 0.0 110.359 -179.959 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.2 mt -79.64 111.36 20.54 Favored Pre-proline 0 CA--C 1.535 0.383 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.258 179.993 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.555 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.6 Cg_endo -71.22 131.31 18.97 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 121.962 1.775 . . . . 0.0 112.302 -179.963 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.64 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -68.19 145.17 97.41 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.352 179.976 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.607 ' HG2' HD23 ' A' ' 61' ' ' LEU . 50.3 Cg_endo -73.34 -28.03 12.78 Favored 'Trans proline' 0 CA--C 1.528 0.222 0 C-N-CA 122.22 1.946 . . . . 0.0 112.276 -179.963 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.607 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.7 OUTLIER -159.59 162.87 35.39 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.357 179.971 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.35 113.81 21.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.332 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.594 ' HA3' ' HB2' ' A' ' 87' ' ' ALA . . . -137.75 -140.7 4.08 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -179.92 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 19.7 m -136.46 139.71 42.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.067 0.46 . . . . 0.0 110.435 179.988 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.716 HG13 HD11 ' A' ' 83' ' ' LEU . 22.3 t -71.09 126.59 31.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.999 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 8.2 t -101.24 -54.47 2.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.665 -179.828 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.2 tptm -157.2 140.27 15.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.602 -179.819 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.742 HG12 HD12 ' A' ' 83' ' ' LEU . 31.3 mt -94.38 140.26 16.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.995 179.719 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.481 HD13 ' HB ' ' A' ' 81' ' ' THR . 22.6 mt -104.84 -37.89 6.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.631 -179.793 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.771 HG11 ' CG1' ' A' ' 76' ' ' VAL . 33.1 m -110.88 148.12 14.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.801 -179.927 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -139.62 166.77 23.7 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.213 179.897 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -58.1 108.91 0.66 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.702 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.04 -31.4 2.81 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -93.19 151.38 19.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.061 0.458 . . . . 0.0 110.481 179.975 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 75' ' ' THR . . . . . 0.435 HG22 ' O ' ' A' ' 100' ' ' GLY . 1.2 m -100.68 148.65 24.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.238 179.879 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.771 ' CG1' HG11 ' A' ' 70' ' ' VAL . 31.6 m -124.99 165.96 21.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.58 -179.824 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.8 tppt? -124.78 153.91 41.74 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.251 179.894 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.617 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.43 97.97 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.541 -179.87 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.16 -36.64 2.11 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.904 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -62.88 139.46 58.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.496 . . . . 0.0 110.563 -179.959 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.481 ' HB ' HD13 ' A' ' 69' ' ' LEU . 6.9 m -67.07 141.87 57.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.282 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.743 HG22 ' O ' ' A' ' 94' ' ' ILE . 31.5 m -113.58 -27.04 2.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.225 -179.604 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.742 HD12 HG12 ' A' ' 68' ' ' ILE . 7.0 tt -168.4 150.99 5.3 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.177 0.513 . . . . 0.0 110.622 -179.619 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -102.83 135.98 37.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.955 179.622 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 1.0 HD12 HD11 ' A' ' 94' ' ' ILE . 17.8 mt -115.2 163.3 15.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.587 -179.681 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -135.64 106.7 6.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.267 179.972 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.594 ' HB2' ' HA3' ' A' ' 63' ' ' GLY . . . -147.48 147.89 30.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.518 -179.965 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 39.3 mmm 60.41 32.62 20.65 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.54 179.986 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 35.2 mtmt 60.03 33.78 21.35 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.618 179.946 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 4.5 ttt -144.69 147.21 32.75 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.521 -179.87 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -92.22 124.48 36.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.378 179.995 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 19.6 m -121.01 125.91 48.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.418 -179.956 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -87.38 143.01 27.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.475 -179.96 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 1.0 HD11 HD12 ' A' ' 85' ' ' LEU . 38.7 mm -105.56 112.06 37.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.373 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -98.48 140.54 32.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.378 -179.945 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.41 142.38 96.27 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.341 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.24 -35.29 5.21 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.16 1.907 . . . . 0.0 112.357 179.95 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.617 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -146.8 162.34 38.79 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.337 -179.968 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -66.67 143.34 57.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.396 179.901 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.435 ' O ' HG22 ' A' ' 75' ' ' THR . . . 173.43 -160.86 31.45 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.972 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 28.6 tttp -130.23 147.23 51.93 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.032 0.444 . . . . 0.0 110.526 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.566 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.3 t -75.67 109.12 8.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.293 179.898 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -93.93 -29.91 15.03 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.76 -179.892 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 29.8 tttt -157.47 128.09 6.49 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.163 0.506 . . . . 0.0 110.642 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.46 HG12 ' O ' ' A' ' 107' ' ' VAL . 29.0 t -102.59 102.45 13.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.224 179.824 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 12.5 mt -76.25 -32.22 58.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.213 179.716 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.633 HG21 HD13 ' A' ' 83' ' ' LEU . 34.8 m -77.86 142.01 14.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.632 -179.978 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.443 ' HA ' HD11 ' A' ' 68' ' ' ILE . 12.7 mmmt -139.82 158.45 44.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.994 179.676 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 109' ' ' GLU . . . . . 0.417 ' O ' ' HG3' ' A' ' 110' ' ' ARG . 13.7 mt-10 -55.81 161.72 2.08 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.976 -179.794 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 110' ' ' ARG . . . . . 0.417 ' HG3' ' O ' ' A' ' 109' ' ' GLU . 0.0 OUTLIER 37.18 41.24 0.21 Allowed 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.486 -179.737 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.692 ' O ' HG23 ' A' ' 65' ' ' VAL . 3.7 t70 -128.99 142.16 51.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.265 179.882 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -93.51 136.99 33.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.623 -179.781 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.1 m -118.8 161.29 17.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.312 179.781 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 -102.06 143.21 32.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.438 -179.998 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.2 108.66 2.02 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.962 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.14 -26.28 10.59 Favored Glycine 0 CA--C 1.528 0.859 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 -179.798 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -58.44 144.73 41.12 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-O 121.134 0.492 . . . . 0.0 110.787 -179.966 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.713 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -60.96 120.74 24.1 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.962 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.64 HD21 ' HB2' ' A' ' 59' ' ' ALA . 89.3 mt -88.01 -59.61 2.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.105 0.478 . . . . 0.0 110.453 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.475 ' CG2' HG13 ' A' ' 102' ' ' VAL . 55.0 mt -140.85 145.2 25.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.377 -179.988 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -91.4 121.56 33.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.167 179.797 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.2 mm -104.29 141.44 19.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.455 -179.957 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.75 0 CA-C-O 117.953 -1.471 . . . . 0.0 110.765 179.988 . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 . . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -177.8 -42.6 0.06 OUTLIER Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 179.951 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -62.82 -177.38 0.15 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.076 0.465 . . . . 0.0 110.448 179.976 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 66.07 -82.64 0.09 OUTLIER Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.996 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -76.79 141.5 40.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.069 0.462 . . . . 0.0 110.443 -179.976 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.85 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -78.22 179.46 6.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.377 -179.998 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 142.21 -35.47 1.75 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.636 -0.985 . . . . 0.0 110.636 179.983 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -89.88 56.48 3.5 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.468 0.651 . . . . 0.0 110.373 179.983 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.77 -30.22 10.14 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.909 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.571 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 45.6 mt-10 -76.57 140.09 40.94 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.212 0.53 . . . . 0.0 110.75 -179.78 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 51.3 mt -81.03 117.1 66.63 Favored Pre-proline 0 CA--C 1.533 0.31 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.14 179.86 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -71.92 137.23 29.04 Favored 'Trans proline' 0 N--CA 1.472 0.228 0 C-N-CA 121.932 1.755 . . . . 0.0 112.315 -179.984 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.664 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -61.44 146.69 89.06 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.389 -179.879 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -72.13 -28.69 15.45 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.2 1.934 . . . . 0.0 112.263 179.928 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -165.32 166.9 18.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.41 -179.965 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.43 85.1 6.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.449 179.949 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.449 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -125.35 -160.94 10.86 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -179.93 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.3 m -114.41 140.62 48.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.122 0.487 . . . . 0.0 110.56 -179.969 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.92 HG13 HD11 ' A' ' 83' ' ' LEU . 29.6 t -64.94 127.67 26.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.194 179.908 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.3 -61.27 1.42 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.703 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.702 ' O ' HD12 ' A' ' 83' ' ' LEU . 40.6 mttt -149.97 145.68 26.59 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.11 0.481 . . . . 0.0 110.654 -179.812 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.5 mt -101.04 125.24 55.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.721 179.443 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.654 HD12 HG22 ' A' ' 81' ' ' THR . 19.8 mt -96.31 -31.21 13.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.979 -179.429 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.735 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.6 m -111.62 147.18 15.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.201 0.524 . . . . 0.0 110.732 -179.719 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.5 163.96 29.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.154 179.795 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.665 ' HG3' HG23 ' A' ' 105' ' ' VAL . 24.6 mt-10 -59.34 102.45 0.14 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.699 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.03 -30.31 2.37 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.974 -0.851 . . . . 0.0 110.974 179.969 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.84 150.91 20.3 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.175 0.512 . . . . 0.0 110.586 -179.866 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.5 m -96.02 148.14 22.97 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.297 179.931 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.673 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.8 m -119.13 166.3 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.513 -179.97 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 32.1 mmtm -128.88 147.84 50.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.24 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.61 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.81 90.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.779 -179.877 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.53 -31.34 2.6 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.827 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -64.1 141.15 58.87 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.171 0.51 . . . . 0.0 110.668 -179.769 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.654 HG22 HD12 ' A' ' 69' ' ' LEU . 6.4 m -65.97 137.01 56.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.082 179.788 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.477 HG12 HG11 ' A' ' 70' ' ' VAL . 31.1 m -121.68 -32.19 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.66 -179.318 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.92 HD11 HG13 ' A' ' 65' ' ' VAL . 16.3 tp -158.97 151.8 22.02 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.083 0.468 . . . . 0.0 110.816 -179.124 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.2 t -113.9 144.08 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.769 179.323 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.712 HD21 HG21 ' A' ' 113' ' ' VAL . 16.6 mt -120.62 158.81 26.58 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.168 0.509 . . . . 0.0 110.789 -179.64 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 -135.84 111.19 9.09 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.385 -179.916 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.51 138.65 24.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.543 179.936 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 12.6 mmt 60.56 32.65 20.47 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.541 179.986 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 42.5 mttt 60.62 33.94 20.26 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.514 -179.998 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 27.2 ttm -137.77 109.67 7.18 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.481 -179.994 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -67.55 127.11 31.5 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.363 179.981 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -123.33 113.24 18.58 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.406 179.968 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -79.5 139.31 37.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.601 -179.889 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.427 ' N ' HD12 ' A' ' 94' ' ' ILE . 5.1 mp -110.27 155.88 11.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.729 179.902 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.416 ' N ' HG22 ' A' ' 94' ' ' ILE . 11.3 m-80 -139.5 152.57 47.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.543 -179.918 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.16 139.75 96.1 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.305 180.0 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -73.77 -35.47 4.46 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.114 1.876 . . . . 0.0 112.153 179.977 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.61 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 24.0 p -144.96 163.17 34.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.343 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -65.28 140.87 58.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.337 179.859 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.34 -159.6 29.74 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.919 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 22.8 ttmt -135.21 148.76 49.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.078 0.466 . . . . 0.0 110.421 -179.901 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.735 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.4 t -78.16 110.4 13.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.197 179.929 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -92.97 -27.54 16.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.884 -179.931 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -157.35 130.82 7.92 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.093 0.473 . . . . 0.0 110.653 -179.773 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.665 HG23 ' HG3' ' A' ' 72' ' ' GLU . 42.7 t -101.32 102.98 14.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.132 179.806 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 14.0 mt -88.31 10.38 19.96 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.531 179.862 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.465 HG21 HD22 ' A' ' 83' ' ' LEU . 31.3 m -123.76 135.42 63.49 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.074 0 CA-C-O 121.177 0.513 . . . . 0.0 110.212 179.705 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 9.7 tttp -123.5 152.9 41.26 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.277 -179.943 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -59.98 146.29 43.07 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.598 -179.967 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 20.8 mtm180 61.02 34.19 19.39 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.505 -179.943 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -120.14 149.74 41.74 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.346 179.819 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.11 135.9 33.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.566 -179.981 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.712 HG21 HD21 ' A' ' 85' ' ' LEU . 27.4 m -121.71 -179.99 2.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.273 179.906 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 11.6 mp0 -138.55 144.7 40.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.423 -179.994 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.51 111.14 3.43 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.962 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 111.86 -28.77 9.06 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.88 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -59.49 135.89 57.81 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.075 0.464 . . . . 0.0 110.573 -179.899 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.85 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.25 116.1 8.85 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.946 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.664 HD11 ' HA ' ' A' ' 59' ' ' ALA . 71.8 mt -88.77 -54.58 4.08 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.017 0.436 . . . . 0.0 110.472 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.615 ' CG2' HG13 ' A' ' 102' ' ' VAL . 49.5 mt -142.7 145.0 23.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.391 -179.975 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 25.1 tttt -98.06 129.0 44.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.453 179.869 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.1 mm -103.54 145.54 12.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.475 -179.782 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.75 0 CA-C-O 118.016 -1.436 . . . . 0.0 110.753 179.891 . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 . . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -166.76 98.75 0.15 Allowed Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.9 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -107.72 127.82 54.02 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.076 0.465 . . . . 0.0 110.439 179.982 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 179.74 137.72 3.1 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 -179.998 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.7 tttt 60.65 109.19 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.066 0.46 . . . . 0.0 110.536 179.961 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.4 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -62.65 178.17 0.46 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.501 179.969 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -160.19 -73.34 0.02 OUTLIER Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.957 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -135.82 111.57 9.39 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.029 0.442 . . . . 0.0 110.453 -179.917 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 115.16 -48.35 0.95 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.946 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -84.19 135.99 34.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.122 0.487 . . . . 0.0 110.435 -179.927 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.454 HD11 HD11 ' A' ' 122' ' ' ILE . 52.5 mt -78.89 112.45 27.45 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.156 179.937 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.09 141.62 40.27 Favored 'Trans proline' 0 N--CA 1.472 0.262 0 C-N-CA 122.115 1.877 . . . . 0.0 112.395 -179.932 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.851 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -79.2 148.59 71.38 Favored Pre-proline 0 CA--C 1.531 0.235 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.423 179.911 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.545 ' HG2' HD23 ' A' ' 61' ' ' LEU . 50.5 Cg_endo -72.2 -27.45 16.67 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.31 2.007 . . . . 0.0 112.365 -179.949 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.545 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.6 OUTLIER -158.61 171.08 20.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.321 179.968 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -91.07 83.43 5.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.415 179.998 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -109.7 -136.16 7.4 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.946 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.402 ' C ' HD23 ' A' ' 85' ' ' LEU . 2.0 m -139.08 138.55 37.2 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.173 0.511 . . . . 0.0 110.488 179.933 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.615 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -66.82 124.0 21.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.284 179.991 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.2 t -98.58 -60.31 1.57 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.478 -179.957 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.8 mttt -148.69 147.3 28.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.461 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.508 HG22 ' H ' ' A' ' 70' ' ' VAL . 24.0 mt -106.04 118.02 52.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.923 179.899 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.5 mt -95.12 21.79 7.41 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.385 -179.525 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.762 ' HB ' HG21 ' A' ' 102' ' ' VAL . 25.2 m -150.0 148.29 15.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 121.239 0.543 . . . . 0.0 110.524 179.812 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 12.0 mtpp -132.17 157.36 44.48 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.185 179.874 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.463 ' HG3' HG23 ' A' ' 105' ' ' VAL . 27.0 mt-10 -59.11 95.33 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.516 179.989 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.15 -30.41 2.35 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.777 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 59.8 m-20 -73.13 146.39 45.72 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.062 0.458 . . . . 0.0 110.319 179.963 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.4 m -98.45 127.68 44.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.423 179.928 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.686 HG11 HG11 ' A' ' 70' ' ' VAL . 22.7 m -112.56 151.79 14.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.409 179.971 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.5 mttp -112.99 149.05 33.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.324 179.908 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.685 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -57.98 95.56 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.803 -179.854 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.39 -33.92 2.24 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.4 tt0 -69.34 140.17 54.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.083 0.468 . . . . 0.0 110.481 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.6 m -60.43 137.82 58.09 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.488 179.905 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.583 ' O ' HG22 ' A' ' 70' ' ' VAL . 34.6 m -113.95 -33.65 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.947 -179.609 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 83' ' ' LEU . . . . . 0.615 HD11 HG13 ' A' ' 65' ' ' VAL . 7.9 tt -161.17 149.61 15.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.583 -179.558 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -104.46 140.69 21.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.183 179.836 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.791 HD12 HD11 ' A' ' 94' ' ' ILE . 3.6 mt -117.75 171.41 8.06 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.44 -179.848 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 -131.14 113.54 14.01 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.422 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.483 ' CB ' HD11 ' A' ' 61' ' ' LEU . . . -145.7 139.86 26.83 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.338 179.974 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 7.7 mtp 60.77 33.01 20.22 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.55 179.992 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 60.92 33.16 19.95 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.329 179.912 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.7 mtt -139.41 160.4 39.93 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.315 -179.999 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -93.19 131.56 38.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.541 179.971 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.6 m -120.76 121.06 37.4 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.212 179.961 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -84.8 131.98 34.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.57 -179.894 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.791 HD11 HD12 ' A' ' 85' ' ' LEU . 38.8 mm -102.25 124.87 56.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.167 179.767 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -103.64 140.94 36.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.345 -179.934 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.464 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . . . -61.29 142.31 93.66 Favored Pre-proline 0 CA--C 1.532 0.26 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.403 -179.872 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.408 ' HD3' HG23 ' A' ' 57' ' ' ILE . 49.1 Cg_endo -72.77 -36.8 4.36 Favored 'Trans proline' 0 N--CA 1.471 0.194 0 C-N-CA 122.109 1.873 . . . . 0.0 112.352 -179.978 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.685 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 23.0 p -149.48 157.48 43.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.321 -179.989 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -63.53 140.85 58.91 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.358 179.91 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.81 -155.99 19.64 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.983 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 5.8 ttmt -136.93 142.23 42.68 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.143 0.497 . . . . 0.0 110.631 -179.931 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.762 HG21 ' HB ' ' A' ' 70' ' ' VAL . 31.3 t -74.12 112.17 10.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.246 179.9 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -96.11 -30.41 13.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.584 179.972 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 29.5 ttmt -158.97 133.77 8.14 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.468 179.954 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.463 HG23 ' HG3' ' A' ' 72' ' ' GLU . 21.1 t -99.93 109.2 24.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.237 -179.977 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.7 mt -90.12 30.34 1.11 Allowed 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.688 179.971 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.459 HG21 HD13 ' A' ' 83' ' ' LEU . 26.7 m -155.46 138.34 7.15 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-O 120.987 0.423 . . . . 0.0 110.261 -179.999 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 21.2 mttt -124.55 162.48 23.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.364 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 53.3 mt-10 -61.22 149.96 36.04 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.445 179.911 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 61.18 32.56 19.5 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.255 -179.803 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -120.18 148.42 43.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.378 179.9 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.47 140.58 29.61 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.472 -179.995 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.782 HG21 HD21 ' A' ' 85' ' ' LEU . 27.8 m -120.35 -179.99 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.5 -179.986 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 5.9 mm-40 -137.5 144.68 42.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.432 179.897 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.76 107.95 1.64 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.969 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.12 -27.96 9.7 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -60.64 137.14 58.21 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 121.199 0.523 . . . . 0.0 110.562 -179.85 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.4 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -60.96 119.19 17.73 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.968 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.851 HD21 ' HB2' ' A' ' 59' ' ' ALA . 59.5 mt -89.96 -49.75 6.42 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.091 0.472 . . . . 0.0 110.573 -179.873 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.494 HD13 HG21 ' A' ' 70' ' ' VAL . 47.8 mt -141.1 138.4 33.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.343 -179.918 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -91.13 130.22 37.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.394 179.887 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.454 HD11 HD11 ' A' ' 57' ' ' ILE . 38.4 mm -108.51 140.75 25.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.408 -179.996 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.834 0 CA-C-O 117.967 -1.463 . . . . 0.0 110.788 179.966 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 . . . . . 0 C--O 1.231 0.122 0 CA-C-O 121.145 0.498 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 51.8 mt -81.7 111.45 26.12 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.242 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.45 136.98 29.76 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.047 1.832 . . . . 0.0 112.305 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.772 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -72.18 147.17 90.48 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.516 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.89 -25.89 16.15 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.252 1.968 . . . . 0.0 112.464 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 pp -165.98 179.32 5.89 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.451 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.34 102.69 9.72 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.437 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.418 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -127.87 171.1 19.22 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.0 m -105.37 135.25 47.09 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.136 0.494 . . . . 0.0 110.416 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.611 HG23 ' O ' ' A' ' 111' ' ' ASP . 26.0 t -69.93 122.14 20.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.129 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -101.03 -54.42 2.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.576 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.3 ttpm? -151.66 145.85 25.37 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.487 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 3.4 mp -105.36 133.7 48.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.115 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.8 mp -98.15 -44.83 6.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.648 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.784 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.9 m -88.67 150.49 3.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.743 -179.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 3.5 ptpt -136.08 161.37 35.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.181 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -61.22 98.6 0.08 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.526 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -29.98 2.38 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.49 148.04 26.74 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.125 0.488 . . . . 0.0 110.578 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 24.5 m -95.2 142.17 27.95 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.192 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.708 HG11 HG11 ' A' ' 70' ' ' VAL . 23.8 m -120.19 163.73 17.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.638 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.1 mttp -123.04 147.47 46.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.153 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.659 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.11 92.9 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.693 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.2 -35.37 2.03 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -63.36 143.51 57.74 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.135 0.493 . . . . 0.0 110.614 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.7 m -66.87 137.2 56.4 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.219 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.514 ' HA ' HG13 ' A' ' 70' ' ' VAL . 30.7 m -115.17 -30.24 2.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.206 -179.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.62 HD13 HG21 ' A' ' 107' ' ' VAL . 9.0 tt -163.27 150.14 12.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.127 0.489 . . . . 0.0 110.855 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 t -102.13 130.59 51.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.998 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.446 HD12 ' CD1' ' A' ' 94' ' ' ILE . 9.6 mt -119.1 132.23 55.98 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.664 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.054 179.547 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 . . . . . 0 N--CA 1.462 0.137 0 CA-C-O 121.14 0.495 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.9 m -118.45 127.67 53.87 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.32 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -84.07 130.85 34.85 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.643 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.446 ' CD1' HD12 ' A' ' 85' ' ' LEU . 38.3 mm -104.94 116.22 48.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.124 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 82.5 m-20 -103.03 143.71 32.22 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.426 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.6 143.3 96.47 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.358 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -73.15 -37.65 3.28 Favored 'Trans proline' 0 CA--C 1.527 0.17 0 C-N-CA 122.072 1.848 . . . . 0.0 112.24 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.659 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 15.6 p -145.78 162.2 38.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.387 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -67.76 142.3 56.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.456 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.57 -157.25 27.52 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.1 ttmt -133.91 147.25 51.09 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.142 0.496 . . . . 0.0 110.544 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.784 HG21 ' HB ' ' A' ' 70' ' ' VAL . 35.2 t -75.32 107.26 5.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.301 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -93.39 -28.04 16.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.65 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -158.56 130.93 6.9 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.077 0.465 . . . . 0.0 110.396 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.427 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.4 t -97.96 109.39 23.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.31 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.2 mt -90.29 30.37 1.13 Allowed 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.641 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.62 HG21 HD13 ' A' ' 83' ' ' LEU . 25.6 m -155.47 137.47 6.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 121.073 0.463 . . . . 0.0 110.252 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 24.9 mmtt -128.9 167.01 18.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.385 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -62.27 147.61 47.53 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.426 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 11.0 mmp_? 60.69 32.32 20.26 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.598 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.611 ' O ' HG23 ' A' ' 65' ' ' VAL . 4.2 t70 -122.74 136.43 54.87 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.354 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.28 136.68 32.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.487 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 63' ' ' GLY . 30.5 m -119.18 150.73 21.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.394 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -98.15 149.28 22.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.449 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.92 117.3 11.16 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 105.84 -28.12 15.18 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 -59.57 138.33 57.74 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 121.041 0.448 . . . . 0.0 110.586 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.68 121.43 26.58 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.772 HD21 ' HB2' ' A' ' 59' ' ' ALA . 24.5 mt -88.92 -51.81 5.43 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.073 0.463 . . . . 0.0 110.404 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 48.4 mt -142.82 144.78 23.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.407 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -96.51 125.29 40.89 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.238 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.6 mm -106.06 143.87 16.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.536 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.772 0 CA-C-O 117.989 -1.45 . . . . 0.0 110.716 179.956 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 121.078 0.466 . . . . 0.0 110.481 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.507 HD11 HD11 ' A' ' 122' ' ' ILE . 28.5 mt -79.01 115.01 49.21 Favored Pre-proline 0 CA--C 1.535 0.386 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.006 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -70.84 140.04 37.76 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 121.963 1.775 . . . . 0.0 112.329 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.67 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -75.25 146.53 81.74 Favored Pre-proline 0 CA--C 1.531 0.219 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.454 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.612 ' HG2' HD23 ' A' ' 61' ' ' LEU . 49.0 Cg_endo -72.71 -24.34 18.42 Favored 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 122.232 1.954 . . . . 0.0 112.47 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.612 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.7 OUTLIER -161.08 175.23 12.65 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.457 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -87.83 110.26 20.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.402 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.451 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -138.09 177.85 19.69 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 18.9 m -104.75 136.58 43.99 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.142 0.496 . . . . 0.0 110.481 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.859 HG13 HD11 ' A' ' 83' ' ' LEU . 32.0 t -70.28 117.83 13.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.25 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.8 p -99.61 -51.86 3.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.525 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.3 ptpt -151.73 145.28 24.9 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.528 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.704 HG12 HD12 ' A' ' 83' ' ' LEU . 10.7 mt -100.77 141.23 17.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.009 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.474 HD13 ' HA ' ' A' ' 69' ' ' LEU . 3.9 mm? -101.6 -30.44 11.37 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.109 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.717 HG11 ' CG1' ' A' ' 76' ' ' VAL . 34.5 m -124.91 133.65 68.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.244 0.545 . . . . 0.0 110.854 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.75 149.3 37.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.853 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.8 121.06 5.96 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.387 0.613 . . . . 0.0 111.108 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.17 -28.83 4.48 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.51 158.82 15.37 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-O 121.054 0.454 . . . . 0.0 110.425 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -97.91 141.22 31.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.428 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.717 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.2 m -123.83 158.31 29.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.485 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 32.3 mttm -117.68 157.83 25.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.35 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.615 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -62.42 106.84 0.82 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.515 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.3 -31.47 4.66 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 -62.77 140.62 58.76 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.125 0.488 . . . . 0.0 110.532 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 7.5 m -67.54 139.38 56.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.305 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CA ' HG22 ' A' ' 70' ' ' VAL . 29.4 m -114.43 -31.54 2.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.053 -179.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.859 HD11 HG13 ' A' ' 65' ' ' VAL . 8.5 tt -166.41 146.9 6.19 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.103 0.478 . . . . 0.0 110.841 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.1 t -103.08 135.88 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.131 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.877 HD12 HD11 ' A' ' 94' ' ' ILE . 51.9 mt -118.32 166.27 12.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.706 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.336 179.911 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 21.5 mt-10 . . . . . 0 C--O 1.23 0.071 0 CA-C-O 121.056 0.455 . . . . 0.0 110.433 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.0 m -117.45 109.04 16.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.276 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -77.97 140.64 39.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.604 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.877 HD11 HD12 ' A' ' 85' ' ' LEU . 37.2 mm -103.68 140.67 21.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.057 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 38.3 m-20 -128.76 143.48 50.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.665 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.25 138.62 96.18 Favored Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.259 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.99 -31.86 11.87 Favored 'Trans proline' 0 N--CA 1.472 0.209 0 C-N-CA 122.09 1.86 . . . . 0.0 112.416 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.615 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 40.9 p -147.17 164.95 31.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.483 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -66.42 143.61 57.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.399 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.48 -160.43 27.98 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -135.02 136.87 42.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.139 0.495 . . . . 0.0 110.431 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.633 HG13 ' CG2' ' A' ' 120' ' ' ILE . 4.2 t -73.16 107.26 3.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.86 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -87.68 -29.39 21.17 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.001 -179.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 13.7 tttt -163.95 138.13 5.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.407 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 107' ' ' VAL . 21.6 t -107.92 110.49 32.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.416 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.8 mt -79.24 -31.59 43.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.394 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.571 HG21 HD13 ' A' ' 83' ' ' LEU . 27.3 m -82.56 142.84 13.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.501 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 54.2 mttt -136.47 163.11 31.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.246 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -60.79 147.29 43.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.519 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 5.5 tpt180 61.13 35.45 18.58 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.479 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.569 ' O ' HG23 ' A' ' 65' ' ' VAL . 8.0 t0 -127.98 140.32 52.05 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.388 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.51 136.24 33.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.517 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 63' ' ' GLY . 26.0 m -120.24 152.06 23.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.341 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -97.36 140.19 32.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.501 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.7 87.92 0.04 OUTLIER Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 137.54 -28.08 2.79 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -61.59 146.93 47.3 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.157 0.503 . . . . 0.0 110.515 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.56 118.87 16.16 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.67 HD21 ' HB2' ' A' ' 59' ' ' ALA . 71.8 mt -87.14 -53.15 5.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.082 0.468 . . . . 0.0 110.485 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.633 ' CG2' HG13 ' A' ' 102' ' ' VAL . 55.5 mt -140.9 151.59 20.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.477 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -97.22 133.99 41.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.209 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.507 HD11 HD11 ' A' ' 57' ' ' ILE . 35.9 mm -114.25 145.18 20.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.438 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.781 0 CA-C-O 118.011 -1.438 . . . . 0.0 110.774 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.998 0.428 . . . . 0.0 110.499 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.772 HD12 ' HD2' ' A' ' 97' ' ' PRO . 46.1 mm -80.22 120.6 80.07 Favored Pre-proline 0 CA--C 1.536 0.431 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.923 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -72.05 128.0 13.47 Favored 'Trans proline' 0 N--CA 1.472 0.222 0 C-N-CA 121.892 1.728 . . . . 0.0 112.1 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.443 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -61.05 142.12 93.22 Favored Pre-proline 0 CA--C 1.532 0.28 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.471 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -73.62 -27.54 12.73 Favored 'Trans proline' 0 CA--C 1.528 0.188 0 C-N-CA 122.181 1.921 . . . . 0.0 112.374 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -161.33 159.92 29.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.472 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.59 125.39 30.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.402 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -159.06 -140.22 2.86 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.621 ' C ' HD23 ' A' ' 85' ' ' LEU . 14.8 m -136.56 139.13 41.96 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.082 0.468 . . . . 0.0 110.406 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.771 HG13 HD11 ' A' ' 83' ' ' LEU . 27.9 t -70.71 124.61 27.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.208 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.0 t -98.42 -54.23 3.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.675 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -153.67 145.02 23.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.529 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.704 HG12 HD12 ' A' ' 83' ' ' LEU . 35.7 mt -99.65 135.16 36.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.118 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.546 HD13 ' HB ' ' A' ' 81' ' ' THR . 12.3 mt -98.48 -44.13 6.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.617 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.689 HG11 ' CG1' ' A' ' 76' ' ' VAL . 34.6 m -98.83 144.69 11.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.502 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 46.1 pttt -137.3 164.28 28.94 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.206 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -57.05 102.29 0.08 Allowed 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.692 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.13 -31.97 2.22 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -90.15 152.94 20.88 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.062 0.458 . . . . 0.0 110.387 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -98.84 146.79 25.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.474 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.689 ' CG1' HG11 ' A' ' 70' ' ' VAL . 28.4 m -121.47 162.44 20.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.344 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -127.29 156.85 41.27 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.488 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.34 90.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.55 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.65 -30.36 3.0 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 16.3 tt0 -61.88 143.32 56.56 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.077 0.465 . . . . 0.0 110.672 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.546 ' HB ' HD13 ' A' ' 69' ' ' LEU . 1.9 m -68.9 138.97 55.1 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.148 179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.529 ' HA ' HG13 ' A' ' 70' ' ' VAL . 28.4 m -117.63 -33.86 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.35 -179.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.771 HD11 HG13 ' A' ' 65' ' ' VAL . 7.6 tt -161.52 153.15 19.02 Favored 'General case' 0 C--N 1.332 -0.175 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.167 -179.303 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.4 t -107.55 138.4 33.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.923 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.678 HD21 ' CG2' ' A' ' 113' ' ' VAL . 0.9 OUTLIER -120.26 168.53 11.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.191 0.52 . . . . 0.0 110.457 -179.808 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.357 179.961 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 121.063 0.459 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.2 m -114.4 122.34 46.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.232 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -82.52 130.22 35.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.62 -179.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.501 HG13 HD12 ' A' ' 85' ' ' LEU . 25.7 mm -103.19 147.45 9.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.011 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -139.27 142.38 37.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.152 0.501 . . . . 0.0 110.779 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.518 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -62.65 109.76 2.72 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.291 179.665 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.772 ' HD2' HD12 ' A' ' 57' ' ' ILE . 41.9 Cg_endo -64.93 -13.77 41.46 Favored 'Trans proline' 0 N--CA 1.476 0.46 0 C-N-CA 122.148 1.899 . . . . 0.0 112.885 179.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -135.94 135.96 40.04 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.097 0.475 . . . . 0.0 110.359 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -63.36 151.29 41.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.422 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 159.36 -154.66 25.73 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.0 ttmt -135.69 148.03 48.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.141 0.496 . . . . 0.0 110.448 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.653 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -75.69 111.26 11.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.208 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -95.21 -30.07 14.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.784 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.7 ttpt -162.01 130.17 4.13 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.569 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.494 HG13 HG12 ' A' ' 120' ' ' ILE . 22.0 t -103.57 113.89 41.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.295 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.0 mt -81.59 -37.17 28.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.374 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.526 HG21 HD13 ' A' ' 83' ' ' LEU . 32.9 m -77.44 147.45 7.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.574 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -133.49 163.68 28.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.075 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -62.71 138.55 58.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.394 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER 67.2 37.16 3.76 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.564 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.41 151.07 40.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.278 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -95.61 133.46 39.63 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.513 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.678 ' CG2' HD21 ' A' ' 85' ' ' LEU . 31.4 m -120.8 179.8 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.356 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 81.7 mm-40 -136.05 147.67 48.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.425 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.32 113.07 5.31 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 111.18 -30.78 7.69 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -60.18 140.33 57.02 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.138 0.494 . . . . 0.0 110.675 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.49 120.49 22.72 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.443 HD21 ' HB2' ' A' ' 59' ' ' ALA . 91.6 mt -87.06 -53.59 4.79 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.103 0.478 . . . . 0.0 110.423 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.562 ' CG2' HG13 ' A' ' 102' ' ' VAL . 52.3 mt -141.32 151.82 19.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.326 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 39.1 mttt -93.76 128.19 39.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.382 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.437 HD12 HG21 ' A' ' 76' ' ' VAL . 37.1 mm -109.87 145.76 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.37 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.748 0 CA-C-O 117.991 -1.449 . . . . 0.0 110.728 179.925 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 . . . . . 0 N--CA 1.46 0.074 0 CA-C-O 121.067 0.46 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.457 HD11 HD11 ' A' ' 122' ' ' ILE . 45.7 mt -78.9 111.45 19.86 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.127 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -70.38 142.42 45.17 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.099 1.866 . . . . 0.0 112.465 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.511 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -77.67 148.53 76.51 Favored Pre-proline 0 CA--C 1.531 0.24 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.521 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -73.11 -26.66 14.71 Favored 'Trans proline' 0 CA--C 1.528 0.212 0 C-N-CA 122.206 1.937 . . . . 0.0 112.461 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -164.63 156.98 16.37 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.472 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.0 121.92 19.07 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.423 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -150.96 -145.17 4.07 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.7 m -136.97 139.02 41.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.138 0.494 . . . . 0.0 110.413 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.629 HG13 HD11 ' A' ' 83' ' ' LEU . 25.2 t -71.98 126.23 32.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.181 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 32.7 t -96.03 -53.41 3.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.655 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.32 150.55 31.62 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.178 0.513 . . . . 0.0 110.74 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.485 HD11 ' HA ' ' A' ' 108' ' ' LYS . 32.8 mt -105.87 116.48 49.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.051 179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 64.2 mt -98.75 13.78 31.05 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.622 -179.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.756 ' HB ' HG21 ' A' ' 102' ' ' VAL . 28.4 m -148.22 133.56 11.0 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 CA-C-O 121.122 0.486 . . . . 0.0 110.691 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -116.86 161.2 19.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.195 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.21 95.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.621 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.22 -35.79 1.86 Allowed Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.52 146.77 47.59 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.093 0.473 . . . . 0.0 110.481 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -96.67 137.51 35.63 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.578 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 18.8 m -126.91 166.76 22.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.395 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -130.3 157.23 43.11 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.309 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.703 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -62.39 88.62 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.401 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.15 -33.51 2.08 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -63.15 145.66 55.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.145 0.498 . . . . 0.0 110.451 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.1 m -67.33 139.57 57.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.425 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.595 ' O ' HG22 ' A' ' 70' ' ' VAL . 28.1 m -120.14 -35.49 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.17 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.629 HD11 HG13 ' A' ' 65' ' ' VAL . 7.6 tt -162.05 152.71 17.45 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.261 0.553 . . . . 0.0 111.032 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.9 t -103.54 145.1 13.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.794 179.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.815 HD12 HD11 ' A' ' 94' ' ' ILE . 11.1 mt -126.67 160.3 31.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.52 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.423 179.907 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 . . . . . 0 C--O 1.231 0.09 0 CA-C-O 121.016 0.436 . . . . 0.0 110.196 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.3 m -118.75 117.58 29.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.393 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -83.04 133.82 35.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.457 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.815 HD11 HD12 ' A' ' 85' ' ' LEU . 33.7 mm -103.71 152.78 6.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.172 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 47.6 m-80 -139.88 148.08 41.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.495 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.89 139.18 95.66 Favored Pre-proline 0 CA--C 1.533 0.316 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.399 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -76.02 -28.65 7.38 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.128 1.886 . . . . 0.0 112.387 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.703 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 3.7 p -145.63 168.27 21.06 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.535 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -69.57 141.71 53.73 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.514 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 159.78 -168.16 35.48 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -129.13 168.4 16.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.229 0.538 . . . . 0.0 110.637 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.756 HG21 ' HB ' ' A' ' 70' ' ' VAL . 27.4 t -82.4 111.56 18.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.439 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -92.95 -30.13 15.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.42 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 4.9 tmtt? -159.05 128.77 5.62 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.275 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.429 HG22 HG11 ' A' ' 102' ' ' VAL . 20.7 t -101.3 105.73 18.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.117 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.0 mt -85.84 9.45 16.66 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.863 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.479 HG21 HD13 ' A' ' 83' ' ' LEU . 28.4 m -129.33 146.0 34.89 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-O 121.192 0.52 . . . . 0.0 110.629 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.485 ' HA ' HD11 ' A' ' 68' ' ' ILE . 20.5 mtpt -128.39 166.5 18.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.263 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -63.49 140.89 58.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.323 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 17.7 mmt85 65.83 36.71 5.96 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.67 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.504 ' O ' HG23 ' A' ' 65' ' ' VAL . 1.8 m-20 -121.89 137.44 54.78 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.272 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.2 134.21 34.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.521 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.2 m -120.72 156.96 23.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.367 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -97.51 144.12 27.53 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.393 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.3 108.05 1.62 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.96 -27.06 9.41 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.05 -0.82 . . . . 0.0 111.05 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 24.1 tt0 -59.83 143.52 50.96 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-O 121.126 0.489 . . . . 0.0 110.631 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.63 119.84 19.93 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.511 HD21 ' HB2' ' A' ' 59' ' ' ALA . 70.6 mt -89.67 -52.82 4.81 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.136 0.493 . . . . 0.0 110.172 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.484 ' CG2' HG13 ' A' ' 102' ' ' VAL . 46.3 mt -145.21 144.14 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.16 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 9.3 tttt -94.99 135.48 36.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.143 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.457 HD11 HD11 ' A' ' 57' ' ' ILE . 40.8 mm -109.2 142.69 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.412 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.815 0 CA-C-O 118.061 -1.41 . . . . 0.0 110.833 -179.919 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.49 ' OE2' HD11 ' A' ' 106' ' ' LEU . 7.6 mm-40 . . . . . 0 C--O 1.232 0.162 0 CA-C-O 121.09 0.471 . . . . 0.0 110.42 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.487 HD11 HD11 ' A' ' 122' ' ' ILE . 48.5 mt -78.29 118.79 74.39 Favored Pre-proline 0 CA--C 1.535 0.39 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.185 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -71.53 135.33 26.14 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 121.98 1.787 . . . . 0.0 112.331 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.764 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -65.52 148.4 98.1 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.456 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.79 -34.73 6.48 Favored 'Trans proline' 0 N--CA 1.472 0.224 0 C-N-CA 122.276 1.984 . . . . 0.0 112.236 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -162.67 159.06 23.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.411 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.77 81.91 0.19 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.288 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.411 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -115.01 -172.79 17.5 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.9 m -109.89 136.7 48.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.061 0.458 . . . . 0.0 110.388 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.507 HG13 HD21 ' A' ' 83' ' ' LEU . 24.3 t -71.73 117.02 14.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.094 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.8 t -92.93 -49.99 5.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.679 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -155.37 148.35 24.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.246 0.546 . . . . 0.0 110.608 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.422 HG22 ' O ' ' A' ' 70' ' ' VAL . 48.5 mt -103.37 130.15 54.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.95 179.696 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.588 HD11 HG23 ' A' ' 84' ' ' VAL . 5.7 mp -94.29 -30.72 14.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.854 -179.599 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.69 HG11 ' CG1' ' A' ' 76' ' ' VAL . 31.0 m -114.72 145.77 20.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.112 0.482 . . . . 0.0 110.728 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -138.88 166.87 23.32 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.331 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -56.96 104.95 0.18 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.839 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 132.1 -31.02 3.1 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -87.35 144.49 26.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.108 0.48 . . . . 0.0 110.57 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.2 m -93.51 150.45 20.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.293 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.69 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.9 m -125.14 166.9 20.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.568 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -129.48 147.51 51.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.204 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.463 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.52 92.02 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.629 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.17 -30.55 2.62 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.6 tt0 -69.25 143.04 54.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.107 0.479 . . . . 0.0 110.618 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.446 ' HB ' HD22 ' A' ' 69' ' ' LEU . 27.1 m -65.02 138.21 58.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.206 179.784 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.694 HG22 ' O ' ' A' ' 94' ' ' ILE . 29.6 m -115.7 -26.38 2.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.449 -179.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.507 HD21 HG13 ' A' ' 65' ' ' VAL . 9.1 tt -165.26 150.02 9.0 Favored 'General case' 0 C--N 1.332 -0.166 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.966 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.588 HG23 HD11 ' A' ' 69' ' ' LEU . 22.0 t -106.74 137.91 35.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.017 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.46 HD23 ' HA ' ' A' ' 85' ' ' LEU . 11.8 mt -115.66 164.75 13.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.184 0.516 . . . . 0.0 110.595 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.363 179.959 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 . . . . . 0 N--CA 1.461 0.108 0 CA-C-O 121.128 0.49 . . . . 0.0 110.55 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.7 m -122.02 112.61 18.48 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.233 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.443 ' HG3' HG22 ' A' ' 84' ' ' VAL . 1.7 mp0 -87.4 143.0 27.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.487 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.694 ' O ' HG22 ' A' ' 82' ' ' VAL . 4.8 mp -116.52 126.24 73.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.123 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -101.07 153.95 19.13 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.261 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.06 141.37 95.77 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.325 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.26 -32.72 7.98 Favored 'Trans proline' 0 N--CA 1.472 0.208 0 C-N-CA 122.133 1.889 . . . . 0.0 112.212 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.463 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 73.1 p -148.16 155.92 41.97 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.348 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -63.73 142.85 58.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.393 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 169.34 -156.38 27.43 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -134.35 150.97 50.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.092 0.472 . . . . 0.0 110.372 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.656 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -78.3 111.03 14.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.276 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -93.55 -30.94 14.74 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.646 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.61 151.74 27.88 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.221 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.495 HG13 HG12 ' A' ' 120' ' ' ILE . 21.9 t -131.95 113.26 21.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.304 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.49 HD11 ' OE2' ' A' ' 56' ' ' GLU . 2.1 mt -84.63 -33.07 23.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.348 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.417 ' O ' HG12 ' A' ' 105' ' ' VAL . 32.7 m -80.46 144.24 11.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.585 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -133.36 164.19 27.67 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.247 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 -61.28 144.35 54.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.458 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 2.5 ttt-85 61.48 35.02 17.78 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.44 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.459 ' O ' HG23 ' A' ' 65' ' ' VAL . 17.2 t0 -124.62 148.04 48.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.428 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.3 141.33 28.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.469 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 63' ' ' GLY . 30.8 m -122.41 156.18 27.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.379 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -100.58 140.18 35.21 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.346 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.51 98.97 0.16 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.3 -27.55 6.32 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.7 tt0 -59.56 142.63 52.28 Favored 'General case' 0 N--CA 1.462 0.127 0 CA-C-O 121.062 0.458 . . . . 0.0 110.656 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.26 121.64 26.03 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.761 -0.935 . . . . 0.0 110.761 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.764 HD21 ' HB2' ' A' ' 59' ' ' ALA . 79.6 mt -87.78 -54.46 4.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.075 0.464 . . . . 0.0 110.394 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.581 ' CG2' HG13 ' A' ' 102' ' ' VAL . 52.9 mt -141.24 149.39 20.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.312 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 14.8 tttp -98.14 126.75 43.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.343 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.487 HD11 HD11 ' A' ' 57' ' ' ILE . 36.7 mm -102.62 145.68 11.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.331 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.689 0 CA-C-O 117.988 -1.451 . . . . 0.0 110.784 179.967 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 121.132 0.492 . . . . 0.0 110.3 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.44 HD11 HD11 ' A' ' 122' ' ' ILE . 54.5 mt -78.04 113.67 35.27 Favored Pre-proline 0 CA--C 1.535 0.395 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.068 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.08 132.71 23.37 Favored 'Trans proline' 0 N--CA 1.472 0.249 0 C-N-CA 122.08 1.853 . . . . 0.0 112.297 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.503 ' HB3' ' O ' ' A' ' 114' ' ' GLN . . . -65.94 147.97 98.54 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.584 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.681 ' HB2' HD23 ' A' ' 61' ' ' LEU . 49.6 Cg_endo -73.33 -29.01 11.77 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.256 1.971 . . . . 0.0 112.314 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.681 HD23 ' HB2' ' A' ' 60' ' ' PRO . 0.2 OUTLIER -163.81 -179.85 6.61 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.528 179.83 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.19 98.45 9.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.42 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.57 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -132.76 -177.55 14.99 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.3 m -113.63 141.27 47.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.132 0.492 . . . . 0.0 110.418 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.706 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -70.89 126.02 30.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.293 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.1 t -100.65 -52.28 3.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.58 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 7.2 ttmm -150.52 148.56 28.85 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.654 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.422 HD11 ' HA ' ' A' ' 108' ' ' LYS . 44.8 mt -102.66 131.71 50.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.019 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.9 mt -99.79 -36.37 9.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.786 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.739 HG11 ' CG1' ' A' ' 76' ' ' VAL . 33.6 m -110.47 146.92 15.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 121.172 0.511 . . . . 0.0 110.835 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.3 pttt -137.3 165.6 25.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.182 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.485 ' HG3' HG23 ' A' ' 105' ' ' VAL . 36.8 mt-10 -58.42 101.74 0.09 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.606 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.07 -32.6 2.17 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -88.54 146.28 25.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.129 0.49 . . . . 0.0 110.392 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.507 HG22 ' O ' ' A' ' 100' ' ' GLY . 0.8 OUTLIER -96.28 148.33 22.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.32 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.739 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.9 m -125.77 169.79 16.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.52 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 43.6 tttt -132.37 153.97 50.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.31 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.656 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.94 97.97 0.07 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.595 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.27 -36.75 2.19 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 14.9 tt0 -62.49 139.08 58.59 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.056 0.455 . . . . 0.0 110.67 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.6 m -65.86 137.11 56.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.206 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.472 ' HA ' HG13 ' A' ' 70' ' ' VAL . 24.3 m -115.67 -31.39 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.229 -179.502 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.706 HD11 HG13 ' A' ' 65' ' ' VAL . 7.5 tt -161.35 153.0 19.18 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.177 0.513 . . . . 0.0 110.86 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -101.35 140.55 19.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.038 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.653 HD12 HD11 ' A' ' 94' ' ' ILE . 12.5 mt -122.78 139.24 54.21 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.161 0.505 . . . . 0.0 110.643 -179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.373 179.931 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.461 0.097 0 CA-C-O 121.117 0.484 . . . . 0.0 110.507 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.6 m -113.5 123.36 49.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.312 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -84.64 130.65 34.69 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.523 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.653 HD11 HD12 ' A' ' 85' ' ' LEU . 35.6 mm -106.23 114.9 46.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.184 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -102.11 146.91 27.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.289 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.09 141.53 95.79 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.322 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.62 -34.78 6.77 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.077 1.852 . . . . 0.0 112.211 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.656 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 17.4 p -147.85 162.57 38.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.271 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -68.19 141.18 56.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.328 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.507 ' O ' HG22 ' A' ' 75' ' ' THR . . . 171.47 -158.34 29.4 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 5.6 ttpm? -132.95 149.7 52.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.976 0.417 . . . . 0.0 110.336 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.66 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -75.99 110.16 10.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.21 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -92.77 -29.97 15.74 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.582 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 27.6 tttm -159.2 129.65 5.85 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.157 0.503 . . . . 0.0 110.486 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.485 HG23 ' HG3' ' A' ' 72' ' ' GLU . 33.2 t -100.19 102.84 13.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.168 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.2 mt -85.24 6.38 26.29 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.64 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.647 HG21 HD13 ' A' ' 83' ' ' LEU . 26.7 m -120.89 136.23 58.54 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.109 0 CA-C-O 121.181 0.515 . . . . 0.0 110.312 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.422 ' HA ' HD11 ' A' ' 68' ' ' ILE . 83.3 mttt -126.23 164.41 21.04 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.313 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -62.1 145.33 53.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.38 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 36.6 mtt180 60.13 35.6 21.18 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.588 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -114.64 141.68 47.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.373 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.61 129.27 38.59 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.572 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.57 HG22 ' O ' ' A' ' 63' ' ' GLY . 27.5 m -119.09 179.7 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.259 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . 0.503 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 64.3 mt-30 -140.68 152.45 45.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.512 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.82 105.09 0.83 Allowed Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.9 -31.39 4.97 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -60.05 135.32 57.68 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.131 0.491 . . . . 0.0 110.541 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.81 121.07 25.4 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.492 ' O ' HG13 ' A' ' 107' ' ' VAL . 62.3 mt -87.36 -56.51 3.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.012 0.434 . . . . 0.0 110.296 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.542 ' CG2' HG13 ' A' ' 102' ' ' VAL . 49.1 mt -143.15 150.89 17.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.126 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -96.2 125.7 40.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.265 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.44 HD11 HD11 ' A' ' 57' ' ' ILE . 37.8 mm -106.46 143.36 17.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.516 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.697 0 CA-C-O 117.951 -1.471 . . . . 0.0 110.767 179.977 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 . . . . . 0 N--CA 1.461 0.101 0 CA-C-O 121.026 0.441 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.465 HG23 ' HD3' ' A' ' 97' ' ' PRO . 54.3 mt -82.11 111.06 24.26 Favored Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.282 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -71.57 142.67 40.71 Favored 'Trans proline' 0 N--CA 1.472 0.263 0 C-N-CA 122.0 1.8 . . . . 0.0 112.295 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.483 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -74.7 147.14 84.15 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.397 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -72.49 -26.51 16.77 Favored 'Trans proline' 0 N--CA 1.471 0.199 0 C-N-CA 122.182 1.921 . . . . 0.0 112.366 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -164.55 157.57 17.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.362 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.502 ' HB2' ' H ' ' A' ' 115' ' ' GLY . . . -73.52 97.15 2.53 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.43 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.86 -144.55 6.22 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 3.9 m -136.54 132.18 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.095 0.474 . . . . 0.0 110.358 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.635 ' CG1' HD11 ' A' ' 83' ' ' LEU . 21.8 t -67.71 130.5 33.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.254 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 4.8 p -101.6 -53.98 2.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.542 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 23.8 ttpt -152.82 147.26 25.82 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.588 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.556 HG12 HD12 ' A' ' 83' ' ' LEU . 47.3 mt -100.23 133.48 43.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.116 179.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.425 HD12 HG22 ' A' ' 81' ' ' THR . 25.7 mt -98.64 -31.3 12.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.638 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.786 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.0 m -104.51 149.95 7.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.701 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 67.7 mttt -137.19 163.43 30.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.206 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -62.36 97.0 0.08 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.258 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.19 -29.19 2.43 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -85.43 147.82 26.3 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.082 0.467 . . . . 0.0 110.442 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.442 HG22 ' O ' ' A' ' 100' ' ' GLY . 0.7 OUTLIER -96.88 150.21 20.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.147 179.878 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.756 HG11 HG11 ' A' ' 70' ' ' VAL . 31.6 m -128.54 170.02 18.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.653 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.5 mmtt -131.38 146.26 52.2 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.22 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.707 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -58.84 96.51 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.717 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.16 -34.5 2.3 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 23.6 tt0 -67.84 144.46 55.3 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.14 0.495 . . . . 0.0 110.515 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.425 HG22 HD12 ' A' ' 69' ' ' LEU . 3.5 m -65.13 136.73 57.05 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.315 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.457 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.3 m -112.73 -33.09 2.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.921 -179.674 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.635 HD11 ' CG1' ' A' ' 65' ' ' VAL . 7.5 tt -160.4 150.75 18.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.686 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.2 t -102.55 136.64 33.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.184 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.695 HD11 HG21 ' A' ' 113' ' ' VAL . 0.7 OUTLIER -117.16 164.1 15.28 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.519 -179.793 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.28 179.985 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 121.068 0.461 . . . . 0.0 110.459 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 24.1 m -116.47 124.64 50.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.388 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -85.01 134.14 34.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.486 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.3 mm -102.66 126.1 56.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.242 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 13.7 p30 -110.25 140.06 44.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.314 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.11 139.24 96.03 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.311 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.465 ' HD3' HG23 ' A' ' 57' ' ' ILE . 49.8 Cg_endo -73.81 -31.04 8.75 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.166 1.911 . . . . 0.0 112.227 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.707 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 78.2 p -147.01 151.31 36.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.344 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -66.78 142.67 57.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.352 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.442 ' O ' HG22 ' A' ' 75' ' ' THR . . . 176.62 -147.93 8.76 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -140.88 145.47 36.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.076 0.465 . . . . 0.0 110.316 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.786 HG21 ' HB ' ' A' ' 70' ' ' VAL . 24.7 t -77.8 107.45 9.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.327 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -91.92 -28.42 17.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.729 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 17.8 ttpt -160.75 130.89 5.14 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.099 0.476 . . . . 0.0 110.544 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.435 HG13 HG12 ' A' ' 120' ' ' ILE . 21.9 t -105.49 109.52 28.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.347 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.6 mt -78.92 -31.8 45.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.476 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.424 HG11 HD23 ' A' ' 119' ' ' LEU . 31.5 m -80.18 152.84 4.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.593 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -135.79 155.11 50.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.268 179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -59.01 141.99 52.44 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.632 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER 60.75 36.39 19.34 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.499 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -119.45 151.11 39.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.286 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -93.64 133.4 37.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.491 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.695 HG21 HD11 ' A' ' 85' ' ' LEU . 29.7 m -120.39 152.01 23.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.453 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -100.17 144.93 28.62 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.354 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.502 ' H ' ' HB2' ' A' ' 62' ' ' ALA . . . -61.62 105.63 0.96 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 117.91 -28.04 7.19 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 37.3 tt0 -59.85 139.96 56.96 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 121.127 0.489 . . . . 0.0 110.597 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.36 126.58 40.3 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.483 HD11 ' HA ' ' A' ' 59' ' ' ALA . 41.5 mt -89.43 -58.94 2.35 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.153 0.501 . . . . 0.0 110.567 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.495 ' CG2' HG13 ' A' ' 102' ' ' VAL . 58.4 mt -140.95 145.57 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.164 -179.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -93.41 123.76 36.94 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.536 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.1 mm -101.23 145.07 12.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.274 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.678 0 CA-C-O 117.947 -1.474 . . . . 0.0 110.875 -179.996 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 . . . . . 0 C--O 1.232 0.145 0 CA-C-O 121.072 0.463 . . . . 0.0 110.453 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.405 HD11 HD11 ' A' ' 122' ' ' ILE . 43.4 mt -79.27 120.22 79.77 Favored Pre-proline 0 CA--C 1.534 0.335 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.157 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.22 138.72 31.01 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 121.998 1.799 . . . . 0.0 112.375 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -75.2 147.92 83.44 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.42 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -72.27 -28.53 15.21 Favored 'Trans proline' 0 CA--C 1.527 0.156 0 C-N-CA 122.324 2.016 . . . . 0.0 112.409 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.6 pp -163.25 163.2 25.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.436 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.16 98.17 5.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.437 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -123.65 -148.04 7.43 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.742 -0.943 . . . . 0.0 110.742 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.1 m -136.4 140.21 43.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.064 0.459 . . . . 0.0 110.439 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.698 HG13 HD11 ' A' ' 83' ' ' LEU . 24.7 t -72.28 120.12 20.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.16 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -96.82 -51.28 4.33 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.693 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -152.97 144.08 23.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.64 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 33.3 mt -97.45 131.46 44.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.0 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.507 HD22 ' HB ' ' A' ' 81' ' ' THR . 5.3 mp -100.11 -29.44 12.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.884 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.877 HG11 HG11 ' A' ' 76' ' ' VAL . 28.3 m -118.71 145.76 24.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-O 121.255 0.55 . . . . 0.0 110.685 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.3 pttm -136.52 167.04 22.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.175 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 9.1 mp0 -60.51 105.27 0.42 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.49 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -31.55 2.26 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 50.4 m-20 -93.82 149.49 21.19 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.064 0.459 . . . . 0.0 110.497 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.57 HG23 ' HB2' ' A' ' 101' ' ' LYS . 0.4 OUTLIER -102.18 143.44 31.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.286 179.941 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.877 HG11 HG11 ' A' ' 70' ' ' VAL . 22.9 m -122.03 162.1 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.551 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -122.98 158.07 31.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.265 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.612 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.47 101.83 0.2 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.518 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.29 -36.09 2.31 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -65.45 137.97 57.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.054 0.454 . . . . 0.0 110.563 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.507 ' HB ' HD22 ' A' ' 69' ' ' LEU . 11.1 m -64.13 139.38 58.76 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.172 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.44 HG22 ' O ' ' A' ' 94' ' ' ILE . 33.1 m -113.96 -30.53 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.19 -179.58 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.698 HD11 HG13 ' A' ' 65' ' ' VAL . 8.9 tt -164.66 151.64 11.17 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.088 0.47 . . . . 0.0 110.782 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.452 HG23 ' CD1' ' A' ' 69' ' ' LEU . 21.9 t -104.21 136.84 35.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.077 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.736 HD12 HD11 ' A' ' 94' ' ' ILE . 16.0 mt -118.07 159.79 22.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.651 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 . . . . . 0 C--N 1.33 -0.242 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.376 179.897 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 . . . . . 0 C--O 1.232 0.164 0 CA-C-O 121.028 0.442 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 24.7 m -116.08 124.41 50.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.341 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -82.17 132.26 35.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.479 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.736 HD11 HD12 ' A' ' 85' ' ' LEU . 36.2 mm -102.15 121.49 53.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.248 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -109.73 143.65 39.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.352 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.57 143.5 93.49 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.407 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -72.67 -35.54 5.85 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.118 1.879 . . . . 0.0 112.223 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.612 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 19.6 p -148.7 166.1 29.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.365 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -66.65 141.59 57.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.471 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.531 ' O ' HG22 ' A' ' 75' ' ' THR . . . 174.04 -162.35 32.91 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . 0.57 ' HB2' HG23 ' A' ' 75' ' ' THR . 6.8 ttpm? -133.07 147.53 52.18 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.034 0.445 . . . . 0.0 110.465 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.575 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.8 t -77.75 111.08 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.166 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -94.86 -30.07 14.38 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.638 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.7 tttp -159.02 131.01 6.54 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.345 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.434 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.3 t -96.66 110.68 25.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.312 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 29.8 mt -90.27 30.24 1.14 Allowed 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.633 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.434 ' H ' HG12 ' A' ' 105' ' ' VAL . 23.2 m -155.59 139.24 8.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-O 121.02 0.438 . . . . 0.0 110.259 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.67 165.13 18.45 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.134 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -60.91 147.19 43.96 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.555 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 60.99 35.76 18.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.505 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.42 ' O ' HG23 ' A' ' 65' ' ' VAL . 6.9 t0 -121.36 137.72 54.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.412 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -89.24 134.75 33.91 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.432 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.0 m -122.39 155.91 27.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.417 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -100.23 145.88 27.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.453 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.17 112.36 4.65 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 109.85 -27.8 11.51 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -57.45 145.33 33.36 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 121.07 0.462 . . . . 0.0 110.779 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.01 122.02 28.37 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 97.8 mt -90.42 -56.77 3.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.114 0.483 . . . . 0.0 110.523 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.482 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.5 mt -140.94 145.74 24.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.301 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 7.2 ttmt -92.46 124.44 36.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.365 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.405 HD11 HD11 ' A' ' 57' ' ' ILE . 37.6 mm -103.46 145.1 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.448 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.218 -0.848 0 CA-C-O 118.076 -1.402 . . . . 0.0 110.701 179.952 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.23 0.073 0 CA-C-O 121.02 0.438 . . . . 0.0 110.382 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 55.3 mt -80.25 111.22 20.53 Favored Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.053 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -70.68 141.86 42.51 Favored 'Trans proline' 0 N--CA 1.472 0.262 0 C-N-CA 122.032 1.821 . . . . 0.0 112.292 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.674 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -75.85 144.89 77.06 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.475 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.684 ' HG2' HD23 ' A' ' 61' ' ' LEU . 50.5 Cg_endo -73.71 -24.74 15.43 Favored 'Trans proline' 0 N--CA 1.472 0.217 0 C-N-CA 122.188 1.925 . . . . 0.0 112.59 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.684 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.9 OUTLIER -161.55 167.54 25.2 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.454 -179.913 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -91.7 95.49 9.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.369 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -122.83 -139.67 5.56 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.9 m -136.12 134.61 38.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.083 0.468 . . . . 0.0 110.406 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.606 HG13 HD11 ' A' ' 83' ' ' LEU . 26.4 t -71.34 125.61 30.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.279 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.9 t -95.7 -54.79 3.23 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.578 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -152.43 149.52 28.67 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.523 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.415 HG12 HD12 ' A' ' 83' ' ' LEU . 48.9 mt -102.27 133.39 46.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.221 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.9 mp -98.82 -31.5 11.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.618 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.687 HG11 ' CG1' ' A' ' 76' ' ' VAL . 33.2 m -114.79 144.91 21.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.681 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.85 165.54 25.39 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.26 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -59.33 101.52 0.1 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.598 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.09 -31.81 2.24 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -90.11 150.03 22.23 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.089 0.471 . . . . 0.0 110.486 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.503 HG22 ' O ' ' A' ' 100' ' ' GLY . 1.0 OUTLIER -96.23 149.43 21.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.332 179.925 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.687 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.3 m -122.73 168.33 15.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.464 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 21.4 ttpt -128.34 148.49 50.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.346 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.637 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.05 100.83 0.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.612 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.11 -31.31 4.75 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.1 tt0 -64.08 143.73 57.65 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.057 0.456 . . . . 0.0 110.67 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 21.4 m -65.44 138.84 58.38 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.219 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.431 ' HA ' HG13 ' A' ' 70' ' ' VAL . 28.4 m -118.49 -32.2 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.384 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.606 HD11 HG13 ' A' ' 65' ' ' VAL . 7.5 tt -161.04 152.28 18.91 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.311 0.577 . . . . 0.0 111.296 -179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.539 HG13 ' O ' ' A' ' 92' ' ' THR . 19.7 t -103.45 147.32 9.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.557 179.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.849 HD12 HD11 ' A' ' 94' ' ' ILE . 7.4 mt -127.48 170.44 12.57 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.156 0.503 . . . . 0.0 110.785 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 . . . . . 0 C--N 1.33 -0.244 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.478 -179.832 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.173 0.511 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.539 ' O ' HG13 ' A' ' 84' ' ' VAL . 0.5 OUTLIER -112.13 176.19 5.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.656 179.594 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.535 ' H ' HG22 ' A' ' 92' ' ' THR . 50.6 mt-10 -146.02 134.87 22.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.28 0.562 . . . . 0.0 110.648 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.849 HD11 HD12 ' A' ' 85' ' ' LEU . 37.3 mm -102.57 153.7 5.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.146 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -136.91 141.45 42.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.353 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.93 135.52 94.65 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.309 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -73.85 -31.64 8.09 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.073 1.849 . . . . 0.0 112.268 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.637 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 25.1 p -146.13 157.57 43.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.411 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -65.86 141.81 58.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.279 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.503 ' O ' HG22 ' A' ' 75' ' ' THR . . . 174.66 -158.52 26.69 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 26.5 ttpt -133.74 148.54 51.42 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.144 0.497 . . . . 0.0 110.413 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.646 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.7 t -75.47 105.83 4.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.27 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -92.49 -26.67 17.85 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.859 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . 0.695 ' HD2' HD21 ' A' ' 106' ' ' LEU . 27.9 ttmt -158.93 129.08 5.81 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.098 0.475 . . . . 0.0 110.635 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 24.9 t -102.29 106.13 19.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.194 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.695 HD21 ' HD2' ' A' ' 104' ' ' LYS . 18.1 mt -89.5 13.33 14.11 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.632 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.441 HG21 HD13 ' A' ' 83' ' ' LEU . 30.7 m -130.12 143.77 40.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 CA-C-O 121.079 0.466 . . . . 0.0 110.312 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 13.6 mtmm -126.08 168.01 14.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.387 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -72.29 143.25 48.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.338 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 16.3 mtm180 61.42 38.5 15.98 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.514 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -126.45 148.04 49.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.336 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.83 140.0 30.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.56 -179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.9 m -122.8 156.02 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.274 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 39.0 mm-40 -101.94 142.39 33.31 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.337 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.38 111.38 3.38 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 108.72 -25.02 20.52 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -59.9 140.97 56.3 Favored 'General case' 0 N--CA 1.462 0.15 0 CA-C-O 121.017 0.437 . . . . 0.0 110.791 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.48 118.37 14.6 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.674 HD21 ' HB2' ' A' ' 59' ' ' ALA . 33.2 mt -88.58 -54.02 4.37 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.124 0.487 . . . . 0.0 110.497 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 52.2 mt -142.4 142.74 26.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.325 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.0 122.49 38.88 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.097 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.0 mm -100.66 142.46 15.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.479 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.667 0 CA-C-O 117.972 -1.46 . . . . 0.0 110.758 179.931 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 121.079 0.466 . . . . 0.0 110.542 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.505 HD11 HD11 ' A' ' 122' ' ' ILE . 48.5 mt -79.49 120.28 79.79 Favored Pre-proline 0 CA--C 1.534 0.348 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.081 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -72.19 146.06 45.27 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 121.996 1.797 . . . . 0.0 112.352 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.62 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -74.55 148.47 85.58 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.41 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.85 -28.5 13.43 Favored 'Trans proline' 0 N--CA 1.472 0.207 0 C-N-CA 122.207 1.938 . . . . 0.0 112.345 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.7 pp -166.27 165.3 17.49 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.494 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.69 84.21 3.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.396 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.448 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -120.92 -166.57 13.06 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.8 m -112.28 135.78 52.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.132 0.492 . . . . 0.0 110.357 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.563 HG13 HD11 ' A' ' 83' ' ' LEU . 25.1 t -70.79 126.11 30.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.247 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 4.5 p -97.82 -61.63 1.36 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.604 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 9.1 mmmt -141.47 150.23 41.97 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.607 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.502 HG22 ' H ' ' A' ' 70' ' ' VAL . 33.6 mt -110.22 120.55 61.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.842 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.4 mt -96.82 27.66 3.85 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.344 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.829 ' HB ' HG21 ' A' ' 102' ' ' VAL . 31.5 m -155.5 151.18 10.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 121.195 0.521 . . . . 0.0 110.483 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.9 pttt -141.6 160.33 40.39 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.054 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -60.34 95.05 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.431 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.18 -26.63 2.57 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -80.64 149.05 29.98 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.161 0.505 . . . . 0.0 110.457 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.6 m -97.32 137.71 35.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.228 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.467 HG11 HG11 ' A' ' 70' ' ' VAL . 34.6 m -119.78 145.03 26.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.556 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 mtmt -108.74 147.53 31.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.235 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.673 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -58.5 102.04 0.1 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.812 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.01 -32.72 3.38 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 12.7 tt0 -65.15 143.9 57.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.055 0.455 . . . . 0.0 110.501 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.9 m -66.95 138.45 57.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.221 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 32.3 m -119.37 -31.29 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.531 -179.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.563 HD11 HG13 ' A' ' 65' ' ' VAL . 9.9 tt -162.37 146.23 11.85 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.129 0.49 . . . . 0.0 111.032 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.471 HG22 ' OE2' ' A' ' 93' ' ' GLU . 22.0 t -108.81 143.08 19.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.89 179.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.458 HD11 HG21 ' A' ' 113' ' ' VAL . 1.0 OUTLIER -124.38 163.59 21.42 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.186 0.517 . . . . 0.0 110.798 -179.6 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.2 mt-10 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.371 179.906 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 121.14 0.495 . . . . 0.0 110.52 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.9 m -113.15 116.55 30.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.22 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.471 ' OE2' HG22 ' A' ' 84' ' ' VAL . 10.2 mm-40 -91.78 125.91 36.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.526 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.494 ' N ' HD12 ' A' ' 94' ' ' ILE . 5.3 mp -108.72 148.46 12.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.954 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -135.89 156.12 49.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.165 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.56 135.58 95.61 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.337 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.37 -32.47 8.05 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.044 1.829 . . . . 0.0 112.224 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.673 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 1.1 p -145.61 159.33 43.3 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.315 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -63.64 140.03 58.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.339 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.17 -161.69 32.78 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.3 ttmp? -135.62 146.75 48.22 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.062 0.458 . . . . 0.0 110.444 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.829 HG21 ' HB ' ' A' ' 70' ' ' VAL . 30.3 t -75.99 114.07 15.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.147 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -94.94 -30.02 14.36 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.778 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 77.6 tttt -159.98 128.91 5.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.546 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 120' ' ' ILE . 22.1 t -107.62 108.71 25.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.271 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 mt -79.21 -31.62 43.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.447 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.44 ' O ' HG12 ' A' ' 105' ' ' VAL . 27.6 m -80.77 145.27 9.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.567 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -130.36 157.67 41.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.21 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 66.5 mt-10 -59.27 143.21 49.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.668 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 24.4 ttt180 61.76 32.84 18.15 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.305 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -116.24 151.06 36.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.427 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.83 135.51 34.06 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.442 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.458 HG21 HD11 ' A' ' 85' ' ' LEU . 30.8 m -120.53 179.67 2.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.43 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -135.42 145.29 47.11 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.366 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.45 109.43 2.48 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.0 -29.32 8.13 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.3 tt0 -60.11 140.82 56.65 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 121.146 0.498 . . . . 0.0 110.609 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.38 122.04 28.06 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.62 HD11 ' HA ' ' A' ' 59' ' ' ALA . 87.7 mt -89.22 -61.63 1.66 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.132 0.491 . . . . 0.0 110.503 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.559 HG12 HG13 ' A' ' 105' ' ' VAL . 55.4 mt -140.96 151.83 20.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.362 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 33.0 tttm -98.63 134.63 41.3 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.386 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.505 HD11 HD11 ' A' ' 57' ' ' ILE . 35.4 mm -108.06 146.87 13.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.424 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.779 0 CA-C-O 118.049 -1.417 . . . . 0.0 110.786 179.958 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 . . . . . 0 C--O 1.231 0.081 0 CA-C-O 121.015 0.435 . . . . 0.0 110.272 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 54.8 mt -80.1 111.41 21.8 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.17 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -71.1 153.41 62.68 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.011 1.807 . . . . 0.0 112.218 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.695 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -78.97 143.05 60.92 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.468 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -74.13 -27.91 11.33 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.121 1.881 . . . . 0.0 112.309 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -163.9 162.91 23.75 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.364 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.56 92.07 5.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.39 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -126.16 -141.85 5.59 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 19.8 m -138.04 138.3 38.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.003 0.43 . . . . 0.0 110.459 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.523 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -70.66 125.31 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.208 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.1 t -98.24 -46.42 5.83 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.564 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 36.0 mtmt -149.16 169.84 19.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.606 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 51.7 mt -129.8 125.81 61.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.946 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.478 HD12 HG22 ' A' ' 81' ' ' THR . 20.4 mt -97.24 -28.11 14.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.12 -179.383 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.872 ' HB ' HG21 ' A' ' 102' ' ' VAL . 32.9 m -101.47 156.77 4.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.346 0.593 . . . . 0.0 111.218 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 22.5 mttp -135.96 151.9 50.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.843 179.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.561 ' HG3' HG23 ' A' ' 105' ' ' VAL . 16.6 mt-10 -60.78 90.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.52 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.09 -25.86 2.63 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 63.8 m-20 -78.72 148.66 32.96 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.143 0.497 . . . . 0.0 110.5 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 5.3 m -97.02 140.04 32.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.184 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.57 HG11 HG11 ' A' ' 70' ' ' VAL . 30.0 m -121.91 171.26 10.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.66 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -127.42 138.66 53.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.191 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.696 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -56.11 100.25 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.029 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.86 -38.84 1.63 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 45.3 tt0 -69.35 144.82 53.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.065 0.459 . . . . 0.0 110.599 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.478 HG22 HD12 ' A' ' 69' ' ' LEU . 17.6 m -65.02 139.11 58.71 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.317 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.587 HG22 ' O ' ' A' ' 94' ' ' ILE . 35.1 m -115.05 -25.88 3.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.397 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.523 HD11 HG13 ' A' ' 65' ' ' VAL . 7.7 tt -166.58 146.52 5.86 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 121.052 0.453 . . . . 0.0 110.702 -179.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -105.1 141.26 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.133 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 85' ' ' LEU . 12.1 mt -120.11 158.28 27.22 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.553 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 . . . . . 0 C--N 1.33 -0.251 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.397 179.94 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 . . . . . 0 N--CA 1.461 0.122 0 CA-C-O 121.171 0.51 . . . . 0.0 110.41 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.8 m -129.0 113.0 14.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.131 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -87.22 142.98 27.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.717 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.649 ' N ' HD12 ' A' ' 94' ' ' ILE . 4.6 mp -115.21 127.08 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.907 179.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 42.4 m-20 -102.5 153.31 20.19 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.207 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.85 136.22 94.84 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.345 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -72.62 -35.25 6.23 Favored 'Trans proline' 0 N--CA 1.471 0.2 0 C-N-CA 122.09 1.86 . . . . 0.0 112.172 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.696 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 2.5 p -147.36 155.32 41.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.296 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -64.49 140.43 58.87 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.384 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.21 -157.94 26.14 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 15.7 ttmm -132.31 143.7 50.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.065 0.459 . . . . 0.0 110.468 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.872 HG21 ' HB ' ' A' ' 70' ' ' VAL . 36.0 t -78.78 110.08 14.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.171 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.09 -29.65 16.43 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.84 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 8.0 ttpt -157.86 131.03 7.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.448 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.561 HG23 ' HG3' ' A' ' 72' ' ' GLU . 21.8 t -101.06 115.46 42.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.243 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.408 ' O ' HG13 ' A' ' 107' ' ' VAL . 19.9 mt -89.95 28.52 1.36 Allowed 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.698 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.503 ' H ' HG12 ' A' ' 105' ' ' VAL . 19.2 m -155.69 142.5 11.3 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 121.038 0.447 . . . . 0.0 110.378 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.5 tttt -125.89 165.03 19.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.188 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -59.61 143.05 51.51 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.615 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 30.2 mtm180 60.14 34.01 21.15 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.558 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -114.21 149.16 36.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.338 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.92 134.98 34.29 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.526 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.6 m -122.38 149.91 25.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.331 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 55.9 mt-30 -99.68 144.1 29.15 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.416 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.42 110.07 2.71 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.739 -0.945 . . . . 0.0 110.739 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 110.24 -27.29 11.85 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -59.64 139.77 56.94 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.056 0.455 . . . . 0.0 110.668 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.12 123.08 31.53 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.695 HD11 ' HA ' ' A' ' 59' ' ' ALA . 65.8 mt -87.57 -54.01 4.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.032 0.444 . . . . 0.0 110.405 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.626 ' CG2' HG13 ' A' ' 102' ' ' VAL . 50.2 mt -141.5 149.64 20.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.426 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.0 tttm -99.25 130.51 45.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.299 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.2 mm -107.63 144.71 15.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.506 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.797 0 CA-C-O 117.964 -1.464 . . . . 0.0 110.806 179.969 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.1 0.476 . . . . 0.0 110.477 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.51 HD11 HD11 ' A' ' 122' ' ' ILE . 45.0 mt -78.82 111.76 22.04 Favored Pre-proline 0 CA--C 1.534 0.363 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.212 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.94 137.82 32.82 Favored 'Trans proline' 0 N--CA 1.473 0.267 0 C-N-CA 122.084 1.856 . . . . 0.0 112.374 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.721 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -68.72 149.13 98.02 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.465 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.52 -27.55 15.53 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.253 1.969 . . . . 0.0 112.414 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 pp -164.79 165.22 20.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.443 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.34 96.49 5.32 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.363 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -128.4 -141.11 5.14 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.776 -0.929 . . . . 0.0 110.776 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.1 m -136.71 141.51 43.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.002 0.43 . . . . 0.0 110.46 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.76 HG13 HD11 ' A' ' 83' ' ' LEU . 23.1 t -71.21 128.64 34.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.218 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 t -98.67 -62.0 1.3 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.518 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 9.8 mtpt -150.16 144.81 25.92 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.457 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.653 HG12 HD12 ' A' ' 83' ' ' LEU . 42.2 mt -99.24 128.85 50.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.039 179.691 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.9 mp -97.67 -36.03 10.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.829 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.688 HG11 HG12 ' A' ' 76' ' ' VAL . 33.7 m -115.17 139.26 42.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.263 0.554 . . . . 0.0 110.78 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 20.9 pttt -135.91 162.75 31.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.793 179.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -54.61 108.64 0.41 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.279 0.561 . . . . 0.0 110.783 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.42 -29.98 2.35 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -102.53 155.12 18.49 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.974 0.416 . . . . 0.0 110.396 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.4 m -96.91 150.43 20.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.43 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.688 HG12 HG11 ' A' ' 70' ' ' VAL . 30.3 m -123.97 168.28 16.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.498 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 28.4 mmtm -129.69 155.28 46.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.448 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.511 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -62.2 105.76 0.64 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.453 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.25 -29.37 7.07 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -61.32 142.7 56.7 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.104 0.478 . . . . 0.0 110.564 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.9 m -67.1 138.14 56.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.271 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.4 m -118.17 -34.26 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.208 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.76 HD11 HG13 ' A' ' 65' ' ' VAL . 6.5 tt -162.11 152.02 16.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.134 0.492 . . . . 0.0 111.078 -179.315 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.682 HG22 ' OE1' ' A' ' 93' ' ' GLU . 22.8 t -102.89 143.15 15.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.654 179.245 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.7 HD11 HG21 ' A' ' 113' ' ' VAL . 0.3 OUTLIER -119.49 167.69 11.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.229 0.538 . . . . 0.0 110.782 -179.559 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.365 179.897 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 . . . . . 0 N--CA 1.461 0.109 0 CA-C-O 121.14 0.495 . . . . 0.0 110.403 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 14.0 m -118.47 123.09 44.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.33 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.682 ' OE1' HG22 ' A' ' 84' ' ' VAL . 6.4 mm-40 -84.51 132.26 34.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.59 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 30.8 mm -105.45 148.72 9.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.049 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -139.29 150.83 45.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.612 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.63 143.73 96.35 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.399 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -72.62 -34.42 7.21 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.186 1.924 . . . . 0.0 112.26 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.511 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 14.3 p -146.95 168.45 21.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.312 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -68.82 142.26 54.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.463 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.1 -161.25 32.27 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.2 ttpt -133.62 138.91 46.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.062 0.458 . . . . 0.0 110.464 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.647 HG13 ' CG2' ' A' ' 120' ' ' ILE . 22.3 t -74.22 123.73 30.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.238 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -99.03 -33.17 10.92 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.588 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . 0.534 ' NZ ' HD23 ' A' ' 106' ' ' LEU . 0.2 OUTLIER -160.88 147.82 15.29 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.412 -179.948 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.506 HG12 ' H ' ' A' ' 107' ' ' VAL . 11.9 t -101.29 119.0 48.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.008 179.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.534 HD23 ' NZ ' ' A' ' 104' ' ' LYS . 6.9 mt -89.53 21.56 3.36 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.919 -179.638 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.506 ' H ' HG12 ' A' ' 105' ' ' VAL . 30.6 m -154.56 156.3 5.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-O 121.093 0.473 . . . . 0.0 110.673 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.5 mtmp? -130.85 159.03 38.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.25 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 64.4 mt-10 -60.51 151.26 28.99 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.513 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? 60.99 32.33 19.92 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.521 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -122.91 150.9 42.31 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.452 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.01 137.56 32.27 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.348 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.7 HG21 HD11 ' A' ' 85' ' ' LEU . 30.5 m -121.12 148.71 24.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.432 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -98.1 140.66 32.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.259 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.54 96.28 0.09 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 127.51 -27.87 4.61 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -59.31 142.71 51.39 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.086 0.47 . . . . 0.0 110.704 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.22 120.93 24.71 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.721 HD11 ' HA ' ' A' ' 59' ' ' ALA . 14.1 mt -89.78 -50.2 6.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.079 0.466 . . . . 0.0 110.418 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.647 ' CG2' HG13 ' A' ' 102' ' ' VAL . 45.9 mt -145.27 147.82 18.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.297 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.5 mttp -95.43 130.34 42.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.158 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.51 HD11 HD11 ' A' ' 57' ' ' ILE . 37.5 mm -110.39 144.67 18.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.357 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.711 0 CA-C-O 117.974 -1.459 . . . . 0.0 110.76 -179.997 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 . . . . . 0 C--O 1.231 0.083 0 CA-C-O 121.107 0.48 . . . . 0.0 110.459 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.636 HD11 HD11 ' A' ' 122' ' ' ILE . 35.5 mt -81.81 112.22 32.93 Favored Pre-proline 0 CA--C 1.535 0.366 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.167 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -70.73 128.56 15.3 Favored 'Trans proline' 0 N--CA 1.472 0.233 0 C-N-CA 122.017 1.811 . . . . 0.0 112.363 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.574 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -61.95 148.64 87.75 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.49 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.99 -26.82 18.08 Favored 'Trans proline' 0 N--CA 1.471 0.15 0 C-N-CA 122.283 1.989 . . . . 0.0 112.509 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -163.75 168.54 19.58 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.423 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.75 102.83 13.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.499 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -133.98 -140.73 4.37 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 16.0 m -137.15 142.1 42.23 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.104 0.478 . . . . 0.0 110.369 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 111' ' ' ASP . 23.1 t -71.96 131.99 33.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.122 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -101.37 -54.17 2.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.502 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 33.5 tttt -155.74 147.0 22.59 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.594 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.483 HD11 ' HA ' ' A' ' 108' ' ' LYS . 8.8 mt -100.43 130.78 49.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.972 179.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.1 mt -101.56 -41.88 6.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.691 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.795 ' HB ' HG21 ' A' ' 102' ' ' VAL . 29.5 m -93.54 149.88 4.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.761 -179.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -135.11 162.22 33.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.255 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.46 ' OE1' HG23 ' A' ' 105' ' ' VAL . 2.6 mp0 -60.94 96.6 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.543 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.0 -31.22 2.3 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -79.78 147.07 31.99 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.127 0.489 . . . . 0.0 110.449 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 6.7 m -95.9 141.12 29.7 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.382 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.707 HG11 HG11 ' A' ' 70' ' ' VAL . 29.9 m -120.06 160.93 20.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.555 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 tttt -120.08 146.97 45.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.311 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.65 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.84 93.46 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.69 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.42 -32.43 2.55 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -67.84 141.12 56.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.976 0.417 . . . . 0.0 110.52 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.0 m -63.34 137.22 58.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.189 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.528 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.6 m -114.01 -35.1 2.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.781 -179.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.567 HD13 HG21 ' A' ' 107' ' ' VAL . 7.0 tt -159.18 151.49 21.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.449 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.2 t -102.9 143.44 15.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.042 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -124.06 164.75 18.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.582 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.338 179.989 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 . . . . . 0 N--CA 1.461 0.102 0 CA-C-O 121.167 0.508 . . . . 0.0 110.43 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.5 m -119.41 120.42 36.8 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.425 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -85.09 129.98 34.7 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.514 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 33.6 mm -103.13 124.55 57.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.327 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -110.29 147.76 33.23 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.376 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.78 138.42 96.96 Favored Pre-proline 0 CA--C 1.532 0.282 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.346 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.65 -32.87 7.18 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.087 1.858 . . . . 0.0 112.162 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.65 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 5.7 p -149.63 155.03 39.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.345 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -61.85 141.96 57.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.443 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 170.07 -157.37 28.75 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.1 ttmp? -134.82 148.07 50.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.129 0.49 . . . . 0.0 110.523 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.795 HG21 ' HB ' ' A' ' 70' ' ' VAL . 26.2 t -77.06 113.54 16.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.326 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -93.26 -30.83 14.97 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.699 -179.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 13.1 ttpt -159.45 133.57 7.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.569 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.46 HG23 ' OE1' ' A' ' 72' ' ' GLU . 21.6 t -101.92 108.11 23.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.144 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mt -89.58 13.13 14.77 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.578 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.567 HG21 HD13 ' A' ' 83' ' ' LEU . 26.3 m -130.72 136.59 57.92 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-O 121.123 0.487 . . . . 0.0 110.186 179.752 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.483 ' HA ' HD11 ' A' ' 68' ' ' ILE . 0.2 OUTLIER -125.49 172.16 9.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.226 -179.782 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -72.05 150.63 43.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.311 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 37.3 mtt-85 61.45 30.89 19.07 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.664 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.515 ' O ' HG23 ' A' ' 65' ' ' VAL . 5.8 m-20 -125.88 139.33 53.56 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.285 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.17 141.57 28.44 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.449 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.2 m -121.09 156.95 24.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.391 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -99.22 144.6 28.15 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.373 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.12 106.08 1.03 Allowed Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 117.56 -28.51 7.08 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.0 tt0 -59.21 137.7 57.87 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.126 0.489 . . . . 0.0 110.713 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.15 123.25 31.96 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.574 HD11 ' HA ' ' A' ' 59' ' ' ALA . 17.1 mt -86.5 -55.85 3.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.191 0.52 . . . . 0.0 110.534 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.655 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.8 mt -140.88 152.31 20.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.336 -179.779 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -96.92 132.52 42.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.476 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.636 HD11 HD11 ' A' ' 57' ' ' ILE . 36.9 mm -109.52 145.18 16.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.303 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.791 0 CA-C-O 118.095 -1.392 . . . . 0.0 110.757 -179.953 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 121.066 0.46 . . . . 0.0 110.354 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.564 HD11 HD11 ' A' ' 122' ' ' ILE . 45.4 mt -79.74 111.63 22.9 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.263 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -72.48 129.8 15.25 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 121.982 1.788 . . . . 0.0 112.217 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.441 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -62.09 139.43 96.0 Favored Pre-proline 0 CA--C 1.532 0.274 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.274 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.409 ' HG2' HD12 ' A' ' 61' ' ' LEU . 48.0 Cg_endo -75.43 -12.0 20.7 Favored 'Trans proline' 0 CA--C 1.533 0.445 0 C-N-CA 122.091 1.861 . . . . 0.0 113.038 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.699 HD22 ' N ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -160.73 179.55 8.44 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-O 121.099 0.476 . . . . 0.0 110.48 179.901 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.699 ' N ' HD22 ' A' ' 61' ' ' LEU . . . -109.76 113.34 26.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.401 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -149.5 -138.87 3.0 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.512 ' C ' HD23 ' A' ' 85' ' ' LEU . 12.3 m -135.82 139.36 43.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.103 0.478 . . . . 0.0 110.411 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.554 HG13 HD11 ' A' ' 83' ' ' LEU . 28.1 t -70.48 126.5 30.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.18 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t -97.04 -55.06 2.98 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.574 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 ttpt -153.08 149.09 27.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.521 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.531 HD11 ' HA ' ' A' ' 108' ' ' LYS . 41.7 mt -103.01 135.66 39.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.059 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.477 HD22 ' HB ' ' A' ' 81' ' ' THR . 9.7 mp -99.72 -45.08 5.88 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.818 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.734 ' HB ' HG21 ' A' ' 102' ' ' VAL . 34.8 m -97.2 148.16 5.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.218 0.532 . . . . 0.0 110.876 -179.688 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 pttt -137.24 163.66 30.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.195 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.425 ' HG3' HG23 ' A' ' 105' ' ' VAL . 14.2 mt-10 -59.64 102.59 0.15 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.584 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.51 2.26 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -91.91 151.45 20.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.119 0.485 . . . . 0.0 110.492 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.562 HG22 ' O ' ' A' ' 100' ' ' GLY . 0.7 OUTLIER -96.58 153.67 17.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.312 179.916 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.712 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.9 m -126.14 167.67 20.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.562 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 mttm -129.05 148.05 50.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.37 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.594 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.16 93.14 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.715 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.88 -34.8 2.17 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -64.0 143.95 57.46 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.086 0.469 . . . . 0.0 110.582 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.477 ' HB ' HD22 ' A' ' 69' ' ' LEU . 9.0 m -66.92 139.58 57.72 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.336 179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 35.6 m -114.11 -32.68 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.939 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.695 HD13 HG21 ' A' ' 107' ' ' VAL . 7.9 tt -161.49 148.38 14.52 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.106 0.479 . . . . 0.0 110.797 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -103.4 140.37 21.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.113 179.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.66 HD21 HG21 ' A' ' 113' ' ' VAL . 2.1 mt -119.83 172.09 7.95 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.56 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.444 179.995 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 121.06 0.457 . . . . 0.0 110.569 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.5 m -112.41 117.54 32.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.283 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -84.99 135.52 33.99 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.56 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.634 HD11 HD12 ' A' ' 85' ' ' LEU . 41.1 mm -106.7 122.33 60.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.255 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -104.95 142.81 34.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.362 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.13 144.11 91.53 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -72.57 -38.95 2.94 Favored 'Trans proline' 0 CA--C 1.528 0.216 0 C-N-CA 122.175 1.917 . . . . 0.0 112.168 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.594 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 2.8 p -148.39 165.14 31.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.309 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -66.6 141.43 57.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.393 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.562 ' O ' HG22 ' A' ' 75' ' ' THR . . . 172.82 -157.37 26.58 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 17.7 ttmt -136.11 146.69 47.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.104 0.478 . . . . 0.0 110.488 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.734 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.0 t -74.7 108.72 6.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.186 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -91.52 -29.12 17.15 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.809 -179.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.4 ttmm -159.33 130.27 6.0 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.095 0.474 . . . . 0.0 110.53 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.425 HG23 ' HG3' ' A' ' 72' ' ' GLU . 32.3 t -102.19 105.72 18.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.184 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.4 mt -88.0 10.21 19.74 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.67 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.695 HG21 HD13 ' A' ' 83' ' ' LEU . 23.7 m -125.59 136.13 61.81 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.062 0 CA-C-O 121.11 0.481 . . . . 0.0 110.258 179.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.531 ' HA ' HD11 ' A' ' 68' ' ' ILE . 2.8 ttpm? -122.56 169.36 11.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.391 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 -66.65 142.5 57.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.356 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER 63.17 38.14 10.82 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.66 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -117.8 142.36 47.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.319 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.91 131.61 36.43 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.427 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.66 HG21 HD21 ' A' ' 85' ' ' LEU . 30.8 m -119.59 179.82 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.452 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -141.46 149.35 40.84 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.427 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.55 104.4 0.7 Allowed Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.64 -31.49 4.57 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -61.64 135.9 57.81 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.091 0.472 . . . . 0.0 110.445 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -63.01 118.89 15.27 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.441 HD21 ' HB2' ' A' ' 59' ' ' ALA . 69.3 mt -88.38 -56.21 3.41 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.074 0.464 . . . . 0.0 110.392 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.528 ' CG2' HG13 ' A' ' 102' ' ' VAL . 50.9 mt -142.26 144.94 24.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.323 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.7 tttt -96.55 132.76 41.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.333 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.564 HD11 HD11 ' A' ' 57' ' ' ILE . 39.2 mm -107.25 144.88 15.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.416 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.738 0 CA-C-O 117.958 -1.468 . . . . 0.0 110.813 -179.992 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 121.104 0.478 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.41 HD11 ' CG1' ' A' ' 122' ' ' ILE . 52.6 mt -77.84 111.67 19.51 Favored Pre-proline 0 CA--C 1.534 0.364 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.175 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -70.83 145.02 49.89 Favored 'Trans proline' 0 N--CA 1.472 0.248 0 C-N-CA 122.035 1.823 . . . . 0.0 112.394 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -82.11 147.52 57.73 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.468 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.661 ' HG2' HD23 ' A' ' 61' ' ' LEU . 48.7 Cg_endo -71.82 -23.26 22.59 Favored 'Trans proline' 0 N--CA 1.472 0.251 0 C-N-CA 122.278 1.986 . . . . 0.0 112.658 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.661 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.8 OUTLIER -161.68 173.38 14.77 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.089 0.471 . . . . 0.0 110.486 -179.991 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.55 91.81 5.23 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.411 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.721 ' HA3' HD23 ' A' ' 85' ' ' LEU . . . -103.42 175.15 23.44 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.4 m -105.81 7.17 32.23 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.639 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t 63.15 117.75 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 CA-C-O 121.075 0.464 . . . . 0.0 110.322 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.5 t -95.89 -57.37 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.577 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 34.4 tttm -155.11 146.38 22.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.59 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.637 HG12 HD12 ' A' ' 83' ' ' LEU . 23.7 mt -105.09 120.82 56.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.867 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 16.8 mt -98.39 25.49 6.26 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.303 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.685 ' HB ' HG21 ' A' ' 102' ' ' VAL . 30.6 m -153.16 147.73 14.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.133 0.492 . . . . 0.0 110.644 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.3 pttt -135.05 161.3 35.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.151 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 51.5 mt-10 -60.07 99.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.519 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -30.45 2.35 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -77.36 151.89 34.68 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.11 0.481 . . . . 0.0 110.412 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 5.1 m -100.77 132.52 46.12 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.488 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.3 m -115.68 150.56 17.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.409 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -111.62 153.62 26.07 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.383 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.609 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.85 100.62 0.11 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.603 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.89 -31.45 4.11 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 5.6 tt0 -63.66 143.81 57.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.117 0.484 . . . . 0.0 110.524 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.2 m -66.27 136.34 55.7 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.334 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.605 ' O ' HG22 ' A' ' 70' ' ' VAL . 27.6 m -119.1 -35.38 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.213 -179.51 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.637 HD12 HG12 ' A' ' 68' ' ' ILE . 7.1 tt -159.64 149.74 18.74 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.838 -179.315 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.418 HG12 ' N ' ' A' ' 85' ' ' LEU . 21.9 t -107.94 154.99 8.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.898 179.471 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.721 HD23 ' HA3' ' A' ' 63' ' ' GLY . 3.5 mp -123.78 173.12 8.36 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.196 0.522 . . . . 0.0 110.636 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 . . . . . 0 C--N 1.33 -0.261 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.308 179.953 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 . . . . . 0 C--O 1.23 0.064 0 CA-C-O 121.134 0.492 . . . . 0.0 110.413 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.21 103.44 9.84 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.291 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -79.85 143.44 34.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.646 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.482 ' CG1' HD13 ' A' ' 85' ' ' LEU . 40.7 mm -105.93 156.31 6.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.052 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.435 ' N ' HG22 ' A' ' 94' ' ' ILE . 22.3 m-80 -134.24 143.07 47.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.47 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.11 142.0 98.17 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.318 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.5 -36.02 4.28 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.12 1.88 . . . . 0.0 112.288 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.609 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 1.7 p -145.76 161.47 39.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.433 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -65.27 142.51 58.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.322 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.8 -158.4 25.32 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.5 ttmt -135.5 145.88 47.55 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.05 0.453 . . . . 0.0 110.549 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.685 HG21 ' HB ' ' A' ' 70' ' ' VAL . 26.2 t -74.33 110.25 8.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.245 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -95.24 -29.54 14.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.723 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -160.51 135.39 7.67 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.517 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.417 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.1 t -101.37 109.27 25.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.21 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 29.4 mt -90.08 29.66 1.19 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.639 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.562 HG21 HD13 ' A' ' 83' ' ' LEU . 29.6 m -155.2 145.17 13.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 121.055 0.455 . . . . 0.0 110.361 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.4 mmtm -127.25 160.85 30.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.259 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -60.02 142.99 52.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.524 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 3.1 ttm180 61.35 34.35 18.45 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.492 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -114.18 140.15 48.77 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.388 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -88.63 126.11 35.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.531 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.7 m -122.11 157.79 26.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.395 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -96.57 143.69 27.33 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.414 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.32 92.64 0.07 OUTLIER Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.6 -27.81 2.92 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -60.94 141.35 57.33 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-O 121.031 0.444 . . . . 0.0 110.54 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.08 123.81 33.6 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.442 ' O ' HG22 ' A' ' 107' ' ' VAL . 92.3 mt -86.61 -51.83 5.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.055 0.455 . . . . 0.0 110.539 -179.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.5 mt -140.88 150.23 20.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.395 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -97.78 128.4 44.4 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.309 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.41 ' CG1' HD11 ' A' ' 57' ' ' ILE . 37.6 mm -107.17 143.61 17.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.478 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.749 0 CA-C-O 117.982 -1.455 . . . . 0.0 110.781 179.975 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 121.08 0.467 . . . . 0.0 110.571 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.598 HD11 HD11 ' A' ' 122' ' ' ILE . 38.5 mt -80.72 111.2 21.21 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.131 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -70.61 135.64 28.89 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 122.085 1.857 . . . . 0.0 112.387 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.591 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -73.02 153.39 90.85 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.398 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.62 -27.9 14.8 Favored 'Trans proline' 0 CA--C 1.528 0.2 0 C-N-CA 122.211 1.941 . . . . 0.0 112.404 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.9 pp -165.95 165.71 17.9 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.418 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.496 ' HB2' ' H ' ' A' ' 115' ' ' GLY . . . -79.76 104.73 10.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.286 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.22 -142.43 4.91 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.9 m -135.78 134.22 38.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.068 0.461 . . . . 0.0 110.468 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.602 ' CG1' HD11 ' A' ' 83' ' ' LEU . 24.9 t -72.14 127.94 34.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.126 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.31 -53.54 3.32 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.68 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 16.8 tttp -152.03 147.19 26.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.598 -179.749 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.571 HG12 HD12 ' A' ' 83' ' ' LEU . 47.9 mt -100.82 133.14 44.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.992 179.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.3 mp -99.6 -29.85 12.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.929 -179.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.777 ' HB ' HG21 ' A' ' 102' ' ' VAL . 34.9 m -110.7 148.66 13.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 121.241 0.543 . . . . 0.0 110.878 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.8 ptpp? -135.13 163.96 28.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.14 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -61.87 99.08 0.11 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.502 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.62 -30.9 2.36 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -84.73 147.53 26.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.14 0.495 . . . . 0.0 110.455 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.5 m -96.38 145.95 25.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.294 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.685 HG11 HG11 ' A' ' 70' ' ' VAL . 26.8 m -120.88 170.42 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.655 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 35.5 mttt -130.19 147.11 51.88 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.199 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.635 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.7 95.89 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.74 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.05 -34.21 2.48 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 11.0 tt0 -66.46 139.25 57.96 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.082 0.467 . . . . 0.0 110.527 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 19.4 m -62.76 137.68 58.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.313 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.455 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.1 m -112.83 -32.27 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.952 -179.653 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.602 HD11 ' CG1' ' A' ' 65' ' ' VAL . 7.1 tt -162.74 150.21 13.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.159 0.504 . . . . 0.0 110.624 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.1 t -103.49 143.57 15.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.119 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.5 tp -124.66 165.81 17.25 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.631 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.321 -179.978 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 . . . . . 0 C--O 1.231 0.095 0 CA-C-O 121.046 0.45 . . . . 0.0 110.423 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.9 m -119.19 115.65 24.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.383 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -83.7 129.93 34.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.489 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 37.3 mm -104.14 122.51 57.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.306 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -109.84 144.01 38.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.253 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.51 141.88 94.4 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.42 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.39 -37.9 3.97 Favored 'Trans proline' 0 N--CA 1.471 0.178 0 C-N-CA 122.125 1.883 . . . . 0.0 112.302 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.635 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 3.0 p -147.19 159.93 43.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.403 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -62.7 141.36 58.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.351 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.3 -157.0 25.47 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -137.95 147.03 43.91 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.081 0.467 . . . . 0.0 110.416 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.777 HG21 ' HB ' ' A' ' 70' ' ' VAL . 25.0 t -76.88 112.61 14.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.191 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -95.31 -30.07 14.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.741 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.2 tttm -159.75 127.43 4.74 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.604 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.483 HG13 HG12 ' A' ' 120' ' ' ILE . 24.1 t -104.16 114.85 44.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.255 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mt -82.31 -39.06 23.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.405 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.549 HG21 HD13 ' A' ' 83' ' ' LEU . 33.2 m -74.64 150.27 7.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.545 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 43.4 mttt -133.6 161.13 35.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.316 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -61.56 139.98 58.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.458 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.44 37.52 16.62 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.354 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -123.92 146.98 48.08 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.386 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.18 138.14 31.78 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.519 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.2 m -122.33 162.39 22.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.336 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 13.6 mt-30 -103.12 141.06 36.49 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.293 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.496 ' H ' ' HB2' ' A' ' 62' ' ' ALA . . . -60.38 105.95 0.92 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.03 -26.97 9.99 Favored Glycine 0 CA--C 1.527 0.831 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 -58.15 148.89 25.3 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-O 121.109 0.48 . . . . 0.0 110.773 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.16 122.85 30.81 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.591 HD21 ' HB2' ' A' ' 59' ' ' ALA . 92.3 mt -89.61 -60.86 1.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.086 0.469 . . . . 0.0 110.423 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.582 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.4 mt -140.95 152.52 20.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.243 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 55.3 mttt -95.86 127.38 41.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.415 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.598 HD11 HD11 ' A' ' 57' ' ' ILE . 37.1 mm -107.15 145.16 14.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.396 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.027 -1.429 . . . . 0.0 110.798 -179.998 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 121.119 0.485 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.489 HD11 HD11 ' A' ' 122' ' ' ILE . 52.4 mt -78.22 111.66 20.16 Favored Pre-proline 0 CA--C 1.535 0.372 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.237 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -71.32 138.39 32.88 Favored 'Trans proline' 0 N--CA 1.472 0.221 0 C-N-CA 121.997 1.798 . . . . 0.0 112.348 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.66 146.66 99.09 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.404 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.81 -27.73 14.4 Favored 'Trans proline' 0 CA--C 1.528 0.196 0 C-N-CA 122.254 1.97 . . . . 0.0 112.291 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -164.64 171.02 14.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.46 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.71 93.53 6.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.447 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.95 -148.76 7.41 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.1 m -136.46 138.0 41.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.071 0.462 . . . . 0.0 110.551 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.571 HG13 HD21 ' A' ' 83' ' ' LEU . 19.5 t -71.05 116.72 13.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.2 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 t -98.61 -48.65 4.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.622 -179.804 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -150.4 144.67 25.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.622 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.622 HD11 ' HA ' ' A' ' 108' ' ' LYS . 21.8 mt -105.35 135.12 44.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.905 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.786 HD22 ' HB ' ' A' ' 81' ' ' THR . 3.6 mp -97.14 -30.62 12.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.846 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.701 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.3 m -119.47 145.7 25.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.187 0.518 . . . . 0.0 110.742 -179.704 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.9 pttm -133.6 164.21 27.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.252 179.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -60.54 103.82 0.28 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.452 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.04 -29.68 2.41 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -94.94 153.15 17.8 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.098 0.475 . . . . 0.0 110.475 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.4 m -96.69 153.08 18.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.311 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.701 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.4 m -128.61 168.64 21.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.73 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.4 mtpp -129.96 151.69 50.24 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.19 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.646 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.57 102.16 0.17 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.71 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.85 -37.74 2.05 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 32.3 tt0 -62.55 140.57 58.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.12 0.486 . . . . 0.0 110.692 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.786 ' HB ' HD22 ' A' ' 69' ' ' LEU . 9.2 m -67.34 141.07 57.26 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.227 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.781 HG22 ' O ' ' A' ' 94' ' ' ILE . 34.9 m -115.61 -24.25 3.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.592 -179.405 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.571 HD21 HG13 ' A' ' 65' ' ' VAL . 8.3 tt -166.26 152.94 9.29 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.211 0.529 . . . . 0.0 110.885 -179.668 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.566 ' N ' HD23 ' A' ' 83' ' ' LEU . 21.8 t -114.9 134.7 57.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.042 179.702 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.45 HD12 HD11 ' A' ' 94' ' ' ILE . 55.8 mt -115.47 161.59 18.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.611 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.132 179.889 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 121.112 0.482 . . . . 0.0 110.569 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.9 m -115.07 123.6 49.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.224 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 14.8 mt-10 -94.07 129.91 40.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.788 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.781 ' O ' HG22 ' A' ' 82' ' ' VAL . 4.4 mp -115.5 112.37 39.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.633 179.489 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -99.48 153.97 18.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.419 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.98 142.54 95.19 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.293 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.33 -36.22 5.67 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.175 1.917 . . . . 0.0 112.196 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.646 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -146.12 168.83 20.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.299 179.846 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -68.55 141.9 55.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.334 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.24 -161.16 31.12 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 74.9 tttt -134.51 148.12 50.47 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.096 0.474 . . . . 0.0 110.429 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.618 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.6 t -74.75 103.7 2.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.202 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -90.39 -29.29 18.11 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.774 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.5 tttt -158.32 123.53 4.37 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.139 0.495 . . . . 0.0 110.518 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.506 HG13 HG12 ' A' ' 120' ' ' ILE . 24.5 t -100.37 106.79 19.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.332 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.41 ' O ' HG13 ' A' ' 107' ' ' VAL . 5.4 mt -90.48 33.76 0.9 Allowed 'General case' 0 CA--C 1.533 0.326 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.421 179.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.43 HG22 ' O ' ' A' ' 119' ' ' LEU . 19.2 m -156.4 137.26 4.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 121.031 0.443 . . . . 0.0 110.101 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.622 ' HA ' HD11 ' A' ' 68' ' ' ILE . 1.4 mptp? -125.85 175.82 7.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.272 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -72.2 147.63 46.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.401 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 63.16 34.51 13.51 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.537 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -121.87 145.0 48.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.26 179.754 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.24 136.99 32.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.629 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 20.7 m -120.23 179.73 2.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.383 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -133.05 141.97 48.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.367 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.8 102.36 0.33 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.849 -0.901 . . . . 0.0 110.849 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.33 -31.32 4.7 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -60.24 142.5 54.44 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.093 0.473 . . . . 0.0 110.583 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -65.45 126.64 30.77 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.43 ' O ' HG22 ' A' ' 107' ' ' VAL . 92.6 mt -89.98 -55.49 3.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.993 0.425 . . . . 0.0 110.271 179.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.538 ' CG2' HG13 ' A' ' 102' ' ' VAL . 45.6 mt -143.51 149.25 18.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.333 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.2 ttmt -96.44 130.84 43.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.276 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.489 HD11 HD11 ' A' ' 57' ' ' ILE . 37.6 mm -107.22 144.17 16.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.49 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.758 0 CA-C-O 117.998 -1.446 . . . . 0.0 110.737 179.991 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 121.116 0.484 . . . . 0.0 110.341 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.427 HD11 HD11 ' A' ' 122' ' ' ILE . 47.4 mt -82.5 114.85 54.6 Favored Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.24 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.38 148.98 55.9 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.054 1.836 . . . . 0.0 112.278 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.586 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -81.13 145.26 56.04 Favored Pre-proline 0 CA--C 1.532 0.25 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.431 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -73.44 -27.34 13.29 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.238 1.958 . . . . 0.0 112.399 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.7 pp -162.57 158.26 23.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.472 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -75.19 91.28 2.61 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.337 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -121.03 -170.24 13.99 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.474 ' C ' HD23 ' A' ' 85' ' ' LEU . 18.9 m -106.93 134.98 49.28 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.057 0.456 . . . . 0.0 110.408 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.756 HG13 HD11 ' A' ' 83' ' ' LEU . 32.6 t -69.59 121.49 19.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.15 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t -95.66 -60.14 1.72 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.398 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -150.32 146.52 26.8 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.465 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.722 HG12 HD12 ' A' ' 83' ' ' LEU . 32.8 mt -102.46 124.05 56.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.922 179.773 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.635 HD22 ' HB ' ' A' ' 81' ' ' THR . 8.4 mp -97.61 27.88 4.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.991 -179.561 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.767 ' HB ' HG21 ' A' ' 102' ' ' VAL . 26.3 m -153.9 154.85 6.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 121.178 0.514 . . . . 0.0 110.486 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -141.6 158.2 44.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.122 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -60.52 92.5 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.45 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.19 -27.06 2.55 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -78.42 144.62 35.7 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.077 0.465 . . . . 0.0 110.489 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -95.54 135.45 37.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.355 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.602 HG11 HG11 ' A' ' 70' ' ' VAL . 26.6 m -115.4 160.28 14.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.573 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 23.8 mttm -118.52 142.91 47.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.286 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.601 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -57.76 95.7 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.761 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.19 -31.88 2.64 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.8 tt0 -68.01 151.17 47.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.137 0.494 . . . . 0.0 110.399 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.635 ' HB ' HD22 ' A' ' 69' ' ' LEU . 4.5 m -69.76 136.65 51.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.401 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.1 m -113.6 -32.11 2.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.901 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.756 HD11 HG13 ' A' ' 65' ' ' VAL . 8.3 tt -160.75 146.76 14.9 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.111 0.482 . . . . 0.0 110.705 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -101.85 137.1 30.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.094 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.737 HD12 HD11 ' A' ' 94' ' ' ILE . 12.8 mt -120.4 165.73 14.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.496 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.3 mt-10 . . . . . 0 C--N 1.331 -0.212 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.327 179.955 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.061 0.458 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.8 m -113.07 120.21 40.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.333 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 -84.65 135.84 34.0 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.492 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.737 HD11 HD12 ' A' ' 85' ' ' LEU . 37.8 mm -104.85 126.85 59.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.296 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -108.73 141.23 41.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.427 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.32 143.17 95.79 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.324 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -73.08 -37.99 3.11 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.121 1.88 . . . . 0.0 112.273 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.601 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 21.2 p -145.01 155.71 43.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.302 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -65.64 141.45 58.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.375 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 178.15 -155.31 16.68 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -134.83 143.44 47.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.023 0.44 . . . . 0.0 110.38 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.767 HG21 ' HB ' ' A' ' 70' ' ' VAL . 26.0 t -79.04 114.13 19.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.139 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -95.44 -30.37 13.92 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.606 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.3 ttpt -158.0 131.89 7.94 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.464 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 26.8 t -108.72 102.22 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.267 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.1 mt -74.32 -33.61 63.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.446 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 119' ' ' LEU . 29.9 m -73.52 150.68 7.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.346 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -140.88 157.29 45.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.473 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 61.7 mt-10 -61.17 145.62 50.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.51 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.14 37.54 17.55 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.33 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.543 ' O ' HG23 ' A' ' 65' ' ' VAL . 15.0 t70 -127.28 145.0 50.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.454 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.9 137.46 32.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.493 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.1 m -121.32 156.12 25.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.376 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 13.6 mt-30 -101.6 144.57 30.17 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.376 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.31 107.18 1.36 Allowed Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.84 -27.64 8.17 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -59.75 141.72 54.67 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.054 0.454 . . . . 0.0 110.645 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.35 127.11 41.55 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.586 HD21 ' HB2' ' A' ' 59' ' ' ALA . 91.7 mt -91.17 -56.29 3.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.086 0.469 . . . . 0.0 110.459 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.578 ' CG2' HG13 ' A' ' 102' ' ' VAL . 53.5 mt -141.12 151.28 19.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.342 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.0 tttt -97.36 126.63 42.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.42 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.427 HD11 HD11 ' A' ' 57' ' ' ILE . 37.5 mm -105.24 145.64 13.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.397 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.82 0 CA-C-O 118.002 -1.443 . . . . 0.0 110.813 179.968 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 . . . . . 0 C--O 1.232 0.169 0 CA-C-O 121.096 0.474 . . . . 0.0 110.506 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.6 mt -79.01 116.69 61.95 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.159 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -71.6 137.62 30.62 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 121.991 1.794 . . . . 0.0 112.279 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.527 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -71.0 148.17 94.3 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.404 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.551 ' HD3' HD12 ' A' ' 94' ' ' ILE . 47.9 Cg_endo -72.58 -28.75 13.96 Favored 'Trans proline' 0 CA--C 1.528 0.194 0 C-N-CA 122.238 1.959 . . . . 0.0 112.216 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.5 pp -162.34 173.51 14.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.511 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -86.67 95.8 9.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.384 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.22 -145.39 6.52 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.534 ' C ' HD23 ' A' ' 85' ' ' LEU . 13.8 m -136.33 139.72 42.79 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.128 0.49 . . . . 0.0 110.512 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.707 HG13 HD11 ' A' ' 83' ' ' LEU . 21.8 t -68.66 121.96 19.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.097 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 92.7 p -99.45 -53.15 3.29 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.627 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.3 tptt -152.33 144.77 24.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.558 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.409 HG12 HD12 ' A' ' 83' ' ' LEU . 21.8 mt -103.14 133.19 47.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.989 179.716 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.412 HD13 ' HB ' ' A' ' 81' ' ' THR . 12.3 mt -99.77 -29.57 12.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.952 -179.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.813 HG11 HG11 ' A' ' 76' ' ' VAL . 32.6 m -110.98 147.87 14.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.249 0.547 . . . . 0.0 110.765 -179.726 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.8 pttt -136.18 166.01 24.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.244 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.5 ' HG3' HG23 ' A' ' 105' ' ' VAL . 14.8 mt-10 -61.79 100.03 0.14 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.495 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.06 -31.98 2.23 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -85.42 147.15 26.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.068 0.461 . . . . 0.0 110.461 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.1 m -98.29 146.8 25.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.348 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.813 HG11 HG11 ' A' ' 70' ' ' VAL . 24.9 m -126.75 165.52 25.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.614 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 22.2 pttt -127.2 150.51 49.49 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.285 179.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.743 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -58.62 98.23 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.748 -179.759 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.31 -37.91 1.83 Allowed Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 21.1 tt0 -65.18 143.82 57.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.072 0.463 . . . . 0.0 110.639 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.412 ' HB ' HD13 ' A' ' 69' ' ' LEU . 4.1 m -67.37 138.93 57.11 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.204 179.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.431 ' HA ' HG13 ' A' ' 70' ' ' VAL . 34.8 m -113.75 -34.38 2.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.84 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.707 HD11 HG13 ' A' ' 65' ' ' VAL . 7.9 tt -160.45 147.34 15.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.788 -179.415 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -104.97 139.43 25.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.001 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.634 HD21 HG21 ' A' ' 113' ' ' VAL . 2.4 mt -120.02 165.36 14.8 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.19 0.519 . . . . 0.0 110.691 -179.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 . . . . . 0 C--N 1.331 -0.22 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.532 -179.833 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 121.14 0.495 . . . . 0.0 110.412 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.2 m -119.85 114.52 22.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.437 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -82.4 143.5 31.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.579 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.551 HD12 ' HD3' ' A' ' 60' ' ' PRO . 39.7 mm -105.14 127.62 59.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.162 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -105.42 142.16 35.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.341 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.86 132.2 91.76 Favored Pre-proline 0 CA--C 1.534 0.33 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.371 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -72.79 -32.19 9.5 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 121.99 1.793 . . . . 0.0 112.243 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.743 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 4.6 p -146.68 156.91 43.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.419 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -68.32 142.73 55.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.44 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 172.19 -156.77 26.1 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -135.43 146.46 48.26 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.057 0.456 . . . . 0.0 110.415 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.69 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.0 t -74.86 107.75 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.271 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . 0.402 ' HG3' ' N ' ' A' ' 104' ' ' LYS . 7.3 pt-20 -90.59 -30.98 16.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.563 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . 0.402 ' N ' ' HG3' ' A' ' 103' ' ' GLU . 1.5 tptm -156.11 130.57 8.87 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.586 -179.787 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.5 HG23 ' HG3' ' A' ' 72' ' ' GLU . 25.4 t -98.92 106.1 18.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.347 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.2 mt -89.59 12.06 17.82 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.511 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.688 HG21 HD13 ' A' ' 83' ' ' LEU . 28.3 m -127.33 136.16 61.38 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.095 0 CA-C-O 121.121 0.486 . . . . 0.0 110.122 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 40.1 tttt -128.5 156.21 43.62 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.373 -179.787 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -60.7 150.22 32.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.487 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 61.45 31.79 19.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.443 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -124.36 142.78 51.01 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.264 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.5 136.84 32.83 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.609 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.634 HG21 HD21 ' A' ' 85' ' ' LEU . 30.4 m -120.69 157.16 23.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.306 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 -100.14 142.19 31.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.504 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.07 107.64 1.41 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.61 -28.32 8.65 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.4 tt0 -57.62 147.14 28.19 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.087 0.47 . . . . 0.0 110.76 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -63.33 121.85 25.38 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.941 -0.863 . . . . 0.0 110.941 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.671 ' O ' HG13 ' A' ' 107' ' ' VAL . 56.5 mt -87.25 -52.56 5.33 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.056 0.455 . . . . 0.0 110.501 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' HG13 ' A' ' 102' ' ' VAL . 48.9 mt -142.31 148.3 20.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.35 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -95.75 128.04 42.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.345 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.4 mm -107.68 145.34 15.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.484 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.798 0 CA-C-O 117.984 -1.454 . . . . 0.0 110.824 179.999 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 . . . . . 0 C--O 1.23 0.071 0 CA-C-O 121.066 0.46 . . . . 0.0 110.357 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.568 HD11 HD11 ' A' ' 122' ' ' ILE . 53.0 mt -79.39 111.45 20.8 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.144 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.33 141.98 40.18 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.016 1.811 . . . . 0.0 112.288 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.411 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -76.75 144.49 73.15 Favored Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.275 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.73 -22.35 20.6 Favored 'Trans proline' 0 CA--C 1.529 0.241 0 C-N-CA 122.181 1.921 . . . . 0.0 112.702 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.5 pp -161.7 167.38 25.19 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.128 0.489 . . . . 0.0 110.457 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -86.37 119.67 26.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.455 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -152.04 -141.4 3.31 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.522 ' C ' HD23 ' A' ' 85' ' ' LEU . 6.6 m -137.56 143.42 41.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.139 0.495 . . . . 0.0 110.439 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.796 HG13 HD11 ' A' ' 83' ' ' LEU . 37.3 t -68.17 128.63 31.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.172 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.6 m -98.18 -59.75 1.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.683 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 12.6 mtpt -149.49 147.18 27.9 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.541 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.474 HD11 ' HA ' ' A' ' 108' ' ' LYS . 51.8 mt -102.87 123.25 56.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.075 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.6 mp -94.09 -46.04 7.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.657 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.683 ' HB ' HG21 ' A' ' 102' ' ' VAL . 33.4 m -95.23 143.9 10.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.694 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 3.5 pttt -133.36 165.33 25.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.182 179.76 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -59.31 102.03 0.12 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.666 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 137.91 -31.89 2.42 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -84.9 149.99 25.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.09 0.471 . . . . 0.0 110.501 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 9.3 m -96.64 142.98 28.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.352 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.674 ' CG1' HG11 ' A' ' 70' ' ' VAL . 31.5 m -120.7 154.22 24.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.548 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 13.0 tptt -116.57 151.22 36.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.192 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.08 96.69 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.647 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.62 -30.81 3.35 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -64.79 139.52 58.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.082 0.468 . . . . 0.0 110.602 -179.857 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.0 m -65.57 136.16 56.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.187 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.493 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.0 m -115.09 -29.57 2.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.294 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.796 HD11 HG13 ' A' ' 65' ' ' VAL . 7.2 tt -165.29 152.22 10.47 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.133 0.492 . . . . 0.0 110.778 -179.451 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -107.66 139.81 28.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.153 179.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.712 HD21 HG21 ' A' ' 113' ' ' VAL . 1.8 mt -120.58 160.78 22.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.497 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.232 179.916 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 . . . . . 0 C--O 1.232 0.148 0 CA-C-O 121.053 0.454 . . . . 0.0 110.372 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.1 m -119.76 126.18 50.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.367 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -82.7 129.9 35.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.361 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.526 HG13 HD12 ' A' ' 85' ' ' LEU . 23.6 mm -106.39 118.2 53.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.188 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 22.9 p30 -110.65 152.18 26.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.333 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.23 142.19 95.91 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.359 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -73.54 -32.97 7.26 Favored 'Trans proline' 0 N--CA 1.471 0.173 0 C-N-CA 122.171 1.914 . . . . 0.0 112.232 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.583 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 1.0 OUTLIER -148.64 161.08 42.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.385 179.999 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -64.24 142.79 58.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.407 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.21 -153.02 19.63 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 26.3 ttmt -139.84 147.07 40.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.103 0.478 . . . . 0.0 110.428 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.683 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -74.74 107.91 5.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.315 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -91.85 -27.74 17.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.865 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -161.4 136.1 7.24 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.07 0.462 . . . . 0.0 110.481 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.417 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.8 t -103.05 108.61 24.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.269 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.6 mt -90.5 31.1 1.06 Allowed 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.605 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.417 ' H ' HG12 ' A' ' 105' ' ' VAL . 25.8 m -155.54 144.54 12.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 121.032 0.444 . . . . 0.0 110.342 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.474 ' HA ' HD11 ' A' ' 68' ' ' ILE . 8.4 mptt -130.52 165.85 21.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.277 179.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -60.99 145.41 50.74 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.472 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 14.2 mmt85 60.64 37.12 19.43 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.507 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -117.93 144.7 45.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.351 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.01 129.24 38.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.457 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.712 HG21 HD21 ' A' ' 85' ' ' LEU . 27.8 m -122.09 150.38 25.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.475 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 -99.44 148.4 24.26 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.432 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -63.59 103.26 0.65 Allowed Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.48 -28.66 5.69 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -59.51 137.89 57.87 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.109 0.481 . . . . 0.0 110.665 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.23 119.73 19.8 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.411 HD21 ' HB2' ' A' ' 59' ' ' ALA . 44.8 mt -87.2 -54.74 4.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.133 0.492 . . . . 0.0 110.484 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.529 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.1 mt -140.99 143.76 27.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.226 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 7.2 tttt -95.16 129.99 42.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.517 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.568 HD11 HD11 ' A' ' 57' ' ' ILE . 37.2 mm -104.62 145.57 13.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.32 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.731 0 CA-C-O 118.011 -1.438 . . . . 0.0 110.768 179.97 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.413 ' OE2' HD11 ' A' ' 106' ' ' LEU . 66.2 mt-10 . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.915 0.388 . . . . 0.0 110.146 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.736 HD12 ' HD2' ' A' ' 97' ' ' PRO . 41.5 mm -83.16 110.49 24.02 Favored Pre-proline 0 CA--C 1.534 0.338 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.068 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -71.57 131.02 18.0 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 121.972 1.782 . . . . 0.0 112.101 -179.741 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.639 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -59.61 145.9 81.75 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.64 -179.867 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -75.62 -29.75 6.98 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.292 1.995 . . . . 0.0 112.5 -179.86 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.429 HD12 ' C ' ' A' ' 61' ' ' LEU . 4.4 pp -157.5 164.43 37.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.552 -179.681 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.9 108.02 13.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.437 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -134.65 -146.63 5.43 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.588 ' O ' HD23 ' A' ' 85' ' ' LEU . 1.8 m -136.33 138.18 41.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.095 0.474 . . . . 0.0 110.401 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.827 HG13 HD11 ' A' ' 83' ' ' LEU . 29.2 t -70.42 118.57 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.039 179.867 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.7 p -96.25 -53.67 3.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.845 -179.749 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 37.9 mttt -148.64 145.28 27.68 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 121.108 0.48 . . . . 0.0 110.703 -179.607 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.522 HD11 ' HA ' ' A' ' 108' ' ' LYS . 38.9 mt -101.78 128.81 53.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.986 179.507 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.429 HD12 HG22 ' A' ' 81' ' ' THR . 15.4 mt -97.64 -49.04 5.0 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.819 -179.592 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.697 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.6 m -93.73 146.04 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.217 0.532 . . . . 0.0 110.797 -179.831 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.8 pttp -135.31 162.72 31.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.034 179.789 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -59.26 103.19 0.16 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.54 -179.971 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.4 2.27 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.881 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -89.79 149.61 22.63 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.135 0.493 . . . . 0.0 110.445 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.4 m -97.22 141.51 30.25 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.444 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.697 ' CG1' HG11 ' A' ' 70' ' ' VAL . 27.1 m -117.43 156.33 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.464 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -117.53 157.03 27.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.438 179.864 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.81 96.48 0.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.557 -179.888 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.52 -28.24 4.52 Favored Glycine 0 CA--C 1.527 0.829 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.806 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -63.3 142.91 58.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.113 0.482 . . . . 0.0 110.684 -179.746 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.429 HG22 HD12 ' A' ' 69' ' ' LEU . 4.9 m -67.65 139.48 56.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.227 179.747 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.566 ' HA ' HG13 ' A' ' 70' ' ' VAL . 30.8 m -119.37 -32.62 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.399 -179.415 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.827 HD11 HG13 ' A' ' 65' ' ' VAL . 7.1 tt -163.09 152.09 14.71 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.228 0.537 . . . . 0.0 111.049 -179.297 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -106.1 139.81 26.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.857 179.574 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.588 HD23 ' O ' ' A' ' 64' ' ' THR . 12.5 mt -122.09 168.01 12.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.153 0.502 . . . . 0.0 110.759 -179.719 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 72.2 mt-10 . . . . . 0 C--N 1.331 -0.23 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.364 179.974 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 . . . . . 0 N--CA 1.461 0.103 0 CA-C-O 121.105 0.478 . . . . 0.0 110.501 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 7.0 m -113.53 115.21 27.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.241 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -80.98 128.66 33.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.525 -179.793 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.568 HD11 HD12 ' A' ' 85' ' ' LEU . 35.4 mm -101.54 144.08 13.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.06 179.707 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -138.14 134.82 35.06 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.731 -179.686 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.513 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -61.89 109.6 2.41 Favored Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.225 179.641 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.736 ' HD2' HD12 ' A' ' 57' ' ' ILE . 41.8 Cg_endo -65.0 -12.49 34.86 Favored 'Trans proline' 0 N--CA 1.475 0.425 0 C-N-CA 122.275 1.983 . . . . 0.0 113.147 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.91 134.83 39.12 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 121.014 0.435 . . . . 0.0 110.54 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -62.57 159.15 16.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.459 -179.911 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 154.29 -156.2 26.69 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.962 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 16.9 ttpt -133.02 146.78 52.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.125 0.488 . . . . 0.0 110.334 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.663 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.4 t -78.53 109.23 12.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.25 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -94.64 -30.53 14.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.59 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -157.1 130.92 8.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.449 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.468 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.2 t -97.92 112.64 30.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.259 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.413 HD11 ' OE2' ' A' ' 56' ' ' GLU . 5.6 mt -90.12 28.48 1.4 Allowed 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.737 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.468 ' H ' HG12 ' A' ' 105' ' ' VAL . 23.2 m -155.39 137.33 6.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.118 0.485 . . . . 0.0 110.336 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.522 ' HA ' HD11 ' A' ' 68' ' ' ILE . 13.8 pttm -127.5 167.01 16.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.346 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -60.09 145.76 45.49 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.77 179.993 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.05 37.41 17.94 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.354 179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.48 ' O ' HG23 ' A' ' 65' ' ' VAL . 8.4 t70 -123.36 138.62 54.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.442 179.983 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.34 131.35 36.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.493 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.0 m -120.95 154.55 24.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.419 179.97 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 19.9 mp0 -96.65 141.93 29.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.325 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.77 90.38 0.06 OUTLIER Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.848 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.3 -30.35 2.81 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -58.63 154.58 14.11 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.115 0.483 . . . . 0.0 110.681 -179.997 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.64 125.76 37.79 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 -179.681 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.639 HD21 ' HB2' ' A' ' 59' ' ' ALA . 58.4 mt -94.77 -59.41 1.93 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.151 0.5 . . . . 0.0 110.225 179.744 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.503 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.9 mt -141.33 141.95 29.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.181 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.3 tttt -88.5 127.06 35.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.433 179.972 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.5 mm -106.82 141.27 22.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.364 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.03 -1.428 . . . . 0.0 110.796 179.959 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.161 0.505 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.432 HD13 ' HD3' ' A' ' 97' ' ' PRO . 53.8 mt -79.01 111.71 22.05 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.154 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -71.09 149.09 57.85 Favored 'Trans proline' 0 N--CA 1.472 0.247 0 C-N-CA 122.074 1.849 . . . . 0.0 112.299 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.852 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -84.24 150.76 58.48 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.447 -179.963 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -72.83 -28.5 13.46 Favored 'Trans proline' 0 CA--C 1.527 0.164 0 C-N-CA 122.251 1.968 . . . . 0.0 112.311 179.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.8 pp -164.84 161.99 20.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.43 179.968 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.67 104.72 2.06 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.386 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.87 178.56 18.05 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.972 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.7 m -104.07 134.86 46.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.084 0.469 . . . . 0.0 110.368 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.644 ' HA ' HD23 ' A' ' 85' ' ' LEU . 24.2 t -72.04 118.66 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.102 179.878 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -100.02 -50.19 4.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.629 -179.72 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.95 140.53 21.61 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.769 -179.653 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.554 HG12 HD12 ' A' ' 83' ' ' LEU . 36.1 mt -105.41 126.15 60.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.836 179.579 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.34 28.65 3.99 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.978 -179.564 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.859 ' HB ' HG21 ' A' ' 102' ' ' VAL . 13.6 m -151.07 153.18 10.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.338 0.59 . . . . 0.0 110.897 -179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -137.26 154.82 50.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.918 179.502 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -58.18 91.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.165 0.507 . . . . 0.0 110.681 -179.881 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.88 -29.1 2.47 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -179.919 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -65.06 148.27 51.96 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.055 0.455 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.2 m -97.67 132.28 43.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.237 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.1 m -121.54 163.77 19.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.633 -179.821 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -129.63 154.18 47.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.593 -0.731 . . . . 0.0 110.184 179.74 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.652 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.01 91.21 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.482 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.07 -34.98 1.95 Allowed Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -62.56 140.03 58.63 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.028 0.442 . . . . 0.0 110.45 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.9 m -66.92 136.84 55.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.124 179.815 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.42 ' O ' HG22 ' A' ' 70' ' ' VAL . 29.8 m -116.97 -29.76 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.493 -179.382 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.644 HD11 HG13 ' A' ' 65' ' ' VAL . 10.2 tt -161.04 159.13 28.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.303 0.573 . . . . 0.0 111.016 -179.439 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.615 ' N ' HD23 ' A' ' 83' ' ' LEU . 21.7 t -125.7 131.69 71.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.809 179.513 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.644 HD23 ' HA ' ' A' ' 65' ' ' VAL . 19.8 mt -116.09 168.95 9.64 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.202 0.525 . . . . 0.0 110.747 -179.554 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.156 179.687 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 121.111 0.482 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 8.7 m -114.46 116.96 29.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.202 179.906 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -84.38 131.7 34.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.438 -179.951 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.428 HG22 ' N ' ' A' ' 95' ' ' ASN . 37.7 mm -106.4 155.95 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.293 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.428 ' N ' HG22 ' A' ' 94' ' ' ILE . 10.6 m120 -142.28 145.42 34.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.455 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.64 142.38 94.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.418 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.432 ' HD3' HD13 ' A' ' 57' ' ' ILE . 50.6 Cg_endo -74.59 -36.24 3.05 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.157 1.905 . . . . 0.0 112.375 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.652 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -146.55 170.45 16.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.413 -179.946 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -69.31 142.2 54.11 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.6 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 160.29 -166.7 35.34 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 -179.989 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 13.9 ptpt -129.17 168.8 15.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.355 0.598 . . . . 0.0 110.657 179.798 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.859 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.6 t -82.48 113.89 22.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.547 -179.72 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -94.61 -33.08 13.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.455 179.894 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.1 ttpp -160.63 123.75 3.37 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.606 179.871 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.54 HG13 HG12 ' A' ' 120' ' ' ILE . 23.1 t -102.1 109.99 27.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.325 179.799 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.4 mt -82.21 -30.43 30.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.452 179.763 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 105' ' ' VAL . 27.6 m -82.04 143.25 12.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.796 -179.824 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 20.2 mmtt -131.32 158.79 39.72 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.107 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -61.99 147.33 47.41 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.496 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 8.1 mmm180 64.16 34.43 11.03 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.759 179.85 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.522 ' O ' HG23 ' A' ' 65' ' ' VAL . 31.4 m-20 -131.98 140.81 49.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.413 179.676 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.8 140.75 29.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.554 -179.904 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.0 m -121.69 163.52 19.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.374 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 12.4 mm100 -98.35 142.63 29.75 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.299 179.966 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.96 106.28 1.06 Allowed Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.749 -0.941 . . . . 0.0 110.749 -179.972 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.63 -25.57 10.19 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -179.833 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 -59.73 143.05 51.9 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 121.102 0.477 . . . . 0.0 110.651 -179.822 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.34 124.84 36.03 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 179.954 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.852 HD21 ' HB2' ' A' ' 59' ' ' ALA . 49.2 mt -89.76 -54.9 3.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.092 0.472 . . . . 0.0 110.452 -179.979 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.54 HG12 HG13 ' A' ' 105' ' ' VAL . 47.3 mt -145.86 147.8 18.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.121 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 14.7 ttmt -95.89 136.44 36.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.153 179.774 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.8 mm -110.0 143.16 20.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.433 -179.899 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.745 0 CA-C-O 117.987 -1.452 . . . . 0.0 110.766 -179.997 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 17.0 mt-10 . . . . . 0 N--CA 1.461 0.099 0 CA-C-O 121.11 0.481 . . . . 0.0 110.465 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.515 HD11 HD11 ' A' ' 122' ' ' ILE . 55.8 mt -79.98 111.61 23.19 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.309 -179.997 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.81 131.67 18.79 Favored 'Trans proline' 0 N--CA 1.472 0.217 0 C-N-CA 122.035 1.823 . . . . 0.0 112.287 179.931 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.46 147.57 98.78 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.396 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -72.29 -27.9 15.86 Favored 'Trans proline' 0 CA--C 1.528 0.205 0 C-N-CA 122.188 1.926 . . . . 0.0 112.325 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.533 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.4 pp -163.92 159.65 21.14 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.464 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.456 ' HB2' ' H ' ' A' ' 115' ' ' GLY . . . -74.72 101.57 4.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.373 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.11 -141.26 5.07 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.94 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.0 m -137.81 135.86 36.66 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.169 0.509 . . . . 0.0 110.45 -179.859 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.753 HG13 HD11 ' A' ' 83' ' ' LEU . 21.7 t -69.64 120.06 16.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.225 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 79.2 p -97.02 -53.45 3.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.749 -179.829 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 45.6 tttt -152.06 148.37 27.6 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.603 -179.813 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.544 HG12 HD12 ' A' ' 83' ' ' LEU . 48.9 mt -104.15 134.39 45.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.061 179.756 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.587 HD12 HG22 ' A' ' 81' ' ' THR . 86.3 mt -99.22 -31.46 11.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.758 -179.694 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.705 HG11 ' CG1' ' A' ' 76' ' ' VAL . 34.5 m -113.18 145.07 19.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.229 0.538 . . . . 0.0 110.589 -179.871 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.78 163.89 30.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.211 179.771 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.438 ' HG3' HG23 ' A' ' 105' ' ' VAL . 33.6 mt-10 -58.36 102.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.582 -179.864 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.25 -28.29 2.48 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.824 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -95.69 151.81 19.02 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.1 0.476 . . . . 0.0 110.421 -179.97 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -98.46 147.58 24.59 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.392 179.894 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.705 ' CG1' HG11 ' A' ' 70' ' ' VAL . 24.9 m -121.83 169.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.498 -179.94 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.2 mmtp -130.23 155.25 46.59 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.36 -179.969 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.543 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.74 103.51 0.35 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.474 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.4 -30.79 5.66 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 179.94 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.8 tt0 -61.29 143.2 56.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.621 -179.853 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.587 HG22 HD12 ' A' ' 69' ' ' LEU . 2.5 m -67.76 138.51 56.26 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.266 179.831 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.476 ' HA ' HG13 ' A' ' 70' ' ' VAL . 28.1 m -118.68 -33.6 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.265 -179.443 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.753 HD11 HG13 ' A' ' 65' ' ' VAL . 7.4 tt -161.05 152.87 19.61 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.21 0.529 . . . . 0.0 111.017 -179.303 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.2 t -106.45 143.34 17.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.999 179.665 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.788 HD21 HG21 ' A' ' 113' ' ' VAL . 14.9 mt -120.55 163.16 18.4 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.51 -179.904 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 . . . . . 0 C--O 1.233 0.197 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.458 -179.944 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 . . . . . 0 C--O 1.23 0.068 0 CA-C-O 121.175 0.512 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 4.1 m -115.87 119.5 36.18 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.277 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 26.3 mt-10 -82.39 131.09 35.23 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.628 -179.82 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.759 HD11 HD12 ' A' ' 85' ' ' LEU . 26.9 mm -105.58 148.54 9.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.093 179.815 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -137.23 151.06 48.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.565 -179.911 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.68 144.88 98.83 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.279 179.976 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.428 ' HD3' HG23 ' A' ' 57' ' ' ILE . 49.1 Cg_endo -73.94 -34.63 5.01 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.153 1.902 . . . . 0.0 112.252 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.543 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 32.9 p -145.65 167.46 23.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.37 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -68.77 142.97 54.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.396 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 170.15 -160.15 32.92 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -133.23 149.24 52.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.145 0.497 . . . . 0.0 110.409 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.68 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.0 t -75.1 106.86 5.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.316 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -92.95 -29.98 15.6 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.725 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.9 tttt -158.02 127.93 6.04 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.466 179.998 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.588 HG13 HG12 ' A' ' 120' ' ' ILE . 20.4 t -100.52 110.8 28.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.322 179.916 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.5 mt -90.09 29.38 1.23 Allowed 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.676 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.436 ' H ' HG12 ' A' ' 105' ' ' VAL . 24.4 m -155.44 142.12 11.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.062 0.458 . . . . 0.0 110.353 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.499 ' HA ' HD11 ' A' ' 68' ' ' ILE . 16.8 mmtt -125.86 175.37 7.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.392 179.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -73.06 148.34 44.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.395 179.937 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.4 34.2 18.39 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.584 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -123.09 149.91 43.86 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.329 179.838 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.17 135.22 33.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.541 -179.952 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.788 HG21 HD21 ' A' ' 85' ' ' LEU . 30.7 m -121.17 151.64 24.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.279 179.919 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -98.56 140.46 32.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.328 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . 0.456 ' H ' ' HB2' ' A' ' 62' ' ' ALA . . . -59.19 108.45 1.63 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 109.53 -26.55 14.31 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -179.782 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -57.63 145.24 34.69 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 121.134 0.492 . . . . 0.0 110.862 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.18 118.21 13.79 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.848 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.405 ' O ' HG22 ' A' ' 107' ' ' VAL . 94.5 mt -88.33 -54.75 4.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.169 0.509 . . . . 0.0 110.177 179.799 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.588 HG12 HG13 ' A' ' 105' ' ' VAL . 44.8 mt -143.18 149.19 18.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.145 179.819 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 42.7 tttt -97.34 130.01 44.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.319 179.885 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.515 HD11 HD11 ' A' ' 57' ' ' ILE . 37.9 mm -107.71 144.44 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.425 -179.843 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.764 0 CA-C-O 118.025 -1.431 . . . . 0.0 110.747 179.955 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.957 0.408 . . . . 0.0 110.421 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 54.3 mt -80.42 111.1 19.81 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.167 -179.984 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -72.31 135.08 23.98 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.024 1.816 . . . . 0.0 112.351 -179.893 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.572 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -70.27 148.89 95.88 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.427 179.977 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -72.31 -28.44 15.19 Favored 'Trans proline' 0 N--CA 1.472 0.207 0 C-N-CA 122.228 1.952 . . . . 0.0 112.303 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.2 pp -164.26 162.71 22.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.389 179.952 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.29 117.84 16.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.443 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -145.83 -146.87 4.49 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 25.9 m -137.18 132.6 34.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.172 0.51 . . . . 0.0 110.376 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.638 ' CG1' HD11 ' A' ' 83' ' ' LEU . 21.4 t -70.23 132.31 33.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.301 179.907 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.0 t -101.52 -57.61 2.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.586 -179.958 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 32.2 ttpt -150.2 146.58 26.93 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.492 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.471 HG12 HD12 ' A' ' 83' ' ' LEU . 21.6 mt -98.92 133.95 39.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.149 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.641 HD11 HG23 ' A' ' 84' ' ' VAL . 5.6 mp -98.23 -31.57 12.01 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.617 -179.828 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.795 HG11 HG11 ' A' ' 76' ' ' VAL . 34.0 m -113.72 145.92 18.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.207 0.527 . . . . 0.0 110.761 -179.841 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.4 ptpp? -133.67 167.13 21.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.042 179.605 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -57.58 113.14 1.67 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.623 -179.972 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.39 21.06 5.29 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.588 -179.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -135.01 141.1 46.12 Favored 'General case' 0 C--O 1.231 0.081 0 CA-C-O 121.094 0.474 . . . . 0.0 110.138 179.601 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -95.29 132.02 40.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.611 -179.711 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.795 HG11 HG11 ' A' ' 70' ' ' VAL . 19.9 m -114.5 168.08 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.312 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 7.8 mmmt -121.65 139.91 52.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.258 179.829 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.656 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -56.27 97.95 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.972 -179.81 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.96 -37.39 1.9 Allowed Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.9 tt0 -66.07 149.12 50.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.033 0.444 . . . . 0.0 110.526 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -67.13 136.51 55.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.295 179.971 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.464 HG11 ' HB2' ' A' ' 96' ' ' ALA . 25.6 m -114.77 -31.5 2.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.124 -179.739 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.638 HD11 ' CG1' ' A' ' 65' ' ' VAL . 7.7 tt -160.67 151.83 19.01 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -179.674 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.641 HG23 HD11 ' A' ' 69' ' ' LEU . 22.0 t -102.87 128.26 55.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.055 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.437 HD11 HG21 ' A' ' 113' ' ' VAL . 1.0 OUTLIER -111.76 159.41 18.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.643 -179.771 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.301 179.867 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 . . . . . 0 C--O 1.231 0.081 0 CA-C-O 121.064 0.459 . . . . 0.0 110.474 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 20.2 m -120.29 139.55 52.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.343 179.894 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -85.92 135.09 33.81 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.481 -179.862 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.1 mm -107.82 119.24 57.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.237 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 14.0 p-10 -104.2 142.36 34.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.457 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.464 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -60.82 141.62 92.79 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.492 -179.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -73.55 -36.45 3.86 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.198 1.932 . . . . 0.0 112.172 179.932 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.656 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 69.4 p -147.24 153.92 40.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.345 -179.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -65.38 141.89 58.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.415 179.863 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.67 -155.34 19.6 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.967 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.7 ttpt -133.48 143.81 49.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.174 0.511 . . . . 0.0 110.593 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.54 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.0 t -75.97 111.23 12.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.079 179.828 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -95.69 -32.49 12.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.82 -179.662 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -161.03 129.84 4.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.117 0.484 . . . . 0.0 110.285 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.715 HG13 HG12 ' A' ' 120' ' ' ILE . 21.8 t -103.85 112.64 38.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.263 179.896 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.3 mt -79.81 -31.62 40.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.562 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.463 HG13 ' HA ' ' A' ' 119' ' ' LEU . 27.0 m -83.76 146.92 6.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.615 -179.801 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 18.9 mttm -129.36 172.15 11.79 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.252 179.943 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.41 139.27 54.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.247 -179.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 60.78 40.85 15.54 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.57 179.965 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -121.94 145.83 47.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.404 179.846 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.86 131.12 37.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.381 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.437 HG21 HD11 ' A' ' 85' ' ' LEU . 31.3 m -120.3 153.26 23.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.37 179.924 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -98.86 145.84 26.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.36 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.9 110.24 2.91 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.998 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.55 -28.73 8.36 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.906 -0.877 . . . . 0.0 110.906 -179.83 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -58.02 141.01 51.19 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 121.128 0.49 . . . . 0.0 110.815 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.3 125.85 36.77 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.87 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.572 HD21 ' HB2' ' A' ' 59' ' ' ALA . 89.9 mt -88.96 -57.23 2.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.009 0.433 . . . . 0.0 110.4 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.715 HG12 HG13 ' A' ' 105' ' ' VAL . 53.2 mt -141.29 151.3 19.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.431 179.926 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.7 mttt -94.02 121.68 35.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.132 179.813 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.3 mm -104.01 142.55 17.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.486 -179.845 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.771 0 CA-C-O 117.97 -1.461 . . . . 0.0 110.777 -179.981 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 14.0 mt-10 . . . . . 0 N--CA 1.461 0.096 0 CA-C-O 121.088 0.47 . . . . 0.0 110.473 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.3 mt -79.15 118.5 72.84 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.213 -179.942 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -71.81 138.03 30.83 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 122.057 1.838 . . . . 0.0 112.343 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.556 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -71.66 147.76 92.28 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.405 179.934 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.29 -26.47 17.48 Favored 'Trans proline' 0 CA--C 1.528 0.207 0 C-N-CA 122.232 1.954 . . . . 0.0 112.451 179.913 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.9 pp -163.07 175.27 11.25 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.485 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -89.79 93.01 9.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.428 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.66 -145.41 6.61 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.5 m -137.03 140.71 42.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.122 0.487 . . . . 0.0 110.415 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.59 HG13 HD11 ' A' ' 83' ' ' LEU . 22.8 t -70.79 127.98 33.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.156 179.949 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 7.9 p -99.55 -54.5 2.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.623 -179.84 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.6 tttt -151.05 147.98 27.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.564 -179.804 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.643 HD11 ' HA ' ' A' ' 108' ' ' LYS . 38.1 mt -102.4 133.15 46.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.151 179.792 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.551 HD12 HG22 ' A' ' 81' ' ' THR . 50.3 mt -99.16 -47.73 5.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.686 -179.809 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.772 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.3 m -99.98 146.91 8.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.552 -179.88 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -137.15 164.21 29.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.119 179.749 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -58.5 106.01 0.35 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.61 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.99 2.22 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -96.63 151.08 19.95 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.129 0.49 . . . . 0.0 110.361 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.546 HG22 ' O ' ' A' ' 100' ' ' GLY . 1.1 m -96.44 151.65 19.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.46 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.772 ' CG1' HG11 ' A' ' 70' ' ' VAL . 26.7 m -125.75 168.22 18.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.49 -179.951 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.1 ttpt -129.57 153.84 47.66 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.322 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.672 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.76 100.8 0.16 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.503 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.19 -32.89 3.47 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.87 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.4 tt0 -63.99 143.12 58.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.038 0.447 . . . . 0.0 110.513 -179.84 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.551 HG22 HD12 ' A' ' 69' ' ' LEU . 2.2 m -67.51 137.57 55.88 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.196 179.838 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.0 m -117.13 -34.02 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.124 -179.497 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.59 HD11 HG13 ' A' ' 65' ' ' VAL . 7.6 tt -161.72 153.62 19.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.227 0.537 . . . . 0.0 110.952 -179.453 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -108.55 143.09 19.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.932 179.52 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.426 HD11 HG21 ' A' ' 113' ' ' VAL . 1.4 tp -122.49 170.63 9.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.675 -179.693 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.466 179.997 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 . . . . . 0 N--CA 1.46 0.061 0 CA-C-O 121.115 0.483 . . . . 0.0 110.539 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -114.72 111.25 20.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.201 179.956 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -81.72 127.94 33.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.586 -179.829 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 34.4 mm -103.97 144.63 13.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.128 179.689 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -135.29 148.87 49.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.426 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.79 138.39 97.37 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.273 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -74.38 -31.2 7.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.052 1.835 . . . . 0.0 112.258 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.672 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 15.9 p -145.74 163.9 33.5 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.435 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -68.11 142.7 55.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.363 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.546 ' O ' HG22 ' A' ' 75' ' ' THR . . . 171.76 -161.41 33.54 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.7 ttpt -132.27 147.25 52.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.412 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.61 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.7 t -75.2 106.68 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.198 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -92.12 -29.13 16.68 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.776 -179.846 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 5.6 tttt -160.07 131.02 5.72 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.112 0.482 . . . . 0.0 110.508 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.423 HG12 ' H ' ' A' ' 107' ' ' VAL . 22.3 t -100.8 109.01 24.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.198 179.897 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 23.5 mt -90.13 31.02 1.02 Allowed 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.65 -179.99 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.449 HG21 HD13 ' A' ' 83' ' ' LEU . 24.6 m -155.58 137.11 5.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-O 121.061 0.458 . . . . 0.0 110.174 -179.993 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.643 ' HA ' HD11 ' A' ' 68' ' ' ILE . 34.1 mtmt -123.63 177.56 5.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.379 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -68.93 144.64 54.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.491 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 34.1 mtt180 60.12 33.25 21.17 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.619 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -111.49 142.86 43.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.36 -179.978 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.75 134.28 34.54 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.5 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.426 HG21 HD11 ' A' ' 85' ' ' LEU . 30.3 m -120.77 -179.92 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.398 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -140.84 147.94 39.77 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.397 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.02 106.43 1.11 Allowed Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 179.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 119.82 -31.79 5.22 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 -179.938 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -60.61 134.49 57.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.064 0.459 . . . . 0.0 110.571 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.14 123.06 31.47 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.781 -0.927 . . . . 0.0 110.781 179.961 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.556 HD21 ' HB2' ' A' ' 59' ' ' ALA . 62.7 mt -88.67 -54.88 3.95 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.068 0.461 . . . . 0.0 110.467 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.525 ' CG2' HG13 ' A' ' 102' ' ' VAL . 52.9 mt -140.93 148.91 21.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.368 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.8 mttt -95.35 127.15 41.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.335 179.885 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.3 mm -108.02 143.52 18.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.359 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.698 0 CA-C-O 117.982 -1.454 . . . . 0.0 110.761 -179.984 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 . . . . . 0 N--CA 1.461 0.105 0 CA-C-O 121.085 0.469 . . . . 0.0 110.427 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.743 HD11 HD11 ' A' ' 122' ' ' ILE . 42.7 mt -80.8 111.13 20.71 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.284 179.885 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -71.02 137.27 31.46 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.079 1.852 . . . . 0.0 112.33 -179.854 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.32 151.01 97.57 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.458 179.994 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.66 ' HB2' HD23 ' A' ' 61' ' ' LEU . 48.9 Cg_endo -72.7 -27.5 15.0 Favored 'Trans proline' 0 CA--C 1.529 0.23 0 C-N-CA 122.212 1.941 . . . . 0.0 112.35 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.66 HD23 ' HB2' ' A' ' 60' ' ' PRO . 0.2 OUTLIER -164.23 172.47 13.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.368 179.97 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.8 92.3 7.22 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.31 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -123.81 -146.16 6.94 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.931 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.3 m -135.79 137.57 41.73 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.102 0.477 . . . . 0.0 110.362 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.774 HG13 HD11 ' A' ' 83' ' ' LEU . 22.1 t -68.22 128.27 31.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.319 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -97.72 -61.55 1.37 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.428 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -149.71 145.87 26.92 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.403 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.565 HG12 HD12 ' A' ' 83' ' ' LEU . 49.5 mt -97.76 129.42 47.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.079 179.789 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.585 HD12 HG22 ' A' ' 81' ' ' THR . 22.3 mt -97.41 -43.54 7.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.818 -179.703 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.769 HG11 ' CG1' ' A' ' 76' ' ' VAL . 31.4 m -104.2 145.83 12.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.216 0.531 . . . . 0.0 110.781 -179.691 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.1 pttt -137.24 161.93 34.89 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.945 179.718 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -57.16 107.88 0.47 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.766 -179.926 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -31.02 2.31 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -179.686 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -98.83 152.71 19.43 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.972 0.415 . . . . 0.0 110.36 179.86 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.522 HG23 ' HB2' ' A' ' 101' ' ' LYS . 0.7 OUTLIER -96.61 151.07 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.45 179.995 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.769 ' CG1' HG11 ' A' ' 70' ' ' VAL . 23.5 m -127.81 169.97 18.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.41 -179.929 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 17.4 mmmt -132.49 153.75 50.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.409 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.514 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.79 104.47 0.36 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.577 -179.845 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 126.35 -34.69 3.14 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.857 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 -64.43 140.43 58.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.116 0.484 . . . . 0.0 110.513 -179.908 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.585 HG22 HD12 ' A' ' 69' ' ' LEU . 11.1 m -67.42 136.55 54.88 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.333 179.915 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 94' ' ' ILE . 30.0 m -112.82 -29.23 2.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.042 -179.737 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.774 HD11 HG13 ' A' ' 65' ' ' VAL . 7.7 tt -163.99 147.53 9.8 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 121.12 0.486 . . . . 0.0 110.86 -179.516 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -98.86 134.15 38.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.961 179.593 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.716 HD11 HG21 ' A' ' 113' ' ' VAL . 1.0 OUTLIER -116.04 167.71 10.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.542 -179.729 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 . . . . . 0 C--N 1.331 -0.239 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.493 179.962 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 121.136 0.493 . . . . 0.0 110.314 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 11.8 m -116.04 128.14 55.47 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.493 -179.931 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -85.51 133.31 34.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.445 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.425 ' O ' HG22 ' A' ' 82' ' ' VAL . 38.2 mm -102.38 118.3 49.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.223 179.869 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -104.24 143.93 32.29 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.315 -179.887 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.21 140.31 91.23 Favored Pre-proline 0 CA--C 1.533 0.32 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.556 -179.983 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -73.25 -33.33 7.33 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.186 1.924 . . . . 0.0 112.338 -179.975 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.514 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 81.1 p -147.84 163.44 36.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.354 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -67.98 142.91 55.82 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.531 179.92 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.503 ' O ' HG22 ' A' ' 75' ' ' THR . . . 171.51 -159.97 31.8 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.995 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . 0.522 ' HB2' HG23 ' A' ' 75' ' ' THR . 13.3 ttmt -136.55 141.61 43.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.105 0.479 . . . . 0.0 110.517 -179.911 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.644 HG13 ' CG2' ' A' ' 120' ' ' ILE . 22.0 t -72.03 125.9 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.262 179.856 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -102.63 -31.23 10.48 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.783 -179.915 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 2.2 ttmt -164.4 139.08 5.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.674 -179.772 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 107' ' ' VAL . 22.0 t -106.67 109.01 26.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.128 179.807 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.4 mt -80.01 -31.81 39.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.302 179.898 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.429 ' O ' HG12 ' A' ' 105' ' ' VAL . 29.0 m -79.85 147.7 6.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.49 -179.965 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 24.3 mttp -127.83 164.1 22.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.149 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -65.95 142.38 57.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.397 179.997 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 63.54 37.77 10.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.619 179.885 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -121.64 152.16 39.63 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.389 179.681 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.97 134.52 34.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.476 -179.909 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.716 HG21 HD11 ' A' ' 85' ' ' LEU . 30.7 m -120.42 150.24 23.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.456 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 21.8 mt-30 -101.17 139.44 36.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.336 179.919 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.38 92.11 0.05 OUTLIER Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 132.81 -28.47 3.37 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.867 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -60.0 144.9 48.13 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 121.108 0.48 . . . . 0.0 110.645 -179.95 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -62.87 122.88 28.97 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.885 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 88.6 mt -88.18 -59.44 2.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.061 0.458 . . . . 0.0 110.385 179.853 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.644 ' CG2' HG13 ' A' ' 102' ' ' VAL . 49.7 mt -141.77 149.21 20.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.358 179.803 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -94.04 131.41 39.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.332 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.743 HD11 HD11 ' A' ' 57' ' ' ILE . 35.7 mm -107.7 146.02 14.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.397 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.718 0 CA-C-O 118.002 -1.443 . . . . 0.0 110.746 179.903 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.466 ' OE2' HD11 ' A' ' 106' ' ' LEU . 33.7 mt-10 . . . . . 0 N--CA 1.462 0.159 0 CA-C-O 121.215 0.531 . . . . 0.0 110.677 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.9 mt -80.45 125.92 79.85 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.341 -179.835 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -74.85 156.65 43.65 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 121.885 1.723 . . . . 0.0 112.247 179.737 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.493 ' HB3' ' H ' ' A' ' 116' ' ' GLY . . . -84.89 143.36 40.15 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.305 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -73.89 -27.93 11.79 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.225 1.95 . . . . 0.0 112.484 -179.97 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -163.65 172.49 14.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.51 -179.908 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.3 98.64 11.7 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.506 179.925 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.68 -144.31 5.62 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 8.9 m -137.71 135.9 36.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.149 0.499 . . . . 0.0 110.458 179.926 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.652 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -71.1 125.89 30.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.24 179.86 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.5 p -98.99 -57.54 2.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.74 -179.707 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.43 ' HD2' HG21 ' A' ' 84' ' ' VAL . 5.6 ptpt -149.52 146.37 27.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.679 -179.728 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.681 HG12 HD12 ' A' ' 83' ' ' LEU . 30.8 mt -101.62 136.83 31.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.16 179.74 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.587 HD12 HG22 ' A' ' 81' ' ' THR . 46.3 mt -100.0 -40.21 7.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.576 -179.847 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.628 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.0 m -100.73 138.15 25.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.148 0.499 . . . . 0.0 110.581 -179.873 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 10.2 pttp -122.7 163.26 20.45 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.044 179.825 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -60.47 104.02 0.3 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.569 -179.895 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 137.56 -31.82 2.46 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -83.17 154.99 23.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.052 0.453 . . . . 0.0 110.557 179.969 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.5 m -98.47 144.78 27.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.322 179.952 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.578 ' CG1' HG11 ' A' ' 70' ' ' VAL . 31.1 m -120.78 158.12 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.511 -179.914 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 41.6 mttt -122.7 151.12 41.87 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.261 179.832 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.458 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.29 90.99 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.694 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.53 -30.36 3.01 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.921 -0.871 . . . . 0.0 110.921 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -61.85 142.8 57.14 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.158 0.504 . . . . 0.0 110.571 -179.855 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.587 HG22 HD12 ' A' ' 69' ' ' LEU . 2.1 m -67.22 140.53 57.42 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.123 179.779 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.599 ' HA ' HG13 ' A' ' 70' ' ' VAL . 32.4 m -121.76 -32.49 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.631 -179.459 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.681 HD12 HG12 ' A' ' 68' ' ' ILE . 8.0 tt -161.23 152.84 19.21 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 120.169 -0.612 . . . . 0.0 111.557 -179.244 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.43 HG21 ' HD2' ' A' ' 67' ' ' LYS . 21.6 t -103.96 137.64 31.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.638 179.405 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.1 tp -121.0 165.7 14.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.176 0.512 . . . . 0.0 110.656 -179.776 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.463 -179.949 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 121.082 0.468 . . . . 0.0 110.288 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.2 m -121.71 129.54 52.8 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.368 -179.987 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -84.29 138.04 33.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.564 -179.902 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.2 mm -103.21 150.48 6.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.077 179.853 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -138.05 142.15 40.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.507 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.11 139.79 96.02 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.293 -179.98 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.1 -30.35 10.8 Favored 'Trans proline' 0 N--CA 1.472 0.223 0 C-N-CA 122.061 1.841 . . . . 0.0 112.081 179.894 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.458 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 6.0 p -147.01 162.79 38.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.198 179.879 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 11.6 p30 -67.54 147.71 52.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.204 0.526 . . . . 0.0 110.315 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 169.92 -160.04 32.87 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -179.832 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -135.58 142.89 45.38 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.068 0.461 . . . . 0.0 110.455 -179.915 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.628 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.6 t -75.59 111.48 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.905 179.699 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -97.36 -31.21 12.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.833 -179.488 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -161.77 132.01 4.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.148 0.499 . . . . 0.0 110.786 -179.878 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.483 HG13 HG12 ' A' ' 120' ' ' ILE . 22.0 t -102.71 123.78 56.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.923 179.685 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.466 HD11 ' OE2' ' A' ' 56' ' ' GLU . 35.3 mt -82.77 -29.92 29.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.98 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.413 ' O ' HG12 ' A' ' 105' ' ' VAL . 35.3 m -95.97 158.82 3.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 121.213 0.53 . . . . 0.0 110.936 -179.677 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 37.2 mttt -132.08 163.53 28.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.167 179.65 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -60.72 141.42 56.89 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.544 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? 61.43 39.11 15.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.393 179.988 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -123.88 151.38 43.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.327 179.852 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.63 144.21 25.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.473 -179.912 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.416 HG13 HG23 ' A' ' 65' ' ' VAL . 33.7 m -126.75 179.53 3.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.37 179.801 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -130.04 140.88 50.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.323 179.937 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -58.78 105.93 0.77 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.837 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.493 ' H ' ' HB3' ' A' ' 59' ' ' ALA . . . 115.99 -31.05 6.24 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.995 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.1 tt0 -58.4 140.61 53.43 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 121.141 0.496 . . . . 0.0 110.763 -179.909 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.71 124.01 34.43 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 179.934 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 90.1 mt -90.38 -49.31 6.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.036 0.446 . . . . 0.0 110.844 -179.585 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.483 HG12 HG13 ' A' ' 105' ' ' VAL . 50.7 mt -142.33 153.61 18.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.576 -179.852 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.403 ' N ' HG22 ' A' ' 120' ' ' ILE . 23.4 tttt -98.19 125.21 43.14 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.354 179.835 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 39.4 mm -108.37 140.4 27.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.397 -179.93 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.701 0 CA-C-O 117.979 -1.456 . . . . 0.0 110.943 179.93 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 . . . . . 0 N--CA 1.462 0.129 0 CA-C-O 121.106 0.479 . . . . 0.0 110.509 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.764 HD12 ' HD2' ' A' ' 97' ' ' PRO . 42.9 mm -79.09 124.48 84.6 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.051 179.879 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.9 132.77 17.42 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 121.924 1.749 . . . . 0.0 112.223 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 114' ' ' GLN . . . -65.34 146.16 98.98 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.427 -179.938 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -72.9 -29.95 11.7 Favored 'Trans proline' 0 N--CA 1.471 0.2 0 C-N-CA 122.191 1.927 . . . . 0.0 112.295 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.454 HD12 ' C ' ' A' ' 61' ' ' LEU . 4.2 pp -163.67 166.38 22.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.393 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.1 101.82 6.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.339 179.929 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.63 -149.91 6.33 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.989 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.8 m -136.21 140.6 43.65 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.149 0.5 . . . . 0.0 110.437 179.933 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.974 HG13 HD11 ' A' ' 83' ' ' LEU . 23.2 t -73.24 121.69 24.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.252 179.918 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -99.49 -49.69 4.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.555 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 17.2 ttpt -152.56 146.51 25.28 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.535 -179.735 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.487 HD12 ' HG2' ' A' ' 109' ' ' GLU . 2.9 mp -105.59 135.82 42.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.09 179.7 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.511 HD11 HG23 ' A' ' 84' ' ' VAL . 7.1 mp -100.03 -36.34 9.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.653 -179.783 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.763 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.0 m -101.16 143.2 14.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.72 -179.819 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.4 pttp -133.47 162.67 31.23 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.063 179.81 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -59.16 101.12 0.09 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.534 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.22 -29.6 2.4 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.836 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -90.7 148.03 22.87 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.093 0.473 . . . . 0.0 110.43 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.6 m -95.72 144.72 25.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.396 179.972 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.668 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.4 m -119.78 160.68 19.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.505 -179.965 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 88.2 mttt -125.06 154.32 41.52 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.327 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.36 97.61 0.05 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.732 -179.802 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.83 -30.66 3.69 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 28.2 tt0 -63.94 141.24 58.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.101 0.477 . . . . 0.0 110.735 -179.816 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.2 m -65.45 138.6 58.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.235 179.744 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.663 HG11 ' HB2' ' A' ' 96' ' ' ALA . 31.4 m -117.91 -32.95 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.247 -179.373 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.974 HD11 HG13 ' A' ' 65' ' ' VAL . 7.8 tt -161.47 153.51 19.61 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.284 0.564 . . . . 0.0 111.111 -179.268 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.511 HG23 HD11 ' A' ' 69' ' ' LEU . 21.3 t -107.01 137.3 38.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.911 179.504 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.573 HD12 HD11 ' A' ' 94' ' ' ILE . 15.3 mt -115.36 162.61 16.88 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.28 0.562 . . . . 0.0 110.782 -179.657 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.274 179.804 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 121.108 0.48 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 11.1 m -112.09 119.58 38.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.318 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -82.1 129.11 34.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.852 -179.587 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.573 HD11 HD12 ' A' ' 85' ' ' LEU . 39.0 mm -101.35 149.45 6.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.997 179.569 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 67.9 m-20 -139.2 134.34 32.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.161 0.505 . . . . 0.0 110.863 -179.665 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.663 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -63.13 110.46 3.56 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.946 179.363 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.764 ' HD2' HD12 ' A' ' 57' ' ' ILE . 40.6 Cg_endo -64.27 -15.13 47.85 Favored 'Trans proline' 0 N--CA 1.476 0.484 0 C-N-CA 122.182 1.921 . . . . 0.0 113.105 179.834 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 61.1 p -135.9 136.66 40.68 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-O 121.145 0.498 . . . . 0.0 110.425 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -64.02 163.31 12.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.468 -179.976 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 149.03 -155.93 26.58 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.5 ttmt -134.55 147.89 50.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.084 0.469 . . . . 0.0 110.506 -179.833 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.763 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.1 t -77.44 111.81 14.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.165 179.802 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -95.94 -27.59 15.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.987 -179.774 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -162.69 127.38 3.14 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.064 0.459 . . . . 0.0 110.453 -179.864 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.503 HG12 ' O ' ' A' ' 107' ' ' VAL . 21.5 t -102.62 112.5 36.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.307 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.5 mt -80.05 -31.44 39.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.503 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.503 ' O ' HG12 ' A' ' 105' ' ' VAL . 33.6 m -87.08 141.56 14.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.71 -179.918 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -128.39 171.54 11.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.438 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . 0.487 ' HG2' HD12 ' A' ' 68' ' ' ILE . 28.5 mt-10 -63.29 137.74 58.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.414 179.995 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.76 38.88 6.57 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.618 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -118.79 144.82 46.06 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.224 179.635 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.98 134.99 34.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.485 -179.955 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.7 m -122.32 179.9 2.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.319 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . 0.452 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 93.8 mt-30 -137.19 147.81 46.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.416 179.891 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.74 114.31 6.45 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.88 -30.37 9.14 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.928 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.4 tt0 -60.9 137.06 58.24 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.034 0.445 . . . . 0.0 110.567 -179.967 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.86 119.19 17.15 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 41.3 mt -88.92 -51.04 5.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.109 0.48 . . . . 0.0 110.378 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.478 ' CG2' HG13 ' A' ' 102' ' ' VAL . 53.5 mt -140.91 144.91 26.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 8.1 tttt -93.94 129.75 40.29 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.357 179.947 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 36.6 mm -106.44 148.82 10.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.426 -179.776 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.739 0 CA-C-O 118.015 -1.436 . . . . 0.0 110.85 -179.991 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 121.187 0.517 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.576 HD11 ' CG1' ' A' ' 122' ' ' ILE . 32.7 mt -80.11 119.93 78.09 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.138 179.756 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -72.19 139.47 32.44 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 122.0 1.8 . . . . 0.0 112.277 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.635 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -71.8 146.77 91.12 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.373 179.948 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -72.85 -27.14 14.91 Favored 'Trans proline' 0 N--CA 1.471 0.184 0 C-N-CA 122.227 1.951 . . . . 0.0 112.393 179.972 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.2 pp -162.18 174.58 12.71 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.394 -179.941 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -90.24 82.21 6.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.306 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -109.26 -144.47 10.63 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.964 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.7 m -136.99 138.8 40.92 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.062 0.458 . . . . 0.0 110.525 -179.943 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.775 HG13 HD21 ' A' ' 83' ' ' LEU . 25.7 t -70.95 124.18 26.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.077 179.897 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.3 t -101.9 -59.12 1.75 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.787 -179.7 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 tptt -149.81 138.79 21.08 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.738 -179.583 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 38.9 mt -95.92 135.52 29.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.965 179.532 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.651 HD13 ' HB ' ' A' ' 81' ' ' THR . 11.5 mt -100.91 -30.82 11.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.93 -179.556 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.691 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.3 m -108.49 149.81 11.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.144 0.497 . . . . 0.0 110.733 -179.854 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 12.6 ptpt -137.66 164.16 29.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.164 179.856 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.424 ' HG3' HG23 ' A' ' 105' ' ' VAL . 39.4 mt-10 -60.58 102.97 0.21 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.5 -179.985 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 138.55 -31.48 2.41 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 23.8 m-20 -88.18 147.6 24.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.108 0.48 . . . . 0.0 110.482 -179.946 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 19.6 m -95.52 142.93 27.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.303 179.914 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.691 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.4 m -119.42 156.63 21.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.53 -179.883 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.4 mptt -117.79 152.58 35.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.288 179.888 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.558 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.24 93.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.644 -179.916 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.23 -31.49 2.78 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 17.7 tt0 -62.42 141.96 58.1 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.078 0.466 . . . . 0.0 110.562 -179.98 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.651 ' HB ' HD13 ' A' ' 69' ' ' LEU . 3.9 m -68.12 138.84 56.03 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.212 179.819 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.53 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.4 m -121.07 -32.42 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.657 -179.243 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.775 HD21 HG13 ' A' ' 65' ' ' VAL . 1.5 tm? -160.34 136.74 8.76 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.863 -179.11 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.757 ' N ' HD22 ' A' ' 83' ' ' LEU . 20.1 t -102.3 136.35 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.459 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.502 HD23 ' HA ' ' A' ' 65' ' ' VAL . 88.4 mt -114.12 166.56 11.5 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.584 -179.874 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.316 179.899 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 . . . . . 0 C--O 1.232 0.137 0 CA-C-O 121.152 0.501 . . . . 0.0 110.526 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 23.9 m -117.44 112.64 20.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.353 179.983 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -80.64 132.97 35.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.765 -179.724 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.424 HG22 ' N ' ' A' ' 95' ' ' ASN . 35.7 mm -101.88 155.91 4.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.066 179.648 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.424 ' N ' HG22 ' A' ' 94' ' ' ILE . 2.1 p30 -136.84 149.34 47.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.568 179.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.71 139.8 97.06 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.242 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.65 -30.99 11.25 Favored 'Trans proline' 0 N--CA 1.472 0.226 0 C-N-CA 122.087 1.858 . . . . 0.0 112.197 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.558 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -147.07 163.61 35.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.313 179.943 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -68.17 141.94 55.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.352 179.969 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.48 -159.48 27.43 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 10.1 ttpt -133.36 143.71 49.14 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.045 0.45 . . . . 0.0 110.338 -179.849 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.678 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -75.72 111.71 12.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.224 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -92.75 -29.72 15.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.69 -179.85 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.5 ttpt -158.79 134.03 8.48 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.127 0.489 . . . . 0.0 110.575 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 107' ' ' VAL . 26.9 t -101.19 107.91 22.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.346 179.96 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.7 mt -80.07 -32.2 39.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.222 179.697 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.44 HG13 ' HA ' ' A' ' 119' ' ' LEU . 31.4 m -77.3 143.63 12.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.416 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 10.6 mmmt -135.05 151.86 51.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.156 179.81 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 16.4 mp0 -58.41 137.74 57.07 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.781 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 8.2 ttp-105 63.41 39.08 9.55 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.344 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.418 ' O ' HG23 ' A' ' 65' ' ' VAL . 5.0 t70 -125.09 144.63 50.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.289 179.815 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.79 140.13 30.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.558 -179.99 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.9 m -121.14 179.93 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.371 179.978 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . 0.448 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 9.3 mt-30 -141.06 146.86 37.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.412 179.976 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.23 103.4 0.53 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.03 -29.78 5.45 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 -179.889 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -61.61 138.51 58.3 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-O 121.066 0.46 . . . . 0.0 110.402 -179.971 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.62 118.46 14.81 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.919 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.635 HD11 ' HA ' ' A' ' 59' ' ' ALA . 64.5 mt -89.02 -54.73 3.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.017 0.436 . . . . 0.0 110.334 179.81 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.509 ' CG2' HG13 ' A' ' 102' ' ' VAL . 46.6 mt -142.79 147.02 21.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.321 179.796 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.2 mtpt -96.22 127.21 42.02 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.339 179.963 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.576 ' CG1' HD11 ' A' ' 57' ' ' ILE . 36.1 mm -109.17 145.03 16.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.552 -179.883 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 117.976 -1.458 . . . . 0.0 110.777 179.971 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 . . . . . 0 C--O 1.23 0.07 0 CA-C-O 121.08 0.467 . . . . 0.0 110.359 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.2 mt -79.64 111.36 20.54 Favored Pre-proline 0 CA--C 1.535 0.383 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.258 179.993 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -71.22 131.31 18.97 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 121.962 1.775 . . . . 0.0 112.302 -179.963 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.64 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -68.19 145.17 97.41 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.352 179.976 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.607 ' HG2' HD23 ' A' ' 61' ' ' LEU . 50.3 Cg_endo -73.34 -28.03 12.78 Favored 'Trans proline' 0 CA--C 1.528 0.222 0 C-N-CA 122.22 1.946 . . . . 0.0 112.276 -179.963 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.607 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.7 OUTLIER -159.59 162.87 35.39 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.357 179.971 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.35 113.81 21.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.332 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -137.75 -140.7 4.08 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -179.92 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 19.7 m -136.46 139.71 42.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.067 0.46 . . . . 0.0 110.435 179.988 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.716 HG13 HD11 ' A' ' 83' ' ' LEU . 22.3 t -71.09 126.59 31.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.999 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 8.2 t -101.24 -54.47 2.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.665 -179.828 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.2 tptm -157.2 140.27 15.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.602 -179.819 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.742 HG12 HD12 ' A' ' 83' ' ' LEU . 31.3 mt -94.38 140.26 16.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.995 179.719 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.481 HD13 ' HB ' ' A' ' 81' ' ' THR . 22.6 mt -104.84 -37.89 6.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.631 -179.793 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.771 HG11 ' CG1' ' A' ' 76' ' ' VAL . 33.1 m -110.88 148.12 14.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.801 -179.927 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -139.62 166.77 23.7 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.213 179.897 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -58.1 108.91 0.66 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.702 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.04 -31.4 2.81 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -93.19 151.38 19.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.061 0.458 . . . . 0.0 110.481 179.975 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . 0.435 HG22 ' O ' ' A' ' 100' ' ' GLY . 1.2 m -100.68 148.65 24.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.238 179.879 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.771 ' CG1' HG11 ' A' ' 70' ' ' VAL . 31.6 m -124.99 165.96 21.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.58 -179.824 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.8 tppt? -124.78 153.91 41.74 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.251 179.894 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.617 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.43 97.97 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.541 -179.87 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.16 -36.64 2.11 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.904 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -62.88 139.46 58.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.496 . . . . 0.0 110.563 -179.959 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.481 ' HB ' HD13 ' A' ' 69' ' ' LEU . 6.9 m -67.07 141.87 57.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.282 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.743 HG22 ' O ' ' A' ' 94' ' ' ILE . 31.5 m -113.58 -27.04 2.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.225 -179.604 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.742 HD12 HG12 ' A' ' 68' ' ' ILE . 7.0 tt -168.4 150.99 5.3 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.177 0.513 . . . . 0.0 110.622 -179.619 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -102.83 135.98 37.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.955 179.622 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 1.0 HD12 HD11 ' A' ' 94' ' ' ILE . 17.8 mt -115.2 163.3 15.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.587 -179.681 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.267 179.972 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 121.14 0.495 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 19.6 m -121.01 125.91 48.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.418 -179.956 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -87.38 143.01 27.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.475 -179.96 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 1.0 HD11 HD12 ' A' ' 85' ' ' LEU . 38.7 mm -105.56 112.06 37.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.373 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -98.48 140.54 32.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.378 -179.945 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.41 142.38 96.27 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.341 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.24 -35.29 5.21 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.16 1.907 . . . . 0.0 112.357 179.95 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.617 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -146.8 162.34 38.79 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.337 -179.968 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -66.67 143.34 57.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.396 179.901 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . 0.435 ' O ' HG22 ' A' ' 75' ' ' THR . . . 173.43 -160.86 31.45 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.972 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 28.6 tttp -130.23 147.23 51.93 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.032 0.444 . . . . 0.0 110.526 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.566 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.3 t -75.67 109.12 8.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.293 179.898 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -93.93 -29.91 15.03 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.76 -179.892 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 29.8 tttt -157.47 128.09 6.49 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.163 0.506 . . . . 0.0 110.642 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.46 HG12 ' O ' ' A' ' 107' ' ' VAL . 29.0 t -102.59 102.45 13.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.224 179.824 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 12.5 mt -76.25 -32.22 58.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.213 179.716 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.633 HG21 HD13 ' A' ' 83' ' ' LEU . 34.8 m -77.86 142.01 14.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.632 -179.978 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.443 ' HA ' HD11 ' A' ' 68' ' ' ILE . 12.7 mmmt -139.82 158.45 44.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.994 179.676 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . 0.417 ' O ' ' HG3' ' A' ' 110' ' ' ARG . 13.7 mt-10 -55.81 161.72 2.08 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.976 -179.794 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . 0.417 ' HG3' ' O ' ' A' ' 109' ' ' GLU . 0.0 OUTLIER 37.18 41.24 0.21 Allowed 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.486 -179.737 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.692 ' O ' HG23 ' A' ' 65' ' ' VAL . 3.7 t70 -128.99 142.16 51.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.265 179.882 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -93.51 136.99 33.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.623 -179.781 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.1 m -118.8 161.29 17.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.312 179.781 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 -102.06 143.21 32.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.438 -179.998 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.2 108.66 2.02 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.962 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.14 -26.28 10.59 Favored Glycine 0 CA--C 1.528 0.859 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 -179.798 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -58.44 144.73 41.12 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-O 121.134 0.492 . . . . 0.0 110.787 -179.966 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.96 120.74 24.1 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.962 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.64 HD21 ' HB2' ' A' ' 59' ' ' ALA . 89.3 mt -88.01 -59.61 2.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.105 0.478 . . . . 0.0 110.453 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.475 ' CG2' HG13 ' A' ' 102' ' ' VAL . 55.0 mt -140.85 145.2 25.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.377 -179.988 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -91.4 121.56 33.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.167 179.797 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.2 mm -104.29 141.44 19.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.455 -179.957 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.75 0 CA-C-O 117.953 -1.471 . . . . 0.0 110.765 179.988 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 . . . . . 0 N--CA 1.462 0.127 0 CA-C-O 121.212 0.53 . . . . 0.0 110.75 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 51.3 mt -81.03 117.1 66.63 Favored Pre-proline 0 CA--C 1.533 0.31 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.14 179.86 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -71.92 137.23 29.04 Favored 'Trans proline' 0 N--CA 1.472 0.228 0 C-N-CA 121.932 1.755 . . . . 0.0 112.315 -179.984 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.664 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -61.44 146.69 89.06 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.389 -179.879 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -72.13 -28.69 15.45 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.2 1.934 . . . . 0.0 112.263 179.928 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -165.32 166.9 18.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.41 -179.965 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.43 85.1 6.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.449 179.949 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.449 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -125.35 -160.94 10.86 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -179.93 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.3 m -114.41 140.62 48.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.122 0.487 . . . . 0.0 110.56 -179.969 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.92 HG13 HD11 ' A' ' 83' ' ' LEU . 29.6 t -64.94 127.67 26.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.194 179.908 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.3 -61.27 1.42 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.703 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.702 ' O ' HD12 ' A' ' 83' ' ' LEU . 40.6 mttt -149.97 145.68 26.59 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.11 0.481 . . . . 0.0 110.654 -179.812 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.5 mt -101.04 125.24 55.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.721 179.443 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.654 HD12 HG22 ' A' ' 81' ' ' THR . 19.8 mt -96.31 -31.21 13.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.979 -179.429 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.735 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.6 m -111.62 147.18 15.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.201 0.524 . . . . 0.0 110.732 -179.719 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.5 163.96 29.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.154 179.795 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.665 ' HG3' HG23 ' A' ' 105' ' ' VAL . 24.6 mt-10 -59.34 102.45 0.14 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.699 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.03 -30.31 2.37 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.974 -0.851 . . . . 0.0 110.974 179.969 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.84 150.91 20.3 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.175 0.512 . . . . 0.0 110.586 -179.866 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.5 m -96.02 148.14 22.97 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.297 179.931 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.673 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.8 m -119.13 166.3 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.513 -179.97 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 32.1 mmtm -128.88 147.84 50.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.24 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.61 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.81 90.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.779 -179.877 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.53 -31.34 2.6 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.827 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -64.1 141.15 58.87 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.171 0.51 . . . . 0.0 110.668 -179.769 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.654 HG22 HD12 ' A' ' 69' ' ' LEU . 6.4 m -65.97 137.01 56.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.082 179.788 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.477 HG12 HG11 ' A' ' 70' ' ' VAL . 31.1 m -121.68 -32.19 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.66 -179.318 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.92 HD11 HG13 ' A' ' 65' ' ' VAL . 16.3 tp -158.97 151.8 22.02 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.083 0.468 . . . . 0.0 110.816 -179.124 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.2 t -113.9 144.08 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.769 179.323 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.712 HD21 HG21 ' A' ' 113' ' ' VAL . 16.6 mt -120.62 158.81 26.58 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.168 0.509 . . . . 0.0 110.789 -179.64 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 . . . . . 0 C--N 1.331 -0.219 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.385 -179.916 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 . . . . . 0 C--O 1.231 0.118 0 CA-C-O 121.088 0.47 . . . . 0.0 110.363 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -123.33 113.24 18.58 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.406 179.968 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -79.5 139.31 37.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.601 -179.889 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.427 ' N ' HD12 ' A' ' 94' ' ' ILE . 5.1 mp -110.27 155.88 11.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.729 179.902 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.416 ' N ' HG22 ' A' ' 94' ' ' ILE . 11.3 m-80 -139.5 152.57 47.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.543 -179.918 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.16 139.75 96.1 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.305 180.0 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -73.77 -35.47 4.46 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.114 1.876 . . . . 0.0 112.153 179.977 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.61 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 24.0 p -144.96 163.17 34.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.343 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -65.28 140.87 58.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.337 179.859 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.34 -159.6 29.74 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.919 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 22.8 ttmt -135.21 148.76 49.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.078 0.466 . . . . 0.0 110.421 -179.901 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.735 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.4 t -78.16 110.4 13.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.197 179.929 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -92.97 -27.54 16.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.884 -179.931 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -157.35 130.82 7.92 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.093 0.473 . . . . 0.0 110.653 -179.773 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.665 HG23 ' HG3' ' A' ' 72' ' ' GLU . 42.7 t -101.32 102.98 14.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.132 179.806 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 14.0 mt -88.31 10.38 19.96 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.531 179.862 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.465 HG21 HD22 ' A' ' 83' ' ' LEU . 31.3 m -123.76 135.42 63.49 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.074 0 CA-C-O 121.177 0.513 . . . . 0.0 110.212 179.705 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 9.7 tttp -123.5 152.9 41.26 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.277 -179.943 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -59.98 146.29 43.07 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.598 -179.967 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 20.8 mtm180 61.02 34.19 19.39 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.505 -179.943 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -120.14 149.74 41.74 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.346 179.819 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.11 135.9 33.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.566 -179.981 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.712 HG21 HD21 ' A' ' 85' ' ' LEU . 27.4 m -121.71 -179.99 2.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.273 179.906 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -138.55 144.7 40.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.423 -179.994 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.51 111.14 3.43 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.962 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 111.86 -28.77 9.06 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.88 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.0 tt0 -59.49 135.89 57.81 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.075 0.464 . . . . 0.0 110.573 -179.899 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.25 116.1 8.85 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.946 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.664 HD11 ' HA ' ' A' ' 59' ' ' ALA . 71.8 mt -88.77 -54.58 4.08 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.017 0.436 . . . . 0.0 110.472 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.615 ' CG2' HG13 ' A' ' 102' ' ' VAL . 49.5 mt -142.7 145.0 23.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.391 -179.975 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 25.1 tttt -98.06 129.0 44.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.453 179.869 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.1 mm -103.54 145.54 12.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.475 -179.782 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.75 0 CA-C-O 118.016 -1.436 . . . . 0.0 110.753 179.891 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 121.122 0.487 . . . . 0.0 110.435 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.454 HD11 HD11 ' A' ' 122' ' ' ILE . 52.5 mt -78.89 112.45 27.45 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.156 179.937 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.09 141.62 40.27 Favored 'Trans proline' 0 N--CA 1.472 0.262 0 C-N-CA 122.115 1.877 . . . . 0.0 112.395 -179.932 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.851 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -79.2 148.59 71.38 Favored Pre-proline 0 CA--C 1.531 0.235 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.423 179.911 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.545 ' HG2' HD23 ' A' ' 61' ' ' LEU . 50.5 Cg_endo -72.2 -27.45 16.67 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.31 2.007 . . . . 0.0 112.365 -179.949 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.545 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.6 OUTLIER -158.61 171.08 20.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.321 179.968 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.438 ' HB2' HE21 ' A' ' 114' ' ' GLN . . . -91.07 83.43 5.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.415 179.998 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -109.7 -136.16 7.4 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.946 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.402 ' C ' HD23 ' A' ' 85' ' ' LEU . 2.0 m -139.08 138.55 37.2 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.173 0.511 . . . . 0.0 110.488 179.933 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.615 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -66.82 124.0 21.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.284 179.991 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.2 t -98.58 -60.31 1.57 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.478 -179.957 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.8 mttt -148.69 147.3 28.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.461 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.508 HG22 ' H ' ' A' ' 70' ' ' VAL . 24.0 mt -106.04 118.02 52.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.923 179.899 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.5 mt -95.12 21.79 7.41 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.385 -179.525 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.762 ' HB ' HG21 ' A' ' 102' ' ' VAL . 25.2 m -150.0 148.29 15.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 121.239 0.543 . . . . 0.0 110.524 179.812 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 12.0 mtpp -132.17 157.36 44.48 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.185 179.874 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.463 ' HG3' HG23 ' A' ' 105' ' ' VAL . 27.0 mt-10 -59.11 95.33 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.516 179.989 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.15 -30.41 2.35 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.777 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 59.8 m-20 -73.13 146.39 45.72 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.062 0.458 . . . . 0.0 110.319 179.963 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.4 m -98.45 127.68 44.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.423 179.928 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.686 HG11 HG11 ' A' ' 70' ' ' VAL . 22.7 m -112.56 151.79 14.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.409 179.971 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.5 mttp -112.99 149.05 33.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.324 179.908 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.685 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -57.98 95.56 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.803 -179.854 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.39 -33.92 2.24 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.4 tt0 -69.34 140.17 54.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.083 0.468 . . . . 0.0 110.481 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.6 m -60.43 137.82 58.09 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.488 179.905 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.583 ' O ' HG22 ' A' ' 70' ' ' VAL . 34.6 m -113.95 -33.65 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.947 -179.609 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 83' ' ' LEU . . . . . 0.615 HD11 HG13 ' A' ' 65' ' ' VAL . 7.9 tt -161.17 149.61 15.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.583 -179.558 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -104.46 140.69 21.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.183 179.836 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.791 HD12 HD11 ' A' ' 94' ' ' ILE . 3.6 mt -117.75 171.41 8.06 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.44 -179.848 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.422 179.994 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 . . . . . 0 C--O 1.231 0.084 0 CA-C-O 121.094 0.473 . . . . 0.0 110.541 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.6 m -120.76 121.06 37.4 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.212 179.961 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -84.8 131.98 34.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.57 -179.894 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.791 HD11 HD12 ' A' ' 85' ' ' LEU . 38.8 mm -102.25 124.87 56.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.167 179.767 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -103.64 140.94 36.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.345 -179.934 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.464 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . . . -61.29 142.31 93.66 Favored Pre-proline 0 CA--C 1.532 0.26 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.403 -179.872 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.408 ' HD3' HG23 ' A' ' 57' ' ' ILE . 49.1 Cg_endo -72.77 -36.8 4.36 Favored 'Trans proline' 0 N--CA 1.471 0.194 0 C-N-CA 122.109 1.873 . . . . 0.0 112.352 -179.978 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.685 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 23.0 p -149.48 157.48 43.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.321 -179.989 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -63.53 140.85 58.91 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.358 179.91 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.81 -155.99 19.64 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.983 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 5.8 ttmt -136.93 142.23 42.68 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.143 0.497 . . . . 0.0 110.631 -179.931 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.762 HG21 ' HB ' ' A' ' 70' ' ' VAL . 31.3 t -74.12 112.17 10.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.246 179.9 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -96.11 -30.41 13.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.584 179.972 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 29.5 ttmt -158.97 133.77 8.14 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.468 179.954 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.463 HG23 ' HG3' ' A' ' 72' ' ' GLU . 21.1 t -99.93 109.2 24.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.237 -179.977 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.7 mt -90.12 30.34 1.11 Allowed 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.688 179.971 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.459 HG21 HD13 ' A' ' 83' ' ' LEU . 26.7 m -155.46 138.34 7.15 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-O 120.987 0.423 . . . . 0.0 110.261 -179.999 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 21.2 mttt -124.55 162.48 23.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.364 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 53.3 mt-10 -61.22 149.96 36.04 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.445 179.911 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 61.18 32.56 19.5 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.255 -179.803 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -120.18 148.42 43.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.378 179.9 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.47 140.58 29.61 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.472 -179.995 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.782 HG21 HD21 ' A' ' 85' ' ' LEU . 27.8 m -120.35 -179.99 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.5 -179.986 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 114' ' ' GLN . . . . . 0.438 HE21 ' HB2' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -137.5 144.68 42.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.432 179.897 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.76 107.95 1.64 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.969 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.12 -27.96 9.7 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -60.64 137.14 58.21 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 121.199 0.523 . . . . 0.0 110.562 -179.85 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -60.96 119.19 17.73 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.968 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.851 HD21 ' HB2' ' A' ' 59' ' ' ALA . 59.5 mt -89.96 -49.75 6.42 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.091 0.472 . . . . 0.0 110.573 -179.873 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.494 HD13 HG21 ' A' ' 70' ' ' VAL . 47.8 mt -141.1 138.4 33.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.343 -179.918 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -91.13 130.22 37.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.394 179.887 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.454 HD11 HD11 ' A' ' 57' ' ' ILE . 38.4 mm -108.51 140.75 25.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.408 -179.996 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.834 0 CA-C-O 117.967 -1.463 . . . . 0.0 110.788 179.966 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 143.31 100.07 0.33 Allowed Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -117.61 156.28 28.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.107 0.48 . . . . 0.0 110.372 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 110.01 51.69 0.63 Allowed Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -171.05 151.66 3.31 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.073 0.463 . . . . 0.0 110.415 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.653 ' HB3' ' HB3' ' A' ' 58' ' ' PRO . . . -88.77 169.74 11.37 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.345 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 154.19 -32.97 0.72 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -90.32 52.27 2.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.308 0.575 . . . . 0.0 110.578 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 94.64 -22.47 37.42 Favored Glycine 0 CA--C 1.529 0.948 0 C-N-CA 120.899 -0.667 . . . . 0.0 111.551 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.636 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 13.8 mt-10 -76.54 139.09 40.59 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-O 121.145 0.498 . . . . 0.0 110.851 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 51.8 mt -81.7 111.45 26.12 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.242 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.653 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.9 Cg_endo -71.45 136.98 29.76 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.047 1.832 . . . . 0.0 112.305 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.772 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -72.18 147.17 90.48 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.516 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.89 -25.89 16.15 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.252 1.968 . . . . 0.0 112.464 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 pp -165.98 179.32 5.89 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.451 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.34 102.69 9.72 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.437 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.418 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -127.87 171.1 19.22 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.0 m -105.37 135.25 47.09 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.136 0.494 . . . . 0.0 110.416 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.611 HG23 ' O ' ' A' ' 111' ' ' ASP . 26.0 t -69.93 122.14 20.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.129 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -101.03 -54.42 2.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.576 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.3 ttpm? -151.66 145.85 25.37 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.487 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 3.4 mp -105.36 133.7 48.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.115 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.8 mp -98.15 -44.83 6.45 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.648 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.784 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.9 m -88.67 150.49 3.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.743 -179.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 3.5 ptpt -136.08 161.37 35.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.181 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -61.22 98.6 0.08 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.526 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -29.98 2.38 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.49 148.04 26.74 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.125 0.488 . . . . 0.0 110.578 -179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 24.5 m -95.2 142.17 27.95 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.192 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.708 HG11 HG11 ' A' ' 70' ' ' VAL . 23.8 m -120.19 163.73 17.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.638 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.1 mttp -123.04 147.47 46.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.153 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.659 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.11 92.9 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.693 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.2 -35.37 2.03 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -63.36 143.51 57.74 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.135 0.493 . . . . 0.0 110.614 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.7 m -66.87 137.2 56.4 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.219 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.514 ' HA ' HG13 ' A' ' 70' ' ' VAL . 30.7 m -115.17 -30.24 2.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.206 -179.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.62 HD13 HG21 ' A' ' 107' ' ' VAL . 9.0 tt -163.27 150.14 12.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.127 0.489 . . . . 0.0 110.855 -179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.9 t -102.13 130.59 51.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.998 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.446 HD12 ' CD1' ' A' ' 94' ' ' ILE . 9.6 mt -119.1 132.23 55.98 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.664 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -100.4 86.94 3.28 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.054 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -96.95 117.81 31.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.081 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 41.0 mtm 61.5 56.08 2.65 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.438 0.637 . . . . 0.0 109.487 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 17.5 pttp 43.79 40.17 2.96 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 115.033 -0.985 . . . . 0.0 111.449 -179.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.0 ttp -136.23 125.93 25.5 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.358 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -70.79 119.24 14.65 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.411 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.9 m -118.45 127.67 53.87 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.32 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -84.07 130.85 34.85 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.643 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.446 ' CD1' HD12 ' A' ' 85' ' ' LEU . 38.3 mm -104.94 116.22 48.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.124 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 82.5 m-20 -103.03 143.71 32.22 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.426 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.6 143.3 96.47 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.358 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -73.15 -37.65 3.28 Favored 'Trans proline' 0 CA--C 1.527 0.17 0 C-N-CA 122.072 1.848 . . . . 0.0 112.24 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.659 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 15.6 p -145.78 162.2 38.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.387 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -67.76 142.3 56.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.456 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.57 -157.25 27.52 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.1 ttmt -133.91 147.25 51.09 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.142 0.496 . . . . 0.0 110.544 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.784 HG21 ' HB ' ' A' ' 70' ' ' VAL . 35.2 t -75.32 107.26 5.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.301 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -93.39 -28.04 16.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.65 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -158.56 130.93 6.9 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.077 0.465 . . . . 0.0 110.396 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.427 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.4 t -97.96 109.39 23.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.31 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.2 mt -90.29 30.37 1.13 Allowed 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.641 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.62 HG21 HD13 ' A' ' 83' ' ' LEU . 25.6 m -155.47 137.47 6.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 121.073 0.463 . . . . 0.0 110.252 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 24.9 mmtt -128.9 167.01 18.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.385 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -62.27 147.61 47.53 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.426 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 11.0 mmp_? 60.69 32.32 20.26 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.598 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.611 ' O ' HG23 ' A' ' 65' ' ' VAL . 4.2 t70 -122.74 136.43 54.87 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.354 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.28 136.68 32.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.487 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.418 HG22 ' O ' ' A' ' 63' ' ' GLY . 30.5 m -119.18 150.73 21.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.394 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -98.15 149.28 22.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.449 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.92 117.3 11.16 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 105.84 -28.12 15.18 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 -59.57 138.33 57.74 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 121.041 0.448 . . . . 0.0 110.586 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.618 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -60.68 121.43 26.58 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.772 HD21 ' HB2' ' A' ' 59' ' ' ALA . 24.5 mt -88.92 -51.81 5.43 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.073 0.463 . . . . 0.0 110.404 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 48.4 mt -142.82 144.78 23.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.407 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -96.51 125.29 40.89 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.238 179.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.6 mm -106.06 143.87 16.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.536 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.772 0 CA-C-O 117.989 -1.45 . . . . 0.0 110.716 179.956 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 124.86 94.58 1.03 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -63.93 -37.13 86.29 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.05 0.452 . . . . 0.0 110.412 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.97 140.14 0.02 OUTLIER Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -99.24 40.73 1.19 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.256 0.55 . . . . 0.0 110.373 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.649 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -143.84 111.34 5.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.394 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -168.63 48.1 0.22 Allowed Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.3 tt0 -165.53 33.39 0.06 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.154 0.502 . . . . 0.0 110.397 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 122.83 -32.15 4.52 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -78.29 134.55 37.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.078 0.466 . . . . 0.0 110.481 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.507 HD11 HD11 ' A' ' 122' ' ' ILE . 28.5 mt -79.01 115.01 49.21 Favored Pre-proline 0 CA--C 1.535 0.386 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.006 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.551 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 46.8 Cg_endo -70.84 140.04 37.76 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 121.963 1.775 . . . . 0.0 112.329 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.67 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -75.25 146.53 81.74 Favored Pre-proline 0 CA--C 1.531 0.219 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.454 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.612 ' HG2' HD23 ' A' ' 61' ' ' LEU . 49.0 Cg_endo -72.71 -24.34 18.42 Favored 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 122.232 1.954 . . . . 0.0 112.47 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.612 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.7 OUTLIER -161.08 175.23 12.65 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.457 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -87.83 110.26 20.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.402 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.451 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -138.09 177.85 19.69 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 18.9 m -104.75 136.58 43.99 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.142 0.496 . . . . 0.0 110.481 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.859 HG13 HD11 ' A' ' 83' ' ' LEU . 32.0 t -70.28 117.83 13.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.25 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.8 p -99.61 -51.86 3.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.525 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.3 ptpt -151.73 145.28 24.9 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.528 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.704 HG12 HD12 ' A' ' 83' ' ' LEU . 10.7 mt -100.77 141.23 17.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.009 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.474 HD13 ' HA ' ' A' ' 69' ' ' LEU . 3.9 mm? -101.6 -30.44 11.37 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.109 -179.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.717 HG11 ' CG1' ' A' ' 76' ' ' VAL . 34.5 m -124.91 133.65 68.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.244 0.545 . . . . 0.0 110.854 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.75 149.3 37.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.853 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.8 121.06 5.96 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.387 0.613 . . . . 0.0 111.108 -179.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.17 -28.83 4.48 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.51 158.82 15.37 Favored 'General case' 0 C--N 1.334 -0.106 0 CA-C-O 121.054 0.454 . . . . 0.0 110.425 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -97.91 141.22 31.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.428 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.717 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.2 m -123.83 158.31 29.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.485 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 32.3 mttm -117.68 157.83 25.75 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.35 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.615 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -62.42 106.84 0.82 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.515 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.3 -31.47 4.66 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 -62.77 140.62 58.76 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.125 0.488 . . . . 0.0 110.532 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 7.5 m -67.54 139.38 56.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.305 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CA ' HG22 ' A' ' 70' ' ' VAL . 29.4 m -114.43 -31.54 2.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.053 -179.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.859 HD11 HG13 ' A' ' 65' ' ' VAL . 8.5 tt -166.41 146.9 6.19 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.103 0.478 . . . . 0.0 110.841 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.1 t -103.08 135.88 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.131 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.877 HD12 HD11 ' A' ' 94' ' ' ILE . 51.9 mt -118.32 166.27 12.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.706 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -141.38 82.63 1.83 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.336 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.41 ' HB2' ' CA ' ' A' ' 63' ' ' GLY . . . -97.11 120.52 37.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.457 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 22.4 mmt 62.35 43.11 8.45 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.413 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.5 mttp 59.81 38.52 21.39 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.628 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 82.8 mtp -131.71 110.54 10.96 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.459 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 21.5 mt-10 -66.08 109.14 2.47 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.433 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.0 m -117.45 109.04 16.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.276 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -77.97 140.64 39.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.604 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.877 HD11 HD12 ' A' ' 85' ' ' LEU . 37.2 mm -103.68 140.67 21.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.057 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 38.3 m-20 -128.76 143.48 50.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.665 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.25 138.62 96.18 Favored Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.259 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.99 -31.86 11.87 Favored 'Trans proline' 0 N--CA 1.472 0.209 0 C-N-CA 122.09 1.86 . . . . 0.0 112.416 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.615 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 40.9 p -147.17 164.95 31.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.483 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -66.42 143.61 57.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.399 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.48 -160.43 27.98 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.6 ttpt -135.02 136.87 42.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.139 0.495 . . . . 0.0 110.431 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.633 HG13 ' CG2' ' A' ' 120' ' ' ILE . 4.2 t -73.16 107.26 3.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.86 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -87.68 -29.39 21.17 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.001 -179.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 13.7 tttt -163.95 138.13 5.69 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.407 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 107' ' ' VAL . 21.6 t -107.92 110.49 32.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.416 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.8 mt -79.24 -31.59 43.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.394 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.571 HG21 HD13 ' A' ' 83' ' ' LEU . 27.3 m -82.56 142.84 13.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.501 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 54.2 mttt -136.47 163.11 31.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.246 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -60.79 147.29 43.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.519 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 5.5 tpt180 61.13 35.45 18.58 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.479 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.569 ' O ' HG23 ' A' ' 65' ' ' VAL . 8.0 t0 -127.98 140.32 52.05 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.388 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.51 136.24 33.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.517 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 63' ' ' GLY . 26.0 m -120.24 152.06 23.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.341 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 25.7 mt-30 -97.36 140.19 32.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.501 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.7 87.92 0.04 OUTLIER Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 137.54 -28.08 2.79 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -61.59 146.93 47.3 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.157 0.503 . . . . 0.0 110.515 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.649 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.56 118.87 16.16 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.67 HD21 ' HB2' ' A' ' 59' ' ' ALA . 71.8 mt -87.14 -53.15 5.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.082 0.468 . . . . 0.0 110.485 -179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.633 ' CG2' HG13 ' A' ' 102' ' ' VAL . 55.5 mt -140.9 151.59 20.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.477 -179.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -97.22 133.99 41.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.209 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.507 HD11 HD11 ' A' ' 57' ' ' ILE . 35.9 mm -114.25 145.18 20.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.438 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.781 0 CA-C-O 118.011 -1.438 . . . . 0.0 110.774 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -159.28 110.78 0.46 Allowed Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -149.75 37.31 0.72 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.28 0.562 . . . . 0.0 110.379 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.85 148.38 45.57 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 39.8 tttm -130.18 159.43 36.85 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.146 0.498 . . . . 0.0 110.394 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.767 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -109.1 179.12 4.26 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.474 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 151.72 -46.09 0.6 Allowed Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -112.77 96.2 5.84 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.116 0.484 . . . . 0.0 110.513 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 93.79 -52.66 2.3 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.702 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 0.6 OUTLIER -82.31 134.8 35.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.998 0.428 . . . . 0.0 110.499 179.991 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.772 HD12 ' HD2' ' A' ' 97' ' ' PRO . 46.1 mm -80.22 120.6 80.07 Favored Pre-proline 0 CA--C 1.536 0.431 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.923 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.576 ' CA ' ' HB3' ' A' ' 52' ' ' ALA . 47.9 Cg_endo -72.05 128.0 13.47 Favored 'Trans proline' 0 N--CA 1.472 0.222 0 C-N-CA 121.892 1.728 . . . . 0.0 112.1 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.443 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -61.05 142.12 93.22 Favored Pre-proline 0 CA--C 1.532 0.28 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.471 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -73.62 -27.54 12.73 Favored 'Trans proline' 0 CA--C 1.528 0.188 0 C-N-CA 122.181 1.921 . . . . 0.0 112.374 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -161.33 159.92 29.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.472 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.59 125.39 30.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.402 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -159.06 -140.22 2.86 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.621 ' C ' HD23 ' A' ' 85' ' ' LEU . 14.8 m -136.56 139.13 41.96 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.082 0.468 . . . . 0.0 110.406 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.771 HG13 HD11 ' A' ' 83' ' ' LEU . 27.9 t -70.71 124.61 27.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.208 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.0 t -98.42 -54.23 3.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.675 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -153.67 145.02 23.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.529 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.704 HG12 HD12 ' A' ' 83' ' ' LEU . 35.7 mt -99.65 135.16 36.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.118 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.546 HD13 ' HB ' ' A' ' 81' ' ' THR . 12.3 mt -98.48 -44.13 6.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.617 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.689 HG11 ' CG1' ' A' ' 76' ' ' VAL . 34.6 m -98.83 144.69 11.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.502 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 46.1 pttt -137.3 164.28 28.94 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.206 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -57.05 102.29 0.08 Allowed 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.692 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.13 -31.97 2.22 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -90.15 152.94 20.88 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.062 0.458 . . . . 0.0 110.387 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -98.84 146.79 25.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.474 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.689 ' CG1' HG11 ' A' ' 70' ' ' VAL . 28.4 m -121.47 162.44 20.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.344 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -127.29 156.85 41.27 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.488 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.34 90.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.55 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.65 -30.36 3.0 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 16.3 tt0 -61.88 143.32 56.56 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.077 0.465 . . . . 0.0 110.672 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.546 ' HB ' HD13 ' A' ' 69' ' ' LEU . 1.9 m -68.9 138.97 55.1 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.148 179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.529 ' HA ' HG13 ' A' ' 70' ' ' VAL . 28.4 m -117.63 -33.86 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.35 -179.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.771 HD11 HG13 ' A' ' 65' ' ' VAL . 7.6 tt -161.52 153.15 19.02 Favored 'General case' 0 C--N 1.332 -0.175 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.167 -179.303 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.4 t -107.55 138.4 33.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.923 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.678 HD21 ' CG2' ' A' ' 113' ' ' VAL . 0.9 OUTLIER -120.26 168.53 11.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.191 0.52 . . . . 0.0 110.457 -179.808 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -133.6 115.38 14.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.357 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.52 142.82 25.17 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.509 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 56.8 mtp 60.36 32.71 20.74 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.6 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.4 33.04 20.76 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.55 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 14.8 ttm -146.69 120.51 9.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.441 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -66.0 128.1 34.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.613 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.2 m -114.4 122.34 46.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.232 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -82.52 130.22 35.07 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.62 -179.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.501 HG13 HD12 ' A' ' 85' ' ' LEU . 25.7 mm -103.19 147.45 9.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.011 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -139.27 142.38 37.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.152 0.501 . . . . 0.0 110.779 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.518 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -62.65 109.76 2.72 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.291 179.665 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.772 ' HD2' HD12 ' A' ' 57' ' ' ILE . 41.9 Cg_endo -64.93 -13.77 41.46 Favored 'Trans proline' 0 N--CA 1.476 0.46 0 C-N-CA 122.148 1.899 . . . . 0.0 112.885 179.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -135.94 135.96 40.04 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.097 0.475 . . . . 0.0 110.359 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -63.36 151.29 41.28 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.422 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 159.36 -154.66 25.73 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.0 ttmt -135.69 148.03 48.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.141 0.496 . . . . 0.0 110.448 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.653 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -75.69 111.26 11.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.208 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -95.21 -30.07 14.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.784 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.7 ttpt -162.01 130.17 4.13 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.569 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.494 HG13 HG12 ' A' ' 120' ' ' ILE . 22.0 t -103.57 113.89 41.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.295 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.0 mt -81.59 -37.17 28.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.374 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.526 HG21 HD13 ' A' ' 83' ' ' LEU . 32.9 m -77.44 147.45 7.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.574 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -133.49 163.68 28.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.075 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -62.71 138.55 58.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.394 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER 67.2 37.16 3.76 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.564 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.41 151.07 40.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.278 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -95.61 133.46 39.63 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.513 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.678 ' CG2' HD21 ' A' ' 85' ' ' LEU . 31.4 m -120.8 179.8 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.356 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 81.7 mm-40 -136.05 147.67 48.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.425 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.32 113.07 5.31 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 111.18 -30.78 7.69 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -60.18 140.33 57.02 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.138 0.494 . . . . 0.0 110.675 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.767 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.49 120.49 22.72 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.443 HD21 ' HB2' ' A' ' 59' ' ' ALA . 91.6 mt -87.06 -53.59 4.79 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.103 0.478 . . . . 0.0 110.423 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.562 ' CG2' HG13 ' A' ' 102' ' ' VAL . 52.3 mt -141.32 151.82 19.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.326 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 39.1 mttt -93.76 128.19 39.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.382 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.437 HD12 HG21 ' A' ' 76' ' ' VAL . 37.1 mm -109.87 145.76 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.37 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.748 0 CA-C-O 117.991 -1.449 . . . . 0.0 110.728 179.925 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 144.79 -40.99 1.11 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -117.45 -70.1 0.81 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.033 0.444 . . . . 0.0 110.359 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -96.55 -160.22 32.1 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -163.71 40.37 0.09 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.266 0.555 . . . . 0.0 110.27 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.776 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -154.84 178.31 10.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.334 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 138.44 -45.84 1.02 Allowed Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -105.38 80.69 1.61 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.259 0.552 . . . . 0.0 110.495 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.99 -48.4 1.01 Allowed Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.724 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 6.8 mt-10 -83.69 128.94 34.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.067 0.46 . . . . 0.0 110.503 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.457 HD11 HD11 ' A' ' 122' ' ' ILE . 45.7 mt -78.9 111.45 19.86 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.127 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.6 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 46.2 Cg_endo -70.38 142.42 45.17 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.099 1.866 . . . . 0.0 112.465 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.511 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -77.67 148.53 76.51 Favored Pre-proline 0 CA--C 1.531 0.24 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.521 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -73.11 -26.66 14.71 Favored 'Trans proline' 0 CA--C 1.528 0.212 0 C-N-CA 122.206 1.937 . . . . 0.0 112.461 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -164.63 156.98 16.37 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.472 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.0 121.92 19.07 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.423 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -150.96 -145.17 4.07 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.7 m -136.97 139.02 41.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.138 0.494 . . . . 0.0 110.413 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.629 HG13 HD11 ' A' ' 83' ' ' LEU . 25.2 t -71.98 126.23 32.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.181 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 32.7 t -96.03 -53.41 3.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.655 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.32 150.55 31.62 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.178 0.513 . . . . 0.0 110.74 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.485 HD11 ' HA ' ' A' ' 108' ' ' LYS . 32.8 mt -105.87 116.48 49.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.051 179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 64.2 mt -98.75 13.78 31.05 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.622 -179.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.756 ' HB ' HG21 ' A' ' 102' ' ' VAL . 28.4 m -148.22 133.56 11.0 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 CA-C-O 121.122 0.486 . . . . 0.0 110.691 179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 17.1 mmtp -116.86 161.2 19.69 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.195 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -58.21 95.53 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.621 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.22 -35.79 1.86 Allowed Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.52 146.77 47.59 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.093 0.473 . . . . 0.0 110.481 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -96.67 137.51 35.63 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.578 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 18.8 m -126.91 166.76 22.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.395 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -130.3 157.23 43.11 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.309 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.703 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -62.39 88.62 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.401 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.15 -33.51 2.08 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -63.15 145.66 55.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.145 0.498 . . . . 0.0 110.451 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.1 m -67.33 139.57 57.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.425 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.595 ' O ' HG22 ' A' ' 70' ' ' VAL . 28.1 m -120.14 -35.49 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.17 -179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.629 HD11 HG13 ' A' ' 65' ' ' VAL . 7.6 tt -162.05 152.71 17.45 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.261 0.553 . . . . 0.0 111.032 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.9 t -103.54 145.1 13.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.794 179.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.815 HD12 HD11 ' A' ' 94' ' ' ILE . 11.1 mt -126.67 160.3 31.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.52 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -131.13 114.37 15.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.423 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.57 140.6 22.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.299 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 34.3 mtt 60.91 32.01 20.0 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.572 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 33.3 mtmt 59.61 31.99 21.27 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.702 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 6.9 mtt -139.82 121.1 14.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.509 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -64.01 127.66 32.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.196 179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.3 m -118.75 117.58 29.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.393 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -83.04 133.82 35.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.457 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.815 HD11 HD12 ' A' ' 85' ' ' LEU . 33.7 mm -103.71 152.78 6.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.172 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 47.6 m-80 -139.88 148.08 41.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.495 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.89 139.18 95.66 Favored Pre-proline 0 CA--C 1.533 0.316 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.399 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -76.02 -28.65 7.38 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.128 1.886 . . . . 0.0 112.387 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.703 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 3.7 p -145.63 168.27 21.06 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.535 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -69.57 141.71 53.73 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.514 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 159.78 -168.16 35.48 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -129.13 168.4 16.18 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.229 0.538 . . . . 0.0 110.637 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.756 HG21 ' HB ' ' A' ' 70' ' ' VAL . 27.4 t -82.4 111.56 18.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.439 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -92.95 -30.13 15.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.42 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 4.9 tmtt? -159.05 128.77 5.62 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.275 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.429 HG22 HG11 ' A' ' 102' ' ' VAL . 20.7 t -101.3 105.73 18.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.117 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.0 mt -85.84 9.45 16.66 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.863 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.479 HG21 HD13 ' A' ' 83' ' ' LEU . 28.4 m -129.33 146.0 34.89 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-O 121.192 0.52 . . . . 0.0 110.629 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.485 ' HA ' HD11 ' A' ' 68' ' ' ILE . 20.5 mtpt -128.39 166.5 18.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.263 179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -63.49 140.89 58.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.323 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 17.7 mmt85 65.83 36.71 5.96 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.67 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.504 ' O ' HG23 ' A' ' 65' ' ' VAL . 1.8 m-20 -121.89 137.44 54.78 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.272 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.2 134.21 34.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.521 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.2 m -120.72 156.96 23.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.367 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -97.51 144.12 27.53 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.393 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.3 108.05 1.62 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.96 -27.06 9.41 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.05 -0.82 . . . . 0.0 111.05 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 24.1 tt0 -59.83 143.52 50.96 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-O 121.126 0.489 . . . . 0.0 110.631 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.776 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.63 119.84 19.93 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.511 HD21 ' HB2' ' A' ' 59' ' ' ALA . 70.6 mt -89.67 -52.82 4.81 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.136 0.493 . . . . 0.0 110.172 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.484 ' CG2' HG13 ' A' ' 102' ' ' VAL . 46.3 mt -145.21 144.14 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.16 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 9.3 tttt -94.99 135.48 36.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.143 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.457 HD11 HD11 ' A' ' 57' ' ' ILE . 40.8 mm -109.2 142.69 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.412 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.815 0 CA-C-O 118.061 -1.41 . . . . 0.0 110.833 -179.919 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.26 174.06 15.25 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.94 -36.67 19.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.17 0.51 . . . . 0.0 110.492 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 68.8 -134.56 27.82 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 63.8 mttt -132.21 40.88 3.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.325 0.584 . . . . 0.0 110.471 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.741 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -148.72 176.69 10.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.456 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.44 -35.8 2.96 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -92.23 52.01 1.88 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.409 0.624 . . . . 0.0 110.437 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 114.76 -40.02 2.6 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.637 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 7.6 mm-40 -85.35 136.56 33.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.09 0.471 . . . . 0.0 110.42 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.487 HD11 HD11 ' A' ' 122' ' ' ILE . 48.5 mt -78.29 118.79 74.39 Favored Pre-proline 0 CA--C 1.535 0.39 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.185 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.498 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 48.4 Cg_endo -71.53 135.33 26.14 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 121.98 1.787 . . . . 0.0 112.331 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.764 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -65.52 148.4 98.1 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.456 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.79 -34.73 6.48 Favored 'Trans proline' 0 N--CA 1.472 0.224 0 C-N-CA 122.276 1.984 . . . . 0.0 112.236 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -162.67 159.06 23.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.411 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.77 81.91 0.19 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.288 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.411 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -115.01 -172.79 17.5 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.9 m -109.89 136.7 48.77 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.061 0.458 . . . . 0.0 110.388 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.507 HG13 HD21 ' A' ' 83' ' ' LEU . 24.3 t -71.73 117.02 14.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.094 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 40.8 t -92.93 -49.99 5.77 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.679 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -155.37 148.35 24.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.246 0.546 . . . . 0.0 110.608 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.422 HG22 ' O ' ' A' ' 70' ' ' VAL . 48.5 mt -103.37 130.15 54.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.95 179.696 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.588 HD11 HG23 ' A' ' 84' ' ' VAL . 5.7 mp -94.29 -30.72 14.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.854 -179.599 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.69 HG11 ' CG1' ' A' ' 76' ' ' VAL . 31.0 m -114.72 145.77 20.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.112 0.482 . . . . 0.0 110.728 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.5 pttt -138.88 166.87 23.32 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.331 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -56.96 104.95 0.18 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.839 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 132.1 -31.02 3.1 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -87.35 144.49 26.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.108 0.48 . . . . 0.0 110.57 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.2 m -93.51 150.45 20.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.293 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.69 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.9 m -125.14 166.9 20.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.568 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -129.48 147.51 51.29 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.204 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.463 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.52 92.02 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.629 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.17 -30.55 2.62 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.6 tt0 -69.25 143.04 54.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.107 0.479 . . . . 0.0 110.618 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.446 ' HB ' HD22 ' A' ' 69' ' ' LEU . 27.1 m -65.02 138.21 58.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.206 179.784 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.694 HG22 ' O ' ' A' ' 94' ' ' ILE . 29.6 m -115.7 -26.38 2.88 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.449 -179.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.507 HD21 HG13 ' A' ' 65' ' ' VAL . 9.1 tt -165.26 150.02 9.0 Favored 'General case' 0 C--N 1.332 -0.166 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.966 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.588 HG23 HD11 ' A' ' 69' ' ' LEU . 22.0 t -106.74 137.91 35.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.017 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.46 HD23 ' HA ' ' A' ' 85' ' ' LEU . 11.8 mt -115.66 164.75 13.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.184 0.516 . . . . 0.0 110.595 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -135.1 101.07 4.75 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.363 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -147.11 150.94 36.0 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.445 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 67.4 mtt 60.17 29.4 18.97 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.872 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 35.0 mtpt 59.46 31.76 21.26 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.886 179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.1 ptp -146.16 139.49 25.96 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.461 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -76.91 125.98 30.21 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.55 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.7 m -122.02 112.61 18.48 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.233 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.443 ' HG3' HG22 ' A' ' 84' ' ' VAL . 1.7 mp0 -87.4 143.0 27.45 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.487 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.694 ' O ' HG22 ' A' ' 82' ' ' VAL . 4.8 mp -116.52 126.24 73.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.123 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.1 m-80 -101.07 153.95 19.13 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.261 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.06 141.37 95.77 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.325 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.26 -32.72 7.98 Favored 'Trans proline' 0 N--CA 1.472 0.208 0 C-N-CA 122.133 1.889 . . . . 0.0 112.212 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.463 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 73.1 p -148.16 155.92 41.97 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.348 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -63.73 142.85 58.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.393 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 169.34 -156.38 27.43 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 29.2 ttpp -134.35 150.97 50.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.092 0.472 . . . . 0.0 110.372 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.656 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -78.3 111.03 14.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.276 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -93.55 -30.94 14.74 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.646 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.61 151.74 27.88 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.221 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.495 HG13 HG12 ' A' ' 120' ' ' ILE . 21.9 t -131.95 113.26 21.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.304 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.49 HD11 ' OE2' ' A' ' 56' ' ' GLU . 2.1 mt -84.63 -33.07 23.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.348 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.417 ' O ' HG12 ' A' ' 105' ' ' VAL . 32.7 m -80.46 144.24 11.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.585 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -133.36 164.19 27.67 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.247 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 -61.28 144.35 54.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.458 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 2.5 ttt-85 61.48 35.02 17.78 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.44 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.459 ' O ' HG23 ' A' ' 65' ' ' VAL . 17.2 t0 -124.62 148.04 48.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.428 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.3 141.33 28.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.469 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 63' ' ' GLY . 30.8 m -122.41 156.18 27.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.379 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -100.58 140.18 35.21 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.346 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.51 98.97 0.16 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.3 -27.55 6.32 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.7 tt0 -59.56 142.63 52.28 Favored 'General case' 0 N--CA 1.462 0.127 0 CA-C-O 121.062 0.458 . . . . 0.0 110.656 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.741 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -62.26 121.64 26.03 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.761 -0.935 . . . . 0.0 110.761 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.764 HD21 ' HB2' ' A' ' 59' ' ' ALA . 79.6 mt -87.78 -54.46 4.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.075 0.464 . . . . 0.0 110.394 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.581 ' CG2' HG13 ' A' ' 102' ' ' VAL . 52.9 mt -141.24 149.39 20.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.312 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 14.8 tttp -98.14 126.75 43.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.343 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.487 HD11 HD11 ' A' ' 57' ' ' ILE . 36.7 mm -102.62 145.68 11.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.331 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.689 0 CA-C-O 117.988 -1.451 . . . . 0.0 110.784 179.967 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -76.77 -91.19 0.25 Allowed Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -121.2 -59.03 1.75 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.164 0.506 . . . . 0.0 110.494 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 98.94 131.87 7.46 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.804 -0.919 . . . . 0.0 110.804 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 17.2 pttt -150.41 151.45 32.81 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.133 0.492 . . . . 0.0 110.474 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.512 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -61.63 173.09 1.04 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.284 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -178.89 -50.71 0.08 OUTLIER Glycine 0 CA--C 1.526 0.738 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.308 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -61.92 -82.37 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.027 0.441 . . . . 0.0 110.709 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -137.64 19.2 3.36 Favored Glycine 0 CA--C 1.528 0.862 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 179.586 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.494 ' HB2' ' HB1' ' A' ' 52' ' ' ALA . 44.8 mt-10 -92.16 139.41 30.65 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 121.132 0.492 . . . . 0.0 110.3 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.44 HD11 HD11 ' A' ' 122' ' ' ILE . 54.5 mt -78.04 113.67 35.27 Favored Pre-proline 0 CA--C 1.535 0.395 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.068 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.08 132.71 23.37 Favored 'Trans proline' 0 N--CA 1.472 0.249 0 C-N-CA 122.08 1.853 . . . . 0.0 112.297 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.503 ' HB3' ' O ' ' A' ' 114' ' ' GLN . . . -65.94 147.97 98.54 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.584 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.681 ' HB2' HD23 ' A' ' 61' ' ' LEU . 49.6 Cg_endo -73.33 -29.01 11.77 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.256 1.971 . . . . 0.0 112.314 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.681 HD23 ' HB2' ' A' ' 60' ' ' PRO . 0.2 OUTLIER -163.81 -179.85 6.61 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.528 179.83 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.19 98.45 9.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.42 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.57 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -132.76 -177.55 14.99 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.3 m -113.63 141.27 47.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.132 0.492 . . . . 0.0 110.418 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.706 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -70.89 126.02 30.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.293 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.1 t -100.65 -52.28 3.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.58 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 7.2 ttmm -150.52 148.56 28.85 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.654 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.422 HD11 ' HA ' ' A' ' 108' ' ' LYS . 44.8 mt -102.66 131.71 50.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.019 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.9 mt -99.79 -36.37 9.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.786 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.739 HG11 ' CG1' ' A' ' 76' ' ' VAL . 33.6 m -110.47 146.92 15.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 121.172 0.511 . . . . 0.0 110.835 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.3 pttt -137.3 165.6 25.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.182 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.485 ' HG3' HG23 ' A' ' 105' ' ' VAL . 36.8 mt-10 -58.42 101.74 0.09 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.606 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.07 -32.6 2.17 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -88.54 146.28 25.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.129 0.49 . . . . 0.0 110.392 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.507 HG22 ' O ' ' A' ' 100' ' ' GLY . 0.8 OUTLIER -96.28 148.33 22.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.32 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.739 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.9 m -125.77 169.79 16.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.52 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 43.6 tttt -132.37 153.97 50.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.31 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.656 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.94 97.97 0.07 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.595 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.27 -36.75 2.19 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 14.9 tt0 -62.49 139.08 58.59 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.056 0.455 . . . . 0.0 110.67 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.6 m -65.86 137.11 56.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.206 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.472 ' HA ' HG13 ' A' ' 70' ' ' VAL . 24.3 m -115.67 -31.39 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.229 -179.502 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.706 HD11 HG13 ' A' ' 65' ' ' VAL . 7.5 tt -161.35 153.0 19.18 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.177 0.513 . . . . 0.0 110.86 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -101.35 140.55 19.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.038 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.653 HD12 HD11 ' A' ' 94' ' ' ILE . 12.5 mt -122.78 139.24 54.21 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.161 0.505 . . . . 0.0 110.643 -179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -102.69 107.74 18.74 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.373 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.1 149.47 31.12 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.476 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 24.4 mmm 60.38 31.07 20.28 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.686 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 38.6 mmtt 59.11 29.28 18.8 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.901 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 20.0 ptp -145.34 161.17 40.27 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.477 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -86.24 127.67 34.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.507 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.6 m -113.5 123.36 49.84 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.312 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -84.64 130.65 34.69 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.523 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.653 HD11 HD12 ' A' ' 85' ' ' LEU . 35.6 mm -106.23 114.9 46.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.184 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -102.11 146.91 27.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.289 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.09 141.53 95.79 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.322 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.62 -34.78 6.77 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.077 1.852 . . . . 0.0 112.211 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.656 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 17.4 p -147.85 162.57 38.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.271 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -68.19 141.18 56.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.328 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.507 ' O ' HG22 ' A' ' 75' ' ' THR . . . 171.47 -158.34 29.4 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 5.6 ttpm? -132.95 149.7 52.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.976 0.417 . . . . 0.0 110.336 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.66 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -75.99 110.16 10.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.21 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -92.77 -29.97 15.74 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.582 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 27.6 tttm -159.2 129.65 5.85 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.157 0.503 . . . . 0.0 110.486 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.485 HG23 ' HG3' ' A' ' 72' ' ' GLU . 33.2 t -100.19 102.84 13.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.168 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.2 mt -85.24 6.38 26.29 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.64 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.647 HG21 HD13 ' A' ' 83' ' ' LEU . 26.7 m -120.89 136.23 58.54 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.109 0 CA-C-O 121.181 0.515 . . . . 0.0 110.312 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.422 ' HA ' HD11 ' A' ' 68' ' ' ILE . 83.3 mttt -126.23 164.41 21.04 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.313 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.6 mt-10 -62.1 145.33 53.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.38 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 36.6 mtt180 60.13 35.6 21.18 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.588 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -114.64 141.68 47.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.373 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.61 129.27 38.59 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.572 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.57 HG22 ' O ' ' A' ' 63' ' ' GLY . 27.5 m -119.09 179.7 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.259 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . 0.503 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 64.3 mt-30 -140.68 152.45 45.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.512 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.82 105.09 0.83 Allowed Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 121.9 -31.39 4.97 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 22.3 tt0 -60.05 135.32 57.68 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.131 0.491 . . . . 0.0 110.541 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.512 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -60.81 121.07 25.4 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.492 ' O ' HG13 ' A' ' 107' ' ' VAL . 62.3 mt -87.36 -56.51 3.33 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.012 0.434 . . . . 0.0 110.296 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.542 ' CG2' HG13 ' A' ' 102' ' ' VAL . 49.1 mt -143.15 150.89 17.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.126 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -96.2 125.7 40.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.265 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.44 HD11 HD11 ' A' ' 57' ' ' ILE . 37.8 mm -106.46 143.36 17.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.516 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.697 0 CA-C-O 117.951 -1.471 . . . . 0.0 110.767 179.977 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -78.19 73.18 2.21 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -131.42 104.29 6.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.135 0.493 . . . . 0.0 110.41 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -179.59 -68.64 0.07 OUTLIER Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -147.35 132.15 17.99 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.07 0.462 . . . . 0.0 110.416 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.662 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -64.59 178.81 0.7 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.416 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -167.6 -69.62 0.03 OUTLIER Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -127.06 114.13 17.35 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.023 0.44 . . . . 0.0 110.378 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 106.69 -52.65 0.66 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -83.34 134.64 34.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.026 0.441 . . . . 0.0 110.38 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.465 HG23 ' HD3' ' A' ' 97' ' ' PRO . 54.3 mt -82.11 111.06 24.26 Favored Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.282 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.449 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 48.1 Cg_endo -71.57 142.67 40.71 Favored 'Trans proline' 0 N--CA 1.472 0.263 0 C-N-CA 122.0 1.8 . . . . 0.0 112.295 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.483 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -74.7 147.14 84.15 Favored Pre-proline 0 CA--C 1.531 0.239 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.397 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -72.49 -26.51 16.77 Favored 'Trans proline' 0 N--CA 1.471 0.199 0 C-N-CA 122.182 1.921 . . . . 0.0 112.366 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -164.55 157.57 17.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.362 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.502 ' HB2' ' H ' ' A' ' 115' ' ' GLY . . . -73.52 97.15 2.53 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.43 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.86 -144.55 6.22 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 3.9 m -136.54 132.18 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.095 0.474 . . . . 0.0 110.358 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.635 ' CG1' HD11 ' A' ' 83' ' ' LEU . 21.8 t -67.71 130.5 33.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.254 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 4.8 p -101.6 -53.98 2.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.542 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 23.8 ttpt -152.82 147.26 25.82 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.588 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.556 HG12 HD12 ' A' ' 83' ' ' LEU . 47.3 mt -100.23 133.48 43.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.116 179.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.425 HD12 HG22 ' A' ' 81' ' ' THR . 25.7 mt -98.64 -31.3 12.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.638 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.786 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.0 m -104.51 149.95 7.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.701 -179.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 67.7 mttt -137.19 163.43 30.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.206 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -62.36 97.0 0.08 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.258 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.19 -29.19 2.43 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -85.43 147.82 26.3 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.082 0.467 . . . . 0.0 110.442 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.442 HG22 ' O ' ' A' ' 100' ' ' GLY . 0.7 OUTLIER -96.88 150.21 20.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.147 179.878 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.756 HG11 HG11 ' A' ' 70' ' ' VAL . 31.6 m -128.54 170.02 18.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.653 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 24.5 mmtt -131.38 146.26 52.2 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.22 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.707 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -58.84 96.51 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.717 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.16 -34.5 2.3 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 23.6 tt0 -67.84 144.46 55.3 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.14 0.495 . . . . 0.0 110.515 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.425 HG22 HD12 ' A' ' 69' ' ' LEU . 3.5 m -65.13 136.73 57.05 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.315 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.457 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.3 m -112.73 -33.09 2.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.921 -179.674 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.635 HD11 ' CG1' ' A' ' 65' ' ' VAL . 7.5 tt -160.4 150.75 18.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.686 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.2 t -102.55 136.64 33.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.184 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.695 HD11 HG21 ' A' ' 113' ' ' VAL . 0.7 OUTLIER -117.16 164.1 15.28 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.519 -179.793 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -135.97 112.84 10.25 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.28 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -145.84 138.61 25.78 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.49 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 12.2 mmt 60.68 32.68 20.31 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.512 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 61.11 33.26 19.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.374 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 28.1 ttm -140.03 121.81 15.42 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.496 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -69.98 125.09 25.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.459 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 24.1 m -116.47 124.64 50.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.388 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -85.01 134.14 34.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.486 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.3 mm -102.66 126.1 56.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.242 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 13.7 p30 -110.25 140.06 44.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.314 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.11 139.24 96.03 Favored Pre-proline 0 CA--C 1.533 0.313 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.311 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.465 ' HD3' HG23 ' A' ' 57' ' ' ILE . 49.8 Cg_endo -73.81 -31.04 8.75 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.166 1.911 . . . . 0.0 112.227 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.707 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 78.2 p -147.01 151.31 36.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.344 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -66.78 142.67 57.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.352 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.442 ' O ' HG22 ' A' ' 75' ' ' THR . . . 176.62 -147.93 8.76 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -140.88 145.47 36.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.076 0.465 . . . . 0.0 110.316 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.786 HG21 ' HB ' ' A' ' 70' ' ' VAL . 24.7 t -77.8 107.45 9.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.327 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -91.92 -28.42 17.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.729 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 17.8 ttpt -160.75 130.89 5.14 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.099 0.476 . . . . 0.0 110.544 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.435 HG13 HG12 ' A' ' 120' ' ' ILE . 21.9 t -105.49 109.52 28.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.347 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.6 mt -78.92 -31.8 45.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.476 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.424 HG11 HD23 ' A' ' 119' ' ' LEU . 31.5 m -80.18 152.84 4.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.593 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -135.79 155.11 50.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.268 179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -59.01 141.99 52.44 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.632 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER 60.75 36.39 19.34 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.499 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 21.6 t0 -119.45 151.11 39.1 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.286 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -93.64 133.4 37.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.491 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.695 HG21 HD11 ' A' ' 85' ' ' LEU . 29.7 m -120.39 152.01 23.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.453 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -100.17 144.93 28.62 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.354 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.502 ' H ' ' HB2' ' A' ' 62' ' ' ALA . . . -61.62 105.63 0.96 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 117.91 -28.04 7.19 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 37.3 tt0 -59.85 139.96 56.96 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 121.127 0.489 . . . . 0.0 110.597 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.662 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.36 126.58 40.3 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.483 HD11 ' HA ' ' A' ' 59' ' ' ALA . 41.5 mt -89.43 -58.94 2.35 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.153 0.501 . . . . 0.0 110.567 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.495 ' CG2' HG13 ' A' ' 102' ' ' VAL . 58.4 mt -140.95 145.57 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.164 -179.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -93.41 123.76 36.94 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.536 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.1 mm -101.23 145.07 12.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.274 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.678 0 CA-C-O 117.947 -1.474 . . . . 0.0 110.875 -179.996 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.89 94.56 2.36 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.729 -0.948 . . . . 0.0 110.729 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.49 84.3 6.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.001 0.429 . . . . 0.0 110.457 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 159.83 -175.85 36.62 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 46.0 mttt -143.61 40.05 1.41 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.338 0.59 . . . . 0.0 110.322 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.68 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -145.66 135.22 23.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.426 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -141.18 -95.34 0.25 Allowed Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.846 -0.902 . . . . 0.0 110.846 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -92.86 114.24 26.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.158 0.504 . . . . 0.0 110.438 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.04 -60.36 0.34 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -83.89 128.35 34.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.072 0.463 . . . . 0.0 110.453 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.405 HD11 HD11 ' A' ' 122' ' ' ILE . 43.4 mt -79.27 120.22 79.77 Favored Pre-proline 0 CA--C 1.534 0.335 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.157 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.424 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 48.6 Cg_endo -72.22 138.72 31.01 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 121.998 1.799 . . . . 0.0 112.375 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -75.2 147.92 83.44 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.42 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -72.27 -28.53 15.21 Favored 'Trans proline' 0 CA--C 1.527 0.156 0 C-N-CA 122.324 2.016 . . . . 0.0 112.409 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.6 pp -163.25 163.2 25.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.436 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.16 98.17 5.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.437 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -123.65 -148.04 7.43 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.742 -0.943 . . . . 0.0 110.742 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.1 m -136.4 140.21 43.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.064 0.459 . . . . 0.0 110.439 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.698 HG13 HD11 ' A' ' 83' ' ' LEU . 24.7 t -72.28 120.12 20.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.16 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -96.82 -51.28 4.33 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.693 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -152.97 144.08 23.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.64 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 33.3 mt -97.45 131.46 44.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.0 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.507 HD22 ' HB ' ' A' ' 81' ' ' THR . 5.3 mp -100.11 -29.44 12.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.884 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.877 HG11 HG11 ' A' ' 76' ' ' VAL . 28.3 m -118.71 145.76 24.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-O 121.255 0.55 . . . . 0.0 110.685 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.3 pttm -136.52 167.04 22.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.175 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 9.1 mp0 -60.51 105.27 0.42 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.49 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -31.55 2.26 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 50.4 m-20 -93.82 149.49 21.19 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.064 0.459 . . . . 0.0 110.497 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.57 HG23 ' HB2' ' A' ' 101' ' ' LYS . 0.4 OUTLIER -102.18 143.44 31.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.286 179.941 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.877 HG11 HG11 ' A' ' 70' ' ' VAL . 22.9 m -122.03 162.1 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.551 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -122.98 158.07 31.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.265 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.612 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.47 101.83 0.2 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.518 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.29 -36.09 2.31 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -65.45 137.97 57.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.054 0.454 . . . . 0.0 110.563 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.507 ' HB ' HD22 ' A' ' 69' ' ' LEU . 11.1 m -64.13 139.38 58.76 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.172 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.44 HG22 ' O ' ' A' ' 94' ' ' ILE . 33.1 m -113.96 -30.53 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.19 -179.58 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.698 HD11 HG13 ' A' ' 65' ' ' VAL . 8.9 tt -164.66 151.64 11.17 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.088 0.47 . . . . 0.0 110.782 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.452 HG23 ' CD1' ' A' ' 69' ' ' LEU . 21.9 t -104.21 136.84 35.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.077 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.736 HD12 HD11 ' A' ' 94' ' ' ILE . 16.0 mt -118.07 159.79 22.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.651 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -132.87 111.11 10.8 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.376 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -145.56 143.95 30.22 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.465 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 42.7 mmm 60.5 33.17 20.59 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.473 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.85 33.8 19.86 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.511 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 2.7 ttt -143.96 136.19 26.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.444 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -82.16 126.17 31.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.517 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 24.7 m -116.08 124.41 50.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.341 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -82.17 132.26 35.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.479 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.736 HD11 HD12 ' A' ' 85' ' ' LEU . 36.2 mm -102.15 121.49 53.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.248 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -109.73 143.65 39.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.352 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.57 143.5 93.49 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.407 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -72.67 -35.54 5.85 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.118 1.879 . . . . 0.0 112.223 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.612 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 19.6 p -148.7 166.1 29.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.365 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -66.65 141.59 57.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.471 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.531 ' O ' HG22 ' A' ' 75' ' ' THR . . . 174.04 -162.35 32.91 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . 0.57 ' HB2' HG23 ' A' ' 75' ' ' THR . 6.8 ttpm? -133.07 147.53 52.18 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.034 0.445 . . . . 0.0 110.465 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.575 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.8 t -77.75 111.08 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.166 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -94.86 -30.07 14.38 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.638 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.7 tttp -159.02 131.01 6.54 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.345 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.434 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.3 t -96.66 110.68 25.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.312 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 29.8 mt -90.27 30.24 1.14 Allowed 'General case' 0 CA--C 1.534 0.333 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.633 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.434 ' H ' HG12 ' A' ' 105' ' ' VAL . 23.2 m -155.59 139.24 8.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-O 121.02 0.438 . . . . 0.0 110.259 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.67 165.13 18.45 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.134 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 52.2 mt-10 -60.91 147.19 43.96 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.555 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 60.99 35.76 18.89 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.505 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.42 ' O ' HG23 ' A' ' 65' ' ' VAL . 6.9 t0 -121.36 137.72 54.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.412 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -89.24 134.75 33.91 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.432 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.0 m -122.39 155.91 27.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.417 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -100.23 145.88 27.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.453 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.17 112.36 4.65 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 109.85 -27.8 11.51 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 11.4 tt0 -57.45 145.33 33.36 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 121.07 0.462 . . . . 0.0 110.779 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.68 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.01 122.02 28.37 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 97.8 mt -90.42 -56.77 3.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.114 0.483 . . . . 0.0 110.523 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.482 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.5 mt -140.94 145.74 24.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.301 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 7.2 ttmt -92.46 124.44 36.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.365 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.405 HD11 HD11 ' A' ' 57' ' ' ILE . 37.6 mm -103.46 145.1 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.448 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.218 -0.848 0 CA-C-O 118.076 -1.402 . . . . 0.0 110.701 179.952 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 118.95 -43.87 1.51 Allowed Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.91 110.17 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.114 0.483 . . . . 0.0 110.553 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 178.61 -153.41 12.66 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 21.5 mmtt -135.24 39.57 2.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.258 0.552 . . . . 0.0 110.421 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.831 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -153.03 162.67 41.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.321 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 156.52 -55.74 0.39 Allowed Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.814 -0.915 . . . . 0.0 110.814 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -102.34 86.48 2.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.089 0.471 . . . . 0.0 110.492 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.04 -49.65 0.92 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.543 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 0.9 OUTLIER -82.92 130.27 35.12 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.02 0.438 . . . . 0.0 110.382 -179.879 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 55.3 mt -80.25 111.22 20.53 Favored Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.053 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.656 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.6 Cg_endo -70.68 141.86 42.51 Favored 'Trans proline' 0 N--CA 1.472 0.262 0 C-N-CA 122.032 1.821 . . . . 0.0 112.292 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.674 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -75.85 144.89 77.06 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.475 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.684 ' HG2' HD23 ' A' ' 61' ' ' LEU . 50.5 Cg_endo -73.71 -24.74 15.43 Favored 'Trans proline' 0 N--CA 1.472 0.217 0 C-N-CA 122.188 1.925 . . . . 0.0 112.59 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.684 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.9 OUTLIER -161.55 167.54 25.2 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.454 -179.913 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -91.7 95.49 9.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.369 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -122.83 -139.67 5.56 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.9 m -136.12 134.61 38.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.083 0.468 . . . . 0.0 110.406 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.606 HG13 HD11 ' A' ' 83' ' ' LEU . 26.4 t -71.34 125.61 30.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.279 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.9 t -95.7 -54.79 3.23 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.578 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -152.43 149.52 28.67 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.523 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.415 HG12 HD12 ' A' ' 83' ' ' LEU . 48.9 mt -102.27 133.39 46.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.221 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.9 mp -98.82 -31.5 11.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.618 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.687 HG11 ' CG1' ' A' ' 76' ' ' VAL . 33.2 m -114.79 144.91 21.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.681 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.85 165.54 25.39 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.26 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -59.33 101.52 0.1 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.598 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.09 -31.81 2.24 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -90.11 150.03 22.23 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.089 0.471 . . . . 0.0 110.486 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.503 HG22 ' O ' ' A' ' 100' ' ' GLY . 1.0 OUTLIER -96.23 149.43 21.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.332 179.925 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.687 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.3 m -122.73 168.33 15.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.464 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 21.4 ttpt -128.34 148.49 50.68 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.346 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.637 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.05 100.83 0.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.612 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.11 -31.31 4.75 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.1 tt0 -64.08 143.73 57.65 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.057 0.456 . . . . 0.0 110.67 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 21.4 m -65.44 138.84 58.38 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.219 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.431 ' HA ' HG13 ' A' ' 70' ' ' VAL . 28.4 m -118.49 -32.2 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.384 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.606 HD11 HG13 ' A' ' 65' ' ' VAL . 7.5 tt -161.04 152.28 18.91 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.311 0.577 . . . . 0.0 111.296 -179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.539 HG13 ' O ' ' A' ' 92' ' ' THR . 19.7 t -103.45 147.32 9.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.557 179.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.849 HD12 HD11 ' A' ' 94' ' ' ILE . 7.4 mt -127.48 170.44 12.57 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.156 0.503 . . . . 0.0 110.785 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -139.28 110.92 7.12 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.478 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -145.88 142.68 29.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.486 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 24.9 mmt 60.52 32.36 20.46 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.572 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 52.4 mttt 60.61 32.69 20.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.476 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -141.28 127.75 20.02 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.412 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -68.58 129.23 39.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.565 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.539 ' O ' HG13 ' A' ' 84' ' ' VAL . 0.5 OUTLIER -112.13 176.19 5.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.656 179.594 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.535 ' H ' HG22 ' A' ' 92' ' ' THR . 50.6 mt-10 -146.02 134.87 22.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.28 0.562 . . . . 0.0 110.648 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.849 HD11 HD12 ' A' ' 85' ' ' LEU . 37.3 mm -102.57 153.7 5.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.146 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -136.91 141.45 42.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.353 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.93 135.52 94.65 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.309 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -73.85 -31.64 8.09 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.073 1.849 . . . . 0.0 112.268 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.637 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 25.1 p -146.13 157.57 43.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.411 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -65.86 141.81 58.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.279 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.503 ' O ' HG22 ' A' ' 75' ' ' THR . . . 174.66 -158.52 26.69 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 26.5 ttpt -133.74 148.54 51.42 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.144 0.497 . . . . 0.0 110.413 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.646 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.7 t -75.47 105.83 4.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.27 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -92.49 -26.67 17.85 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.859 -179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . 0.695 ' HD2' HD21 ' A' ' 106' ' ' LEU . 27.9 ttmt -158.93 129.08 5.81 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.098 0.475 . . . . 0.0 110.635 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 24.9 t -102.29 106.13 19.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.194 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.695 HD21 ' HD2' ' A' ' 104' ' ' LYS . 18.1 mt -89.5 13.33 14.11 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.632 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.441 HG21 HD13 ' A' ' 83' ' ' LEU . 30.7 m -130.12 143.77 40.02 Favored 'Isoleucine or valine' 0 C--O 1.231 0.11 0 CA-C-O 121.079 0.466 . . . . 0.0 110.312 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 13.6 mtmm -126.08 168.01 14.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.387 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -72.29 143.25 48.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.338 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 16.3 mtm180 61.42 38.5 15.98 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.514 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -126.45 148.04 49.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.336 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.83 140.0 30.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.56 -179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.9 m -122.8 156.02 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.274 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 39.0 mm-40 -101.94 142.39 33.31 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.337 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.38 111.38 3.38 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 108.72 -25.02 20.52 Favored Glycine 0 CA--C 1.528 0.872 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -59.9 140.97 56.3 Favored 'General case' 0 N--CA 1.462 0.15 0 CA-C-O 121.017 0.437 . . . . 0.0 110.791 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.831 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -60.48 118.37 14.6 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.674 HD21 ' HB2' ' A' ' 59' ' ' ALA . 33.2 mt -88.58 -54.02 4.37 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.124 0.487 . . . . 0.0 110.497 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 52.2 mt -142.4 142.74 26.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.325 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.0 122.49 38.88 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.097 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.0 mm -100.66 142.46 15.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.479 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.667 0 CA-C-O 117.972 -1.46 . . . . 0.0 110.758 179.931 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -144.79 170.46 26.32 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.801 -0.919 . . . . 0.0 110.801 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -133.65 113.15 12.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.1 0.476 . . . . 0.0 110.468 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 111.89 39.27 1.31 Allowed Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 46.3 mtmt -126.02 154.52 42.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.107 0.479 . . . . 0.0 110.464 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.666 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -84.54 169.89 13.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.417 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 141.01 47.25 0.05 OUTLIER Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -167.52 33.82 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.099 0.476 . . . . 0.0 110.391 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 117.11 -32.42 5.45 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -77.28 140.48 40.06 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.079 0.466 . . . . 0.0 110.542 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.505 HD11 HD11 ' A' ' 122' ' ' ILE . 48.5 mt -79.49 120.28 79.79 Favored Pre-proline 0 CA--C 1.534 0.348 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.081 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -72.19 146.06 45.27 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 121.996 1.797 . . . . 0.0 112.352 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.62 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -74.55 148.47 85.58 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.41 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.85 -28.5 13.43 Favored 'Trans proline' 0 N--CA 1.472 0.207 0 C-N-CA 122.207 1.938 . . . . 0.0 112.345 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.7 pp -166.27 165.3 17.49 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.494 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.69 84.21 3.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.396 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.521 ' CA ' ' HB2' ' A' ' 87' ' ' ALA . . . -120.92 -166.57 13.06 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.8 m -112.28 135.78 52.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.132 0.492 . . . . 0.0 110.357 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.563 HG13 HD11 ' A' ' 83' ' ' LEU . 25.1 t -70.79 126.11 30.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.247 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 4.5 p -97.82 -61.63 1.36 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.604 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 9.1 mmmt -141.47 150.23 41.97 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.607 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.502 HG22 ' H ' ' A' ' 70' ' ' VAL . 33.6 mt -110.22 120.55 61.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.842 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 12.4 mt -96.82 27.66 3.85 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.344 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.829 ' HB ' HG21 ' A' ' 102' ' ' VAL . 31.5 m -155.5 151.18 10.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 121.195 0.521 . . . . 0.0 110.483 179.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.9 pttt -141.6 160.33 40.39 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.054 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -60.34 95.05 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.431 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.18 -26.63 2.57 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -80.64 149.05 29.98 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.161 0.505 . . . . 0.0 110.457 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.6 m -97.32 137.71 35.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.228 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.467 HG11 HG11 ' A' ' 70' ' ' VAL . 34.6 m -119.78 145.03 26.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.556 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 mtmt -108.74 147.53 31.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.235 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.673 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -58.5 102.04 0.1 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.812 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.01 -32.72 3.38 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 12.7 tt0 -65.15 143.9 57.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.055 0.455 . . . . 0.0 110.501 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 13.9 m -66.95 138.45 57.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.221 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 32.3 m -119.37 -31.29 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.531 -179.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.563 HD11 HG13 ' A' ' 65' ' ' VAL . 9.9 tt -162.37 146.23 11.85 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 121.129 0.49 . . . . 0.0 111.032 -179.475 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.471 HG22 ' OE2' ' A' ' 93' ' ' GLU . 22.0 t -108.81 143.08 19.74 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.89 179.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.458 HD11 HG21 ' A' ' 113' ' ' VAL . 1.0 OUTLIER -124.38 163.59 21.42 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.186 0.517 . . . . 0.0 110.798 -179.6 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.2 mt-10 -137.22 111.39 8.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.371 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.521 ' HB2' ' CA ' ' A' ' 63' ' ' GLY . . . -147.38 146.87 29.78 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.5 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 7.8 mmt 60.34 34.04 20.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.822 -0.627 . . . . 0.0 110.584 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 27.1 mtpt 60.92 33.4 19.86 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.495 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 12.9 mtm -141.75 155.81 45.61 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.399 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -98.15 128.68 44.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.52 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.9 m -113.15 116.55 30.02 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.22 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.471 ' OE2' HG22 ' A' ' 84' ' ' VAL . 10.2 mm-40 -91.78 125.91 36.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.526 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.494 ' N ' HD12 ' A' ' 94' ' ' ILE . 5.3 mp -108.72 148.46 12.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.954 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -135.89 156.12 49.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.165 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.56 135.58 95.61 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.337 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.37 -32.47 8.05 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.044 1.829 . . . . 0.0 112.224 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.673 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 1.1 p -145.61 159.33 43.3 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.315 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -63.64 140.03 58.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.339 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.17 -161.69 32.78 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.3 ttmp? -135.62 146.75 48.22 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.062 0.458 . . . . 0.0 110.444 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.829 HG21 ' HB ' ' A' ' 70' ' ' VAL . 30.3 t -75.99 114.07 15.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.147 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -94.94 -30.02 14.36 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.778 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 77.6 tttt -159.98 128.91 5.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.546 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.559 HG13 HG12 ' A' ' 120' ' ' ILE . 22.1 t -107.62 108.71 25.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.271 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.0 mt -79.21 -31.62 43.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.447 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.44 ' O ' HG12 ' A' ' 105' ' ' VAL . 27.6 m -80.77 145.27 9.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.567 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -130.36 157.67 41.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.21 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 66.5 mt-10 -59.27 143.21 49.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.668 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 24.4 ttt180 61.76 32.84 18.15 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.305 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -116.24 151.06 36.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.427 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.83 135.51 34.06 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.442 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.458 HG21 HD11 ' A' ' 85' ' ' LEU . 30.8 m -120.53 179.67 2.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.43 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -135.42 145.29 47.11 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.366 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.45 109.43 2.48 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.0 -29.32 8.13 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.3 tt0 -60.11 140.82 56.65 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 121.146 0.498 . . . . 0.0 110.609 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.666 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.38 122.04 28.06 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.62 HD11 ' HA ' ' A' ' 59' ' ' ALA . 87.7 mt -89.22 -61.63 1.66 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.132 0.491 . . . . 0.0 110.503 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.559 HG12 HG13 ' A' ' 105' ' ' VAL . 55.4 mt -140.96 151.83 20.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.362 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 33.0 tttm -98.63 134.63 41.3 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.386 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.505 HD11 HD11 ' A' ' 57' ' ' ILE . 35.4 mm -108.06 146.87 13.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.424 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.779 0 CA-C-O 118.049 -1.417 . . . . 0.0 110.786 179.958 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -149.21 -152.88 5.85 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.62 161.99 0.06 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.12 0.486 . . . . 0.0 110.518 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 88.4 -78.63 1.73 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 16.5 ttmt -142.22 142.26 32.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.108 0.48 . . . . 0.0 110.353 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.491 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -64.75 175.47 1.45 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.382 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -175.59 -43.9 0.06 OUTLIER Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -63.72 -149.85 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.472 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -87.98 18.12 42.07 Favored Glycine 0 CA--C 1.534 1.272 0 C-N-CA 120.576 -0.821 . . . . 0.0 111.907 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -81.84 152.41 26.9 Favored 'General case' 0 C--O 1.231 0.081 0 CA-C-O 121.015 0.435 . . . . 0.0 110.272 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 54.8 mt -80.1 111.41 21.8 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.17 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -71.1 153.41 62.68 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.011 1.807 . . . . 0.0 112.218 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.695 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -78.97 143.05 60.92 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.468 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -74.13 -27.91 11.33 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.121 1.881 . . . . 0.0 112.309 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -163.9 162.91 23.75 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.364 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.56 92.07 5.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.39 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.545 ' HA3' ' HB2' ' A' ' 87' ' ' ALA . . . -126.16 -141.85 5.59 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 19.8 m -138.04 138.3 38.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.003 0.43 . . . . 0.0 110.459 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.523 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -70.66 125.31 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.208 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.1 t -98.24 -46.42 5.83 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.564 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 36.0 mtmt -149.16 169.84 19.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.606 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 51.7 mt -129.8 125.81 61.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.946 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.478 HD12 HG22 ' A' ' 81' ' ' THR . 20.4 mt -97.24 -28.11 14.22 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.12 -179.383 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.872 ' HB ' HG21 ' A' ' 102' ' ' VAL . 32.9 m -101.47 156.77 4.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.346 0.593 . . . . 0.0 111.218 -179.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 22.5 mttp -135.96 151.9 50.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.843 179.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.561 ' HG3' HG23 ' A' ' 105' ' ' VAL . 16.6 mt-10 -60.78 90.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.52 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.09 -25.86 2.63 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 63.8 m-20 -78.72 148.66 32.96 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.143 0.497 . . . . 0.0 110.5 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 5.3 m -97.02 140.04 32.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.184 179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.57 HG11 HG11 ' A' ' 70' ' ' VAL . 30.0 m -121.91 171.26 10.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.66 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -127.42 138.66 53.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.191 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.696 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -56.11 100.25 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.029 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 138.86 -38.84 1.63 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 45.3 tt0 -69.35 144.82 53.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.065 0.459 . . . . 0.0 110.599 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.478 HG22 HD12 ' A' ' 69' ' ' LEU . 17.6 m -65.02 139.11 58.71 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.317 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.587 HG22 ' O ' ' A' ' 94' ' ' ILE . 35.1 m -115.05 -25.88 3.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.397 -179.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.523 HD11 HG13 ' A' ' 65' ' ' VAL . 7.7 tt -166.58 146.52 5.86 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 121.052 0.453 . . . . 0.0 110.702 -179.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -105.1 141.26 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.18 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.133 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 85' ' ' LEU . 12.1 mt -120.11 158.28 27.22 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.553 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 -137.53 114.89 11.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.397 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.545 ' HB2' ' HA3' ' A' ' 63' ' ' GLY . . . -149.76 136.76 19.58 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 69.0 mtp 60.68 32.22 20.26 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.537 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 11.5 mtmm 60.53 32.68 20.51 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.568 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.1 ttt -135.71 104.74 5.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.381 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -62.04 128.52 36.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.41 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.8 m -129.0 113.0 14.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.131 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -87.22 142.98 27.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.717 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.649 ' N ' HD12 ' A' ' 94' ' ' ILE . 4.6 mp -115.21 127.08 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.907 179.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 42.4 m-20 -102.5 153.31 20.19 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.207 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.85 136.22 94.84 Favored Pre-proline 0 CA--C 1.533 0.312 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.345 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -72.62 -35.25 6.23 Favored 'Trans proline' 0 N--CA 1.471 0.2 0 C-N-CA 122.09 1.86 . . . . 0.0 112.172 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.696 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 2.5 p -147.36 155.32 41.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.296 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -64.49 140.43 58.87 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.384 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.21 -157.94 26.14 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 15.7 ttmm -132.31 143.7 50.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.065 0.459 . . . . 0.0 110.468 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.872 HG21 ' HB ' ' A' ' 70' ' ' VAL . 36.0 t -78.78 110.08 14.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.171 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.09 -29.65 16.43 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.84 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 8.0 ttpt -157.86 131.03 7.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.448 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.561 HG23 ' HG3' ' A' ' 72' ' ' GLU . 21.8 t -101.06 115.46 42.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.243 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.408 ' O ' HG13 ' A' ' 107' ' ' VAL . 19.9 mt -89.95 28.52 1.36 Allowed 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.698 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.503 ' H ' HG12 ' A' ' 105' ' ' VAL . 19.2 m -155.69 142.5 11.3 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.139 0 CA-C-O 121.038 0.447 . . . . 0.0 110.378 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.5 tttt -125.89 165.03 19.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.188 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -59.61 143.05 51.51 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.615 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 30.2 mtm180 60.14 34.01 21.15 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.558 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -114.21 149.16 36.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.338 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.92 134.98 34.29 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.526 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.6 m -122.38 149.91 25.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.331 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 55.9 mt-30 -99.68 144.1 29.15 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.416 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.42 110.07 2.71 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.739 -0.945 . . . . 0.0 110.739 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 110.24 -27.29 11.85 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -59.64 139.77 56.94 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.056 0.455 . . . . 0.0 110.668 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.491 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.12 123.08 31.53 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.695 HD11 ' HA ' ' A' ' 59' ' ' ALA . 65.8 mt -87.57 -54.01 4.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.032 0.444 . . . . 0.0 110.405 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.626 ' CG2' HG13 ' A' ' 102' ' ' VAL . 50.2 mt -141.5 149.64 20.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.426 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 13.0 tttm -99.25 130.51 45.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.299 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.2 mm -107.63 144.71 15.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.506 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.797 0 CA-C-O 117.964 -1.464 . . . . 0.0 110.806 179.969 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -99.87 117.01 5.74 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -162.21 89.25 0.69 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.096 0.474 . . . . 0.0 110.41 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 134.98 139.06 4.0 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 46.6 mttp -120.43 40.73 3.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.326 0.584 . . . . 0.0 110.394 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.708 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -151.44 179.51 8.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.433 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.71 -49.03 0.93 Allowed Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.716 -0.953 . . . . 0.0 110.716 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -92.46 75.55 5.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.273 0.559 . . . . 0.0 110.408 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 99.78 -41.51 2.17 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.605 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 32.9 mt-10 -83.92 130.04 34.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.1 0.476 . . . . 0.0 110.477 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.51 HD11 HD11 ' A' ' 122' ' ' ILE . 45.0 mt -78.82 111.76 22.04 Favored Pre-proline 0 CA--C 1.534 0.363 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.212 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.541 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.3 Cg_endo -70.94 137.82 32.82 Favored 'Trans proline' 0 N--CA 1.473 0.267 0 C-N-CA 122.084 1.856 . . . . 0.0 112.374 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.721 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -68.72 149.13 98.02 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.465 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.52 -27.55 15.53 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.253 1.969 . . . . 0.0 112.414 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 pp -164.79 165.22 20.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.443 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.34 96.49 5.32 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.363 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -128.4 -141.11 5.14 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.776 -0.929 . . . . 0.0 110.776 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.1 m -136.71 141.51 43.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.002 0.43 . . . . 0.0 110.46 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.76 HG13 HD11 ' A' ' 83' ' ' LEU . 23.1 t -71.21 128.64 34.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.218 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 t -98.67 -62.0 1.3 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.518 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 9.8 mtpt -150.16 144.81 25.92 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.457 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.653 HG12 HD12 ' A' ' 83' ' ' LEU . 42.2 mt -99.24 128.85 50.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.039 179.691 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.9 mp -97.67 -36.03 10.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.829 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.688 HG11 HG12 ' A' ' 76' ' ' VAL . 33.7 m -115.17 139.26 42.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.263 0.554 . . . . 0.0 110.78 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 20.9 pttt -135.91 162.75 31.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.793 179.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -54.61 108.64 0.41 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.279 0.561 . . . . 0.0 110.783 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.42 -29.98 2.35 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -102.53 155.12 18.49 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.974 0.416 . . . . 0.0 110.396 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.4 m -96.91 150.43 20.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.43 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.688 HG12 HG11 ' A' ' 70' ' ' VAL . 30.3 m -123.97 168.28 16.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.498 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 28.4 mmtm -129.69 155.28 46.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.448 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.511 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -62.2 105.76 0.64 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.453 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.25 -29.37 7.07 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 19.1 tt0 -61.32 142.7 56.7 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.104 0.478 . . . . 0.0 110.564 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 20.9 m -67.1 138.14 56.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.271 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.4 m -118.17 -34.26 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.208 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.76 HD11 HG13 ' A' ' 65' ' ' VAL . 6.5 tt -162.11 152.02 16.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.134 0.492 . . . . 0.0 111.078 -179.315 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.682 HG22 ' OE1' ' A' ' 93' ' ' GLU . 22.8 t -102.89 143.15 15.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.654 179.245 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.7 HD11 HG21 ' A' ' 113' ' ' VAL . 0.3 OUTLIER -119.49 167.69 11.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.229 0.538 . . . . 0.0 110.782 -179.559 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -138.33 109.21 6.7 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.365 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.57 133.72 17.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.333 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 66.9 mtm 61.06 50.71 4.84 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.26 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.2 ptpp? 41.41 32.22 0.21 Allowed 'General case' 0 N--CA 1.474 0.739 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.984 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 19.5 ttm -139.52 112.3 7.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.424 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 -61.8 130.75 47.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.403 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 14.0 m -118.47 123.09 44.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.33 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.682 ' OE1' HG22 ' A' ' 84' ' ' VAL . 6.4 mm-40 -84.51 132.26 34.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.59 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 30.8 mm -105.45 148.72 9.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.049 179.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -139.29 150.83 45.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.612 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.63 143.73 96.35 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.399 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -72.62 -34.42 7.21 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.186 1.924 . . . . 0.0 112.26 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.511 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 14.3 p -146.95 168.45 21.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.312 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -68.82 142.26 54.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.463 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.1 -161.25 32.27 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.2 ttpt -133.62 138.91 46.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.062 0.458 . . . . 0.0 110.464 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.647 HG13 ' CG2' ' A' ' 120' ' ' ILE . 22.3 t -74.22 123.73 30.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.238 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -99.03 -33.17 10.92 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.588 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . 0.534 ' NZ ' HD23 ' A' ' 106' ' ' LEU . 0.2 OUTLIER -160.88 147.82 15.29 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.412 -179.948 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.506 HG12 ' H ' ' A' ' 107' ' ' VAL . 11.9 t -101.29 119.0 48.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.008 179.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.534 HD23 ' NZ ' ' A' ' 104' ' ' LYS . 6.9 mt -89.53 21.56 3.36 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.919 -179.638 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.506 ' H ' HG12 ' A' ' 105' ' ' VAL . 30.6 m -154.56 156.3 5.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-O 121.093 0.473 . . . . 0.0 110.673 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.5 mtmp? -130.85 159.03 38.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.25 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 64.4 mt-10 -60.51 151.26 28.99 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.513 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? 60.99 32.33 19.92 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.521 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -122.91 150.9 42.31 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.452 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.01 137.56 32.27 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.348 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.7 HG21 HD11 ' A' ' 85' ' ' LEU . 30.5 m -121.12 148.71 24.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.432 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -98.1 140.66 32.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.259 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.54 96.28 0.09 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 127.51 -27.87 4.61 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -59.31 142.71 51.39 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.086 0.47 . . . . 0.0 110.704 -179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.708 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.22 120.93 24.71 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.896 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.721 HD11 ' HA ' ' A' ' 59' ' ' ALA . 14.1 mt -89.78 -50.2 6.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.079 0.466 . . . . 0.0 110.418 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.647 ' CG2' HG13 ' A' ' 102' ' ' VAL . 45.9 mt -145.27 147.82 18.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.297 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.5 mttp -95.43 130.34 42.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.158 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.51 HD11 HD11 ' A' ' 57' ' ' ILE . 37.5 mm -110.39 144.67 18.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.357 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.711 0 CA-C-O 117.974 -1.459 . . . . 0.0 110.76 -179.997 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 143.97 -33.04 1.76 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -176.75 116.86 0.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.047 0.451 . . . . 0.0 110.435 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 68.27 -163.11 48.91 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 2.4 mtpm? -160.88 40.74 0.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.301 0.572 . . . . 0.0 110.494 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.727 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -145.42 99.12 3.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.344 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -104.6 -75.19 1.01 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.836 -0.905 . . . . 0.0 110.836 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -123.82 100.46 6.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.101 0.477 . . . . 0.0 110.443 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 130.17 -57.93 0.71 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.687 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 24.8 mt-10 -83.97 137.06 33.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.107 0.48 . . . . 0.0 110.459 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.636 HD11 HD11 ' A' ' 122' ' ' ILE . 35.5 mt -81.81 112.22 32.93 Favored Pre-proline 0 CA--C 1.535 0.366 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.167 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.705 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 46.9 Cg_endo -70.73 128.56 15.3 Favored 'Trans proline' 0 N--CA 1.472 0.233 0 C-N-CA 122.017 1.811 . . . . 0.0 112.363 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.574 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -61.95 148.64 87.75 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.49 -179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.99 -26.82 18.08 Favored 'Trans proline' 0 N--CA 1.471 0.15 0 C-N-CA 122.283 1.989 . . . . 0.0 112.509 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -163.75 168.54 19.58 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.423 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.75 102.83 13.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.499 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -133.98 -140.73 4.37 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 16.0 m -137.15 142.1 42.23 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.104 0.478 . . . . 0.0 110.369 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 111' ' ' ASP . 23.1 t -71.96 131.99 33.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.122 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -101.37 -54.17 2.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.502 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 33.5 tttt -155.74 147.0 22.59 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.594 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.483 HD11 ' HA ' ' A' ' 108' ' ' LYS . 8.8 mt -100.43 130.78 49.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.972 179.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 67.1 mt -101.56 -41.88 6.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.691 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.795 ' HB ' HG21 ' A' ' 102' ' ' VAL . 29.5 m -93.54 149.88 4.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.761 -179.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -135.11 162.22 33.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.255 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.46 ' OE1' HG23 ' A' ' 105' ' ' VAL . 2.6 mp0 -60.94 96.6 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.543 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.0 -31.22 2.3 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -79.78 147.07 31.99 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.127 0.489 . . . . 0.0 110.449 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 6.7 m -95.9 141.12 29.7 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.382 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.707 HG11 HG11 ' A' ' 70' ' ' VAL . 29.9 m -120.06 160.93 20.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.555 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 tttt -120.08 146.97 45.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.311 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.65 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.84 93.46 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.69 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.42 -32.43 2.55 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -67.84 141.12 56.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.976 0.417 . . . . 0.0 110.52 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.0 m -63.34 137.22 58.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.189 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.528 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.6 m -114.01 -35.1 2.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.781 -179.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.567 HD13 HG21 ' A' ' 107' ' ' VAL . 7.0 tt -159.18 151.49 21.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.449 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.2 t -102.9 143.44 15.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.042 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -124.06 164.75 18.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.582 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -137.38 115.42 11.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.338 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.65 136.95 23.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.391 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 15.7 mtt 60.83 32.93 20.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.514 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.9 mptt 60.95 35.14 19.21 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.477 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.7 mtt -139.43 126.77 21.43 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.461 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -71.05 128.68 36.75 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.43 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.5 m -119.41 120.42 36.8 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.425 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -85.09 129.98 34.7 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.514 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 33.6 mm -103.13 124.55 57.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.327 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -110.29 147.76 33.23 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.376 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.78 138.42 96.96 Favored Pre-proline 0 CA--C 1.532 0.282 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.346 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -73.65 -32.87 7.18 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.087 1.858 . . . . 0.0 112.162 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.65 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 5.7 p -149.63 155.03 39.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.345 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -61.85 141.96 57.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.443 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 170.07 -157.37 28.75 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.1 ttmp? -134.82 148.07 50.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.129 0.49 . . . . 0.0 110.523 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.795 HG21 ' HB ' ' A' ' 70' ' ' VAL . 26.2 t -77.06 113.54 16.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.326 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -93.26 -30.83 14.97 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.699 -179.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 13.1 ttpt -159.45 133.57 7.56 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.569 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.46 HG23 ' OE1' ' A' ' 72' ' ' GLU . 21.6 t -101.92 108.11 23.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.144 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.9 mt -89.58 13.13 14.77 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.578 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.567 HG21 HD13 ' A' ' 83' ' ' LEU . 26.3 m -130.72 136.59 57.92 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-O 121.123 0.487 . . . . 0.0 110.186 179.752 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.483 ' HA ' HD11 ' A' ' 68' ' ' ILE . 0.2 OUTLIER -125.49 172.16 9.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.226 -179.782 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -72.05 150.63 43.78 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.311 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 37.3 mtt-85 61.45 30.89 19.07 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.664 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.515 ' O ' HG23 ' A' ' 65' ' ' VAL . 5.8 m-20 -125.88 139.33 53.56 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.285 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.17 141.57 28.44 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.449 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.2 m -121.09 156.95 24.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.391 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 77.0 mt-30 -99.22 144.6 28.15 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.373 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.12 106.08 1.03 Allowed Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 117.56 -28.51 7.08 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.0 tt0 -59.21 137.7 57.87 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.126 0.489 . . . . 0.0 110.713 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.727 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.15 123.25 31.96 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.574 HD11 ' HA ' ' A' ' 59' ' ' ALA . 17.1 mt -86.5 -55.85 3.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.191 0.52 . . . . 0.0 110.534 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.655 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.8 mt -140.88 152.31 20.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.336 -179.779 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -96.92 132.52 42.62 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.476 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.636 HD11 HD11 ' A' ' 57' ' ' ILE . 36.9 mm -109.52 145.18 16.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.303 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.791 0 CA-C-O 118.095 -1.392 . . . . 0.0 110.757 -179.953 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 176.54 90.79 0.08 OUTLIER Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -97.77 145.37 26.43 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.127 0.489 . . . . 0.0 110.433 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -95.18 -55.17 1.4 Allowed Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 11.3 ptmt -152.46 145.06 24.19 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.08 0.466 . . . . 0.0 110.424 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.571 ' HB1' ' HB2' ' A' ' 56' ' ' GLU . . . -70.74 178.18 3.2 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.483 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -179.05 95.89 0.1 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 59.2 101.6 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.132 0.491 . . . . 0.0 110.731 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 118.2 -61.17 0.46 Allowed Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.571 ' HB2' ' HB1' ' A' ' 52' ' ' ALA . 16.5 mt-10 -83.51 136.76 34.16 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.066 0.46 . . . . 0.0 110.354 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.564 HD11 HD11 ' A' ' 122' ' ' ILE . 45.4 mt -79.74 111.63 22.9 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.263 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -72.48 129.8 15.25 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 121.982 1.788 . . . . 0.0 112.217 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.441 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -62.09 139.43 96.0 Favored Pre-proline 0 CA--C 1.532 0.274 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.274 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.409 ' HG2' HD12 ' A' ' 61' ' ' LEU . 48.0 Cg_endo -75.43 -12.0 20.7 Favored 'Trans proline' 0 CA--C 1.533 0.445 0 C-N-CA 122.091 1.861 . . . . 0.0 113.038 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.699 HD22 ' N ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -160.73 179.55 8.44 Favored 'General case' 0 N--CA 1.462 0.163 0 CA-C-O 121.099 0.476 . . . . 0.0 110.48 179.901 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.699 ' N ' HD22 ' A' ' 61' ' ' LEU . . . -109.76 113.34 26.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.401 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -149.5 -138.87 3.0 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.512 ' C ' HD23 ' A' ' 85' ' ' LEU . 12.3 m -135.82 139.36 43.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.103 0.478 . . . . 0.0 110.411 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.554 HG13 HD11 ' A' ' 83' ' ' LEU . 28.1 t -70.48 126.5 30.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.18 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t -97.04 -55.06 2.98 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.574 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 ttpt -153.08 149.09 27.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.521 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.531 HD11 ' HA ' ' A' ' 108' ' ' LYS . 41.7 mt -103.01 135.66 39.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.059 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.477 HD22 ' HB ' ' A' ' 81' ' ' THR . 9.7 mp -99.72 -45.08 5.88 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.818 -179.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.734 ' HB ' HG21 ' A' ' 102' ' ' VAL . 34.8 m -97.2 148.16 5.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.218 0.532 . . . . 0.0 110.876 -179.688 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 pttt -137.24 163.66 30.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.195 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.425 ' HG3' HG23 ' A' ' 105' ' ' VAL . 14.2 mt-10 -59.64 102.59 0.15 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.584 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.51 2.26 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -91.91 151.45 20.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.119 0.485 . . . . 0.0 110.492 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.562 HG22 ' O ' ' A' ' 100' ' ' GLY . 0.7 OUTLIER -96.58 153.67 17.72 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.312 179.916 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.712 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.9 m -126.14 167.67 20.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.562 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 14.0 mttm -129.05 148.05 50.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.37 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.594 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.16 93.14 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.715 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.88 -34.8 2.17 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 33.3 tt0 -64.0 143.95 57.46 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.086 0.469 . . . . 0.0 110.582 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.477 ' HB ' HD22 ' A' ' 69' ' ' LEU . 9.0 m -66.92 139.58 57.72 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.336 179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 35.6 m -114.11 -32.68 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.939 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.695 HD13 HG21 ' A' ' 107' ' ' VAL . 7.9 tt -161.49 148.38 14.52 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.106 0.479 . . . . 0.0 110.797 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -103.4 140.37 21.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.113 179.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.66 HD21 HG21 ' A' ' 113' ' ' VAL . 2.1 mt -119.83 172.09 7.95 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.56 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -135.09 106.71 6.91 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.444 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -149.92 152.26 34.72 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.465 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 16.4 mtt 60.02 30.5 19.98 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.648 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 52.5 mttt 59.81 31.54 20.84 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.684 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 14.8 ptp -148.72 153.41 38.17 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.352 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 33.4 mt-10 -80.79 128.24 33.43 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.569 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.5 m -112.41 117.54 32.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.283 179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -84.99 135.52 33.99 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.56 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.634 HD11 HD12 ' A' ' 85' ' ' LEU . 41.1 mm -106.7 122.33 60.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.255 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -104.95 142.81 34.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.362 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.13 144.11 91.53 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -72.57 -38.95 2.94 Favored 'Trans proline' 0 CA--C 1.528 0.216 0 C-N-CA 122.175 1.917 . . . . 0.0 112.168 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.594 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 2.8 p -148.39 165.14 31.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.309 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -66.6 141.43 57.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.393 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.562 ' O ' HG22 ' A' ' 75' ' ' THR . . . 172.82 -157.37 26.58 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 17.7 ttmt -136.11 146.69 47.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.104 0.478 . . . . 0.0 110.488 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.734 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.0 t -74.7 108.72 6.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.186 179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -91.52 -29.12 17.15 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.809 -179.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.4 ttmm -159.33 130.27 6.0 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.095 0.474 . . . . 0.0 110.53 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.425 HG23 ' HG3' ' A' ' 72' ' ' GLU . 32.3 t -102.19 105.72 18.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.184 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 11.4 mt -88.0 10.21 19.74 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.67 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.695 HG21 HD13 ' A' ' 83' ' ' LEU . 23.7 m -125.59 136.13 61.81 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.062 0 CA-C-O 121.11 0.481 . . . . 0.0 110.258 179.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.531 ' HA ' HD11 ' A' ' 68' ' ' ILE . 2.8 ttpm? -122.56 169.36 11.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.391 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 -66.65 142.5 57.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.356 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER 63.17 38.14 10.82 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.66 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -117.8 142.36 47.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.319 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.91 131.61 36.43 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.427 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.66 HG21 HD21 ' A' ' 85' ' ' LEU . 30.8 m -119.59 179.82 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.452 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -141.46 149.35 40.84 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.427 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.55 104.4 0.7 Allowed Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.64 -31.49 4.57 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.0 tt0 -61.64 135.9 57.81 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.091 0.472 . . . . 0.0 110.445 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.471 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -63.01 118.89 15.27 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.441 HD21 ' HB2' ' A' ' 59' ' ' ALA . 69.3 mt -88.38 -56.21 3.41 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.074 0.464 . . . . 0.0 110.392 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.528 ' CG2' HG13 ' A' ' 102' ' ' VAL . 50.9 mt -142.26 144.94 24.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.323 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.7 tttt -96.55 132.76 41.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.333 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.564 HD11 HD11 ' A' ' 57' ' ' ILE . 39.2 mm -107.25 144.88 15.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.416 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.738 0 CA-C-O 117.958 -1.468 . . . . 0.0 110.813 -179.992 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 99.95 -98.97 1.98 Allowed Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.69 95.68 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.105 0.479 . . . . 0.0 110.501 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -101.55 143.32 16.03 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 14.5 pttm -162.67 142.48 9.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.085 0.469 . . . . 0.0 110.453 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.557 ' HB2' ' N ' ' A' ' 118' ' ' GLY . . . -63.43 178.77 0.51 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.391 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.87 -88.72 0.07 OUTLIER Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.0 tm-20 -128.59 124.15 35.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.111 0.482 . . . . 0.0 110.458 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 107.93 -49.73 0.84 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -84.26 136.39 33.95 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.104 0.478 . . . . 0.0 110.438 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.41 HD11 ' CG1' ' A' ' 122' ' ' ILE . 52.6 mt -77.84 111.67 19.51 Favored Pre-proline 0 CA--C 1.534 0.364 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.175 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.513 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.9 Cg_endo -70.83 145.02 49.89 Favored 'Trans proline' 0 N--CA 1.472 0.248 0 C-N-CA 122.035 1.823 . . . . 0.0 112.394 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -82.11 147.52 57.73 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.468 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.661 ' HG2' HD23 ' A' ' 61' ' ' LEU . 48.7 Cg_endo -71.82 -23.26 22.59 Favored 'Trans proline' 0 N--CA 1.472 0.251 0 C-N-CA 122.278 1.986 . . . . 0.0 112.658 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.661 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.8 OUTLIER -161.68 173.38 14.77 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.089 0.471 . . . . 0.0 110.486 -179.991 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.55 91.81 5.23 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.411 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.721 ' HA3' HD23 ' A' ' 85' ' ' LEU . . . -103.42 175.15 23.44 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 1.4 m -105.81 7.17 32.23 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.639 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 24.7 t 63.15 117.75 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 CA-C-O 121.075 0.464 . . . . 0.0 110.322 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.5 t -95.89 -57.37 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.577 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 34.4 tttm -155.11 146.38 22.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.59 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.637 HG12 HD12 ' A' ' 83' ' ' LEU . 23.7 mt -105.09 120.82 56.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.867 179.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 16.8 mt -98.39 25.49 6.26 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.303 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.685 ' HB ' HG21 ' A' ' 102' ' ' VAL . 30.6 m -153.16 147.73 14.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 121.133 0.492 . . . . 0.0 110.644 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.3 pttt -135.05 161.3 35.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.151 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 51.5 mt-10 -60.07 99.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.519 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -30.45 2.35 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -77.36 151.89 34.68 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.11 0.481 . . . . 0.0 110.412 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 5.1 m -100.77 132.52 46.12 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.488 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.3 m -115.68 150.56 17.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.409 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 46.2 mttt -111.62 153.62 26.07 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.383 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.609 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.85 100.62 0.11 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.603 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.89 -31.45 4.11 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 5.6 tt0 -63.66 143.81 57.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.117 0.484 . . . . 0.0 110.524 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.2 m -66.27 136.34 55.7 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.334 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.605 ' O ' HG22 ' A' ' 70' ' ' VAL . 27.6 m -119.1 -35.38 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.213 -179.51 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.637 HD12 HG12 ' A' ' 68' ' ' ILE . 7.1 tt -159.64 149.74 18.74 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.838 -179.315 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.418 HG12 ' N ' ' A' ' 85' ' ' LEU . 21.9 t -107.94 154.99 8.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.898 179.471 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.721 HD23 ' HA3' ' A' ' 63' ' ' GLY . 3.5 mp -123.78 173.12 8.36 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.196 0.522 . . . . 0.0 110.636 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -137.52 106.72 6.04 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.308 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.93 135.71 22.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.49 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 26.8 mtt 60.15 29.29 18.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.704 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.9 mtpt 59.42 35.46 22.98 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.712 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 10.7 mmm -133.61 130.81 38.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.546 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.7 mt-10 -70.9 117.49 12.48 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.413 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.21 103.44 9.84 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.291 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -79.85 143.44 34.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.646 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.482 ' CG1' HD13 ' A' ' 85' ' ' LEU . 40.7 mm -105.93 156.31 6.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.052 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.435 ' N ' HG22 ' A' ' 94' ' ' ILE . 22.3 m-80 -134.24 143.07 47.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.47 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.11 142.0 98.17 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.318 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -73.5 -36.02 4.28 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.12 1.88 . . . . 0.0 112.288 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.609 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 1.7 p -145.76 161.47 39.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.433 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -65.27 142.51 58.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.322 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.8 -158.4 25.32 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.5 ttmt -135.5 145.88 47.55 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.05 0.453 . . . . 0.0 110.549 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.685 HG21 ' HB ' ' A' ' 70' ' ' VAL . 26.2 t -74.33 110.25 8.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.245 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -95.24 -29.54 14.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.723 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -160.51 135.39 7.67 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.517 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.417 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.1 t -101.37 109.27 25.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.21 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 29.4 mt -90.08 29.66 1.19 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.639 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.562 HG21 HD13 ' A' ' 83' ' ' LEU . 29.6 m -155.2 145.17 13.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-O 121.055 0.455 . . . . 0.0 110.361 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 8.4 mmtm -127.25 160.85 30.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.259 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -60.02 142.99 52.99 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.524 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 3.1 ttm180 61.35 34.35 18.45 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.492 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -114.18 140.15 48.77 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.388 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -88.63 126.11 35.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.531 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.7 m -122.11 157.79 26.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.395 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -96.57 143.69 27.33 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.414 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.32 92.64 0.07 OUTLIER Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 136.6 -27.81 2.92 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -60.94 141.35 57.33 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-O 121.031 0.444 . . . . 0.0 110.54 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.557 ' N ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.08 123.81 33.6 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.442 ' O ' HG22 ' A' ' 107' ' ' VAL . 92.3 mt -86.61 -51.83 5.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.055 0.455 . . . . 0.0 110.539 -179.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 54.5 mt -140.88 150.23 20.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.395 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -97.78 128.4 44.4 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.309 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.41 ' CG1' HD11 ' A' ' 57' ' ' ILE . 37.6 mm -107.17 143.61 17.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.478 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.749 0 CA-C-O 117.982 -1.455 . . . . 0.0 110.781 179.975 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -102.91 -138.48 9.98 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -98.31 114.33 26.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.101 0.477 . . . . 0.0 110.434 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 114.49 179.36 18.85 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.1 mtmt -141.93 41.96 1.68 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.338 0.59 . . . . 0.0 110.332 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.765 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -147.35 179.23 7.8 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.432 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 154.9 -85.59 0.14 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.791 -0.923 . . . . 0.0 110.791 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -83.79 96.19 8.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.035 0.445 . . . . 0.0 110.574 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.6 -54.92 0.65 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.659 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 23.8 mt-10 -82.28 124.85 30.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.08 0.467 . . . . 0.0 110.571 -179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.598 HD11 HD11 ' A' ' 122' ' ' ILE . 38.5 mt -80.72 111.2 21.21 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.131 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.597 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 46.2 Cg_endo -70.61 135.64 28.89 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 122.085 1.857 . . . . 0.0 112.387 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.591 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -73.02 153.39 90.85 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.398 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.62 -27.9 14.8 Favored 'Trans proline' 0 CA--C 1.528 0.2 0 C-N-CA 122.211 1.941 . . . . 0.0 112.404 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.561 HD11 ' CB ' ' A' ' 87' ' ' ALA . 3.9 pp -165.95 165.71 17.9 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.418 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.496 ' HB2' ' H ' ' A' ' 115' ' ' GLY . . . -79.76 104.73 10.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.286 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.22 -142.43 4.91 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.9 m -135.78 134.22 38.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.068 0.461 . . . . 0.0 110.468 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.602 ' CG1' HD11 ' A' ' 83' ' ' LEU . 24.9 t -72.14 127.94 34.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.126 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.31 -53.54 3.32 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.68 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 16.8 tttp -152.03 147.19 26.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.598 -179.749 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.571 HG12 HD12 ' A' ' 83' ' ' LEU . 47.9 mt -100.82 133.14 44.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.992 179.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.3 mp -99.6 -29.85 12.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.929 -179.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.777 ' HB ' HG21 ' A' ' 102' ' ' VAL . 34.9 m -110.7 148.66 13.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 121.241 0.543 . . . . 0.0 110.878 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.8 ptpp? -135.13 163.96 28.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.14 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -61.87 99.08 0.11 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.502 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.62 -30.9 2.36 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.899 -0.88 . . . . 0.0 110.899 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -84.73 147.53 26.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.14 0.495 . . . . 0.0 110.455 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.5 m -96.38 145.95 25.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.294 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.685 HG11 HG11 ' A' ' 70' ' ' VAL . 26.8 m -120.88 170.42 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.655 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 35.5 mttt -130.19 147.11 51.88 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.199 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.635 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.7 95.89 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.74 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.05 -34.21 2.48 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 11.0 tt0 -66.46 139.25 57.96 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.082 0.467 . . . . 0.0 110.527 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 19.4 m -62.76 137.68 58.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.313 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.455 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.1 m -112.83 -32.27 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.952 -179.653 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.602 HD11 ' CG1' ' A' ' 65' ' ' VAL . 7.1 tt -162.74 150.21 13.53 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.159 0.504 . . . . 0.0 110.624 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 15.1 t -103.49 143.57 15.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.119 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.5 tp -124.66 165.81 17.25 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.631 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -132.54 118.75 19.64 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.321 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.561 ' CB ' HD11 ' A' ' 61' ' ' LEU . . . -148.0 151.74 36.28 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.545 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 2.5 ptt? 41.8 39.92 1.36 Allowed 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 115.598 -0.728 . . . . 0.0 112.069 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.6 mttt 59.79 39.41 20.75 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.608 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.4 ttt -148.7 140.17 23.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.436 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -78.65 133.1 37.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.423 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.9 m -119.19 115.65 24.67 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.383 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -83.7 129.93 34.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.489 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 37.3 mm -104.14 122.51 57.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.306 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -109.84 144.01 38.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.253 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.51 141.88 94.4 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.42 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -72.39 -37.9 3.97 Favored 'Trans proline' 0 N--CA 1.471 0.178 0 C-N-CA 122.125 1.883 . . . . 0.0 112.302 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.635 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 3.0 p -147.19 159.93 43.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.403 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -62.7 141.36 58.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.351 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.3 -157.0 25.47 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -137.95 147.03 43.91 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.081 0.467 . . . . 0.0 110.416 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.777 HG21 ' HB ' ' A' ' 70' ' ' VAL . 25.0 t -76.88 112.61 14.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.191 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -95.31 -30.07 14.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.741 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.2 tttm -159.75 127.43 4.74 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.604 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.483 HG13 HG12 ' A' ' 120' ' ' ILE . 24.1 t -104.16 114.85 44.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.255 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.9 mt -82.31 -39.06 23.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.405 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.549 HG21 HD13 ' A' ' 83' ' ' LEU . 33.2 m -74.64 150.27 7.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.545 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 43.4 mttt -133.6 161.13 35.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.316 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -61.56 139.98 58.18 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.458 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.44 37.52 16.62 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.354 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -123.92 146.98 48.08 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.386 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.18 138.14 31.78 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.519 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.2 m -122.33 162.39 22.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.336 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 13.6 mt-30 -103.12 141.06 36.49 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.293 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.496 ' H ' ' HB2' ' A' ' 62' ' ' ALA . . . -60.38 105.95 0.92 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.03 -26.97 9.99 Favored Glycine 0 CA--C 1.527 0.831 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 16.6 tt0 -58.15 148.89 25.3 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-O 121.109 0.48 . . . . 0.0 110.773 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.765 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.16 122.85 30.81 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.591 HD21 ' HB2' ' A' ' 59' ' ' ALA . 92.3 mt -89.61 -60.86 1.83 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.086 0.469 . . . . 0.0 110.423 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.582 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.4 mt -140.95 152.52 20.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.243 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 55.3 mttt -95.86 127.38 41.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.415 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.598 HD11 HD11 ' A' ' 57' ' ' ILE . 37.1 mm -107.15 145.16 14.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.396 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.027 -1.429 . . . . 0.0 110.798 -179.998 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -166.94 116.69 0.69 Allowed Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.809 -0.917 . . . . 0.0 110.809 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -145.05 32.69 1.11 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.057 0.456 . . . . 0.0 110.45 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -143.51 84.55 0.19 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 3.1 ttpt -174.81 128.85 0.31 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.071 0.462 . . . . 0.0 110.443 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.526 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -72.81 179.24 3.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.503 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.79 -103.87 0.4 Allowed Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.742 -0.943 . . . . 0.0 110.742 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 65.4 mt-10 -113.28 120.65 41.91 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.062 0.458 . . . . 0.0 110.398 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 110.62 -48.46 0.93 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -84.03 133.59 34.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.119 0.485 . . . . 0.0 110.405 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.489 HD11 HD11 ' A' ' 122' ' ' ILE . 52.4 mt -78.22 111.66 20.16 Favored Pre-proline 0 CA--C 1.535 0.372 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.237 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.435 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 48.1 Cg_endo -71.32 138.39 32.88 Favored 'Trans proline' 0 N--CA 1.472 0.221 0 C-N-CA 121.997 1.798 . . . . 0.0 112.348 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -66.66 146.66 99.09 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.404 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.81 -27.73 14.4 Favored 'Trans proline' 0 CA--C 1.528 0.196 0 C-N-CA 122.254 1.97 . . . . 0.0 112.291 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -164.64 171.02 14.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.46 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.71 93.53 6.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.447 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.95 -148.76 7.41 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.1 m -136.46 138.0 41.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.071 0.462 . . . . 0.0 110.551 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.571 HG13 HD21 ' A' ' 83' ' ' LEU . 19.5 t -71.05 116.72 13.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.2 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.4 t -98.61 -48.65 4.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.622 -179.804 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -150.4 144.67 25.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.622 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.622 HD11 ' HA ' ' A' ' 108' ' ' LYS . 21.8 mt -105.35 135.12 44.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.905 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.786 HD22 ' HB ' ' A' ' 81' ' ' THR . 3.6 mp -97.14 -30.62 12.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.846 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.701 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.3 m -119.47 145.7 25.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.187 0.518 . . . . 0.0 110.742 -179.704 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.9 pttm -133.6 164.21 27.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.252 179.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -60.54 103.82 0.28 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.452 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.04 -29.68 2.41 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -94.94 153.15 17.8 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.098 0.475 . . . . 0.0 110.475 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.4 m -96.69 153.08 18.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.311 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.701 ' CG1' HG11 ' A' ' 70' ' ' VAL . 30.4 m -128.61 168.64 21.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.73 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.4 mtpp -129.96 151.69 50.24 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.19 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.646 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.57 102.16 0.17 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.71 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.85 -37.74 2.05 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 32.3 tt0 -62.55 140.57 58.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.12 0.486 . . . . 0.0 110.692 -179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.786 ' HB ' HD22 ' A' ' 69' ' ' LEU . 9.2 m -67.34 141.07 57.26 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.227 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.781 HG22 ' O ' ' A' ' 94' ' ' ILE . 34.9 m -115.61 -24.25 3.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.592 -179.405 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.571 HD21 HG13 ' A' ' 65' ' ' VAL . 8.3 tt -166.26 152.94 9.29 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.211 0.529 . . . . 0.0 110.885 -179.668 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.566 ' N ' HD23 ' A' ' 83' ' ' LEU . 21.8 t -114.9 134.7 57.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.042 179.702 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.45 HD12 HD11 ' A' ' 94' ' ' ILE . 55.8 mt -115.47 161.59 18.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.611 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -139.11 82.33 1.89 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.132 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -92.66 104.75 17.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.245 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 55.1 mtp 64.95 48.24 2.38 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.339 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.4 mtpt 60.96 39.45 16.56 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.625 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 13.6 tpp -127.72 101.06 6.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.46 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.12 113.53 3.2 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.569 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.9 m -115.07 123.6 49.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.224 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 14.8 mt-10 -94.07 129.91 40.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.788 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.781 ' O ' HG22 ' A' ' 82' ' ' VAL . 4.4 mp -115.5 112.37 39.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.633 179.489 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -99.48 153.97 18.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.419 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.98 142.54 95.19 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.293 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.33 -36.22 5.67 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.175 1.917 . . . . 0.0 112.196 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.646 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -146.12 168.83 20.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.299 179.846 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -68.55 141.9 55.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.334 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 174.24 -161.16 31.12 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 74.9 tttt -134.51 148.12 50.47 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.096 0.474 . . . . 0.0 110.429 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.618 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.6 t -74.75 103.7 2.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.202 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -90.39 -29.29 18.11 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.774 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 18.5 tttt -158.32 123.53 4.37 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.139 0.495 . . . . 0.0 110.518 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.506 HG13 HG12 ' A' ' 120' ' ' ILE . 24.5 t -100.37 106.79 19.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.332 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.41 ' O ' HG13 ' A' ' 107' ' ' VAL . 5.4 mt -90.48 33.76 0.9 Allowed 'General case' 0 CA--C 1.533 0.326 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.421 179.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.43 HG22 ' O ' ' A' ' 119' ' ' LEU . 19.2 m -156.4 137.26 4.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 121.031 0.443 . . . . 0.0 110.101 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.622 ' HA ' HD11 ' A' ' 68' ' ' ILE . 1.4 mptp? -125.85 175.82 7.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.272 179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -72.2 147.63 46.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.401 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 1.2 tpp180 63.16 34.51 13.51 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.537 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -121.87 145.0 48.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.26 179.754 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.24 136.99 32.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.629 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 20.7 m -120.23 179.73 2.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.383 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 63.9 mt-30 -133.05 141.97 48.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.367 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.8 102.36 0.33 Allowed Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.849 -0.901 . . . . 0.0 110.849 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 123.33 -31.32 4.7 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -60.24 142.5 54.44 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.093 0.473 . . . . 0.0 110.583 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.526 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -65.45 126.64 30.77 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 -179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.43 ' O ' HG22 ' A' ' 107' ' ' VAL . 92.6 mt -89.98 -55.49 3.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.993 0.425 . . . . 0.0 110.271 179.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.538 ' CG2' HG13 ' A' ' 102' ' ' VAL . 45.6 mt -143.51 149.25 18.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.333 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 24.2 ttmt -96.44 130.84 43.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.276 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.489 HD11 HD11 ' A' ' 57' ' ' ILE . 37.6 mm -107.22 144.17 16.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.49 -179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.758 0 CA-C-O 117.998 -1.446 . . . . 0.0 110.737 179.991 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -91.98 -163.55 38.15 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -123.36 -69.64 0.81 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.141 0.496 . . . . 0.0 110.502 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 160.33 -43.2 0.43 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 26.8 pttt -175.03 130.6 0.3 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.067 0.46 . . . . 0.0 110.494 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.652 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -69.92 179.13 2.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.414 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 140.68 46.67 0.06 OUTLIER Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -172.51 36.22 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.122 0.487 . . . . 0.0 110.386 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 116.21 -31.81 5.87 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -78.29 142.54 37.71 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.116 0.484 . . . . 0.0 110.341 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.427 HD11 HD11 ' A' ' 122' ' ' ILE . 47.4 mt -82.5 114.85 54.6 Favored Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.24 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.38 148.98 55.9 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.054 1.836 . . . . 0.0 112.278 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.586 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -81.13 145.26 56.04 Favored Pre-proline 0 CA--C 1.532 0.25 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.431 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -73.44 -27.34 13.29 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.238 1.958 . . . . 0.0 112.399 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.7 pp -162.57 158.26 23.19 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.472 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -75.19 91.28 2.61 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.337 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -121.03 -170.24 13.99 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.474 ' C ' HD23 ' A' ' 85' ' ' LEU . 18.9 m -106.93 134.98 49.28 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.057 0.456 . . . . 0.0 110.408 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.756 HG13 HD11 ' A' ' 83' ' ' LEU . 32.6 t -69.59 121.49 19.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.15 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t -95.66 -60.14 1.72 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.398 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.4 mtpt -150.32 146.52 26.8 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.465 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.722 HG12 HD12 ' A' ' 83' ' ' LEU . 32.8 mt -102.46 124.05 56.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.922 179.773 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.635 HD22 ' HB ' ' A' ' 81' ' ' THR . 8.4 mp -97.61 27.88 4.1 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.991 -179.561 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.767 ' HB ' HG21 ' A' ' 102' ' ' VAL . 26.3 m -153.9 154.85 6.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 121.178 0.514 . . . . 0.0 110.486 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -141.6 158.2 44.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.122 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -60.52 92.5 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.45 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.19 -27.06 2.55 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -78.42 144.62 35.7 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.077 0.465 . . . . 0.0 110.489 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.2 m -95.54 135.45 37.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.355 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.602 HG11 HG11 ' A' ' 70' ' ' VAL . 26.6 m -115.4 160.28 14.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.573 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 23.8 mttm -118.52 142.91 47.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.286 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.601 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -57.76 95.7 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.761 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.19 -31.88 2.64 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.8 tt0 -68.01 151.17 47.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.137 0.494 . . . . 0.0 110.399 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.635 ' HB ' HD22 ' A' ' 69' ' ' LEU . 4.5 m -69.76 136.65 51.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.401 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 27.1 m -113.6 -32.11 2.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.901 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.756 HD11 HG13 ' A' ' 65' ' ' VAL . 8.3 tt -160.75 146.76 14.9 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.111 0.482 . . . . 0.0 110.705 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -101.85 137.1 30.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.094 179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.737 HD12 HD11 ' A' ' 94' ' ' ILE . 12.8 mt -120.4 165.73 14.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.496 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.3 mt-10 -131.07 110.94 11.56 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.327 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.49 141.62 30.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.374 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 68.5 mtp 60.6 32.66 20.41 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.601 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.1 mmmt 60.87 33.1 20.05 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.557 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -142.0 142.89 32.96 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.403 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -81.1 122.78 27.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.394 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.8 m -113.07 120.21 40.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.333 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 -84.65 135.84 34.0 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.492 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.737 HD11 HD12 ' A' ' 85' ' ' LEU . 37.8 mm -104.85 126.85 59.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.296 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -108.73 141.23 41.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.427 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.32 143.17 95.79 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.324 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -73.08 -37.99 3.11 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.121 1.88 . . . . 0.0 112.273 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.601 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 21.2 p -145.01 155.71 43.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.302 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -65.64 141.45 58.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.375 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 178.15 -155.31 16.68 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.3 tppp? -134.83 143.44 47.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.023 0.44 . . . . 0.0 110.38 -179.781 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.767 HG21 ' HB ' ' A' ' 70' ' ' VAL . 26.0 t -79.04 114.13 19.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.139 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -95.44 -30.37 13.92 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.606 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.3 ttpt -158.0 131.89 7.94 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.464 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 26.8 t -108.72 102.22 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.267 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 5.1 mt -74.32 -33.61 63.21 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.446 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 119' ' ' LEU . 29.9 m -73.52 150.68 7.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.346 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -140.88 157.29 45.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.473 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 61.7 mt-10 -61.17 145.62 50.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.51 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.14 37.54 17.55 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.33 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.543 ' O ' HG23 ' A' ' 65' ' ' VAL . 15.0 t70 -127.28 145.0 50.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.454 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.9 137.46 32.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.493 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.1 m -121.32 156.12 25.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.376 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 13.6 mt-30 -101.6 144.57 30.17 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.376 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.31 107.18 1.36 Allowed Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 115.84 -27.64 8.17 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -59.75 141.72 54.67 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.054 0.454 . . . . 0.0 110.645 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.652 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.35 127.11 41.55 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.586 HD21 ' HB2' ' A' ' 59' ' ' ALA . 91.7 mt -91.17 -56.29 3.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.086 0.469 . . . . 0.0 110.459 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.578 ' CG2' HG13 ' A' ' 102' ' ' VAL . 53.5 mt -141.12 151.28 19.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.342 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 15.0 tttt -97.36 126.63 42.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.42 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.427 HD11 HD11 ' A' ' 57' ' ' ILE . 37.5 mm -105.24 145.64 13.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.397 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.82 0 CA-C-O 118.002 -1.443 . . . . 0.0 110.813 179.968 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -172.32 -76.37 0.05 OUTLIER Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.59 97.87 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.119 0.485 . . . . 0.0 110.528 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 173.99 76.86 0.05 OUTLIER Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 33.1 mttt -129.61 134.29 47.63 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.157 0.503 . . . . 0.0 110.374 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.632 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -62.42 176.62 0.6 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.445 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.79 46.54 0.07 OUTLIER Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -169.74 35.01 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.18 0.514 . . . . 0.0 110.369 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 116.4 -32.98 5.33 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -80.09 143.33 34.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.096 0.474 . . . . 0.0 110.506 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 53.6 mt -79.01 116.69 61.95 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.159 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.611 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 48.4 Cg_endo -71.6 137.62 30.62 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 121.991 1.794 . . . . 0.0 112.279 -179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.527 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -71.0 148.17 94.3 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.404 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.551 ' HD3' HD12 ' A' ' 94' ' ' ILE . 47.9 Cg_endo -72.58 -28.75 13.96 Favored 'Trans proline' 0 CA--C 1.528 0.194 0 C-N-CA 122.238 1.959 . . . . 0.0 112.216 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.5 pp -162.34 173.51 14.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.511 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -86.67 95.8 9.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.384 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -125.22 -145.39 6.52 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.534 ' C ' HD23 ' A' ' 85' ' ' LEU . 13.8 m -136.33 139.72 42.79 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.128 0.49 . . . . 0.0 110.512 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.707 HG13 HD11 ' A' ' 83' ' ' LEU . 21.8 t -68.66 121.96 19.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.097 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 92.7 p -99.45 -53.15 3.29 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.627 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.3 tptt -152.33 144.77 24.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.558 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.409 HG12 HD12 ' A' ' 83' ' ' LEU . 21.8 mt -103.14 133.19 47.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.989 179.716 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.412 HD13 ' HB ' ' A' ' 81' ' ' THR . 12.3 mt -99.77 -29.57 12.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.952 -179.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.813 HG11 HG11 ' A' ' 76' ' ' VAL . 32.6 m -110.98 147.87 14.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.249 0.547 . . . . 0.0 110.765 -179.726 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.8 pttt -136.18 166.01 24.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.244 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.5 ' HG3' HG23 ' A' ' 105' ' ' VAL . 14.8 mt-10 -61.79 100.03 0.14 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.495 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.06 -31.98 2.23 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -85.42 147.15 26.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.068 0.461 . . . . 0.0 110.461 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.1 m -98.29 146.8 25.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.348 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.813 HG11 HG11 ' A' ' 70' ' ' VAL . 24.9 m -126.75 165.52 25.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.614 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 22.2 pttt -127.2 150.51 49.49 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.285 179.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.743 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -58.62 98.23 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.748 -179.759 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.31 -37.91 1.83 Allowed Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 21.1 tt0 -65.18 143.82 57.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.072 0.463 . . . . 0.0 110.639 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.412 ' HB ' HD13 ' A' ' 69' ' ' LEU . 4.1 m -67.37 138.93 57.11 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.204 179.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.431 ' HA ' HG13 ' A' ' 70' ' ' VAL . 34.8 m -113.75 -34.38 2.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.84 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.707 HD11 HG13 ' A' ' 65' ' ' VAL . 7.9 tt -160.45 147.34 15.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.788 -179.415 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -104.97 139.43 25.99 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.001 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.634 HD21 HG21 ' A' ' 113' ' ' VAL . 2.4 mt -120.02 165.36 14.8 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.19 0.519 . . . . 0.0 110.691 -179.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -135.36 112.81 10.65 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.532 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.31 142.06 27.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.388 179.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 4.5 mtp 60.54 33.72 20.44 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.528 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.3 mttt 60.91 34.45 19.53 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.465 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.1 tpp -140.26 141.61 35.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.49 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -89.8 122.36 32.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.412 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.2 m -119.85 114.52 22.22 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.437 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -82.4 143.5 31.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.579 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.551 HD12 ' HD3' ' A' ' 60' ' ' PRO . 39.7 mm -105.14 127.62 59.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.162 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -105.42 142.16 35.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.341 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.86 132.2 91.76 Favored Pre-proline 0 CA--C 1.534 0.33 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.371 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -72.79 -32.19 9.5 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 121.99 1.793 . . . . 0.0 112.243 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.743 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 4.6 p -146.68 156.91 43.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.419 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -68.32 142.73 55.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.44 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 172.19 -156.77 26.1 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -135.43 146.46 48.26 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.057 0.456 . . . . 0.0 110.415 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.69 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.0 t -74.86 107.75 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.271 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . 0.402 ' HG3' ' N ' ' A' ' 104' ' ' LYS . 7.3 pt-20 -90.59 -30.98 16.87 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.563 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . 0.402 ' N ' ' HG3' ' A' ' 103' ' ' GLU . 1.5 tptm -156.11 130.57 8.87 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.586 -179.787 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.5 HG23 ' HG3' ' A' ' 72' ' ' GLU . 25.4 t -98.92 106.1 18.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.347 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.2 mt -89.59 12.06 17.82 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.511 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.688 HG21 HD13 ' A' ' 83' ' ' LEU . 28.3 m -127.33 136.16 61.38 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.095 0 CA-C-O 121.121 0.486 . . . . 0.0 110.122 179.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 40.1 tttt -128.5 156.21 43.62 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.373 -179.787 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -60.7 150.22 32.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.487 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 61.45 31.79 19.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.443 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -124.36 142.78 51.01 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.264 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.5 136.84 32.83 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.609 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.634 HG21 HD21 ' A' ' 85' ' ' LEU . 30.4 m -120.69 157.16 23.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.306 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 -100.14 142.19 31.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.504 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.07 107.64 1.41 Allowed Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.764 -0.935 . . . . 0.0 110.764 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.61 -28.32 8.65 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.4 tt0 -57.62 147.14 28.19 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.087 0.47 . . . . 0.0 110.76 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.632 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -63.33 121.85 25.38 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.941 -0.863 . . . . 0.0 110.941 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.671 ' O ' HG13 ' A' ' 107' ' ' VAL . 56.5 mt -87.25 -52.56 5.33 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.056 0.455 . . . . 0.0 110.501 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.477 ' CG2' HG13 ' A' ' 102' ' ' VAL . 48.9 mt -142.31 148.3 20.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.35 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -95.75 128.04 42.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.345 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.4 mm -107.68 145.34 15.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.484 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.798 0 CA-C-O 117.984 -1.454 . . . . 0.0 110.824 179.999 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 105.72 79.13 1.24 Allowed Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -158.92 173.47 16.46 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.107 0.48 . . . . 0.0 110.444 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -171.13 158.96 30.71 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 19.1 mtpt 60.65 161.27 0.05 Allowed 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.111 0.481 . . . . 0.0 110.503 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.521 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -115.31 178.05 4.44 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.422 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -158.69 -105.04 0.21 Allowed Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -108.17 120.89 43.63 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.08 0.467 . . . . 0.0 110.382 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 107.41 -48.5 0.94 Allowed Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -83.62 131.86 34.93 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.066 0.46 . . . . 0.0 110.357 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.568 HD11 HD11 ' A' ' 122' ' ' ILE . 53.0 mt -79.39 111.45 20.8 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.144 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.483 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.7 Cg_endo -71.33 141.98 40.18 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.016 1.811 . . . . 0.0 112.288 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.411 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -76.75 144.49 73.15 Favored Pre-proline 0 CA--C 1.532 0.272 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.275 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -72.73 -22.35 20.6 Favored 'Trans proline' 0 CA--C 1.529 0.241 0 C-N-CA 122.181 1.921 . . . . 0.0 112.702 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.5 pp -161.7 167.38 25.19 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.128 0.489 . . . . 0.0 110.457 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -86.37 119.67 26.88 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.455 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -152.04 -141.4 3.31 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.522 ' C ' HD23 ' A' ' 85' ' ' LEU . 6.6 m -137.56 143.42 41.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.139 0.495 . . . . 0.0 110.439 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.796 HG13 HD11 ' A' ' 83' ' ' LEU . 37.3 t -68.17 128.63 31.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.172 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.6 m -98.18 -59.75 1.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.683 -179.758 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 12.6 mtpt -149.49 147.18 27.9 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.541 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.474 HD11 ' HA ' ' A' ' 108' ' ' LYS . 51.8 mt -102.87 123.25 56.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.075 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.6 mp -94.09 -46.04 7.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.657 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.683 ' HB ' HG21 ' A' ' 102' ' ' VAL . 33.4 m -95.23 143.9 10.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.694 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 3.5 pttt -133.36 165.33 25.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.182 179.76 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -59.31 102.03 0.12 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.666 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 137.91 -31.89 2.42 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -84.9 149.99 25.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.09 0.471 . . . . 0.0 110.501 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 9.3 m -96.64 142.98 28.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.352 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.674 ' CG1' HG11 ' A' ' 70' ' ' VAL . 31.5 m -120.7 154.22 24.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.548 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 13.0 tptt -116.57 151.22 36.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.192 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.08 96.69 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.647 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 130.62 -30.81 3.35 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 -64.79 139.52 58.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.082 0.468 . . . . 0.0 110.602 -179.857 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 4.0 m -65.57 136.16 56.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.187 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.493 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.0 m -115.09 -29.57 2.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.294 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.796 HD11 HG13 ' A' ' 65' ' ' VAL . 7.2 tt -165.29 152.22 10.47 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.133 0.492 . . . . 0.0 110.778 -179.451 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -107.66 139.81 28.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.153 179.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.712 HD21 HG21 ' A' ' 113' ' ' VAL . 1.8 mt -120.58 160.78 22.54 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.497 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -133.16 120.53 21.32 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.232 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.08 146.33 30.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.287 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 6.8 ptm 41.77 40.6 1.53 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.968 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 19.5 mtpp 61.11 40.28 15.11 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.599 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 35.3 ttp -144.71 121.7 11.37 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.501 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -79.44 127.6 32.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.372 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 5.1 m -119.76 126.18 50.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.367 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -82.7 129.9 35.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.361 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.526 HG13 HD12 ' A' ' 85' ' ' LEU . 23.6 mm -106.39 118.2 53.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.188 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 22.9 p30 -110.65 152.18 26.8 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.333 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.23 142.19 95.91 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.359 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -73.54 -32.97 7.26 Favored 'Trans proline' 0 N--CA 1.471 0.173 0 C-N-CA 122.171 1.914 . . . . 0.0 112.232 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.583 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 1.0 OUTLIER -148.64 161.08 42.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.385 179.999 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -64.24 142.79 58.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.407 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 171.21 -153.02 19.63 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 26.3 ttmt -139.84 147.07 40.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.103 0.478 . . . . 0.0 110.428 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.683 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -74.74 107.91 5.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.315 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -91.85 -27.74 17.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.865 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -161.4 136.1 7.24 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.07 0.462 . . . . 0.0 110.481 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.417 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.8 t -103.05 108.61 24.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.269 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 8.6 mt -90.5 31.1 1.06 Allowed 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.605 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.417 ' H ' HG12 ' A' ' 105' ' ' VAL . 25.8 m -155.54 144.54 12.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-O 121.032 0.444 . . . . 0.0 110.342 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.474 ' HA ' HD11 ' A' ' 68' ' ' ILE . 8.4 mptt -130.52 165.85 21.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.277 179.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -60.99 145.41 50.74 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.472 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 14.2 mmt85 60.64 37.12 19.43 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.507 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -117.93 144.7 45.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.351 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.01 129.24 38.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.457 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.712 HG21 HD21 ' A' ' 85' ' ' LEU . 27.8 m -122.09 150.38 25.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.475 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 -99.44 148.4 24.26 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.432 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -63.59 103.26 0.65 Allowed Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.48 -28.66 5.69 Favored Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -59.51 137.89 57.87 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.109 0.481 . . . . 0.0 110.665 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.521 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.23 119.73 19.8 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.411 HD21 ' HB2' ' A' ' 59' ' ' ALA . 44.8 mt -87.2 -54.74 4.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.133 0.492 . . . . 0.0 110.484 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.529 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.1 mt -140.99 143.76 27.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.226 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 7.2 tttt -95.16 129.99 42.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.517 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.568 HD11 HD11 ' A' ' 57' ' ' ILE . 37.2 mm -104.62 145.57 13.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.32 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.731 0 CA-C-O 118.011 -1.438 . . . . 0.0 110.768 179.97 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -116.54 -75.43 0.57 Allowed Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.984 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -108.1 33.57 4.05 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.191 0.52 . . . . 0.0 110.446 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.85 162.67 12.99 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 2.9 ptpt -169.43 60.55 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.334 0.588 . . . . 0.0 110.801 179.883 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.752 ' HB2' ' N ' ' A' ' 118' ' ' GLY . . . -132.19 147.24 52.41 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.44 179.692 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.39 -169.62 16.64 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.518 -1.033 . . . . 0.0 110.518 179.735 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 60.2 -145.71 0.49 Allowed 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -89.72 20.95 32.32 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.632 179.814 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.413 ' OE2' HD11 ' A' ' 106' ' ' LEU . 66.2 mt-10 -83.72 137.56 33.7 Favored 'General case' 0 C--O 1.23 0.076 0 CA-C-O 120.915 0.388 . . . . 0.0 110.146 179.725 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.736 HD12 ' HD2' ' A' ' 97' ' ' PRO . 41.5 mm -83.16 110.49 24.02 Favored Pre-proline 0 CA--C 1.534 0.338 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.068 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.483 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 48.7 Cg_endo -71.57 131.02 18.0 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 121.972 1.782 . . . . 0.0 112.101 -179.741 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.639 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -59.61 145.9 81.75 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.64 -179.867 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -75.62 -29.75 6.98 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.292 1.995 . . . . 0.0 112.5 -179.86 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.429 HD12 ' C ' ' A' ' 61' ' ' LEU . 4.4 pp -157.5 164.43 37.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.552 -179.681 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -79.9 108.02 13.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.437 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -134.65 -146.63 5.43 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.982 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.588 ' O ' HD23 ' A' ' 85' ' ' LEU . 1.8 m -136.33 138.18 41.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.095 0.474 . . . . 0.0 110.401 -179.991 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.827 HG13 HD11 ' A' ' 83' ' ' LEU . 29.2 t -70.42 118.57 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.039 179.867 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.7 p -96.25 -53.67 3.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.845 -179.749 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 37.9 mttt -148.64 145.28 27.68 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 121.108 0.48 . . . . 0.0 110.703 -179.607 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.522 HD11 ' HA ' ' A' ' 108' ' ' LYS . 38.9 mt -101.78 128.81 53.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.986 179.507 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.429 HD12 HG22 ' A' ' 81' ' ' THR . 15.4 mt -97.64 -49.04 5.0 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.819 -179.592 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.697 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.6 m -93.73 146.04 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.217 0.532 . . . . 0.0 110.797 -179.831 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.8 pttp -135.31 162.72 31.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.034 179.789 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -59.26 103.19 0.16 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.54 -179.971 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.4 2.27 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.881 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -89.79 149.61 22.63 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.135 0.493 . . . . 0.0 110.445 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 4.4 m -97.22 141.51 30.25 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.444 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.697 ' CG1' HG11 ' A' ' 70' ' ' VAL . 27.1 m -117.43 156.33 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.464 179.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.0 ttmt -117.53 157.03 27.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.438 179.864 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -61.81 96.48 0.07 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.557 -179.888 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.52 -28.24 4.52 Favored Glycine 0 CA--C 1.527 0.829 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.806 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -63.3 142.91 58.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.113 0.482 . . . . 0.0 110.684 -179.746 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.429 HG22 HD12 ' A' ' 69' ' ' LEU . 4.9 m -67.65 139.48 56.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.227 179.747 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.566 ' HA ' HG13 ' A' ' 70' ' ' VAL . 30.8 m -119.37 -32.62 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.399 -179.415 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.827 HD11 HG13 ' A' ' 65' ' ' VAL . 7.1 tt -163.09 152.09 14.71 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.228 0.537 . . . . 0.0 111.049 -179.297 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.3 t -106.1 139.81 26.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.857 179.574 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.588 HD23 ' O ' ' A' ' 64' ' ' THR . 12.5 mt -122.09 168.01 12.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.153 0.502 . . . . 0.0 110.759 -179.719 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 72.2 mt-10 -131.5 113.19 13.38 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.364 179.974 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -144.37 138.68 27.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.533 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 4.1 mmt 60.13 32.47 20.95 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.628 179.913 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 19.3 mttt 60.69 32.9 20.32 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.417 -179.979 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -142.4 122.24 13.54 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.19 -179.961 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -62.01 126.13 26.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.501 -179.956 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 7.0 m -113.53 115.21 27.62 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.241 179.862 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -80.98 128.66 33.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.525 -179.793 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.568 HD11 HD12 ' A' ' 85' ' ' LEU . 35.4 mm -101.54 144.08 13.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.06 179.707 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 -138.14 134.82 35.06 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.731 -179.686 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.513 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -61.89 109.6 2.41 Favored Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.225 179.641 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.736 ' HD2' HD12 ' A' ' 57' ' ' ILE . 41.8 Cg_endo -65.0 -12.49 34.86 Favored 'Trans proline' 0 N--CA 1.475 0.425 0 C-N-CA 122.275 1.983 . . . . 0.0 113.147 179.955 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.91 134.83 39.12 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 121.014 0.435 . . . . 0.0 110.54 179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -62.57 159.15 16.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.459 -179.911 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 154.29 -156.2 26.69 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.962 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 16.9 ttpt -133.02 146.78 52.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.125 0.488 . . . . 0.0 110.334 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.663 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.4 t -78.53 109.23 12.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.25 -179.966 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -94.64 -30.53 14.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.59 -179.941 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -157.1 130.92 8.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.449 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.468 HG12 ' H ' ' A' ' 107' ' ' VAL . 21.2 t -97.92 112.64 30.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.259 -179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.413 HD11 ' OE2' ' A' ' 56' ' ' GLU . 5.6 mt -90.12 28.48 1.4 Allowed 'General case' 0 CA--C 1.534 0.329 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.737 179.984 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.468 ' H ' HG12 ' A' ' 105' ' ' VAL . 23.2 m -155.39 137.33 6.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-O 121.118 0.485 . . . . 0.0 110.336 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.522 ' HA ' HD11 ' A' ' 68' ' ' ILE . 13.8 pttm -127.5 167.01 16.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.346 179.954 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -60.09 145.76 45.49 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.77 179.993 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.05 37.41 17.94 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.354 179.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.48 ' O ' HG23 ' A' ' 65' ' ' VAL . 8.4 t70 -123.36 138.62 54.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.442 179.983 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.34 131.35 36.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.493 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.0 m -120.95 154.55 24.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.419 179.97 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 19.9 mp0 -96.65 141.93 29.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.325 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.77 90.38 0.06 OUTLIER Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.848 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.3 -30.35 2.81 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -58.63 154.58 14.11 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.115 0.483 . . . . 0.0 110.681 -179.997 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.752 ' N ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.64 125.76 37.79 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 -179.681 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.639 HD21 ' HB2' ' A' ' 59' ' ' ALA . 58.4 mt -94.77 -59.41 1.93 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.151 0.5 . . . . 0.0 110.225 179.744 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.503 ' CG2' HG13 ' A' ' 102' ' ' VAL . 54.9 mt -141.33 141.95 29.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.181 179.884 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.3 tttt -88.5 127.06 35.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.433 179.972 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 37.5 mm -106.82 141.27 22.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.364 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.03 -1.428 . . . . 0.0 110.796 179.959 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 169.5 175.73 38.87 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 179.957 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -87.19 -32.77 19.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.048 0.451 . . . . 0.0 110.417 179.992 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -68.23 143.24 40.74 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.918 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -137.99 41.58 2.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.356 0.598 . . . . 0.0 110.222 179.918 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.735 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -157.5 -179.46 8.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.49 -179.936 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 130.98 -49.07 0.94 Allowed Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.761 -0.935 . . . . 0.0 110.761 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -80.45 63.32 4.86 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.394 0.616 . . . . 0.0 110.425 -179.86 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.25 -37.86 3.51 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 179.778 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.617 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 57.8 mt-10 -82.96 129.25 35.01 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.161 0.505 . . . . 0.0 110.554 -179.823 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.432 HD13 ' HD3' ' A' ' 97' ' ' PRO . 53.8 mt -79.01 111.71 22.05 Favored Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.154 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.626 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.1 Cg_endo -71.09 149.09 57.85 Favored 'Trans proline' 0 N--CA 1.472 0.247 0 C-N-CA 122.074 1.849 . . . . 0.0 112.299 -179.953 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.852 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -84.24 150.76 58.48 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.447 -179.963 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -72.83 -28.5 13.46 Favored 'Trans proline' 0 CA--C 1.527 0.164 0 C-N-CA 122.251 1.968 . . . . 0.0 112.311 179.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.8 pp -164.84 161.99 20.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.43 179.968 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.67 104.72 2.06 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.386 -179.965 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.472 ' CA ' ' HB2' ' A' ' 87' ' ' ALA . . . -132.87 178.56 18.05 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 23.7 m -104.07 134.86 46.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.084 0.469 . . . . 0.0 110.368 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.644 ' HA ' HD23 ' A' ' 85' ' ' LEU . 24.2 t -72.04 118.66 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.102 179.878 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -100.02 -50.19 4.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.629 -179.72 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.95 140.53 21.61 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.769 -179.653 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.554 HG12 HD12 ' A' ' 83' ' ' LEU . 36.1 mt -105.41 126.15 60.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.836 179.579 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.8 mp -98.34 28.65 3.99 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.978 -179.564 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.859 ' HB ' HG21 ' A' ' 102' ' ' VAL . 13.6 m -151.07 153.18 10.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 121.338 0.59 . . . . 0.0 110.897 -179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt -137.26 154.82 50.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.918 179.502 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -58.18 91.7 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.165 0.507 . . . . 0.0 110.681 -179.881 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.88 -29.1 2.47 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -179.919 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -65.06 148.27 51.96 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.055 0.455 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 2.2 m -97.67 132.28 43.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.237 179.896 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 28.1 m -121.54 163.77 19.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.633 -179.821 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -129.63 154.18 47.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.593 -0.731 . . . . 0.0 110.184 179.74 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.652 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.01 91.21 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.482 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.07 -34.98 1.95 Allowed Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 179.976 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -62.56 140.03 58.63 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.028 0.442 . . . . 0.0 110.45 179.999 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 2.9 m -66.92 136.84 55.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.124 179.815 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.42 ' O ' HG22 ' A' ' 70' ' ' VAL . 29.8 m -116.97 -29.76 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.493 -179.382 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.644 HD11 HG13 ' A' ' 65' ' ' VAL . 10.2 tt -161.04 159.13 28.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.303 0.573 . . . . 0.0 111.016 -179.439 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.615 ' N ' HD23 ' A' ' 83' ' ' LEU . 21.7 t -125.7 131.69 71.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.809 179.513 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.644 HD23 ' HA ' ' A' ' 65' ' ' VAL . 19.8 mt -116.09 168.95 9.64 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.202 0.525 . . . . 0.0 110.747 -179.554 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -139.9 80.71 1.78 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.156 179.687 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.472 ' HB2' ' CA ' ' A' ' 63' ' ' GLY . . . -92.37 124.89 36.76 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.609 -179.675 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 13.8 mmt 60.34 39.21 19.03 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.38 179.788 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 59.9 mttt 61.67 40.15 13.55 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.238 -179.908 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 11.4 tpp -135.13 114.21 12.15 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.591 -179.915 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -63.69 118.57 8.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.446 179.822 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 8.7 m -114.46 116.96 29.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.202 179.906 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -84.38 131.7 34.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.438 -179.951 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.428 HG22 ' N ' ' A' ' 95' ' ' ASN . 37.7 mm -106.4 155.95 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.293 179.991 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.428 ' N ' HG22 ' A' ' 94' ' ' ILE . 10.6 m120 -142.28 145.42 34.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.455 -179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.64 142.38 94.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.418 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.432 ' HD3' HD13 ' A' ' 57' ' ' ILE . 50.6 Cg_endo -74.59 -36.24 3.05 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.157 1.905 . . . . 0.0 112.375 -179.929 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.652 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -146.55 170.45 16.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.413 -179.946 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -69.31 142.2 54.11 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.6 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 160.29 -166.7 35.34 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 -179.989 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 13.9 ptpt -129.17 168.8 15.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.355 0.598 . . . . 0.0 110.657 179.798 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.859 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.6 t -82.48 113.89 22.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.547 -179.72 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -94.61 -33.08 13.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.455 179.894 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.1 ttpp -160.63 123.75 3.37 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.606 179.871 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.54 HG13 HG12 ' A' ' 120' ' ' ILE . 23.1 t -102.1 109.99 27.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.325 179.799 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.4 mt -82.21 -30.43 30.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.452 179.763 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 105' ' ' VAL . 27.6 m -82.04 143.25 12.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.796 -179.824 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 20.2 mmtt -131.32 158.79 39.72 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.107 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -61.99 147.33 47.41 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.496 -179.995 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 8.1 mmm180 64.16 34.43 11.03 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.759 179.85 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.522 ' O ' HG23 ' A' ' 65' ' ' VAL . 31.4 m-20 -131.98 140.81 49.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.413 179.676 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.8 140.75 29.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.554 -179.904 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.0 m -121.69 163.52 19.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.374 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 12.4 mm100 -98.35 142.63 29.75 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.299 179.966 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.96 106.28 1.06 Allowed Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.749 -0.941 . . . . 0.0 110.749 -179.972 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 114.63 -25.57 10.19 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 -179.833 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 -59.73 143.05 51.9 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 121.102 0.477 . . . . 0.0 110.651 -179.822 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.735 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -61.34 124.84 36.03 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.852 HD21 ' HB2' ' A' ' 59' ' ' ALA . 49.2 mt -89.76 -54.9 3.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.092 0.472 . . . . 0.0 110.452 -179.979 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.54 HG12 HG13 ' A' ' 105' ' ' VAL . 47.3 mt -145.86 147.8 18.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.121 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 14.7 ttmt -95.89 136.44 36.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.153 179.774 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.8 mm -110.0 143.16 20.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.433 -179.899 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.745 0 CA-C-O 117.987 -1.452 . . . . 0.0 110.766 -179.997 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 118.35 -48.23 0.96 Allowed Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.967 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.48 160.97 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.134 0.492 . . . . 0.0 110.591 -179.997 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.4 136.22 0.21 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.971 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 35.3 mttp -142.18 41.29 1.64 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.261 0.553 . . . . 0.0 110.287 179.932 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.743 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -150.54 -179.56 7.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.528 179.985 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.61 -46.16 1.09 Allowed Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -93.89 72.49 4.13 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.313 0.578 . . . . 0.0 110.367 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 102.23 -41.97 2.01 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.583 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 17.0 mt-10 -83.82 134.14 34.72 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.11 0.481 . . . . 0.0 110.465 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.515 HD11 HD11 ' A' ' 122' ' ' ILE . 55.8 mt -79.98 111.61 23.19 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.309 -179.997 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.551 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.7 Cg_endo -71.81 131.67 18.79 Favored 'Trans proline' 0 N--CA 1.472 0.217 0 C-N-CA 122.035 1.823 . . . . 0.0 112.287 179.931 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.46 147.57 98.78 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.396 179.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -72.29 -27.9 15.86 Favored 'Trans proline' 0 CA--C 1.528 0.205 0 C-N-CA 122.188 1.926 . . . . 0.0 112.325 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.533 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.4 pp -163.92 159.65 21.14 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.464 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.456 ' HB2' ' H ' ' A' ' 115' ' ' GLY . . . -74.72 101.57 4.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.373 -179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.11 -141.26 5.07 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.94 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.0 m -137.81 135.86 36.66 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.169 0.509 . . . . 0.0 110.45 -179.859 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.753 HG13 HD11 ' A' ' 83' ' ' LEU . 21.7 t -69.64 120.06 16.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.225 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 79.2 p -97.02 -53.45 3.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.749 -179.829 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 45.6 tttt -152.06 148.37 27.6 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.603 -179.813 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.544 HG12 HD12 ' A' ' 83' ' ' LEU . 48.9 mt -104.15 134.39 45.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.061 179.756 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.587 HD12 HG22 ' A' ' 81' ' ' THR . 86.3 mt -99.22 -31.46 11.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.758 -179.694 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.705 HG11 ' CG1' ' A' ' 76' ' ' VAL . 34.5 m -113.18 145.07 19.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 121.229 0.538 . . . . 0.0 110.589 -179.871 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.78 163.89 30.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.211 179.771 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.438 ' HG3' HG23 ' A' ' 105' ' ' VAL . 33.6 mt-10 -58.36 102.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.582 -179.864 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.25 -28.29 2.48 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.824 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 43.6 m-20 -95.69 151.81 19.02 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.1 0.476 . . . . 0.0 110.421 -179.97 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -98.46 147.58 24.59 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.392 179.894 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.705 ' CG1' HG11 ' A' ' 70' ' ' VAL . 24.9 m -121.83 169.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.498 -179.94 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.2 mmtp -130.23 155.25 46.59 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.36 -179.969 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.543 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.74 103.51 0.35 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.474 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.4 -30.79 5.66 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 179.94 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.8 tt0 -61.29 143.2 56.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.181 0.515 . . . . 0.0 110.621 -179.853 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.587 HG22 HD12 ' A' ' 69' ' ' LEU . 2.5 m -67.76 138.51 56.26 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.266 179.831 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.476 ' HA ' HG13 ' A' ' 70' ' ' VAL . 28.1 m -118.68 -33.6 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.265 -179.443 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.753 HD11 HG13 ' A' ' 65' ' ' VAL . 7.4 tt -161.05 152.87 19.61 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.21 0.529 . . . . 0.0 111.017 -179.303 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.2 t -106.45 143.34 17.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.999 179.665 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.788 HD21 HG21 ' A' ' 113' ' ' VAL . 14.9 mt -120.55 163.16 18.4 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.51 -179.904 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -133.52 103.49 5.95 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.458 -179.944 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -148.52 153.15 38.03 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.247 179.908 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 32.1 mtp 60.54 31.06 20.18 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.699 -179.931 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 3.4 tttp 59.12 29.37 18.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.765 179.791 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 12.9 ptm -148.66 133.91 18.39 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.106 0.479 . . . . 0.0 110.464 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -70.51 130.61 42.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.592 -179.852 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 4.1 m -115.87 119.5 36.18 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.277 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 26.3 mt-10 -82.39 131.09 35.23 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.628 -179.82 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.759 HD11 HD12 ' A' ' 85' ' ' LEU . 26.9 mm -105.58 148.54 9.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.093 179.815 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 1.5 p30 -137.23 151.06 48.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.565 -179.911 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.68 144.88 98.83 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.279 179.976 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.428 ' HD3' HG23 ' A' ' 57' ' ' ILE . 49.1 Cg_endo -73.94 -34.63 5.01 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.153 1.902 . . . . 0.0 112.252 -179.998 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.543 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 32.9 p -145.65 167.46 23.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.37 179.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -68.77 142.97 54.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.396 179.98 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 170.15 -160.15 32.92 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 -179.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 80.7 tttt -133.23 149.24 52.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.145 0.497 . . . . 0.0 110.409 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.68 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.0 t -75.1 106.86 5.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.316 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -92.95 -29.98 15.6 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.725 179.95 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 10.9 tttt -158.02 127.93 6.04 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.466 179.998 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.588 HG13 HG12 ' A' ' 120' ' ' ILE . 20.4 t -100.52 110.8 28.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.322 179.916 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.5 mt -90.09 29.38 1.23 Allowed 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.676 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.436 ' H ' HG12 ' A' ' 105' ' ' VAL . 24.4 m -155.44 142.12 11.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 121.062 0.458 . . . . 0.0 110.353 179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.499 ' HA ' HD11 ' A' ' 68' ' ' ILE . 16.8 mmtt -125.86 175.37 7.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.392 179.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -73.06 148.34 44.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.395 179.937 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.4 34.2 18.39 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.584 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -123.09 149.91 43.86 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.329 179.838 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.17 135.22 33.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.541 -179.952 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.788 HG21 HD21 ' A' ' 85' ' ' LEU . 30.7 m -121.17 151.64 24.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.279 179.919 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -98.56 140.46 32.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.328 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . 0.456 ' H ' ' HB2' ' A' ' 62' ' ' ALA . . . -59.19 108.45 1.63 Allowed Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.982 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 109.53 -26.55 14.31 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -179.782 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -57.63 145.24 34.69 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 121.134 0.492 . . . . 0.0 110.862 -179.938 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.743 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -62.18 118.21 13.79 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.848 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.405 ' O ' HG22 ' A' ' 107' ' ' VAL . 94.5 mt -88.33 -54.75 4.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.169 0.509 . . . . 0.0 110.177 179.799 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.588 HG12 HG13 ' A' ' 105' ' ' VAL . 44.8 mt -143.18 149.19 18.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.145 179.819 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 42.7 tttt -97.34 130.01 44.55 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.319 179.885 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.515 HD11 HD11 ' A' ' 57' ' ' ILE . 37.9 mm -107.71 144.44 16.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.425 -179.843 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.764 0 CA-C-O 118.025 -1.431 . . . . 0.0 110.747 179.955 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 174.87 -178.12 46.73 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -89.43 -70.85 0.63 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.108 0.48 . . . . 0.0 110.438 -179.999 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -65.81 -176.66 6.6 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 179.999 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.5 mttt -156.93 40.07 0.32 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.235 0.541 . . . . 0.0 110.42 179.986 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.779 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -151.63 141.36 21.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.253 179.83 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -177.63 -39.56 0.06 OUTLIER Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.164 -0.774 . . . . 0.0 111.164 179.94 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -77.9 -79.98 0.11 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.086 0.469 . . . . 0.0 110.891 -179.669 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -117.64 -4.61 15.03 Favored Glycine 0 CA--C 1.531 1.067 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.562 179.721 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.716 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 37.2 mt-10 -92.18 132.77 36.38 Favored 'General case' 0 C--O 1.23 0.049 0 O-C-N 122.494 -0.415 . . . . 0.0 110.421 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 54.3 mt -80.42 111.1 19.81 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.167 -179.984 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.61 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 50.3 Cg_endo -72.31 135.08 23.98 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.024 1.816 . . . . 0.0 112.351 -179.893 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.572 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -70.27 148.89 95.88 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.427 179.977 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -72.31 -28.44 15.19 Favored 'Trans proline' 0 N--CA 1.472 0.207 0 C-N-CA 122.228 1.952 . . . . 0.0 112.303 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.2 pp -164.26 162.71 22.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.389 179.952 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.29 117.84 16.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.443 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -145.83 -146.87 4.49 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 25.9 m -137.18 132.6 34.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.172 0.51 . . . . 0.0 110.376 -179.974 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.638 ' CG1' HD11 ' A' ' 83' ' ' LEU . 21.4 t -70.23 132.31 33.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.301 179.907 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.0 t -101.52 -57.61 2.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.586 -179.958 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 32.2 ttpt -150.2 146.58 26.93 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.492 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.471 HG12 HD12 ' A' ' 83' ' ' LEU . 21.6 mt -98.92 133.95 39.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.149 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.641 HD11 HG23 ' A' ' 84' ' ' VAL . 5.6 mp -98.23 -31.57 12.01 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.617 -179.828 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.795 HG11 HG11 ' A' ' 76' ' ' VAL . 34.0 m -113.72 145.92 18.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.207 0.527 . . . . 0.0 110.761 -179.841 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.4 ptpp? -133.67 167.13 21.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.042 179.605 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -57.58 113.14 1.67 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.623 -179.972 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.39 21.06 5.29 Favored Glycine 0 CA--C 1.531 1.057 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.588 -179.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -135.01 141.1 46.12 Favored 'General case' 0 C--O 1.231 0.081 0 CA-C-O 121.094 0.474 . . . . 0.0 110.138 179.601 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -95.29 132.02 40.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.611 -179.711 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.795 HG11 HG11 ' A' ' 70' ' ' VAL . 19.9 m -114.5 168.08 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.312 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 7.8 mmmt -121.65 139.91 52.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.258 179.829 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.656 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -56.27 97.95 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.972 -179.81 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.96 -37.39 1.9 Allowed Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.9 tt0 -66.07 149.12 50.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.033 0.444 . . . . 0.0 110.526 -179.953 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.3 m -67.13 136.51 55.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.295 179.971 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.464 HG11 ' HB2' ' A' ' 96' ' ' ALA . 25.6 m -114.77 -31.5 2.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.124 -179.739 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.638 HD11 ' CG1' ' A' ' 65' ' ' VAL . 7.7 tt -160.67 151.83 19.01 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -179.674 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.641 HG23 HD11 ' A' ' 69' ' ' LEU . 22.0 t -102.87 128.26 55.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.055 179.871 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.437 HD11 HG21 ' A' ' 113' ' ' VAL . 1.0 OUTLIER -111.76 159.41 18.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.643 -179.771 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -139.84 84.3 1.97 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.301 179.867 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -91.17 112.63 24.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.368 -179.836 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 35.4 mtt 63.61 46.03 4.36 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.393 0.615 . . . . 0.0 110.265 179.829 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 18.4 mtmt 61.06 39.81 15.83 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.396 179.909 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 1.2 tpt -129.34 96.4 4.28 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.359 179.922 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -62.44 112.23 2.36 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.474 179.967 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 20.2 m -120.29 139.55 52.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.343 179.894 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -85.92 135.09 33.81 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.481 -179.862 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.1 mm -107.82 119.24 57.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.237 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 14.0 p-10 -104.2 142.36 34.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.457 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.464 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -60.82 141.62 92.79 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.492 -179.963 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -73.55 -36.45 3.86 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.198 1.932 . . . . 0.0 112.172 179.932 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.656 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 69.4 p -147.24 153.92 40.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.345 -179.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -65.38 141.89 58.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.415 179.863 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.67 -155.34 19.6 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.967 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.7 ttpt -133.48 143.81 49.04 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.174 0.511 . . . . 0.0 110.593 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.54 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.0 t -75.97 111.23 12.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.079 179.828 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -95.69 -32.49 12.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.82 -179.662 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -161.03 129.84 4.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.117 0.484 . . . . 0.0 110.285 -179.954 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.715 HG13 HG12 ' A' ' 120' ' ' ILE . 21.8 t -103.85 112.64 38.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.263 179.896 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.3 mt -79.81 -31.62 40.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.562 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.463 HG13 ' HA ' ' A' ' 119' ' ' LEU . 27.0 m -83.76 146.92 6.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.615 -179.801 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 18.9 mttm -129.36 172.15 11.79 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.252 179.943 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.41 139.27 54.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.247 -179.983 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 60.78 40.85 15.54 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.57 179.965 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -121.94 145.83 47.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.404 179.846 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.86 131.12 37.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.381 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.437 HG21 HD11 ' A' ' 85' ' ' LEU . 31.3 m -120.3 153.26 23.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.37 179.924 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -98.86 145.84 26.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.36 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.9 110.24 2.91 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.998 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.55 -28.73 8.36 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.906 -0.877 . . . . 0.0 110.906 -179.83 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -58.02 141.01 51.19 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 121.128 0.49 . . . . 0.0 110.815 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.779 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -62.3 125.85 36.77 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.87 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.572 HD21 ' HB2' ' A' ' 59' ' ' ALA . 89.9 mt -88.96 -57.23 2.98 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.009 0.433 . . . . 0.0 110.4 -179.994 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.715 HG12 HG13 ' A' ' 105' ' ' VAL . 53.2 mt -141.29 151.3 19.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.431 179.926 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.7 mttt -94.02 121.68 35.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.132 179.813 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.3 mm -104.01 142.55 17.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.486 -179.845 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.771 0 CA-C-O 117.97 -1.461 . . . . 0.0 110.777 -179.981 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.41 -59.21 0.11 Allowed Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -141.85 78.07 1.61 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.271 0.558 . . . . 0.0 110.318 179.924 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 168.58 43.28 0.03 OUTLIER Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.871 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.8 pttt -153.64 143.56 21.99 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.051 0.453 . . . . 0.0 110.404 179.964 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 56' ' ' GLU . . . -62.04 173.74 1.03 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.492 -179.9 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -162.04 -66.92 0.02 OUTLIER Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 179.95 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -134.48 105.85 6.75 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.121 0.486 . . . . 0.0 110.451 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 116.14 -52.06 0.69 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.986 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.484 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 14.0 mt-10 -83.84 132.99 34.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.088 0.47 . . . . 0.0 110.473 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.3 mt -79.15 118.5 72.84 Favored Pre-proline 0 CA--C 1.534 0.342 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.213 -179.942 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -71.81 138.03 30.83 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 122.057 1.838 . . . . 0.0 112.343 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.556 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -71.66 147.76 92.28 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.405 179.934 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.29 -26.47 17.48 Favored 'Trans proline' 0 CA--C 1.528 0.207 0 C-N-CA 122.232 1.954 . . . . 0.0 112.451 179.913 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.9 pp -163.07 175.27 11.25 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.485 -179.937 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -89.79 93.01 9.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.428 179.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.66 -145.41 6.61 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 22.5 m -137.03 140.71 42.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.122 0.487 . . . . 0.0 110.415 179.99 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.59 HG13 HD11 ' A' ' 83' ' ' LEU . 22.8 t -70.79 127.98 33.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.156 179.949 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 7.9 p -99.55 -54.5 2.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.623 -179.84 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.6 tttt -151.05 147.98 27.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.564 -179.804 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.643 HD11 ' HA ' ' A' ' 108' ' ' LYS . 38.1 mt -102.4 133.15 46.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.151 179.792 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.551 HD12 HG22 ' A' ' 81' ' ' THR . 50.3 mt -99.16 -47.73 5.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.686 -179.809 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.772 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.3 m -99.98 146.91 8.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.552 -179.88 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -137.15 164.21 29.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.119 179.749 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -58.5 106.01 0.35 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.61 -179.934 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.11 -31.99 2.22 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -96.63 151.08 19.95 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.129 0.49 . . . . 0.0 110.361 179.915 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.546 HG22 ' O ' ' A' ' 100' ' ' GLY . 1.1 m -96.44 151.65 19.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.46 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.772 ' CG1' HG11 ' A' ' 70' ' ' VAL . 26.7 m -125.75 168.22 18.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.49 -179.951 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 4.1 ttpt -129.57 153.84 47.66 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.322 179.978 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.672 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.76 100.8 0.16 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.503 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.19 -32.89 3.47 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 179.87 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.4 tt0 -63.99 143.12 58.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.038 0.447 . . . . 0.0 110.513 -179.84 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.551 HG22 HD12 ' A' ' 69' ' ' LEU . 2.2 m -67.51 137.57 55.88 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.196 179.838 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 29.0 m -117.13 -34.02 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.124 -179.497 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.59 HD11 HG13 ' A' ' 65' ' ' VAL . 7.6 tt -161.72 153.62 19.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.227 0.537 . . . . 0.0 110.952 -179.453 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -108.55 143.09 19.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.932 179.52 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.426 HD11 HG21 ' A' ' 113' ' ' VAL . 1.4 tp -122.49 170.63 9.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.675 -179.693 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -137.83 117.6 13.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.466 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -148.96 133.7 17.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.399 179.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 12.5 mtt 60.66 33.2 20.33 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.468 -179.99 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 28.3 mmtt 60.23 33.96 20.99 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.609 -179.946 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 4.2 mmt -136.99 122.43 19.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.419 179.958 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -62.9 128.33 35.38 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.539 -179.969 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -114.72 111.25 20.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.201 179.956 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -81.72 127.94 33.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.586 -179.829 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 34.4 mm -103.97 144.63 13.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.128 179.689 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -135.29 148.87 49.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.426 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.79 138.39 97.37 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.273 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -74.38 -31.2 7.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.052 1.835 . . . . 0.0 112.258 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.672 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 15.9 p -145.74 163.9 33.5 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.435 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -68.11 142.7 55.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.363 179.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.546 ' O ' HG22 ' A' ' 75' ' ' THR . . . 171.76 -161.41 33.54 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 27.7 ttpt -132.27 147.25 52.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.412 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.61 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.7 t -75.2 106.68 5.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.198 -179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -92.12 -29.13 16.68 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.776 -179.846 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 5.6 tttt -160.07 131.02 5.72 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.112 0.482 . . . . 0.0 110.508 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.423 HG12 ' H ' ' A' ' 107' ' ' VAL . 22.3 t -100.8 109.01 24.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.198 179.897 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 23.5 mt -90.13 31.02 1.02 Allowed 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.65 -179.99 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.449 HG21 HD13 ' A' ' 83' ' ' LEU . 24.6 m -155.58 137.11 5.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-O 121.061 0.458 . . . . 0.0 110.174 -179.993 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.643 ' HA ' HD11 ' A' ' 68' ' ' ILE . 34.1 mtmt -123.63 177.56 5.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.379 -179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -68.93 144.64 54.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.491 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 34.1 mtt180 60.12 33.25 21.17 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.619 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -111.49 142.86 43.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.36 -179.978 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.75 134.28 34.54 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.5 179.984 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.426 HG21 HD11 ' A' ' 85' ' ' LEU . 30.3 m -120.77 -179.92 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.398 179.997 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -140.84 147.94 39.77 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.397 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.02 106.43 1.11 Allowed Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 179.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 119.82 -31.79 5.22 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 -179.938 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -60.61 134.49 57.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.064 0.459 . . . . 0.0 110.571 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.472 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.14 123.06 31.47 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.781 -0.927 . . . . 0.0 110.781 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.556 HD21 ' HB2' ' A' ' 59' ' ' ALA . 62.7 mt -88.67 -54.88 3.95 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.068 0.461 . . . . 0.0 110.467 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.525 ' CG2' HG13 ' A' ' 102' ' ' VAL . 52.9 mt -140.93 148.91 21.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.368 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.8 mttt -95.35 127.15 41.16 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.335 179.885 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.3 mm -108.02 143.52 18.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.359 -179.952 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.698 0 CA-C-O 117.982 -1.454 . . . . 0.0 110.761 -179.984 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -178.57 68.74 0.08 OUTLIER Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.964 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.55 89.91 5.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.121 0.486 . . . . 0.0 110.394 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 138.76 -146.79 18.62 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.942 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 58.1 mttm -153.68 40.5 0.51 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.235 0.54 . . . . 0.0 110.418 179.968 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.799 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -148.47 132.98 17.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.353 179.837 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -141.86 -91.41 0.17 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 35.5 mt-10 -99.89 93.88 6.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.057 0.456 . . . . 0.0 110.529 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 128.88 -56.9 0.73 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.758 -0.937 . . . . 0.0 110.758 179.936 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.65 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 7.7 mt-10 -84.62 129.67 34.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.085 0.469 . . . . 0.0 110.427 179.992 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.743 HD11 HD11 ' A' ' 122' ' ' ILE . 42.7 mt -80.8 111.13 20.71 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.284 179.885 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.606 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.1 Cg_endo -71.02 137.27 31.46 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.079 1.852 . . . . 0.0 112.33 -179.854 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -67.32 151.01 97.57 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.458 179.994 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.66 ' HB2' HD23 ' A' ' 61' ' ' LEU . 48.9 Cg_endo -72.7 -27.5 15.0 Favored 'Trans proline' 0 CA--C 1.529 0.23 0 C-N-CA 122.212 1.941 . . . . 0.0 112.35 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.66 HD23 ' HB2' ' A' ' 60' ' ' PRO . 0.2 OUTLIER -164.23 172.47 13.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.368 179.97 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -82.8 92.3 7.22 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.31 179.951 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -123.81 -146.16 6.94 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.931 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.3 m -135.79 137.57 41.73 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.102 0.477 . . . . 0.0 110.362 179.99 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.774 HG13 HD11 ' A' ' 83' ' ' LEU . 22.1 t -68.22 128.27 31.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.319 179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -97.72 -61.55 1.37 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.428 179.938 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -149.71 145.87 26.92 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.403 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.565 HG12 HD12 ' A' ' 83' ' ' LEU . 49.5 mt -97.76 129.42 47.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.079 179.789 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.585 HD12 HG22 ' A' ' 81' ' ' THR . 22.3 mt -97.41 -43.54 7.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.818 -179.703 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.769 HG11 ' CG1' ' A' ' 76' ' ' VAL . 31.4 m -104.2 145.83 12.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.216 0.531 . . . . 0.0 110.781 -179.691 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.1 pttt -137.24 161.93 34.89 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.945 179.718 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -57.16 107.88 0.47 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.766 -179.926 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.1 -31.02 2.31 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -179.686 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -98.83 152.71 19.43 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.972 0.415 . . . . 0.0 110.36 179.86 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.522 HG23 ' HB2' ' A' ' 101' ' ' LYS . 0.7 OUTLIER -96.61 151.07 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.45 179.995 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.769 ' CG1' HG11 ' A' ' 70' ' ' VAL . 23.5 m -127.81 169.97 18.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.41 -179.929 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 17.4 mmmt -132.49 153.75 50.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.409 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.514 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -60.79 104.47 0.36 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.577 -179.845 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 126.35 -34.69 3.14 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.857 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 -64.43 140.43 58.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.116 0.484 . . . . 0.0 110.513 -179.908 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.585 HG22 HD12 ' A' ' 69' ' ' LEU . 11.1 m -67.42 136.55 54.88 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.333 179.915 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.425 HG22 ' O ' ' A' ' 94' ' ' ILE . 30.0 m -112.82 -29.23 2.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.042 -179.737 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.774 HD11 HG13 ' A' ' 65' ' ' VAL . 7.7 tt -163.99 147.53 9.8 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 121.12 0.486 . . . . 0.0 110.86 -179.516 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.5 t -98.86 134.15 38.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.961 179.593 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.716 HD11 HG21 ' A' ' 113' ' ' VAL . 1.0 OUTLIER -116.04 167.71 10.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.542 -179.729 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -136.33 110.93 8.61 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.493 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -147.27 143.35 28.05 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.49 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 9.5 mmt 60.43 31.72 20.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.682 179.959 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.7 mmtp 59.78 34.56 21.94 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.464 -179.944 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.2 mtt -147.28 118.08 7.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.482 -179.87 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -62.95 127.07 29.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.314 179.939 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 11.8 m -116.04 128.14 55.47 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.493 -179.931 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 15.5 mt-10 -85.51 133.31 34.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.445 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.425 ' O ' HG22 ' A' ' 82' ' ' VAL . 38.2 mm -102.38 118.3 49.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.223 179.869 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 5.0 p-10 -104.24 143.93 32.29 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.315 -179.887 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.21 140.31 91.23 Favored Pre-proline 0 CA--C 1.533 0.32 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.556 -179.983 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -73.25 -33.33 7.33 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.186 1.924 . . . . 0.0 112.338 -179.975 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.514 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 81.1 p -147.84 163.44 36.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.354 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -67.98 142.91 55.82 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.531 179.92 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.503 ' O ' HG22 ' A' ' 75' ' ' THR . . . 171.51 -159.97 31.8 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.995 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . 0.522 ' HB2' HG23 ' A' ' 75' ' ' THR . 13.3 ttmt -136.55 141.61 43.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.105 0.479 . . . . 0.0 110.517 -179.911 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.644 HG13 ' CG2' ' A' ' 120' ' ' ILE . 22.0 t -72.03 125.9 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.262 179.856 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -102.63 -31.23 10.48 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.783 -179.915 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 2.2 ttmt -164.4 139.08 5.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.674 -179.772 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 107' ' ' VAL . 22.0 t -106.67 109.01 26.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.128 179.807 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 3.4 mt -80.01 -31.81 39.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.302 179.898 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.429 ' O ' HG12 ' A' ' 105' ' ' VAL . 29.0 m -79.85 147.7 6.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.49 -179.965 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 24.3 mttp -127.83 164.1 22.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.149 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -65.95 142.38 57.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.397 179.997 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 63.54 37.77 10.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.619 179.885 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -121.64 152.16 39.63 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.389 179.681 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.97 134.52 34.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.476 -179.909 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.716 HG21 HD11 ' A' ' 85' ' ' LEU . 30.7 m -120.42 150.24 23.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.456 179.943 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 21.8 mt-30 -101.17 139.44 36.85 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.336 179.919 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.38 92.11 0.05 OUTLIER Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 132.81 -28.47 3.37 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.867 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -60.0 144.9 48.13 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 121.108 0.48 . . . . 0.0 110.645 -179.95 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.799 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -62.87 122.88 28.97 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.885 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 88.6 mt -88.18 -59.44 2.24 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.061 0.458 . . . . 0.0 110.385 179.853 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.644 ' CG2' HG13 ' A' ' 102' ' ' VAL . 49.7 mt -141.77 149.21 20.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.358 179.803 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 34.3 mttp -94.04 131.41 39.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.332 179.847 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.743 HD11 HD11 ' A' ' 57' ' ' ILE . 35.7 mm -107.7 146.02 14.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.397 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.718 0 CA-C-O 118.002 -1.443 . . . . 0.0 110.746 179.903 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.54 58.56 0.39 Allowed Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.931 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -174.79 119.45 0.21 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.072 0.463 . . . . 0.0 110.349 179.966 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -153.35 165.1 31.25 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 179.952 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 12.5 pttm -140.96 149.23 41.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.136 0.493 . . . . 0.0 110.386 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.588 ' HB3' ' HB3' ' A' ' 58' ' ' PRO . . . -61.79 -179.96 0.23 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.487 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 172.88 -45.06 0.17 Allowed Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 -179.965 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -66.32 -148.86 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.525 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -70.91 -7.09 61.35 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.17 -179.83 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.466 ' OE2' HD11 ' A' ' 106' ' ' LEU . 33.7 mt-10 -76.61 143.18 40.38 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 121.215 0.531 . . . . 0.0 110.677 -179.621 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 48.9 mt -80.45 125.92 79.85 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.341 -179.835 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.588 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 51.8 Cg_endo -74.85 156.65 43.65 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 121.885 1.723 . . . . 0.0 112.247 179.737 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.493 ' HB3' ' H ' ' A' ' 116' ' ' GLY . . . -84.89 143.36 40.15 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.305 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -73.89 -27.93 11.79 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.225 1.95 . . . . 0.0 112.484 -179.97 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.3 pp -163.65 172.49 14.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.51 -179.908 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -88.3 98.64 11.7 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.506 179.925 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.68 -144.31 5.62 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 8.9 m -137.71 135.9 36.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.149 0.499 . . . . 0.0 110.458 179.926 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.652 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -71.1 125.89 30.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.24 179.86 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.5 p -98.99 -57.54 2.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.74 -179.707 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.43 ' HD2' HG21 ' A' ' 84' ' ' VAL . 5.6 ptpt -149.52 146.37 27.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.679 -179.728 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.681 HG12 HD12 ' A' ' 83' ' ' LEU . 30.8 mt -101.62 136.83 31.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.16 179.74 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.587 HD12 HG22 ' A' ' 81' ' ' THR . 46.3 mt -100.0 -40.21 7.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.576 -179.847 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.628 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.0 m -100.73 138.15 25.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.148 0.499 . . . . 0.0 110.581 -179.873 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 10.2 pttp -122.7 163.26 20.45 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.044 179.825 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -60.47 104.02 0.3 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.569 -179.895 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 137.56 -31.82 2.46 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 75.9 m-20 -83.17 154.99 23.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.052 0.453 . . . . 0.0 110.557 179.969 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.5 m -98.47 144.78 27.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.322 179.952 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.578 ' CG1' HG11 ' A' ' 70' ' ' VAL . 31.1 m -120.78 158.12 23.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.511 -179.914 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 41.6 mttt -122.7 151.12 41.87 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.261 179.832 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.458 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.29 90.99 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.694 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.53 -30.36 3.01 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.921 -0.871 . . . . 0.0 110.921 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -61.85 142.8 57.14 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.158 0.504 . . . . 0.0 110.571 -179.855 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.587 HG22 HD12 ' A' ' 69' ' ' LEU . 2.1 m -67.22 140.53 57.42 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.123 179.779 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.599 ' HA ' HG13 ' A' ' 70' ' ' VAL . 32.4 m -121.76 -32.49 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.631 -179.459 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.681 HD12 HG12 ' A' ' 68' ' ' ILE . 8.0 tt -161.23 152.84 19.21 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 120.169 -0.612 . . . . 0.0 111.557 -179.244 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.43 HG21 ' HD2' ' A' ' 67' ' ' LYS . 21.6 t -103.96 137.64 31.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.638 179.405 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 1.1 tp -121.0 165.7 14.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.176 0.512 . . . . 0.0 110.656 -179.776 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -138.24 120.11 15.36 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.463 -179.949 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -150.63 138.61 20.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.397 179.983 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 44.8 mtp 60.73 36.12 19.46 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.598 -179.954 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 60.52 31.21 20.23 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.53 179.983 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 9.4 ttt -141.01 121.12 13.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.568 179.991 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -73.48 130.38 39.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.288 179.917 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.2 m -121.71 129.54 52.8 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.368 -179.987 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -84.29 138.04 33.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.564 -179.902 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 38.2 mm -103.21 150.48 6.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.077 179.853 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -138.05 142.15 40.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.507 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.11 139.79 96.02 Favored Pre-proline 0 CA--C 1.533 0.302 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.293 -179.98 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -73.1 -30.35 10.8 Favored 'Trans proline' 0 N--CA 1.472 0.223 0 C-N-CA 122.061 1.841 . . . . 0.0 112.081 179.894 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.458 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 6.0 p -147.01 162.79 38.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.198 179.879 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 11.6 p30 -67.54 147.71 52.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.204 0.526 . . . . 0.0 110.315 -179.972 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 169.92 -160.04 32.87 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -179.832 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 16.0 ttmt -135.58 142.89 45.38 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.068 0.461 . . . . 0.0 110.455 -179.915 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.628 HG21 ' HB ' ' A' ' 70' ' ' VAL . 23.6 t -75.59 111.48 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.905 179.699 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -97.36 -31.21 12.51 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.833 -179.488 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -161.77 132.01 4.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.148 0.499 . . . . 0.0 110.786 -179.878 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.483 HG13 HG12 ' A' ' 120' ' ' ILE . 22.0 t -102.71 123.78 56.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.923 179.685 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.466 HD11 ' OE2' ' A' ' 56' ' ' GLU . 35.3 mt -82.77 -29.92 29.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.98 -179.587 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.413 ' O ' HG12 ' A' ' 105' ' ' VAL . 35.3 m -95.97 158.82 3.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 121.213 0.53 . . . . 0.0 110.936 -179.677 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 37.2 mttt -132.08 163.53 28.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.167 179.65 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -60.72 141.42 56.89 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.544 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? 61.43 39.11 15.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.393 179.988 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -123.88 151.38 43.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.327 179.852 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.63 144.21 25.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.473 -179.912 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.416 HG13 HG23 ' A' ' 65' ' ' VAL . 33.7 m -126.75 179.53 3.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.37 179.801 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -130.04 140.88 50.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.323 179.937 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -58.78 105.93 0.77 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.837 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.493 ' H ' ' HB3' ' A' ' 59' ' ' ALA . . . 115.99 -31.05 6.24 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.995 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 21.1 tt0 -58.4 140.61 53.43 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 121.141 0.496 . . . . 0.0 110.763 -179.909 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.528 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -60.71 124.01 34.43 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 179.934 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 90.1 mt -90.38 -49.31 6.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.036 0.446 . . . . 0.0 110.844 -179.585 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.483 HG12 HG13 ' A' ' 105' ' ' VAL . 50.7 mt -142.33 153.61 18.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.576 -179.852 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.403 ' N ' HG22 ' A' ' 120' ' ' ILE . 23.4 tttt -98.19 125.21 43.14 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.354 179.835 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 39.4 mm -108.37 140.4 27.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.397 -179.93 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.701 0 CA-C-O 117.979 -1.456 . . . . 0.0 110.943 179.93 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -127.13 84.71 0.34 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.994 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 60.64 104.07 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.07 0.462 . . . . 0.0 110.567 -179.913 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -125.3 58.72 0.66 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 -179.927 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.3 mtmt -147.43 166.77 26.22 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.003 0.43 . . . . 0.0 110.439 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.634 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -118.07 128.64 54.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.399 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -176.53 42.89 0.11 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.706 -0.958 . . . . 0.0 110.706 179.983 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.3 tt0 -164.02 32.2 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.106 0.479 . . . . 0.0 110.503 -179.966 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 122.53 -32.26 4.54 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.995 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.607 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 13.8 mt-10 -80.45 139.98 36.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.106 0.479 . . . . 0.0 110.509 -179.846 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.764 HD12 ' HD2' ' A' ' 97' ' ' PRO . 42.9 mm -79.09 124.48 84.6 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.051 179.879 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.9 132.77 17.42 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 121.924 1.749 . . . . 0.0 112.223 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 114' ' ' GLN . . . -65.34 146.16 98.98 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.427 -179.938 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -72.9 -29.95 11.7 Favored 'Trans proline' 0 N--CA 1.471 0.2 0 C-N-CA 122.191 1.927 . . . . 0.0 112.295 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.454 HD12 ' C ' ' A' ' 61' ' ' LEU . 4.2 pp -163.67 166.38 22.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.393 179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.1 101.82 6.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.339 179.929 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -132.63 -149.91 6.33 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.989 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.8 m -136.21 140.6 43.65 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.149 0.5 . . . . 0.0 110.437 179.933 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.974 HG13 HD11 ' A' ' 83' ' ' LEU . 23.2 t -73.24 121.69 24.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.252 179.918 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.1 m -99.49 -49.69 4.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.555 -179.95 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 17.2 ttpt -152.56 146.51 25.28 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.535 -179.735 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.487 HD12 ' HG2' ' A' ' 109' ' ' GLU . 2.9 mp -105.59 135.82 42.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.09 179.7 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.511 HD11 HG23 ' A' ' 84' ' ' VAL . 7.1 mp -100.03 -36.34 9.39 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.653 -179.783 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.763 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.0 m -101.16 143.2 14.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.72 -179.819 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.4 pttp -133.47 162.67 31.23 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.063 179.81 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -59.16 101.12 0.09 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.534 179.959 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.22 -29.6 2.4 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.836 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -90.7 148.03 22.87 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.093 0.473 . . . . 0.0 110.43 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 3.6 m -95.72 144.72 25.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.396 179.972 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.668 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.4 m -119.78 160.68 19.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.505 -179.965 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 88.2 mttt -125.06 154.32 41.52 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.327 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -60.36 97.61 0.05 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.732 -179.802 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 128.83 -30.66 3.69 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.831 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 28.2 tt0 -63.94 141.24 58.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.101 0.477 . . . . 0.0 110.735 -179.816 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 18.2 m -65.45 138.6 58.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.235 179.744 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.663 HG11 ' HB2' ' A' ' 96' ' ' ALA . 31.4 m -117.91 -32.95 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.247 -179.373 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.974 HD11 HG13 ' A' ' 65' ' ' VAL . 7.8 tt -161.47 153.51 19.61 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 121.284 0.564 . . . . 0.0 111.111 -179.268 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.511 HG23 HD11 ' A' ' 69' ' ' LEU . 21.3 t -107.01 137.3 38.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.911 179.504 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.573 HD12 HD11 ' A' ' 94' ' ' ILE . 15.3 mt -115.36 162.61 16.88 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.28 0.562 . . . . 0.0 110.782 -179.657 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -140.14 79.68 1.72 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.274 179.804 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -94.8 119.83 34.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.436 -179.854 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 37.0 mtt 62.66 39.64 11.06 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.361 179.846 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.2 mtmt 62.06 40.03 12.49 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.588 179.742 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 6.5 mmt -131.96 113.17 13.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.246 179.654 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -65.71 109.96 2.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.721 -179.845 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 11.1 m -112.09 119.58 38.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.318 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -82.1 129.11 34.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.852 -179.587 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.573 HD11 HD12 ' A' ' 85' ' ' LEU . 39.0 mm -101.35 149.45 6.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.997 179.569 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 67.9 m-20 -139.2 134.34 32.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.161 0.505 . . . . 0.0 110.863 -179.665 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.663 ' HB2' HG11 ' A' ' 82' ' ' VAL . . . -63.13 110.46 3.56 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.946 179.363 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.764 ' HD2' HD12 ' A' ' 57' ' ' ILE . 40.6 Cg_endo -64.27 -15.13 47.85 Favored 'Trans proline' 0 N--CA 1.476 0.484 0 C-N-CA 122.182 1.921 . . . . 0.0 113.105 179.834 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 61.1 p -135.9 136.66 40.68 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-O 121.145 0.498 . . . . 0.0 110.425 179.858 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -64.02 163.31 12.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.468 -179.976 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 149.03 -155.93 26.58 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 19.5 ttmt -134.55 147.89 50.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.084 0.469 . . . . 0.0 110.506 -179.833 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.763 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.1 t -77.44 111.81 14.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.165 179.802 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -95.94 -27.59 15.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.987 -179.774 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 36.1 tttt -162.69 127.38 3.14 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.064 0.459 . . . . 0.0 110.453 -179.864 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.503 HG12 ' O ' ' A' ' 107' ' ' VAL . 21.5 t -102.62 112.5 36.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.307 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 4.5 mt -80.05 -31.44 39.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.503 -179.989 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.503 ' O ' HG12 ' A' ' 105' ' ' VAL . 33.6 m -87.08 141.56 14.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.71 -179.918 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -128.39 171.54 11.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.438 179.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . 0.487 ' HG2' HD12 ' A' ' 68' ' ' ILE . 28.5 mt-10 -63.29 137.74 58.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.414 179.995 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.76 38.88 6.57 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.618 179.979 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -118.79 144.82 46.06 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.224 179.635 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.98 134.99 34.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.485 -179.955 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 27.7 m -122.32 179.9 2.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.319 180.0 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . 0.452 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 93.8 mt-30 -137.19 147.81 46.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.416 179.891 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.74 114.31 6.45 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.88 -30.37 9.14 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.909 -0.877 . . . . 0.0 110.909 -179.928 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 27.4 tt0 -60.9 137.06 58.24 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.034 0.445 . . . . 0.0 110.567 -179.967 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.634 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.86 119.19 17.15 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 -179.988 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 41.3 mt -88.92 -51.04 5.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.109 0.48 . . . . 0.0 110.378 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.478 ' CG2' HG13 ' A' ' 102' ' ' VAL . 53.5 mt -140.91 144.91 26.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 8.1 tttt -93.94 129.75 40.29 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.357 179.947 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 36.6 mm -106.44 148.82 10.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.426 -179.776 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.739 0 CA-C-O 118.015 -1.436 . . . . 0.0 110.85 -179.991 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 63.79 -100.73 0.4 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 -179.928 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -159.79 89.27 0.87 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.078 0.466 . . . . 0.0 110.41 179.956 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 165.67 -156.31 28.18 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 3.5 mtpm? 60.63 177.44 0.1 Allowed 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.1 0.476 . . . . 0.0 110.538 -179.917 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.615 ' HB1' ' O ' ' A' ' 56' ' ' GLU . . . -131.32 179.39 6.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.355 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 133.95 -33.24 2.56 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.992 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -91.12 51.91 2.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.265 0.555 . . . . 0.0 110.548 -179.836 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.44 -28.17 15.37 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 179.828 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.615 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 7.2 mt-10 -76.6 138.44 40.12 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.187 0.517 . . . . 0.0 110.698 -179.694 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.576 HD11 ' CG1' ' A' ' 122' ' ' ILE . 32.7 mt -80.11 119.93 78.09 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.138 179.756 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.499 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.6 Cg_endo -72.19 139.47 32.44 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 122.0 1.8 . . . . 0.0 112.277 -179.965 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.635 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -71.8 146.77 91.12 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.373 179.948 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -72.85 -27.14 14.91 Favored 'Trans proline' 0 N--CA 1.471 0.184 0 C-N-CA 122.227 1.951 . . . . 0.0 112.393 179.972 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.2 pp -162.18 174.58 12.71 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.394 -179.941 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -90.24 82.21 6.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.306 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.424 ' HA3' ' HB2' ' A' ' 87' ' ' ALA . . . -109.26 -144.47 10.63 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.731 -0.947 . . . . 0.0 110.731 -179.964 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 24.7 m -136.99 138.8 40.92 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.062 0.458 . . . . 0.0 110.525 -179.943 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.775 HG13 HD21 ' A' ' 83' ' ' LEU . 25.7 t -70.95 124.18 26.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.077 179.897 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.3 t -101.9 -59.12 1.75 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.787 -179.7 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 18.9 tptt -149.81 138.79 21.08 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.738 -179.583 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 38.9 mt -95.92 135.52 29.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.965 179.532 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.651 HD13 ' HB ' ' A' ' 81' ' ' THR . 11.5 mt -100.91 -30.82 11.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.93 -179.556 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.691 HG11 ' CG1' ' A' ' 76' ' ' VAL . 35.3 m -108.49 149.81 11.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 121.144 0.497 . . . . 0.0 110.733 -179.854 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 12.6 ptpt -137.66 164.16 29.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.164 179.856 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.424 ' HG3' HG23 ' A' ' 105' ' ' VAL . 39.4 mt-10 -60.58 102.97 0.21 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.5 -179.985 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 138.55 -31.48 2.41 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.965 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 23.8 m-20 -88.18 147.6 24.8 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.108 0.48 . . . . 0.0 110.482 -179.946 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 19.6 m -95.52 142.93 27.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.303 179.914 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.691 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.4 m -119.42 156.63 21.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.53 -179.883 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 8.4 mptt -117.79 152.58 35.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.288 179.888 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.558 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.24 93.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.644 -179.916 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.23 -31.49 2.78 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.946 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 17.7 tt0 -62.42 141.96 58.1 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.078 0.466 . . . . 0.0 110.562 -179.98 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.651 ' HB ' HD13 ' A' ' 69' ' ' LEU . 3.9 m -68.12 138.84 56.03 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.212 179.819 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.53 ' HA ' HG13 ' A' ' 70' ' ' VAL . 27.4 m -121.07 -32.42 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.657 -179.243 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.775 HD21 HG13 ' A' ' 65' ' ' VAL . 1.5 tm? -160.34 136.74 8.76 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.863 -179.11 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.757 ' N ' HD22 ' A' ' 83' ' ' LEU . 20.1 t -102.3 136.35 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.459 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.502 HD23 ' HA ' ' A' ' 65' ' ' VAL . 88.4 mt -114.12 166.56 11.5 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.584 -179.874 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -142.19 80.81 1.72 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.316 179.899 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.424 ' HB2' ' HA3' ' A' ' 63' ' ' GLY . . . -92.24 115.04 27.74 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.349 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 8.5 mtp 62.73 46.03 5.5 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.237 179.94 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 50.2 mttt 60.35 30.97 20.24 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.553 -179.823 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 9.0 tpt -118.44 95.93 5.08 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.41 -179.989 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -61.39 107.75 0.83 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.526 -179.898 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 23.9 m -117.44 112.64 20.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.353 179.983 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -80.64 132.97 35.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.765 -179.724 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.424 HG22 ' N ' ' A' ' 95' ' ' ASN . 35.7 mm -101.88 155.91 4.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.066 179.648 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.424 ' N ' HG22 ' A' ' 94' ' ' ILE . 2.1 p30 -136.84 149.34 47.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.568 179.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.71 139.8 97.06 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.242 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -72.65 -30.99 11.25 Favored 'Trans proline' 0 N--CA 1.472 0.226 0 C-N-CA 122.087 1.858 . . . . 0.0 112.197 179.911 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.558 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -147.07 163.61 35.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.313 179.943 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -68.17 141.94 55.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.352 179.969 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 175.48 -159.48 27.43 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.988 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 10.1 ttpt -133.36 143.71 49.14 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.045 0.45 . . . . 0.0 110.338 -179.849 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.678 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.9 t -75.72 111.71 12.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.224 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -92.75 -29.72 15.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.69 -179.85 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 12.5 ttpt -158.79 134.03 8.48 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.127 0.489 . . . . 0.0 110.575 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 107' ' ' VAL . 26.9 t -101.19 107.91 22.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.346 179.96 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.7 mt -80.07 -32.2 39.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.222 179.697 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.44 HG13 ' HA ' ' A' ' 119' ' ' LEU . 31.4 m -77.3 143.63 12.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.416 179.917 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 10.6 mmmt -135.05 151.86 51.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.156 179.81 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 16.4 mp0 -58.41 137.74 57.07 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.781 -179.984 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 8.2 ttp-105 63.41 39.08 9.55 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.344 -179.896 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.418 ' O ' HG23 ' A' ' 65' ' ' VAL . 5.0 t70 -125.09 144.63 50.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.289 179.815 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -90.79 140.13 30.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.558 -179.99 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 28.9 m -121.14 179.93 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.371 179.978 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . 0.448 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 9.3 mt-30 -141.06 146.86 37.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.412 179.976 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.23 103.4 0.53 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.03 -29.78 5.45 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 -179.889 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -61.61 138.51 58.3 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-O 121.066 0.46 . . . . 0.0 110.402 -179.971 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -61.62 118.46 14.81 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.919 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.635 HD11 ' HA ' ' A' ' 59' ' ' ALA . 64.5 mt -89.02 -54.73 3.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.017 0.436 . . . . 0.0 110.334 179.81 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.509 ' CG2' HG13 ' A' ' 102' ' ' VAL . 46.6 mt -142.79 147.02 21.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.321 179.796 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 19.2 mtpt -96.22 127.21 42.02 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.339 179.963 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.576 ' CG1' HD11 ' A' ' 57' ' ' ILE . 36.1 mm -109.17 145.03 16.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.552 -179.883 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 117.976 -1.458 . . . . 0.0 110.777 179.971 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -178.74 122.89 0.83 Allowed Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.942 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -143.23 -49.13 0.32 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.047 0.451 . . . . 0.0 110.346 -179.956 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -99.53 128.62 9.63 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.784 -0.927 . . . . 0.0 110.784 179.972 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 19.1 mttm -109.32 41.14 1.7 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.368 0.604 . . . . 0.0 110.429 179.97 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.713 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -147.63 94.97 2.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.396 179.848 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -86.58 -90.58 0.96 Allowed Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.756 -0.937 . . . . 0.0 110.756 179.944 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -110.79 129.15 55.93 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.108 0.48 . . . . 0.0 110.383 179.935 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.69 -53.12 0.84 Allowed Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 -179.908 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.504 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 20.5 mt-10 -82.82 128.28 34.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.08 0.467 . . . . 0.0 110.359 -179.959 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 52.2 mt -79.64 111.36 20.54 Favored Pre-proline 0 CA--C 1.535 0.383 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.258 179.993 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.555 ' HB3' ' HB3' ' A' ' 52' ' ' ALA . 47.6 Cg_endo -71.22 131.31 18.97 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 121.962 1.775 . . . . 0.0 112.302 -179.963 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.64 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -68.19 145.17 97.41 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.352 179.976 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.607 ' HG2' HD23 ' A' ' 61' ' ' LEU . 50.3 Cg_endo -73.34 -28.03 12.78 Favored 'Trans proline' 0 CA--C 1.528 0.222 0 C-N-CA 122.22 1.946 . . . . 0.0 112.276 -179.963 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.607 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.7 OUTLIER -159.59 162.87 35.39 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.357 179.971 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -84.35 113.81 21.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.332 179.996 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.594 ' HA3' ' HB2' ' A' ' 87' ' ' ALA . . . -137.75 -140.7 4.08 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -179.92 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 19.7 m -136.46 139.71 42.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.067 0.46 . . . . 0.0 110.435 179.988 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.716 HG13 HD11 ' A' ' 83' ' ' LEU . 22.3 t -71.09 126.59 31.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.999 179.982 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 8.2 t -101.24 -54.47 2.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.665 -179.828 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 6.2 tptm -157.2 140.27 15.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.602 -179.819 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.742 HG12 HD12 ' A' ' 83' ' ' LEU . 31.3 mt -94.38 140.26 16.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.995 179.719 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.481 HD13 ' HB ' ' A' ' 81' ' ' THR . 22.6 mt -104.84 -37.89 6.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.631 -179.793 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.771 HG11 ' CG1' ' A' ' 76' ' ' VAL . 33.1 m -110.88 148.12 14.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.801 -179.927 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -139.62 166.77 23.7 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.213 179.897 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -58.1 108.91 0.66 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.702 179.997 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.04 -31.4 2.81 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 -179.94 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -93.19 151.38 19.86 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.061 0.458 . . . . 0.0 110.481 179.975 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . 0.435 HG22 ' O ' ' A' ' 100' ' ' GLY . 1.2 m -100.68 148.65 24.63 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.238 179.879 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.771 ' CG1' HG11 ' A' ' 70' ' ' VAL . 31.6 m -124.99 165.96 21.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.58 -179.824 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 1.8 tppt? -124.78 153.91 41.74 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.251 179.894 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.617 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -61.43 97.97 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.541 -179.87 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 133.16 -36.64 2.11 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.904 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 31.3 tt0 -62.88 139.46 58.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.496 . . . . 0.0 110.563 -179.959 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.481 ' HB ' HD13 ' A' ' 69' ' ' LEU . 6.9 m -67.07 141.87 57.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.282 -179.997 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.743 HG22 ' O ' ' A' ' 94' ' ' ILE . 31.5 m -113.58 -27.04 2.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.225 -179.604 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.742 HD12 HG12 ' A' ' 68' ' ' ILE . 7.0 tt -168.4 150.99 5.3 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.177 0.513 . . . . 0.0 110.622 -179.619 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -102.83 135.98 37.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.955 179.622 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 1.0 HD12 HD11 ' A' ' 94' ' ' ILE . 17.8 mt -115.2 163.3 15.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.587 -179.681 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -135.64 106.7 6.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.267 179.972 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.594 ' HB2' ' HA3' ' A' ' 63' ' ' GLY . . . -147.48 147.89 30.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.518 -179.965 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 39.3 mmm 60.41 32.62 20.65 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.54 179.986 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 35.2 mtmt 60.03 33.78 21.35 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.618 179.946 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 4.5 ttt -144.69 147.21 32.75 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.521 -179.87 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -92.22 124.48 36.33 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.378 179.995 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 19.6 m -121.01 125.91 48.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.418 -179.956 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -87.38 143.01 27.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.475 -179.96 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 1.0 HD11 HD12 ' A' ' 85' ' ' LEU . 38.7 mm -105.56 112.06 37.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.373 179.962 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -98.48 140.54 32.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.378 -179.945 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.41 142.38 96.27 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.341 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.24 -35.29 5.21 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.16 1.907 . . . . 0.0 112.357 179.95 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.617 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 0.8 OUTLIER -146.8 162.34 38.79 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.337 -179.968 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -66.67 143.34 57.04 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.396 179.901 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.435 ' O ' HG22 ' A' ' 75' ' ' THR . . . 173.43 -160.86 31.45 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.972 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 28.6 tttp -130.23 147.23 51.93 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.032 0.444 . . . . 0.0 110.526 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.566 HG21 ' HB ' ' A' ' 70' ' ' VAL . 21.3 t -75.67 109.12 8.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.293 179.898 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -93.93 -29.91 15.03 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.76 -179.892 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 29.8 tttt -157.47 128.09 6.49 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.163 0.506 . . . . 0.0 110.642 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.46 HG12 ' O ' ' A' ' 107' ' ' VAL . 29.0 t -102.59 102.45 13.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.224 179.824 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 12.5 mt -76.25 -32.22 58.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.213 179.716 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.633 HG21 HD13 ' A' ' 83' ' ' LEU . 34.8 m -77.86 142.01 14.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.632 -179.978 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.443 ' HA ' HD11 ' A' ' 68' ' ' ILE . 12.7 mmmt -139.82 158.45 44.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.994 179.676 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . 0.417 ' O ' ' HG3' ' A' ' 110' ' ' ARG . 13.7 mt-10 -55.81 161.72 2.08 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.976 -179.794 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . 0.417 ' HG3' ' O ' ' A' ' 109' ' ' GLU . 0.0 OUTLIER 37.18 41.24 0.21 Allowed 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.486 -179.737 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.692 ' O ' HG23 ' A' ' 65' ' ' VAL . 3.7 t70 -128.99 142.16 51.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.265 179.882 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -93.51 136.99 33.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.623 -179.781 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 26.1 m -118.8 161.29 17.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.312 179.781 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 -102.06 143.21 32.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.438 -179.998 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -61.2 108.66 2.02 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.962 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 113.14 -26.28 10.59 Favored Glycine 0 CA--C 1.528 0.859 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 -179.798 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -58.44 144.73 41.12 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-O 121.134 0.492 . . . . 0.0 110.787 -179.966 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.713 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -60.96 120.74 24.1 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.962 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.64 HD21 ' HB2' ' A' ' 59' ' ' ALA . 89.3 mt -88.01 -59.61 2.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.105 0.478 . . . . 0.0 110.453 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.475 ' CG2' HG13 ' A' ' 102' ' ' VAL . 55.0 mt -140.85 145.2 25.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.377 -179.988 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 74.7 mttt -91.4 121.56 33.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.167 179.797 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.2 mm -104.29 141.44 19.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.455 -179.957 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.75 0 CA-C-O 117.953 -1.471 . . . . 0.0 110.765 179.988 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -177.8 -42.6 0.06 OUTLIER Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 179.951 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -62.82 -177.38 0.15 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.076 0.465 . . . . 0.0 110.448 179.976 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 66.07 -82.64 0.09 OUTLIER Glycine 0 CA--C 1.525 0.657 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.996 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 22.5 tttt -76.79 141.5 40.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.069 0.462 . . . . 0.0 110.443 -179.976 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.85 ' HB2' ' HA2' ' A' ' 118' ' ' GLY . . . -78.22 179.46 6.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.377 -179.998 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 142.21 -35.47 1.75 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.636 -0.985 . . . . 0.0 110.636 179.983 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -89.88 56.48 3.5 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.468 0.651 . . . . 0.0 110.373 179.983 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.77 -30.22 10.14 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.909 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.571 ' O ' ' HB1' ' A' ' 52' ' ' ALA . 45.6 mt-10 -76.57 140.09 40.94 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.212 0.53 . . . . 0.0 110.75 -179.78 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 51.3 mt -81.03 117.1 66.63 Favored Pre-proline 0 CA--C 1.533 0.31 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.14 179.86 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -71.92 137.23 29.04 Favored 'Trans proline' 0 N--CA 1.472 0.228 0 C-N-CA 121.932 1.755 . . . . 0.0 112.315 -179.984 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.664 ' HA ' HD11 ' A' ' 119' ' ' LEU . . . -61.44 146.69 89.06 Favored Pre-proline 0 CA--C 1.532 0.266 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.389 -179.879 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -72.13 -28.69 15.45 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.2 1.934 . . . . 0.0 112.263 179.928 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.4 pp -165.32 166.9 18.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.41 -179.965 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.43 85.1 6.52 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.449 179.949 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.449 ' O ' HG22 ' A' ' 113' ' ' VAL . . . -125.35 -160.94 10.86 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -179.93 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.3 m -114.41 140.62 48.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.122 0.487 . . . . 0.0 110.56 -179.969 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.92 HG13 HD11 ' A' ' 83' ' ' LEU . 29.6 t -64.94 127.67 26.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.194 179.908 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.3 -61.27 1.42 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.703 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.702 ' O ' HD12 ' A' ' 83' ' ' LEU . 40.6 mttt -149.97 145.68 26.59 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.11 0.481 . . . . 0.0 110.654 -179.812 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.5 mt -101.04 125.24 55.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.721 179.443 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.654 HD12 HG22 ' A' ' 81' ' ' THR . 19.8 mt -96.31 -31.21 13.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.979 -179.429 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.735 ' HB ' HG21 ' A' ' 102' ' ' VAL . 35.6 m -111.62 147.18 15.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.201 0.524 . . . . 0.0 110.732 -179.719 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.5 163.96 29.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.154 179.795 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.665 ' HG3' HG23 ' A' ' 105' ' ' VAL . 24.6 mt-10 -59.34 102.45 0.14 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.699 -179.919 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.03 -30.31 2.37 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.974 -0.851 . . . . 0.0 110.974 179.969 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -92.84 150.91 20.3 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.175 0.512 . . . . 0.0 110.586 -179.866 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 7.5 m -96.02 148.14 22.97 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.297 179.931 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.673 ' CG1' HG11 ' A' ' 70' ' ' VAL . 29.8 m -119.13 166.3 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.513 -179.97 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 32.1 mmtm -128.88 147.84 50.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.24 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.61 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -59.81 90.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.779 -179.877 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.53 -31.34 2.6 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.827 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -64.1 141.15 58.87 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.171 0.51 . . . . 0.0 110.668 -179.769 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.654 HG22 HD12 ' A' ' 69' ' ' LEU . 6.4 m -65.97 137.01 56.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.082 179.788 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.477 HG12 HG11 ' A' ' 70' ' ' VAL . 31.1 m -121.68 -32.19 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.66 -179.318 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.92 HD11 HG13 ' A' ' 65' ' ' VAL . 16.3 tp -158.97 151.8 22.02 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.083 0.468 . . . . 0.0 110.816 -179.124 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.2 t -113.9 144.08 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.769 179.323 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.712 HD21 HG21 ' A' ' 113' ' ' VAL . 16.6 mt -120.62 158.81 26.58 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.168 0.509 . . . . 0.0 110.789 -179.64 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 14.1 mt-10 -135.84 111.19 9.09 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.385 -179.916 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -146.51 138.65 24.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.543 179.936 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 12.6 mmt 60.56 32.65 20.47 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.541 179.986 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 42.5 mttt 60.62 33.94 20.26 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.514 -179.998 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 27.2 ttm -137.77 109.67 7.18 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.481 -179.994 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -67.55 127.11 31.5 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.363 179.981 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -123.33 113.24 18.58 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.406 179.968 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -79.5 139.31 37.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.601 -179.889 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.427 ' N ' HD12 ' A' ' 94' ' ' ILE . 5.1 mp -110.27 155.88 11.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.729 179.902 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.416 ' N ' HG22 ' A' ' 94' ' ' ILE . 11.3 m-80 -139.5 152.57 47.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.543 -179.918 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.16 139.75 96.1 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.305 180.0 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -73.77 -35.47 4.46 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.114 1.876 . . . . 0.0 112.153 179.977 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.61 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 24.0 p -144.96 163.17 34.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.343 179.944 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -65.28 140.87 58.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.337 179.859 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 173.34 -159.6 29.74 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.919 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 22.8 ttmt -135.21 148.76 49.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.078 0.466 . . . . 0.0 110.421 -179.901 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.735 HG21 ' HB ' ' A' ' 70' ' ' VAL . 22.4 t -78.16 110.4 13.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.197 179.929 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -92.97 -27.54 16.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.884 -179.931 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -157.35 130.82 7.92 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.093 0.473 . . . . 0.0 110.653 -179.773 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.665 HG23 ' HG3' ' A' ' 72' ' ' GLU . 42.7 t -101.32 102.98 14.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.132 179.806 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 14.0 mt -88.31 10.38 19.96 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.531 179.862 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.465 HG21 HD22 ' A' ' 83' ' ' LEU . 31.3 m -123.76 135.42 63.49 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.074 0 CA-C-O 121.177 0.513 . . . . 0.0 110.212 179.705 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 9.7 tttp -123.5 152.9 41.26 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.277 -179.943 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 17.8 mt-10 -59.98 146.29 43.07 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.598 -179.967 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 20.8 mtm180 61.02 34.19 19.39 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.505 -179.943 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -120.14 149.74 41.74 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.346 179.819 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -92.11 135.9 33.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.566 -179.981 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.712 HG21 HD21 ' A' ' 85' ' ' LEU . 27.4 m -121.71 -179.99 2.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.273 179.906 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -138.55 144.7 40.0 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.423 -179.994 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.51 111.14 3.43 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.962 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 111.86 -28.77 9.06 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.88 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.0 tt0 -59.49 135.89 57.81 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.075 0.464 . . . . 0.0 110.573 -179.899 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.85 ' HA2' ' HB2' ' A' ' 52' ' ' ALA . . . -61.25 116.1 8.85 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 -179.946 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.664 HD11 ' HA ' ' A' ' 59' ' ' ALA . 71.8 mt -88.77 -54.58 4.08 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.017 0.436 . . . . 0.0 110.472 -179.954 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.615 ' CG2' HG13 ' A' ' 102' ' ' VAL . 49.5 mt -142.7 145.0 23.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.391 -179.975 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 25.1 tttt -98.06 129.0 44.92 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.453 179.869 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 38.1 mm -103.54 145.54 12.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.475 -179.782 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.75 0 CA-C-O 118.016 -1.436 . . . . 0.0 110.753 179.891 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -166.76 98.75 0.15 Allowed Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.9 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -107.72 127.82 54.02 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.076 0.465 . . . . 0.0 110.439 179.982 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 179.74 137.72 3.1 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 -179.998 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.7 tttt 60.65 109.19 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.066 0.46 . . . . 0.0 110.536 179.961 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.4 ' HB2' ' CA ' ' A' ' 118' ' ' GLY . . . -62.65 178.17 0.46 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.501 179.969 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -160.19 -73.34 0.02 OUTLIER Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.957 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.1 tt0 -135.82 111.57 9.39 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.029 0.442 . . . . 0.0 110.453 -179.917 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 115.16 -48.35 0.95 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.946 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -84.19 135.99 34.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.122 0.487 . . . . 0.0 110.435 -179.927 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.454 HD11 HD11 ' A' ' 122' ' ' ILE . 52.5 mt -78.89 112.45 27.45 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.156 179.937 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.09 141.62 40.27 Favored 'Trans proline' 0 N--CA 1.472 0.262 0 C-N-CA 122.115 1.877 . . . . 0.0 112.395 -179.932 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.851 ' HB2' HD21 ' A' ' 119' ' ' LEU . . . -79.2 148.59 71.38 Favored Pre-proline 0 CA--C 1.531 0.235 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.423 179.911 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.545 ' HG2' HD23 ' A' ' 61' ' ' LEU . 50.5 Cg_endo -72.2 -27.45 16.67 Favored 'Trans proline' 0 N--CA 1.471 0.195 0 C-N-CA 122.31 2.007 . . . . 0.0 112.365 -179.949 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.545 HD23 ' HG2' ' A' ' 60' ' ' PRO . 0.6 OUTLIER -158.61 171.08 20.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.321 179.968 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.438 ' HB2' HE21 ' A' ' 114' ' ' GLN . . . -91.07 83.43 5.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.415 179.998 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -109.7 -136.16 7.4 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.946 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.402 ' C ' HD23 ' A' ' 85' ' ' LEU . 2.0 m -139.08 138.55 37.2 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.173 0.511 . . . . 0.0 110.488 179.933 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.615 HG13 HD11 ' A' ' 83' ' ' LEU . 21.9 t -66.82 124.0 21.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.284 179.991 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.2 t -98.58 -60.31 1.57 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.478 -179.957 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.8 mttt -148.69 147.3 28.74 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.461 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.508 HG22 ' H ' ' A' ' 70' ' ' VAL . 24.0 mt -106.04 118.02 52.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.923 179.899 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.5 mt -95.12 21.79 7.41 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.385 -179.525 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.762 ' HB ' HG21 ' A' ' 102' ' ' VAL . 25.2 m -150.0 148.29 15.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 CA-C-O 121.239 0.543 . . . . 0.0 110.524 179.812 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 12.0 mtpp -132.17 157.36 44.48 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.185 179.874 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.463 ' HG3' HG23 ' A' ' 105' ' ' VAL . 27.0 mt-10 -59.11 95.33 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.516 179.989 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 140.15 -30.41 2.35 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.777 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 59.8 m-20 -73.13 146.39 45.72 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.062 0.458 . . . . 0.0 110.319 179.963 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 1.4 m -98.45 127.68 44.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.423 179.928 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.686 HG11 HG11 ' A' ' 70' ' ' VAL . 22.7 m -112.56 151.79 14.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.409 179.971 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 15.5 mttp -112.99 149.05 33.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.324 179.908 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.685 ' HB2' ' HA ' ' A' ' 98' ' ' THR . . . -57.98 95.56 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.803 -179.854 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.39 -33.92 2.24 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.4 tt0 -69.34 140.17 54.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.083 0.468 . . . . 0.0 110.481 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 23.6 m -60.43 137.82 58.09 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.488 179.905 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.583 ' O ' HG22 ' A' ' 70' ' ' VAL . 34.6 m -113.95 -33.65 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.947 -179.609 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 83' ' ' LEU . . . . . 0.615 HD11 HG13 ' A' ' 65' ' ' VAL . 7.9 tt -161.17 149.61 15.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.583 -179.558 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.7 t -104.46 140.69 21.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.183 179.836 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.791 HD12 HD11 ' A' ' 94' ' ' ILE . 3.6 mt -117.75 171.41 8.06 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.44 -179.848 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 9.1 mt-10 -131.14 113.54 14.01 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.422 179.994 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.483 ' CB ' HD11 ' A' ' 61' ' ' LEU . . . -145.7 139.86 26.83 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.338 179.974 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 88' ' ' MET . . . . . . . . . . . . . 7.7 mtp 60.77 33.01 20.22 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.55 179.992 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 60.92 33.16 19.95 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.329 179.912 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.7 mtt -139.41 160.4 39.93 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.315 -179.999 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 91' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -93.19 131.56 38.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.541 179.971 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 2.6 m -120.76 121.06 37.4 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.212 179.961 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -84.8 131.98 34.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.57 -179.894 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.791 HD11 HD12 ' A' ' 85' ' ' LEU . 38.8 mm -102.25 124.87 56.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.167 179.767 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -103.64 140.94 36.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.345 -179.934 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.464 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . . . -61.29 142.31 93.66 Favored Pre-proline 0 CA--C 1.532 0.26 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.403 -179.872 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.408 ' HD3' HG23 ' A' ' 57' ' ' ILE . 49.1 Cg_endo -72.77 -36.8 4.36 Favored 'Trans proline' 0 N--CA 1.471 0.194 0 C-N-CA 122.109 1.873 . . . . 0.0 112.352 -179.978 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.685 ' HA ' ' HB2' ' A' ' 78' ' ' ALA . 23.0 p -149.48 157.48 43.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.321 -179.989 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -63.53 140.85 58.91 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.358 179.91 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 176.81 -155.99 19.64 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.983 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 5.8 ttmt -136.93 142.23 42.68 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.143 0.497 . . . . 0.0 110.631 -179.931 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.762 HG21 ' HB ' ' A' ' 70' ' ' VAL . 31.3 t -74.12 112.17 10.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.246 179.9 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -96.11 -30.41 13.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.584 179.972 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 104' ' ' LYS . . . . . . . . . . . . . 29.5 ttmt -158.97 133.77 8.14 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.468 179.954 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.463 HG23 ' HG3' ' A' ' 72' ' ' GLU . 21.1 t -99.93 109.2 24.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.237 -179.977 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 10.7 mt -90.12 30.34 1.11 Allowed 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.688 179.971 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.459 HG21 HD13 ' A' ' 83' ' ' LEU . 26.7 m -155.46 138.34 7.15 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-O 120.987 0.423 . . . . 0.0 110.261 -179.999 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 21.2 mttt -124.55 162.48 23.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.364 -179.978 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 53.3 mt-10 -61.22 149.96 36.04 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.445 179.911 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 110' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER 61.18 32.56 19.5 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.255 -179.803 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -120.18 148.42 43.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.378 179.9 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -91.47 140.58 29.61 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.472 -179.995 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.782 HG21 HD21 ' A' ' 85' ' ' LEU . 27.8 m -120.35 -179.99 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.5 -179.986 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 114' ' ' GLN . . . . . 0.438 HE21 ' HB2' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -137.5 144.68 42.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.432 179.897 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.76 107.95 1.64 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.969 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.12 -27.96 9.7 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.857 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -60.64 137.14 58.21 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 121.199 0.523 . . . . 0.0 110.562 -179.85 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.4 ' CA ' ' HB2' ' A' ' 52' ' ' ALA . . . -60.96 119.19 17.73 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.968 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.851 HD21 ' HB2' ' A' ' 59' ' ' ALA . 59.5 mt -89.96 -49.75 6.42 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.091 0.472 . . . . 0.0 110.573 -179.873 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.494 HD13 HG21 ' A' ' 70' ' ' VAL . 47.8 mt -141.1 138.4 33.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.343 -179.918 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 20.0 tttt -91.13 130.22 37.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.394 179.887 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.454 HD11 HD11 ' A' ' 57' ' ' ILE . 38.4 mm -108.51 140.75 25.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.408 -179.996 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.834 0 CA-C-O 117.967 -1.463 . . . . 0.0 110.788 179.966 . . . . . . . . 0 0 . 1 stop_ save_